Document,Phrase,MLVal,RefinedWord,RefinedVal,ManRefWord,ManRefVal
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,models,0.53762007,model,0.8940372,markov-model,0.7015921
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,discussed,0.32159716,of,0.5174893,confusion-matrix,0.45636517
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,internal,0.22486365,of,0.4487089,dimensionality-reduction,0.37939572
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,validation,0.5362086,cross-validation,0.74016297,cross-validation,0.74016297
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,internal-validation,0.5682592,cross-validation,0.7429799,cross-validation,0.7429799
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,predict,0.51602554,model,0.53463185,classification-algorithm,0.52342355
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,risk,0.35860935,recurrent,0.53675485,logistic-regression,0.52381086
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,allows,0.45551884,of,0.5544299,stochastic,0.53129333
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,healthcare,0.40112603,data-science,0.6050074,data-science,0.6050074
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,providers,0.42136738,decision,0.6396354,data-science,0.54606366
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,healthcare-providers,0.40970185,data-science,0.5534869,data-science,0.5534869
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,hf,0.293398,long-short-term,0.35116297,long-short-term,0.35116297
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,present,0.39618495,of,0.63723874,generative,0.48216146
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,particular,0.41020766,of,0.6936578,generative,0.5711796
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,concerns,0.33428794,confusion,0.6494896,confusion-matrix,0.47983494
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,according,0.3602386,classification,0.6492659,classification,0.6492659
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,assessed,0.33986524,of,0.605934,component-analysis,0.41855076
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,using,0.47332245,analysis,0.5968549,component-analysis,0.526608
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,prediction,0.6361519,classification-algorithm,0.67946094,classification-algorithm,0.67946094
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,model,0.48485535,model,1.0,markov-model,0.7005576
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,risk,0.35860935,recurrent,0.53675485,logistic-regression,0.52381086
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,prediction-model,0.70854896,markov-model,0.7148334,markov-model,0.7148334
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,identify,0.46963936,analysis,0.5445881,clustering,0.4863696
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,risk,0.35860935,recurrent,0.53675485,logistic-regression,0.52381086
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,prediction,0.6361519,classification-algorithm,0.67946094,classification-algorithm,0.67946094
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,models,0.53762007,model,0.8940372,markov-model,0.7015921
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,conducted,0.39637828,data,0.556862,statistical,0.4670034
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,risk-prediction,0.64593977,classification-algorithm,0.71407217,classification-algorithm,0.71407217
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,prediction-models,0.719873,machine-learning,0.719873,machine-learning,0.719873
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,risk-prediction-models,0.7157521,classification-algorithm,0.73765415,classification-algorithm,0.73765415
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,left,0.2544507,tracking,0.42924023,object-tracking,0.3633091
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,ventricular,0.24852064,rate,0.37094042,long-short-term,0.34148398
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,ejection,0.30230433,function,0.43955976,gradient,0.35697576
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,fraction,0.25137818,component,0.50911963,gradient,0.48876822
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,left-ventricular,0.30000108,batch-normalization,0.40942025,batch-normalization,0.40942025
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,ventricular-ejection,0.26988763,rate,0.43059248,gradient,0.41159958
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,ejection-fraction,0.36681443,stochastic-gradient,0.5523829,stochastic-gradient,0.5523829
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,external,0.24276523,connected,0.4833919,data-augmentation,0.40820563
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,validation,0.5362086,cross-validation,0.74016297,cross-validation,0.74016297
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,external-validation,0.5778746,cross-validation,0.7483893,cross-validation,0.7483893
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,distinct,0.36295342,feature,0.580647,clustering,0.5409523
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,risk,0.35860935,recurrent,0.53675485,logistic-regression,0.52381086
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,prediction,0.6361519,classification-algorithm,0.67946094,classification-algorithm,0.67946094
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,variables,0.4636312,logistic-regression,0.6604836,logistic-regression,0.6604836
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,risk-prediction,0.64593977,classification-algorithm,0.71407217,classification-algorithm,0.71407217
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,distinct,0.36295342,feature,0.580647,clustering,0.5409523
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,predictor,0.43901688,regression,0.5961869,regression,0.5961869
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,variables,0.4636312,logistic-regression,0.6604836,logistic-regression,0.6604836
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,predictor-variables,0.5922495,logistic-regression,0.7615812,logistic-regression,0.7615812
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,characteristics,0.345204,of,0.5401758,feature-engineering,0.49030614
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,including,0.3233776,of,0.6619886,clustering,0.40625107
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,male,0.26790547,naive,0.47688544,generative,0.42885694
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,sex,0.24554862,regression,0.45148212,regression,0.45148212
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,characteristics-including,0.4578284,feature,0.62525475,feature-engineering,0.58091754
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,male-sex,0.13433254,descent,0.35201824,generative,0.33672026
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,models,0.53762007,model,0.8940372,markov-model,0.7015921
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,assessed,0.33986524,of,0.605934,component-analysis,0.41855076
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,hf,0.293398,long-short-term,0.35116297,long-short-term,0.35116297
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,hospitalizations,0.2612055,logistic-regression,0.4695824,logistic-regression,0.4695824
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,hf-hospitalizations,0.32690173,short-term,0.49902228,logistic-regression,0.47951394
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,cardiovascular,0.31674606,short-term,0.442761,learning-function,0.4027721
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,death,0.21479979,of,0.42234862,dropout,0.37818787
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,cardiovascular-death,0.3670898,learning-function,0.44179285,learning-function,0.44179285
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,models,0.53762007,model,0.8940372,markov-model,0.7015921
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,risk,0.35860935,recurrent,0.53675485,logistic-regression,0.52381086
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,prediction,0.6361519,classification-algorithm,0.67946094,classification-algorithm,0.67946094
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,models,0.53762007,model,0.8940372,markov-model,0.7015921
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,risk-prediction,0.64593977,classification-algorithm,0.71407217,classification-algorithm,0.71407217
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,prediction-models,0.719873,machine-learning,0.719873,machine-learning,0.719873
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,risk-prediction-models,0.7157521,classification-algorithm,0.73765415,classification-algorithm,0.73765415
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,identify,0.46963936,analysis,0.5445881,clustering,0.4863696
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,common,0.32574984,feature,0.5597373,clustering,0.43115532
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,variables,0.4636312,logistic-regression,0.6604836,logistic-regression,0.6604836
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,identify,0.46963936,analysis,0.5445881,clustering,0.4863696
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,hf,0.293398,long-short-term,0.35116297,long-short-term,0.35116297
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,risk,0.35860935,recurrent,0.53675485,logistic-regression,0.52381086
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,hf-risk,0.3265609,logistic-regression,0.5065303,logistic-regression,0.5065303
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,terminal,0.1515508,long,0.5815784,generative,0.39005107
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,prohormone,0.2787227,processing,0.47166103,graphics-processing,0.3765043
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,brain,0.31704307,neural,0.57897407,learning-rate,0.44069666
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,systolic,0.25626805,function,0.41296047,gradient,0.40985143
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,blood,0.16939776,normalization,0.4272251,batch-normalization,0.40715772
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,pressure,0.2060274,gradient,0.4962673,gradient,0.4962673
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,systolic-blood,0.24753866,batch-normalization,0.4520945,batch-normalization,0.4520945
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,blood-pressure,0.2672683,batch-normalization,0.4510358,batch-normalization,0.4510358
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,systolic-blood-pressure,0.2801193,batch-normalization,0.46667916,batch-normalization,0.46667916
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,patients,0.30007,recurrent,0.5332828,dropout,0.3918751
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,might,0.3331341,of,0.5952132,long-short-term,0.42997545
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,benefit,0.39640212,short-term,0.5466547,long-short-term,0.48296973
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,patients-might,0.3612241,recurrent,0.50128734,dropout,0.4666061
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,machine,0.7094662,machine,1.0,machine-learning,0.7094662
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,learning,0.709237,learning,1.0,deep-learning,0.8286492
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,tools,0.65752256,data-engineering,0.6720511,data-engineering,0.6720511
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,machine-learning,1.0,machine-learning,1.0,machine-learning,1.0
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,handling,0.40444896,processing,0.5399337,batch-normalization,0.5022036
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,missing,0.40578157,hidden,0.5782455,overfitting,0.5296333
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,data,0.46434748,data,1.0,data-science,0.5533528
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,missing-data,0.622204,overfitting,0.6792558,overfitting,0.6792558
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,blood,0.16939776,normalization,0.4272251,batch-normalization,0.40715772
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,urea,0.2245125,batch-normalization,0.3623508,batch-normalization,0.3623508
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,nitrogen,0.25959074,forest,0.46643505,feature-reduction,0.3711414
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,blood-urea,0.2559372,batch-normalization,0.44665098,batch-normalization,0.44665098
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,urea-nitrogen,0.2386516,batch,0.45680302,batch-normalization,0.39665717
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,blood-urea-nitrogen,0.2849993,batch-normalization,0.49116284,batch-normalization,0.49116284
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,identified,0.35725033,analysis,0.56593037,clustering,0.45719695
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,risk,0.35860935,recurrent,0.53675485,logistic-regression,0.52381086
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,systematic,0.48676366,statistical,0.54231316,statistical,0.54231316
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,literature,0.42831737,data,0.58552843,data-science,0.5381381
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,review,0.41215214,data,0.5581161,data-science,0.47600204
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,systematic-literature,0.5408546,natural-language,0.61705226,natural-language,0.61705226
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,literature-review,0.47830695,data,0.57625806,natural-language,0.56798154
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,systematic-literature-review,0.5314252,natural-language,0.6156083,natural-language,0.6156083
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,assess,0.36162603,of,0.49566716,decision-tree,0.39463407
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,statistical,0.6074636,statistical,1.0,statistical,1.0
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,approach,0.5412675,segmentation-algorithm,0.6046611,segmentation-algorithm,0.6046611
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,publications,0.42699853,data-science,0.65373355,data-science,0.65373355
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,reported,0.27641866,of,0.6039252,long-short-term,0.38086164
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,detail,0.38293496,fully,0.5417851,feature-engineering,0.502215
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,overall,0.37212962,rate,0.62994075,dropout,0.45315623
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,low,0.23602332,of,0.5820825,long-short-term,0.45172954
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,rob,0.24440461,relu,0.32457215,relu,0.32457215
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,overall-low,0.2904926,rate,0.49496448,long-short-term,0.44974095
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,bias,0.3643996,overfitting,0.54791117,overfitting,0.54791117
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,assessment,0.4002061,analysis,0.5275976,component-analysis,0.49803802
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,tool,0.58027077,machine-learning,0.58027077,machine-learning,0.58027077
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,bias-assessment,0.5288885,classification-algorithm,0.601976,classification-algorithm,0.601976
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,assessment-tool,0.5553417,data-science,0.6099194,data-science,0.6099194
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,prediction,0.6361519,classification-algorithm,0.67946094,classification-algorithm,0.67946094
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,models,0.53762007,model,0.8940372,markov-model,0.7015921
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,prediction-models,0.719873,machine-learning,0.719873,machine-learning,0.719873
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,risk,0.35860935,recurrent,0.53675485,logistic-regression,0.52381086
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,assess,0.36162603,of,0.49566716,decision-tree,0.39463407
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,risk,0.35860935,recurrent,0.53675485,logistic-regression,0.52381086
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,cardiovascular,0.31674606,short-term,0.442761,learning-function,0.4027721
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,death,0.21479979,of,0.42234862,dropout,0.37818787
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,cardiovascular-death,0.3670898,learning-function,0.44179285,learning-function,0.44179285
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,prediction,0.6361519,classification-algorithm,0.67946094,classification-algorithm,0.67946094
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,publications,0.42699853,data-science,0.65373355,data-science,0.65373355
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,hf,0.293398,long-short-term,0.35116297,long-short-term,0.35116297
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,outcomes,0.38239923,short-term,0.6164659,long-short-term,0.5239928
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,assessed,0.33986524,of,0.605934,component-analysis,0.41855076
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,ranked,0.47250757,classifiers,0.5532665,classifiers,0.5532665
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,according,0.3602386,classification,0.6492659,classification,0.6492659
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,publications,0.42699853,data-science,0.65373355,data-science,0.65373355
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,non,0.2869836,of,0.5523051,generative,0.4181043
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,may,0.30907542,of,0.58654004,long-short-term,0.43985203
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,march,0.25898194,science,0.47958314,data-science,0.40582275
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,hf,0.293398,long-short-term,0.35116297,long-short-term,0.35116297
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,hospitalization,0.23343414,confusion,0.51795703,logistic-regression,0.47011706
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,hf-hospitalization,0.3093966,short-term,0.50356686,logistic-regression,0.47130394
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,rob,0.24440461,relu,0.32457215,relu,0.32457215
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,assessment,0.4002061,analysis,0.5275976,component-analysis,0.49803802
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,literature,0.42831737,data,0.58552843,data-science,0.5381381
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,databases,0.5307106,data-science,0.6526401,data-science,0.6526401
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,rob,0.24440461,relu,0.32457215,relu,0.32457215
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,registration,0.36279953,segmentation,0.4889227,segmentation,0.4889227
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,number,0.2996383,few,0.57847273,clustering,0.4387715
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,registration-number,0.48800468,segmentation-algorithm,0.57006085,segmentation-algorithm,0.57006085
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,primary,0.24268678,principal,0.5205563,long-short-term,0.38049072
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,outcomes,0.38239923,short-term,0.6164659,long-short-term,0.5239928
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,predictors,0.46376368,logistic,0.67381907,logistic-regression,0.66900885
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,included,0.34673893,of,0.58040446,component-analysis,0.47413814
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,potential,0.3558654,of,0.5645705,generative-model,0.46479023
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,utility,0.4781499,discriminative,0.54359984,feature-engineering,0.50812626
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,nyha,0.29739815,classification,0.3432895,classification,0.3432895
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,class,0.353845,multi-class,0.5162764,classification,0.4708274
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,nyha-class,0.3579088,classification,0.4558469,classification,0.4558469
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,novel,0.4652171,feature-engineering,0.5132146,feature-engineering,0.5132146
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,approaches,0.55614823,feature-engineering,0.60571706,feature-engineering,0.60571706
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,natriuretic,0.26007023,function,0.33372766,learning-function,0.3213495
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,peptide,0.3208105,encoding,0.44188768,boosting,0.35291767
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,natriuretic-peptide,0.31423682,batch-normalization,0.36770314,batch-normalization,0.36770314
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,mainly,0.24372631,of,0.6151813,clustering,0.43261412
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,due,0.21681537,of,0.5734476,confusion-matrix,0.40250766
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,justify,0.34884375,support,0.51228774,decision-tree,0.4434775
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,clinical,0.44080526,data,0.48532635,data-science,0.45343333
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,hospital,0.2768838,unit,0.588941,data-science,0.39080185
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,setting,0.34333664,decision,0.51606584,supervised,0.4146531
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,hospital-setting,0.38185513,decision-tree,0.5036858,decision-tree,0.5036858
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,heart,0.28300244,rate,0.49867767,batch-normalization,0.3427502
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,rate,0.24866687,rate,1.0,dropout,0.44953537
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,heart-rate,0.4407577,learning-rate,0.54865026,learning-rate,0.54865026
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,heart,0.28300244,rate,0.49867767,batch-normalization,0.3427502
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,failure,0.32964212,recurrent,0.52057266,confusion-matrix,0.44323406
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,heart-failure,0.36450487,long-short-term,0.44014218,long-short-term,0.44014218
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,generally,0.31490302,few,0.62595755,long-short-term,0.51732695
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,better,0.4230538,of,0.5337099,feature-reduction,0.47485045
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,economic,0.3636144,decision-tree,0.5450494,decision-tree,0.5450494
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,value,0.3544725,of,0.52001536,statistical,0.45314136
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,duplicated,0.25495446,encoding,0.5094908,segmentation,0.42386281
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,citations,0.4351179,data-science,0.63035893,data-science,0.63035893
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,composite,0.3212868,hierarchical,0.520792,hierarchical-clustering,0.4888802
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,endpoints,0.30993629,short-term,0.5226814,logistic-regression,0.44424108
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,certain,0.33025417,of,0.63117075,generative,0.50536466
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,therapies,0.3593281,engineering,0.4572313,data-engineering,0.44749197
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,cause,0.19388393,of,0.47843847,confusion-matrix,0.34079778
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,mortality,0.2609817,short-term,0.505676,logistic-regression,0.49414968
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,cause-mortality,0.3407904,logistic-regression,0.5863885,logistic-regression,0.5863885
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,validation,0.5362086,cross-validation,0.74016297,cross-validation,0.74016297
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,probast,0.3131503,of,0.40734065,recurrent-neural-network,0.36209145
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,discriminatory,0.49986887,discriminative,0.7926174,classifiers,0.5809241
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,ability,0.39144984,function,0.5937173,generative,0.47758824
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,deemed,0.33895594,decision,0.5426328,supervised,0.46045095
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,relevant,0.4346258,of,0.5628227,natural-language,0.5076148
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,conducted,0.39637828,data,0.556862,statistical,0.4670034
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,hf,0.293398,long-short-term,0.35116297,long-short-term,0.35116297
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,including,0.3233776,of,0.6619886,clustering,0.40625107
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,rob,0.24440461,relu,0.32457215,relu,0.32457215
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,identified,0.35725033,analysis,0.56593037,clustering,0.45719695
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,bias,0.3643996,overfitting,0.54791117,overfitting,0.54791117
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,relevant,0.4346258,of,0.5628227,natural-language,0.5076148
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,probast,0.3131503,of,0.40734065,recurrent-neural-network,0.36209145
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,ability,0.39144984,function,0.5937173,generative,0.47758824
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,yet,0.3648664,fully,0.6829063,generative,0.4089093
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,within,0.2920679,of,0.57602364,clustering,0.4610753
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,understand,0.38325277,feature-engineering,0.47215402,feature-engineering,0.47215402
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,total,0.21723771,of,0.5102532,principal-components,0.3630478
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,studies,0.30135098,data,0.6349237,component-analysis,0.41327482
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,sodium,0.16956227,rectified,0.40903348,gradient,0.39663744
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,slr,0.31604955,forward,0.440682,segmentation-algorithm,0.41304338
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,searched,0.4273297,science,0.52080786,data-science,0.49690884
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,robustness,0.5587801,cross-entropy,0.7043761,cross-entropy,0.7043761
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,results,0.32376552,data,0.6932311,batch-normalization,0.44826904
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,registered,0.30168146,federated,0.50540304,data-science,0.3977031
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,prospero,0.25987327,bag-of-words,0.357287,bag-of-words,0.357287
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,propose,0.5486929,convolutional,0.57577854,convolutional,0.57577854
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,predicting,0.521454,classification-algorithm,0.5589481,classification-algorithm,0.5589481
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,payers,0.38047796,decision,0.60616624,data-science,0.5631958
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,n,0.24332823,of,0.45693433,long-short-term,0.34114176
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,methods,0.50049126,data,0.5400177,machine-learning,0.50049126
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,majority,0.29875737,few,0.59443223,clustering,0.40575084
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,lack,0.28208154,of,0.6011338,long-short-term,0.4458025
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,incorporation,0.29220945,engineering,0.46341723,feature-engineering,0.43810168
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,id,0.2541087,softmax,0.41776973,softmax,0.41776973
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,extent,0.258318,of,0.64978826,dimensionality-reduction,0.43577164
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,diabetes,0.29301462,logistic-regression,0.35688502,logistic-regression,0.35688502
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,determined,0.2643224,of,0.6221287,batch-normalization,0.4203323
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,demands,0.41717237,style,0.5753275,artificial-intelligence,0.52735466
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,creatinine,0.22273314,batch-normalization,0.44722414,batch-normalization,0.44722414
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,conclusions,0.37109232,data,0.55923915,long-short-term,0.4627594
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,co,0.23682216,ground,0.42757797,feature-reduction,0.3969199
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,calibration,0.50641084,batch-normalization,0.6344988,batch-normalization,0.6344988
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,bmi,0.29358342,logistic,0.48363185,logistic-regression,0.48014313
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,based,0.49998575,classification-algorithm,0.5639226,classification-algorithm,0.5639226
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,background,0.3259285,of,0.51277274,long-short-term,0.46426663
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,application,0.46535254,data-engineering,0.5603031,data-engineering,0.5603031
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,age,0.30743492,intelligence,0.4774798,regression,0.47452933
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,adults,0.2950639,short-term,0.48601514,long-short-term,0.43684626
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,resulting,0.2720453,of,0.6416826,generative,0.46999967
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,comprehensive,0.5203603,data,0.6056672,data-engineering,0.58421016
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,volumetric,0.42083275,segmentation,0.5662037,segmentation,0.5662037
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,feature,0.5878884,feature,0.99999994,feature-selection,0.6322505
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,matrix,0.36017767,matrix,0.99999994,confusion-matrix,0.6947298
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,captures,0.5121325,stochastic,0.57588017,stochastic,0.57588017
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,diagnostic,0.47116143,classification,0.5651491,classification,0.5651491
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,clinical,0.44080526,data,0.48532635,data-science,0.45343333
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,procedure,0.37380904,data-augmentation,0.50385594,data-augmentation,0.50385594
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,data,0.46434748,data,1.0,data-science,0.5533528
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,diagnostic-clinical,0.5096397,classification-algorithm,0.5807953,classification-algorithm,0.5807953
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,cardiac,0.29562658,of,0.42777455,long-short-term,0.35708636
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,magnetic,0.35912114,few-shot,0.5247891,tensorflow,0.48732442
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,resonance,0.3709978,fourier-transform,0.5879004,fourier-transform,0.5879004
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,imaging,0.41700524,tracking,0.55048084,segmentation,0.5337068
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,provides,0.41792372,of,0.5261056,feature-engineering,0.4872959
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,high,0.267004,of,0.57459104,gradient,0.44240427
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,spatial,0.49177253,object,0.63807136,object-tracking,0.6315731
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,resolution,0.31286857,tracking,0.46759,segmentation,0.44991145
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,cardiac-magnetic,0.3852008,few-shot,0.54899335,tensorflow,0.4926487
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,magnetic-resonance,0.38880104,fourier-transform,0.60486764,fourier-transform,0.60486764
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,resonance-imaging,0.44783336,few-shot,0.59180355,fourier-transform,0.5769083
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,high-spatial,0.4917518,few-shot,0.67010194,object-tracking,0.5855648
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,spatial-resolution,0.5503999,few-shot,0.69890904,object-tracking,0.6563449
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,cardiac-magnetic-resonance,0.4126357,few-shot,0.58544767,fourier-transform,0.576841
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,magnetic-resonance-imaging,0.45447147,few-shot,0.61939245,fourier-transform,0.59741056
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,high-spatial-resolution,0.5170434,few-shot,0.72004366,segmentation,0.6122299
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,top,0.29891562,forward,0.47741628,bagging,0.40812773
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,average,0.3150683,rate,0.48881143,batch-normalization,0.44438002
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,dice,0.52186275,ground-truth,0.60934126,ground-truth,0.60934126
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,index,0.27978244,function,0.407383,classification-algorithm,0.3994653
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,scores,0.40591323,intelligence,0.56987673,principal-components,0.4971624
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,achieved,0.33526158,of,0.5726348,batch-normalization,0.47712192
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,index-scores,0.41410083,classification-algorithm,0.5433916,classification-algorithm,0.5433916
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,robust,0.50920165,hierarchical,0.6267712,hierarchical-clustering,0.6142049
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,dilated,0.22810468,function,0.40786004,confusion-matrix,0.32808268
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,convolutional,0.77214557,convolutional,1.0,convolutional,1.0
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,neural,0.5080686,neural,1.0,neural-network,0.7153882
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,network,0.50771487,network,1.0,neural-network,0.7589166
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,architecture,0.48544616,network,0.66117644,feature-engineering,0.65043306
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,neural-network,0.7034505,neural-network,1.0,neural-network,1.0
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,network-architecture,0.60374427,network,0.8268081,neural-network,0.77438855
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,approach,0.5412675,segmentation-algorithm,0.6046611,segmentation-algorithm,0.6046611
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,evaluated,0.35501102,of,0.6190806,supervised,0.4124783
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,anonymized,0.46234396,data,0.6066266,data-science,0.55255294
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,cardiac,0.29562658,of,0.42777455,long-short-term,0.35708636
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,images,0.46598992,segmentation,0.6703193,segmentation,0.6703193
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,cardiac,0.29562658,of,0.42777455,long-short-term,0.35708636
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,cine,0.4256821,segmentation,0.5653922,segmentation,0.5653922
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,sequencing,0.46356243,analysis,0.5534786,machine-learning,0.46356243
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,provides,0.41792372,of,0.5261056,feature-engineering,0.4872959
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,reproducible,0.4221531,batch-normalization,0.49679825,batch-normalization,0.49679825
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,cardiac,0.29562658,of,0.42777455,long-short-term,0.35708636
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,pathological,0.35600212,of,0.48665273,classification,0.46512192
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,assessment,0.4002061,analysis,0.5275976,component-analysis,0.49803802
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,advanced,0.4209618,of,0.47114033,machine-learning,0.4209618
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,machine,0.7094662,machine,1.0,machine-learning,0.7094662
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,learning,0.709237,learning,1.0,deep-learning,0.8286492
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,methods,0.50049126,data,0.5400177,machine-learning,0.50049126
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,machine-learning,1.0,machine-learning,1.0,machine-learning,1.0
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,fully,0.35142052,fully,1.0,fully-connected,0.479315
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,automatic,0.6066911,graphics-processing,0.6762357,graphics-processing,0.6762357
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,processing,0.46109343,processing,1.0,graphics-processing,0.75397617
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,pipeline,0.6340066,machine-learning,0.6340066,machine-learning,0.6340066
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,fully-automatic,0.6691327,segmentation-algorithm,0.7182019,segmentation-algorithm,0.7182019
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,automatic-processing,0.6478294,graphics-processing,0.8677411,graphics-processing,0.8677411
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,independent,0.39991486,of,0.5904635,regression,0.57876456
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,test,0.4037762,statistical,0.5031551,statistical,0.5031551
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,set,0.5244544,of,0.5846941,classifiers,0.5500933
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,using,0.47332245,analysis,0.5968549,component-analysis,0.526608
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,independent-test,0.5318514,logistic-regression,0.6908941,logistic-regression,0.6908941
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,test-set,0.4657093,cross-validation,0.5603128,cross-validation,0.5603128
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,initial,0.31501165,of,0.6574379,batch-normalization,0.5031359
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,processing,0.46109343,processing,1.0,graphics-processing,0.75397617
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,element,0.30212426,component,0.47262436,component-analysis,0.46868354
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,consists,0.2985474,of,0.54870045,fully-connected,0.47400513
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,ary,0.28084993,confusion,0.5037112,generative,0.3960401
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,pathology,0.34800982,of,0.4805,generative-model,0.43246388
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,classification,0.5994266,classification,1.0,classification,1.0
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,accuracy,0.5511073,cross-validation,0.64088035,cross-validation,0.64088035
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,patients,0.30007,recurrent,0.5332828,dropout,0.3918751
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,per,0.22352321,unit,0.5148517,supervised,0.33758792
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,group,0.26103544,of,0.44356787,statistical,0.3923795
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,per-group,0.41011247,statistical,0.56719226,statistical,0.56719226
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,training,0.54553735,learning,0.69909495,supervised,0.6973169
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,data,0.46434748,data,1.0,data-science,0.5533528
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,set,0.5244544,of,0.5846941,classifiers,0.5500933
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,training-data,0.65902066,learning-rate,0.713682,learning-rate,0.713682
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,data-set,0.6032697,data,0.7093594,data-science,0.6625358
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,training-data-set,0.6780228,learning-rate,0.6946944,learning-rate,0.6946944
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,cardiac,0.29562658,of,0.42777455,long-short-term,0.35708636
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,pathology,0.34800982,of,0.4805,generative-model,0.43246388
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,classifier,0.7923145,classifiers,0.9369072,classifiers,0.9369072
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,quantify,0.41074482,tracking,0.5184422,stochastic,0.46153936
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,cardiac,0.29562658,of,0.42777455,long-short-term,0.35708636
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,measures,0.3789752,principal-components,0.5349536,principal-components,0.5349536
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,manual,0.48911166,computer-vision,0.57726485,computer-vision,0.57726485
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,cardiac,0.29562658,of,0.42777455,long-short-term,0.35708636
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,evaluation,0.39017528,analysis,0.5728766,component-analysis,0.5049392
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,final,0.2900907,of,0.54912525,statistical,0.42519492
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,processing,0.46109343,processing,1.0,graphics-processing,0.75397617
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,element,0.30212426,component,0.47262436,component-analysis,0.46868354
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,healthy,0.31399268,naive,0.5051062,artificial-intelligence,0.3681498
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,group,0.26103544,of,0.44356787,statistical,0.3923795
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,healthy-group,0.3484077,style,0.47613317,natural-language-processing,0.42974564
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,rv,0.21948624,support-vector,0.35124844,support-vector,0.35124844
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,respectively,0.23184536,of,0.43360457,cross-validation,0.35765702
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,performance,0.50728506,learning-function,0.63351834,learning-function,0.63351834
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,results,0.32376552,data,0.6932311,batch-normalization,0.44826904
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,demonstrate,0.37134898,of,0.5097414,feature-engineering,0.4652517
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,results-demonstrate,0.45842522,data,0.60937816,dimensionality-reduction,0.53237516
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,enabling,0.46592075,feature-engineering,0.6214503,feature-engineering,0.6214503
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,improved,0.40049985,normalization,0.5598826,boosting,0.5069493
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,extraction,0.414975,batch-normalization,0.5036997,batch-normalization,0.5036997
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,pathology,0.34800982,of,0.4805,generative-model,0.43246388
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,groups,0.2727722,statistical,0.4438421,statistical,0.4438421
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,cardiovascular,0.31674606,short-term,0.442761,learning-function,0.4027721
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,disease,0.296938,recurrent,0.4731025,classification,0.35271814
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,staging,0.4282661,classification,0.6301632,classification,0.6301632
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,cardiovascular-disease,0.39733815,logistic-regression,0.43556237,logistic-regression,0.43556237
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,disease-staging,0.43390074,classification-algorithm,0.48105857,classification-algorithm,0.48105857
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,lv,0.2556107,tensorflow,0.3751968,tensorflow,0.3751968
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,myocardium,0.2283036,function,0.3991398,segmentation,0.3548869
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,combining,0.54477555,feature-engineering,0.60671854,feature-engineering,0.60671854
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,semantic,0.6095071,semantic,1.0,semantic,1.0
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,segmentation,0.62158525,segmentation,1.0,segmentation,1.0
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,patients,0.30007,recurrent,0.5332828,dropout,0.3918751
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,disease,0.296938,recurrent,0.4731025,classification,0.35271814
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,classification,0.5994266,classification,1.0,classification,1.0
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,disease-classification,0.6227312,classification,0.8231561,classification,0.8231561
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,wise,0.42522556,decision,0.5402862,bagging,0.49406698
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,segmentation,0.62158525,segmentation,1.0,segmentation,1.0
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,ventricular,0.24852064,rate,0.37094042,long-short-term,0.34148398
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,cavities,0.26235616,layer,0.48358744,fully-connected,0.48017
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,university,0.39088657,science,0.60339034,data-science,0.5440467
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,hospital,0.2768838,unit,0.588941,data-science,0.39080185
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,university-hospital,0.41749215,data-science,0.5646092,data-science,0.5646092
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,structure,0.3356646,hierarchical,0.5517567,hierarchical-clustering,0.5486842
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,segmentation,0.62158525,segmentation,1.0,segmentation,1.0
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,right,0.24704936,confusion,0.43681273,segmentation,0.36243528
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,ventricle,0.20552546,segmentation,0.33557552,segmentation,0.33557552
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,right-ventricle,0.28284913,learning-function,0.38180315,learning-function,0.38180315
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,observer,0.49416912,ground-truth,0.6332816,ground-truth,0.6332816
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,bias,0.3643996,overfitting,0.54791117,overfitting,0.54791117
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,observer-bias,0.5442112,cross-entropy,0.67847157,cross-entropy,0.67847157
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,morphological,0.38724077,feature,0.5468423,generative,0.5159291
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,features,0.51742536,feature,0.8268872,feature-selection,0.5487305
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,left,0.2544507,tracking,0.42924023,object-tracking,0.3633091
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,ventricle,0.20552546,segmentation,0.33557552,segmentation,0.33557552
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,left-ventricle,0.2691546,batch-normalization,0.40726915,batch-normalization,0.40726915
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,important,0.33620566,principal,0.5803634,feature-engineering,0.43471682
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,functional,0.3902081,function,0.728652,learning-function,0.5807885
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,ejection,0.30230433,function,0.43955976,gradient,0.35697576
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,fraction,0.25137818,component,0.50911963,gradient,0.48876822
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,ejection-fraction,0.36681443,stochastic-gradient,0.5523829,stochastic-gradient,0.5523829
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,deliver,0.37858978,boosting,0.51354825,boosting,0.51354825
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,accurate,0.50905025,algorithm,0.5474155,algorithm,0.5474155
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,trained,0.56898797,supervised,0.69370055,supervised,0.69370055
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,model,0.48485535,model,1.0,markov-model,0.7005576
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,segmentation,0.62158525,segmentation,1.0,segmentation,1.0
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,myocardium,0.2283036,function,0.3991398,segmentation,0.3548869
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,model,0.48485535,model,1.0,markov-model,0.7005576
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,voxel,0.4538867,ground-truth,0.5924628,ground-truth,0.5924628
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,utilized,0.48087895,of,0.59412074,feature-engineering,0.5390619
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,recorded,0.299657,rectified,0.55581653,computer-vision,0.443301
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,presented,0.41586217,of,0.5919795,confusion-matrix,0.4850164
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,potential,0.3558654,of,0.5645705,generative-model,0.46479023
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,method,0.482283,algorithm,0.63295126,algorithm,0.63295126
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,expense,0.27034575,reduction,0.5199926,generative,0.4742434
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,examined,0.295101,of,0.66699874,generative,0.4320032
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,efficient,0.44278914,feature-engineering,0.5657042,feature-engineering,0.5657042
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,dijon,0.2800066,federated,0.44586384,data-science,0.3570836
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,curtails,0.20899647,reduction,0.5070071,boosting,0.46634346
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,basis,0.43144745,of,0.5813806,classification,0.53126585
Physiological Assessment of Coronary Lesions in 2020.,term,0.33795053,term,1.0,long-short-term,0.62770975
Physiological Assessment of Coronary Lesions in 2020.,data,0.46434748,data,1.0,data-science,0.5533528
Physiological Assessment of Coronary Lesions in 2020.,demonstrating,0.32530028,of,0.67624867,generative,0.46174815
Physiological Assessment of Coronary Lesions in 2020.,improved,0.40049985,normalization,0.5598826,boosting,0.5069493
Physiological Assessment of Coronary Lesions in 2020.,outcomes,0.38239923,short-term,0.6164659,long-short-term,0.5239928
Physiological Assessment of Coronary Lesions in 2020.,determine,0.3371361,of,0.55401844,regression,0.40314794
Physiological Assessment of Coronary Lesions in 2020.,lesion,0.29133987,segmentation,0.43485674,segmentation,0.43485674
Physiological Assessment of Coronary Lesions in 2020.,functional,0.3902081,function,0.728652,learning-function,0.5807885
Physiological Assessment of Coronary Lesions in 2020.,significance,0.39249778,statistical,0.67423874,statistical,0.67423874
Physiological Assessment of Coronary Lesions in 2020.,functional-significance,0.5965787,statistical,0.6878141,statistical,0.6878141
Physiological Assessment of Coronary Lesions in 2020.,beyond,0.34655812,of,0.53781354,dimensionality-reduction,0.42561156
Physiological Assessment of Coronary Lesions in 2020.,fractional,0.33375564,tensorflow,0.5310539,tensorflow,0.5310539
Physiological Assessment of Coronary Lesions in 2020.,flow,0.2860778,gradient,0.52486,gradient,0.52486
Physiological Assessment of Coronary Lesions in 2020.,reserve,0.29258314,function,0.5072979,long-short-term,0.3666694
Physiological Assessment of Coronary Lesions in 2020.,fractional-flow,0.46620142,stochastic-gradient,0.6700879,stochastic-gradient,0.6700879
Physiological Assessment of Coronary Lesions in 2020.,flow-reserve,0.29431742,tensorflow,0.46672893,tensorflow,0.46672893
Physiological Assessment of Coronary Lesions in 2020.,fractional-flow-reserve,0.4394424,stochastic-gradient,0.629344,stochastic-gradient,0.629344
Physiological Assessment of Coronary Lesions in 2020.,ffrct,0.4549108,ground-truth,0.5213028,ground-truth,0.5213028
Physiological Assessment of Coronary Lesions in 2020.,invasive,0.27886397,recurrent,0.44204783,confusion-matrix,0.3438056
Physiological Assessment of Coronary Lesions in 2020.,angiography,0.28203487,segmentation,0.4276855,segmentation,0.4276855
Physiological Assessment of Coronary Lesions in 2020.,guided,0.44118792,tracking,0.5554749,generative,0.48707482
Physiological Assessment of Coronary Lesions in 2020.,percutaneous,0.26580995,short-term,0.41344544,data-augmentation,0.38650423
Physiological Assessment of Coronary Lesions in 2020.,coronary,0.25158757,of,0.3349695,segmentation-algorithm,0.31949025
Physiological Assessment of Coronary Lesions in 2020.,intervention,0.350297,supervised,0.5352158,supervised,0.5352158
Physiological Assessment of Coronary Lesions in 2020.,guided-percutaneous,0.39286777,transfer-learning,0.45905107,transfer-learning,0.45905107
Physiological Assessment of Coronary Lesions in 2020.,percutaneous-coronary,0.2850216,augmentation,0.4207856,data-augmentation,0.3907336
Physiological Assessment of Coronary Lesions in 2020.,coronary-intervention,0.37353748,logistic-regression,0.46325302,logistic-regression,0.46325302
Physiological Assessment of Coronary Lesions in 2020.,percutaneous-coronary-intervention,0.37004828,data-augmentation,0.46930572,data-augmentation,0.46930572
Physiological Assessment of Coronary Lesions in 2020.,evaluating,0.4632738,of,0.6040422,component-analysis,0.51576006
Physiological Assessment of Coronary Lesions in 2020.,coronary,0.25158757,of,0.3349695,segmentation-algorithm,0.31949025
Physiological Assessment of Coronary Lesions in 2020.,stenosis,0.2649675,recurrent,0.46872523,gradient,0.42727166
Physiological Assessment of Coronary Lesions in 2020.,physiology,0.34364453,function,0.6008383,learning-function,0.4614325
Physiological Assessment of Coronary Lesions in 2020.,coronary-stenosis,0.27483904,segmentation-algorithm,0.4207997,segmentation-algorithm,0.4207997
Physiological Assessment of Coronary Lesions in 2020.,coronary,0.25158757,of,0.3349695,segmentation-algorithm,0.31949025
Physiological Assessment of Coronary Lesions in 2020.,physiological,0.3332913,function,0.550024,learning-function,0.4524702
Physiological Assessment of Coronary Lesions in 2020.,assessment,0.4002061,analysis,0.5275976,component-analysis,0.49803802
Physiological Assessment of Coronary Lesions in 2020.,remains,0.24202663,fully,0.5171005,bagging,0.35608193
Physiological Assessment of Coronary Lesions in 2020.,assessment-remains,0.42391506,intelligence,0.5429003,data-science,0.51249754
Physiological Assessment of Coronary Lesions in 2020.,invasive,0.27886397,recurrent,0.44204783,confusion-matrix,0.3438056
Physiological Assessment of Coronary Lesions in 2020.,coronary,0.25158757,of,0.3349695,segmentation-algorithm,0.31949025
Physiological Assessment of Coronary Lesions in 2020.,ct,0.30965078,computer,0.4188078,ground-truth,0.40364322
Physiological Assessment of Coronary Lesions in 2020.,coronary-ct,0.2942065,segmentation-algorithm,0.40550995,segmentation-algorithm,0.40550995
Physiological Assessment of Coronary Lesions in 2020.,coronary,0.25158757,of,0.3349695,segmentation-algorithm,0.31949025
Physiological Assessment of Coronary Lesions in 2020.,physiological,0.3332913,function,0.550024,learning-function,0.4524702
Physiological Assessment of Coronary Lesions in 2020.,assessment,0.4002061,analysis,0.5275976,component-analysis,0.49803802
Physiological Assessment of Coronary Lesions in 2020.,coronary,0.25158757,of,0.3349695,segmentation-algorithm,0.31949025
Physiological Assessment of Coronary Lesions in 2020.,artery,0.24677014,augmentation,0.4092986,regression,0.358252
Physiological Assessment of Coronary Lesions in 2020.,disease,0.296938,recurrent,0.4731025,classification,0.35271814
Physiological Assessment of Coronary Lesions in 2020.,coronary-artery,0.26203495,short-term,0.35952243,segmentation-algorithm,0.3447641
Physiological Assessment of Coronary Lesions in 2020.,artery-disease,0.37250388,logistic-regression,0.45708418,logistic-regression,0.45708418
Physiological Assessment of Coronary Lesions in 2020.,coronary-artery-disease,0.34540182,logistic-regression,0.40786052,logistic-regression,0.40786052
Physiological Assessment of Coronary Lesions in 2020.,acute,0.21222305,short-term,0.51624244,long-short-term,0.3867746
Physiological Assessment of Coronary Lesions in 2020.,coronary,0.25158757,of,0.3349695,segmentation-algorithm,0.31949025
Physiological Assessment of Coronary Lesions in 2020.,syndromes,0.28148353,recurrent,0.4603182,confusion-matrix,0.40664154
Physiological Assessment of Coronary Lesions in 2020.,acute-coronary,0.2686993,confusion-matrix,0.37422916,confusion-matrix,0.37422916
Physiological Assessment of Coronary Lesions in 2020.,acute-coronary-syndromes,0.3136798,confusion-matrix,0.4491312,confusion-matrix,0.4491312
Physiological Assessment of Coronary Lesions in 2020.,technical,0.42449474,data-engineering,0.5428559,data-engineering,0.5428559
Physiological Assessment of Coronary Lesions in 2020.,aspects,0.38811684,components,0.5821936,feature-engineering,0.5173804
Physiological Assessment of Coronary Lesions in 2020.,involved,0.26651675,of,0.5396308,feed-forward,0.42281044
Physiological Assessment of Coronary Lesions in 2020.,rest,0.30493355,short,0.50681746,supervised,0.47476995
Physiological Assessment of Coronary Lesions in 2020.,without,0.31691062,of,0.5951073,long-short-term,0.4268921
Physiological Assessment of Coronary Lesions in 2020.,hyperemia,0.22010125,vision,0.40469524,dropout,0.36308688
Physiological Assessment of Coronary Lesions in 2020.,residual,0.28154147,of,0.55126905,batch-normalization,0.41545758
Physiological Assessment of Coronary Lesions in 2020.,ischemia,0.24609071,normalization,0.40115163,long-short-term,0.36769903
Physiological Assessment of Coronary Lesions in 2020.,post,0.27536392,confusion,0.47820356,bagging,0.44161102
Physiological Assessment of Coronary Lesions in 2020.,optical,0.41040304,fourier-transform,0.63333535,fourier-transform,0.63333535
Physiological Assessment of Coronary Lesions in 2020.,coherence,0.39348912,regularization,0.5546586,cross-entropy,0.53685623
Physiological Assessment of Coronary Lesions in 2020.,tomography,0.37376836,computer,0.48697567,segmentation,0.4668427
Physiological Assessment of Coronary Lesions in 2020.,optical-coherence,0.45506707,few-shot,0.6808274,fourier,0.63143253
Physiological Assessment of Coronary Lesions in 2020.,coherence-tomography,0.51663184,ground-truth,0.6277213,ground-truth,0.6277213
Physiological Assessment of Coronary Lesions in 2020.,optical-coherence-tomography,0.5078306,few-shot,0.69420284,convolutional-layer,0.6391543
Physiological Assessment of Coronary Lesions in 2020.,interventional,0.38382417,decision,0.50072825,supervised,0.48652557
Physiological Assessment of Coronary Lesions in 2020.,cardiology,0.36460787,data-science,0.5008054,data-science,0.5008054
Physiological Assessment of Coronary Lesions in 2020.,toolbox,0.58276075,data-engineering,0.65363467,data-engineering,0.65363467
Physiological Assessment of Coronary Lesions in 2020.,improve,0.45207965,boosting,0.5098576,boosting,0.5098576
Physiological Assessment of Coronary Lesions in 2020.,patient,0.2998137,confusion,0.5356896,confusion-matrix,0.41404122
Physiological Assessment of Coronary Lesions in 2020.,care,0.3144728,decision,0.58130515,data-science,0.46943653
Physiological Assessment of Coronary Lesions in 2020.,improve-patient,0.45880362,confusion,0.5682962,batch-normalization,0.5205523
Physiological Assessment of Coronary Lesions in 2020.,patient-care,0.42835277,decision,0.5498397,data-science,0.51768845
Physiological Assessment of Coronary Lesions in 2020.,hyperemic,0.21825886,augmentation,0.3841874,convolutional-layer,0.37207556
Physiological Assessment of Coronary Lesions in 2020.,pressure,0.2060274,gradient,0.4962673,gradient,0.4962673
Physiological Assessment of Coronary Lesions in 2020.,ratios,0.18493193,rate,0.42238456,regression,0.41522446
Physiological Assessment of Coronary Lesions in 2020.,exciting,0.40806,engineering,0.5904034,data-engineering,0.58520335
Physiological Assessment of Coronary Lesions in 2020.,technological,0.50801206,data-engineering,0.7099455,data-engineering,0.7099455
Physiological Assessment of Coronary Lesions in 2020.,future,0.42505926,data-engineering,0.5647982,data-engineering,0.5647982
Physiological Assessment of Coronary Lesions in 2020.,enable,0.48487508,feature-engineering,0.6139262,feature-engineering,0.6139262
Physiological Assessment of Coronary Lesions in 2020.,detailed,0.4132024,data,0.659509,data-engineering,0.52353954
Physiological Assessment of Coronary Lesions in 2020.,pre,0.25544113,confusion,0.45880464,supervised,0.38061306
Physiological Assessment of Coronary Lesions in 2020.,artificial,0.4622418,artificial,1.0,artificial-intelligence,0.6597898
Physiological Assessment of Coronary Lesions in 2020.,intelligence,0.5350207,intelligence,0.99999994,artificial-intelligence,0.8106787
Physiological Assessment of Coronary Lesions in 2020.,algorithms,0.7612198,algorithm,0.9050166,algorithm,0.9050166
Physiological Assessment of Coronary Lesions in 2020.,artificial-intelligence,0.64611053,artificial-intelligence,1.0,artificial-intelligence,1.0
Physiological Assessment of Coronary Lesions in 2020.,alternative,0.40815938,selection,0.5193968,feature-reduction,0.51698333
Physiological Assessment of Coronary Lesions in 2020.,ffr,0.32875013,ground-truth,0.4316448,ground-truth,0.4316448
Physiological Assessment of Coronary Lesions in 2020.,approaches,0.55614823,feature-engineering,0.60571706,feature-engineering,0.60571706
Physiological Assessment of Coronary Lesions in 2020.,assess,0.36162603,of,0.49566716,decision-tree,0.39463407
Physiological Assessment of Coronary Lesions in 2020.,coronary,0.25158757,of,0.3349695,segmentation-algorithm,0.31949025
Physiological Assessment of Coronary Lesions in 2020.,physiology,0.34364453,function,0.6008383,learning-function,0.4614325
Physiological Assessment of Coronary Lesions in 2020.,refine,0.5651985,machine-learning,0.5651985,machine-learning,0.5651985
Physiological Assessment of Coronary Lesions in 2020.,clinical,0.44080526,data,0.48532635,data-science,0.45343333
Physiological Assessment of Coronary Lesions in 2020.,practice,0.50552624,decision,0.59237766,data-science,0.5843962
Physiological Assessment of Coronary Lesions in 2020.,clinical-practice,0.5274042,data-science,0.57205796,data-science,0.57205796
Physiological Assessment of Coronary Lesions in 2020.,ffr,0.32875013,ground-truth,0.4316448,ground-truth,0.4316448
Physiological Assessment of Coronary Lesions in 2020.,non,0.2869836,of,0.5523051,generative,0.4181043
Physiological Assessment of Coronary Lesions in 2020.,physiological,0.3332913,function,0.550024,learning-function,0.4524702
Physiological Assessment of Coronary Lesions in 2020.,assessment,0.4002061,analysis,0.5275976,component-analysis,0.49803802
Physiological Assessment of Coronary Lesions in 2020.,coronary,0.25158757,of,0.3349695,segmentation-algorithm,0.31949025
Physiological Assessment of Coronary Lesions in 2020.,physiology,0.34364453,function,0.6008383,learning-function,0.4614325
Physiological Assessment of Coronary Lesions in 2020.,remains,0.24202663,fully,0.5171005,bagging,0.35608193
Physiological Assessment of Coronary Lesions in 2020.,underutilized,0.39705396,hidden,0.45796257,data-engineering,0.4374687
Physiological Assessment of Coronary Lesions in 2020.,ffroct,0.34635532,ground-truth,0.5418042,ground-truth,0.5418042
Physiological Assessment of Coronary Lesions in 2020.,ffrangio,0.35094407,ground-truth,0.5328435,ground-truth,0.5328435
Physiological Assessment of Coronary Lesions in 2020.,current,0.3530666,rectified,0.52906346,generative-model,0.40904555
Physiological Assessment of Coronary Lesions in 2020.,practice,0.50552624,decision,0.59237766,data-science,0.5843962
Physiological Assessment of Coronary Lesions in 2020.,current-practice,0.47616035,artificial-intelligence,0.57868874,artificial-intelligence,0.57868874
Physiological Assessment of Coronary Lesions in 2020.,clinical,0.44080526,data,0.48532635,data-science,0.45343333
Physiological Assessment of Coronary Lesions in 2020.,scenarios,0.48046267,random-forest,0.57221806,random-forest,0.57221806
Physiological Assessment of Coronary Lesions in 2020.,clinical-scenarios,0.5765663,decision-tree,0.58770037,decision-tree,0.58770037
Physiological Assessment of Coronary Lesions in 2020.,well,0.34264985,of,0.59718275,bagging,0.4145819
Physiological Assessment of Coronary Lesions in 2020.,established,0.40618747,of,0.60100454,classification,0.47434023
Physiological Assessment of Coronary Lesions in 2020.,well-established,0.4767154,model,0.5686673,generative-model,0.56675625
Physiological Assessment of Coronary Lesions in 2020.,serial,0.32573372,normalization,0.55320406,batch-normalization,0.499547
Physiological Assessment of Coronary Lesions in 2020.,lesions,0.32295382,recurrent,0.46750677,segmentation,0.40412176
Physiological Assessment of Coronary Lesions in 2020.,robust,0.50920165,hierarchical,0.6267712,hierarchical-clustering,0.6142049
Physiological Assessment of Coronary Lesions in 2020.,tools,0.65752256,data-engineering,0.6720511,data-engineering,0.6720511
Physiological Assessment of Coronary Lesions in 2020.,related,0.30849367,of,0.6150687,clustering,0.41455543
Physiological Assessment of Coronary Lesions in 2020.,arteries,0.2030431,augmentation,0.39080167,segmentation,0.35854268
Physiological Assessment of Coronary Lesions in 2020.,recent,0.35249484,of,0.545993,data-engineering,0.4259707
Physiological Assessment of Coronary Lesions in 2020.,findings,0.35685748,data,0.65714294,component-analysis,0.38599753
Physiological Assessment of Coronary Lesions in 2020.,left,0.2544507,tracking,0.42924023,object-tracking,0.3633091
Physiological Assessment of Coronary Lesions in 2020.,main,0.3070703,principal,0.7875631,principal-components,0.51314574
Physiological Assessment of Coronary Lesions in 2020.,left-main,0.31685337,semantic,0.45114893,semantic,0.45114893
Physiological Assessment of Coronary Lesions in 2020.,latest,0.3843079,data,0.52763456,data-science,0.45281935
Physiological Assessment of Coronary Lesions in 2020.,developments,0.44840753,data-engineering,0.62717235,data-engineering,0.62717235
Physiological Assessment of Coronary Lesions in 2020.,indispensable,0.33267903,function,0.51005954,feature-engineering,0.4509773
Physiological Assessment of Coronary Lesions in 2020.,tool,0.58027077,machine-learning,0.58027077,machine-learning,0.58027077
Physiological Assessment of Coronary Lesions in 2020.,including,0.3233776,of,0.6619886,clustering,0.40625107
Physiological Assessment of Coronary Lesions in 2020.,non,0.2869836,of,0.5523051,generative,0.4181043
Physiological Assessment of Coronary Lesions in 2020.,essential,0.28451368,components,0.5479382,component-analysis,0.4103359
Physiological Assessment of Coronary Lesions in 2020.,component,0.29999307,component,1.0,principal-component,0.687786
Physiological Assessment of Coronary Lesions in 2020.,especially,0.32290015,of,0.63661283,long-short-term,0.46837103
Physiological Assessment of Coronary Lesions in 2020.,helpful,0.36611858,decision,0.4478773,confusion-matrix,0.4255041
Physiological Assessment of Coronary Lesions in 2020.,despite,0.27514282,few,0.5803892,long-short-term,0.43284553
Physiological Assessment of Coronary Lesions in 2020.,long,0.20028201,long,1.0,long-short-term,0.6505779
Physiological Assessment of Coronary Lesions in 2020.,catheterization,0.2943902,bag,0.40318906,batch-normalization,0.37907535
Physiological Assessment of Coronary Lesions in 2020.,laboratory,0.36435357,data,0.49052244,batch-normalization,0.46476662
Physiological Assessment of Coronary Lesions in 2020.,catheterization-laboratory,0.4476415,batch-normalization,0.5541384,batch-normalization,0.5541384
Physiological Assessment of Coronary Lesions in 2020.,also,0.32850838,of,0.65908813,clustering,0.45826355
Physiological Assessment of Coronary Lesions in 2020.,emerging,0.45052218,feature-engineering,0.5309333,feature-engineering,0.5309333
Physiological Assessment of Coronary Lesions in 2020.,additional,0.35377294,of,0.63162684,feature-reduction,0.4511183
Physiological Assessment of Coronary Lesions in 2020.,advances,0.45830926,data-engineering,0.5886656,data-engineering,0.5886656
Physiological Assessment of Coronary Lesions in 2020.,stable,0.23790932,transfer,0.47683778,bagging,0.37850022
Physiological Assessment of Coronary Lesions in 2020.,cad,0.39436132,machine,0.41960585,machine-learning,0.39436132
Physiological Assessment of Coronary Lesions in 2020.,stable-cad,0.3591835,support-vector-machine,0.47098196,support-vector-machine,0.47098196
Physiological Assessment of Coronary Lesions in 2020.,multivessel,0.36372745,logistic,0.41827607,logistic-regression,0.41300714
Physiological Assessment of Coronary Lesions in 2020.,cad,0.39436132,machine,0.41960585,machine-learning,0.39436132
Physiological Assessment of Coronary Lesions in 2020.,multivessel-cad,0.39261997,segmentation-algorithm,0.47987887,segmentation-algorithm,0.47987887
Physiological Assessment of Coronary Lesions in 2020.,review,0.41215214,data,0.5581161,data-science,0.47600204
Physiological Assessment of Coronary Lesions in 2020.,outlines,0.46365082,data-engineering,0.5532028,data-engineering,0.5532028
Physiological Assessment of Coronary Lesions in 2020.,physiology,0.34364453,function,0.6008383,learning-function,0.4614325
Physiological Assessment of Coronary Lesions in 2020.,intervention,0.350297,supervised,0.5352158,supervised,0.5352158
Physiological Assessment of Coronary Lesions in 2020.,non,0.2869836,of,0.5523051,generative,0.4181043
Physiological Assessment of Coronary Lesions in 2020.,cad,0.39436132,machine,0.41960585,machine-learning,0.39436132
Physiological Assessment of Coronary Lesions in 2020.,review,0.41215214,data,0.5581161,data-science,0.47600204
Physiological Assessment of Coronary Lesions in 2020.,virtual,0.5364634,computer,0.6670566,computer-vision,0.61284316
Physiological Assessment of Coronary Lesions in 2020.,today,0.31416783,confusion,0.5164013,bagging,0.44597396
Physiological Assessment of Coronary Lesions in 2020.,realized,0.4078693,connected,0.5841261,dimensionality-reduction,0.57203305
Physiological Assessment of Coronary Lesions in 2020.,purpose,0.4149922,of,0.5072116,feature-engineering,0.43333688
Physiological Assessment of Coronary Lesions in 2020.,procedure,0.37380904,data-augmentation,0.50385594,data-augmentation,0.50385594
Physiological Assessment of Coronary Lesions in 2020.,pci,0.27945596,transfer,0.3493846,vector-machine,0.33855107
Physiological Assessment of Coronary Lesions in 2020.,nhpr,0.20858274,tfidf,0.3621239,tfidf,0.3621239
Physiological Assessment of Coronary Lesions in 2020.,infarct,0.17899722,normalization,0.35862643,confusion-matrix,0.35025
Physiological Assessment of Coronary Lesions in 2020.,indications,0.32133296,of,0.52539456,classification,0.4246995
Physiological Assessment of Coronary Lesions in 2020.,however,0.31437585,few,0.63182676,statistical,0.44065386
Physiological Assessment of Coronary Lesions in 2020.,focusing,0.39624733,generative-model,0.558784,generative-model,0.558784
Physiological Assessment of Coronary Lesions in 2020.,field,0.3582328,forward,0.4830246,generative-model,0.46159878
Physiological Assessment of Coronary Lesions in 2020.,benefits,0.41087294,short-term,0.59437555,long-short-term,0.5303442
Physiological Assessment of Coronary Lesions in 2020.,addition,0.30500388,of,0.6910241,feature-reduction,0.48914018
Physiological Assessment of Coronary Lesions in 2020.,abound,0.37412956,few,0.6173513,generative,0.5185565
Of Machines and Men: Intelligent Diagnosis and the Shape of Things to Come.,ai,0.25513044,artificial-intelligence,0.38274616,artificial-intelligence,0.38274616
Of Machines and Men: Intelligent Diagnosis and the Shape of Things to Come.,although,0.29321635,few,0.63117087,long-short-term,0.46243888
Of Machines and Men: Intelligent Diagnosis and the Shape of Things to Come.,well,0.34264985,of,0.59718275,bagging,0.4145819
Of Machines and Men: Intelligent Diagnosis and the Shape of Things to Come.,established,0.40618747,of,0.60100454,classification,0.47434023
Of Machines and Men: Intelligent Diagnosis and the Shape of Things to Come.,well-established,0.4767154,model,0.5686673,generative-model,0.56675625
Of Machines and Men: Intelligent Diagnosis and the Shape of Things to Come.,editorial,0.343749,science,0.61768115,data-science,0.5612227
Of Machines and Men: Intelligent Diagnosis and the Shape of Things to Come.,review,0.41215214,data,0.5581161,data-science,0.47600204
Of Machines and Men: Intelligent Diagnosis and the Shape of Things to Come.,highlights,0.39811388,of,0.5411649,feature-engineering,0.53502977
Of Machines and Men: Intelligent Diagnosis and the Shape of Things to Come.,progress,0.36981016,confusion,0.49840045,data-engineering,0.47150356
Of Machines and Men: Intelligent Diagnosis and the Shape of Things to Come.,common,0.32574984,feature,0.5597373,clustering,0.43115532
Of Machines and Men: Intelligent Diagnosis and the Shape of Things to Come.,clinical,0.44080526,data,0.48532635,data-science,0.45343333
Of Machines and Men: Intelligent Diagnosis and the Shape of Things to Come.,conditions,0.21472734,short-term,0.4503411,feature-reduction,0.43574768
Of Machines and Men: Intelligent Diagnosis and the Shape of Things to Come.,many,0.40940517,few,0.752018,feature-engineering,0.48454586
Of Machines and Men: Intelligent Diagnosis and the Shape of Things to Come.,areas,0.3090546,forest,0.4990691,ground-truth,0.40763968
Of Machines and Men: Intelligent Diagnosis and the Shape of Things to Come.,everyday,0.49276018,natural-language,0.62514055,natural-language,0.62514055
Of Machines and Men: Intelligent Diagnosis and the Shape of Things to Come.,life,0.3004927,style,0.49334684,long-short-term,0.46358624
Of Machines and Men: Intelligent Diagnosis and the Shape of Things to Come.,everyday-life,0.43990186,style,0.6166811,artificial-intelligence,0.60805416
Of Machines and Men: Intelligent Diagnosis and the Shape of Things to Come.,artificial,0.4622418,artificial,1.0,artificial-intelligence,0.6597898
Of Machines and Men: Intelligent Diagnosis and the Shape of Things to Come.,intelligence,0.5350207,intelligence,0.99999994,artificial-intelligence,0.8106787
Of Machines and Men: Intelligent Diagnosis and the Shape of Things to Come.,artificial-intelligence,0.64611053,artificial-intelligence,1.0,artificial-intelligence,1.0
Of Machines and Men: Intelligent Diagnosis and the Shape of Things to Come.,ai,0.25513044,artificial-intelligence,0.38274616,artificial-intelligence,0.38274616
Of Machines and Men: Intelligent Diagnosis and the Shape of Things to Come.,conditions,0.21472734,short-term,0.4503411,feature-reduction,0.43574768
Of Machines and Men: Intelligent Diagnosis and the Shape of Things to Come.,trials,0.31393725,short-term,0.4483273,data-science,0.40647802
Of Machines and Men: Intelligent Diagnosis and the Shape of Things to Come.,trialed,0.3621012,bagging,0.5678998,bagging,0.5678998
Of Machines and Men: Intelligent Diagnosis and the Shape of Things to Come.,suggests,0.2920464,of,0.59897435,long-short-term,0.4247542
Of Machines and Men: Intelligent Diagnosis and the Shape of Things to Come.,recently,0.39159477,few,0.51658726,confusion-matrix,0.4137478
Of Machines and Men: Intelligent Diagnosis and the Shape of Things to Come.,management,0.38786528,decision,0.59816897,decision-tree,0.49756956
Of Machines and Men: Intelligent Diagnosis and the Shape of Things to Come.,improvements,0.44787854,reduction,0.58757085,dimensionality-reduction,0.5122088
Of Machines and Men: Intelligent Diagnosis and the Shape of Things to Come.,hypertension,0.28340828,dropout,0.4223115,dropout,0.4223115
Of Machines and Men: Intelligent Diagnosis and the Shape of Things to Come.,diagnosis,0.32391536,classification,0.53521544,classification,0.53521544
Of Machines and Men: Intelligent Diagnosis and the Shape of Things to Come.,date,0.3268688,data,0.53012,data-science,0.3910877
"Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses.",unsorted,0.36152917,naive,0.54387605,naive-bayes,0.5132836
"Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses.",cortical,0.3398322,neural,0.6137136,convolutional,0.5222789
"Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses.",tissue,0.23679586,of,0.5202017,segmentation,0.4076932
"Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses.",liver,0.22774608,of,0.3980642,batch-normalization,0.34184414
"Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses.",cortical-tissue,0.40857667,neural,0.5810493,recurrent-neural-network,0.5655613
"Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses.",neurodegenerative,0.36640078,generative-model,0.4714227,generative-model,0.4714227
"Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses.",ataxia,0.24969502,confusion,0.43527046,learning-function,0.36006874
"Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses.",slowing,0.27702895,rate,0.564112,learning-rate,0.45324916
"Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses.",pick,0.3652042,bag,0.47676528,bagging,0.47645462
"Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses.",disease,0.296938,recurrent,0.4731025,classification,0.35271814
"Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses.",type,0.21671848,of,0.48202556,classification,0.43098688
"Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses.",c,0.17513797,of,0.44327667,gradient,0.31114018
"Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses.",pick-disease,0.5452776,hidden-markov-model,0.5498706,hidden-markov-model,0.5498706
"Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses.",disease-type,0.40714398,generative-model,0.46073887,generative-model,0.46073887
"Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses.",type-c,0.17479959,classification,0.37354773,classification,0.37354773
"Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses.",optimized,0.48725927,feature-engineering,0.5677966,feature-engineering,0.5677966
"Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses.",dual,0.31490225,of,0.49372235,feature-reduction,0.4387607
"Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses.",aavs,0.33221972,vector,0.47772348,vector-machine,0.45323426
"Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses.",enable,0.48487508,feature-engineering,0.6139262,feature-engineering,0.6139262
"Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses.",therapeutically,0.31710795,of,0.48143375,generative-model,0.4250128
"Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses.",relevant,0.4346258,of,0.5628227,natural-language,0.5076148
"Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses.",efficiencies,0.30309498,batch,0.5145185,stochastic-gradient,0.42702383
"Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses.",therapeutically-relevant,0.41418827,natural,0.5416982,feature-engineering,0.5340669
"Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses.",targeted,0.37903738,of,0.52138686,feature-engineering,0.502902
"Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses.",point,0.30596262,forward,0.54533786,statistical,0.44868034
"Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses.",mutations,0.30690983,encoding,0.48844272,feature-selection,0.4252736
"Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses.",point-mutations,0.3784965,feature-selection,0.5316872,feature-selection,0.5316872
"Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses.",relevant,0.4346258,of,0.5628227,natural-language,0.5076148
"Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses.",cell,0.2212203,of,0.48460138,generative,0.39753264
"Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses.",types,0.34274656,components,0.5868779,classification,0.4932717
"Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses.",cell-types,0.35450315,generative,0.5232724,generative,0.5232724
"Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses.",mouse,0.30437678,model,0.5410154,generative-model,0.41324437
"Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses.",brain,0.31704307,neural,0.57897407,learning-rate,0.44069666
"Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses.",tissue,0.23679586,of,0.5202017,segmentation,0.4076932
"Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses.",mouse-brain,0.35151413,neural,0.46998808,recurrent-neural-network,0.4515977
"Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses.",brain-tissue,0.38064748,neural,0.5236989,neural-network,0.4667321
"Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses.",genetic,0.44218406,selection,0.53394234,clustering,0.53279865
"Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses.",diseases,0.31957155,recurrent,0.41244444,classification,0.40266854
"Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses.",depends,0.28999913,of,0.60277516,stochastic,0.50174546
"Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses.",aav,0.31184915,vector,0.5496615,vector-machine,0.48073572
"Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses.",packaging,0.32522196,processing,0.57989526,graphics-processing,0.5125098
"Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses.",capacity,0.29071927,function,0.5448774,boosting,0.4162461
"Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses.",aav-packaging,0.3324455,vector-machine,0.52897334,vector-machine,0.52897334
"Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses.",optimized,0.48725927,feature-engineering,0.5677966,feature-engineering,0.5677966
"Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses.",delivery,0.32787693,transfer,0.49930203,boosting,0.47409874
"Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses.",vectors,0.42283016,vector,0.9334005,vector-machine,0.711414
"Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses.",base,0.2404853,ground,0.4544053,nearest-neighbors,0.36215717
"Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses.",editing,0.49607563,data-engineering,0.5273895,data-engineering,0.5273895
"Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses.",corrects,0.26724613,normalization,0.4228359,batch-normalization,0.37118188
"Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses.",base-editing,0.49165717,data-engineering,0.55091304,data-engineering,0.55091304
"Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses.",length,0.1402078,long,0.6515323,long-short-term,0.43421984
"Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses.",base,0.2404853,ground,0.4544053,nearest-neighbors,0.36215717
"Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses.",editors,0.42302838,science,0.64426833,data-science,0.61993945
"Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses.",length-base,0.32238108,long-short,0.53030443,nearest-neighbors,0.51668644
"Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses.",adenine,0.2295933,nearest-neighbors,0.38359052,nearest-neighbors,0.38359052
"Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses.",base,0.2404853,ground,0.4544053,nearest-neighbors,0.36215717
"Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses.",editors,0.42302838,science,0.64426833,data-science,0.61993945
"Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses.",adenine-base,0.26621142,nearest-neighbors,0.47442836,nearest-neighbors,0.47442836
"Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses.",delivery,0.32787693,transfer,0.49930203,boosting,0.47409874
"Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses.",via,0.29305607,connected,0.5425352,feed-forward,0.46278888
"Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses.",adeno,0.23027354,recurrent,0.4056735,vector-machine,0.35522962
"Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses.",xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
"Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses.",retina,0.22385705,vision,0.57937396,segmentation,0.3758524
"Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses.",xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
"Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses.",heart,0.28300244,rate,0.49867767,batch-normalization,0.3427502
"Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses.",vivo,0.31561637,of,0.48691544,generative-model,0.4255858
"Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses.",base,0.2404853,ground,0.4544053,nearest-neighbors,0.36215717
"Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses.",editing,0.49607563,data-engineering,0.5273895,data-engineering,0.5273895
"Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses.",base-editing,0.49165717,data-engineering,0.55091304,data-engineering,0.55091304
"Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses.",base,0.2404853,ground,0.4544053,nearest-neighbors,0.36215717
"Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses.",editors,0.42302838,science,0.64426833,data-science,0.61993945
"Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses.",dual,0.31490225,of,0.49372235,feature-reduction,0.4387607
"Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses.",aavs,0.33221972,vector,0.47772348,vector-machine,0.45323426
"Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses.",mouse,0.30437678,model,0.5410154,generative-model,0.41324437
"Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses.",brain,0.31704307,neural,0.57897407,learning-rate,0.44069666
"Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses.",mouse-brain,0.35151413,neural,0.46998808,recurrent-neural-network,0.4515977
"Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses.",xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
"Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses.",xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
"Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses.",therapeutic,0.3659354,of,0.48352462,boosting,0.41573292
"Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses.",interest,0.4194936,of,0.5624063,feature-engineering,0.5448084
"Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses.",split,0.31843358,one,0.49212015,one-shot,0.44960362
"Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses.",cytosine,0.2525351,nearest-neighbors,0.36984622,nearest-neighbors,0.36984622
"Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses.",splicing,0.36834973,encoding,0.5448055,feature-selection,0.42678797
"Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses.",inteins,0.4171951,encoding,0.50572073,feature-engineering,0.47737765
"Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses.",skeletal,0.21809755,of,0.4196552,segmentation,0.33136374
"Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses.",muscle,0.19602863,neural,0.42647707,supervised,0.33558244
"Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses.",skeletal-muscle,0.19935827,of,0.34726727,long-short-term,0.31534088
"Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses.",multiple,0.39569393,of,0.53341115,regression,0.48948324
"Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses.",tissues,0.21297011,of,0.47614664,generative,0.371554
"Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses.",multiple-tissues,0.5275977,generative-model,0.6108149,generative-model,0.6108149
"Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses.",increasing,0.30868235,of,0.6603997,boosting,0.50417006
"Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses.",lifespan,0.23719244,long-short-term-memory,0.4500984,long-short-term-memory,0.4500984
"Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses.",efficient,0.44278914,feature-engineering,0.5657042,feature-engineering,0.5657042
"Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses.",introduction,0.37159568,of,0.5877248,feature-engineering,0.47346386
"Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses.",causes,0.19757006,of,0.55089116,long-short-term,0.3616379
"Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses.",niemann,0.16787082,pytorch,0.344078,pytorch,0.344078
"Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses.",associated,0.30827495,of,0.57598466,long-short-term,0.46578532
"Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses.",viruses,0.31189218,forest,0.41539922,vector-machine,0.413148
"Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses.",also,0.32850838,of,0.65908813,clustering,0.45826355
"Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses.",show,0.33248252,of,0.51487744,feature-selection,0.44449317
"Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses.",delivery,0.32787693,transfer,0.49930203,boosting,0.47409874
"Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses.",aavs,0.33221972,vector,0.47772348,vector-machine,0.45323426
"Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses.",xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
"Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses.",vivo,0.31561637,of,0.48691544,generative-model,0.4255858
"Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses.",use,0.43753043,of,0.5506158,feature-reduction,0.49910897
"Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses.",treatment,0.239264,short-term,0.5206091,long-short-term,0.41699445
"Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses.",trans,0.14103875,unit,0.42789114,nearest-neighbors,0.32006127
"Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses.",success,0.37704816,rate,0.58078337,dropout,0.49389052
"Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses.",study,0.3645851,of,0.5728763,statistical,0.44204497
"Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses.",report,0.3090002,of,0.56646246,data-engineering,0.3762592
"Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses.",reconstituted,0.24508128,fully,0.502514,feature-engineering,0.36642826
"Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses.",precludes,0.28486174,of,0.60137224,stochastic,0.4304813
"Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses.",neurodegeneration,0.35290885,memory,0.49154523,learning-function,0.46631312
"Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses.",mutation,0.27265835,encoding,0.44449022,feature-selection,0.4163742
"Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses.",limited,0.33893847,of,0.6210327,long-short-term,0.4736513
"Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses.",full,0.3269437,fully,0.61890495,softmax,0.42416686
"Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses.",facilitate,0.4181755,support,0.56775236,feature-engineering,0.53415316
"Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses.",dosages,0.18682033,feed,0.46353167,batch-normalization,0.39099985
"Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses.",deliver,0.37858978,boosting,0.51354825,boosting,0.51354825
"Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses.",application,0.46535254,data-engineering,0.5603031,data-engineering,0.5603031
"Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses.",ability,0.39144984,function,0.5937173,generative,0.47758824
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,also,0.32850838,of,0.65908813,clustering,0.45826355
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,revealed,0.23368785,analysis,0.608845,principal-component,0.3856352
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,chronic,0.22727785,recurrent,0.5279353,long-short-term,0.4292153
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,neurologic,0.29418164,confusion,0.4881196,learning-function,0.4061073
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,sequelae,0.22910868,recurrent,0.5361336,long-short-term,0.41649765
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,related,0.30849367,of,0.6150687,clustering,0.41455543
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,sequelae-related,0.29849517,recurrent,0.5614454,long-short-term,0.45182383
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,current,0.3530666,rectified,0.52906346,generative-model,0.40904555
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,literature,0.42831737,data,0.58552843,data-science,0.5381381
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,exists,0.29686826,of,0.5387765,long-short-term,0.40844843
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,regarding,0.3395273,decision,0.5699087,statistical,0.42642856
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,also,0.32850838,of,0.65908813,clustering,0.45826355
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,cause,0.19388393,of,0.47843847,confusion-matrix,0.34079778
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,significant,0.29367286,statistical,0.582669,statistical,0.582669
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,lesions,0.32295382,recurrent,0.46750677,segmentation,0.40412176
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,cause-significant,0.37949347,logistic-regression,0.6402677,logistic-regression,0.6402677
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,less,0.2680999,of,0.53796744,long-short-term,0.4390034
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,commonly,0.38716513,of,0.49960154,confusion-matrix,0.4359238
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,affected,0.21424896,of,0.60785514,generative,0.36098677
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,species,0.31081003,forest,0.5343407,random-forest,0.4811191
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,less-commonly,0.36901253,one,0.47907206,feature-selection,0.46476415
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,human,0.30336243,of,0.5175895,feature-engineering,0.40631005
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,arboviral,0.33647367,forest,0.5325057,random-forest,0.48272857
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,neuroinvasive,0.26504734,forest,0.390643,short-term-memory,0.33723718
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,disease,0.296938,recurrent,0.4731025,classification,0.35271814
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,west,0.2518829,forest,0.5750145,random-forest,0.47122505
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,nile,0.20186284,forest,0.44751444,pytorch,0.3881479
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,virus,0.27194685,vector,0.4519252,vector-machine,0.4189635
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,infection,0.22309746,recurrent,0.4494667,boosting,0.3635876
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,west-nile,0.28416643,forest,0.5333621,random-forest,0.50200605
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,nile-virus,0.28534275,vector-machine,0.43564287,vector-machine,0.43564287
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,virus-infection,0.2452448,naive,0.45064992,boosting,0.3793174
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,west-nile-virus,0.33787173,random-forest,0.47537354,random-forest,0.47537354
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,prior,0.3322774,of,0.5738043,bagging,0.45032665
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,human,0.30336243,of,0.5175895,feature-engineering,0.40631005
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,wnv,0.25634736,forest,0.42472255,random-forest,0.39768142
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,infection,0.22309746,recurrent,0.4494667,boosting,0.3635876
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,wnv-infection,0.29073554,naive,0.4632975,boosting,0.40017858
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,also,0.32850838,of,0.65908813,clustering,0.45826355
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,briefly,0.3702798,few,0.55407876,confusion-matrix,0.45703876
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,discussed,0.32159716,of,0.5174893,confusion-matrix,0.45636517
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,west,0.2518829,forest,0.5750145,random-forest,0.47122505
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,nile,0.20186284,forest,0.44751444,pytorch,0.3881479
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,virus,0.27194685,vector,0.4519252,vector-machine,0.4189635
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,west-nile,0.28416643,forest,0.5333621,random-forest,0.50200605
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,nile-virus,0.28534275,vector-machine,0.43564287,vector-machine,0.43564287
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,west-nile-virus,0.33787173,random-forest,0.47537354,random-forest,0.47537354
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,commonly,0.38716513,of,0.49960154,confusion-matrix,0.4359238
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,affected,0.21424896,of,0.60785514,generative,0.36098677
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,birds,0.2546286,feed,0.54631436,random-forest,0.43101487
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,affected-birds,0.36216125,artificial-intelligence,0.56891936,artificial-intelligence,0.56891936
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,human,0.30336243,of,0.5175895,feature-engineering,0.40631005
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,infection,0.22309746,recurrent,0.4494667,boosting,0.3635876
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,involve,0.262366,cascade,0.5192841,feed-forward,0.44048977
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,viral,0.31455237,vector-machine,0.44016975,vector-machine,0.44016975
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,pathogenesis,0.28404242,recurrent,0.44000214,classification,0.37820187
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,derived,0.3584563,of,0.54769456,generative,0.5265686
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,severe,0.24462184,recurrent,0.581337,confusion-matrix,0.37568426
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,systemic,0.28055844,of,0.49342385,boosting,0.37910926
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,disease,0.296938,recurrent,0.4731025,classification,0.35271814
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,systemic-disease,0.44710273,logistic-regression,0.4775613,logistic-regression,0.4775613
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,renal,0.24304676,of,0.44795883,batch-normalization,0.32135162
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,injury,0.262506,shot,0.44338763,data-augmentation,0.37271294
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,leading,0.2514689,of,0.59935343,generative,0.44480726
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,renal-injury,0.3099011,dropout,0.40446192,dropout,0.40446192
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,central,0.26715183,connected,0.51433957,segmentation,0.35878396
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,nervous,0.27056697,neural,0.6121676,recurrent-neural-network,0.40811306
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,system,0.3589455,generative-model,0.49815983,generative-model,0.49815983
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,central-nervous,0.36151135,neural,0.57494175,recurrent-neural-network,0.5184515
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,nervous-system,0.27770603,neural,0.51351804,generative-model,0.43068177
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,central-nervous-system,0.3520585,neural,0.5314915,recurrent-neural-network,0.5033282
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,experimental,0.40167695,model,0.6248311,generative-model,0.6004326
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,animal,0.3921889,model,0.61759067,generative-model,0.52223754
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,models,0.53762007,model,0.8940372,markov-model,0.7015921
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,experimental-animal,0.4945343,generative-model,0.6152773,generative-model,0.6152773
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,animal-models,0.6079529,model,0.72360504,markov-model,0.69941235
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,neurologic,0.29418164,confusion,0.4881196,learning-function,0.4061073
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,disease,0.296938,recurrent,0.4731025,classification,0.35271814
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,neurologic-disease,0.44228786,logistic-regression,0.49374974,logistic-regression,0.49374974
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,wnv,0.25634736,forest,0.42472255,random-forest,0.39768142
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,infection,0.22309746,recurrent,0.4494667,boosting,0.3635876
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,wnv-infection,0.29073554,naive,0.4632975,boosting,0.40017858
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,virus,0.27194685,vector,0.4519252,vector-machine,0.4189635
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,propagation,0.3947974,backpropagation,0.6999179,backpropagation,0.6999179
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,virus-propagation,0.43776035,backpropagation,0.639086,backpropagation,0.639086
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,major,0.2356064,principal,0.70253855,principal-components,0.42016473
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,cause,0.19388393,of,0.47843847,confusion-matrix,0.34079778
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,major-cause,0.29041767,logistic-regression,0.47297361,logistic-regression,0.47297361
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,avian,0.25014114,neural,0.39959413,feature-engineering,0.380341
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,species,0.31081003,forest,0.5343407,random-forest,0.4811191
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,animal,0.3921889,model,0.61759067,generative-model,0.52223754
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,models,0.53762007,model,0.8940372,markov-model,0.7015921
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,animal-models,0.6079529,model,0.72360504,markov-model,0.69941235
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,human,0.30336243,of,0.5175895,feature-engineering,0.40631005
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,animals,0.28808814,naive,0.5114135,short-term-memory,0.39487725
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,human-animals,0.3764789,artificial-intelligence,0.50099826,artificial-intelligence,0.50099826
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,human,0.30336243,of,0.5175895,feature-engineering,0.40631005
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,non,0.2869836,of,0.5523051,generative,0.4181043
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,human-non,0.39232302,feature-engineering,0.5022883,feature-engineering,0.5022883
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,human,0.30336243,of,0.5175895,feature-engineering,0.40631005
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,vertebrates,0.30866122,neural,0.48635703,generative,0.46138185
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,wnv,0.25634736,forest,0.42472255,random-forest,0.39768142
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,pathology,0.34800982,of,0.4805,generative-model,0.43246388
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,wnv,0.25634736,forest,0.42472255,random-forest,0.39768142
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,maintenance,0.288974,of,0.54740524,long-short-term,0.50844586
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,vertebrate,0.32463515,neural,0.494695,generative,0.4678856
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,host,0.24465643,natural,0.49335045,generative,0.42575628
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,vertebrate-host,0.3599885,random-forest,0.4833972,random-forest,0.4833972
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,review,0.41215214,data,0.5581161,data-science,0.47600204
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,summarizes,0.39623377,data,0.5136334,data-engineering,0.4779332
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,prominent,0.25377822,feature,0.58036757,generative,0.45552078
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,manifestation,0.2869243,feature,0.6082738,generative,0.40160602
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,pathology,0.34800982,of,0.4805,generative-model,0.43246388
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,seen,0.2411227,of,0.61171174,long-short-term,0.3944841
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,pathology,0.34800982,of,0.4805,generative-model,0.43246388
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,caused,0.14436965,of,0.53973085,long-short-term,0.3204536
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,particularly,0.32789055,of,0.62868786,long-short-term,0.49770588
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,diverse,0.38913006,of,0.5461366,feature-engineering,0.51537836
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,natural,0.34621036,natural,1.0,natural-language,0.49809957
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,infections,0.23728761,recurrent,0.48452243,keras,0.30937475
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,known,0.3344566,of,0.5873189,clustering,0.4164055
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,findings,0.35685748,data,0.65714294,component-analysis,0.38599753
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,knowledge,0.5362035,science,0.551701,data-science,0.5440523
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,gaps,0.32191202,few,0.4649526,nearest-neighbors,0.4472242
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,knowledge-gaps,0.68189955,deep-learning,0.68835974,deep-learning,0.68835974
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,knowledge,0.5362035,science,0.551701,data-science,0.5440523
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,gains,0.37131023,reduction,0.4767465,learning-function,0.44464046
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,knowledge-gains,0.7061268,machine-learning,0.7061268,machine-learning,0.7061268
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,host,0.24465643,natural,0.49335045,generative,0.42575628
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,animals,0.28808814,naive,0.5114135,short-term-memory,0.39487725
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,host-animals,0.29999322,random-forest,0.45546162,random-forest,0.45546162
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,future,0.42505926,data-engineering,0.5647982,data-engineering,0.5647982
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,directions,0.36279577,forward,0.6668327,dimensionality-reduction,0.49469164
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,susceptible,0.17623605,naive,0.44422033,long-short-term,0.36155635
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,non,0.2869836,of,0.5523051,generative,0.4181043
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,neurotropic,0.22572404,neural,0.43880284,boosting,0.3674753
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,nature,0.2731439,of,0.5463233,generative,0.5272707
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,neurologic,0.29418164,confusion,0.4881196,learning-function,0.4061073
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,wnv,0.25634736,forest,0.42472255,random-forest,0.39768142
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,non,0.2869836,of,0.5523051,generative,0.4181043
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,vertebrates,0.30866122,neural,0.48635703,generative,0.46138185
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,nature,0.2731439,of,0.5463233,generative,0.5272707
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,well,0.34264985,of,0.59718275,bagging,0.4145819
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,transmission,0.27285886,clustering,0.44531485,clustering,0.44531485
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,time,0.31186903,long,0.57547164,batch-normalization,0.47628766
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,similarly,0.28201446,of,0.5816662,long-short-term,0.47558495
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,serve,0.37730122,of,0.4837274,feature-engineering,0.47067174
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,research,0.45694843,science,0.7194936,data-science,0.70924157
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,relationship,0.31931284,regression,0.5493294,regression,0.5493294
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,ranging,0.25077263,of,0.45827153,gradient,0.3299821
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,occur,0.24370867,of,0.53400475,long-short-term,0.41742977
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,kidneys,0.17478287,function,0.3129201,batch-normalization,0.25441462
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,intestinal,0.18789442,of,0.42052382,gradient-descent,0.3017878
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,humans,0.34170303,natural,0.5139721,generative-model,0.41706812
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,however,0.31437585,few,0.63182676,statistical,0.44065386
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,horses,0.2748825,ground,0.41862962,random-forest,0.355581
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,heart,0.28300244,rate,0.49867767,batch-normalization,0.3427502
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,gap,0.24506995,rectified,0.44764388,nearest-neighbors,0.40462983
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,eyes,0.20276245,vision,0.57959235,keras,0.4049166
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,death,0.21479979,of,0.42234862,dropout,0.37818787
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,continues,0.29897273,confusion,0.51704437,bagging,0.41660193
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,cardiac,0.29562658,of,0.42777455,long-short-term,0.35708636
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,alligators,0.22983667,tree,0.43356058,artificial-intelligence,0.38245833
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,addressed,0.41896707,of,0.5700326,data-engineering,0.52741253
Photoplethysmography based atrial fibrillation detection: a review.,sensors,0.39629486,data-engineering,0.52682287,data-engineering,0.52682287
Photoplethysmography based atrial fibrillation detection: a review.,record,0.35823005,data,0.5543083,computer-vision,0.5094532
Photoplethysmography based atrial fibrillation detection: a review.,blood,0.16939776,normalization,0.4272251,batch-normalization,0.40715772
Photoplethysmography based atrial fibrillation detection: a review.,volume,0.268351,segmentation,0.4447226,segmentation,0.4447226
Photoplethysmography based atrial fibrillation detection: a review.,variations,0.30773562,of,0.53369737,batch-normalization,0.5106003
Photoplethysmography based atrial fibrillation detection: a review.,blood-volume,0.3231122,batch-normalization,0.48716542,batch-normalization,0.48716542
Photoplethysmography based atrial fibrillation detection: a review.,challenges,0.4537933,data-engineering,0.57894987,data-engineering,0.57894987
Photoplethysmography based atrial fibrillation detection: a review.,towards,0.26157683,forward,0.5590818,generative,0.45313805
Photoplethysmography based atrial fibrillation detection: a review.,clinical,0.44080526,data,0.48532635,data-science,0.45343333
Photoplethysmography based atrial fibrillation detection: a review.,applications,0.4878226,data-engineering,0.70112944,data-engineering,0.70112944
Photoplethysmography based atrial fibrillation detection: a review.,clinical-applications,0.45906395,short-term,0.49521232,artificial-intelligence,0.47579312
Photoplethysmography based atrial fibrillation detection: a review.,deep,0.38070458,deep,0.99999994,deep-learning,0.4875875
Photoplethysmography based atrial fibrillation detection: a review.,learning,0.709237,learning,1.0,deep-learning,0.8286492
Photoplethysmography based atrial fibrillation detection: a review.,approaches,0.55614823,feature-engineering,0.60571706,feature-engineering,0.60571706
Photoplethysmography based atrial fibrillation detection: a review.,used,0.46049535,of,0.5630944,generative-model,0.4901716
Photoplethysmography based atrial fibrillation detection: a review.,deep-learning,0.80843407,deep-learning,1.0,deep-learning,1.0
Photoplethysmography based atrial fibrillation detection: a review.,learning-approaches,0.67542875,learning,0.83603513,reinforcement-learning,0.78956765
Photoplethysmography based atrial fibrillation detection: a review.,cardiac,0.29562658,of,0.42777455,long-short-term,0.35708636
Photoplethysmography based atrial fibrillation detection: a review.,rhythm,0.27131873,learning-rate,0.4338305,learning-rate,0.4338305
Photoplethysmography based atrial fibrillation detection: a review.,disorder,0.28393638,dropout,0.44668275,dropout,0.44668275
Photoplethysmography based atrial fibrillation detection: a review.,associated,0.30827495,of,0.57598466,long-short-term,0.46578532
Photoplethysmography based atrial fibrillation detection: a review.,cardiac-rhythm,0.34504285,learning-rate,0.5012814,learning-rate,0.5012814
Photoplethysmography based atrial fibrillation detection: a review.,rhythm-disorder,0.3735093,recurrent-neural-network,0.49360913,recurrent-neural-network,0.49360913
Photoplethysmography based atrial fibrillation detection: a review.,disorder-associated,0.37123576,clustering,0.5177102,clustering,0.5177102
Photoplethysmography based atrial fibrillation detection: a review.,af,0.24542028,recurrent,0.4039285,long-short-term,0.39781147
Photoplethysmography based atrial fibrillation detection: a review.,detection,0.39447892,analysis,0.48924,classification,0.46944988
Photoplethysmography based atrial fibrillation detection: a review.,using,0.47332245,analysis,0.5968549,component-analysis,0.526608
Photoplethysmography based atrial fibrillation detection: a review.,ppg,0.3116963,segmentation-algorithm,0.37808627,segmentation-algorithm,0.37808627
Photoplethysmography based atrial fibrillation detection: a review.,implement,0.6016326,data-engineering,0.63081384,data-engineering,0.63081384
Photoplethysmography based atrial fibrillation detection: a review.,optical,0.41040304,fourier-transform,0.63333535,fourier-transform,0.63333535
Photoplethysmography based atrial fibrillation detection: a review.,sensors,0.39629486,data-engineering,0.52682287,data-engineering,0.52682287
Photoplethysmography based atrial fibrillation detection: a review.,optical-sensors,0.424906,few-shot,0.5769418,feature-engineering,0.54919124
Photoplethysmography based atrial fibrillation detection: a review.,possible,0.35543737,of,0.6754589,confusion-matrix,0.4598599
Photoplethysmography based atrial fibrillation detection: a review.,using,0.47332245,analysis,0.5968549,component-analysis,0.526608
Photoplethysmography based atrial fibrillation detection: a review.,low,0.23602332,of,0.5820825,long-short-term,0.45172954
Photoplethysmography based atrial fibrillation detection: a review.,possible-using,0.4547919,feature-reduction,0.5775137,feature-reduction,0.5775137
Photoplethysmography based atrial fibrillation detection: a review.,patient,0.2998137,confusion,0.5356896,confusion-matrix,0.41404122
Photoplethysmography based atrial fibrillation detection: a review.,management,0.38786528,decision,0.59816897,decision-tree,0.49756956
Photoplethysmography based atrial fibrillation detection: a review.,tools,0.65752256,data-engineering,0.6720511,data-engineering,0.6720511
Photoplethysmography based atrial fibrillation detection: a review.,patient-management,0.49625677,decision,0.5863574,decision-tree,0.55497044
Photoplethysmography based atrial fibrillation detection: a review.,new,0.43019778,of,0.526482,feature-reduction,0.4579819
Photoplethysmography based atrial fibrillation detection: a review.,wearable,0.53930736,data-engineering,0.6004859,data-engineering,0.6004859
Photoplethysmography based atrial fibrillation detection: a review.,devices,0.37494427,data-engineering,0.5315442,data-engineering,0.5315442
Photoplethysmography based atrial fibrillation detection: a review.,wearable-devices,0.5386116,artificial-intelligence,0.6357069,artificial-intelligence,0.6357069
Photoplethysmography based atrial fibrillation detection: a review.,leading,0.2514689,of,0.59935343,generative,0.44480726
Photoplethysmography based atrial fibrillation detection: a review.,risk,0.35860935,recurrent,0.53675485,logistic-regression,0.52381086
Photoplethysmography based atrial fibrillation detection: a review.,factor,0.23388772,component,0.48280093,principal-components,0.43733668
Photoplethysmography based atrial fibrillation detection: a review.,risk-factor,0.43057653,logistic-regression,0.59899676,logistic-regression,0.59899676
Photoplethysmography based atrial fibrillation detection: a review.,large,0.2849899,few,0.5687306,clustering,0.4101745
Photoplethysmography based atrial fibrillation detection: a review.,prospective,0.38588464,data,0.49630898,logistic-regression,0.4399855
Photoplethysmography based atrial fibrillation detection: a review.,trials,0.31393725,short-term,0.4483273,data-science,0.40647802
Photoplethysmography based atrial fibrillation detection: a review.,grade,0.2647515,classification,0.4900908,classification,0.4900908
Photoplethysmography based atrial fibrillation detection: a review.,wearable,0.53930736,data-engineering,0.6004859,data-engineering,0.6004859
Photoplethysmography based atrial fibrillation detection: a review.,devices,0.37494427,data-engineering,0.5315442,data-engineering,0.5315442
Photoplethysmography based atrial fibrillation detection: a review.,wearable-devices,0.5386116,artificial-intelligence,0.6357069,artificial-intelligence,0.6357069
Photoplethysmography based atrial fibrillation detection: a review.,enabling,0.46592075,feature-engineering,0.6214503,feature-engineering,0.6214503
Photoplethysmography based atrial fibrillation detection: a review.,transformative,0.49453783,transform,0.69973785,generative,0.6726635
Photoplethysmography based atrial fibrillation detection: a review.,diagnostic,0.47116143,classification,0.5651491,classification,0.5651491
Photoplethysmography based atrial fibrillation detection: a review.,devices,0.37494427,data-engineering,0.5315442,data-engineering,0.5315442
Photoplethysmography based atrial fibrillation detection: a review.,would,0.3569631,of,0.55908126,boosting,0.43412957
Photoplethysmography based atrial fibrillation detection: a review.,allow,0.4373722,of,0.5533963,feature-engineering,0.5170868
Photoplethysmography based atrial fibrillation detection: a review.,devices-would,0.36586514,artificial-intelligence,0.5381638,artificial-intelligence,0.5381638
Photoplethysmography based atrial fibrillation detection: a review.,today,0.31416783,confusion,0.5164013,bagging,0.44597396
Photoplethysmography based atrial fibrillation detection: a review.,possible,0.35543737,of,0.6754589,confusion-matrix,0.4598599
Photoplethysmography based atrial fibrillation detection: a review.,thanks,0.40033776,data-engineering,0.51027095,data-engineering,0.51027095
Photoplethysmography based atrial fibrillation detection: a review.,today-possible,0.3151394,confusion,0.49035096,bagging,0.41979647
Photoplethysmography based atrial fibrillation detection: a review.,possible-thanks,0.48730236,dimensionality-reduction,0.5805583,dimensionality-reduction,0.5805583
Photoplethysmography based atrial fibrillation detection: a review.,secondary,0.25856274,recurrent,0.5339868,feature-reduction,0.37561154
Photoplethysmography based atrial fibrillation detection: a review.,stroke,0.30895793,language,0.41435713,learning-function,0.39194655
Photoplethysmography based atrial fibrillation detection: a review.,prevention,0.29446518,recurrent,0.44918782,feature-reduction,0.4041679
Photoplethysmography based atrial fibrillation detection: a review.,secondary-stroke,0.49296248,transfer-learning,0.51594436,transfer-learning,0.51594436
Photoplethysmography based atrial fibrillation detection: a review.,stroke-prevention,0.33897945,learning-function,0.42428982,learning-function,0.42428982
Photoplethysmography based atrial fibrillation detection: a review.,secondary-stroke-prevention,0.48112884,learning-function,0.5138985,learning-function,0.5138985
Photoplethysmography based atrial fibrillation detection: a review.,cardiac,0.29562658,of,0.42777455,long-short-term,0.35708636
Photoplethysmography based atrial fibrillation detection: a review.,rhythm,0.27131873,learning-rate,0.4338305,learning-rate,0.4338305
Photoplethysmography based atrial fibrillation detection: a review.,cardiac-rhythm,0.34504285,learning-rate,0.5012814,learning-rate,0.5012814
Photoplethysmography based atrial fibrillation detection: a review.,ppg,0.3116963,segmentation-algorithm,0.37808627,segmentation-algorithm,0.37808627
Photoplethysmography based atrial fibrillation detection: a review.,machine,0.7094662,machine,1.0,machine-learning,0.7094662
Photoplethysmography based atrial fibrillation detection: a review.,learning,0.709237,learning,1.0,deep-learning,0.8286492
Photoplethysmography based atrial fibrillation detection: a review.,machine-learning,1.0,machine-learning,1.0,machine-learning,1.0
Photoplethysmography based atrial fibrillation detection: a review.,af,0.24542028,recurrent,0.4039285,long-short-term,0.39781147
Photoplethysmography based atrial fibrillation detection: a review.,detection,0.39447892,analysis,0.48924,classification,0.46944988
Photoplethysmography based atrial fibrillation detection: a review.,early,0.32400474,short-term,0.57188475,long-short-term,0.50726265
Photoplethysmography based atrial fibrillation detection: a review.,detection,0.39447892,analysis,0.48924,classification,0.46944988
Photoplethysmography based atrial fibrillation detection: a review.,early-detection,0.50396746,classification-algorithm,0.5532572,classification-algorithm,0.5532572
Photoplethysmography based atrial fibrillation detection: a review.,today,0.31416783,confusion,0.5164013,bagging,0.44597396
Photoplethysmography based atrial fibrillation detection: a review.,equip,0.49611846,data-engineering,0.60955584,data-engineering,0.60955584
Photoplethysmography based atrial fibrillation detection: a review.,prevent,0.23429571,of,0.49340016,long-short-term,0.38102832
Photoplethysmography based atrial fibrillation detection: a review.,stroke,0.30895793,language,0.41435713,learning-function,0.39194655
Photoplethysmography based atrial fibrillation detection: a review.,cardioembolic,0.3105955,recurrent,0.438199,confusion-matrix,0.38440335
Photoplethysmography based atrial fibrillation detection: a review.,stroke,0.30895793,language,0.41435713,learning-function,0.39194655
Photoplethysmography based atrial fibrillation detection: a review.,user,0.5892831,graphics,0.6527882,computer-vision,0.62567556
Photoplethysmography based atrial fibrillation detection: a review.,activity,0.21813896,function,0.53536034,boosting,0.38798416
Photoplethysmography based atrial fibrillation detection: a review.,thorough,0.40099895,of,0.5185302,data-engineering,0.48454803
Photoplethysmography based atrial fibrillation detection: a review.,account,0.38509363,of,0.53262895,stochastic,0.5254493
Photoplethysmography based atrial fibrillation detection: a review.,technology,0.48836875,data-engineering,0.7060051,data-engineering,0.7060051
Photoplethysmography based atrial fibrillation detection: a review.,known,0.3344566,of,0.5873189,clustering,0.4164055
Photoplethysmography based atrial fibrillation detection: a review.,technology-known,0.62411565,data-engineering,0.7126329,data-engineering,0.7126329
Photoplethysmography based atrial fibrillation detection: a review.,signal,0.35809803,cascade,0.5273956,segmentation,0.5076722
Photoplethysmography based atrial fibrillation detection: a review.,processing,0.46109343,processing,1.0,graphics-processing,0.75397617
Photoplethysmography based atrial fibrillation detection: a review.,signal-processing,0.65010893,graphics-processing,0.82270694,graphics-processing,0.82270694
Photoplethysmography based atrial fibrillation detection: a review.,physiological,0.3332913,function,0.550024,learning-function,0.4524702
Photoplethysmography based atrial fibrillation detection: a review.,parameters,0.38939354,normalization,0.54973936,batch-normalization,0.547323
Photoplethysmography based atrial fibrillation detection: a review.,increased,0.26921988,reduction,0.6514183,boosting,0.46515882
Photoplethysmography based atrial fibrillation detection: a review.,morbidity,0.27463242,recurrent,0.47132403,logistic-regression,0.42021167
Photoplethysmography based atrial fibrillation detection: a review.,heart,0.28300244,rate,0.49867767,batch-normalization,0.3427502
Photoplethysmography based atrial fibrillation detection: a review.,rate,0.24866687,rate,1.0,dropout,0.44953537
Photoplethysmography based atrial fibrillation detection: a review.,heart-rate,0.4407577,learning-rate,0.54865026,learning-rate,0.54865026
Photoplethysmography based atrial fibrillation detection: a review.,early,0.32400474,short-term,0.57188475,long-short-term,0.50726265
Photoplethysmography based atrial fibrillation detection: a review.,screening,0.38869897,selection,0.4576743,data-engineering,0.4313178
Photoplethysmography based atrial fibrillation detection: a review.,early-screening,0.4504961,decision-tree,0.4760525,decision-tree,0.4760525
Photoplethysmography based atrial fibrillation detection: a review.,cost,0.3742721,dimensionality-reduction,0.51791906,dimensionality-reduction,0.51791906
Photoplethysmography based atrial fibrillation detection: a review.,easy,0.4278534,one-shot,0.47654885,one-shot,0.47654885
Photoplethysmography based atrial fibrillation detection: a review.,atrial,0.2285939,long-short,0.40266213,long-short-term,0.38994598
Photoplethysmography based atrial fibrillation detection: a review.,fibrillation,0.29544818,recurrent,0.4121878,long-short-term,0.3982905
Photoplethysmography based atrial fibrillation detection: a review.,atrial-fibrillation,0.26383367,long-short,0.47894955,long-short-term,0.454661
Photoplethysmography based atrial fibrillation detection: a review.,continuous,0.41333556,short-term,0.5995445,long-short-term,0.56591904
Photoplethysmography based atrial fibrillation detection: a review.,monitoring,0.34263974,tracking,0.5622334,batch-normalization,0.44004613
Photoplethysmography based atrial fibrillation detection: a review.,continuous-monitoring,0.534325,artificial-intelligence,0.5932392,artificial-intelligence,0.5932392
Photoplethysmography based atrial fibrillation detection: a review.,af,0.24542028,recurrent,0.4039285,long-short-term,0.39781147
Photoplethysmography based atrial fibrillation detection: a review.,monitoring,0.34263974,tracking,0.5622334,batch-normalization,0.44004613
Photoplethysmography based atrial fibrillation detection: a review.,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
Photoplethysmography based atrial fibrillation detection: a review.,work,0.42713583,support,0.5373766,learning-function,0.5011815
Photoplethysmography based atrial fibrillation detection: a review.,wearables,0.5480883,data-engineering,0.6127137,data-engineering,0.6127137
Photoplethysmography based atrial fibrillation detection: a review.,therapy,0.2707135,short-term,0.45926765,boosting,0.40244865
Photoplethysmography based atrial fibrillation detection: a review.,summary,0.3869185,data,0.59051514,component-analysis,0.44181547
Photoplethysmography based atrial fibrillation detection: a review.,studies,0.30135098,data,0.6349237,component-analysis,0.41327482
Photoplethysmography based atrial fibrillation detection: a review.,sleep,0.3478906,learning-function,0.4834276,learning-function,0.4834276
Photoplethysmography based atrial fibrillation detection: a review.,review,0.41215214,data,0.5581161,data-science,0.47600204
Photoplethysmography based atrial fibrillation detection: a review.,recently,0.39159477,few,0.51658726,confusion-matrix,0.4137478
Photoplethysmography based atrial fibrillation detection: a review.,primary,0.24268678,principal,0.5205563,long-short-term,0.38049072
Photoplethysmography based atrial fibrillation detection: a review.,presented,0.41586217,of,0.5919795,confusion-matrix,0.4850164
Photoplethysmography based atrial fibrillation detection: a review.,photoplethysmography,0.3991384,computer-vision,0.5155152,computer-vision,0.5155152
Photoplethysmography based atrial fibrillation detection: a review.,mortality,0.2609817,short-term,0.505676,logistic-regression,0.49414968
Photoplethysmography based atrial fibrillation detection: a review.,majority,0.29875737,few,0.59443223,clustering,0.40575084
Photoplethysmography based atrial fibrillation detection: a review.,limitations,0.47029686,data-engineering,0.55192065,data-engineering,0.55192065
Photoplethysmography based atrial fibrillation detection: a review.,introduced,0.43058684,selection,0.545887,feature-engineering,0.50600016
Photoplethysmography based atrial fibrillation detection: a review.,initiation,0.25985026,of,0.5214617,long-short-term,0.40874436
Photoplethysmography based atrial fibrillation detection: a review.,inform,0.4818013,decision,0.6638433,decision-tree,0.5625328
Photoplethysmography based atrial fibrillation detection: a review.,health,0.36509717,data-science,0.5754831,data-science,0.5754831
Photoplethysmography based atrial fibrillation detection: a review.,followed,0.25369444,of,0.5874107,supervised,0.45495358
Photoplethysmography based atrial fibrillation detection: a review.,fitness,0.38461295,selection,0.52502364,learning-function,0.47855592
Photoplethysmography based atrial fibrillation detection: a review.,extracted,0.39326945,analysis,0.5438888,principal-components,0.4903554
Photoplethysmography based atrial fibrillation detection: a review.,evidenced,0.24030338,of,0.60966724,dimensionality-reduction,0.3977116
Photoplethysmography based atrial fibrillation detection: a review.,discussion,0.40282863,decision,0.59222,data-science,0.5158012
Photoplethysmography based atrial fibrillation detection: a review.,crucial,0.31994545,feature,0.5223625,feature-engineering,0.4773315
Photoplethysmography based atrial fibrillation detection: a review.,consumer,0.36925697,data-science,0.58476865,data-science,0.58476865
Photoplethysmography based atrial fibrillation detection: a review.,cases,0.31566036,recurrent,0.52791375,classification,0.4471408
Photoplethysmography based atrial fibrillation detection: a review.,capable,0.36948127,fully,0.5240339,boosting,0.47305846
Photoplethysmography based atrial fibrillation detection: a review.,body,0.2149021,of,0.4173455,segmentation,0.3712382
Photoplethysmography based atrial fibrillation detection: a review.,author,0.4029289,adversarial,0.58311844,data-science,0.55950665
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",cell,0.2212203,of,0.48460138,generative,0.39753264
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",mass,0.22818582,fourier-transform,0.42889374,fourier-transform,0.42889374
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",cytometry,0.35215917,analysis,0.47600478,fourier-transform,0.40641344
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",time,0.31186903,long,0.57547164,batch-normalization,0.47628766
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",course,0.27956843,of,0.49587014,long-short-term,0.41009617
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",dataset,0.6046342,data,0.68842554,classifiers,0.6499833
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",cell-mass,0.26468298,fourier-transform,0.5018606,fourier-transform,0.5018606
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",mass-cytometry,0.35948592,analysis,0.5036693,fourier-transform,0.49687552
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",time-course,0.3798409,normalization,0.56562436,batch-normalization,0.5627151
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",source,0.2654278,principal,0.47472525,generative-model,0.4532325
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",r,0.19974674,linear,0.4376427,regression,0.37550592
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",package,0.5160412,graphics,0.5980517,graphics-processing,0.56616294
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",via,0.29305607,connected,0.5425352,feed-forward,0.46278888
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",source-r,0.36999422,random-forest,0.55843157,random-forest,0.55843157
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",r-package,0.5069811,graphics-processing,0.56833243,graphics-processing,0.56833243
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",mouse,0.30437678,model,0.5410154,generative-model,0.41324437
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",embryonic,0.2113533,neural,0.5669645,generative,0.46570677
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",stem,0.2836631,neural,0.48491934,generative,0.47532985
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",cells,0.20327199,naive,0.5115537,generative,0.40616876
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",differentiating,0.36452085,feature,0.5412579,generative,0.51151234
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",mouse-embryonic,0.2741443,generative,0.5162684,generative,0.5162684
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",embryonic-stem,0.2721191,neural,0.5291401,generative,0.50078696
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",stem-cells,0.29156178,neural,0.5044761,generative,0.5010562
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",cell,0.2212203,of,0.48460138,generative,0.39753264
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",technologies,0.5210018,data-engineering,0.7016501,data-engineering,0.7016501
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",present,0.39618495,of,0.63723874,generative,0.48216146
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",new,0.43019778,of,0.526482,feature-reduction,0.4579819
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",opportunities,0.49326023,data-engineering,0.6166402,data-engineering,0.6166402
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",cell-technologies,0.5301908,data-engineering,0.7460046,data-engineering,0.7460046
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",present-new,0.4611332,natural-language-processing,0.49272954,natural-language-processing,0.49272954
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",gui,0.5069991,graphics,0.585279,scikit-learn,0.57882667
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",based,0.49998575,classification-algorithm,0.5639226,classification-algorithm,0.5639226
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",software,0.6104226,computer,0.74513555,computer-vision,0.6394764
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",tool,0.58027077,machine-learning,0.58027077,machine-learning,0.58027077
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",software-tool,0.65810776,computer-vision,0.7429948,computer-vision,0.7429948
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",vitro,0.292481,of,0.48112682,generative,0.40355864
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",stem,0.2836631,neural,0.48491934,generative,0.47532985
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",cell,0.2212203,of,0.48460138,generative,0.39753264
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",differentiation,0.28601187,neural,0.5331595,generative,0.49685726
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",stem-cell,0.30539137,neural,0.44801706,generative,0.44345847
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",cell-differentiation,0.31840712,generative,0.46358204,generative,0.46358204
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",change,0.30684608,reduction,0.5973228,feature-reduction,0.46143895
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",across,0.3330416,gradient,0.4622073,gradient,0.4622073
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",time,0.31186903,long,0.57547164,batch-normalization,0.47628766
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",points,0.3419253,of,0.4826713,segmentation-algorithm,0.44694978
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",across-time,0.51390994,cross-entropy,0.66775525,cross-entropy,0.66775525
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",time-points,0.33956447,short-term,0.44880888,batch-normalization,0.41509414
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",cell,0.2212203,of,0.48460138,generative,0.39753264
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",time,0.31186903,long,0.57547164,batch-normalization,0.47628766
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",course,0.27956843,of,0.49587014,long-short-term,0.41009617
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",datasets,0.6397797,data,0.71337724,classifiers,0.68077624
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",cell-time,0.354227,stochastic,0.53800094,stochastic,0.53800094
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",time-course,0.3798409,normalization,0.56562436,batch-normalization,0.5627151
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",identify,0.46963936,analysis,0.5445881,clustering,0.4863696
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",unique,0.3996781,feature,0.6177588,feature-engineering,0.5304749
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",cell,0.2212203,of,0.48460138,generative,0.39753264
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",populations,0.27454638,selection,0.5276309,clustering,0.4946172
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",cell-populations,0.38804924,stochastic,0.5797018,stochastic,0.5797018
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",previously,0.31365848,fully,0.5461891,long-short-term,0.40718085
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",published,0.42179614,data,0.6147139,data-science,0.54664624
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",scrnaseq,0.54480934,machine-learning,0.54480934,machine-learning,0.54480934
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",dataset,0.6046342,data,0.68842554,classifiers,0.6499833
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",previously-published,0.5093185,data,0.6091289,graphics-processing,0.55212224
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",uses,0.53785723,machine,0.5476687,machine-learning,0.53785723
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",graph,0.6444392,convolutional,0.7260572,convolutional,0.7260572
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",layout,0.54662675,graphics-processing,0.69058204,graphics-processing,0.69058204
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",analysis,0.46507934,analysis,0.99999994,component-analysis,0.69613737
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",graph-layout,0.7115454,graphics-processing,0.7615695,graphics-processing,0.7615695
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",sequential,0.40497702,one-shot,0.53973305,one-shot,0.53973305
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",time,0.31186903,long,0.57547164,batch-normalization,0.47628766
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",ordering,0.34481263,dimensionality-reduction,0.5669514,dimensionality-reduction,0.5669514
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",time-ordering,0.5108955,cross-entropy,0.7234305,cross-entropy,0.7234305
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",cell,0.2212203,of,0.48460138,generative,0.39753264
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",signaling,0.29640946,cascade,0.70725644,feed-forward,0.5819744
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",dynamics,0.40255624,stochastic,0.70136905,stochastic,0.70136905
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",cell-signaling,0.3557333,cascade,0.6883489,feed-forward,0.58976066
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",cell,0.2212203,of,0.48460138,generative,0.39753264
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",rna,0.357179,encoding,0.44869584,vector-machine,0.39839315
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",sequencing,0.46356243,analysis,0.5534786,machine-learning,0.46356243
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",cell-rna,0.31248993,feature-engineering,0.40060058,feature-engineering,0.40060058
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",rna-sequencing,0.5253725,analysis,0.56563675,machine-learning,0.5253725
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",cell,0.2212203,of,0.48460138,generative,0.39753264
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",datasets,0.6397797,data,0.71337724,classifiers,0.68077624
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",obtained,0.32073808,of,0.62274206,batch-normalization,0.46598285
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",cell,0.2212203,of,0.48460138,generative,0.39753264
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",analysis,0.46507934,analysis,0.99999994,component-analysis,0.69613737
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",methods,0.50049126,data,0.5400177,machine-learning,0.50049126
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",cell-analysis,0.5000341,component-analysis,0.6922015,component-analysis,0.6922015
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",analysis-methods,0.53046936,analysis,0.74070466,principal-component-analysis,0.69377303
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",visualize,0.3941273,tracking,0.5251137,segmentation,0.4844771
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",cellular,0.33255053,of,0.55018497,generative,0.4558165
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",trajectories,0.43871754,tracking,0.580979,dimensionality-reduction,0.5503274
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",three,0.36911732,one,0.78425425,clustering,0.4299444
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",germ,0.18560004,generative,0.4655689,generative,0.4655689
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",layers,0.24290167,layer,0.92980385,convolutional-layer,0.6185621
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",three-germ,0.38187248,generative,0.5117266,generative,0.5117266
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",germ-layers,0.28896898,layer,0.62475955,hidden-layer,0.5464656
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",resulting,0.2720453,of,0.6416826,generative,0.46999967
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",datasets,0.6397797,data,0.71337724,classifiers,0.68077624
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",makes,0.41276824,of,0.5783402,generative,0.48640794
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",one,0.335046,one,1.0,one-hot,0.4275648
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",particular,0.41020766,of,0.6936578,generative,0.5711796
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",challenge,0.32916635,boosting,0.49348646,boosting,0.49348646
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",one-particular,0.42872047,dimensionality-reduction,0.6294992,dimensionality-reduction,0.6294992
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",many,0.40940517,few,0.752018,feature-engineering,0.48454586
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",dynamic,0.4720998,stochastic,0.62950635,stochastic,0.62950635
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",processes,0.34218454,processing,0.59430957,generative,0.5664364
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",graphical,0.6967974,graphics,0.80647004,graphics-processing,0.7357422
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",user,0.5892831,graphics,0.6527882,computer-vision,0.62567556
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",interface,0.35153443,layer,0.5218713,feature-engineering,0.47348917
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",graphical-user,0.62780607,natural-language-processing,0.6802122,natural-language-processing,0.6802122
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",user-interface,0.6008419,graphics-processing,0.65482885,graphics-processing,0.65482885
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",graphical-user-interface,0.63086784,graphics-processing,0.69087,graphics-processing,0.69087
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",perform,0.48924625,supervised,0.522915,supervised,0.522915
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",comprehensive,0.5203603,data,0.6056672,data-engineering,0.58421016
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",analysis,0.46507934,analysis,0.99999994,component-analysis,0.69613737
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",mass,0.22818582,fourier-transform,0.42889374,fourier-transform,0.42889374
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",cytometry,0.35215917,analysis,0.47600478,fourier-transform,0.40641344
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",mass-cytometry,0.35948592,analysis,0.5036693,fourier-transform,0.49687552
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",map,0.3543614,bagging,0.4165985,bagging,0.4165985
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",analysis,0.46507934,analysis,0.99999994,component-analysis,0.69613737
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",side,0.16146374,connected,0.47764254,feature-reduction,0.35291326
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",map-analysis,0.6023921,analysis,0.76088333,principal-component-analysis,0.7174326
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",based,0.49998575,classification-algorithm,0.5639226,classification-algorithm,0.5639226
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",commands,0.32612354,words,0.5745237,object-tracking,0.4444731
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",flow,0.2860778,gradient,0.52486,gradient,0.52486
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",cytometry,0.35215917,analysis,0.47600478,fourier-transform,0.40641344
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",flow-cytometry,0.34293124,analysis,0.48240748,stochastic-gradient,0.40600675
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",experimental,0.40167695,model,0.6248311,generative-model,0.6004326
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",datasets,0.6397797,data,0.71337724,classifiers,0.68077624
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",map,0.3543614,bagging,0.4165985,bagging,0.4165985
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",analysis,0.46507934,analysis,0.99999994,component-analysis,0.69613737
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",map-analysis,0.6023921,analysis,0.76088333,principal-component-analysis,0.7174326
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",step,0.34883037,forward,0.61124456,feature-reduction,0.52921283
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",analysis,0.46507934,analysis,0.99999994,component-analysis,0.69613737
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",step-analysis,0.5844366,principal-component-analysis,0.70091486,principal-component-analysis,0.70091486
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",vivo,0.31561637,of,0.48691544,generative-model,0.4255858
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",development,0.34732813,generative,0.56588423,generative,0.56588423
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",vivo-development,0.43083572,generative,0.5698283,generative,0.5698283
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",protocol,0.3712751,algorithm,0.5198414,algorithm,0.5198414
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",takes,0.36065453,of,0.5360304,stochastic,0.46484494
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",map,0.3543614,bagging,0.4165985,bagging,0.4165985
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",algorithm,0.7180419,algorithm,1.0,algorithm,1.0
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",map-algorithm,0.70576906,algorithm,0.8804121,algorithm,0.8804121
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",drug,0.31867066,of,0.44600964,confusion-matrix,0.3956731
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",resistance,0.23395967,selection,0.4553234,long-short-term,0.34529024
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",drug-resistance,0.3336764,selection,0.47363564,feature-selection,0.43084586
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",detailed,0.4132024,data,0.659509,data-engineering,0.52353954
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",description,0.46729785,feature,0.54665416,classification,0.52730817
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",complex,0.27214053,components,0.5436033,component-analysis,0.4161712
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",nature,0.2731439,of,0.5463233,generative,0.5272707
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",biological,0.44501913,natural,0.6314477,feature-engineering,0.5497216
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",discovery,0.46891084,data-engineering,0.5077522,data-engineering,0.5077522
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",perform,0.48924625,supervised,0.522915,supervised,0.522915
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",flow,0.2860778,gradient,0.52486,gradient,0.52486
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",developed,0.44693142,fully,0.53855187,generative-model,0.49309453
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",flow,0.2860778,gradient,0.52486,gradient,0.52486
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",min,0.2854834,ground,0.46791777,bagging,0.4175465
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",h,0.19856977,short-term,0.43919927,long-short-term,0.36116964
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",map,0.3543614,bagging,0.4165985,bagging,0.4165985
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",approach,0.5412675,segmentation-algorithm,0.6046611,segmentation-algorithm,0.6046611
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",dimensional,0.48426318,dimensionality,0.8024132,dimensionality-reduction,0.765376
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",single,0.31087106,one,0.6951874,one-shot,0.4602274
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",demonstrate,0.37134898,of,0.5097414,feature-engineering,0.4652517
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",flow,0.2860778,gradient,0.52486,gradient,0.52486
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",gui,0.5069991,graphics,0.585279,scikit-learn,0.57882667
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",analysis,0.46507934,analysis,0.99999994,component-analysis,0.69613737
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",scrnaseq,0.54480934,machine-learning,0.54480934,machine-learning,0.54480934
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",side,0.16146374,connected,0.47764254,feature-reduction,0.35291326
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",perform,0.48924625,supervised,0.522915,supervised,0.522915
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",map,0.3543614,bagging,0.4165985,bagging,0.4165985
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",flow,0.2860778,gradient,0.52486,gradient,0.52486
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",step,0.34883037,forward,0.61124456,feature-reduction,0.52921283
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",single,0.31087106,one,0.6951874,one-shot,0.4602274
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",demonstrate,0.37134898,of,0.5097414,feature-engineering,0.4652517
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",approach,0.5412675,segmentation-algorithm,0.6046611,segmentation-algorithm,0.6046611
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",using,0.47332245,analysis,0.5968549,component-analysis,0.526608
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",use,0.43753043,of,0.5506158,feature-reduction,0.49910897
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",track,0.4388718,tracking,0.7933724,object-tracking,0.5832878
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",text,0.4370507,natural-language,0.62596047,natural-language,0.62596047
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",synthetic,0.36333895,natural,0.65921676,feature-engineering,0.5027765
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",provide,0.40841419,support,0.64934516,feature-engineering,0.47702065
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",open,0.29023892,words,0.38941926,object-tracking,0.38015112
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",oncogenesis,0.33203745,cascade,0.46835172,feed-forward,0.4614825
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",mesoderm,0.20977855,neural,0.5841744,segmentation,0.47007188
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",including,0.3233776,of,0.6619886,clustering,0.40625107
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",illustrate,0.5323536,feature-engineering,0.58056897,feature-engineering,0.58056897
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",high,0.267004,of,0.57459104,gradient,0.44240427
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",facilitate,0.4181755,support,0.56775236,feature-engineering,0.53415316
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",experiments,0.36827093,data,0.55053914,stochastic-gradient,0.48057425
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",endoderm,0.2126756,neural,0.5582444,segmentation,0.4386606
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",emergence,0.3708834,selection,0.5590699,generative,0.5377345
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",ectoderm,0.17971158,neural,0.5761968,segmentation,0.4198795
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",complete,0.23073666,of,0.51385504,batch-normalization,0.37797216
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",comparison,0.38020527,analysis,0.5798166,statistical,0.52489424
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",challenging,0.4561266,hidden,0.5622939,feature-engineering,0.53377354
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",applied,0.44175404,of,0.5047146,bagging,0.47554293
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",advantageous,0.41566703,feature-reduction,0.5687482,feature-reduction,0.5687482
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",addition,0.30500388,of,0.6910241,feature-reduction,0.48914018
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,yet,0.3648664,fully,0.6829063,generative,0.4089093
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,available,0.4144769,data,0.62807965,data-science,0.46192533
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,methods,0.50049126,data,0.5400177,machine-learning,0.50049126
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,using,0.47332245,analysis,0.5968549,component-analysis,0.526608
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,pcr,0.34162766,analysis,0.4623741,logistic-regression,0.38891542
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,methods-using,0.61448824,machine-learning,0.61448824,machine-learning,0.61448824
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,virus,0.27194685,vector,0.4519252,vector-machine,0.4189635
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,detection,0.39447892,analysis,0.48924,classification,0.46944988
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,using,0.47332245,analysis,0.5968549,component-analysis,0.526608
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,arboviral,0.33647367,forest,0.5325057,random-forest,0.48272857
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,virus-detection,0.47304392,vector-machine,0.5311064,vector-machine,0.5311064
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,enriching,0.47314703,feature-engineering,0.5668068,feature-engineering,0.5668068
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,targeted,0.37903738,of,0.52138686,feature-engineering,0.502902
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,rna,0.357179,encoding,0.44869584,vector-machine,0.39839315
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,viral,0.31455237,vector-machine,0.44016975,vector-machine,0.44016975
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,sequences,0.42743993,encoding,0.6398073,clustering,0.46130267
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,targeted-rna,0.43786317,feature-selection,0.54209864,feature-selection,0.54209864
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,rna-viral,0.31179506,vector-machine,0.4475261,vector-machine,0.4475261
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,successfully,0.37413275,fully,0.61316407,one-shot,0.4433375
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,enriched,0.33487642,components,0.46452388,clustering,0.4599933
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,using,0.47332245,analysis,0.5968549,component-analysis,0.526608
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,additional,0.35377294,of,0.63162684,feature-reduction,0.4511183
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,target,0.31799266,of,0.4775706,feature-selection,0.44359237
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,enrichment,0.42827362,clustering,0.52783626,clustering,0.52783626
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,step,0.34883037,forward,0.61124456,feature-reduction,0.52921283
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,additional-target,0.488917,feature-reduction,0.609262,feature-reduction,0.609262
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,target-enrichment,0.51567173,batch-normalization,0.57500994,batch-normalization,0.57500994
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,enrichment-step,0.45752725,dimensionality-reduction,0.5614479,dimensionality-reduction,0.5614479
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,haemorrhagic,0.18677878,recurrent,0.44126588,confusion-matrix,0.3108676
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,fever,0.25835532,confusion,0.5624304,confusion-matrix,0.37892723
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,viral,0.31455237,vector-machine,0.44016975,vector-machine,0.44016975
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,panels,0.38360304,classifiers,0.47793716,classifiers,0.47793716
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,increase,0.28092995,reduction,0.7624404,boosting,0.49543357
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,simultaneously,0.4054132,of,0.560508,one-shot,0.47678354
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,retaining,0.337342,of,0.6146524,feature-engineering,0.5014172
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,metagenomic,0.5814501,machine-learning,0.5814501,machine-learning,0.5814501
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,sensitivity,0.28808302,discriminative,0.5372434,cross-validation,0.48943394
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,spiked,0.30152807,batch,0.5232992,batch-normalization,0.46591318
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,primer,0.34476227,nearest-neighbors,0.40374738,nearest-neighbors,0.40374738
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,enrichment,0.42827362,clustering,0.52783626,clustering,0.52783626
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,median,0.20747668,logistic-regression,0.37743634,logistic-regression,0.37743634
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,tenfold,0.27704242,reduction,0.4831685,cross-validation,0.43470728
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,enrichment,0.42827362,clustering,0.52783626,clustering,0.52783626
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,yellow,0.20481865,bag,0.47563648,bagging,0.40073705
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,fever,0.25835532,confusion,0.5624304,confusion-matrix,0.37892723
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,viruses,0.31189218,forest,0.41539922,vector-machine,0.413148
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,yellow-fever,0.23359606,forest,0.42276686,pytorch,0.35857403
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,spectrum,0.29038134,fourier-transform,0.5137286,fourier-transform,0.5137286
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,pathogen,0.3132059,adversarial,0.3762204,random-forest,0.3666752
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,detection,0.39447892,analysis,0.48924,classification,0.46944988
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,pathogen-detection,0.48702738,multi-class,0.5047034,decision-tree,0.49354318
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,portable,0.32024455,computer,0.47698617,computer-vision,0.42617443
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,nanopore,0.3961905,stochastic-gradient,0.49272817,stochastic-gradient,0.49272817
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,sequencers,0.56104493,data-science,0.56772554,data-science,0.56772554
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,sensitivity,0.28808302,discriminative,0.5372434,cross-validation,0.48943394
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,pathogen,0.3132059,adversarial,0.3762204,random-forest,0.3666752
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,identification,0.4527572,analysis,0.6100153,classification,0.5378393
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,different,0.37681934,of,0.61590904,clustering,0.46857932
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,viruses,0.31189218,forest,0.41539922,vector-machine,0.413148
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,developed,0.44693142,fully,0.53855187,generative-model,0.49309453
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,metagenomic,0.5814501,machine-learning,0.5814501,machine-learning,0.5814501
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,sequencing,0.46356243,analysis,0.5534786,machine-learning,0.46356243
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,metagenomic-sequencing,0.6044957,machine-learning,0.6044957,machine-learning,0.6044957
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,method,0.482283,algorithm,0.63295126,algorithm,0.63295126
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,directly,0.29203913,of,0.58113813,clustering,0.40171087
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,applicable,0.4603178,feature-engineering,0.55273116,feature-engineering,0.55273116
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,viral,0.31455237,vector-machine,0.44016975,vector-machine,0.44016975
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,outbreaks,0.30490595,forest,0.4478733,random-forest,0.43302718
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,specifically,0.35122672,of,0.59676015,generative,0.5001233
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,targeted,0.37903738,of,0.52138686,feature-engineering,0.502902
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,specifically-targeted,0.41573107,feature-engineering,0.5579135,feature-engineering,0.5579135
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,specific,0.3244285,of,0.6059094,clustering,0.45887482
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,pcr,0.34162766,analysis,0.4623741,logistic-regression,0.38891542
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,specific-pcr,0.3222002,analysis,0.45307487,logistic-regression,0.41988492
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,metagenomic,0.5814501,machine-learning,0.5814501,machine-learning,0.5814501
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,next,0.40917856,one,0.57568586,boosting,0.43394256
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,evaluated,0.35501102,of,0.6190806,supervised,0.4124783
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,mean,0.24598047,reduction,0.46440193,batch-normalization,0.434582
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,demonstrating,0.32530028,of,0.67624867,generative,0.46174815
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,infecting,0.26964712,of,0.42200112,generative,0.35807377
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,viruses,0.31189218,forest,0.41539922,vector-machine,0.413148
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,shotgun,0.4586174,multi-class,0.48903677,unsupervised,0.4757133
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,sequencing,0.46356243,analysis,0.5534786,machine-learning,0.46356243
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,shotgun-sequencing,0.53099,analysis,0.55106246,machine-learning,0.53099
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,generation,0.3480911,generative,0.6357137,generative,0.6357137
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,sequencing,0.46356243,analysis,0.5534786,machine-learning,0.46356243
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,generation-sequencing,0.59803015,generative-model,0.6363071,generative-model,0.6363071
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,titre,0.17154607,batch-normalization,0.37632293,batch-normalization,0.37632293
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,infections,0.23728761,recurrent,0.48452243,keras,0.30937475
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,proved,0.3263085,of,0.5691227,feature-reduction,0.41771907
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,useful,0.40063038,discriminative,0.489146,feature-engineering,0.43842706
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,plasma,0.21912897,normalization,0.4569842,batch-normalization,0.43571177
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,samples,0.3088399,analysis,0.4981357,batch-normalization,0.44174457
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,plasma-samples,0.3857342,batch-normalization,0.57754487,batch-normalization,0.57754487
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,narrow,0.22576897,short,0.53904533,gradient,0.43443504
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,scope,0.35657495,data-science,0.5055933,data-science,0.5055933
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,narrow-scope,0.3753678,segmentation-algorithm,0.48387522,segmentation-algorithm,0.48387522
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,mngs,0.3434385,few,0.39801887,clustering,0.35897
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,alone,0.30137342,short-term,0.55139315,boosting,0.46337873
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,mngs,0.3434385,few,0.39801887,clustering,0.35897
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,lengthy,0.27003402,long,0.68639255,long-short-term,0.52059746
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,protocols,0.42072165,short-term,0.496592,data-engineering,0.48155844
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,infected,0.19365644,naive,0.53080636,boosting,0.33861458
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,patients,0.30007,recurrent,0.5332828,dropout,0.3918751
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,infected-patients,0.36213875,naive,0.58906835,logistic-regression,0.4482524
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,including,0.3233776,of,0.6619886,clustering,0.40625107
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,powassan,0.2588578,forest,0.453434,pytorch,0.42218047
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,genomic,0.45244905,encoding,0.50617117,clustering,0.48942614
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,surveillance,0.36354175,data,0.4825469,decision-tree,0.45256552
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,genome,0.4030719,encoding,0.5035916,clustering,0.41891688
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,coverage,0.25723937,shot,0.4265539,boosting,0.41374356
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,genome-coverage,0.44518697,clustering,0.52858996,clustering,0.52858996
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,generally,0.31490302,few,0.62595755,long-short-term,0.51732695
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,needed,0.36127746,support,0.5796853,supervised,0.43152136
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,field,0.3582328,forward,0.4830246,generative-model,0.46159878
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,use,0.43753043,of,0.5506158,feature-reduction,0.49910897
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,field-use,0.43295962,stochastic-gradient,0.5580542,stochastic-gradient,0.5580542
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,either,0.26875237,of,0.590966,long-short-term,0.46668065
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,benchtop,0.49814567,machine,0.5920449,data-engineering,0.57984376
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,diagnostic,0.47116143,classification,0.5651491,classification,0.5651491
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,laboratory,0.36435357,data,0.49052244,batch-normalization,0.46476662
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,diagnostic-laboratory,0.48742115,classification-algorithm,0.57854015,classification-algorithm,0.57854015
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,clinical,0.44080526,data,0.48532635,data-science,0.45343333
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,samples,0.3088399,analysis,0.4981357,batch-normalization,0.44174457
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,capture,0.4189438,tracking,0.5820073,object-tracking,0.4910211
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,probes,0.3147098,encoding,0.44489568,feature-selection,0.37664336
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,capture-probes,0.45918813,ground-truth,0.4865476,ground-truth,0.4865476
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,low,0.23602332,of,0.5820825,long-short-term,0.45172954
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,cost,0.3742721,dimensionality-reduction,0.51791906,dimensionality-reduction,0.51791906
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,low-cost,0.46327153,data-engineering,0.5901852,data-engineering,0.5901852
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,high,0.267004,of,0.57459104,gradient,0.44240427
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,cost,0.3742721,dimensionality-reduction,0.51791906,dimensionality-reduction,0.51791906
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,high-cost,0.44621217,data-engineering,0.5274703,data-engineering,0.5274703
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,sequences,0.42743993,encoding,0.6398073,clustering,0.46130267
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,rna,0.357179,encoding,0.44869584,vector-machine,0.39839315
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,detection,0.39447892,analysis,0.48924,classification,0.46944988
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,sensitivity,0.28808302,discriminative,0.5372434,cross-validation,0.48943394
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,method,0.482283,algorithm,0.63295126,algorithm,0.63295126
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,low,0.23602332,of,0.5820825,long-short-term,0.45172954
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,high,0.267004,of,0.57459104,gradient,0.44240427
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,zika,0.29848903,pytorch,0.41637605,pytorch,0.41637605
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,yielding,0.3140251,of,0.5396658,feature-reduction,0.42955723
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,usutu,0.22652793,forest,0.4096648,random-forest,0.3962029
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,simple,0.44104093,one-shot,0.5431666,one-shot,0.5431666
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,priori,0.55914986,statistical,0.6305603,statistical,0.6305603
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,pathogens,0.322322,natural,0.41354448,vector-machine,0.3437519
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,notably,0.31266075,of,0.64324886,clustering,0.4725143
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,making,0.46086103,decision,0.71635526,generative,0.51182055
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,limited,0.33893847,of,0.6210327,long-short-term,0.4736513
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,fast,0.37414896,shot,0.54270613,stochastic-gradient,0.5091015
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,emerging,0.45052218,feature-engineering,0.5309333,feature-engineering,0.5309333
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,ebola,0.29404354,vector-machine,0.39460585,vector-machine,0.39460585
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,dna,0.33955812,of,0.4467932,feature-selection,0.37733126
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,deployable,0.4532599,data-engineering,0.5987423,data-engineering,0.5987423
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,dengue,0.33957413,forest,0.46315083,random-forest,0.42327094
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,cross,0.22060364,shot,0.42420566,cross-entropy,0.41595078
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,contamination,0.3030899,of,0.49959168,batch-normalization,0.4555264
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,comparable,0.29340464,short-term,0.5384172,long-short-term,0.45359015
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,co,0.23682216,ground,0.42757797,feature-reduction,0.3969199
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,chikungunya,0.28476888,forest,0.41472054,random-forest,0.39030978
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,broad,0.27333328,of,0.4837885,generative,0.4327035
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,breadth,0.32727832,data-engineering,0.43520874,data-engineering,0.43520874
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,accuracy,0.5511073,cross-validation,0.64088035,cross-validation,0.64088035
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,infinium,0.4214696,centroid-based,0.44801107,centroid-based,0.44801107
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,human,0.30336243,of,0.5175895,feature-engineering,0.40631005
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,methylation,0.32889837,of,0.43450922,clustering,0.4034455
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,k,0.16369987,rectified,0.45026273,nearest-neighbors,0.34698594
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,beadchip,0.40787792,k-means,0.44957402,k-means,0.44957402
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,human-methylation,0.4055978,forest,0.48864675,random-forest,0.46280354
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,necs,0.2344274,neural,0.45443088,recurrent-neural-network,0.38797715
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,might,0.3331341,of,0.5952132,long-short-term,0.42997545
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,provide,0.40841419,support,0.64934516,feature-engineering,0.47702065
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,better,0.4230538,of,0.5337099,feature-reduction,0.47485045
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,diagnostic,0.47116143,classification,0.5651491,classification,0.5651491
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,accuracy,0.5511073,cross-validation,0.64088035,cross-validation,0.64088035
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,diagnostic-accuracy,0.60124797,classification-algorithm,0.7229502,classification-algorithm,0.7229502
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,based,0.49998575,classification-algorithm,0.5639226,classification-algorithm,0.5639226
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,methylation,0.32889837,of,0.43450922,clustering,0.4034455
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,data,0.46434748,data,1.0,data-science,0.5533528
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,yielded,0.30928922,of,0.5085689,cross-validation,0.42442602
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,loci,0.31453508,encoding,0.48002276,clustering,0.44868216
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,random,0.45551494,random,1.0,random-forest,0.65894985
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,forest,0.4787075,forest,1.0,random-forest,0.7738863
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,classification,0.5994266,classification,1.0,classification,1.0
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,algorithm,0.7180419,algorithm,1.0,algorithm,1.0
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,revealed,0.23368785,analysis,0.608845,principal-component,0.3856352
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,random-forest,0.6331641,random-forest,1.0,random-forest,1.0
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,forest-classification,0.6530472,classification,0.81802857,classification,0.81802857
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,classification-algorithm,0.74099064,classification-algorithm,1.0,classification-algorithm,1.0
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,dnam,0.38259852,naive-bayes,0.4475433,naive-bayes,0.4475433
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,markers,0.32439512,of,0.43581337,clustering,0.41091266
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,across,0.3330416,gradient,0.4622073,gradient,0.4622073
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,three,0.36911732,one,0.78425425,clustering,0.4299444
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,tissues,0.21297011,of,0.47614664,generative,0.371554
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,three,0.36911732,one,0.78425425,clustering,0.4299444
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,different,0.37681934,of,0.61590904,clustering,0.46857932
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,sample,0.34877062,random,0.5580652,cross-validation,0.4811297
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,sources,0.32459462,data,0.5118194,data-science,0.4587717
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,three-different,0.4282337,convolutional-layer,0.5688442,convolutional-layer,0.5688442
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,different-sample,0.4559382,statistical,0.6078414,statistical,0.6078414
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,gene,0.32125705,encoding,0.7317275,clustering,0.4378482
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,might,0.3331341,of,0.5952132,long-short-term,0.42997545
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,interact,0.3160934,connected,0.5165992,generative,0.4085296
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,peripheral,0.27531123,of,0.47952008,short-term-memory,0.3612224
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,blood,0.16939776,normalization,0.4272251,batch-normalization,0.40715772
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,mononuclear,0.21703532,naive,0.4278235,centroid-based,0.31788713
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,cells,0.20327199,naive,0.5115537,generative,0.40616876
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,peripheral-blood,0.30652508,naive,0.49009967,short-term-memory,0.41375494
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,blood-mononuclear,0.292135,gradient-descent,0.43035108,gradient-descent,0.43035108
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,mononuclear-cells,0.23713692,of,0.40309358,generative,0.3814335
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,peripheral-blood-mononuclear,0.33100605,naive,0.4748993,gradient-descent,0.42257446
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,central,0.26715183,connected,0.51433957,segmentation,0.35878396
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,airway,0.22946814,bagging,0.39862382,bagging,0.39862382
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,epithelial,0.19645312,layer,0.4889314,convolutional-layer,0.39676607
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,cells,0.20327199,naive,0.5115537,generative,0.40616876
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,central-airway,0.32471025,segmentation-algorithm,0.42501605,segmentation-algorithm,0.42501605
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,airway-epithelial,0.19905269,layer,0.41133666,convolutional-layer,0.3746703
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,epithelial-cells,0.17336152,matrix,0.49068755,recurrent-neural-network,0.38291073
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,based,0.49998575,classification-algorithm,0.5639226,classification-algorithm,0.5639226
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,dnam,0.38259852,naive-bayes,0.4475433,naive-bayes,0.4475433
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,signatures,0.5135738,feature,0.63312745,classifiers,0.5664035
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,exerted,0.1707829,of,0.5055257,feed-forward,0.40725064
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,wide,0.28586882,long,0.5053593,dimensionality-reduction,0.4077506
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,dna,0.33955812,of,0.4467932,feature-selection,0.37733126
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,methylation,0.32889837,of,0.43450922,clustering,0.4034455
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,levels,0.20457911,normalization,0.52984333,batch-normalization,0.45617118
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,dna-methylation,0.33232796,feature-selection,0.39783704,feature-selection,0.39783704
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,specific,0.3244285,of,0.6059094,clustering,0.45887482
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,dnam,0.38259852,naive-bayes,0.4475433,naive-bayes,0.4475433
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,markers,0.32439512,of,0.43581337,clustering,0.41091266
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,classify,0.6052253,classification,0.76345325,classification,0.76345325
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,pbmc,0.20951746,naive,0.50896466,naive-bayes,0.35101295
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,nec,0.26141056,feed,0.44413128,bagging,0.38542318
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,loci,0.31453508,encoding,0.48002276,clustering,0.44868216
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,associated,0.30827495,of,0.57598466,long-short-term,0.46578532
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,methylation,0.32889837,of,0.43450922,clustering,0.4034455
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,markers,0.32439512,of,0.43581337,clustering,0.41091266
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,associated-methylation,0.40934917,analysis,0.48627883,regression,0.4721424
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,based,0.49998575,classification-algorithm,0.5639226,classification-algorithm,0.5639226
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,dnam,0.38259852,naive-bayes,0.4475433,naive-bayes,0.4475433
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,markers,0.32439512,of,0.43581337,clustering,0.41091266
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,nasal,0.20994884,augmentation,0.40727264,bagging,0.36662692
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,epithelial,0.19645312,layer,0.4889314,convolutional-layer,0.39676607
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,cells,0.20327199,naive,0.5115537,generative,0.40616876
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,nasal-epithelial,0.24478343,convolutional-layer,0.4377751,convolutional-layer,0.4377751
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,epithelial-cells,0.17336152,matrix,0.49068755,recurrent-neural-network,0.38291073
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,asthma,0.23373649,recurrent,0.34173506,dropout,0.3397969
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,across,0.3330416,gradient,0.4622073,gradient,0.4622073
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,tissues,0.21297011,of,0.47614664,generative,0.371554
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,across-tissues,0.4283137,cross-entropy,0.55741453,cross-entropy,0.55741453
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,machine,0.7094662,machine,1.0,machine-learning,0.7094662
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,learning,0.709237,learning,1.0,deep-learning,0.8286492
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,algorithm,0.7180419,algorithm,1.0,algorithm,1.0
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,machine-learning,1.0,machine-learning,1.0,machine-learning,1.0
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,lower,0.20975146,of,0.5471319,regression,0.3982392
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,classification,0.5994266,classification,1.0,classification,1.0
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,error,0.4427557,overfitting,0.6119009,overfitting,0.6119009
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,classification-error,0.7006217,classification-algorithm,0.8918416,classification-algorithm,0.8918416
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,overlap,0.38858992,feature,0.58340186,clustering,0.5132319
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,analysis,0.46507934,analysis,0.99999994,component-analysis,0.69613737
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,across,0.3330416,gradient,0.4622073,gradient,0.4622073
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,analysis-across,0.5100717,analysis,0.72938144,principal-component-analysis,0.706383
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,top,0.29891562,forward,0.47741628,bagging,0.40812773
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,asthma,0.23373649,recurrent,0.34173506,dropout,0.3397969
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,obtained,0.32073808,of,0.62274206,batch-normalization,0.46598285
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,subjects,0.34547177,descent,0.47816435,short-term-memory,0.43421033
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,unique,0.3996781,feature,0.6177588,feature-engineering,0.5304749
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,pathophysiological,0.3716724,feature,0.48018768,feed-forward,0.43921173
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,processes,0.34218454,processing,0.59430957,generative,0.5664364
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,bag,0.28671136,bag,1.0,bagging,0.53626317
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,errors,0.4355805,overfitting,0.5895048,overfitting,0.5895048
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,using,0.47332245,analysis,0.5968549,component-analysis,0.526608
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,dna,0.33955812,of,0.4467932,feature-selection,0.37733126
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,methylation,0.32889837,of,0.43450922,clustering,0.4034455
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,dna-methylation,0.33232796,feature-selection,0.39783704,feature-selection,0.39783704
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,loci,0.31453508,encoding,0.48002276,clustering,0.44868216
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,predict,0.51602554,model,0.53463185,classification-algorithm,0.52342355
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,asthma,0.23373649,recurrent,0.34173506,dropout,0.3397969
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,risk,0.35860935,recurrent,0.53675485,logistic-regression,0.52381086
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,asthma-risk,0.27074775,logistic-regression,0.39924872,logistic-regression,0.39924872
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,specific,0.3244285,of,0.6059094,clustering,0.45887482
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,markers,0.32439512,of,0.43581337,clustering,0.41091266
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,specific-markers,0.41397345,analysis,0.51745296,component-analysis,0.51503277
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,analysis,0.46507934,analysis,0.99999994,component-analysis,0.69613737
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,based,0.49998575,classification-algorithm,0.5639226,classification-algorithm,0.5639226
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,analysis-based,0.6785206,analysis,0.77399796,principal-component-analysis,0.7347829
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,diagnostic,0.47116143,classification,0.5651491,classification,0.5651491
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,performance,0.50728506,learning-function,0.63351834,learning-function,0.63351834
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,necs,0.2344274,neural,0.45443088,recurrent-neural-network,0.38797715
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,dnam,0.38259852,naive-bayes,0.4475433,naive-bayes,0.4475433
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,levels,0.20457911,normalization,0.52984333,batch-normalization,0.45617118
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,subjects,0.34547177,descent,0.47816435,short-term-memory,0.43421033
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,controls,0.2521493,naive,0.47579613,statistical,0.41853178
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,gene,0.32125705,encoding,0.7317275,clustering,0.4378482
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,pathway,0.27141988,cascade,0.7127757,feed-forward,0.5331765
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,levels,0.20457911,normalization,0.52984333,batch-normalization,0.45617118
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,pathway-levels,0.4928047,cascade,0.5784364,batch-normalization,0.55791724
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,pathological,0.35600212,of,0.48665273,classification,0.46512192
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,processes,0.34218454,processing,0.59430957,generative,0.5664364
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,jointly,0.5237156,clustering,0.5639065,clustering,0.5639065
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,predict,0.51602554,model,0.53463185,classification-algorithm,0.52342355
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,efficacy,0.30193827,short-term,0.5894643,long-short-term,0.48695186
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,levels,0.20457911,normalization,0.52984333,batch-normalization,0.45617118
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,results,0.32376552,data,0.6932311,batch-normalization,0.44826904
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,using,0.47332245,analysis,0.5968549,component-analysis,0.526608
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,results-using,0.46982992,data,0.5733055,batch-normalization,0.48212063
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,pivotal,0.24934559,cascade,0.514973,feed-forward,0.4552944
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,role,0.2562992,function,0.5340955,feed-forward,0.4137928
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,pathological,0.35600212,of,0.48665273,classification,0.46512192
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,changes,0.28767496,normalization,0.57879114,batch-normalization,0.43861648
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,pathological-changes,0.40971887,normalization,0.49582613,classification,0.4793505
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,optimal,0.39098042,selection,0.5284126,algorithm,0.5276129
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,subset,0.42092714,feature,0.57910776,clustering,0.5495737
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,measured,0.25103813,of,0.539739,batch-normalization,0.45439726
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,using,0.47332245,analysis,0.5968549,component-analysis,0.526608
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,may,0.30907542,of,0.58654004,long-short-term,0.43985203
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,play,0.23933098,feature,0.4321588,feed-forward,0.39953205
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,key,0.35973132,principal,0.614877,feature-engineering,0.498355
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,role,0.2562992,function,0.5340955,feed-forward,0.4137928
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,key-role,0.3073906,principal,0.5076912,feed-forward,0.4910158
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,investigate,0.3396353,of,0.48247698,feature-engineering,0.41061842
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,shared,0.47417486,clustering,0.6025158,clustering,0.6025158
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,current,0.3530666,rectified,0.52906346,generative-model,0.40904555
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,study,0.3645851,of,0.5728763,statistical,0.44204497
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,current-study,0.4162369,recurrent-neural-network,0.539132,recurrent-neural-network,0.539132
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,cpg,0.2894129,xgboost,0.33794534,xgboost,0.33794534
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,sites,0.24239984,of,0.48146656,nearest-neighbors,0.4093466
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,cpg-sites,0.28919333,nearest-neighbors,0.44398972,nearest-neighbors,0.44398972
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,also,0.32850838,of,0.65908813,clustering,0.45826355
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,discovered,0.33516258,of,0.52953655,generative,0.40468198
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,locus,0.20351046,encoding,0.52211213,clustering,0.37987733
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,interaction,0.32838812,function,0.4945054,nearest-neighbors,0.47909442
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,locus,0.20351046,encoding,0.52211213,clustering,0.37987733
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,effects,0.2624804,short-term,0.63497096,long-short-term,0.5306107
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,pbmcs,0.2369566,naive,0.53126955,naive-bayes,0.35046965
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,cell,0.2212203,of,0.48460138,generative,0.39753264
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,junction,0.17754713,layer,0.4439217,recurrent-neural-network,0.42140397
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,cell-junction,0.21652737,layer,0.52696604,recurrent-neural-network,0.5120568
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,dnam,0.38259852,naive-bayes,0.4475433,naive-bayes,0.4475433
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,necs,0.2344274,neural,0.45443088,recurrent-neural-network,0.38797715
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,pbmc,0.20951746,naive,0.50896466,naive-bayes,0.35101295
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,nec,0.26141056,feed,0.44413128,bagging,0.38542318
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,asthma,0.23373649,recurrent,0.34173506,dropout,0.3397969
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,using,0.47332245,analysis,0.5968549,component-analysis,0.526608
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,risk,0.35860935,recurrent,0.53675485,logistic-regression,0.52381086
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,locus,0.20351046,encoding,0.52211213,clustering,0.37987733
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,pbmcs,0.2369566,naive,0.53126955,naive-bayes,0.35046965
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,cell,0.2212203,of,0.48460138,generative,0.39753264
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,warranted,0.3144392,support,0.52350307,long-short-term,0.4132567
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,value,0.3544725,of,0.52001536,statistical,0.45314136
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,tissue,0.23679586,of,0.5202017,segmentation,0.4076932
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,suggests,0.2920464,of,0.59897435,long-short-term,0.4247542
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,studied,0.26534057,of,0.63097596,generative-model,0.40392917
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,respectively,0.23184536,of,0.43360457,cross-validation,0.35765702
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,research,0.45694843,science,0.7194936,data-science,0.70924157
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,profiles,0.32975978,analysis,0.60014224,component-analysis,0.47511807
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,p,0.26795468,support,0.40805867,regression,0.40253854
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,multi,0.37771758,multi-class,0.4810482,segmentation,0.43055838
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,goal,0.39629012,feed,0.4949946,reinforcement-learning,0.43070507
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,found,0.2840244,of,0.6208722,clustering,0.44675255
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,focused,0.39696395,of,0.5549927,feature-engineering,0.52445924
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,evaluate,0.37214977,of,0.4977158,decision-tree,0.4090718
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,epigenome,0.44188404,generative,0.50734746,generative,0.50734746
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,dataset,0.6046342,data,0.68842554,classifiers,0.6499833
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,curve,0.29765248,linear,0.52257633,regression,0.49561262
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,context,0.48856658,feature-engineering,0.6062584,feature-engineering,0.6062584
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,compare,0.43674475,short-term,0.510365,statistical,0.44797724
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,classifiers,0.8333409,classifiers,1.0,classifiers,1.0
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,auc,0.32985288,cross-validation,0.5105883,cross-validation,0.5105883
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,area,0.23419946,layer,0.46823567,ground-truth,0.38642365
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,aecs,0.20496786,matrix,0.41518283,long-short-term,0.29340628
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,aec,0.17402305,matrix,0.32813162,cnn,0.2961669
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,additionally,0.37098312,of,0.6596129,feature-reduction,0.453403
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,ecg,0.36941645,regularization,0.4321748,batch-normalization,0.42148602
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,based,0.49998575,classification-algorithm,0.5639226,classification-algorithm,0.5639226
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,hypoglycemic,0.2170633,confusion,0.39128256,long-short-term,0.31063414
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,detection,0.39447892,analysis,0.48924,classification,0.46944988
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,systems,0.40840507,components,0.5468041,feature-engineering,0.5135208
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,reliably,0.4868253,discriminative,0.61839235,machine-learning,0.4868253
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,invasive,0.27886397,recurrent,0.44204783,confusion-matrix,0.3438056
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,hypoglycemia,0.24938315,confusion,0.47909623,long-short-term,0.3573985
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,alarming,0.34472185,confusion,0.5721258,overfitting,0.45968503
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,system,0.3589455,generative-model,0.49815983,generative-model,0.49815983
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,using,0.47332245,analysis,0.5968549,component-analysis,0.526608
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,short,0.24294135,short,0.99999994,long-short-term,0.66049826
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,excerpts,0.4045947,words,0.6212273,natural-language,0.5946132
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,current,0.3530666,rectified,0.52906346,generative-model,0.40904555
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,study,0.3645851,of,0.5728763,statistical,0.44204497
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,used,0.46049535,of,0.5630944,generative-model,0.4901716
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,personalised,0.5478668,decision,0.619262,data-science,0.6179105
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,medicine,0.41121995,science,0.6522808,data-science,0.6045255
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,approach,0.5412675,segmentation-algorithm,0.6046611,segmentation-algorithm,0.6046611
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,current-study,0.4162369,recurrent-neural-network,0.539132,recurrent-neural-network,0.539132
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,personalised-medicine,0.5626936,data-science,0.68972945,data-science,0.68972945
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,automatically,0.65330756,segmentation,0.6840899,segmentation,0.6840899
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,detect,0.41183126,analysis,0.51244676,clustering,0.43602985
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,nocturnal,0.28182456,short-term,0.45020837,long-short-term,0.42642573
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,hypoglycemia,0.24938315,confusion,0.47909623,long-short-term,0.3573985
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,using,0.47332245,analysis,0.5968549,component-analysis,0.526608
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,visualisation,0.46047622,segmentation,0.6485542,segmentation,0.6485542
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,method,0.482283,algorithm,0.63295126,algorithm,0.63295126
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,enabling,0.46592075,feature-engineering,0.6214503,feature-engineering,0.6214503
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,clinicians,0.48196417,decision,0.63309145,data-science,0.5435997
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,tight,0.22112727,network,0.46802372,convolutional-layer,0.42014277
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,glucose,0.22612295,batch-normalization,0.39605165,batch-normalization,0.39605165
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,monitoring,0.34263974,tracking,0.5622334,batch-normalization,0.44004613
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,reduces,0.2596901,reduction,0.6328956,boosting,0.4721025
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,glucose-monitoring,0.39623946,artificial-intelligence,0.46890262,artificial-intelligence,0.46890262
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,raw,0.35584602,processing,0.48935872,graphics-processing,0.4796581
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,ecg,0.36941645,regularization,0.4321748,batch-normalization,0.42148602
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,signal,0.35809803,cascade,0.5273956,segmentation,0.5076722
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,recorded,0.299657,rectified,0.55581653,computer-vision,0.443301
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,ecg-signal,0.42895967,segmentation-algorithm,0.5742419,segmentation-algorithm,0.5742419
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,previous,0.32983518,data,0.5377847,long-short-term,0.40795568
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,studies,0.30135098,data,0.6349237,component-analysis,0.41327482
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,based,0.49998575,classification-algorithm,0.5639226,classification-algorithm,0.5639226
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,studies-based,0.56039476,data-engineering,0.6397649,data-engineering,0.6397649
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,blood,0.16939776,normalization,0.4272251,batch-normalization,0.40715772
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,glucose,0.22612295,batch-normalization,0.39605165,batch-normalization,0.39605165
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,levels,0.20457911,normalization,0.52984333,batch-normalization,0.45617118
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,blood-glucose,0.2670272,batch-normalization,0.4206398,batch-normalization,0.4206398
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,glucose-levels,0.2895565,batch,0.47202122,batch-normalization,0.4628988
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,blood-glucose-levels,0.30526316,batch-normalization,0.48006305,batch-normalization,0.48006305
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,consecutive,0.32570636,one,0.46467566,long-short-term,0.38155502
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,days,0.20857571,short-term,0.53915894,long-short-term,0.4190845
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,consecutive-days,0.336783,short-term,0.5007262,supervised,0.4666696
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,monitored,0.23013821,of,0.51608944,batch-normalization,0.38326645
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,hours,0.2621256,short-term,0.4799012,supervised,0.38109756
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,crucial,0.31994545,feature,0.5223625,feature-engineering,0.4773315
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,diabetic,0.24483135,of,0.40444782,generative-model,0.34931552
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,patients,0.30007,recurrent,0.5332828,dropout,0.3918751
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,diabetic-patients,0.31063533,logistic-regression,0.44135565,logistic-regression,0.44135565
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,ecg,0.36941645,regularization,0.4321748,batch-normalization,0.42148602
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,signal,0.35809803,cascade,0.5273956,segmentation,0.5076722
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,ecg-signal,0.42895967,segmentation-algorithm,0.5742419,segmentation-algorithm,0.5742419
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,hypoglycemic,0.2170633,confusion,0.39128256,long-short-term,0.31063414
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,event,0.3164068,of,0.5311934,stochastic,0.4744684
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,hypoglycemia,0.24938315,confusion,0.47909623,long-short-term,0.3573985
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,affects,0.21790305,of,0.5773267,long-short-term,0.4001173
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,diabetic,0.24483135,of,0.40444782,generative-model,0.34931552
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,patients,0.30007,recurrent,0.5332828,dropout,0.3918751
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,diabetic-patients,0.31063533,logistic-regression,0.44135565,logistic-regression,0.44135565
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,wearable,0.53930736,data-engineering,0.6004859,data-engineering,0.6004859
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,devices,0.37494427,data-engineering,0.5315442,data-engineering,0.5315442
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,wearable-devices,0.5386116,artificial-intelligence,0.6357069,artificial-intelligence,0.6357069
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,subjects,0.34547177,descent,0.47816435,short-term-memory,0.43421033
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,failed,0.26734912,fully,0.52885306,long-short-term,0.36265334
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,strong,0.2620057,of,0.4821326,boosting,0.45579183
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,inter,0.27781403,short,0.5159079,statistical,0.42732772
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,specific,0.3244285,of,0.6059094,clustering,0.45887482
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,conditions,0.21472734,short-term,0.4503411,feature-reduction,0.43574768
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,specific-conditions,0.41799623,stochastic-gradient,0.54371107,stochastic-gradient,0.54371107
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,significantly,0.27887642,of,0.5214151,long-short-term,0.39056638
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,associated,0.30827495,of,0.57598466,long-short-term,0.46578532
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,significantly-associated,0.37644428,of,0.5940436,clustering,0.514508
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,results,0.32376552,data,0.6932311,batch-normalization,0.44826904
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,advance,0.42053145,feed,0.53599316,data-science,0.4783376
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,learning,0.709237,learning,1.0,deep-learning,0.8286492
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,methods,0.50049126,data,0.5400177,machine-learning,0.50049126
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,invasive,0.27886397,recurrent,0.44204783,confusion-matrix,0.3438056
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,intelligibility,0.4887145,language,0.6942723,natural-language,0.69081223
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,problem,0.51235586,hidden,0.61261725,overfitting,0.60956573
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,healthy,0.31399268,naive,0.5051062,artificial-intelligence,0.3681498
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,subjects,0.34547177,descent,0.47816435,short-term-memory,0.43421033
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,healthy-subjects,0.47015825,natural-language-processing,0.53944534,natural-language-processing,0.53944534
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,healthy,0.31399268,naive,0.5051062,artificial-intelligence,0.3681498
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,individuals,0.32092994,naive,0.486303,dropout,0.42173886
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,g,0.17250246,feed,0.40076,n-gram,0.27758121
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,deploy,0.44857013,data-engineering,0.5443614,data-engineering,0.5443614
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,electrocardiogram,0.38706088,computer,0.45127177,batch-normalization,0.44866163
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,artificial,0.4622418,artificial,1.0,artificial-intelligence,0.6597898
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,intelligence,0.5350207,intelligence,0.99999994,artificial-intelligence,0.8106787
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,artificial-intelligence,0.64611053,artificial-intelligence,1.0,artificial-intelligence,1.0
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,hypoglycemia,0.24938315,confusion,0.47909623,long-short-term,0.3573985
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,subject,0.39455077,of,0.55199313,statistical,0.5067352
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,heterogeneity,0.35684997,clustering,0.58751535,clustering,0.58751535
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,subject,0.39455077,of,0.55199313,statistical,0.5067352
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,wave,0.30110258,fourier,0.49904785,fourier,0.49904785
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,visualise,0.40951866,segmentation,0.5089809,segmentation,0.5089809
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,tracking,0.4962936,tracking,1.0,object-tracking,0.72676957
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,time,0.31186903,long,0.57547164,batch-normalization,0.47628766
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,st,0.22907814,confusion,0.43447053,long-short-term,0.42084157
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,series,0.3238523,of,0.55379033,dimensionality-reduction,0.4308661
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,seizure,0.31986094,confusion,0.49985316,learning-rate,0.43644643
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,risk,0.35860935,recurrent,0.53675485,logistic-regression,0.52381086
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,result,0.28892678,of,0.60232913,batch-normalization,0.47043157
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,real,0.4954688,truth,0.5802553,ground-truth,0.56635034
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,present,0.39618495,of,0.63723874,generative,0.48216146
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,part,0.25869048,of,0.6214935,component-analysis,0.47792363
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,overcoming,0.40629593,feature-engineering,0.56253797,feature-engineering,0.56253797
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,non,0.2869836,of,0.5523051,generative,0.4181043
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,irritability,0.270576,confusion,0.5956775,dropout,0.43848532
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,interval,0.25114498,decision,0.39202803,bayesian,0.37118626
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,important,0.33620566,principal,0.5803634,feature-engineering,0.43471682
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,however,0.31437585,few,0.63182676,statistical,0.44065386
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,heartbeats,0.4436208,segmentation-algorithm,0.50312483,segmentation-algorithm,0.50312483
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,heart,0.28300244,rate,0.49867767,batch-normalization,0.3427502
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,fluctuations,0.33684564,stochastic,0.61881655,stochastic,0.61881655
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,feasibility,0.45202792,data-engineering,0.52147615,data-engineering,0.52147615
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,fatal,0.22288792,recurrent,0.51778686,confusion-matrix,0.3668948
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,even,0.3460787,of,0.6281029,long-short-term,0.5172001
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,especially,0.32290015,of,0.63661283,long-short-term,0.46837103
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,electrophysiology,0.39042884,computer,0.46139443,learning-function,0.46077174
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,e,0.13297717,natural,0.39189428,component-analysis,0.28603846
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,due,0.21681537,of,0.5734476,confusion-matrix,0.40250766
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,deep,0.38070458,deep,0.99999994,deep-learning,0.4875875
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,confusion,0.38791996,confusion,1.0,confusion-matrix,0.71561706
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,complications,0.26551193,recurrent,0.5320816,overfitting,0.39361054
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,cohort,0.3892265,logistic-regression,0.5412916,logistic-regression,0.5412916
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,ai,0.25513044,artificial-intelligence,0.38274616,artificial-intelligence,0.38274616
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,additionally,0.37098312,of,0.6596129,feature-reduction,0.453403
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,induced,0.2259351,of,0.5615651,boosting,0.4303583
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,cardiac,0.29562658,of,0.42777455,long-short-term,0.35708636
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,toxicity,0.2518801,short-term,0.4928156,long-short-term,0.40697476
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,among,0.33676732,of,0.57348,clustering,0.49404603
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,patients,0.30007,recurrent,0.5332828,dropout,0.3918751
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,induced-cardiac,0.34756464,neural,0.4832075,long-short-term,0.4778292
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,repeat,0.18560003,short,0.46157068,dropout,0.34574726
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,ann,0.57569355,perceptron,0.68935764,perceptron,0.68935764
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,analysis,0.46507934,analysis,0.99999994,component-analysis,0.69613737
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,using,0.47332245,analysis,0.5968549,component-analysis,0.526608
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,dosimetry,0.3595756,monte,0.59576285,monte,0.59576285
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,ann-analysis,0.633528,principal-component-analysis,0.73231584,principal-component-analysis,0.73231584
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,analysis-using,0.57197005,analysis,0.78061044,principal-component-analysis,0.68111634
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,undergone,0.2585662,recurrent,0.41912213,segmentation-algorithm,0.337775
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,stereotactic,0.35575053,segmentation,0.45944965,segmentation,0.45944965
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,ablative,0.29328078,recurrent,0.43912005,data-augmentation,0.41304716
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,radiotherapy,0.31119072,xgboost,0.4302898,xgboost,0.4302898
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,dose,0.24218819,shot,0.48689568,boosting,0.43495926
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,neutral,0.21335869,dimensionality-reduction,0.4136101,dimensionality-reduction,0.4136101
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,structure,0.3356646,hierarchical,0.5517567,hierarchical-clustering,0.5486842
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,confirmed,0.25544786,of,0.58156097,component-analysis,0.390182
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,dose-neutral,0.35174385,monte-carlo,0.42399347,monte-carlo,0.42399347
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,including,0.3233776,of,0.6619886,clustering,0.40625107
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,cardiac,0.29562658,of,0.42777455,long-short-term,0.35708636
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,dosimetry,0.3595756,monte,0.59576285,monte,0.59576285
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,parameters,0.38939354,normalization,0.54973936,batch-normalization,0.547323
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,stage,0.30396575,classification,0.4731305,classification,0.4731305
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,nsclc,0.27414334,recurrent-neural-network,0.32799056,recurrent-neural-network,0.32799056
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,undergoing,0.27656338,short-term,0.4795418,long-short-term,0.4059016
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,sabr,0.3738943,xgboost,0.4783165,xgboost,0.4783165
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,modulate,0.28013808,function,0.51941574,feed-forward,0.47073716
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,confounding,0.41785493,logistic-regression,0.6530719,logistic-regression,0.6530719
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,behaviors,0.3500839,style,0.5685219,reinforcement-learning,0.5534936
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,locally,0.3436939,of,0.49396628,generative,0.46592766
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,advanced,0.4209618,of,0.47114033,machine-learning,0.4209618
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,non,0.2869836,of,0.5523051,generative,0.4181043
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,locally-advanced,0.43383747,recurrent,0.53516424,recurrent-neural-network,0.4501211
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,advanced-non,0.39847356,naive,0.43495184,recurrent-neural-network,0.416449
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,cell,0.2212203,of,0.48460138,generative,0.39753264
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,lung,0.26692057,of,0.3928769,bagging,0.36409828
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,cancer,0.27383438,recurrent,0.4065063,generative,0.3468409
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,cell-lung,0.29238558,recurrent-neural-network,0.36538395,recurrent-neural-network,0.36538395
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,lung-cancer,0.29581597,decision-tree,0.3364873,decision-tree,0.3364873
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,artificial,0.4622418,artificial,1.0,artificial-intelligence,0.6597898
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,neural,0.5080686,neural,1.0,neural-network,0.7153882
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,network,0.50771487,network,1.0,neural-network,0.7589166
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,artificial-neural,0.5541204,recurrent-neural-network,0.7487964,recurrent-neural-network,0.7487964
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,neural-network,0.7034505,neural-network,1.0,neural-network,1.0
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,artificial-neural-network,0.6767229,neural-network,0.9082352,neural-network,0.9082352
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,years,0.32825696,intelligence,0.42702603,regression,0.3811771
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,vs,0.22635552,transfer,0.4263924,statistical,0.3002486
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,input,0.49092877,feed-forward,0.58275104,feed-forward,0.58275104
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,features,0.51742536,feature,0.8268872,feature-selection,0.5487305
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,cardiac,0.29562658,of,0.42777455,long-short-term,0.35708636
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,radiation,0.2630006,of,0.44937658,monte,0.44931024
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,dosimetry,0.3595756,monte,0.59576285,monte,0.59576285
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,radiation-dosimetry,0.41191894,monte,0.6051575,monte,0.6051575
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,years,0.32825696,intelligence,0.42702603,regression,0.3811771
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,cardiac,0.29562658,of,0.42777455,long-short-term,0.35708636
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,substructures,0.44179884,hierarchical-clustering,0.5832661,hierarchical-clustering,0.5832661
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,significantly,0.27887642,of,0.5214151,long-short-term,0.39056638
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,longer,0.23865971,long,0.7401756,long-short-term,0.6004038
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,os,0.23001403,logistic-regression,0.36984953,logistic-regression,0.36984953
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,cardiac,0.29562658,of,0.42777455,long-short-term,0.35708636
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,radiation,0.2630006,of,0.44937658,monte,0.44931024
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,dose,0.24218819,shot,0.48689568,boosting,0.43495926
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,radiation-dose,0.31693178,monte,0.50392485,monte,0.50392485
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,rv,0.21948624,support-vector,0.35124844,support-vector,0.35124844
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,dose,0.24218819,shot,0.48689568,boosting,0.43495926
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,cardiac,0.29562658,of,0.42777455,long-short-term,0.35708636
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,toxicity,0.2518801,short-term,0.4928156,long-short-term,0.40697476
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,cardiac,0.29562658,of,0.42777455,long-short-term,0.35708636
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,dosimetry,0.3595756,monte,0.59576285,monte,0.59576285
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,stage,0.30396575,classification,0.4731305,classification,0.4731305
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,nsclc,0.27414334,recurrent-neural-network,0.32799056,recurrent-neural-network,0.32799056
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,os,0.23001403,logistic-regression,0.36984953,logistic-regression,0.36984953
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,using,0.47332245,analysis,0.5968549,component-analysis,0.526608
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,patients,0.30007,recurrent,0.5332828,dropout,0.3918751
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,cardiac,0.29562658,of,0.42777455,long-short-term,0.35708636
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,substructures,0.44179884,hierarchical-clustering,0.5832661,hierarchical-clustering,0.5832661
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,undergone,0.2585662,recurrent,0.41912213,segmentation-algorithm,0.337775
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,sabr,0.3738943,xgboost,0.4783165,xgboost,0.4783165
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,nsclc,0.27414334,recurrent-neural-network,0.32799056,recurrent-neural-network,0.32799056
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,ann,0.57569355,perceptron,0.68935764,perceptron,0.68935764
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,analysis,0.46507934,analysis,0.99999994,component-analysis,0.69613737
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,ann-analysis,0.633528,principal-component-analysis,0.73231584,principal-component-analysis,0.73231584
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,radiation,0.2630006,of,0.44937658,monte,0.44931024
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,dose,0.24218819,shot,0.48689568,boosting,0.43495926
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,radiation-dose,0.31693178,monte,0.50392485,monte,0.50392485
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,cardiac,0.29562658,of,0.42777455,long-short-term,0.35708636
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,follow,0.28552625,tracking,0.48513734,batch-normalization,0.39173082
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,mean,0.24598047,reduction,0.46440193,batch-normalization,0.434582
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,dose,0.24218819,shot,0.48689568,boosting,0.43495926
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,mean-dose,0.37465927,batch-normalization,0.5786869,batch-normalization,0.5786869
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,maximum,0.27634987,reduction,0.4912275,batch-normalization,0.4584134
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,dose,0.24218819,shot,0.48689568,boosting,0.43495926
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,maximum-dose,0.3888941,bayesian,0.5248509,bayesian,0.5248509
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,present,0.39618495,of,0.63723874,generative,0.48216146
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,analysis,0.46507934,analysis,0.99999994,component-analysis,0.69613737
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,test,0.4037762,statistical,0.5031551,statistical,0.5031551
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,accuracy,0.5511073,cross-validation,0.64088035,cross-validation,0.64088035
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,test-accuracy,0.5972656,cross-validation,0.6548753,cross-validation,0.6548753
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,single,0.31087106,one,0.6951874,one-shot,0.4602274
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,institution,0.36944404,decision,0.51479137,data-science,0.46497375
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,single-institution,0.43298322,recurrent,0.48752233,logistic-regression,0.46518105
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,rv,0.21948624,support-vector,0.35124844,support-vector,0.35124844
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,risk,0.35860935,recurrent,0.53675485,logistic-regression,0.52381086
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,might,0.3331341,of,0.5952132,long-short-term,0.42997545
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,risk-might,0.4277785,decision,0.58768183,decision-tree,0.5712042
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,rights,0.3170033,adversarial,0.6281444,data-science,0.57488894
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,reserved,0.28677964,of,0.4776592,supervised,0.3944377
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,right,0.24704936,confusion,0.43681273,segmentation,0.36243528
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,ventricle,0.20552546,segmentation,0.33557552,segmentation,0.33557552
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,right-ventricle,0.28284913,learning-function,0.38180315,learning-function,0.38180315
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,predictive,0.55290145,cross-validation,0.6141345,cross-validation,0.6141345
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,power,0.40041247,cross-entropy,0.52311826,cross-entropy,0.52311826
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,meier,0.35437143,logistic,0.57740426,logistic-regression,0.55255646
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,method,0.482283,algorithm,0.63295126,algorithm,0.63295126
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,less,0.2680999,of,0.53796744,long-short-term,0.4390034
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,well,0.34264985,of,0.59718275,bagging,0.4145819
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,less-well,0.31431755,fully-connected,0.4435653,fully-connected,0.4435653
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,important,0.33620566,principal,0.5803634,feature-engineering,0.43471682
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,predictor,0.43901688,regression,0.5961869,regression,0.5961869
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,dosimetric,0.42624038,monte,0.6102265,monte,0.6102265
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,variables,0.4636312,logistic-regression,0.6604836,logistic-regression,0.6604836
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,decreased,0.23506472,reduction,0.66483074,boosting,0.42738107
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,os,0.23001403,logistic-regression,0.36984953,logistic-regression,0.36984953
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,data,0.46434748,data,1.0,data-science,0.5533528
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,support,0.3815906,support,1.0,support-vector,0.66958183
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,data-support,0.6433534,support-vector-machine,0.7185054,support-vector-machine,0.7185054
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,whole,0.3066609,of,0.548425,batch-normalization,0.49255443
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,heart,0.28300244,rate,0.49867767,batch-normalization,0.3427502
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,whole-heart,0.45891154,segmentation,0.5279184,segmentation,0.5279184
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,overall,0.37212962,rate,0.62994075,dropout,0.45315623
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,survival,0.29004025,short-term,0.53135407,long-short-term,0.4573617
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,overall-survival,0.3594483,logistic-regression,0.5240103,logistic-regression,0.5240103
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,negatively,0.19863382,function,0.50118184,regression,0.35049492
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,predicted,0.423177,function,0.49677318,classification-algorithm,0.45761842
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,negatively-predicted,0.47887415,classifiers,0.5444492,classifiers,0.5444492
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,patients,0.30007,recurrent,0.5332828,dropout,0.3918751
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,ann,0.57569355,perceptron,0.68935764,perceptron,0.68935764
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,analysis,0.46507934,analysis,0.99999994,component-analysis,0.69613737
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,sabr,0.3738943,xgboost,0.4783165,xgboost,0.4783165
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,radiation,0.2630006,of,0.44937658,monte,0.44931024
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,rv,0.21948624,support-vector,0.35124844,support-vector,0.35124844
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,os,0.23001403,logistic-regression,0.36984953,logistic-regression,0.36984953
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,survival,0.29004025,short-term,0.53135407,long-short-term,0.4573617
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,predicted,0.423177,function,0.49677318,classification-algorithm,0.45761842
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,heart,0.28300244,rate,0.49867767,batch-normalization,0.3427502
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,warranted,0.3144392,support,0.52350307,long-short-term,0.4132567
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,total,0.21723771,of,0.5102532,principal-components,0.3630478
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,subvolumes,0.46408096,segmentation,0.5908458,segmentation,0.5908458
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,small,0.28058842,few,0.5791491,bagging,0.40911084
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,results,0.32376552,data,0.6932311,batch-normalization,0.44826904
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,received,0.24654314,one,0.48884487,supervised,0.36404985
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,prioritizing,0.5676816,decision,0.6184697,decision-tree,0.61099756
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,predict,0.51602554,model,0.53463185,classification-algorithm,0.52342355
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,performed,0.3864032,analysis,0.5711501,supervised,0.4789877
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,organ,0.21443385,generative,0.39718252,generative,0.39718252
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,objective,0.4122544,of,0.5255821,component-analysis,0.42220753
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,minimizing,0.38426906,overfitting,0.5859595,overfitting,0.5859595
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,methods,0.50049126,data,0.5400177,machine-learning,0.50049126
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,materials,0.37203065,data-engineering,0.54111993,data-engineering,0.54111993
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,kaplan,0.3273802,logistic,0.4897979,logistic-regression,0.48124322
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,introduction,0.37159568,of,0.5877248,feature-engineering,0.47346386
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,included,0.34673893,of,0.58040446,component-analysis,0.47413814
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,importance,0.3427571,of,0.5794183,feature-engineering,0.46667784
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,however,0.31437585,few,0.63182676,statistical,0.44065386
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,early,0.32400474,short-term,0.57188475,long-short-term,0.50726265
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,considered,0.36321384,of,0.60548925,feature-reduction,0.4442021
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,conclusion,0.35530132,data,0.5299138,long-short-term,0.45073265
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,characterized,0.27792567,feature,0.5646106,fourier,0.42356855
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,associations,0.41113383,regression,0.58898914,regression,0.58898914
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,association,0.32292235,regression,0.5094141,regression,0.5094141
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,associated,0.30827495,of,0.57598466,long-short-term,0.46578532
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,assess,0.36162603,of,0.49566716,decision-tree,0.39463407
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,analyzed,0.38529366,analysis,0.6994013,component-analysis,0.5263994
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,additionally,0.37098312,of,0.6596129,feature-reduction,0.453403
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,based,0.49998575,classification-algorithm,0.5639226,classification-algorithm,0.5639226
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,image,0.5164337,segmentation,0.7261368,segmentation,0.7261368
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,quantification,0.40637213,analysis,0.5695292,segmentation,0.5086152
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,revealed,0.23368785,analysis,0.608845,principal-component,0.3856352
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,positive,0.26811236,of,0.49572036,component-analysis,0.37181294
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,correlations,0.37863168,statistical,0.5762194,statistical,0.5762194
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,based-image,0.595109,segmentation-algorithm,0.67763567,segmentation-algorithm,0.67763567
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,image-quantification,0.57298064,segmentation,0.6721445,segmentation,0.6721445
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,positive-correlations,0.5217807,cross-entropy,0.65359306,cross-entropy,0.65359306
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,various,0.35606545,of,0.6378319,generative,0.45850474
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,renal,0.24304676,of,0.44795883,batch-normalization,0.32135162
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,pathologies,0.36750844,feature,0.47752935,generative-model,0.44772106
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,remain,0.23401183,fully,0.5900476,long-short-term,0.39730668
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,poorly,0.28902727,fully,0.6905947,long-short-term,0.39858708
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,defined,0.3575971,of,0.529315,classification,0.50848204
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,poorly-defined,0.31526434,feature,0.4638324,classification,0.45774955
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,induced,0.2259351,of,0.5615651,boosting,0.4303583
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,injury,0.262506,shot,0.44338763,data-augmentation,0.37271294
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,models,0.53762007,model,0.8940372,markov-model,0.7015921
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,representing,0.37807727,of,0.60317135,generative,0.47135577
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,ckd,0.30266297,logistic-regression,0.3485912,logistic-regression,0.3485912
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,induced-injury,0.26540527,short-term,0.43627116,generative-model,0.41029733
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,reperfusion,0.25349236,normalization,0.42956924,batch-normalization,0.38744473
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,injury,0.262506,shot,0.44338763,data-augmentation,0.37271294
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,model,0.48485535,model,1.0,markov-model,0.7005576
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,showed,0.20766163,of,0.5296177,regression,0.37027335
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,increase,0.28092995,reduction,0.7624404,boosting,0.49543357
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,reperfusion-injury,0.27433425,confusion-matrix,0.4009061,confusion-matrix,0.4009061
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,injury-model,0.4423967,model,0.5849784,generative-model,0.5835452
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,implicates,0.29174647,of,0.5207428,feed-forward,0.4549361
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,aryl,0.16281155,centroid-based,0.41494918,centroid-based,0.41494918
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,hydrocarbon,0.220102,natural,0.41993973,centroid-based,0.36709273
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,receptor,0.22411162,function,0.41526195,clustering,0.36801085
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,aryl-hydrocarbon,0.22834972,cascade,0.39589208,centroid-based,0.37233686
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,hydrocarbon-receptor,0.29171473,cascade,0.44225267,feature-reduction,0.44132608
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,aryl-hydrocarbon-receptor,0.27266246,cascade,0.4468075,centroid-based,0.419942
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,blood,0.16939776,normalization,0.4272251,batch-normalization,0.40715772
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,urea,0.2245125,batch-normalization,0.3623508,batch-normalization,0.3623508
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,nitrogen,0.25959074,forest,0.46643505,feature-reduction,0.3711414
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,levels,0.20457911,normalization,0.52984333,batch-normalization,0.45617118
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,blood-urea,0.2559372,batch-normalization,0.44665098,batch-normalization,0.44665098
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,urea-nitrogen,0.2386516,batch,0.45680302,batch-normalization,0.39665717
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,blood-urea-nitrogen,0.2849993,batch-normalization,0.49116284,batch-normalization,0.49116284
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,transgenic,0.32568008,vector,0.4939092,generative,0.41478235
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,mouse,0.30437678,model,0.5410154,generative-model,0.41324437
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,line,0.22275111,of,0.4227432,generative,0.38747817
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,expressing,0.25940266,encoding,0.59442365,boosting,0.42904755
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,transgenic-mouse,0.33238703,model,0.4525719,generative-model,0.42532787
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,mouse-line,0.2891805,naive,0.4544508,batch-normalization,0.4018843
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,line-expressing,0.35483557,naive,0.5357204,generative,0.49155968
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,translationally,0.36525565,encoding,0.58189636,generative,0.48580003
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,relevant,0.4346258,of,0.5628227,natural-language,0.5076148
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,animal,0.3921889,model,0.61759067,generative-model,0.52223754
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,models,0.53762007,model,0.8940372,markov-model,0.7015921
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,translationally-relevant,0.47977734,feature-selection,0.5949507,feature-selection,0.5949507
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,animal-models,0.6079529,model,0.72360504,markov-model,0.69941235
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,serum,0.20734212,normalization,0.47724307,batch-normalization,0.4486353
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,indoxyl,0.21393235,matrix,0.33828473,batch-normalization,0.29906857
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,sulfate,0.19182658,layer,0.40709388,gradient,0.38957754
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,levels,0.20457911,normalization,0.52984333,batch-normalization,0.45617118
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,indoxyl-sulfate,0.20810455,matrix,0.36644286,principal-components,0.32232097
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,acute,0.21222305,short-term,0.51624244,long-short-term,0.3867746
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,kidney,0.15772529,function,0.35472965,batch-normalization,0.2715908
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,injury,0.262506,shot,0.44338763,data-augmentation,0.37271294
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,kidney-injury,0.24282429,function,0.3807814,dropout,0.33214512
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,acute-kidney-injury,0.22075397,short-term,0.3692364,batch-normalization,0.33826312
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,serum,0.20734212,normalization,0.47724307,batch-normalization,0.4486353
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,indoxyl,0.21393235,matrix,0.33828473,batch-normalization,0.29906857
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,sulfate,0.19182658,layer,0.40709388,gradient,0.38957754
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,indoxyl-sulfate,0.20810455,matrix,0.36644286,principal-components,0.32232097
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,reporter,0.31360114,vector,0.55062973,data-engineering,0.4215237
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,gene,0.32125705,encoding,0.7317275,clustering,0.4378482
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,mouse,0.30437678,model,0.5410154,generative-model,0.41324437
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,reporter-gene,0.34441066,feature-selection,0.50599724,feature-selection,0.50599724
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,gene-mouse,0.34595066,vector,0.44725254,vector-machine,0.4317097
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,distal,0.18749598,long,0.4588611,segmentation,0.36233157
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,renal,0.24304676,of,0.44795883,batch-normalization,0.32135162
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,tubules,0.14827141,layer,0.4342669,convolutional-layer,0.38427174
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,renal-tubules,0.14639589,gradient-descent,0.34786165,gradient-descent,0.34786165
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,persisted,0.19274907,of,0.5315399,long-short-term,0.46574908
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,despite,0.27514282,few,0.5803892,long-short-term,0.43284553
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,reduction,0.22531602,reduction,1.0,feature-reduction,0.59547573
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,kidney,0.15772529,function,0.35472965,batch-normalization,0.2715908
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,diseases,0.31957155,recurrent,0.41244444,classification,0.40266854
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,using,0.47332245,analysis,0.5968549,component-analysis,0.526608
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,kidney-diseases,0.37285793,generative-model,0.4159481,generative-model,0.4159481
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,indoxyl,0.21393235,matrix,0.33828473,batch-normalization,0.29906857
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,sulfate,0.19182658,layer,0.40709388,gradient,0.38957754
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,levels,0.20457911,normalization,0.52984333,batch-normalization,0.45617118
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,indoxyl-sulfate,0.20810455,matrix,0.36644286,principal-components,0.32232097
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,following,0.27415842,of,0.60616374,long-short-term,0.4591148
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,validation,0.5362086,cross-validation,0.74016297,cross-validation,0.74016297
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,using,0.47332245,analysis,0.5968549,component-analysis,0.526608
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,fed,0.301457,feed,0.7557408,supervised,0.35448015
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,mice,0.24457785,naive,0.4783403,short-term-memory,0.38200378
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,showed,0.20766163,of,0.5296177,regression,0.37027335
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,fed-mice,0.27086926,feed,0.46290284,batch-normalization,0.39187187
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,mice-showed,0.216853,long-short-term-memory,0.42279625,long-short-term-memory,0.42279625
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,dioxin,0.23647483,feed,0.35174596,ground-truth,0.3177573
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,derivative,0.23549923,transform,0.42700642,fourier,0.4179231
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,chronic,0.22727785,recurrent,0.5279353,long-short-term,0.4292153
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,kidney,0.15772529,function,0.35472965,batch-normalization,0.2715908
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,disease,0.296938,recurrent,0.4731025,classification,0.35271814
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,chronic-kidney,0.23062408,short-term,0.40376043,short-term-memory,0.36933333
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,kidney-disease,0.3797998,logistic-regression,0.42294642,logistic-regression,0.42294642
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,chronic-kidney-disease,0.3595866,logistic-regression,0.43127578,logistic-regression,0.43127578
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,galactosidase,0.19778757,encoding,0.41865906,support-vector,0.3610133
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,increase,0.28092995,reduction,0.7624404,boosting,0.49543357
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,coincided,0.21534881,of,0.5705139,gradient,0.39934623
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,galactosidase,0.19778757,encoding,0.41865906,support-vector,0.3610133
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,reporter,0.31360114,vector,0.55062973,data-engineering,0.4215237
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,gene,0.32125705,encoding,0.7317275,clustering,0.4378482
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,reporter-gene,0.34441066,feature-selection,0.50599724,feature-selection,0.50599724
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,canonical,0.48526978,feed-forward,0.5661752,feed-forward,0.5661752
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,ahr,0.17252883,naive,0.3219453,centroid-based,0.30249912
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,ligand,0.266578,nearest-neighbors,0.4023533,nearest-neighbors,0.4023533
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,ahr-ligand,0.31058037,centroid-based,0.44022158,centroid-based,0.44022158
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,aki,0.3459489,logistic-regression,0.35593563,logistic-regression,0.35593563
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,respectively,0.23184536,of,0.43360457,cross-validation,0.35765702
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,animal,0.3921889,model,0.61759067,generative-model,0.52223754
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,models,0.53762007,model,0.8940372,markov-model,0.7015921
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,animal-models,0.6079529,model,0.72360504,markov-model,0.69941235
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,renal,0.24304676,of,0.44795883,batch-normalization,0.32135162
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,tubules,0.14827141,layer,0.4342669,convolutional-layer,0.38427174
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,renal-tubules,0.14639589,gradient-descent,0.34786165,gradient-descent,0.34786165
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,various,0.35606545,of,0.6378319,generative,0.45850474
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,tissues,0.21297011,of,0.47614664,generative,0.371554
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,indoxyl,0.21393235,matrix,0.33828473,batch-normalization,0.29906857
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,sulfate,0.19182658,layer,0.40709388,gradient,0.38957754
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,indoxyl-sulfate,0.20810455,matrix,0.36644286,principal-components,0.32232097
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,significant,0.29367286,statistical,0.582669,statistical,0.582669
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,increase,0.28092995,reduction,0.7624404,boosting,0.49543357
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,significant-increase,0.3675148,reduction,0.6572373,statistical,0.502928
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,discrete,0.48449236,generative,0.6152396,generative,0.6152396
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,models,0.53762007,model,0.8940372,markov-model,0.7015921
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,specific,0.3244285,of,0.6059094,clustering,0.45887482
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,model,0.48485535,model,1.0,markov-model,0.7005576
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,transgenic,0.32568008,vector,0.4939092,generative,0.41478235
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,mice,0.24457785,naive,0.4783403,short-term-memory,0.38200378
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,transgenic-mice,0.2773012,naive,0.45729056,long-short-term-memory,0.36821145
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,galactosidase,0.19778757,encoding,0.41865906,support-vector,0.3610133
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,expression,0.32038707,encoding,0.59633577,clustering,0.442253
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,uremic,0.24009383,of,0.37126812,batch-normalization,0.35515535
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,toxicity,0.2518801,short-term,0.4928156,long-short-term,0.40697476
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,study,0.3645851,of,0.5728763,statistical,0.44204497
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,demonstrates,0.32810378,of,0.5866501,feature-engineering,0.42233235
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,results,0.32376552,data,0.6932311,batch-normalization,0.44826904
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,demonstrate,0.37134898,of,0.5097414,feature-engineering,0.4652517
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,results-demonstrate,0.45842522,data,0.60937816,dimensionality-reduction,0.53237516
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,provide,0.40841419,support,0.64934516,feature-engineering,0.47702065
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,hypothesis,0.3707978,support,0.5685151,generative,0.5120144
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,promoter,0.2784518,encoding,0.59602714,feed-forward,0.39776367
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,tethered,0.22186951,connected,0.46844316,fully-connected,0.41294166
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,promoter-tethered,0.31497705,encoding,0.5408498,feature-selection,0.47115535
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,generating,0.44281042,generative,0.69901055,generative,0.69901055
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,insights,0.40557843,feature-engineering,0.5365702,feature-engineering,0.5365702
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,emerging,0.45052218,feature-engineering,0.5309333,feature-engineering,0.5309333
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,evidence,0.28723752,data,0.5728123,generative,0.3943918
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,elsevier,0.26603332,science,0.59524655,data-science,0.53140587
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,inc,0.2706048,bag,0.52860194,bagging,0.41463643
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,drinking,0.31476432,feed,0.52662104,reinforcement-learning,0.4468941
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,water,0.30284643,feed,0.5419835,gradient,0.42149428
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,drinking-water,0.32435203,feed,0.5478481,random-forest,0.407558
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,dependent,0.2523393,of,0.585135,generative,0.43066898
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,activation,0.23066127,cascade,0.649269,feed-forward,0.4652444
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,dependent-activation,0.37881428,of,0.54613173,component-analysis,0.50030845
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,comprehensive,0.5203603,data,0.6056672,data-engineering,0.58421016
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,analysis,0.46507934,analysis,0.99999994,component-analysis,0.69613737
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,cerebral,0.26178035,neural,0.43627065,language-processing,0.40046412
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,cortex,0.29446456,neural,0.5333335,language-processing,0.48932254
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,cerebral-cortex,0.27658474,neural,0.5174473,learning-rate,0.47580922
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,cardiac,0.29562658,of,0.42777455,long-short-term,0.35708636
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,myocytes,0.18731987,rectified,0.40493298,long-short-term,0.35546944
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,cardiac-myocytes,0.272059,neural,0.42712831,recurrent-neural-network,0.37916648
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,artificially,0.3536541,artificial,0.71282935,artificial-intelligence,0.52531946
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,increased,0.26921988,reduction,0.6514183,boosting,0.46515882
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,artificially-increased,0.44409227,artificial,0.70751685,artificial-intelligence,0.55062896
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,ahr,0.17252883,naive,0.3219453,centroid-based,0.30249912
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,responsive,0.19582266,fully,0.44069856,generative,0.34531492
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,ahr-responsive,0.24757577,naive,0.39661682,feed-forward,0.3685075
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,ahr,0.17252883,naive,0.3219453,centroid-based,0.30249912
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,induction,0.22102317,of,0.52603287,long-short-term,0.44878548
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,ahr-induction,0.24211371,short-term,0.46199858,long-short-term,0.42126876
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,ahr,0.17252883,naive,0.3219453,centroid-based,0.30249912
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,activation,0.23066127,cascade,0.649269,feed-forward,0.4652444
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,ahr-activation,0.26693863,cascade,0.5060307,batch-normalization,0.43178886
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,specific,0.3244285,of,0.6059094,clustering,0.45887482
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,manifestations,0.3043628,feature,0.51774037,classification,0.3863002
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,probe,0.29815102,tracking,0.47452274,transfer-learning,0.39548388
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,tissue,0.23679586,of,0.5202017,segmentation,0.4076932
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,probe-tissue,0.36386687,ground-truth,0.509969,ground-truth,0.509969
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,reperfusion,0.25349236,normalization,0.42956924,batch-normalization,0.38744473
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,levels,0.20457911,normalization,0.52984333,batch-normalization,0.45617118
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,induced,0.2259351,of,0.5615651,boosting,0.4303583
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,ckd,0.30266297,logistic-regression,0.3485912,logistic-regression,0.3485912
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,galactosidase,0.19778757,encoding,0.41865906,support-vector,0.3610133
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,mice,0.24457785,naive,0.4783403,short-term-memory,0.38200378
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,aki,0.3459489,logistic-regression,0.35593563,logistic-regression,0.35593563
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,ahr,0.17252883,naive,0.3219453,centroid-based,0.30249912
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,specific,0.3244285,of,0.6059094,clustering,0.45887482
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,tissue,0.23679586,of,0.5202017,segmentation,0.4076932
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,warrant,0.3024001,support,0.5495419,long-short-term,0.4196959
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,use,0.43753043,of,0.5506158,feature-reduction,0.49910897
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,urine,0.23483443,bag,0.47614056,batch-normalization,0.34953934
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,uremia,0.24292353,confusion,0.47330403,batch-normalization,0.40816027
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,time,0.31186903,long,0.57547164,batch-normalization,0.47628766
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,thus,0.33923393,of,0.6779618,feature-reduction,0.46172875
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,subjected,0.30235678,analysis,0.5038986,one-hot,0.3941942
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,signaling,0.29640946,cascade,0.70725644,feed-forward,0.5819744
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,response,0.2143969,of,0.52661085,boosting,0.48192608
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,relationship,0.31931284,regression,0.5493294,regression,0.5493294
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,recapitulated,0.3614174,model,0.5336694,feature-engineering,0.46609974
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,published,0.42179614,data,0.6147139,data-science,0.54664624
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,proximal,0.20720702,long,0.4762103,gradient,0.37478507
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,pattern,0.33640617,feature,0.582756,clustering,0.5010694
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,microvasculature,0.30200186,function,0.48680872,segmentation,0.47189847
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,mediator,0.21336918,cascade,0.57955897,feed-forward,0.4572916
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,mechanism,0.2780391,cascade,0.59194523,feed-forward,0.5341974
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,machine,0.7094662,machine,1.0,machine-learning,0.7094662
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,learning,0.709237,learning,1.0,deep-learning,0.8286492
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,ischemia,0.24609071,normalization,0.40115163,long-short-term,0.36769903
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,investigation,0.33686116,analysis,0.63110995,component-analysis,0.46827114
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,inhibiting,0.22481132,of,0.5194954,boosting,0.46549222
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,humans,0.34170303,natural,0.5139721,generative-model,0.41706812
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,however,0.31437585,few,0.63182676,statistical,0.44065386
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,hepatocytes,0.20851298,naive,0.3839169,batch-normalization,0.3146521
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,excretion,0.171234,feed,0.39966434,batch-normalization,0.38007438
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,distinct,0.36295342,feature,0.580647,clustering,0.5409523
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,details,0.35898703,data,0.58424294,graphics-processing,0.46380037
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,conducted,0.39637828,data,0.556862,statistical,0.4670034
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,changes,0.28767496,normalization,0.57879114,batch-normalization,0.43861648
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,adenine,0.2295933,nearest-neighbors,0.38359052,nearest-neighbors,0.38359052
Excess brain age in the sleep electroencephalogram predicts reduced life expectancy.,evaluate,0.37214977,of,0.4977158,decision-tree,0.4090718
Excess brain age in the sleep electroencephalogram predicts reduced life expectancy.,whether,0.32171756,short-term,0.5290759,long-short-term,0.47851244
Excess brain age in the sleep electroencephalogram predicts reduced life expectancy.,bai,0.20064913,xgboost,0.34807512,xgboost,0.34807512
Excess brain age in the sleep electroencephalogram predicts reduced life expectancy.,predicts,0.42171925,model,0.5194405,long-short-term,0.4803096
Excess brain age in the sleep electroencephalogram predicts reduced life expectancy.,life,0.3004927,style,0.49334684,long-short-term,0.46358624
Excess brain age in the sleep electroencephalogram predicts reduced life expectancy.,expectancy,0.3097231,intelligence,0.49717343,long-short-term,0.46241578
Excess brain age in the sleep electroencephalogram predicts reduced life expectancy.,life-expectancy,0.30224794,decision-tree,0.47952503,decision-tree,0.47952503
Excess brain age in the sleep electroencephalogram predicts reduced life expectancy.,previously,0.31365848,fully,0.5461891,long-short-term,0.40718085
Excess brain age in the sleep electroencephalogram predicts reduced life expectancy.,published,0.42179614,data,0.6147139,data-science,0.54664624
Excess brain age in the sleep electroencephalogram predicts reduced life expectancy.,machine,0.7094662,machine,1.0,machine-learning,0.7094662
Excess brain age in the sleep electroencephalogram predicts reduced life expectancy.,learning,0.709237,learning,1.0,deep-learning,0.8286492
Excess brain age in the sleep electroencephalogram predicts reduced life expectancy.,algorithm,0.7180419,algorithm,1.0,algorithm,1.0
Excess brain age in the sleep electroencephalogram predicts reduced life expectancy.,previously-published,0.5093185,data,0.6091289,graphics-processing,0.55212224
Excess brain age in the sleep electroencephalogram predicts reduced life expectancy.,machine-learning,1.0,machine-learning,1.0,machine-learning,1.0
Excess brain age in the sleep electroencephalogram predicts reduced life expectancy.,participants,0.4160846,object-tracking,0.5017827,object-tracking,0.5017827
Excess brain age in the sleep electroencephalogram predicts reduced life expectancy.,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
Excess brain age in the sleep electroencephalogram predicts reduced life expectancy.,years,0.32825696,intelligence,0.42702603,regression,0.3811771
Excess brain age in the sleep electroencephalogram predicts reduced life expectancy.,old,0.300273,of,0.41376436,generative,0.36879528
Excess brain age in the sleep electroencephalogram predicts reduced life expectancy.,years-old,0.2734174,intelligence,0.40207994,logistic-regression,0.3220154
Excess brain age in the sleep electroencephalogram predicts reduced life expectancy.,sleep,0.3478906,learning-function,0.4834276,learning-function,0.4834276
Excess brain age in the sleep electroencephalogram predicts reduced life expectancy.,heart,0.28300244,rate,0.49867767,batch-normalization,0.3427502
Excess brain age in the sleep electroencephalogram predicts reduced life expectancy.,health,0.36509717,data-science,0.5754831,data-science,0.5754831
Excess brain age in the sleep electroencephalogram predicts reduced life expectancy.,study,0.3645851,of,0.5728763,statistical,0.44204497
Excess brain age in the sleep electroencephalogram predicts reduced life expectancy.,heart-health,0.43311024,data-science,0.53928626,data-science,0.53928626
Excess brain age in the sleep electroencephalogram predicts reduced life expectancy.,health-study,0.38698035,data-science,0.5559055,data-science,0.5559055
Excess brain age in the sleep electroencephalogram predicts reduced life expectancy.,years,0.32825696,intelligence,0.42702603,regression,0.3811771
Excess brain age in the sleep electroencephalogram predicts reduced life expectancy.,per,0.22352321,unit,0.5148517,supervised,0.33758792
Excess brain age in the sleep electroencephalogram predicts reduced life expectancy.,standard,0.3833671,batch-normalization,0.52681863,batch-normalization,0.52681863
Excess brain age in the sleep electroencephalogram predicts reduced life expectancy.,per-standard,0.43974933,classification-algorithm,0.5446986,classification-algorithm,0.5446986
Excess brain age in the sleep electroencephalogram predicts reduced life expectancy.,reduced,0.24137571,reduction,0.7564339,boosting,0.47559226
Excess brain age in the sleep electroencephalogram predicts reduced life expectancy.,life,0.3004927,style,0.49334684,long-short-term,0.46358624
Excess brain age in the sleep electroencephalogram predicts reduced life expectancy.,expectancy,0.3097231,intelligence,0.49717343,long-short-term,0.46241578
Excess brain age in the sleep electroencephalogram predicts reduced life expectancy.,life-expectancy,0.30224794,decision-tree,0.47952503,decision-tree,0.47952503
Excess brain age in the sleep electroencephalogram predicts reduced life expectancy.,life,0.3004927,style,0.49334684,long-short-term,0.46358624
Excess brain age in the sleep electroencephalogram predicts reduced life expectancy.,expectancy,0.3097231,intelligence,0.49717343,long-short-term,0.46241578
Excess brain age in the sleep electroencephalogram predicts reduced life expectancy.,decreased,0.23506472,reduction,0.66483074,boosting,0.42738107
Excess brain age in the sleep electroencephalogram predicts reduced life expectancy.,life-expectancy,0.30224794,decision-tree,0.47952503,decision-tree,0.47952503
Excess brain age in the sleep electroencephalogram predicts reduced life expectancy.,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
Excess brain age in the sleep electroencephalogram predicts reduced life expectancy.,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
Excess brain age in the sleep electroencephalogram predicts reduced life expectancy.,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
Excess brain age in the sleep electroencephalogram predicts reduced life expectancy.,p,0.26795468,support,0.40805867,regression,0.40253854
Excess brain age in the sleep electroencephalogram predicts reduced life expectancy.,adjusted,0.33626905,logistic,0.654571,logistic-regression,0.64486897
Excess brain age in the sleep electroencephalogram predicts reduced life expectancy.,hazard,0.35112607,logistic,0.6028925,logistic-regression,0.5981426
Excess brain age in the sleep electroencephalogram predicts reduced life expectancy.,ratio,0.19492707,rate,0.48224086,regression,0.41092375
Excess brain age in the sleep electroencephalogram predicts reduced life expectancy.,adjusted-hazard,0.37488252,logistic,0.676689,logistic-regression,0.6752348
Excess brain age in the sleep electroencephalogram predicts reduced life expectancy.,hazard-ratio,0.40377024,logistic-regression,0.6386619,logistic-regression,0.6386619
Excess brain age in the sleep electroencephalogram predicts reduced life expectancy.,adjusted-hazard-ratio,0.40739828,logistic-regression,0.69552445,logistic-regression,0.69552445
Excess brain age in the sleep electroencephalogram predicts reduced life expectancy.,overnight,0.24178603,bag,0.5848429,bagging,0.46611938
Excess brain age in the sleep electroencephalogram predicts reduced life expectancy.,sleep,0.3478906,learning-function,0.4834276,learning-function,0.4834276
Excess brain age in the sleep electroencephalogram predicts reduced life expectancy.,electroencephalogram,0.4216392,learning-function,0.51480573,learning-function,0.51480573
Excess brain age in the sleep electroencephalogram predicts reduced life expectancy.,sleep-electroencephalogram,0.4173324,learning-function,0.54470426,learning-function,0.54470426
Excess brain age in the sleep electroencephalogram predicts reduced life expectancy.,age,0.30743492,intelligence,0.4774798,regression,0.47452933
Excess brain age in the sleep electroencephalogram predicts reduced life expectancy.,norms,0.37719822,style,0.6176006,natural-language,0.5928556
Excess brain age in the sleep electroencephalogram predicts reduced life expectancy.,age-norms,0.37391555,intelligence,0.56537265,natural-language-processing,0.55092525
Excess brain age in the sleep electroencephalogram predicts reduced life expectancy.,excess,0.15883704,reduction,0.5961697,batch-normalization,0.39163512
Excess brain age in the sleep electroencephalogram predicts reduced life expectancy.,brain,0.31704307,neural,0.57897407,learning-rate,0.44069666
Excess brain age in the sleep electroencephalogram predicts reduced life expectancy.,age,0.30743492,intelligence,0.4774798,regression,0.47452933
Excess brain age in the sleep electroencephalogram predicts reduced life expectancy.,brain-age,0.41315168,intelligence,0.58781,learning-function,0.55559003
Excess brain age in the sleep electroencephalogram predicts reduced life expectancy.,comparing,0.42273027,of,0.5523274,statistical,0.50475013
Excess brain age in the sleep electroencephalogram predicts reduced life expectancy.,eeg,0.41578054,learning-rate,0.52234596,learning-rate,0.52234596
Excess brain age in the sleep electroencephalogram predicts reduced life expectancy.,features,0.51742536,feature,0.8268872,feature-selection,0.5487305
Excess brain age in the sleep electroencephalogram predicts reduced life expectancy.,eeg-features,0.67111313,classifiers,0.6953459,classifiers,0.6953459
Excess brain age in the sleep electroencephalogram predicts reduced life expectancy.,brain,0.31704307,neural,0.57897407,learning-rate,0.44069666
Excess brain age in the sleep electroencephalogram predicts reduced life expectancy.,age,0.30743492,intelligence,0.4774798,regression,0.47452933
Excess brain age in the sleep electroencephalogram predicts reduced life expectancy.,index,0.27978244,function,0.407383,classification-algorithm,0.3994653
Excess brain age in the sleep electroencephalogram predicts reduced life expectancy.,brain-age,0.41315168,intelligence,0.58781,learning-function,0.55559003
Excess brain age in the sleep electroencephalogram predicts reduced life expectancy.,life,0.3004927,style,0.49334684,long-short-term,0.46358624
Excess brain age in the sleep electroencephalogram predicts reduced life expectancy.,expectancy,0.3097231,intelligence,0.49717343,long-short-term,0.46241578
Excess brain age in the sleep electroencephalogram predicts reduced life expectancy.,life-expectancy,0.30224794,decision-tree,0.47952503,decision-tree,0.47952503
Excess brain age in the sleep electroencephalogram predicts reduced life expectancy.,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
Excess brain age in the sleep electroencephalogram predicts reduced life expectancy.,brain,0.31704307,neural,0.57897407,learning-rate,0.44069666
Excess brain age in the sleep electroencephalogram predicts reduced life expectancy.,age,0.30743492,intelligence,0.4774798,regression,0.47452933
Excess brain age in the sleep electroencephalogram predicts reduced life expectancy.,brain-age,0.41315168,intelligence,0.58781,learning-function,0.55559003
Excess brain age in the sleep electroencephalogram predicts reduced life expectancy.,sleep,0.3478906,learning-function,0.4834276,learning-function,0.4834276
Excess brain age in the sleep electroencephalogram predicts reduced life expectancy.,microstructure,0.35639802,layer,0.58495235,convolutional-layer,0.5500895
Excess brain age in the sleep electroencephalogram predicts reduced life expectancy.,sleep,0.3478906,learning-function,0.4834276,learning-function,0.4834276
Excess brain age in the sleep electroencephalogram predicts reduced life expectancy.,eeg,0.41578054,learning-rate,0.52234596,learning-rate,0.52234596
Excess brain age in the sleep electroencephalogram predicts reduced life expectancy.,sleep-eeg,0.36761066,learning-function,0.4833198,learning-function,0.4833198
Excess brain age in the sleep electroencephalogram predicts reduced life expectancy.,chronological,0.39234942,language-processing,0.52847624,language-processing,0.52847624
Excess brain age in the sleep electroencephalogram predicts reduced life expectancy.,age,0.30743492,intelligence,0.4774798,regression,0.47452933
Excess brain age in the sleep electroencephalogram predicts reduced life expectancy.,chronological-age,0.38924122,natural-language-processing,0.54236734,natural-language-processing,0.54236734
Excess brain age in the sleep electroencephalogram predicts reduced life expectancy.,rights,0.3170033,adversarial,0.6281444,data-science,0.57488894
Excess brain age in the sleep electroencephalogram predicts reduced life expectancy.,reserved,0.28677964,of,0.4776592,supervised,0.3944377
Excess brain age in the sleep electroencephalogram predicts reduced life expectancy.,quantified,0.37021068,analysis,0.5436782,batch-normalization,0.45715806
Excess brain age in the sleep electroencephalogram predicts reduced life expectancy.,using,0.47332245,analysis,0.5968549,component-analysis,0.526608
Excess brain age in the sleep electroencephalogram predicts reduced life expectancy.,patterns,0.37740147,of,0.55208683,clustering,0.526253
Excess brain age in the sleep electroencephalogram predicts reduced life expectancy.,normal,0.22889833,function,0.57724285,batch-normalization,0.4663512
Excess brain age in the sleep electroencephalogram predicts reduced life expectancy.,independent,0.39991486,of,0.5904635,regression,0.57876456
Excess brain age in the sleep electroencephalogram predicts reduced life expectancy.,predictor,0.43901688,regression,0.5961869,regression,0.5961869
Excess brain age in the sleep electroencephalogram predicts reduced life expectancy.,independent-predictor,0.6123905,logistic-regression,0.70282865,logistic-regression,0.70282865
Excess brain age in the sleep electroencephalogram predicts reduced life expectancy.,findings,0.35685748,data,0.65714294,component-analysis,0.38599753
Excess brain age in the sleep electroencephalogram predicts reduced life expectancy.,show,0.33248252,of,0.51487744,feature-selection,0.44449317
Excess brain age in the sleep electroencephalogram predicts reduced life expectancy.,based,0.49998575,classification-algorithm,0.5639226,classification-algorithm,0.5639226
Excess brain age in the sleep electroencephalogram predicts reduced life expectancy.,biomarker,0.43929577,classifiers,0.45752043,classifiers,0.45752043
Excess brain age in the sleep electroencephalogram predicts reduced life expectancy.,deviation,0.27602112,batch-normalization,0.5026854,batch-normalization,0.5026854
Excess brain age in the sleep electroencephalogram predicts reduced life expectancy.,increase,0.28092995,reduction,0.7624404,boosting,0.49543357
Excess brain age in the sleep electroencephalogram predicts reduced life expectancy.,deviation-increase,0.39181018,normalization,0.6088642,batch-normalization,0.5889802
Excess brain age in the sleep electroencephalogram predicts reduced life expectancy.,ca,0.20045865,of,0.41283906,clustering,0.3339435
Excess brain age in the sleep electroencephalogram predicts reduced life expectancy.,bai,0.20064913,xgboost,0.34807512,xgboost,0.34807512
Excess brain age in the sleep electroencephalogram predicts reduced life expectancy.,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
Excess brain age in the sleep electroencephalogram predicts reduced life expectancy.,sleep,0.3478906,learning-function,0.4834276,learning-function,0.4834276
Excess brain age in the sleep electroencephalogram predicts reduced life expectancy.,age,0.30743492,intelligence,0.4774798,regression,0.47452933
Excess brain age in the sleep electroencephalogram predicts reduced life expectancy.,eeg,0.41578054,learning-rate,0.52234596,learning-rate,0.52234596
Excess brain age in the sleep electroencephalogram predicts reduced life expectancy.,deviation,0.27602112,batch-normalization,0.5026854,batch-normalization,0.5026854
Excess brain age in the sleep electroencephalogram predicts reduced life expectancy.,ca,0.20045865,of,0.41283906,clustering,0.3339435
Excess brain age in the sleep electroencephalogram predicts reduced life expectancy.,underwent,0.251209,recurrent,0.4136293,supervised,0.35678548
Excess brain age in the sleep electroencephalogram predicts reduced life expectancy.,part,0.25869048,of,0.6214935,component-analysis,0.47792363
Excess brain age in the sleep electroencephalogram predicts reduced life expectancy.,n,0.24332823,of,0.45693433,long-short-term,0.34114176
Excess brain age in the sleep electroencephalogram predicts reduced life expectancy.,measures,0.3789752,principal-components,0.5349536,principal-components,0.5349536
Excess brain age in the sleep electroencephalogram predicts reduced life expectancy.,individual,0.4013941,of,0.6520203,dimensionality-reduction,0.564764
Excess brain age in the sleep electroencephalogram predicts reduced life expectancy.,estimated,0.3423246,rate,0.5632778,regression,0.49483663
Excess brain age in the sleep electroencephalogram predicts reduced life expectancy.,difference,0.30501923,statistical,0.58389574,statistical,0.58389574
Excess brain age in the sleep electroencephalogram predicts reduced life expectancy.,cohort,0.3892265,logistic-regression,0.5412916,logistic-regression,0.5412916
Excess brain age in the sleep electroencephalogram predicts reduced life expectancy.,ba,0.14832494,of,0.37663195,principal-components,0.3525193
Excess brain age in the sleep electroencephalogram predicts reduced life expectancy.,associated,0.30827495,of,0.57598466,long-short-term,0.46578532
Excess brain age in the sleep electroencephalogram predicts reduced life expectancy.,apparent,0.22103967,of,0.58568347,confusion-matrix,0.4399731
Gated recurrent unit-based heart sound analysis for heart failure screening.,novel,0.4652171,feature-engineering,0.5132146,feature-engineering,0.5132146
Gated recurrent unit-based heart sound analysis for heart failure screening.,hf,0.293398,long-short-term,0.35116297,long-short-term,0.35116297
Gated recurrent unit-based heart sound analysis for heart failure screening.,screening,0.38869897,selection,0.4576743,data-engineering,0.4313178
Gated recurrent unit-based heart sound analysis for heart failure screening.,framework,0.5690361,hierarchical,0.6853048,hierarchical-clustering,0.6804691
Gated recurrent unit-based heart sound analysis for heart failure screening.,based,0.49998575,classification-algorithm,0.5639226,classification-algorithm,0.5639226
Gated recurrent unit-based heart sound analysis for heart failure screening.,hf-screening,0.4420681,computer-vision,0.45912063,computer-vision,0.45912063
Gated recurrent unit-based heart sound analysis for heart failure screening.,framework-based,0.65389234,hierarchical,0.710599,hierarchical-clustering,0.69644606
Gated recurrent unit-based heart sound analysis for heart failure screening.,conveys,0.3283953,of,0.50973374,generative,0.49321663
Gated recurrent unit-based heart sound analysis for heart failure screening.,relevant,0.4346258,of,0.5628227,natural-language,0.5076148
Gated recurrent unit-based heart sound analysis for heart failure screening.,information,0.5191034,data,0.708436,data-science,0.5937191
Gated recurrent unit-based heart sound analysis for heart failure screening.,related,0.30849367,of,0.6150687,clustering,0.41455543
Gated recurrent unit-based heart sound analysis for heart failure screening.,information-related,0.53686243,dimensionality-reduction,0.58584666,dimensionality-reduction,0.58584666
Gated recurrent unit-based heart sound analysis for heart failure screening.,hf,0.293398,long-short-term,0.35116297,long-short-term,0.35116297
Gated recurrent unit-based heart sound analysis for heart failure screening.,screening,0.38869897,selection,0.4576743,data-engineering,0.4313178
Gated recurrent unit-based heart sound analysis for heart failure screening.,without,0.31691062,of,0.5951073,long-short-term,0.4268921
Gated recurrent unit-based heart sound analysis for heart failure screening.,de,0.31196046,monte,0.4464782,monte,0.4464782
Gated recurrent unit-based heart sound analysis for heart failure screening.,hf-screening,0.4420681,computer-vision,0.45912063,computer-vision,0.45912063
Gated recurrent unit-based heart sound analysis for heart failure screening.,reduced,0.24137571,reduction,0.7564339,boosting,0.47559226
Gated recurrent unit-based heart sound analysis for heart failure screening.,ejection,0.30230433,function,0.43955976,gradient,0.35697576
Gated recurrent unit-based heart sound analysis for heart failure screening.,fraction,0.25137818,component,0.50911963,gradient,0.48876822
Gated recurrent unit-based heart sound analysis for heart failure screening.,automatically,0.65330756,segmentation,0.6840899,segmentation,0.6840899
Gated recurrent unit-based heart sound analysis for heart failure screening.,reduced-ejection,0.3536169,data-augmentation,0.49796093,data-augmentation,0.49796093
Gated recurrent unit-based heart sound analysis for heart failure screening.,ejection-fraction,0.36681443,stochastic-gradient,0.5523829,stochastic-gradient,0.5523829
Gated recurrent unit-based heart sound analysis for heart failure screening.,preserved,0.28254378,function,0.6360263,short-term-memory,0.44489402
Gated recurrent unit-based heart sound analysis for heart failure screening.,ejection,0.30230433,function,0.43955976,gradient,0.35697576
Gated recurrent unit-based heart sound analysis for heart failure screening.,fraction,0.25137818,component,0.50911963,gradient,0.48876822
Gated recurrent unit-based heart sound analysis for heart failure screening.,preserved-ejection,0.305955,batch-normalization,0.5166229,batch-normalization,0.5166229
Gated recurrent unit-based heart sound analysis for heart failure screening.,ejection-fraction,0.36681443,stochastic-gradient,0.5523829,stochastic-gradient,0.5523829
Gated recurrent unit-based heart sound analysis for heart failure screening.,based,0.49998575,classification-algorithm,0.5639226,classification-algorithm,0.5639226
Gated recurrent unit-based heart sound analysis for heart failure screening.,hidden,0.58507276,hidden,0.99999994,hidden-markov,0.6948478
Gated recurrent unit-based heart sound analysis for heart failure screening.,semi,0.358493,ground,0.5386474,monte,0.4239909
Gated recurrent unit-based heart sound analysis for heart failure screening.,hf,0.293398,long-short-term,0.35116297,long-short-term,0.35116297
Gated recurrent unit-based heart sound analysis for heart failure screening.,early,0.32400474,short-term,0.57188475,long-short-term,0.50726265
Gated recurrent unit-based heart sound analysis for heart failure screening.,screening,0.38869897,selection,0.4576743,data-engineering,0.4313178
Gated recurrent unit-based heart sound analysis for heart failure screening.,hf-early,0.22888368,long-short-term,0.4041075,long-short-term,0.4041075
Gated recurrent unit-based heart sound analysis for heart failure screening.,early-screening,0.4504961,decision-tree,0.4760525,decision-tree,0.4760525
Gated recurrent unit-based heart sound analysis for heart failure screening.,gated,0.3476143,function,0.49369168,segmentation,0.47012198
Gated recurrent unit-based heart sound analysis for heart failure screening.,recurrent,0.32854465,recurrent,1.0,recurrent-neural-network,0.59633
Gated recurrent unit-based heart sound analysis for heart failure screening.,unit,0.25243485,unit,1.0,graphics-processing-unit,0.44255573
Gated recurrent unit-based heart sound analysis for heart failure screening.,crafted,0.5124461,feature-engineering,0.662228,feature-engineering,0.662228
Gated recurrent unit-based heart sound analysis for heart failure screening.,feature,0.5878884,feature,0.99999994,feature-selection,0.6322505
Gated recurrent unit-based heart sound analysis for heart failure screening.,extraction,0.414975,batch-normalization,0.5036997,batch-normalization,0.5036997
Gated recurrent unit-based heart sound analysis for heart failure screening.,feature-extraction,0.6154202,principal-component-analysis,0.6529901,principal-component-analysis,0.6529901
Gated recurrent unit-based heart sound analysis for heart failure screening.,cardiovascular,0.31674606,short-term,0.442761,learning-function,0.4027721
Gated recurrent unit-based heart sound analysis for heart failure screening.,disease,0.296938,recurrent,0.4731025,classification,0.35271814
Gated recurrent unit-based heart sound analysis for heart failure screening.,caused,0.14436965,of,0.53973085,long-short-term,0.3204536
Gated recurrent unit-based heart sound analysis for heart failure screening.,cardiovascular-disease,0.39733815,logistic-regression,0.43556237,logistic-regression,0.43556237
Gated recurrent unit-based heart sound analysis for heart failure screening.,disease-caused,0.34113565,recurrent,0.44584918,stochastic,0.43148383
Gated recurrent unit-based heart sound analysis for heart failure screening.,abnormal,0.27085721,normalization,0.55760914,batch-normalization,0.43939346
Gated recurrent unit-based heart sound analysis for heart failure screening.,cardiac,0.29562658,of,0.42777455,long-short-term,0.35708636
Gated recurrent unit-based heart sound analysis for heart failure screening.,structure,0.3356646,hierarchical,0.5517567,hierarchical-clustering,0.5486842
Gated recurrent unit-based heart sound analysis for heart failure screening.,good,0.29142508,few,0.4427599,bagging,0.41576368
Gated recurrent unit-based heart sound analysis for heart failure screening.,performance,0.50728506,learning-function,0.63351834,learning-function,0.63351834
Gated recurrent unit-based heart sound analysis for heart failure screening.,demonstrates,0.32810378,of,0.5866501,feature-engineering,0.42233235
Gated recurrent unit-based heart sound analysis for heart failure screening.,good-performance,0.52928585,learning-function,0.6162779,learning-function,0.6162779
Gated recurrent unit-based heart sound analysis for heart failure screening.,gru,0.23813292,unit,0.4147297,graphics-processing-unit,0.36511666
Gated recurrent unit-based heart sound analysis for heart failure screening.,model,0.48485535,model,1.0,markov-model,0.7005576
Gated recurrent unit-based heart sound analysis for heart failure screening.,gives,0.29249048,of,0.5415878,generative,0.46116185
Gated recurrent unit-based heart sound analysis for heart failure screening.,segment,0.1674358,long,0.5143941,segmentation,0.46774617
Gated recurrent unit-based heart sound analysis for heart failure screening.,hs,0.2673457,one,0.43101203,relu,0.41677517
Gated recurrent unit-based heart sound analysis for heart failure screening.,frames,0.4001165,encoding,0.6336179,object-tracking,0.4804302
Gated recurrent unit-based heart sound analysis for heart failure screening.,proposed,0.55786884,classification-algorithm,0.6311488,classification-algorithm,0.6311488
Gated recurrent unit-based heart sound analysis for heart failure screening.,gru,0.23813292,unit,0.4147297,graphics-processing-unit,0.36511666
Gated recurrent unit-based heart sound analysis for heart failure screening.,model,0.48485535,model,1.0,markov-model,0.7005576
Gated recurrent unit-based heart sound analysis for heart failure screening.,early,0.32400474,short-term,0.57188475,long-short-term,0.50726265
Gated recurrent unit-based heart sound analysis for heart failure screening.,screening,0.38869897,selection,0.4576743,data-engineering,0.4313178
Gated recurrent unit-based heart sound analysis for heart failure screening.,early-screening,0.4504961,decision-tree,0.4760525,decision-tree,0.4760525
Gated recurrent unit-based heart sound analysis for heart failure screening.,therefore,0.37519994,of,0.6409915,feature-reduction,0.45783085
Gated recurrent unit-based heart sound analysis for heart failure screening.,based,0.49998575,classification-algorithm,0.5639226,classification-algorithm,0.5639226
Gated recurrent unit-based heart sound analysis for heart failure screening.,automatically,0.65330756,segmentation,0.6840899,segmentation,0.6840899
Gated recurrent unit-based heart sound analysis for heart failure screening.,learn,0.6603636,learning,0.7921181,deep-learning,0.717052
Gated recurrent unit-based heart sound analysis for heart failure screening.,normalized,0.3501855,normalization,0.79768026,batch-normalization,0.69691867
Gated recurrent unit-based heart sound analysis for heart failure screening.,frames,0.4001165,encoding,0.6336179,object-tracking,0.4804302
Gated recurrent unit-based heart sound analysis for heart failure screening.,proposed,0.55786884,classification-algorithm,0.6311488,classification-algorithm,0.6311488
Gated recurrent unit-based heart sound analysis for heart failure screening.,model,0.48485535,model,1.0,markov-model,0.7005576
Gated recurrent unit-based heart sound analysis for heart failure screening.,proposed-model,0.66141236,markov-model,0.79401195,markov-model,0.79401195
Gated recurrent unit-based heart sound analysis for heart failure screening.,markov,0.6343037,markov,1.0,markov,1.0
Gated recurrent unit-based heart sound analysis for heart failure screening.,model,0.48485535,model,1.0,markov-model,0.7005576
Gated recurrent unit-based heart sound analysis for heart failure screening.,markov-model,0.65443003,markov-model,1.0,markov-model,1.0
Gated recurrent unit-based heart sound analysis for heart failure screening.,timely,0.3652631,decision,0.5888524,decision-tree,0.4443227
Gated recurrent unit-based heart sound analysis for heart failure screening.,manner,0.26802608,fully,0.46465638,feed-forward,0.4349473
Gated recurrent unit-based heart sound analysis for heart failure screening.,satisfactory,0.26833487,cross-validation,0.44676808,cross-validation,0.44676808
Gated recurrent unit-based heart sound analysis for heart failure screening.,performance,0.50728506,learning-function,0.63351834,learning-function,0.63351834
Gated recurrent unit-based heart sound analysis for heart failure screening.,logistic,0.5418149,logistic,1.0,logistic-regression,0.9215903
Gated recurrent unit-based heart sound analysis for heart failure screening.,regression,0.4967034,regression,1.0,regression,1.0
Gated recurrent unit-based heart sound analysis for heart failure screening.,logistic-regression,0.5787163,logistic-regression,0.99999994,logistic-regression,0.99999994
Gated recurrent unit-based heart sound analysis for heart failure screening.,learn,0.6603636,learning,0.7921181,deep-learning,0.717052
Gated recurrent unit-based heart sound analysis for heart failure screening.,features,0.51742536,feature,0.8268872,feature-selection,0.5487305
Gated recurrent unit-based heart sound analysis for heart failure screening.,important,0.33620566,principal,0.5803634,feature-engineering,0.43471682
Gated recurrent unit-based heart sound analysis for heart failure screening.,implication,0.35317189,of,0.6111196,feature-engineering,0.47362676
Gated recurrent unit-based heart sound analysis for heart failure screening.,identify,0.46963936,analysis,0.5445881,clustering,0.4863696
Gated recurrent unit-based heart sound analysis for heart failure screening.,subjects,0.34547177,descent,0.47816435,short-term-memory,0.43421033
Gated recurrent unit-based heart sound analysis for heart failure screening.,hs,0.2673457,one,0.43101203,relu,0.41677517
Gated recurrent unit-based heart sound analysis for heart failure screening.,signals,0.3700128,components,0.5488684,feed-forward,0.52579325
Gated recurrent unit-based heart sound analysis for heart failure screening.,hs,0.2673457,one,0.43101203,relu,0.41677517
Gated recurrent unit-based heart sound analysis for heart failure screening.,directly,0.29203913,of,0.58113813,clustering,0.40171087
Gated recurrent unit-based heart sound analysis for heart failure screening.,heart,0.28300244,rate,0.49867767,batch-normalization,0.3427502
Gated recurrent unit-based heart sound analysis for heart failure screening.,sound,0.38553363,ground,0.5200351,natural-language-processing,0.49441797
Gated recurrent unit-based heart sound analysis for heart failure screening.,heart-sound,0.4708497,segmentation-algorithm,0.50187725,segmentation-algorithm,0.50187725
Gated recurrent unit-based heart sound analysis for heart failure screening.,heart,0.28300244,rate,0.49867767,batch-normalization,0.3427502
Gated recurrent unit-based heart sound analysis for heart failure screening.,failure,0.32964212,recurrent,0.52057266,confusion-matrix,0.44323406
Gated recurrent unit-based heart sound analysis for heart failure screening.,heart-failure,0.36450487,long-short-term,0.44014218,long-short-term,0.44014218
Gated recurrent unit-based heart sound analysis for heart failure screening.,expert,0.5552304,data-science,0.6404677,data-science,0.6404677
Gated recurrent unit-based heart sound analysis for heart failure screening.,knowledge,0.5362035,science,0.551701,data-science,0.5440523
Gated recurrent unit-based heart sound analysis for heart failure screening.,expert-knowledge,0.65679336,data-science,0.7110015,data-science,0.7110015
Gated recurrent unit-based heart sound analysis for heart failure screening.,efficient,0.44278914,feature-engineering,0.5657042,feature-engineering,0.5657042
Gated recurrent unit-based heart sound analysis for heart failure screening.,tool,0.58027077,machine-learning,0.58027077,machine-learning,0.58027077
Gated recurrent unit-based heart sound analysis for heart failure screening.,deep,0.38070458,deep,0.99999994,deep-learning,0.4875875
Gated recurrent unit-based heart sound analysis for heart failure screening.,features,0.51742536,feature,0.8268872,feature-selection,0.5487305
Gated recurrent unit-based heart sound analysis for heart failure screening.,average,0.3150683,rate,0.48881143,batch-normalization,0.44438002
Gated recurrent unit-based heart sound analysis for heart failure screening.,accuracy,0.5511073,cross-validation,0.64088035,cross-validation,0.64088035
Gated recurrent unit-based heart sound analysis for heart failure screening.,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
Gated recurrent unit-based heart sound analysis for heart failure screening.,three,0.36911732,one,0.78425425,clustering,0.4299444
Gated recurrent unit-based heart sound analysis for heart failure screening.,methods,0.50049126,data,0.5400177,machine-learning,0.50049126
Gated recurrent unit-based heart sound analysis for heart failure screening.,three-methods,0.5221853,principal-component-analysis,0.6077428,principal-component-analysis,0.6077428
Gated recurrent unit-based heart sound analysis for heart failure screening.,results,0.32376552,data,0.6932311,batch-normalization,0.44826904
Gated recurrent unit-based heart sound analysis for heart failure screening.,show,0.33248252,of,0.51487744,feature-selection,0.44449317
Gated recurrent unit-based heart sound analysis for heart failure screening.,hs,0.2673457,one,0.43101203,relu,0.41677517
Gated recurrent unit-based heart sound analysis for heart failure screening.,analysis,0.46507934,analysis,0.99999994,component-analysis,0.69613737
Gated recurrent unit-based heart sound analysis for heart failure screening.,comparison,0.38020527,analysis,0.5798166,statistical,0.52489424
Gated recurrent unit-based heart sound analysis for heart failure screening.,models,0.53762007,model,0.8940372,markov-model,0.7015921
Gated recurrent unit-based heart sound analysis for heart failure screening.,hf,0.293398,long-short-term,0.35116297,long-short-term,0.35116297
Gated recurrent unit-based heart sound analysis for heart failure screening.,gru,0.23813292,unit,0.4147297,graphics-processing-unit,0.36511666
Gated recurrent unit-based heart sound analysis for heart failure screening.,model,0.48485535,model,1.0,markov-model,0.7005576
Gated recurrent unit-based heart sound analysis for heart failure screening.,proposed,0.55786884,classification-algorithm,0.6311488,classification-algorithm,0.6311488
Gated recurrent unit-based heart sound analysis for heart failure screening.,performance,0.50728506,learning-function,0.63351834,learning-function,0.63351834
Gated recurrent unit-based heart sound analysis for heart failure screening.,hs,0.2673457,one,0.43101203,relu,0.41677517
Gated recurrent unit-based heart sound analysis for heart failure screening.,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
Gated recurrent unit-based heart sound analysis for heart failure screening.,results,0.32376552,data,0.6932311,batch-normalization,0.44826904
Gated recurrent unit-based heart sound analysis for heart failure screening.,methods,0.50049126,data,0.5400177,machine-learning,0.50049126
Gated recurrent unit-based heart sound analysis for heart failure screening.,comparison,0.38020527,analysis,0.5798166,statistical,0.52489424
Gated recurrent unit-based heart sound analysis for heart failure screening.,analysis,0.46507934,analysis,0.99999994,component-analysis,0.69613737
Gated recurrent unit-based heart sound analysis for heart failure screening.,used,0.46049535,of,0.5630944,generative-model,0.4901716
Gated recurrent unit-based heart sound analysis for heart failure screening.,type,0.21671848,of,0.48202556,classification,0.43098688
Gated recurrent unit-based heart sound analysis for heart failure screening.,treatment,0.239264,short-term,0.5206091,long-short-term,0.41699445
Gated recurrent unit-based heart sound analysis for heart failure screening.,taken,0.31208742,data,0.5517592,supervised,0.41763523
Gated recurrent unit-based heart sound analysis for heart failure screening.,study,0.3645851,of,0.5728763,statistical,0.44204497
Gated recurrent unit-based heart sound analysis for heart failure screening.,objective,0.4122544,of,0.5255821,component-analysis,0.42220753
Gated recurrent unit-based heart sound analysis for heart failure screening.,nosing,0.31570312,of,0.48118138,generative,0.44629794
Gated recurrent unit-based heart sound analysis for heart failure screening.,normal,0.22889833,function,0.57724285,batch-normalization,0.4663512
Gated recurrent unit-based heart sound analysis for heart failure screening.,means,0.38858432,of,0.5759921,dimensionality-reduction,0.53678924
Gated recurrent unit-based heart sound analysis for heart failure screening.,input,0.49092877,feed-forward,0.58275104,feed-forward,0.58275104
Gated recurrent unit-based heart sound analysis for heart failure screening.,independent,0.39991486,of,0.5904635,regression,0.57876456
Gated recurrent unit-based heart sound analysis for heart failure screening.,hand,0.3085481,of,0.49105775,one-hot,0.40915227
Gated recurrent unit-based heart sound analysis for heart failure screening.,function,0.3447219,function,1.0,learning-function,0.5767432
Gated recurrent unit-based heart sound analysis for heart failure screening.,evaluate,0.37214977,of,0.4977158,decision-tree,0.4090718
Gated recurrent unit-based heart sound analysis for heart failure screening.,effectiveness,0.38338125,short-term,0.6059195,dimensionality-reduction,0.5238044
Gated recurrent unit-based heart sound analysis for heart failure screening.,develop,0.4619095,generative,0.52892005,generative,0.52892005
Gated recurrent unit-based heart sound analysis for heart failure screening.,conclusion,0.35530132,data,0.5299138,long-short-term,0.45073265
Gated recurrent unit-based heart sound analysis for heart failure screening.,complete,0.23073666,of,0.51385504,batch-normalization,0.37797216
Gated recurrent unit-based heart sound analysis for heart failure screening.,better,0.4230538,of,0.5337099,feature-reduction,0.47485045
Gated recurrent unit-based heart sound analysis for heart failure screening.,background,0.3259285,of,0.51277274,long-short-term,0.46426663
Gated recurrent unit-based heart sound analysis for heart failure screening.,adopted,0.5152594,feature-engineering,0.5414686,feature-engineering,0.5414686
Gated recurrent unit-based heart sound analysis for heart failure screening.,addition,0.30500388,of,0.6910241,feature-reduction,0.48914018
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,apolipoprotein,0.25016165,tf-idf,0.31200302,tf-idf,0.31200302
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,b,0.19558734,of,0.43435428,short-term-memory,0.31717262
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,quartiles,0.26269093,logistic,0.5587156,logistic-regression,0.53158706
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,produced,0.26875606,of,0.57611185,generative,0.45561808
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,better,0.4230538,of,0.5337099,feature-reduction,0.47485045
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,resolution,0.31286857,tracking,0.46759,segmentation,0.44991145
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,apolipoprotein-b,0.2448067,tf-idf,0.32602477,tf-idf,0.32602477
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,improve,0.45207965,boosting,0.5098576,boosting,0.5098576
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,coronary,0.25158757,of,0.3349695,segmentation-algorithm,0.31949025
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,heart,0.28300244,rate,0.49867767,batch-normalization,0.3427502
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,disease,0.296938,recurrent,0.4731025,classification,0.35271814
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,coronary-heart,0.24738656,long-short-term,0.33648896,long-short-term,0.33648896
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,heart-disease,0.35198575,long-short-term,0.43214932,long-short-term,0.43214932
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,coronary-heart-disease,0.3109823,long-short-term,0.40599877,long-short-term,0.40599877
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,even,0.3460787,of,0.6281029,long-short-term,0.5172001
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,advanced,0.4209618,of,0.47114033,machine-learning,0.4209618
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,multivariate,0.54642415,logistic,0.86571586,logistic-regression,0.84866464
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,subgrouping,0.4920114,classification,0.7210405,classification,0.7210405
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,comprehensive,0.5203603,data,0.6056672,data-engineering,0.58421016
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,lipoprotein,0.22208765,tf-idf,0.3608624,tf-idf,0.3608624
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,subclass,0.29691276,classification,0.44419107,classification,0.44419107
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,data,0.46434748,data,1.0,data-science,0.5533528
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,lipoprotein-subclass,0.32997024,tf-idf,0.41224098,tf-idf,0.41224098
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,advance,0.42053145,feed,0.53599316,data-science,0.4783376
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,chd,0.3007669,logistic-regression,0.39436275,logistic-regression,0.39436275
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,risk,0.35860935,recurrent,0.53675485,logistic-regression,0.52381086
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,assessment,0.4002061,analysis,0.5275976,component-analysis,0.49803802
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,chd-risk,0.30764726,logistic-regression,0.44936946,logistic-regression,0.44936946
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,risk-assessment,0.5291727,decision-tree,0.6316601,decision-tree,0.6316601
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,apolipoprotein,0.25016165,tf-idf,0.31200302,tf-idf,0.31200302
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,b,0.19558734,of,0.43435428,short-term-memory,0.31717262
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,quartiles,0.26269093,logistic,0.5587156,logistic-regression,0.53158706
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,apolipoprotein-b,0.2448067,tf-idf,0.32602477,tf-idf,0.32602477
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,artificial,0.4622418,artificial,1.0,artificial-intelligence,0.6597898
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,intelligence,0.5350207,intelligence,0.99999994,artificial-intelligence,0.8106787
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,methodology,0.5520129,data-engineering,0.61297953,data-engineering,0.61297953
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,artificial-intelligence,0.64611053,artificial-intelligence,1.0,artificial-intelligence,1.0
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,also,0.32850838,of,0.65908813,clustering,0.45826355
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,striking,0.30150783,feature,0.5761874,clustering,0.46928287
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,dose,0.24218819,shot,0.48689568,boosting,0.43495926
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,driven,0.33295566,stochastic,0.55241346,stochastic,0.55241346
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,metabolic,0.3235007,of,0.46523505,batch-normalization,0.4536144
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,subgrouping,0.4920114,classification,0.7210405,classification,0.7210405
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,distinct,0.36295342,feature,0.580647,clustering,0.5409523
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,lipoprotein,0.22208765,tf-idf,0.3608624,tf-idf,0.3608624
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,profiles,0.32975978,analysis,0.60014224,component-analysis,0.47511807
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,detailed,0.4132024,data,0.659509,data-engineering,0.52353954
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,lipoprotein,0.22208765,tf-idf,0.3608624,tf-idf,0.3608624
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,profiles,0.32975978,analysis,0.60014224,component-analysis,0.47511807
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,containing,0.25114298,of,0.51960796,fully-connected,0.38334632
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,lipoprotein,0.22208765,tf-idf,0.3608624,tf-idf,0.3608624
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,particles,0.25576374,stochastic-gradient,0.48749006,stochastic-gradient,0.48749006
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,containing-lipoprotein,0.24905613,components,0.46994668,principal-components,0.39169094
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,lipoprotein-particles,0.34635645,stochastic-gradient,0.49495187,stochastic-gradient,0.49495187
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,scale,0.32819444,intelligence,0.5046051,dimensionality-reduction,0.48168033
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,population,0.2958798,selection,0.5071889,clustering,0.47966808
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,cohorts,0.38747132,logistic-regression,0.5306275,logistic-regression,0.5306275
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,population-cohorts,0.45782065,stochastic,0.59629357,stochastic,0.59629357
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,identified,0.35725033,analysis,0.56593037,clustering,0.45719695
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,four,0.34899807,one,0.769816,clustering,0.40005642
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,som,0.43019444,convolutional-layer,0.47520134,convolutional-layer,0.47520134
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,identified-four,0.4334566,principal-component-analysis,0.52996206,principal-component-analysis,0.52996206
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,mediated,0.1966965,cascade,0.5268023,feed-forward,0.4459417
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,chd,0.3007669,logistic-regression,0.39436275,logistic-regression,0.39436275
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,risk,0.35860935,recurrent,0.53675485,logistic-regression,0.52381086
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,chd-risk,0.30764726,logistic-regression,0.44936946,logistic-regression,0.44936946
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,define,0.43066585,feature,0.5180392,classification-algorithm,0.48079586
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,subgroups,0.3467481,classification,0.5433718,classification,0.5433718
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,based,0.49998575,classification-algorithm,0.5639226,classification-algorithm,0.5639226
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,subgroups-based,0.5029166,classification-algorithm,0.6136053,classification-algorithm,0.6136053
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,apolipoprotein,0.25016165,tf-idf,0.31200302,tf-idf,0.31200302
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,b,0.19558734,of,0.43435428,short-term-memory,0.31717262
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,apolipoprotein-b,0.2448067,tf-idf,0.32602477,tf-idf,0.32602477
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,comprehensive,0.5203603,data,0.6056672,data-engineering,0.58421016
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,data,0.46434748,data,1.0,data-science,0.5533528
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,risk,0.35860935,recurrent,0.53675485,logistic-regression,0.52381086
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,assessment,0.4002061,analysis,0.5275976,component-analysis,0.49803802
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,risk-assessment,0.5291727,decision-tree,0.6316601,decision-tree,0.6316601
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,elsevier,0.26603332,science,0.59524655,data-science,0.53140587
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,b,0.19558734,of,0.43435428,short-term-memory,0.31717262
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,chd,0.3007669,logistic-regression,0.39436275,logistic-regression,0.39436275
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,risk,0.35860935,recurrent,0.53675485,logistic-regression,0.52381086
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,chd-risk,0.30764726,logistic-regression,0.44936946,logistic-regression,0.44936946
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,univariate,0.50082326,logistic,0.8635771,logistic-regression,0.8482128
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,subgrouping,0.4920114,classification,0.7210405,classification,0.7210405
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,population,0.2958798,selection,0.5071889,clustering,0.47966808
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,subgrouping,0.4920114,classification,0.7210405,classification,0.7210405
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,unsupervised,0.76376486,unsupervised,0.99999994,unsupervised,0.99999994
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,data,0.46434748,data,1.0,data-science,0.5533528
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,lipoprotein,0.22208765,tf-idf,0.3608624,tf-idf,0.3608624
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,metabolism,0.23515728,function,0.4646009,batch-normalization,0.37767193
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,lipoprotein-metabolism,0.30226082,batch-normalization,0.40606296,batch-normalization,0.40606296
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,based,0.49998575,classification-algorithm,0.5639226,classification-algorithm,0.5639226
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,subgroups,0.3467481,classification,0.5433718,classification,0.5433718
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,lowest,0.23623991,rate,0.46416223,statistical,0.3728755
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,risk,0.35860935,recurrent,0.53675485,logistic-regression,0.52381086
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,lowest-risk,0.3213824,logistic-regression,0.46697256,logistic-regression,0.46697256
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,would,0.3569631,of,0.55908126,boosting,0.43412957
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,work,0.42713583,support,0.5373766,learning-function,0.5011815
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,trained,0.56898797,supervised,0.69370055,supervised,0.69370055
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,som,0.43019444,convolutional-layer,0.47520134,convolutional-layer,0.47520134
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,rights,0.3170033,adversarial,0.6281444,data-science,0.57488894
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,reserved,0.28677964,of,0.4776592,supervised,0.3944377
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,response,0.2143969,of,0.52661085,boosting,0.48192608
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,behaviour,0.29581106,style,0.5553138,reinforcement-learning,0.5048617
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,organizing,0.39680806,generative,0.52276504,generative,0.52276504
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,map,0.3543614,bagging,0.4165985,bagging,0.4165985
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,lowest,0.23623991,rate,0.46416223,statistical,0.3728755
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,concentrations,0.16781005,of,0.4458394,batch-normalization,0.42195582
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,independent,0.39991486,of,0.5904635,regression,0.57876456
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,cohort,0.3892265,logistic-regression,0.5412916,logistic-regression,0.5412916
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,hdl,0.19749369,tf-idf,0.41316777,tf-idf,0.41316777
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,measures,0.3789752,principal-components,0.5349536,principal-components,0.5349536
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,based,0.49998575,classification-algorithm,0.5639226,classification-algorithm,0.5639226
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,cohort,0.3892265,logistic-regression,0.5412916,logistic-regression,0.5412916
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,based-cohort,0.54979813,markov-model,0.60628796,markov-model,0.60628796
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,results,0.32376552,data,0.6932311,batch-normalization,0.44826904
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,suggest,0.26874092,data,0.5391823,long-short-term,0.40288782
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,results-suggest,0.39010245,data,0.5769403,batch-normalization,0.5080625
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,highest,0.25175208,of,0.5054526,boosting,0.3963222
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,concentrations,0.16781005,of,0.4458394,batch-normalization,0.42195582
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,based,0.49998575,classification-algorithm,0.5639226,classification-algorithm,0.5639226
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,subgroup,0.30281192,analysis,0.5028211,classification,0.50108194
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,lipoprotein,0.22208765,tf-idf,0.3608624,tf-idf,0.3608624
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,chd,0.3007669,logistic-regression,0.39436275,logistic-regression,0.39436275
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,risk,0.35860935,recurrent,0.53675485,logistic-regression,0.52381086
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,som,0.43019444,convolutional-layer,0.47520134,convolutional-layer,0.47520134
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,population,0.2958798,selection,0.5071889,clustering,0.47966808
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,based,0.49998575,classification-algorithm,0.5639226,classification-algorithm,0.5639226
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,subgroup,0.30281192,analysis,0.5028211,classification,0.50108194
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,results,0.32376552,data,0.6932311,batch-normalization,0.44826904
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,highest,0.25175208,of,0.5054526,boosting,0.3963222
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,v,0.16266164,rate,0.35976145,softmax,0.2951627
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,utilised,0.467104,data-engineering,0.549142,data-engineering,0.549142
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,therefore,0.37519994,of,0.6409915,feature-reduction,0.45783085
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,suggested,0.30397683,of,0.6234695,clustering,0.4426524
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,self,0.3628102,style,0.5880609,confusion-matrix,0.4790911
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,published,0.42179614,data,0.6147139,data-science,0.54664624
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,non,0.2869836,of,0.5523051,generative,0.4181043
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,n,0.24332823,of,0.45693433,long-short-term,0.34114176
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,methods,0.50049126,data,0.5400177,machine-learning,0.50049126
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,means,0.38858432,of,0.5759921,dimensionality-reduction,0.53678924
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,may,0.30907542,of,0.58654004,long-short-term,0.43985203
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,majority,0.29875737,few,0.59443223,clustering,0.40575084
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,large,0.2849899,few,0.5687306,clustering,0.4101745
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,individuals,0.32092994,naive,0.486303,dropout,0.42173886
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,however,0.31437585,few,0.63182676,statistical,0.44065386
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,explored,0.42671436,of,0.58866113,feature-engineering,0.5368307
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,explained,0.28867537,of,0.516951,dimensionality-reduction,0.46577448
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,conclusions,0.37109232,data,0.55923915,long-short-term,0.4627594
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,compared,0.3359061,of,0.52794564,long-short-term,0.42386633
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,background,0.3259285,of,0.51277274,long-short-term,0.46426663
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,authors,0.45811802,data,0.5259881,natural-language-processing,0.4706872
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,applied,0.44175404,of,0.5047146,bagging,0.47554293
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,aims,0.42995954,of,0.465683,feature-engineering,0.4555406
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,show,0.33248252,of,0.51487744,feature-selection,0.44449317
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,instead,0.3573236,of,0.5891031,feature-reduction,0.5188961
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,lower,0.20975146,of,0.5471319,regression,0.3982392
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,tg,0.14175858,naive,0.3233659,long-short-term-memory,0.30497348
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,lower-tg,0.22293681,long-short-term-memory,0.40067017,long-short-term-memory,0.40067017
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,targets,0.3564865,components,0.46861184,feature-selection,0.44291896
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,also,0.32850838,of,0.65908813,clustering,0.45826355
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,partially,0.20260045,fully,0.7885939,feature-reduction,0.4023255
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,reduces,0.2596901,reduction,0.6328956,boosting,0.4721025
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,ldl,0.16037413,tf-idf,0.38286388,tf-idf,0.38286388
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,c,0.17513797,of,0.44327667,gradient,0.31114018
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,ascvd,0.3325327,logistic-regression,0.43486148,logistic-regression,0.43486148
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,risk,0.35860935,recurrent,0.53675485,logistic-regression,0.52381086
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,ascvd-risk,0.3343684,logistic-regression,0.48624206,logistic-regression,0.48624206
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,new,0.43019778,of,0.526482,feature-reduction,0.4579819
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,therapeutic,0.3659354,of,0.48352462,boosting,0.41573292
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,targets,0.3564865,components,0.46861184,feature-selection,0.44291896
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,new-therapeutic,0.3548655,normalization,0.42601833,one-shot,0.41742682
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,therapeutic-targets,0.42219388,feature-engineering,0.523913,feature-engineering,0.523913
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,ascvd,0.3325327,logistic-regression,0.43486148,logistic-regression,0.43486148
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,genetic,0.44218406,selection,0.53394234,clustering,0.53279865
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,metabolic,0.3235007,of,0.46523505,batch-normalization,0.4536144
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,abnormalities,0.3212605,normalization,0.5461266,segmentation,0.4475795
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,characterized,0.27792567,feature,0.5646106,fourier,0.42356855
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,better,0.4230538,of,0.5337099,feature-reduction,0.47485045
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,pharmacological,0.32013503,of,0.48491696,learning-function,0.4119643
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,target,0.31799266,of,0.4775706,feature-selection,0.44359237
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,pharmacological-target,0.44234714,feature-engineering,0.52574766,feature-engineering,0.52574766
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,atherosclerotic,0.24541524,of,0.33148155,generative-model,0.3187185
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,cardiovascular,0.31674606,short-term,0.442761,learning-function,0.4027721
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,disease,0.296938,recurrent,0.4731025,classification,0.35271814
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,atherosclerotic-cardiovascular,0.29341784,logistic-regression,0.36804122,logistic-regression,0.36804122
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,cardiovascular-disease,0.39733815,logistic-regression,0.43556237,logistic-regression,0.43556237
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,atherosclerotic-cardiovascular-disease,0.3574118,logistic-regression,0.419603,logistic-regression,0.419603
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,induces,0.18429779,of,0.44929433,boosting,0.3954177
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,activation,0.23066127,cascade,0.649269,feed-forward,0.4652444
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,major,0.2356064,principal,0.70253855,principal-components,0.42016473
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,side,0.16146374,connected,0.47764254,feature-reduction,0.35291326
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,effects,0.2624804,short-term,0.63497096,long-short-term,0.5306107
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,side-effects,0.22787218,short-term,0.49080825,dropout,0.45228943
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,clinical,0.44080526,data,0.48532635,data-science,0.45343333
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,trials,0.31393725,short-term,0.4483273,data-science,0.40647802
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,clinical-trials,0.4615081,data-science,0.54023623,data-science,0.54023623
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,lpl,0.16198428,tf-idf,0.39271903,tf-idf,0.39271903
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,antagonizing,0.23304124,feed-forward,0.48078427,feed-forward,0.48078427
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,like,0.32318482,of,0.5448733,relu,0.44626954
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,proteins,0.35976675,components,0.56075835,component-analysis,0.40436536
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,like-proteins,0.34096283,components,0.5113381,component-analysis,0.42976564
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,antisense,0.2656379,vector,0.5177654,vector-machine,0.37872872
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,oligonucleotide,0.3101916,nearest-neighbors,0.4233013,nearest-neighbors,0.4233013
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,antisense-oligonucleotide,0.28766325,vector,0.45202926,feature-selection,0.38809127
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,density,0.25813383,layer,0.4929318,gradient,0.48885438
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,lipoprotein,0.22208765,tf-idf,0.3608624,tf-idf,0.3608624
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,cholesterol,0.15921682,reduction,0.33627644,gradient,0.32767534
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,density-lipoprotein,0.2429603,tf-idf,0.4027466,tf-idf,0.4027466
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,lipoprotein-cholesterol,0.2143431,tf-idf,0.33285147,tf-idf,0.33285147
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,density-lipoprotein-cholesterol,0.22921449,batch-normalization,0.37548044,batch-normalization,0.37548044
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,also,0.32850838,of,0.65908813,clustering,0.45826355
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,dependent,0.2523393,of,0.585135,generative,0.43066898
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,new,0.43019778,of,0.526482,feature-reduction,0.4579819
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,density,0.25813383,layer,0.4929318,gradient,0.48885438
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,lipoprotein,0.22208765,tf-idf,0.3608624,tf-idf,0.3608624
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,density-lipoprotein,0.2429603,tf-idf,0.4027466,tf-idf,0.4027466
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,ldl,0.16037413,tf-idf,0.38286388,tf-idf,0.38286388
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,receptor,0.22411162,function,0.41526195,clustering,0.36801085
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,ldl-receptor,0.21912806,tf-idf,0.38305622,tf-idf,0.38305622
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,tg,0.14175858,naive,0.3233659,long-short-term-memory,0.30497348
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,plasma,0.21912897,normalization,0.4569842,batch-normalization,0.43571177
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,tg,0.14175858,naive,0.3233659,long-short-term-memory,0.30497348
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,plasma-tg,0.20368697,batch-normalization,0.4446597,batch-normalization,0.4446597
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,major,0.2356064,principal,0.70253855,principal-components,0.42016473
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,role,0.2562992,function,0.5340955,feed-forward,0.4137928
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,antisense,0.2656379,vector,0.5177654,vector-machine,0.37872872
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,oligonucleotides,0.29278323,nearest-neighbors,0.43656915,nearest-neighbors,0.43656915
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,antisense-oligonucleotides,0.28634167,vector,0.44505072,feature-selection,0.38145763
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,antagonists,0.24215083,discriminative,0.39012936,learning-function,0.31474212
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,phase,0.23814097,hidden-layer,0.45645207,hidden-layer,0.45645207
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,lipoprotein,0.22208765,tf-idf,0.3608624,tf-idf,0.3608624
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,lipase,0.17566128,encoding,0.33917344,batch-normalization,0.30007666
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,lipoprotein-lipase,0.24399365,tf-idf,0.35040405,tf-idf,0.35040405
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,still,0.32258964,fully,0.6496037,long-short-term,0.43228805
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,needed,0.36127746,support,0.5796853,supervised,0.43152136
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,still-needed,0.4453098,confusion,0.5381022,reinforcement-learning,0.52222574
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,similar,0.29237732,of,0.56832373,long-short-term,0.4732089
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,evidence,0.28723752,data,0.5728123,generative,0.3943918
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,significant,0.29367286,statistical,0.582669,statistical,0.582669
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,increase,0.28092995,reduction,0.7624404,boosting,0.49543357
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,significant-increase,0.3675148,reduction,0.6572373,statistical,0.502928
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,provided,0.3982859,of,0.61110586,supervised,0.49344742
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,data,0.46434748,data,1.0,data-science,0.5533528
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,prandial,0.27111372,feed,0.45172724,batch-normalization,0.3841824
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,levels,0.20457911,normalization,0.52984333,batch-normalization,0.45617118
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,plasma,0.21912897,normalization,0.4569842,batch-normalization,0.43571177
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,levels,0.20457911,normalization,0.52984333,batch-normalization,0.45617118
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,plasma-levels,0.24892072,batch-normalization,0.54759187,batch-normalization,0.54759187
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,murine,0.28323686,model,0.51846504,generative-model,0.36259758
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,models,0.53762007,model,0.8940372,markov-model,0.7015921
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,monoclonal,0.2925569,of,0.35092515,clustering,0.32119817
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,antibodies,0.26727155,of,0.3949049,boosting,0.37627226
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,monoclonal-antibodies,0.26963526,component-analysis,0.3812047,component-analysis,0.3812047
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,marked,0.19470066,of,0.5952639,long-short-term,0.40309682
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,reduction,0.22531602,reduction,1.0,feature-reduction,0.59547573
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,including,0.3233776,of,0.6619886,clustering,0.40625107
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,non,0.2869836,of,0.5523051,generative,0.4181043
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,human,0.30336243,of,0.5175895,feature-engineering,0.40631005
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,primates,0.36819577,natural,0.48468482,object-tracking,0.43964654
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,genetic,0.44218406,selection,0.53394234,clustering,0.53279865
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,studies,0.30135098,data,0.6349237,component-analysis,0.41327482
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,genetic-studies,0.44823605,feature-engineering,0.54175353,feature-engineering,0.54175353
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,function,0.3447219,function,1.0,learning-function,0.5767432
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,mutations,0.30690983,encoding,0.48844272,feature-selection,0.4252736
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,function-mutations,0.52019143,feature-selection,0.6110313,feature-selection,0.6110313
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,experimental,0.40167695,model,0.6248311,generative-model,0.6004326
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,evidence,0.28723752,data,0.5728123,generative,0.3943918
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,experimental-evidence,0.52550054,generative-model,0.62795126,generative-model,0.62795126
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,elsevier,0.26603332,science,0.59524655,data-science,0.53140587
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,ltd,0.17568776,long-short-term-memory,0.37555107,long-short-term-memory,0.37555107
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,elevated,0.19494015,normalization,0.5246306,batch-normalization,0.44167417
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,fasting,0.22235955,normalization,0.46940017,batch-normalization,0.4534999
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,efficacy,0.30193827,short-term,0.5894643,long-short-term,0.48695186
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,profile,0.29077405,analysis,0.5635588,component-analysis,0.44242257
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,conclusive,0.3358189,data,0.5729934,statistical,0.5009525
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,data,0.46434748,data,1.0,data-science,0.5533528
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,atherogenic,0.27139077,batch-normalization,0.3767841,batch-normalization,0.3767841
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,dyslipidemias,0.30723953,classification-algorithm,0.3558741,classification-algorithm,0.3558741
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,apparently,0.21803677,of,0.6490056,generative,0.4610135
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,without,0.31691062,of,0.5951073,long-short-term,0.4268921
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,animal,0.3921889,model,0.61759067,generative-model,0.52223754
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,models,0.53762007,model,0.8940372,markov-model,0.7015921
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,animal-models,0.6079529,model,0.72360504,markov-model,0.69941235
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,term,0.33795053,term,1.0,long-short-term,0.62770975
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,treatment,0.239264,short-term,0.5206091,long-short-term,0.41699445
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,term-treatment,0.292279,short-term,0.6025617,long-short-term,0.5401151
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,head,0.20004128,shot,0.45843315,one-hot,0.34099656
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,comparison,0.38020527,analysis,0.5798166,statistical,0.52489424
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,hdl,0.19749369,tf-idf,0.41316777,tf-idf,0.41316777
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,beyond,0.34655812,of,0.53781354,dimensionality-reduction,0.42561156
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,low,0.23602332,of,0.5820825,long-short-term,0.45172954
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,rich,0.3160888,natural,0.5082195,generative,0.4519166
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,lipoproteins,0.21669655,components,0.37059355,tf-idf,0.33776158
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,rich-lipoproteins,0.25440428,tf-idf,0.40041518,tf-idf,0.40041518
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,ldl,0.16037413,tf-idf,0.38286388,tf-idf,0.38286388
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,tg,0.14175858,naive,0.3233659,long-short-term-memory,0.30497348
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,c,0.17513797,of,0.44327667,gradient,0.31114018
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,lpl,0.16198428,tf-idf,0.39271903,tf-idf,0.39271903
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,treatment,0.239264,short-term,0.5206091,long-short-term,0.41699445
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,studies,0.30135098,data,0.6349237,component-analysis,0.41327482
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,rich,0.3160888,natural,0.5082195,generative,0.4519166
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,low,0.23602332,of,0.5820825,long-short-term,0.45172954
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,lipoproteins,0.21669655,components,0.37059355,tf-idf,0.33776158
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,head,0.20004128,shot,0.45843315,one-hot,0.34099656
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,hdl,0.19749369,tf-idf,0.41316777,tf-idf,0.41316777
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,way,0.4425121,forward,0.5844119,generative,0.55701363
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,vldl,0.17931633,tf-idf,0.40512678,tf-idf,0.40512678
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,triglycerides,0.17761004,batch-normalization,0.3502633,batch-normalization,0.3502633
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,short,0.24294135,short,0.99999994,long-short-term,0.66049826
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,safety,0.3095734,short-term,0.530321,long-short-term,0.44178027
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,remnants,0.24958368,layer,0.47159594,segmentation,0.38732517
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,relevance,0.48173976,of,0.5866257,feature-engineering,0.50181127
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,regulating,0.26515597,function,0.55162895,feed-forward,0.5337373
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,published,0.42179614,data,0.6147139,data-science,0.54664624
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,proven,0.375184,of,0.5508748,generative-model,0.42086476
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,post,0.27536392,confusion,0.47820356,bagging,0.44161102
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,paved,0.4547429,engineering,0.6095296,data-engineering,0.60655236
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,order,0.38454574,of,0.59467053,dimensionality-reduction,0.481972
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,observed,0.23725806,of,0.64367145,long-short-term,0.4519785
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,modest,0.25316665,reduction,0.58270836,long-short-term,0.51194596
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,lrx,0.3194589,nlp,0.41305602,nlp,0.41305602
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,loss,0.26544642,reduction,0.62177265,dropout,0.42517614
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,inhibition,0.21671593,reduction,0.58642584,feed-forward,0.44581953
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,independent,0.39991486,of,0.5904635,regression,0.57876456
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,indeed,0.38695717,of,0.64832246,generative,0.51532495
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,hypertriglyceridemia,0.25163418,batch-normalization,0.3739865,batch-normalization,0.3739865
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,hydrolysis,0.20217773,processing,0.45997787,graphics-processing-unit,0.37448466
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,humans,0.34170303,natural,0.5139721,generative-model,0.41706812
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,high,0.267004,of,0.57459104,gradient,0.44240427
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,found,0.2840244,of,0.6208722,clustering,0.44675255
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,former,0.27170816,of,0.5781311,long-short-term,0.44034702
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,development,0.34732813,generative,0.56588423,generative,0.56588423
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,determinants,0.3090787,of,0.5299541,clustering,0.44416586
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,demonstrated,0.2929331,of,0.6025795,feature-reduction,0.39724052
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,define,0.43066585,feature,0.5180392,classification-algorithm,0.48079586
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,cluster,0.35344368,clustering,0.6817189,clustering,0.6817189
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,carriers,0.19384606,transfer,0.36606938,gradient-descent,0.335905
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,associated,0.30827495,of,0.57598466,long-short-term,0.46578532
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,angiopoietin,0.26601,matrix,0.43060976,feed-forward,0.3491551
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,among,0.33676732,of,0.57348,clustering,0.49404603
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,activity,0.21813896,function,0.53536034,boosting,0.38798416
Macrophages induce malignant traits in mammary epithelium via IKKε/TBK1 kinases and the serine biosynthesis pathway.,breast,0.28445923,of,0.40638393,clustering,0.34891048
Macrophages induce malignant traits in mammary epithelium via IKKε/TBK1 kinases and the serine biosynthesis pathway.,epithelial,0.19645312,layer,0.4889314,convolutional-layer,0.39676607
Macrophages induce malignant traits in mammary epithelium via IKKε/TBK1 kinases and the serine biosynthesis pathway.,cells,0.20327199,naive,0.5115537,generative,0.40616876
Macrophages induce malignant traits in mammary epithelium via IKKε/TBK1 kinases and the serine biosynthesis pathway.,acquire,0.44839007,transform,0.5710312,generative,0.5300425
Macrophages induce malignant traits in mammary epithelium via IKKε/TBK1 kinases and the serine biosynthesis pathway.,malignant,0.28279346,recurrent,0.52490234,recurrent-neural-network,0.38119292
Macrophages induce malignant traits in mammary epithelium via IKKε/TBK1 kinases and the serine biosynthesis pathway.,properties,0.31064022,function,0.5521828,feature-engineering,0.53029627
Macrophages induce malignant traits in mammary epithelium via IKKε/TBK1 kinases and the serine biosynthesis pathway.,breast-epithelial,0.23559353,matrix,0.41021046,keras,0.4059115
Macrophages induce malignant traits in mammary epithelium via IKKε/TBK1 kinases and the serine biosynthesis pathway.,epithelial-cells,0.17336152,matrix,0.49068755,recurrent-neural-network,0.38291073
Macrophages induce malignant traits in mammary epithelium via IKKε/TBK1 kinases and the serine biosynthesis pathway.,approved,0.29450935,federated,0.4836949,data-engineering,0.39570063
Macrophages induce malignant traits in mammary epithelium via IKKε/TBK1 kinases and the serine biosynthesis pathway.,drug,0.31867066,of,0.44600964,confusion-matrix,0.3956731
Macrophages induce malignant traits in mammary epithelium via IKKε/TBK1 kinases and the serine biosynthesis pathway.,targeting,0.35599935,boosting,0.504551,boosting,0.504551
Macrophages induce malignant traits in mammary epithelium via IKKε/TBK1 kinases and the serine biosynthesis pathway.,approved-drug,0.4012571,confusion-matrix,0.4843945,confusion-matrix,0.4843945
Macrophages induce malignant traits in mammary epithelium via IKKε/TBK1 kinases and the serine biosynthesis pathway.,drug-targeting,0.52431834,feature-engineering,0.57894486,feature-engineering,0.57894486
Macrophages induce malignant traits in mammary epithelium via IKKε/TBK1 kinases and the serine biosynthesis pathway.,combined,0.39749897,of,0.5690281,one-shot,0.52384484
Macrophages induce malignant traits in mammary epithelium via IKKε/TBK1 kinases and the serine biosynthesis pathway.,genetic,0.44218406,selection,0.53394234,clustering,0.53279865
Macrophages induce malignant traits in mammary epithelium via IKKε/TBK1 kinases and the serine biosynthesis pathway.,mouse,0.30437678,model,0.5410154,generative-model,0.41324437
Macrophages induce malignant traits in mammary epithelium via IKKε/TBK1 kinases and the serine biosynthesis pathway.,model,0.48485535,model,1.0,markov-model,0.7005576
Macrophages induce malignant traits in mammary epithelium via IKKε/TBK1 kinases and the serine biosynthesis pathway.,mouse-model,0.47823092,model,0.68659,generative-model,0.6659167
Macrophages induce malignant traits in mammary epithelium via IKKε/TBK1 kinases and the serine biosynthesis pathway.,human,0.30336243,of,0.5175895,feature-engineering,0.40631005
Macrophages induce malignant traits in mammary epithelium via IKKε/TBK1 kinases and the serine biosynthesis pathway.,breast,0.28445923,of,0.40638393,clustering,0.34891048
Macrophages induce malignant traits in mammary epithelium via IKKε/TBK1 kinases and the serine biosynthesis pathway.,cancer,0.27383438,recurrent,0.4065063,generative,0.3468409
Macrophages induce malignant traits in mammary epithelium via IKKε/TBK1 kinases and the serine biosynthesis pathway.,tissues,0.21297011,of,0.47614664,generative,0.371554
Macrophages induce malignant traits in mammary epithelium via IKKε/TBK1 kinases and the serine biosynthesis pathway.,human-breast,0.41877323,ground-truth,0.45542166,ground-truth,0.45542166
Macrophages induce malignant traits in mammary epithelium via IKKε/TBK1 kinases and the serine biosynthesis pathway.,breast-cancer,0.24357814,recurrent,0.31327358,component-analysis,0.311931
Macrophages induce malignant traits in mammary epithelium via IKKε/TBK1 kinases and the serine biosynthesis pathway.,breast,0.28445923,of,0.40638393,clustering,0.34891048
Macrophages induce malignant traits in mammary epithelium via IKKε/TBK1 kinases and the serine biosynthesis pathway.,cancer,0.27383438,recurrent,0.4065063,generative,0.3468409
Macrophages induce malignant traits in mammary epithelium via IKKε/TBK1 kinases and the serine biosynthesis pathway.,oncogene,0.26876208,encoding,0.42158,recurrent-neural-network,0.35501975
Macrophages induce malignant traits in mammary epithelium via IKKε/TBK1 kinases and the serine biosynthesis pathway.,breast-cancer,0.24357814,recurrent,0.31327358,component-analysis,0.311931
Macrophages induce malignant traits in mammary epithelium via IKKε/TBK1 kinases and the serine biosynthesis pathway.,cancer-oncogene,0.26866552,recurrent-neural-network,0.35679364,recurrent-neural-network,0.35679364
Macrophages induce malignant traits in mammary epithelium via IKKε/TBK1 kinases and the serine biosynthesis pathway.,breast,0.28445923,of,0.40638393,clustering,0.34891048
Macrophages induce malignant traits in mammary epithelium via IKKε/TBK1 kinases and the serine biosynthesis pathway.,cancer,0.27383438,recurrent,0.4065063,generative,0.3468409
Macrophages induce malignant traits in mammary epithelium via IKKε/TBK1 kinases and the serine biosynthesis pathway.,associated,0.30827495,of,0.57598466,long-short-term,0.46578532
Macrophages induce malignant traits in mammary epithelium via IKKε/TBK1 kinases and the serine biosynthesis pathway.,breast-cancer,0.24357814,recurrent,0.31327358,component-analysis,0.311931
Macrophages induce malignant traits in mammary epithelium via IKKε/TBK1 kinases and the serine biosynthesis pathway.,cancer-associated,0.33132327,recurrent,0.47446868,clustering,0.39902323
Macrophages induce malignant traits in mammary epithelium via IKKε/TBK1 kinases and the serine biosynthesis pathway.,breast-cancer-associated,0.32272765,recurrent,0.45061225,clustering,0.4003142
Macrophages induce malignant traits in mammary epithelium via IKKε/TBK1 kinases and the serine biosynthesis pathway.,breast,0.28445923,of,0.40638393,clustering,0.34891048
Macrophages induce malignant traits in mammary epithelium via IKKε/TBK1 kinases and the serine biosynthesis pathway.,tissue,0.23679586,of,0.5202017,segmentation,0.4076932
Macrophages induce malignant traits in mammary epithelium via IKKε/TBK1 kinases and the serine biosynthesis pathway.,leading,0.2514689,of,0.59935343,generative,0.44480726
Macrophages induce malignant traits in mammary epithelium via IKKε/TBK1 kinases and the serine biosynthesis pathway.,breast-tissue,0.3055821,matrix,0.4406802,component-analysis,0.40944076
Macrophages induce malignant traits in mammary epithelium via IKKε/TBK1 kinases and the serine biosynthesis pathway.,human,0.30336243,of,0.5175895,feature-engineering,0.40631005
Macrophages induce malignant traits in mammary epithelium via IKKε/TBK1 kinases and the serine biosynthesis pathway.,healthy,0.31399268,naive,0.5051062,artificial-intelligence,0.3681498
Macrophages induce malignant traits in mammary epithelium via IKKε/TBK1 kinases and the serine biosynthesis pathway.,donors,0.18242757,transfer,0.4040379,dropout,0.31109774
Macrophages induce malignant traits in mammary epithelium via IKKε/TBK1 kinases and the serine biosynthesis pathway.,healthy-donors,0.29492062,naive,0.4526356,dimensionality-reduction,0.3687513
Macrophages induce malignant traits in mammary epithelium via IKKε/TBK1 kinases and the serine biosynthesis pathway.,vivo,0.31561637,of,0.48691544,generative-model,0.4255858
Macrophages induce malignant traits in mammary epithelium via IKKε/TBK1 kinases and the serine biosynthesis pathway.,tumour,0.20690809,of,0.39267477,regression,0.35077095
Macrophages induce malignant traits in mammary epithelium via IKKε/TBK1 kinases and the serine biosynthesis pathway.,formation,0.17913832,of,0.50848174,generative,0.45268857
Macrophages induce malignant traits in mammary epithelium via IKKε/TBK1 kinases and the serine biosynthesis pathway.,vivo-tumour,0.25327113,naive,0.42656016,naive-bayes,0.32051897
Macrophages induce malignant traits in mammary epithelium via IKKε/TBK1 kinases and the serine biosynthesis pathway.,tumour-formation,0.28131106,of,0.4800616,generative,0.45298672
Macrophages induce malignant traits in mammary epithelium via IKKε/TBK1 kinases and the serine biosynthesis pathway.,serine,0.26492563,encoding,0.5007918,graphics-processing,0.31994233
Macrophages induce malignant traits in mammary epithelium via IKKε/TBK1 kinases and the serine biosynthesis pathway.,biosynthesis,0.22972566,encoding,0.49827692,feature-engineering,0.40851718
Macrophages induce malignant traits in mammary epithelium via IKKε/TBK1 kinases and the serine biosynthesis pathway.,pathway,0.27141988,cascade,0.7127757,feed-forward,0.5331765
Macrophages induce malignant traits in mammary epithelium via IKKε/TBK1 kinases and the serine biosynthesis pathway.,serine-biosynthesis,0.31073827,encoding,0.54855895,feature-engineering,0.43231407
Macrophages induce malignant traits in mammary epithelium via IKKε/TBK1 kinases and the serine biosynthesis pathway.,biosynthesis-pathway,0.32887065,encoding,0.47877502,feature-engineering,0.4408354
Macrophages induce malignant traits in mammary epithelium via IKKε/TBK1 kinases and the serine biosynthesis pathway.,potential,0.3558654,of,0.5645705,generative-model,0.46479023
Macrophages induce malignant traits in mammary epithelium via IKKε/TBK1 kinases and the serine biosynthesis pathway.,therapeutic,0.3659354,of,0.48352462,boosting,0.41573292
Macrophages induce malignant traits in mammary epithelium via IKKε/TBK1 kinases and the serine biosynthesis pathway.,strategy,0.47490904,feature-engineering,0.59725416,feature-engineering,0.59725416
Macrophages induce malignant traits in mammary epithelium via IKKε/TBK1 kinases and the serine biosynthesis pathway.,potential-therapeutic,0.39089105,generative-model,0.49393243,generative-model,0.49393243
Macrophages induce malignant traits in mammary epithelium via IKKε/TBK1 kinases and the serine biosynthesis pathway.,factor,0.23388772,component,0.48280093,principal-components,0.43733668
Macrophages induce malignant traits in mammary epithelium via IKKε/TBK1 kinases and the serine biosynthesis pathway.,considered,0.36321384,of,0.60548925,feature-reduction,0.4442021
Macrophages induce malignant traits in mammary epithelium via IKKε/TBK1 kinases and the serine biosynthesis pathway.,responsible,0.19506086,of,0.5890902,clustering,0.37603408
Macrophages induce malignant traits in mammary epithelium via IKKε/TBK1 kinases and the serine biosynthesis pathway.,pathway,0.27141988,cascade,0.7127757,feed-forward,0.5331765
Macrophages induce malignant traits in mammary epithelium via IKKε/TBK1 kinases and the serine biosynthesis pathway.,connecting,0.3403536,connected,0.80230516,fully-connected,0.64915884
Macrophages induce malignant traits in mammary epithelium via IKKε/TBK1 kinases and the serine biosynthesis pathway.,obesity,0.3146031,descent,0.41921628,logistic-regression,0.39891833
Macrophages induce malignant traits in mammary epithelium via IKKε/TBK1 kinases and the serine biosynthesis pathway.,pathway-connecting,0.49908677,network,0.7193179,fully-connected,0.6888702
Macrophages induce malignant traits in mammary epithelium via IKKε/TBK1 kinases and the serine biosynthesis pathway.,grade,0.2647515,classification,0.4900908,classification,0.4900908
Macrophages induce malignant traits in mammary epithelium via IKKε/TBK1 kinases and the serine biosynthesis pathway.,chronic,0.22727785,recurrent,0.5279353,long-short-term,0.4292153
Macrophages induce malignant traits in mammary epithelium via IKKε/TBK1 kinases and the serine biosynthesis pathway.,inflammation,0.22370426,cascade,0.4429949,generative-model,0.3706867
Macrophages induce malignant traits in mammary epithelium via IKKε/TBK1 kinases and the serine biosynthesis pathway.,chronic-inflammation,0.2850436,generative-model,0.48091027,generative-model,0.48091027
Macrophages induce malignant traits in mammary epithelium via IKKε/TBK1 kinases and the serine biosynthesis pathway.,breast,0.28445923,of,0.40638393,clustering,0.34891048
Macrophages induce malignant traits in mammary epithelium via IKKε/TBK1 kinases and the serine biosynthesis pathway.,cancer,0.27383438,recurrent,0.4065063,generative,0.3468409
Macrophages induce malignant traits in mammary epithelium via IKKε/TBK1 kinases and the serine biosynthesis pathway.,breast-cancer,0.24357814,recurrent,0.31327358,component-analysis,0.311931
Macrophages induce malignant traits in mammary epithelium via IKKε/TBK1 kinases and the serine biosynthesis pathway.,pharmacological,0.32013503,of,0.48491696,learning-function,0.4119643
Macrophages induce malignant traits in mammary epithelium via IKKε/TBK1 kinases and the serine biosynthesis pathway.,tools,0.65752256,data-engineering,0.6720511,data-engineering,0.6720511
Macrophages induce malignant traits in mammary epithelium via IKKε/TBK1 kinases and the serine biosynthesis pathway.,medium,0.20851013,batch,0.4689771,gradient,0.4530819
Macrophages induce malignant traits in mammary epithelium via IKKε/TBK1 kinases and the serine biosynthesis pathway.,conditioned,0.30672413,reinforcement,0.53536177,reinforcement-learning,0.52225894
Macrophages induce malignant traits in mammary epithelium via IKKε/TBK1 kinases and the serine biosynthesis pathway.,medium-conditioned,0.31258792,short-term,0.48428464,long-short-term,0.4779448
Macrophages induce malignant traits in mammary epithelium via IKKε/TBK1 kinases and the serine biosynthesis pathway.,macrophages,0.20754936,naive,0.47024828,short-term-memory,0.3296041
Macrophages induce malignant traits in mammary epithelium via IKKε/TBK1 kinases and the serine biosynthesis pathway.,infiltrate,0.24787581,confusion,0.43310353,confusion-matrix,0.3650477
Macrophages induce malignant traits in mammary epithelium via IKKε/TBK1 kinases and the serine biosynthesis pathway.,macrophages,0.20754936,naive,0.47024828,short-term-memory,0.3296041
Macrophages induce malignant traits in mammary epithelium via IKKε/TBK1 kinases and the serine biosynthesis pathway.,derived,0.3584563,of,0.54769456,generative,0.5265686
Macrophages induce malignant traits in mammary epithelium via IKKε/TBK1 kinases and the serine biosynthesis pathway.,macrophages-derived,0.29756448,naive,0.48438752,clustering,0.37850606
Macrophages induce malignant traits in mammary epithelium via IKKε/TBK1 kinases and the serine biosynthesis pathway.,induced,0.2259351,of,0.5615651,boosting,0.4303583
Macrophages induce malignant traits in mammary epithelium via IKKε/TBK1 kinases and the serine biosynthesis pathway.,obesity,0.3146031,descent,0.41921628,logistic-regression,0.39891833
Macrophages induce malignant traits in mammary epithelium via IKKε/TBK1 kinases and the serine biosynthesis pathway.,induced-obesity,0.365354,generative-model,0.46477383,generative-model,0.46477383
Macrophages induce malignant traits in mammary epithelium via IKKε/TBK1 kinases and the serine biosynthesis pathway.,homologue,0.21736166,encoding,0.6060314,feature-selection,0.34954956
Macrophages induce malignant traits in mammary epithelium via IKKε/TBK1 kinases and the serine biosynthesis pathway.,formally,0.42676532,fully,0.65909165,dimensionality-reduction,0.50689435
Macrophages induce malignant traits in mammary epithelium via IKKε/TBK1 kinases and the serine biosynthesis pathway.,demonstrate,0.37134898,of,0.5097414,feature-engineering,0.4652517
Macrophages induce malignant traits in mammary epithelium via IKKε/TBK1 kinases and the serine biosynthesis pathway.,fat,0.22005057,feed,0.48228577,segmentation,0.36863354
Macrophages induce malignant traits in mammary epithelium via IKKε/TBK1 kinases and the serine biosynthesis pathway.,diet,0.23870954,feed,0.6865525,supervised,0.36359084
Macrophages induce malignant traits in mammary epithelium via IKKε/TBK1 kinases and the serine biosynthesis pathway.,fat-diet,0.20103073,feed,0.47533706,kernel,0.34574616
Macrophages induce malignant traits in mammary epithelium via IKKε/TBK1 kinases and the serine biosynthesis pathway.,driven,0.33295566,stochastic,0.55241346,stochastic,0.55241346
Macrophages induce malignant traits in mammary epithelium via IKKε/TBK1 kinases and the serine biosynthesis pathway.,inflammation,0.22370426,cascade,0.4429949,generative-model,0.3706867
Macrophages induce malignant traits in mammary epithelium via IKKε/TBK1 kinases and the serine biosynthesis pathway.,downstream,0.2769811,cascade,0.61652684,feed-forward,0.4971591
Macrophages induce malignant traits in mammary epithelium via IKKε/TBK1 kinases and the serine biosynthesis pathway.,target,0.31799266,of,0.4775706,feature-selection,0.44359237
Macrophages induce malignant traits in mammary epithelium via IKKε/TBK1 kinases and the serine biosynthesis pathway.,downstream-target,0.39146706,cascade,0.53762674,feed-forward,0.50627196
Macrophages induce malignant traits in mammary epithelium via IKKε/TBK1 kinases and the serine biosynthesis pathway.,cellular,0.33255053,of,0.55018497,generative,0.4558165
Macrophages induce malignant traits in mammary epithelium via IKKε/TBK1 kinases and the serine biosynthesis pathway.,metabolism,0.23515728,function,0.4646009,batch-normalization,0.37767193
Macrophages induce malignant traits in mammary epithelium via IKKε/TBK1 kinases and the serine biosynthesis pathway.,cellular-metabolism,0.376521,generative-model,0.51164246,generative-model,0.51164246
Macrophages induce malignant traits in mammary epithelium via IKKε/TBK1 kinases and the serine biosynthesis pathway.,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
Macrophages induce malignant traits in mammary epithelium via IKKε/TBK1 kinases and the serine biosynthesis pathway.,license,0.37433738,data-science,0.4810462,data-science,0.4810462
Macrophages induce malignant traits in mammary epithelium via IKKε/TBK1 kinases and the serine biosynthesis pathway.,higher,0.27819592,reduction,0.545787,boosting,0.41506222
Macrophages induce malignant traits in mammary epithelium via IKKε/TBK1 kinases and the serine biosynthesis pathway.,risk,0.35860935,recurrent,0.53675485,logistic-regression,0.52381086
Macrophages induce malignant traits in mammary epithelium via IKKε/TBK1 kinases and the serine biosynthesis pathway.,higher-risk,0.39451247,classification-algorithm,0.4998359,classification-algorithm,0.4998359
Macrophages induce malignant traits in mammary epithelium via IKKε/TBK1 kinases and the serine biosynthesis pathway.,genetic,0.44218406,selection,0.53394234,clustering,0.53279865
Macrophages induce malignant traits in mammary epithelium via IKKε/TBK1 kinases and the serine biosynthesis pathway.,obesity,0.3146031,descent,0.41921628,logistic-regression,0.39891833
Macrophages induce malignant traits in mammary epithelium via IKKε/TBK1 kinases and the serine biosynthesis pathway.,inflammation,0.22370426,cascade,0.4429949,generative-model,0.3706867
Macrophages induce malignant traits in mammary epithelium via IKKε/TBK1 kinases and the serine biosynthesis pathway.,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
Macrophages induce malignant traits in mammary epithelium via IKKε/TBK1 kinases and the serine biosynthesis pathway.,risk,0.35860935,recurrent,0.53675485,logistic-regression,0.52381086
Macrophages induce malignant traits in mammary epithelium via IKKε/TBK1 kinases and the serine biosynthesis pathway.,validated,0.5041009,cross-validation,0.58167183,cross-validation,0.58167183
Macrophages induce malignant traits in mammary epithelium via IKKε/TBK1 kinases and the serine biosynthesis pathway.,terms,0.43271685,term,0.61106205,dimensionality-reduction,0.5960058
Macrophages induce malignant traits in mammary epithelium via IKKε/TBK1 kinases and the serine biosynthesis pathway.,reduce,0.314935,reduction,0.63468504,boosting,0.4613787
Macrophages induce malignant traits in mammary epithelium via IKKε/TBK1 kinases and the serine biosynthesis pathway.,published,0.42179614,data,0.6147139,data-science,0.54664624
Macrophages induce malignant traits in mammary epithelium via IKKε/TBK1 kinases and the serine biosynthesis pathway.,mediated,0.1966965,cascade,0.5268023,feed-forward,0.4459417
Macrophages induce malignant traits in mammary epithelium via IKKε/TBK1 kinases and the serine biosynthesis pathway.,low,0.23602332,of,0.5820825,long-short-term,0.45172954
Macrophages induce malignant traits in mammary epithelium via IKKε/TBK1 kinases and the serine biosynthesis pathway.,link,0.37692028,network,0.59004486,feed-forward,0.5209384
Macrophages induce malignant traits in mammary epithelium via IKKε/TBK1 kinases and the serine biosynthesis pathway.,identified,0.35725033,analysis,0.56593037,clustering,0.45719695
Macrophages induce malignant traits in mammary epithelium via IKKε/TBK1 kinases and the serine biosynthesis pathway.,high,0.267004,of,0.57459104,gradient,0.44240427
Macrophages induce malignant traits in mammary epithelium via IKKε/TBK1 kinases and the serine biosynthesis pathway.,furthermore,0.33438665,of,0.5529862,clustering,0.42723072
Macrophages induce malignant traits in mammary epithelium via IKKε/TBK1 kinases and the serine biosynthesis pathway.,finally,0.426572,of,0.64012104,generative,0.48128563
Macrophages induce malignant traits in mammary epithelium via IKKε/TBK1 kinases and the serine biosynthesis pathway.,fda,0.29815304,data-science,0.44345552,data-science,0.44345552
Macrophages induce malignant traits in mammary epithelium via IKKε/TBK1 kinases and the serine biosynthesis pathway.,exposed,0.17486927,of,0.4483599,long-short-term,0.37024927
Macrophages induce malignant traits in mammary epithelium via IKKε/TBK1 kinases and the serine biosynthesis pathway.,effects,0.2624804,short-term,0.63497096,long-short-term,0.5306107
Macrophages induce malignant traits in mammary epithelium via IKKε/TBK1 kinases and the serine biosynthesis pathway.,demonstrated,0.2929331,of,0.6025795,feature-reduction,0.39724052
Macrophages induce malignant traits in mammary epithelium via IKKε/TBK1 kinases and the serine biosynthesis pathway.,delayed,0.24917814,short-term,0.5145566,long-short-term,0.49292946
Macrophages induce malignant traits in mammary epithelium via IKKε/TBK1 kinases and the serine biosynthesis pathway.,cc,0.25479054,bag,0.47037008,bagging,0.34975946
Macrophages induce malignant traits in mammary epithelium via IKKε/TBK1 kinases and the serine biosynthesis pathway.,authors,0.45811802,data,0.5259881,natural-language-processing,0.4706872
Macrophages induce malignant traits in mammary epithelium via IKKε/TBK1 kinases and the serine biosynthesis pathway.,amlexanox,0.25203618,augmentation,0.330248,scikit-learn,0.30196905
Macrophages induce malignant traits in mammary epithelium via IKKε/TBK1 kinases and the serine biosynthesis pathway.,altogether,0.34802556,data,0.5542451,clustering,0.3638755
Macrophages induce malignant traits in mammary epithelium via IKKε/TBK1 kinases and the serine biosynthesis pathway.,alteration,0.29010773,of,0.61640024,batch-normalization,0.45421952
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,smart,0.48875675,data-engineering,0.59458923,data-engineering,0.59458923
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,clothing,0.3408624,style,0.56307065,bagging,0.49970078
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,system,0.3589455,generative-model,0.49815983,generative-model,0.49815983
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,targeting,0.35599935,boosting,0.504551,boosting,0.504551
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,clinically,0.3702051,recurrent,0.5046643,confusion-matrix,0.40397355
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,high,0.267004,of,0.57459104,gradient,0.44240427
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,smart-clothing,0.5113994,support-vector-machine,0.5870191,support-vector-machine,0.5870191
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,system-targeting,0.45816422,feature-engineering,0.6107052,feature-engineering,0.6107052
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,technologies,0.5210018,data-engineering,0.7016501,data-engineering,0.7016501
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,mostly,0.27980685,few,0.6887947,generative,0.4405978
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,target,0.31799266,of,0.4775706,feature-selection,0.44359237
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,older,0.38174838,short-term,0.49749964,short-term-memory,0.4763971
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,adults,0.2950639,short-term,0.48601514,long-short-term,0.43684626
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,older-adults,0.34902018,intelligence,0.4723326,natural-language,0.4543073
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,included,0.34673893,of,0.58040446,component-analysis,0.47413814
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,three,0.36911732,one,0.78425425,clustering,0.4299444
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,external,0.24276523,connected,0.4833919,data-augmentation,0.40820563
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,variables,0.4636312,logistic-regression,0.6604836,logistic-regression,0.6604836
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,using,0.47332245,analysis,0.5968549,component-analysis,0.526608
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,wearable,0.53930736,data-engineering,0.6004859,data-engineering,0.6004859
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,healthcare,0.40112603,data-science,0.6050074,data-science,0.6050074
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,technologies,0.5210018,data-engineering,0.7016501,data-engineering,0.7016501
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,e,0.13297717,natural,0.39189428,component-analysis,0.28603846
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,technology,0.48836875,data-engineering,0.7060051,data-engineering,0.7060051
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,anxiety,0.325352,confusion,0.56180894,reinforcement-learning,0.4749429
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,perceived,0.40143436,style,0.61272097,dimensionality-reduction,0.5584763
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,ubiquity,0.39669192,feature,0.53377724,stochastic,0.50163764
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,construct,0.4047066,vector,0.6145139,support-vector,0.58696413
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,affects,0.21790305,of,0.5773267,long-short-term,0.4001173
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,wearing,0.32128468,machine,0.52409935,computer-vision,0.4950474
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,smart,0.48875675,data-engineering,0.59458923,data-engineering,0.59458923
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,clothes,0.29014444,bag,0.53854716,bagging,0.43872726
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,sensor,0.39054433,tracking,0.4828847,neural-network,0.47259283
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,technologies,0.5210018,data-engineering,0.7016501,data-engineering,0.7016501
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,represent,0.37514454,feature,0.5787041,generative,0.46606725
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,sensor-technologies,0.57750046,data-engineering,0.71345353,data-engineering,0.71345353
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,including,0.3233776,of,0.6619886,clustering,0.40625107
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,older,0.38174838,short-term,0.49749964,short-term-memory,0.4763971
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,adults,0.2950639,short-term,0.48601514,long-short-term,0.43684626
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,older-adults,0.34902018,intelligence,0.4723326,natural-language,0.4543073
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,using,0.47332245,analysis,0.5968549,component-analysis,0.526608
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,new,0.43019778,of,0.526482,feature-reduction,0.4579819
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,technology,0.48836875,data-engineering,0.7060051,data-engineering,0.7060051
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,new-technology,0.5377019,data-engineering,0.7264513,data-engineering,0.7264513
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,hypothesized,0.35693395,short-term,0.53707504,long-short-term,0.52520865
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,model,0.48485535,model,1.0,markov-model,0.7005576
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,showed,0.20766163,of,0.5296177,regression,0.37027335
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,everyday,0.49276018,natural-language,0.62514055,natural-language,0.62514055
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,health,0.36509717,data-science,0.5754831,data-science,0.5754831
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,conditions,0.21472734,short-term,0.4503411,feature-reduction,0.43574768
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,health-conditions,0.39169306,style,0.53779995,dimensionality-reduction,0.53725386
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,continuously,0.33059904,connected,0.51027673,artificial-intelligence,0.42137086
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,recording,0.38693938,computer-vision,0.5761625,computer-vision,0.5761625
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,people,0.36805943,natural-language,0.4770279,natural-language,0.4770279
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,continuously-recording,0.47800323,computer-vision,0.57110685,computer-vision,0.57110685
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,among,0.33676732,of,0.57348,clustering,0.49404603
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,older,0.38174838,short-term,0.49749964,short-term-memory,0.4763971
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,adults,0.2950639,short-term,0.48601514,long-short-term,0.43684626
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,older-adults,0.34902018,intelligence,0.4723326,natural-language,0.4543073
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,mobile,0.35376322,computer,0.52361166,computer-vision,0.44501945
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,wireless,0.4929701,computer,0.5995302,artificial-intelligence,0.5756812
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,technologies,0.5210018,data-engineering,0.7016501,data-engineering,0.7016501
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,mobile-wireless,0.4863511,computer-vision,0.60374737,computer-vision,0.60374737
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,technology,0.48836875,data-engineering,0.7060051,data-engineering,0.7060051
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,acceptance,0.36980695,decision,0.60256815,dimensionality-reduction,0.5247774
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,model,0.48485535,model,1.0,markov-model,0.7005576
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,technology-acceptance,0.5522584,data-engineering,0.65430915,data-engineering,0.65430915
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,technology,0.48836875,data-engineering,0.7060051,data-engineering,0.7060051
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,acceptance,0.36980695,decision,0.60256815,dimensionality-reduction,0.5247774
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,behavior,0.3131135,style,0.5405977,reinforcement-learning,0.5272814
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,technology-acceptance,0.5522584,data-engineering,0.65430915,data-engineering,0.65430915
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,participants,0.4160846,object-tracking,0.5017827,object-tracking,0.5017827
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,determining,0.34762657,of,0.6342732,stochastic,0.46742433
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,older,0.38174838,short-term,0.49749964,short-term-memory,0.4763971
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,users,0.44838846,computer,0.47765467,computer-vision,0.47360408
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,older,0.38174838,short-term,0.49749964,short-term-memory,0.4763971
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,adults,0.2950639,short-term,0.48601514,long-short-term,0.43684626
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,older-adults,0.34902018,intelligence,0.4723326,natural-language,0.4543073
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,technology,0.48836875,data-engineering,0.7060051,data-engineering,0.7060051
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,anxiety,0.325352,confusion,0.56180894,reinforcement-learning,0.4749429
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,perceived,0.40143436,style,0.61272097,dimensionality-reduction,0.5584763
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,ubiquity,0.39669192,feature,0.53377724,stochastic,0.50163764
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,wearable,0.53930736,data-engineering,0.6004859,data-engineering,0.6004859
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,devices,0.37494427,data-engineering,0.5315442,data-engineering,0.5315442
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,wearable-devices,0.5386116,artificial-intelligence,0.6357069,artificial-intelligence,0.6357069
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,outpatients,0.31696147,recurrent,0.4245981,supervised,0.4127279
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,relationships,0.38856623,regression,0.5087007,regression,0.5087007
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,among,0.33676732,of,0.57348,clustering,0.49404603
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,perceived,0.40143436,style,0.61272097,dimensionality-reduction,0.5584763
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,usefulness,0.42202902,of,0.48999286,one-shot,0.43799803
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,perceived,0.40143436,style,0.61272097,dimensionality-reduction,0.5584763
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,ease,0.419994,confusion,0.5272181,dimensionality-reduction,0.52301335
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,user,0.5892831,graphics,0.6527882,computer-vision,0.62567556
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,groups,0.2727722,statistical,0.4438421,statistical,0.4438421
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,user-groups,0.62587893,statistical,0.63596046,statistical,0.63596046
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,traditional,0.49153316,style,0.54303825,dimensionality-reduction,0.5295658
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,components,0.34729862,components,1.0,principal-components,0.7107156
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,original,0.41515705,of,0.5401661,feature-reduction,0.51911664
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,constructs,0.3142286,feature-engineering,0.53626406,feature-engineering,0.53626406
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,negative,0.21900582,of,0.48486513,feed-forward,0.34958985
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,effect,0.21449387,short-term,0.5886732,long-short-term,0.47619703
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,negative-effect,0.38197434,dimensionality-reduction,0.55654955,dimensionality-reduction,0.55654955
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,may,0.30907542,of,0.58654004,long-short-term,0.43985203
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,enhance,0.37389398,boosting,0.56649625,boosting,0.56649625
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,indirect,0.24084951,component-analysis,0.46268535,component-analysis,0.46268535
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,effect,0.21449387,short-term,0.5886732,long-short-term,0.47619703
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,indirect-effect,0.36815178,cross-entropy,0.5814971,cross-entropy,0.5814971
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,cardiovascular,0.31674606,short-term,0.442761,learning-function,0.4027721
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,disease,0.296938,recurrent,0.4731025,classification,0.35271814
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,cardiovascular-disease,0.39733815,logistic-regression,0.43556237,logistic-regression,0.43556237
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,biomedical,0.52170414,science,0.73414767,data-science,0.7338134
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,signals,0.3700128,components,0.5488684,feed-forward,0.52579325
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,behavioral,0.43270424,learning,0.645051,reinforcement-learning,0.6396035
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,intention,0.43114117,decision,0.6505537,supervised,0.5194858
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,behavioral-intention,0.5175701,reinforcement-learning,0.75359833,reinforcement-learning,0.75359833
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,affect,0.23161066,of,0.50835335,long-short-term,0.3772871
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,users,0.44838846,computer,0.47765467,computer-vision,0.47360408
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,tam,0.2131903,naive,0.35184306,naive-bayes,0.33861217
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,extended,0.35070464,long,0.59380597,long-short-term,0.4819066
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,tam,0.2131903,naive,0.35184306,naive-bayes,0.33861217
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,extended-tam,0.3060661,one-shot,0.46003205,one-shot,0.46003205
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,risk,0.35860935,recurrent,0.53675485,logistic-regression,0.52381086
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,patients,0.30007,recurrent,0.5332828,dropout,0.3918751
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,risk-patients,0.3696401,logistic-regression,0.5086636,logistic-regression,0.5086636
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,technology,0.48836875,data-engineering,0.7060051,data-engineering,0.7060051
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,wireless,0.4929701,computer,0.5995302,artificial-intelligence,0.5756812
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,users,0.44838846,computer,0.47765467,computer-vision,0.47360408
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,tam,0.2131903,naive,0.35184306,naive-bayes,0.33861217
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,patients,0.30007,recurrent,0.5332828,dropout,0.3918751
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,validity,0.4588105,cross-validation,0.63885003,cross-validation,0.63885003
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,validated,0.5041009,cross-validation,0.58167183,cross-validation,0.58167183
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,use,0.43753043,of,0.5506158,feature-reduction,0.49910897
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,understanding,0.42499995,feature-engineering,0.552827,feature-engineering,0.552827
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,treatment,0.239264,short-term,0.5206091,long-short-term,0.41699445
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,study,0.3645851,of,0.5728763,statistical,0.44204497
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,shown,0.30073658,of,0.5506151,long-short-term,0.40438446
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,results,0.32376552,data,0.6932311,batch-normalization,0.44826904
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,resistance,0.23395967,selection,0.4553234,long-short-term,0.34529024
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,perception,0.43414065,vision,0.65704286,learning-function,0.58715904
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,obtain,0.38573402,of,0.51702356,batch-normalization,0.46553272
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,method,0.482283,algorithm,0.63295126,algorithm,0.63295126
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,interestingly,0.25179884,of,0.49645597,clustering,0.410362
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,given,0.30785376,of,0.54849017,boosting,0.4329715
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,general,0.3977576,of,0.5577996,learning-function,0.47885123
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,found,0.2840244,of,0.6208722,clustering,0.44675255
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,examine,0.3674211,of,0.5306053,generative-model,0.43169063
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,diagnosis,0.32391536,classification,0.53521544,classification,0.53521544
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,considered,0.36321384,of,0.60548925,feature-reduction,0.4442021
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,confirm,0.28446677,support,0.5519786,component-analysis,0.36139983
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,characteristic,0.34942827,feature,0.7124056,clustering,0.48287967
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,change,0.30684608,reduction,0.5973228,feature-reduction,0.46143895
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,attitude,0.38956326,style,0.692235,artificial-intelligence,0.51968205
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,advances,0.45830926,data-engineering,0.5886656,data-engineering,0.5886656
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,addition,0.30500388,of,0.6910241,feature-reduction,0.48914018
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,yet,0.3648664,fully,0.6829063,generative,0.4089093
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,less,0.2680999,of,0.53796744,long-short-term,0.4390034
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,met,0.2686899,support,0.44825336,supervised,0.37491822
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,f,0.2169397,confusion-matrix,0.37468427,confusion-matrix,0.37468427
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,met-f,0.21653226,tfidf,0.2997638,tfidf,0.2997638
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,four,0.34899807,one,0.769816,clustering,0.40005642
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,thousand,0.28883603,one,0.47491425,nearest-neighbors,0.32248813
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,three,0.36911732,one,0.78425425,clustering,0.4299444
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,hundred,0.28113165,one,0.48517382,machine-learning,0.28113165
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,thirty,0.328524,one,0.5351969,machine-learning,0.328524
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,four-thousand,0.40661386,one,0.54046917,one-hot,0.47674128
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,thousand-three,0.30587876,one,0.56013656,one-hot,0.4345969
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,three-hundred,0.3280068,one,0.42566687,machine-learning,0.3280068
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,hundred-thirty,0.279886,one,0.46211058,one-hot,0.31376827
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,three-hundred-thirty,0.30828965,one,0.4203308,one-hot,0.3092742
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,population,0.2958798,selection,0.5071889,clustering,0.47966808
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,reporting,0.41789776,data,0.54032123,natural-language,0.48204225
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,positive,0.26811236,of,0.49572036,component-analysis,0.37181294
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,dietary,0.2304514,feed,0.59213865,principal-components,0.35903007
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,behaviours,0.36764926,style,0.6176375,reinforcement-learning,0.56195223
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,nationally,0.42458823,federated,0.6275694,data-science,0.53262234
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,representative,0.39455557,data,0.5936315,clustering,0.48485303
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,surveys,0.381772,data,0.5966315,data-science,0.5135532
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,nationally-representative,0.48325336,federated,0.6035398,natural-language,0.54659235
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,males,0.23722412,descent,0.48490888,generative,0.409998
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,reported,0.27641866,of,0.6039252,long-short-term,0.38086164
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,positive,0.26811236,of,0.49572036,component-analysis,0.37181294
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,sub,0.24888316,deep,0.47158134,dimensionality-reduction,0.38515002
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,sub,0.24888316,deep,0.47158134,dimensionality-reduction,0.38515002
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,meeting,0.33862334,federated,0.52050734,data-science,0.50054747
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,fruit,0.29721212,kernel,0.5478446,kernel,0.5478446
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,related,0.30849367,of,0.6150687,clustering,0.41455543
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,cvd,0.25363478,hierarchical,0.35325012,logistic-regression,0.34885177
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,risk,0.35860935,recurrent,0.53675485,logistic-regression,0.52381086
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,factors,0.3420733,components,0.5413606,logistic-regression,0.48293567
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,cvd-risk,0.32805383,logistic-regression,0.4636621,logistic-regression,0.4636621
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,risk-factors,0.40161455,logistic-regression,0.57501113,logistic-regression,0.57501113
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,positive,0.26811236,of,0.49572036,component-analysis,0.37181294
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,salt,0.17142805,gradient,0.4197693,gradient,0.4197693
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,use,0.43753043,of,0.5506158,feature-reduction,0.49910897
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,behaviour,0.29581106,style,0.5553138,reinforcement-learning,0.5048617
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,salt-use,0.28787887,stochastic-gradient,0.39222005,stochastic-gradient,0.39222005
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,three,0.36911732,one,0.78425425,clustering,0.4299444
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,dietary,0.2304514,feed,0.59213865,principal-components,0.35903007
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,behaviours,0.36764926,style,0.6176375,reinforcement-learning,0.56195223
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,dietary,0.2304514,feed,0.59213865,principal-components,0.35903007
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,behaviours,0.36764926,style,0.6176375,reinforcement-learning,0.56195223
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,related,0.30849367,of,0.6150687,clustering,0.41455543
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,behaviours-related,0.4327207,learning,0.5291576,learning-function,0.52558017
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,positive,0.26811236,of,0.49572036,component-analysis,0.37181294
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,behaviours,0.36764926,style,0.6176375,reinforcement-learning,0.56195223
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,increases,0.2716412,reduction,0.73312634,boosting,0.5263907
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,generalized,0.44367343,regression,0.54602534,regression,0.54602534
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,linear,0.42916322,linear,0.99999994,regression,0.66034734
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,models,0.53762007,model,0.8940372,markov-model,0.7015921
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,generalized-linear,0.6441962,cross-entropy,0.71580327,cross-entropy,0.71580327
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,dietary,0.2304514,feed,0.59213865,principal-components,0.35903007
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,behaviour,0.29581106,style,0.5553138,reinforcement-learning,0.5048617
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,measurements,0.31488982,data,0.56587404,batch-normalization,0.52457345
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,cvd,0.25363478,hierarchical,0.35325012,logistic-regression,0.34885177
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,risk,0.35860935,recurrent,0.53675485,logistic-regression,0.52381086
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,factors,0.3420733,components,0.5413606,logistic-regression,0.48293567
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,cvd-risk,0.32805383,logistic-regression,0.4636621,logistic-regression,0.4636621
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,risk-factors,0.40161455,logistic-regression,0.57501113,logistic-regression,0.57501113
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,varying,0.29625484,of,0.6121373,gradient,0.43225324
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,middle,0.19510958,deep,0.45081678,language-processing,0.36516818
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,income,0.33334333,intelligence,0.510766,logistic-regression,0.5021742
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,countries,0.32370913,federated,0.55801976,data-science,0.4527291
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,middle-income,0.36061543,natural-language,0.45970684,natural-language,0.45970684
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,income-countries,0.37615108,random-forest,0.5103078,random-forest,0.5103078
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,middle-income-countries,0.36996788,federated,0.4970691,natural-language-processing,0.47613394
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,vegetable,0.29064924,feed,0.560959,kernel,0.44656372
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,oil,0.21031478,feed,0.44002843,kernel,0.40903962
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,rather,0.34622794,of,0.6500968,generative,0.54707265
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,vegetable-oil,0.23086956,feed,0.54753494,kernel,0.40869454
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,understand,0.38325277,feature-engineering,0.47215402,feature-engineering,0.47215402
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,whether,0.32171756,short-term,0.5290759,long-short-term,0.47851244
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,associations,0.41113383,regression,0.58898914,regression,0.58898914
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,sex,0.24554862,regression,0.45148212,regression,0.45148212
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,would,0.3569631,of,0.55908126,boosting,0.43412957
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,change,0.30684608,reduction,0.5973228,feature-reduction,0.46143895
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,p,0.26795468,support,0.40805867,regression,0.40253854
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,dietary,0.2304514,feed,0.59213865,principal-components,0.35903007
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,behaviours,0.36764926,style,0.6176375,reinforcement-learning,0.56195223
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,dietary,0.2304514,feed,0.59213865,principal-components,0.35903007
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,behaviour,0.29581106,style,0.5553138,reinforcement-learning,0.5048617
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,meeting,0.33862334,federated,0.52050734,data-science,0.50054747
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,f,0.2169397,confusion-matrix,0.37468427,confusion-matrix,0.37468427
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,cvd,0.25363478,hierarchical,0.35325012,logistic-regression,0.34885177
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,risk,0.35860935,recurrent,0.53675485,logistic-regression,0.52381086
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,cvd-risk,0.32805383,logistic-regression,0.4636621,logistic-regression,0.4636621
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,positive,0.26811236,of,0.49572036,component-analysis,0.37181294
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,subs,0.27259362,components,0.4842629,bagging,0.4310057
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,positive,0.26811236,of,0.49572036,component-analysis,0.37181294
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,manner,0.26802608,fully,0.46465638,feed-forward,0.4349473
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,poor,0.31379676,confusion,0.5027573,long-short-term,0.43808374
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,sub,0.24888316,deep,0.47158134,dimensionality-reduction,0.38515002
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,understand,0.38325277,feature-engineering,0.47215402,feature-engineering,0.47215402
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,whether,0.32171756,short-term,0.5290759,long-short-term,0.47851244
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,increase,0.28092995,reduction,0.7624404,boosting,0.49543357
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,f,0.2169397,confusion-matrix,0.37468427,confusion-matrix,0.37468427
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,vs,0.22635552,transfer,0.4263924,statistical,0.3002486
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,vs,0.22635552,transfer,0.4263924,statistical,0.3002486
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,seven,0.34317708,one,0.6849233,principal-components,0.39034536
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,countries,0.32370913,federated,0.55801976,data-science,0.4527291
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,seven-countries,0.40955457,federated,0.5430186,data-science,0.5087806
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,waist,0.21817927,logistic-regression,0.39899153,logistic-regression,0.39899153
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,circumference,0.21110922,descent,0.4283415,regression,0.41496205
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,waist-circumference,0.2272197,regression,0.41331822,regression,0.41331822
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,urgently,0.3494968,fully,0.49317503,data-engineering,0.4369593
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,needed,0.36127746,support,0.5796853,supervised,0.43152136
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,urgently-needed,0.4286217,decision,0.55887413,supervised,0.49753678
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,urgent,0.33045825,decision,0.5188651,decision-tree,0.42648524
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,action,0.25617146,of,0.5591097,generative,0.46361452
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,two,0.35955608,one,0.79919666,clustering,0.43817294
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,participants,0.4160846,object-tracking,0.5017827,object-tracking,0.5017827
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,two-participants,0.4924361,logistic-regression,0.5554377,logistic-regression,0.5554377
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,st,0.22907814,confusion,0.43447053,long-short-term,0.42084157
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,vincent,0.33328038,federated,0.47499448,relu,0.43228495
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,st-vincent,0.31338787,federated,0.47093832,confusion-matrix,0.4085638
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,small,0.28058842,few,0.5791491,bagging,0.40911084
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,proportion,0.24881616,reduction,0.5001526,clustering,0.44429505
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,small-proportion,0.4235497,stochastic-gradient,0.53758323,stochastic-gradient,0.53758323
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,sex,0.24554862,regression,0.45148212,regression,0.45148212
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,differences,0.3361535,statistical,0.57447433,statistical,0.57447433
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,sex-differences,0.33257008,dimensionality-reduction,0.48488295,dimensionality-reduction,0.48488295
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,nutrition,0.30815834,feed,0.6000953,data-science,0.4027332
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,transition,0.2521789,ground,0.5124147,transfer-learning,0.4300129
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,notably,0.31266075,of,0.64324886,clustering,0.4725143
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,different,0.37681934,of,0.61590904,clustering,0.46857932
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,lmic,0.3793212,data-science,0.4918881,data-science,0.4918881
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,leading,0.2514689,of,0.59935343,generative,0.44480726
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,causes,0.19757006,of,0.55089116,long-short-term,0.3616379
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,interaction,0.32838812,function,0.4945054,nearest-neighbors,0.47909442
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,terms,0.43271685,term,0.61106205,dimensionality-reduction,0.5960058
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,interaction-terms,0.54904807,learning-function,0.61434776,learning-function,0.61434776
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,included,0.34673893,of,0.58040446,component-analysis,0.47413814
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,countries,0.32370913,federated,0.55801976,data-science,0.4527291
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,diets,0.24409598,feed,0.6872177,random-forest,0.34590763
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,high,0.267004,of,0.57459104,gradient,0.44240427
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,diagnosed,0.29304254,recurrent,0.56110895,classification,0.43035528
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,hypertension,0.28340828,dropout,0.4223115,dropout,0.4223115
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,diagnosed-hypertension,0.3761344,classification-algorithm,0.45550227,classification-algorithm,0.45550227
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,cardiovascular,0.31674606,short-term,0.442761,learning-function,0.4027721
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,diseases,0.31957155,recurrent,0.41244444,classification,0.40266854
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,cardiovascular-diseases,0.3900246,learning-function,0.41476324,learning-function,0.41476324
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,animal,0.3921889,model,0.61759067,generative-model,0.52223754
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,fats,0.21491627,feed,0.5461409,tfidf,0.38704574
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,animal-fats,0.3740701,feed,0.55693454,random-forest,0.4471174
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,aid,0.45667556,computer,0.55178434,artificial-intelligence,0.5012631
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,identification,0.4527572,analysis,0.6100153,classification,0.5378393
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,v,0.16266164,rate,0.35976145,softmax,0.2951627
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,intake,0.22508445,feed,0.66565716,reinforcement-learning,0.35915208
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,undiagnosed,0.30389208,recurrent,0.54493415,logistic-regression,0.38000566
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,hypertension,0.28340828,dropout,0.4223115,dropout,0.4223115
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,undiagnosed-hypertension,0.36994272,logistic-regression,0.46094924,logistic-regression,0.46094924
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,increasing,0.30868235,of,0.6603997,boosting,0.50417006
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,prevalence,0.2908883,rate,0.45596814,dropout,0.4310696
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,included,0.34673893,of,0.58040446,component-analysis,0.47413814
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,data,0.46434748,data,1.0,data-science,0.5533528
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,higher,0.27819592,reduction,0.545787,boosting,0.41506222
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,prevalence,0.2908883,rate,0.45596814,dropout,0.4310696
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,higher-prevalence,0.38651976,random-forest,0.5185909,random-forest,0.5185909
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,high,0.267004,of,0.57459104,gradient,0.44240427
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,wc,0.20091897,tfidf,0.41808814,tfidf,0.41808814
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,high-wc,0.27245462,long-short-term-memory,0.37743318,long-short-term-memory,0.37743318
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,effective,0.32842147,of,0.50971246,boosting,0.48854327
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,interventions,0.3916263,decision,0.5218073,reinforcement-learning,0.50423867
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,v,0.16266164,rate,0.35976145,softmax,0.2951627
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,recommendations,0.40738833,decision,0.6199442,classification-algorithm,0.5130223
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,undiagnosed,0.30389208,recurrent,0.54493415,logistic-regression,0.38000566
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,diabetes,0.29301462,logistic-regression,0.35688502,logistic-regression,0.35688502
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,reporting,0.41789776,data,0.54032123,natural-language,0.48204225
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,f,0.2169397,confusion-matrix,0.37468427,confusion-matrix,0.37468427
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,use,0.43753043,of,0.5506158,feature-reduction,0.49910897
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,salt,0.17142805,gradient,0.4197693,gradient,0.4197693
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,males,0.23722412,descent,0.48490888,generative,0.409998
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,fruit,0.29721212,kernel,0.5478446,kernel,0.5478446
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,cvd,0.25363478,hierarchical,0.35325012,logistic-regression,0.34885177
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,vegetable,0.29064924,feed,0.560959,kernel,0.44656372
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,sex,0.24554862,regression,0.45148212,regression,0.45148212
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,p,0.26795468,support,0.40805867,regression,0.40253854
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,vs,0.22635552,transfer,0.4263924,statistical,0.3002486
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,v,0.16266164,rate,0.35976145,softmax,0.2951627
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,undiagnosed,0.30389208,recurrent,0.54493415,logistic-regression,0.38000566
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,prevalence,0.2908883,rate,0.45596814,dropout,0.4310696
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,included,0.34673893,of,0.58040446,component-analysis,0.47413814
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,wc,0.20091897,tfidf,0.41808814,tfidf,0.41808814
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,recommendations,0.40738833,decision,0.6199442,classification-algorithm,0.5130223
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,interventions,0.3916263,decision,0.5218073,reinforcement-learning,0.50423867
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,diabetes,0.29301462,logistic-regression,0.35688502,logistic-regression,0.35688502
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,women,0.25528732,descent,0.50278515,dropout,0.37675467
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,vegetables,0.26544034,feed,0.5275343,kernel,0.4067747
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,value,0.3544725,of,0.52001536,statistical,0.45314136
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,used,0.46049535,of,0.5630944,generative-model,0.4901716
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,twenty,0.3365708,one,0.55018187,machine-learning,0.3365708
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,trend,0.30273274,statistical,0.5180256,statistical,0.5180256
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,test,0.4037762,statistical,0.5031551,statistical,0.5031551
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,sugar,0.21723293,feed,0.4361885,n-gram,0.31442612
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,sexes,0.24578363,descent,0.46037877,regression,0.44622678
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,reverse,0.2939736,forward,0.5330905,feature-reduction,0.40937227
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,results,0.32376552,data,0.6932311,batch-normalization,0.44826904
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,research,0.45694843,science,0.7194936,data-science,0.70924157
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,required,0.28895828,of,0.603855,bagging,0.39730927
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,recorded,0.299657,rectified,0.55581653,computer-vision,0.443301
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,parallel,0.38849422,convolutional-layer,0.55327755,convolutional-layer,0.55327755
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,nepal,0.31497085,forest,0.5139922,random-forest,0.4473628
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,need,0.40584964,confusion,0.57364553,dimensionality-reduction,0.4553358
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,methods,0.50049126,data,0.5400177,machine-learning,0.50049126
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,men,0.23664121,descent,0.5239919,regression,0.38136965
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,low,0.23602332,of,0.5820825,long-short-term,0.45172954
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,lmics,0.40983337,data-science,0.54139376,data-science,0.54139376
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,limited,0.33893847,of,0.6210327,long-short-term,0.4736513
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,kenya,0.26800698,random-forest,0.47965443,random-forest,0.47965443
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,investigated,0.30147675,of,0.6179704,generative-model,0.42952073
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,investigate,0.3396353,of,0.48247698,feature-engineering,0.41061842
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,interactions,0.34362614,nearest-neighbors,0.5320788,nearest-neighbors,0.5320788
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,identifies,0.4679339,feature,0.5498267,clustering,0.5299643
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,however,0.31437585,few,0.63182676,statistical,0.44065386
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,guyana,0.29834455,keras,0.5244895,keras,0.5244895
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,grenadines,0.2278375,natural,0.41268426,keras,0.357306
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,georgia,0.25665957,federated,0.56989217,random-forest,0.43549582
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,findings,0.35685748,data,0.65714294,component-analysis,0.38599753
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,females,0.23467627,descent,0.45827615,generative,0.39833257
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,fat,0.22005057,feed,0.48228577,segmentation,0.36863354
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,eswatini,0.31643218,pytorch,0.44960588,pytorch,0.44960588
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,diet,0.23870954,feed,0.6865525,supervised,0.36359084
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,death,0.21479979,of,0.42234862,dropout,0.37818787
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,dataset,0.6046342,data,0.68842554,classifiers,0.6499833
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,crucial,0.31994545,feature,0.5223625,feature-engineering,0.4773315
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,country,0.34733737,federated,0.568089,data-science,0.5095874
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,cooking,0.29605862,feed,0.56942815,bagging,0.45054686
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,conclusion,0.35530132,data,0.5299138,long-short-term,0.45073265
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,bhutan,0.3052978,forest,0.51840997,random-forest,0.47755867
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,background,0.3259285,of,0.51277274,long-short-term,0.46426663
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,association,0.32292235,regression,0.5094141,regression,0.5094141
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,associated,0.30827495,of,0.57598466,long-short-term,0.46578532
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,adults,0.2950639,short-term,0.48601514,long-short-term,0.43684626
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,added,0.32371867,of,0.5926449,batch-normalization,0.4530739
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",plus,0.26799425,of,0.5028229,long-short-term,0.429379
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",norethisterone,0.19210629,short-term,0.3321573,centroid-based,0.31974292
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",acetate,0.1438339,gradient,0.39459032,gradient,0.39459032
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",daily,0.3039257,short-term,0.50002974,supervised,0.42771563
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",norethisterone-acetate,0.19040425,convolutional-layer,0.35536146,convolutional-layer,0.35536146
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",enriched,0.33487642,components,0.46452388,clustering,0.4599933
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",subfraction,0.2172106,components,0.49018633,gradient,0.4354213
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",p,0.26795468,support,0.40805867,regression,0.40253854
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",neta,0.24048287,relu,0.34105378,relu,0.34105378
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",lowered,0.18627976,reduction,0.65848374,boosting,0.464316
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",plasma,0.21912897,normalization,0.4569842,batch-normalization,0.43571177
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",total,0.21723771,of,0.5102532,principal-components,0.3630478
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",cholesterol,0.15921682,reduction,0.33627644,gradient,0.32767534
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",concentrations,0.16781005,of,0.4458394,batch-normalization,0.42195582
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",relative,0.28452736,of,0.6192827,long-short-term,0.43953407
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",plasma-total,0.17934321,batch-normalization,0.48306152,batch-normalization,0.48306152
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",total-cholesterol,0.20466265,batch-normalization,0.41337907,batch-normalization,0.41337907
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",continuous,0.41333556,short-term,0.5995445,long-short-term,0.56591904
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",combined,0.39749897,of,0.5690281,one-shot,0.52384484
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",oestrogen,0.17003752,short-term,0.36506286,long-short-term,0.3087231
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",plus,0.26799425,of,0.5028229,long-short-term,0.429379
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",progestogen,0.19266337,term,0.3635558,long-short-term,0.32515305
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",continuous-combined,0.45793346,one-shot,0.558377,one-shot,0.558377
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",combined-oestrogen,0.289914,short-term,0.48105964,long-short-term,0.41733915
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",three,0.36911732,one,0.78425425,clustering,0.4299444
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",groups,0.2727722,statistical,0.4438421,statistical,0.4438421
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",taking,0.39087248,feed,0.5260685,supervised,0.49332055
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",daily,0.3039257,short-term,0.50002974,supervised,0.42771563
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",three-groups,0.46776178,principal-components,0.5749112,principal-components,0.5749112
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",groups-taking,0.430569,reinforcement-learning,0.54294944,reinforcement-learning,0.54294944
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",suggesting,0.24045295,of,0.6157647,clustering,0.43733796
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",decreased,0.23506472,reduction,0.66483074,boosting,0.42738107
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",cholesterol,0.15921682,reduction,0.33627644,gradient,0.32767534
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",loading,0.29240596,of,0.47450465,batch-normalization,0.44969252
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",cholesterol-loading,0.23724233,feature-reduction,0.39536962,feature-reduction,0.39536962
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",apolipoprotein,0.25016165,tf-idf,0.31200302,tf-idf,0.31200302
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",ai,0.25513044,artificial-intelligence,0.38274616,artificial-intelligence,0.38274616
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",apolipoprotein-ai,0.26221758,tf-idf,0.34865075,tf-idf,0.34865075
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",neta,0.24048287,relu,0.34105378,relu,0.34105378
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",reduces,0.2596901,reduction,0.6328956,boosting,0.4721025
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",ldl,0.16037413,tf-idf,0.38286388,tf-idf,0.38286388
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",cholesterol,0.15921682,reduction,0.33627644,gradient,0.32767534
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",ldl-cholesterol,0.1916017,batch-normalization,0.38746154,batch-normalization,0.38746154
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",tibolone,0.15253127,short-term,0.3328038,confusion-matrix,0.28006086
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",reduces,0.2596901,reduction,0.6328956,boosting,0.4721025
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",serum,0.20734212,normalization,0.47724307,batch-normalization,0.4486353
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",hdl,0.19749369,tf-idf,0.41316777,tf-idf,0.41316777
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",serum-hdl,0.12181549,tf-idf,0.3777948,tf-idf,0.3777948
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",principal,0.3794123,principal,1.0,principal-components,0.72193956
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",hdl,0.19749369,tf-idf,0.41316777,tf-idf,0.41316777
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",protein,0.31929362,encoding,0.5525089,clustering,0.36023882
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",component,0.29999307,component,1.0,principal-component,0.687786
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",hdl-protein,0.2658828,batch-normalization,0.3767724,batch-normalization,0.3767724
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",protein-component,0.4278004,components,0.69443274,component-analysis,0.62694734
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",similarly,0.28201446,of,0.5816662,long-short-term,0.47558495
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",diminished,0.2149298,reduction,0.48049104,bagging,0.41987002
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",relative,0.28452736,of,0.6192827,long-short-term,0.43953407
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",reduced,0.24137571,reduction,0.7564339,boosting,0.47559226
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",continuous,0.41333556,short-term,0.5995445,long-short-term,0.56591904
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",oral,0.24590528,of,0.46959797,boosting,0.3483035
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",oestradiol,0.1324808,short-term,0.34671706,batch-normalization,0.2834422
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",apolipoprotein,0.25016165,tf-idf,0.31200302,tf-idf,0.31200302
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",concentrations,0.16781005,of,0.4458394,batch-normalization,0.42195582
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",measured,0.25103813,of,0.539739,batch-normalization,0.45439726
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",apolipoprotein-concentrations,0.33406612,batch-normalization,0.4662756,batch-normalization,0.4662756
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",tibolone,0.15253127,short-term,0.3328038,confusion-matrix,0.28006086
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",neta,0.24048287,relu,0.34105378,relu,0.34105378
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",reduced,0.24137571,reduction,0.7564339,boosting,0.47559226
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",hdl,0.19749369,tf-idf,0.41316777,tf-idf,0.41316777
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",c,0.17513797,of,0.44327667,gradient,0.31114018
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",main,0.3070703,principal,0.7875631,principal-components,0.51314574
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",outcome,0.33788118,short-term,0.5818455,long-short-term,0.48316076
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",measures,0.3789752,principal-components,0.5349536,principal-components,0.5349536
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",main-outcome,0.4388028,dimensionality-reduction,0.54660535,dimensionality-reduction,0.54660535
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",outcome-measures,0.5463372,classification-algorithm,0.60786396,classification-algorithm,0.60786396
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",fasting,0.22235955,normalization,0.46940017,batch-normalization,0.4534999
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",serum,0.20734212,normalization,0.47724307,batch-normalization,0.4486353
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",lipid,0.23492281,of,0.44637915,clustering,0.37238947
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",fasting-serum,0.29681677,batch-normalization,0.5141444,batch-normalization,0.5141444
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",serum-lipid,0.19388384,batch-normalization,0.4184449,batch-normalization,0.4184449
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",cvd,0.25363478,hierarchical,0.35325012,logistic-regression,0.34885177
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",risk,0.35860935,recurrent,0.53675485,logistic-regression,0.52381086
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",needs,0.38735956,support,0.555194,natural-language,0.45190576
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",cvd-risk,0.32805383,logistic-regression,0.4636621,logistic-regression,0.4636621
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",risk-needs,0.44376343,decision,0.64108485,decision-tree,0.6125533
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",blind,0.3706082,vision,0.5683825,computer-vision,0.498325
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",study,0.3645851,of,0.5728763,statistical,0.44204497
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",patients,0.30007,recurrent,0.5332828,dropout,0.3918751
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",blind-study,0.36587763,object-tracking,0.50137913,object-tracking,0.50137913
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",study-patients,0.3744889,logistic-regression,0.4868214,logistic-regression,0.4868214
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",tibolone,0.15253127,short-term,0.3328038,confusion-matrix,0.28006086
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",density,0.25813383,layer,0.4929318,gradient,0.48885438
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",lipoprotein,0.22208765,tf-idf,0.3608624,tf-idf,0.3608624
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",cholesterol,0.15921682,reduction,0.33627644,gradient,0.32767534
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",density-lipoprotein,0.2429603,tf-idf,0.4027466,tf-idf,0.4027466
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",lipoprotein-cholesterol,0.2143431,tf-idf,0.33285147,tf-idf,0.33285147
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",density-lipoprotein-cholesterol,0.22921449,batch-normalization,0.37548044,batch-normalization,0.37548044
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",plasma,0.21912897,normalization,0.4569842,batch-normalization,0.43571177
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",lipid,0.23492281,of,0.44637915,clustering,0.37238947
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",plasma-lipid,0.18679354,batch-normalization,0.40360844,batch-normalization,0.40360844
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",hdl,0.19749369,tf-idf,0.41316777,tf-idf,0.41316777
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",concentrations,0.16781005,of,0.4458394,batch-normalization,0.42195582
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",hdl-concentrations,0.269459,batch-normalization,0.5571636,batch-normalization,0.5571636
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",protein,0.31929362,encoding,0.5525089,clustering,0.36023882
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",component,0.29999307,component,1.0,principal-component,0.687786
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",protein-component,0.4278004,components,0.69443274,component-analysis,0.62694734
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",post,0.27536392,confusion,0.47820356,bagging,0.44161102
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",months,0.25947675,short-term,0.51117545,regression,0.43146035
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",apolipoprotein,0.25016165,tf-idf,0.31200302,tf-idf,0.31200302
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",b,0.19558734,of,0.43435428,short-term-memory,0.31717262
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",apolipoprotein-b,0.2448067,tf-idf,0.32602477,tf-idf,0.32602477
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",hdl,0.19749369,tf-idf,0.41316777,tf-idf,0.41316777
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",apolipoproteins,0.26247928,components,0.36930004,tf-idf,0.32594717
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",hdl-apolipoproteins,0.22666645,tf-idf,0.3631204,tf-idf,0.3631204
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",study,0.3645851,of,0.5728763,statistical,0.44204497
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",design,0.47555828,data-engineering,0.6477308,data-engineering,0.6477308
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",study-design,0.45001322,data-engineering,0.5413737,data-engineering,0.5413737
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",cardiovascular,0.31674606,short-term,0.442761,learning-function,0.4027721
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",risk,0.35860935,recurrent,0.53675485,logistic-regression,0.52381086
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",cardiovascular-risk,0.3523693,logistic-regression,0.46172044,logistic-regression,0.46172044
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",sons,0.24153107,neighbors,0.42599985,artificial-intelligence,0.3507973
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",ltd,0.17568776,long-short-term-memory,0.37555107,long-short-term-memory,0.37555107
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",respectively,0.23184536,of,0.43360457,cross-validation,0.35765702
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",p,0.26795468,support,0.40805867,regression,0.40253854
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",menopausal,0.22709613,regression,0.3406949,regression,0.3406949
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",women,0.25528732,descent,0.50278515,dropout,0.37675467
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",menopausal-women,0.24172068,descent,0.39846224,natural-language,0.3517479
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",lipoprotein,0.22208765,tf-idf,0.3608624,tf-idf,0.3608624
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",markers,0.32439512,of,0.43581337,clustering,0.41091266
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",lesser,0.15235366,of,0.57503545,long-short-term,0.37152597
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",extent,0.258318,of,0.64978826,dimensionality-reduction,0.43577164
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",lesser-extent,0.31546515,of,0.5118722,dimensionality-reduction,0.45190287
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",healthy,0.31399268,naive,0.5051062,artificial-intelligence,0.3681498
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",post,0.27536392,confusion,0.47820356,bagging,0.44161102
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",greatest,0.25896034,of,0.57135177,boosting,0.42160904
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",reduction,0.22531602,reduction,1.0,feature-reduction,0.59547573
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",changes,0.28767496,normalization,0.57879114,batch-normalization,0.43861648
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",may,0.30907542,of,0.58654004,long-short-term,0.43985203
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",also,0.32850838,of,0.65908813,clustering,0.45826355
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",apparent,0.22103967,of,0.58568347,confusion-matrix,0.4399731
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",cholesterol,0.15921682,reduction,0.33627644,gradient,0.32767534
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",neta,0.24048287,relu,0.34105378,relu,0.34105378
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",significant,0.29367286,statistical,0.582669,statistical,0.582669
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",effect,0.21449387,short-term,0.5886732,long-short-term,0.47619703
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",significant-effect,0.4285237,statistical,0.6677017,statistical,0.6677017
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",greatest,0.25896034,of,0.57135177,boosting,0.42160904
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",effect,0.21449387,short-term,0.5886732,long-short-term,0.47619703
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",hdl,0.19749369,tf-idf,0.41316777,tf-idf,0.41316777
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",tibolone,0.15253127,short-term,0.3328038,confusion-matrix,0.28006086
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",ldl,0.16037413,tf-idf,0.38286388,tf-idf,0.38286388
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",lipoprotein,0.22208765,tf-idf,0.3608624,tf-idf,0.3608624
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",density,0.25813383,layer,0.4929318,gradient,0.48885438
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",c,0.17513797,of,0.44327667,gradient,0.31114018
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",effect,0.21449387,short-term,0.5886732,long-short-term,0.47619703
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",vldl,0.17931633,tf-idf,0.40512678,tf-idf,0.40512678
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",treatment,0.239264,short-term,0.5206091,long-short-term,0.41699445
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",single,0.31087106,one,0.6951874,one-shot,0.4602274
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",results,0.32376552,data,0.6932311,batch-normalization,0.44826904
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",randomised,0.32199043,supervised,0.42737898,supervised,0.42737898
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",placebo,0.21232492,short-term,0.4439273,dropout,0.37253323
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",one,0.335046,one,1.0,one-hot,0.4275648
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",objective,0.4122544,of,0.5255821,component-analysis,0.42220753
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",low,0.23602332,of,0.5820825,long-short-term,0.45172954
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",investigation,0.33686116,analysis,0.63110995,component-analysis,0.46827114
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",impact,0.3818503,of,0.5528908,dimensionality-reduction,0.4648105
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",however,0.31437585,few,0.63182676,statistical,0.44065386
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",high,0.267004,of,0.57459104,gradient,0.44240427
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",effects,0.2624804,short-term,0.63497096,long-short-term,0.5306107
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",double,0.17489362,one,0.4589219,one-hot,0.42127374
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",controlled,0.25206095,of,0.4703986,supervised,0.39651048
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",contrast,0.24962384,of,0.5428885,feature-reduction,0.41914925
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",conclusion,0.35530132,data,0.5299138,long-short-term,0.45073265
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",compare,0.43674475,short-term,0.510365,statistical,0.44797724
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",centre,0.22271128,unit,0.5901463,data-science,0.38517424
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",baseline,0.32763094,normalization,0.56518495,batch-normalization,0.4727359
Heart Failure With Mid-range Ejection Fraction.,randomized,0.35587335,short-term,0.45843548,supervised,0.43708503
Heart Failure With Mid-range Ejection Fraction.,controlled,0.25206095,of,0.4703986,supervised,0.39651048
Heart Failure With Mid-range Ejection Fraction.,trials,0.31393725,short-term,0.4483273,data-science,0.40647802
Heart Failure With Mid-range Ejection Fraction.,exist,0.33952302,few,0.54263353,clustering,0.42993432
Heart Failure With Mid-range Ejection Fraction.,randomized-controlled,0.4034369,short-term,0.4853552,supervised,0.4496856
Heart Failure With Mid-range Ejection Fraction.,controlled-trials,0.3558599,object-tracking,0.4862421,object-tracking,0.4862421
Heart Failure With Mid-range Ejection Fraction.,randomized-controlled-trials,0.3943098,object-tracking,0.47047678,object-tracking,0.47047678
Heart Failure With Mid-range Ejection Fraction.,aha,0.24828324,classification-algorithm,0.31225228,classification-algorithm,0.31225228
Heart Failure With Mid-range Ejection Fraction.,american,0.31403136,federated,0.55841243,classification,0.43444416
Heart Failure With Mid-range Ejection Fraction.,college,0.4001669,science,0.5562495,data-science,0.50345683
Heart Failure With Mid-range Ejection Fraction.,ef,0.32227567,function,0.46732792,learning-function,0.37073672
Heart Failure With Mid-range Ejection Fraction.,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
Heart Failure With Mid-range Ejection Fraction.,ef,0.32227567,function,0.46732792,learning-function,0.37073672
Heart Failure With Mid-range Ejection Fraction.,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
Heart Failure With Mid-range Ejection Fraction.,unique,0.3996781,feature,0.6177588,feature-engineering,0.5304749
Heart Failure With Mid-range Ejection Fraction.,phenotype,0.28173286,feature,0.51151407,feature-selection,0.4975547
Heart Failure With Mid-range Ejection Fraction.,altogether,0.34802556,data,0.5542451,clustering,0.3638755
Heart Failure With Mid-range Ejection Fraction.,remains,0.24202663,fully,0.5171005,bagging,0.35608193
Heart Failure With Mid-range Ejection Fraction.,poorly,0.28902727,fully,0.6905947,long-short-term,0.39858708
Heart Failure With Mid-range Ejection Fraction.,understood,0.33540633,fully,0.5863327,stochastic,0.4766314
Heart Failure With Mid-range Ejection Fraction.,poorly-understood,0.36790985,feature,0.49439994,confusion-matrix,0.47433245
Heart Failure With Mid-range Ejection Fraction.,mortality,0.2609817,short-term,0.505676,logistic-regression,0.49414968
Heart Failure With Mid-range Ejection Fraction.,rates,0.24094881,rate,0.8800579,dropout,0.48159522
Heart Failure With Mid-range Ejection Fraction.,among,0.33676732,of,0.57348,clustering,0.49404603
Heart Failure With Mid-range Ejection Fraction.,mortality-rates,0.3457303,rate,0.52726305,logistic-regression,0.5160084
Heart Failure With Mid-range Ejection Fraction.,rates-among,0.2976452,rate,0.45142972,random-forest,0.4267065
Heart Failure With Mid-range Ejection Fraction.,include,0.32050848,of,0.60518813,feature-reduction,0.45980722
Heart Failure With Mid-range Ejection Fraction.,overlap,0.38858992,feature,0.58340186,clustering,0.5132319
Heart Failure With Mid-range Ejection Fraction.,suggest,0.26874092,data,0.5391823,long-short-term,0.40288782
Heart Failure With Mid-range Ejection Fraction.,heterogeneous,0.36404067,feature,0.5641245,hierarchical-clustering,0.5368855
Heart Failure With Mid-range Ejection Fraction.,clinical,0.44080526,data,0.48532635,data-science,0.45343333
Heart Failure With Mid-range Ejection Fraction.,characteristics,0.345204,of,0.5401758,feature-engineering,0.49030614
Heart Failure With Mid-range Ejection Fraction.,clinical-characteristics,0.48064718,feature,0.6024677,component-analysis,0.5396
Heart Failure With Mid-range Ejection Fraction.,american,0.31403136,federated,0.55841243,classification,0.43444416
Heart Failure With Mid-range Ejection Fraction.,heart,0.28300244,rate,0.49867767,batch-normalization,0.3427502
Heart Failure With Mid-range Ejection Fraction.,association,0.32292235,regression,0.5094141,regression,0.5094141
Heart Failure With Mid-range Ejection Fraction.,heart-association,0.4604499,clustering,0.5147429,clustering,0.5147429
Heart Failure With Mid-range Ejection Fraction.,american-heart-association,0.5014194,segmentation-algorithm,0.5262896,segmentation-algorithm,0.5262896
Heart Failure With Mid-range Ejection Fraction.,mineralocorticoid,0.2177006,short-term,0.3448191,long-short-term,0.32826918
Heart Failure With Mid-range Ejection Fraction.,receptor,0.22411162,function,0.41526195,clustering,0.36801085
Heart Failure With Mid-range Ejection Fraction.,antagonists,0.24215083,discriminative,0.39012936,learning-function,0.31474212
Heart Failure With Mid-range Ejection Fraction.,mineralocorticoid-receptor,0.24360989,function,0.35304862,batch-normalization,0.34086508
Heart Failure With Mid-range Ejection Fraction.,receptor-antagonists,0.23002487,discriminative,0.38725716,feed-forward,0.3471454
Heart Failure With Mid-range Ejection Fraction.,mineralocorticoid-receptor-antagonists,0.2412014,short-term,0.36669463,feed-forward,0.34416416
Heart Failure With Mid-range Ejection Fraction.,reduced,0.24137571,reduction,0.7564339,boosting,0.47559226
Heart Failure With Mid-range Ejection Fraction.,ejection,0.30230433,function,0.43955976,gradient,0.35697576
Heart Failure With Mid-range Ejection Fraction.,fraction,0.25137818,component,0.50911963,gradient,0.48876822
Heart Failure With Mid-range Ejection Fraction.,reduced-ejection,0.3536169,data-augmentation,0.49796093,data-augmentation,0.49796093
Heart Failure With Mid-range Ejection Fraction.,ejection-fraction,0.36681443,stochastic-gradient,0.5523829,stochastic-gradient,0.5523829
Heart Failure With Mid-range Ejection Fraction.,preserved,0.28254378,function,0.6360263,short-term-memory,0.44489402
Heart Failure With Mid-range Ejection Fraction.,ejection,0.30230433,function,0.43955976,gradient,0.35697576
Heart Failure With Mid-range Ejection Fraction.,fraction,0.25137818,component,0.50911963,gradient,0.48876822
Heart Failure With Mid-range Ejection Fraction.,preserved-ejection,0.305955,batch-normalization,0.5166229,batch-normalization,0.5166229
Heart Failure With Mid-range Ejection Fraction.,ejection-fraction,0.36681443,stochastic-gradient,0.5523829,stochastic-gradient,0.5523829
Heart Failure With Mid-range Ejection Fraction.,times,0.27272475,one,0.5606727,long-short-term,0.43909302
Heart Failure With Mid-range Ejection Fraction.,resembles,0.24474618,feature,0.5545042,generative,0.38160205
Heart Failure With Mid-range Ejection Fraction.,hfref,0.30238003,dropout,0.33754063,dropout,0.33754063
Heart Failure With Mid-range Ejection Fraction.,angiotensin,0.21236175,matrix,0.35242182,feed-forward,0.31253523
Heart Failure With Mid-range Ejection Fraction.,receptor,0.22411162,function,0.41526195,clustering,0.36801085
Heart Failure With Mid-range Ejection Fraction.,blockers,0.19200467,augmentation,0.36206824,long-short-term,0.31719163
Heart Failure With Mid-range Ejection Fraction.,angiotensin-receptor,0.24978769,matrix,0.3305658,confusion-matrix,0.30484858
Heart Failure With Mid-range Ejection Fraction.,receptor-blockers,0.22819279,short-term,0.3749142,regression,0.3211386
Heart Failure With Mid-range Ejection Fraction.,angiotensin-receptor-blockers,0.217114,short-term,0.34574157,dropout,0.30021757
Heart Failure With Mid-range Ejection Fraction.,range,0.23189357,linear,0.4532097,gradient,0.36315575
Heart Failure With Mid-range Ejection Fraction.,ejection,0.30230433,function,0.43955976,gradient,0.35697576
Heart Failure With Mid-range Ejection Fraction.,fraction,0.25137818,component,0.50911963,gradient,0.48876822
Heart Failure With Mid-range Ejection Fraction.,ejection-fraction,0.36681443,stochastic-gradient,0.5523829,stochastic-gradient,0.5523829
Heart Failure With Mid-range Ejection Fraction.,hfmref,0.30193725,tfidf,0.35980028,tfidf,0.35980028
Heart Failure With Mid-range Ejection Fraction.,patients,0.30007,recurrent,0.5332828,dropout,0.3918751
Heart Failure With Mid-range Ejection Fraction.,represent,0.37514454,feature,0.5787041,generative,0.46606725
Heart Failure With Mid-range Ejection Fraction.,ejection,0.30230433,function,0.43955976,gradient,0.35697576
Heart Failure With Mid-range Ejection Fraction.,fraction,0.25137818,component,0.50911963,gradient,0.48876822
Heart Failure With Mid-range Ejection Fraction.,ejection-fraction,0.36681443,stochastic-gradient,0.5523829,stochastic-gradient,0.5523829
Heart Failure With Mid-range Ejection Fraction.,angiotensin,0.21236175,matrix,0.35242182,feed-forward,0.31253523
Heart Failure With Mid-range Ejection Fraction.,receptor,0.22411162,function,0.41526195,clustering,0.36801085
Heart Failure With Mid-range Ejection Fraction.,angiotensin-receptor,0.24978769,matrix,0.3305658,confusion-matrix,0.30484858
Heart Failure With Mid-range Ejection Fraction.,heart,0.28300244,rate,0.49867767,batch-normalization,0.3427502
Heart Failure With Mid-range Ejection Fraction.,failure,0.32964212,recurrent,0.52057266,confusion-matrix,0.44323406
Heart Failure With Mid-range Ejection Fraction.,heart-failure,0.36450487,long-short-term,0.44014218,long-short-term,0.44014218
Heart Failure With Mid-range Ejection Fraction.,beta,0.16640052,of,0.43937695,long-short-term,0.33801323
Heart Failure With Mid-range Ejection Fraction.,blockers,0.19200467,augmentation,0.36206824,long-short-term,0.31719163
Heart Failure With Mid-range Ejection Fraction.,beta-blockers,0.22262444,dropout,0.38301587,dropout,0.38301587
Heart Failure With Mid-range Ejection Fraction.,ultimately,0.32798043,of,0.6012498,generative,0.48520207
Heart Failure With Mid-range Ejection Fraction.,came,0.30467743,confusion,0.5533096,bagging,0.44769236
Heart Failure With Mid-range Ejection Fraction.,though,0.28958118,few,0.67055815,long-short-term,0.41782194
Heart Failure With Mid-range Ejection Fraction.,hfref,0.30238003,dropout,0.33754063,dropout,0.33754063
Heart Failure With Mid-range Ejection Fraction.,recent,0.35249484,of,0.545993,data-engineering,0.4259707
Heart Failure With Mid-range Ejection Fraction.,findings,0.35685748,data,0.65714294,component-analysis,0.38599753
Heart Failure With Mid-range Ejection Fraction.,potential,0.3558654,of,0.5645705,generative-model,0.46479023
Heart Failure With Mid-range Ejection Fraction.,benefit,0.39640212,short-term,0.5466547,long-short-term,0.48296973
Heart Failure With Mid-range Ejection Fraction.,others,0.3625402,one,0.56551903,generative,0.4840395
Heart Failure With Mid-range Ejection Fraction.,still,0.32258964,fully,0.6496037,long-short-term,0.43228805
Heart Failure With Mid-range Ejection Fraction.,neprilysin,0.32175615,matrix,0.42883646,graphics-processing,0.36731273
Heart Failure With Mid-range Ejection Fraction.,inhibitors,0.25381407,cascade,0.4157439,feed-forward,0.3175553
Heart Failure With Mid-range Ejection Fraction.,hfmref,0.30193725,tfidf,0.35980028,tfidf,0.35980028
Heart Failure With Mid-range Ejection Fraction.,population,0.2958798,selection,0.5071889,clustering,0.47966808
Heart Failure With Mid-range Ejection Fraction.,hfmref,0.30193725,tfidf,0.35980028,tfidf,0.35980028
Heart Failure With Mid-range Ejection Fraction.,gray,0.32850122,deep,0.4598344,convolutional,0.45331883
Heart Failure With Mid-range Ejection Fraction.,zone,0.227958,layer,0.5408096,gradient,0.5057796
Heart Failure With Mid-range Ejection Fraction.,gray-zone,0.42488545,segmentation-algorithm,0.555791,segmentation-algorithm,0.555791
Heart Failure With Mid-range Ejection Fraction.,future,0.42505926,data-engineering,0.5647982,data-engineering,0.5647982
Heart Failure With Mid-range Ejection Fraction.,research,0.45694843,science,0.7194936,data-science,0.70924157
Heart Failure With Mid-range Ejection Fraction.,future-research,0.49550766,data-science,0.66124153,data-science,0.66124153
Heart Failure With Mid-range Ejection Fraction.,complex,0.27214053,components,0.5436033,component-analysis,0.4161712
Heart Failure With Mid-range Ejection Fraction.,disorder,0.28393638,dropout,0.44668275,dropout,0.44668275
Heart Failure With Mid-range Ejection Fraction.,classification,0.5994266,classification,1.0,classification,1.0
Heart Failure With Mid-range Ejection Fraction.,created,0.44611198,feature-engineering,0.5674809,feature-engineering,0.5674809
Heart Failure With Mid-range Ejection Fraction.,better,0.4230538,of,0.5337099,feature-reduction,0.47485045
Heart Failure With Mid-range Ejection Fraction.,elucidate,0.32682708,of,0.44897896,feature-engineering,0.4259497
Heart Failure With Mid-range Ejection Fraction.,better-elucidate,0.38998413,dimensionality-reduction,0.5170221,dimensionality-reduction,0.5170221
Heart Failure With Mid-range Ejection Fraction.,others,0.3625402,one,0.56551903,generative,0.4840395
Heart Failure With Mid-range Ejection Fraction.,hfpef,0.33180216,dropout,0.33254394,dropout,0.33254394
Heart Failure With Mid-range Ejection Fraction.,hfpef,0.33180216,dropout,0.33254394,dropout,0.33254394
Heart Failure With Mid-range Ejection Fraction.,studies,0.30135098,data,0.6349237,component-analysis,0.41327482
Heart Failure With Mid-range Ejection Fraction.,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
Heart Failure With Mid-range Ejection Fraction.,ef,0.32227567,function,0.46732792,learning-function,0.37073672
Heart Failure With Mid-range Ejection Fraction.,range,0.23189357,linear,0.4532097,gradient,0.36315575
Heart Failure With Mid-range Ejection Fraction.,patients,0.30007,recurrent,0.5332828,dropout,0.3918751
Heart Failure With Mid-range Ejection Fraction.,hfref,0.30238003,dropout,0.33754063,dropout,0.33754063
Heart Failure With Mid-range Ejection Fraction.,hfmref,0.30193725,tfidf,0.35980028,tfidf,0.35980028
Heart Failure With Mid-range Ejection Fraction.,hfpef,0.33180216,dropout,0.33254394,dropout,0.33254394
Heart Failure With Mid-range Ejection Fraction.,similar,0.29237732,of,0.56832373,long-short-term,0.4732089
Heart Failure With Mid-range Ejection Fraction.,significant,0.29367286,statistical,0.582669,statistical,0.582669
Heart Failure With Mid-range Ejection Fraction.,review,0.41215214,data,0.5581161,data-science,0.47600204
Heart Failure With Mid-range Ejection Fraction.,purpose,0.4149922,of,0.5072116,feature-engineering,0.43333688
Heart Failure With Mid-range Ejection Fraction.,prognosis,0.32841474,recurrent,0.50268024,classification,0.44778624
Heart Failure With Mid-range Ejection Fraction.,pathophysiology,0.33863446,feature,0.44530085,classification,0.3943317
Heart Failure With Mid-range Ejection Fraction.,needed,0.36127746,support,0.5796853,supervised,0.43152136
Heart Failure With Mid-range Ejection Fraction.,mid,0.23007318,bagging,0.4472025,bagging,0.4472025
Heart Failure With Mid-range Ejection Fraction.,management,0.38786528,decision,0.59816897,decision-tree,0.49756956
Heart Failure With Mid-range Ejection Fraction.,known,0.3344566,of,0.5873189,clustering,0.4164055
Heart Failure With Mid-range Ejection Fraction.,group,0.26103544,of,0.44356787,statistical,0.3923795
Heart Failure With Mid-range Ejection Fraction.,epidemiology,0.37457433,data-science,0.48592803,data-science,0.48592803
Heart Failure With Mid-range Ejection Fraction.,efs,0.24923551,short-term,0.39576766,long-short-term,0.36689356
Heart Failure With Mid-range Ejection Fraction.,describe,0.47142854,feature-engineering,0.5045319,feature-engineering,0.5045319
Heart Failure With Mid-range Ejection Fraction.,condition,0.23345311,confusion,0.47072208,confusion-matrix,0.4222471
Heart Failure With Mid-range Ejection Fraction.,cardiology,0.36460787,data-science,0.5008054,data-science,0.5008054
Heart Failure With Mid-range Ejection Fraction.,borderline,0.2588775,confusion,0.47102094,statistical,0.44439808
Heart Failure With Mid-range Ejection Fraction.,assigned,0.33371645,one,0.48061687,supervised,0.45563483
Heart Failure With Mid-range Ejection Fraction.,acc,0.26615047,of,0.4258749,recurrent-neural-network,0.41090712
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,determine,0.3371361,of,0.55401844,regression,0.40314794
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,consistent,0.2827828,of,0.55118144,clustering,0.43242198
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,pathways,0.30476987,cascade,0.6938149,feed-forward,0.5254793
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,introducing,0.46572757,feature-engineering,0.63279194,feature-engineering,0.63279194
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,predictive,0.55290145,cross-validation,0.6141345,cross-validation,0.6141345
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,medicine,0.41121995,science,0.6522808,data-science,0.6045255
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,new,0.43019778,of,0.526482,feature-reduction,0.4579819
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,statistical,0.6074636,statistical,1.0,statistical,1.0
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,nonlinear,0.54885405,stochastic,0.72081184,stochastic,0.72081184
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,models,0.53762007,model,0.8940372,markov-model,0.7015921
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,enabling,0.46592075,feature-engineering,0.6214503,feature-engineering,0.6214503
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,results,0.32376552,data,0.6932311,batch-normalization,0.44826904
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,simple,0.44104093,one-shot,0.5431666,one-shot,0.5431666
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,adequate,0.29751444,support,0.50622886,batch-normalization,0.4286505
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,diagnosis,0.32391536,classification,0.53521544,classification,0.53521544
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,approach,0.5412675,segmentation-algorithm,0.6046611,segmentation-algorithm,0.6046611
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,enabling,0.46592075,feature-engineering,0.6214503,feature-engineering,0.6214503
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,simple-adequate,0.41197506,natural-language,0.4965045,natural-language,0.4965045
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,obtain,0.38573402,of,0.51702356,batch-normalization,0.46553272
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,efficient,0.44278914,feature-engineering,0.5657042,feature-engineering,0.5657042
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,algorithm,0.7180419,algorithm,1.0,algorithm,1.0
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,classification,0.5994266,classification,1.0,classification,1.0
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,models,0.53762007,model,0.8940372,markov-model,0.7015921
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,femoral,0.23573844,augmentation,0.4722973,principal-components,0.3622526
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,pulse,0.30733106,few-shot,0.54626846,gradient,0.47678465
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,wave,0.30110258,fourier,0.49904785,fourier,0.49904785
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,velocity,0.26671168,gradient,0.5517495,gradient,0.5517495
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,femoral-pulse,0.3433392,few-shot,0.5309127,data-augmentation,0.49928448
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,pulse-wave,0.35420927,fourier,0.52744704,fourier,0.52744704
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,wave-velocity,0.30878156,fourier,0.5693445,fourier,0.5693445
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,pulse-wave-velocity,0.34844136,fourier,0.5911093,fourier,0.5911093
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,artificial,0.4622418,artificial,1.0,artificial-intelligence,0.6597898
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,neural,0.5080686,neural,1.0,neural-network,0.7153882
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,networks,0.53880787,network,0.91573685,neural-network,0.776492
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,artificial-neural,0.5541204,recurrent-neural-network,0.7487964,recurrent-neural-network,0.7487964
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,neural-networks,0.6930727,neural-network,0.983446,neural-network,0.983446
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,artificial-neural-networks,0.6783948,neural-network,0.9029462,neural-network,0.9029462
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,renal,0.24304676,of,0.44795883,batch-normalization,0.32135162
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,circulations,0.29020122,connected,0.46312892,gradient,0.419077
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,models,0.53762007,model,0.8940372,markov-model,0.7015921
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,measured,0.25103813,of,0.539739,batch-normalization,0.45439726
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,using,0.47332245,analysis,0.5968549,component-analysis,0.526608
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,carotid,0.21185519,augmentation,0.3569665,regression,0.33368263
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,mean,0.24598047,reduction,0.46440193,batch-normalization,0.434582
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,blood,0.16939776,normalization,0.4272251,batch-normalization,0.40715772
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,pressure,0.2060274,gradient,0.4962673,gradient,0.4962673
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,blood-pressure,0.2672683,batch-normalization,0.4510358,batch-normalization,0.4510358
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,mean-blood-pressure,0.36643043,batch-normalization,0.5844802,batch-normalization,0.5844802
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,pwv,0.28622276,backpropagation,0.36445284,backpropagation,0.36445284
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,index,0.27978244,function,0.407383,classification-algorithm,0.3994653
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,determinations,0.25224018,analysis,0.57278895,batch-normalization,0.5467147
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,individual,0.4013941,of,0.6520203,dimensionality-reduction,0.564764
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,pwv,0.28622276,backpropagation,0.36445284,backpropagation,0.36445284
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,index,0.27978244,function,0.407383,classification-algorithm,0.3994653
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,usual,0.28942436,supervised,0.48482984,supervised,0.48482984
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,clinical,0.44080526,data,0.48532635,data-science,0.45343333
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,practice,0.50552624,decision,0.59237766,data-science,0.5843962
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,clinical-practice,0.5274042,data-science,0.57205796,data-science,0.57205796
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,high,0.267004,of,0.57459104,gradient,0.44240427
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,cardiovascular,0.31674606,short-term,0.442761,learning-function,0.4027721
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,risk,0.35860935,recurrent,0.53675485,logistic-regression,0.52381086
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,high-cardiovascular,0.33360592,short-term,0.49153328,long-short-term,0.4760727
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,cardiovascular-risk,0.3523693,logistic-regression,0.46172044,logistic-regression,0.46172044
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,high-cardiovascular-risk,0.3754827,logistic-regression,0.4788453,logistic-regression,0.4788453
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,large,0.2849899,few,0.5687306,clustering,0.4101745
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,arteries,0.2030431,augmentation,0.39080167,segmentation,0.35854268
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,prediction,0.6361519,classification-algorithm,0.67946094,classification-algorithm,0.67946094
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,large-arteries,0.31295007,convolutional-layer,0.41428128,convolutional-layer,0.41428128
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,angiographic,0.30043295,ground-truth,0.43024242,ground-truth,0.43024242
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,chd,0.3007669,logistic-regression,0.39436275,logistic-regression,0.39436275
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,decisions,0.41949308,decision,0.89543855,decision-tree,0.6363974
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,pwv,0.28622276,backpropagation,0.36445284,backpropagation,0.36445284
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,particularly,0.32789055,of,0.62868786,long-short-term,0.49770588
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,present,0.39618495,of,0.63723874,generative,0.48216146
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,review,0.41215214,data,0.5581161,data-science,0.47600204
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,focuses,0.42775822,feature-engineering,0.5459945,feature-engineering,0.5459945
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,index,0.27978244,function,0.407383,classification-algorithm,0.3994653
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,involving,0.25723106,of,0.54600704,generative,0.40481192
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,age,0.30743492,intelligence,0.4774798,regression,0.47452933
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,coronary,0.25158757,of,0.3349695,segmentation-algorithm,0.31949025
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,heart,0.28300244,rate,0.49867767,batch-normalization,0.3427502
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,disease,0.296938,recurrent,0.4731025,classification,0.35271814
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,coronary-heart,0.24738656,long-short-term,0.33648896,long-short-term,0.33648896
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,heart-disease,0.35198575,long-short-term,0.43214932,long-short-term,0.43214932
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,coronary-heart-disease,0.3109823,long-short-term,0.40599877,long-short-term,0.40599877
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,pwv,0.28622276,backpropagation,0.36445284,backpropagation,0.36445284
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,index,0.27978244,function,0.407383,classification-algorithm,0.3994653
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,may,0.30907542,of,0.58654004,long-short-term,0.43985203
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,defined,0.3575971,of,0.529315,classification,0.50848204
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,chd,0.3007669,logistic-regression,0.39436275,logistic-regression,0.39436275
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,prediction,0.6361519,classification-algorithm,0.67946094,classification-algorithm,0.67946094
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,artificial,0.4622418,artificial,1.0,artificial-intelligence,0.6597898
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,intelligence,0.5350207,intelligence,0.99999994,artificial-intelligence,0.8106787
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,artificial-intelligence,0.64611053,artificial-intelligence,1.0,artificial-intelligence,1.0
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,coronary,0.25158757,of,0.3349695,segmentation-algorithm,0.31949025
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,prediction,0.6361519,classification-algorithm,0.67946094,classification-algorithm,0.67946094
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,particularly,0.32789055,of,0.62868786,long-short-term,0.49770588
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,relevant,0.4346258,of,0.5628227,natural-language,0.5076148
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,high,0.267004,of,0.57459104,gradient,0.44240427
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,levels,0.20457911,normalization,0.52984333,batch-normalization,0.45617118
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,high-levels,0.32237482,short-term,0.47779873,short-term-memory,0.44049025
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,heart,0.28300244,rate,0.49867767,batch-normalization,0.3427502
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,rate,0.24866687,rate,1.0,dropout,0.44953537
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,heart-rate,0.4407577,learning-rate,0.54865026,learning-rate,0.54865026
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,clinical,0.44080526,data,0.48532635,data-science,0.45343333
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,characteristics,0.345204,of,0.5401758,feature-engineering,0.49030614
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,clinical-characteristics,0.48064718,feature,0.6024677,component-analysis,0.5396
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,chd,0.3007669,logistic-regression,0.39436275,logistic-regression,0.39436275
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,vulnerable,0.2726673,adversarial,0.4775309,long-short-term,0.426799
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,plaques,0.27645454,layer,0.3803522,confusion-matrix,0.35955548
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,substantial,0.29639626,reduction,0.60217476,long-short-term,0.47712374
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,marker,0.31352368,of,0.4506512,clustering,0.37936708
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,recent,0.35249484,of,0.545993,data-engineering,0.4259707
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,works,0.4442468,data,0.5234174,graphics-processing,0.50902706
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,recent,0.35249484,of,0.545993,data-engineering,0.4259707
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,findings,0.35685748,data,0.65714294,component-analysis,0.38599753
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,major,0.2356064,principal,0.70253855,principal-components,0.42016473
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,predictor,0.43901688,regression,0.5961869,regression,0.5961869
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,enabling,0.46592075,feature-engineering,0.6214503,feature-engineering,0.6214503
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,decision,0.5239193,decision,1.0,decision-tree,0.75800127
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,tree,0.44976014,tree,1.0000001,random-forest,0.5821787
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,decision-tree,0.67884475,decision-tree,1.0,decision-tree,1.0
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,aortic,0.23288518,gradient,0.37829,gradient,0.37829
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,stiffness,0.2883107,confusion-matrix,0.44212747,confusion-matrix,0.44212747
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,also,0.32850838,of,0.65908813,clustering,0.45826355
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,used,0.46049535,of,0.5630944,generative-model,0.4901716
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,models,0.53762007,model,0.8940372,markov-model,0.7015921
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,widely,0.36366525,of,0.42793494,generative-model,0.39908314
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,associated,0.30827495,of,0.57598466,long-short-term,0.46578532
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,widely-associated,0.44748485,clustering,0.5549735,clustering,0.5549735
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,results,0.32376552,data,0.6932311,batch-normalization,0.44826904
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,pwv,0.28622276,backpropagation,0.36445284,backpropagation,0.36445284
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,prediction,0.6361519,classification-algorithm,0.67946094,classification-algorithm,0.67946094
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,chd,0.3007669,logistic-regression,0.39436275,logistic-regression,0.39436275
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,review,0.41215214,data,0.5581161,data-science,0.47600204
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,may,0.30907542,of,0.58654004,long-short-term,0.43985203
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,involving,0.25723106,of,0.54600704,generative,0.40481192
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,associated,0.30827495,of,0.57598466,long-short-term,0.46578532
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,variability,0.38345394,batch-normalization,0.53292775,batch-normalization,0.53292775
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,use,0.43753043,of,0.5506158,feature-reduction,0.49910897
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,together,0.37164533,data,0.5860126,principal-components,0.4491613
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,symptoms,0.2751398,confusion,0.5089627,dropout,0.40571758
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,relation,0.30160776,of,0.5984683,regression,0.51309836
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,purpose,0.4149922,of,0.5072116,feature-engineering,0.43333688
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,presence,0.2137551,of,0.6171463,gradient,0.4189303
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,possible,0.35543737,of,0.6754589,confusion-matrix,0.4598599
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,patients,0.30007,recurrent,0.5332828,dropout,0.3918751
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,parameter,0.45709252,regularization,0.6041261,batch-normalization,0.585888
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,measurement,0.35434127,batch-normalization,0.5963583,batch-normalization,0.5963583
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,interest,0.4194936,of,0.5624063,feature-engineering,0.5448084
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,improve,0.45207965,boosting,0.5098576,boosting,0.5098576
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,imperfections,0.40264106,overfitting,0.60140806,overfitting,0.60140806
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,hypertension,0.28340828,dropout,0.4223115,dropout,0.4223115
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,gender,0.3412779,logistic,0.5728083,logistic-regression,0.5565392
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,due,0.21681537,of,0.5734476,confusion-matrix,0.40250766
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,damage,0.27088127,function,0.48203948,generative,0.40220195
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,constitute,0.33524704,of,0.5690476,feature-engineering,0.4536295
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,considered,0.36321384,of,0.60548925,feature-reduction,0.4442021
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,consider,0.39825162,decision,0.60730267,stochastic,0.47927415
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,cerebrovascular,0.29193234,recurrent,0.3992598,semantic,0.37770933
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,calculation,0.5091191,monte-carlo,0.67405605,monte-carlo,0.67405605
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,addition,0.30500388,of,0.6910241,feature-reduction,0.48914018
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,accuracy,0.5511073,cross-validation,0.64088035,cross-validation,0.64088035
Transcriptional programming and T cell receptor repertoires distinguish human lung and lymph node memory T cells.,cell,0.2212203,of,0.48460138,generative,0.39753264
Transcriptional programming and T cell receptor repertoires distinguish human lung and lymph node memory T cells.,subsets,0.43637866,naive,0.6284895,clustering,0.53487885
Transcriptional programming and T cell receptor repertoires distinguish human lung and lymph node memory T cells.,compared,0.3359061,of,0.52794564,long-short-term,0.42386633
Transcriptional programming and T cell receptor repertoires distinguish human lung and lymph node memory T cells.,across,0.3330416,gradient,0.4622073,gradient,0.4622073
Transcriptional programming and T cell receptor repertoires distinguish human lung and lymph node memory T cells.,tissues,0.21297011,of,0.47614664,generative,0.371554
Transcriptional programming and T cell receptor repertoires distinguish human lung and lymph node memory T cells.,cell-subsets,0.3999497,clustering,0.5178171,clustering,0.5178171
Transcriptional programming and T cell receptor repertoires distinguish human lung and lymph node memory T cells.,across-tissues,0.4283137,cross-entropy,0.55741453,cross-entropy,0.55741453
Transcriptional programming and T cell receptor repertoires distinguish human lung and lymph node memory T cells.,provide,0.40841419,support,0.64934516,feature-engineering,0.47702065
Transcriptional programming and T cell receptor repertoires distinguish human lung and lymph node memory T cells.,effective,0.32842147,of,0.50971246,boosting,0.48854327
Transcriptional programming and T cell receptor repertoires distinguish human lung and lymph node memory T cells.,recall,0.44827557,memory,0.7156959,short-term-memory,0.699399
Transcriptional programming and T cell receptor repertoires distinguish human lung and lymph node memory T cells.,responses,0.23078328,naive,0.5126229,boosting,0.49454907
Transcriptional programming and T cell receptor repertoires distinguish human lung and lymph node memory T cells.,lung,0.26692057,of,0.3928769,bagging,0.36409828
Transcriptional programming and T cell receptor repertoires distinguish human lung and lymph node memory T cells.,draining,0.24557845,bag,0.54941475,bagging,0.3873034
Transcriptional programming and T cell receptor repertoires distinguish human lung and lymph node memory T cells.,lymph,0.2794639,naive,0.3598475,logistic-regression,0.32720378
Transcriptional programming and T cell receptor repertoires distinguish human lung and lymph node memory T cells.,node,0.33007902,recurrent-neural-network,0.46002018,recurrent-neural-network,0.46002018
Transcriptional programming and T cell receptor repertoires distinguish human lung and lymph node memory T cells.,lung-draining,0.27909917,naive,0.4423924,bagging,0.38623133
Transcriptional programming and T cell receptor repertoires distinguish human lung and lymph node memory T cells.,draining-lymph,0.31451496,bag,0.48773816,convolutional,0.38470116
Transcriptional programming and T cell receptor repertoires distinguish human lung and lymph node memory T cells.,lymph-node,0.27277827,recurrent-neural-network,0.35196376,recurrent-neural-network,0.35196376
Transcriptional programming and T cell receptor repertoires distinguish human lung and lymph node memory T cells.,draining-lymph-node,0.33706567,bag,0.39745492,recurrent-neural-network,0.39688003
Transcriptional programming and T cell receptor repertoires distinguish human lung and lymph node memory T cells.,abundance,0.31865036,forest,0.4966442,clustering,0.48465613
Transcriptional programming and T cell receptor repertoires distinguish human lung and lymph node memory T cells.,throughout,0.2455861,few,0.5455184,supervised,0.44606155
Transcriptional programming and T cell receptor repertoires distinguish human lung and lymph node memory T cells.,tissues,0.21297011,of,0.47614664,generative,0.371554
Transcriptional programming and T cell receptor repertoires distinguish human lung and lymph node memory T cells.,cell,0.2212203,of,0.48460138,generative,0.39753264
Transcriptional programming and T cell receptor repertoires distinguish human lung and lymph node memory T cells.,receptor,0.22411162,function,0.41526195,clustering,0.36801085
Transcriptional programming and T cell receptor repertoires distinguish human lung and lymph node memory T cells.,analysis,0.46507934,analysis,0.99999994,component-analysis,0.69613737
Transcriptional programming and T cell receptor repertoires distinguish human lung and lymph node memory T cells.,cell-receptor,0.3144027,feature-engineering,0.43735832,feature-engineering,0.43735832
Transcriptional programming and T cell receptor repertoires distinguish human lung and lymph node memory T cells.,receptor-analysis,0.39364058,component-analysis,0.6094633,component-analysis,0.6094633
Transcriptional programming and T cell receptor repertoires distinguish human lung and lymph node memory T cells.,recognize,0.37905318,feature,0.48402858,feature-engineering,0.39049122
Transcriptional programming and T cell receptor repertoires distinguish human lung and lymph node memory T cells.,distinct,0.36295342,feature,0.580647,clustering,0.5409523
Transcriptional programming and T cell receptor repertoires distinguish human lung and lymph node memory T cells.,antigens,0.27430183,components,0.4447758,boosting,0.39514953
Transcriptional programming and T cell receptor repertoires distinguish human lung and lymph node memory T cells.,including,0.3233776,of,0.6619886,clustering,0.40625107
Transcriptional programming and T cell receptor repertoires distinguish human lung and lymph node memory T cells.,higher,0.27819592,reduction,0.545787,boosting,0.41506222
Transcriptional programming and T cell receptor repertoires distinguish human lung and lymph node memory T cells.,expression,0.32038707,encoding,0.59633577,clustering,0.442253
Transcriptional programming and T cell receptor repertoires distinguish human lung and lymph node memory T cells.,higher-expression,0.3837926,encoding,0.55230385,clustering,0.47862777
Transcriptional programming and T cell receptor repertoires distinguish human lung and lymph node memory T cells.,different,0.37681934,of,0.61590904,clustering,0.46857932
Transcriptional programming and T cell receptor repertoires distinguish human lung and lymph node memory T cells.,precursor,0.23746365,processing,0.5186899,generative,0.42359084
Transcriptional programming and T cell receptor repertoires distinguish human lung and lymph node memory T cells.,pools,0.2752549,forest,0.4465345,stochastic-gradient,0.4186231
Transcriptional programming and T cell receptor repertoires distinguish human lung and lymph node memory T cells.,paired,0.3996978,component-analysis,0.46069485,component-analysis,0.46069485
Transcriptional programming and T cell receptor repertoires distinguish human lung and lymph node memory T cells.,human,0.30336243,of,0.5175895,feature-engineering,0.40631005
Transcriptional programming and T cell receptor repertoires distinguish human lung and lymph node memory T cells.,lung,0.26692057,of,0.3928769,bagging,0.36409828
Transcriptional programming and T cell receptor repertoires distinguish human lung and lymph node memory T cells.,human-lung,0.4063427,ground-truth,0.42191526,ground-truth,0.42191526
Transcriptional programming and T cell receptor repertoires distinguish human lung and lymph node memory T cells.,innate,0.33910936,naive,0.49273443,boosting,0.4610679
Transcriptional programming and T cell receptor repertoires distinguish human lung and lymph node memory T cells.,immune,0.2619304,naive,0.47885698,boosting,0.47579303
Transcriptional programming and T cell receptor repertoires distinguish human lung and lymph node memory T cells.,receptors,0.2335811,function,0.40644348,clustering,0.36239648
Transcriptional programming and T cell receptor repertoires distinguish human lung and lymph node memory T cells.,innate-immune,0.34751916,naive,0.5632742,boosting,0.46316183
Transcriptional programming and T cell receptor repertoires distinguish human lung and lymph node memory T cells.,immune-receptors,0.2498722,naive,0.45147318,clustering,0.34104043
Transcriptional programming and T cell receptor repertoires distinguish human lung and lymph node memory T cells.,identified,0.35725033,analysis,0.56593037,clustering,0.45719695
Transcriptional programming and T cell receptor repertoires distinguish human lung and lymph node memory T cells.,substantial,0.29639626,reduction,0.60217476,long-short-term,0.47712374
Transcriptional programming and T cell receptor repertoires distinguish human lung and lymph node memory T cells.,differences,0.3361535,statistical,0.57447433,statistical,0.57447433
Transcriptional programming and T cell receptor repertoires distinguish human lung and lymph node memory T cells.,clonal,0.29953825,clustering,0.48181134,clustering,0.48181134
Transcriptional programming and T cell receptor repertoires distinguish human lung and lymph node memory T cells.,overlap,0.38858992,feature,0.58340186,clustering,0.5132319
Transcriptional programming and T cell receptor repertoires distinguish human lung and lymph node memory T cells.,observed,0.23725806,of,0.64367145,long-short-term,0.4519785
Transcriptional programming and T cell receptor repertoires distinguish human lung and lymph node memory T cells.,cell,0.2212203,of,0.48460138,generative,0.39753264
Transcriptional programming and T cell receptor repertoires distinguish human lung and lymph node memory T cells.,subsets,0.43637866,naive,0.6284895,clustering,0.53487885
Transcriptional programming and T cell receptor repertoires distinguish human lung and lymph node memory T cells.,within,0.2920679,of,0.57602364,clustering,0.4610753
Transcriptional programming and T cell receptor repertoires distinguish human lung and lymph node memory T cells.,cell-subsets,0.3999497,clustering,0.5178171,clustering,0.5178171
Transcriptional programming and T cell receptor repertoires distinguish human lung and lymph node memory T cells.,cell,0.2212203,of,0.48460138,generative,0.39753264
Transcriptional programming and T cell receptor repertoires distinguish human lung and lymph node memory T cells.,subsets,0.43637866,naive,0.6284895,clustering,0.53487885
Transcriptional programming and T cell receptor repertoires distinguish human lung and lymph node memory T cells.,cell-subsets,0.3999497,clustering,0.5178171,clustering,0.5178171
Transcriptional programming and T cell receptor repertoires distinguish human lung and lymph node memory T cells.,immune,0.2619304,naive,0.47885698,boosting,0.47579303
Transcriptional programming and T cell receptor repertoires distinguish human lung and lymph node memory T cells.,responses,0.23078328,naive,0.5126229,boosting,0.49454907
Transcriptional programming and T cell receptor repertoires distinguish human lung and lymph node memory T cells.,immune-responses,0.26914084,naive,0.51852834,boosting,0.41194022
Transcriptional programming and T cell receptor repertoires distinguish human lung and lymph node memory T cells.,clonal,0.29953825,clustering,0.48181134,clustering,0.48181134
Transcriptional programming and T cell receptor repertoires distinguish human lung and lymph node memory T cells.,overlap,0.38858992,feature,0.58340186,clustering,0.5132319
Transcriptional programming and T cell receptor repertoires distinguish human lung and lymph node memory T cells.,transcriptional,0.33864313,encoding,0.5598241,feed-forward,0.5453118
Transcriptional programming and T cell receptor repertoires distinguish human lung and lymph node memory T cells.,landscape,0.47856253,random-forest,0.61013126,random-forest,0.61013126
Transcriptional programming and T cell receptor repertoires distinguish human lung and lymph node memory T cells.,study,0.3645851,of,0.5728763,statistical,0.44204497
Transcriptional programming and T cell receptor repertoires distinguish human lung and lymph node memory T cells.,focused,0.39696395,of,0.5549927,feature-engineering,0.52445924
Transcriptional programming and T cell receptor repertoires distinguish human lung and lymph node memory T cells.,study-focused,0.45686287,data-science,0.58820605,data-science,0.58820605
Transcriptional programming and T cell receptor repertoires distinguish human lung and lymph node memory T cells.,separate,0.43314856,one,0.6195628,principal-components,0.56720483
Transcriptional programming and T cell receptor repertoires distinguish human lung and lymph node memory T cells.,roles,0.29737037,function,0.5381723,generative,0.4343859
Transcriptional programming and T cell receptor repertoires distinguish human lung and lymph node memory T cells.,results,0.32376552,data,0.6932311,batch-normalization,0.44826904
Transcriptional programming and T cell receptor repertoires distinguish human lung and lymph node memory T cells.,suggest,0.26874092,data,0.5391823,long-short-term,0.40288782
Transcriptional programming and T cell receptor repertoires distinguish human lung and lymph node memory T cells.,results-suggest,0.39010245,data,0.5769403,batch-normalization,0.5080625
Transcriptional programming and T cell receptor repertoires distinguish human lung and lymph node memory T cells.,flow,0.2860778,gradient,0.52486,gradient,0.52486
Transcriptional programming and T cell receptor repertoires distinguish human lung and lymph node memory T cells.,cytometry,0.35215917,analysis,0.47600478,fourier-transform,0.40641344
Transcriptional programming and T cell receptor repertoires distinguish human lung and lymph node memory T cells.,flow-cytometry,0.34293124,analysis,0.48240748,stochastic-gradient,0.40600675
Transcriptional programming and T cell receptor repertoires distinguish human lung and lymph node memory T cells.,specific,0.3244285,of,0.6059094,clustering,0.45887482
Transcriptional programming and T cell receptor repertoires distinguish human lung and lymph node memory T cells.,memory,0.4292574,memory,1.0,short-term-memory,0.84619105
Transcriptional programming and T cell receptor repertoires distinguish human lung and lymph node memory T cells.,specific-memory,0.48637038,short-term-memory,0.8153988,short-term-memory,0.8153988
Transcriptional programming and T cell receptor repertoires distinguish human lung and lymph node memory T cells.,many,0.40940517,few,0.752018,feature-engineering,0.48454586
Transcriptional programming and T cell receptor repertoires distinguish human lung and lymph node memory T cells.,memory,0.4292574,memory,1.0,short-term-memory,0.84619105
Transcriptional programming and T cell receptor repertoires distinguish human lung and lymph node memory T cells.,cells,0.20327199,naive,0.5115537,generative,0.40616876
Transcriptional programming and T cell receptor repertoires distinguish human lung and lymph node memory T cells.,persist,0.26016572,few,0.57312584,long-short-term,0.505196
Transcriptional programming and T cell receptor repertoires distinguish human lung and lymph node memory T cells.,cells,0.20327199,naive,0.5115537,generative,0.40616876
Transcriptional programming and T cell receptor repertoires distinguish human lung and lymph node memory T cells.,originate,0.22072819,connected,0.50265175,generative,0.46339196
Transcriptional programming and T cell receptor repertoires distinguish human lung and lymph node memory T cells.,ldln,0.115503795,tf-idf,0.3474837,tf-idf,0.3474837
Transcriptional programming and T cell receptor repertoires distinguish human lung and lymph node memory T cells.,memory,0.4292574,memory,1.0,short-term-memory,0.84619105
Transcriptional programming and T cell receptor repertoires distinguish human lung and lymph node memory T cells.,memory,0.4292574,memory,1.0,short-term-memory,0.84619105
Transcriptional programming and T cell receptor repertoires distinguish human lung and lymph node memory T cells.,subsets,0.43637866,naive,0.6284895,clustering,0.53487885
Transcriptional programming and T cell receptor repertoires distinguish human lung and lymph node memory T cells.,lung,0.26692057,of,0.3928769,bagging,0.36409828
Transcriptional programming and T cell receptor repertoires distinguish human lung and lymph node memory T cells.,within,0.2920679,of,0.57602364,clustering,0.4610753
Transcriptional programming and T cell receptor repertoires distinguish human lung and lymph node memory T cells.,identified,0.35725033,analysis,0.56593037,clustering,0.45719695
Transcriptional programming and T cell receptor repertoires distinguish human lung and lymph node memory T cells.,memory,0.4292574,memory,1.0,short-term-memory,0.84619105
Transcriptional programming and T cell receptor repertoires distinguish human lung and lymph node memory T cells.,cells,0.20327199,naive,0.5115537,generative,0.40616876
Transcriptional programming and T cell receptor repertoires distinguish human lung and lymph node memory T cells.,ldln,0.115503795,tf-idf,0.3474837,tf-idf,0.3474837
Transcriptional programming and T cell receptor repertoires distinguish human lung and lymph node memory T cells.,years,0.32825696,intelligence,0.42702603,regression,0.3811771
Transcriptional programming and T cell receptor repertoires distinguish human lung and lymph node memory T cells.,validated,0.5041009,cross-validation,0.58167183,cross-validation,0.58167183
Transcriptional programming and T cell receptor repertoires distinguish human lung and lymph node memory T cells.,using,0.47332245,analysis,0.5968549,component-analysis,0.526608
Transcriptional programming and T cell receptor repertoires distinguish human lung and lymph node memory T cells.,samples,0.3088399,analysis,0.4981357,batch-normalization,0.44174457
Transcriptional programming and T cell receptor repertoires distinguish human lung and lymph node memory T cells.,pathogen,0.3132059,adversarial,0.3762204,random-forest,0.3666752
Transcriptional programming and T cell receptor repertoires distinguish human lung and lymph node memory T cells.,likely,0.28872275,one,0.55131567,generative,0.3953101
Transcriptional programming and T cell receptor repertoires distinguish human lung and lymph node memory T cells.,greater,0.2528603,of,0.59163296,long-short-term,0.44578376
Transcriptional programming and T cell receptor repertoires distinguish human lung and lymph node memory T cells.,exposure,0.22801533,short-term,0.55545235,long-short-term,0.45469296
Transcriptional programming and T cell receptor repertoires distinguish human lung and lymph node memory T cells.,differ,0.26580223,of,0.45475316,statistical,0.3820433
Transcriptional programming and T cell receptor repertoires distinguish human lung and lymph node memory T cells.,determined,0.2643224,of,0.6221287,batch-normalization,0.4203323
Transcriptional programming and T cell receptor repertoires distinguish human lung and lymph node memory T cells.,array,0.35354632,fully-connected,0.49267963,fully-connected,0.49267963
Transcriptional programming and T cell receptor repertoires distinguish human lung and lymph node memory T cells.,antigen,0.2626214,encoding,0.425888,boosting,0.4008458
Generation of mesenchyme free intestinal organoids from human induced pluripotent stem cells.,measure,0.3901039,tracking,0.5169115,dimensionality-reduction,0.5135913
Generation of mesenchyme free intestinal organoids from human induced pluripotent stem cells.,cftr,0.19663587,rectified,0.32657117,bag-of-words,0.2734954
Generation of mesenchyme free intestinal organoids from human induced pluripotent stem cells.,function,0.3447219,function,1.0,learning-function,0.5767432
Generation of mesenchyme free intestinal organoids from human induced pluripotent stem cells.,using,0.47332245,analysis,0.5968549,component-analysis,0.526608
Generation of mesenchyme free intestinal organoids from human induced pluripotent stem cells.,cystic,0.20371206,recurrent,0.4181977,dropout,0.34525713
Generation of mesenchyme free intestinal organoids from human induced pluripotent stem cells.,fibrosis,0.26237673,dropout,0.39932662,dropout,0.39932662
Generation of mesenchyme free intestinal organoids from human induced pluripotent stem cells.,patient,0.2998137,confusion,0.5356896,confusion-matrix,0.41404122
Generation of mesenchyme free intestinal organoids from human induced pluripotent stem cells.,cystic-fibrosis,0.23823963,recurrent,0.39831293,dropout,0.39800635
Generation of mesenchyme free intestinal organoids from human induced pluripotent stem cells.,hipsc,0.35133272,feature-engineering,0.47951186,feature-engineering,0.47951186
Generation of mesenchyme free intestinal organoids from human induced pluripotent stem cells.,derived,0.3584563,of,0.54769456,generative,0.5265686
Generation of mesenchyme free intestinal organoids from human induced pluripotent stem cells.,human,0.30336243,of,0.5175895,feature-engineering,0.40631005
Generation of mesenchyme free intestinal organoids from human induced pluripotent stem cells.,intestinal,0.18789442,of,0.42052382,gradient-descent,0.3017878
Generation of mesenchyme free intestinal organoids from human induced pluripotent stem cells.,organoids,0.37304088,feature-engineering,0.49608588,feature-engineering,0.49608588
Generation of mesenchyme free intestinal organoids from human induced pluripotent stem cells.,derived-human,0.3189071,feature-engineering,0.48533708,feature-engineering,0.48533708
Generation of mesenchyme free intestinal organoids from human induced pluripotent stem cells.,human-intestinal,0.3580268,stochastic-gradient,0.43669224,stochastic-gradient,0.43669224
Generation of mesenchyme free intestinal organoids from human induced pluripotent stem cells.,human,0.30336243,of,0.5175895,feature-engineering,0.40631005
Generation of mesenchyme free intestinal organoids from human induced pluripotent stem cells.,induced,0.2259351,of,0.5615651,boosting,0.4303583
Generation of mesenchyme free intestinal organoids from human induced pluripotent stem cells.,pluripotent,0.36851317,neural,0.5311127,generative,0.5096332
Generation of mesenchyme free intestinal organoids from human induced pluripotent stem cells.,stem,0.2836631,neural,0.48491934,generative,0.47532985
Generation of mesenchyme free intestinal organoids from human induced pluripotent stem cells.,cell,0.2212203,of,0.48460138,generative,0.39753264
Generation of mesenchyme free intestinal organoids from human induced pluripotent stem cells.,human-induced,0.4140622,forest,0.5584233,stochastic,0.54619956
Generation of mesenchyme free intestinal organoids from human induced pluripotent stem cells.,induced-pluripotent,0.39766502,neural,0.5740938,feature-engineering,0.5438956
Generation of mesenchyme free intestinal organoids from human induced pluripotent stem cells.,pluripotent-stem,0.39105156,feature-engineering,0.5326755,feature-engineering,0.5326755
Generation of mesenchyme free intestinal organoids from human induced pluripotent stem cells.,stem-cell,0.30539137,neural,0.44801706,generative,0.44345847
Generation of mesenchyme free intestinal organoids from human induced pluripotent stem cells.,induced-pluripotent-stem,0.42487574,feature-engineering,0.5752955,feature-engineering,0.5752955
Generation of mesenchyme free intestinal organoids from human induced pluripotent stem cells.,pluripotent-stem-cell,0.3921157,feature-engineering,0.54266226,feature-engineering,0.54266226
Generation of mesenchyme free intestinal organoids from human induced pluripotent stem cells.,free,0.22085115,of,0.48528847,batch-normalization,0.3670413
Generation of mesenchyme free intestinal organoids from human induced pluripotent stem cells.,organoids,0.37304088,feature-engineering,0.49608588,feature-engineering,0.49608588
Generation of mesenchyme free intestinal organoids from human induced pluripotent stem cells.,expressing,0.25940266,encoding,0.59442365,boosting,0.42904755
Generation of mesenchyme free intestinal organoids from human induced pluripotent stem cells.,characteristic,0.34942827,feature,0.7124056,clustering,0.48287967
Generation of mesenchyme free intestinal organoids from human induced pluripotent stem cells.,markers,0.32439512,of,0.43581337,clustering,0.41091266
Generation of mesenchyme free intestinal organoids from human induced pluripotent stem cells.,expression,0.32038707,encoding,0.59633577,clustering,0.442253
Generation of mesenchyme free intestinal organoids from human induced pluripotent stem cells.,throughout,0.2455861,few,0.5455184,supervised,0.44606155
Generation of mesenchyme free intestinal organoids from human induced pluripotent stem cells.,directed,0.29751354,of,0.55436456,boosting,0.4654734
Generation of mesenchyme free intestinal organoids from human induced pluripotent stem cells.,differentiation,0.28601187,neural,0.5331595,generative,0.49685726
Generation of mesenchyme free intestinal organoids from human induced pluripotent stem cells.,directed-differentiation,0.43087506,generative,0.5806898,generative,0.5806898
Generation of mesenchyme free intestinal organoids from human induced pluripotent stem cells.,directed,0.29751354,of,0.55436456,boosting,0.4654734
Generation of mesenchyme free intestinal organoids from human induced pluripotent stem cells.,differentiation,0.28601187,neural,0.5331595,generative,0.49685726
Generation of mesenchyme free intestinal organoids from human induced pluripotent stem cells.,protocol,0.3712751,algorithm,0.5198414,algorithm,0.5198414
Generation of mesenchyme free intestinal organoids from human induced pluripotent stem cells.,directed-differentiation,0.43087506,generative,0.5806898,generative,0.5806898
Generation of mesenchyme free intestinal organoids from human induced pluripotent stem cells.,derived,0.3584563,of,0.54769456,generative,0.5265686
Generation of mesenchyme free intestinal organoids from human induced pluripotent stem cells.,ipsc,0.32410383,backpropagation,0.44187766,backpropagation,0.44187766
Generation of mesenchyme free intestinal organoids from human induced pluripotent stem cells.,lines,0.2397678,of,0.42859763,generative,0.3835748
Generation of mesenchyme free intestinal organoids from human induced pluripotent stem cells.,ipsc-lines,0.3657961,naive-bayes,0.43077394,naive-bayes,0.43077394
Generation of mesenchyme free intestinal organoids from human induced pluripotent stem cells.,free,0.22085115,of,0.48528847,batch-normalization,0.3670413
Generation of mesenchyme free intestinal organoids from human induced pluripotent stem cells.,defined,0.3575971,of,0.529315,classification,0.50848204
Generation of mesenchyme free intestinal organoids from human induced pluripotent stem cells.,conditions,0.21472734,short-term,0.4503411,feature-reduction,0.43574768
Generation of mesenchyme free intestinal organoids from human induced pluripotent stem cells.,free-defined,0.4727044,stochastic-gradient,0.525913,stochastic-gradient,0.525913
Generation of mesenchyme free intestinal organoids from human induced pluripotent stem cells.,proximal,0.20720702,long,0.4762103,gradient,0.37478507
Generation of mesenchyme free intestinal organoids from human induced pluripotent stem cells.,intestinal,0.18789442,of,0.42052382,gradient-descent,0.3017878
Generation of mesenchyme free intestinal organoids from human induced pluripotent stem cells.,lineages,0.32924712,generative,0.4927646,generative,0.4927646
Generation of mesenchyme free intestinal organoids from human induced pluripotent stem cells.,therapeutic,0.3659354,of,0.48352462,boosting,0.41573292
Generation of mesenchyme free intestinal organoids from human induced pluripotent stem cells.,screening,0.38869897,selection,0.4576743,data-engineering,0.4313178
Generation of mesenchyme free intestinal organoids from human induced pluripotent stem cells.,applications,0.4878226,data-engineering,0.70112944,data-engineering,0.70112944
Generation of mesenchyme free intestinal organoids from human induced pluripotent stem cells.,cystic,0.20371206,recurrent,0.4181977,dropout,0.34525713
Generation of mesenchyme free intestinal organoids from human induced pluripotent stem cells.,fibrosis,0.26237673,dropout,0.39932662,dropout,0.39932662
Generation of mesenchyme free intestinal organoids from human induced pluripotent stem cells.,cystic-fibrosis,0.23823963,recurrent,0.39831293,dropout,0.39800635
Generation of mesenchyme free intestinal organoids from human induced pluripotent stem cells.,ipsc,0.32410383,backpropagation,0.44187766,backpropagation,0.44187766
Generation of mesenchyme free intestinal organoids from human induced pluripotent stem cells.,knock,0.30279905,vector,0.447145,vector-machine,0.39184567
Generation of mesenchyme free intestinal organoids from human induced pluripotent stem cells.,inflammatory,0.19824001,cascade,0.43951106,generative-model,0.38795525
Generation of mesenchyme free intestinal organoids from human induced pluripotent stem cells.,bowel,0.21975456,bag,0.49017194,softmax,0.3282876
Generation of mesenchyme free intestinal organoids from human induced pluripotent stem cells.,disease,0.296938,recurrent,0.4731025,classification,0.35271814
Generation of mesenchyme free intestinal organoids from human induced pluripotent stem cells.,inflammatory-bowel,0.21926284,cascade,0.4062354,generative-model,0.40495318
Generation of mesenchyme free intestinal organoids from human induced pluripotent stem cells.,bowel-disease,0.404159,hidden,0.45123625,semantic,0.43714932
Generation of mesenchyme free intestinal organoids from human induced pluripotent stem cells.,employ,0.5189007,feature-engineering,0.59643865,feature-engineering,0.59643865
Generation of mesenchyme free intestinal organoids from human induced pluripotent stem cells.,hios,0.29189453,fully,0.45107353,artificial-intelligence,0.42658636
Generation of mesenchyme free intestinal organoids from human induced pluripotent stem cells.,generated,0.38782007,generative,0.5987155,generative,0.5987155
Generation of mesenchyme free intestinal organoids from human induced pluripotent stem cells.,cftr,0.19663587,rectified,0.32657117,bag-of-words,0.2734954
Generation of mesenchyme free intestinal organoids from human induced pluripotent stem cells.,mutation,0.27265835,encoding,0.44449022,feature-selection,0.4163742
Generation of mesenchyme free intestinal organoids from human induced pluripotent stem cells.,cftr-mutation,0.28691918,feature-selection,0.34897006,feature-selection,0.34897006
Generation of mesenchyme free intestinal organoids from human induced pluripotent stem cells.,free,0.22085115,of,0.48528847,batch-normalization,0.3670413
Generation of mesenchyme free intestinal organoids from human induced pluripotent stem cells.,hios,0.29189453,fully,0.45107353,artificial-intelligence,0.42658636
Generation of mesenchyme free intestinal organoids from human induced pluripotent stem cells.,small,0.28058842,few,0.5791491,bagging,0.40911084
Generation of mesenchyme free intestinal organoids from human induced pluripotent stem cells.,intestinal,0.18789442,of,0.42052382,gradient-descent,0.3017878
Generation of mesenchyme free intestinal organoids from human induced pluripotent stem cells.,small-intestinal,0.23718542,of,0.40795934,gradient-descent,0.36573362
Generation of mesenchyme free intestinal organoids from human induced pluripotent stem cells.,intestinal,0.18789442,of,0.42052382,gradient-descent,0.3017878
Generation of mesenchyme free intestinal organoids from human induced pluripotent stem cells.,progenitors,0.29125455,neural,0.5270762,generative,0.5071701
Generation of mesenchyme free intestinal organoids from human induced pluripotent stem cells.,disease,0.296938,recurrent,0.4731025,classification,0.35271814
Generation of mesenchyme free intestinal organoids from human induced pluripotent stem cells.,modeling,0.6237119,model,0.757579,generative-model,0.6999146
Generation of mesenchyme free intestinal organoids from human induced pluripotent stem cells.,disease-modeling,0.54838747,generative-model,0.6530531,generative-model,0.6530531
Generation of mesenchyme free intestinal organoids from human induced pluripotent stem cells.,would,0.3569631,of,0.55908126,boosting,0.43412957
Generation of mesenchyme free intestinal organoids from human induced pluripotent stem cells.,facilitate,0.4181755,support,0.56775236,feature-engineering,0.53415316
Generation of mesenchyme free intestinal organoids from human induced pluripotent stem cells.,vitro,0.292481,of,0.48112682,generative,0.40355864
Generation of mesenchyme free intestinal organoids from human induced pluripotent stem cells.,models,0.53762007,model,0.8940372,markov-model,0.7015921
Generation of mesenchyme free intestinal organoids from human induced pluripotent stem cells.,vitro-models,0.47803777,model,0.60113066,markov-model,0.54461765
Generation of mesenchyme free intestinal organoids from human induced pluripotent stem cells.,using,0.47332245,analysis,0.5968549,component-analysis,0.526608
Generation of mesenchyme free intestinal organoids from human induced pluripotent stem cells.,reporter,0.31360114,vector,0.55062973,data-engineering,0.4215237
Generation of mesenchyme free intestinal organoids from human induced pluripotent stem cells.,line,0.22275111,of,0.4227432,generative,0.38747817
Generation of mesenchyme free intestinal organoids from human induced pluripotent stem cells.,primed,0.30227113,naive,0.5963541,boosting,0.49572575
Generation of mesenchyme free intestinal organoids from human induced pluripotent stem cells.,towards,0.26157683,forward,0.5590818,generative,0.45313805
Generation of mesenchyme free intestinal organoids from human induced pluripotent stem cells.,hindgut,0.17741796,feed,0.4312333,segmentation,0.3445137
Generation of mesenchyme free intestinal organoids from human induced pluripotent stem cells.,progenitors,0.29125455,neural,0.5270762,generative,0.5071701
Generation of mesenchyme free intestinal organoids from human induced pluripotent stem cells.,gastrointestinal,0.21264678,recurrent,0.42192185,long-short-term,0.2837069
Generation of mesenchyme free intestinal organoids from human induced pluripotent stem cells.,tract,0.17745402,recurrent,0.5062193,generative,0.32561263
Generation of mesenchyme free intestinal organoids from human induced pluripotent stem cells.,gastrointestinal-tract,0.22865033,recurrent,0.44006336,long-short-term,0.32591748
Generation of mesenchyme free intestinal organoids from human induced pluripotent stem cells.,future,0.42505926,data-engineering,0.5647982,data-engineering,0.5647982
Generation of mesenchyme free intestinal organoids from human induced pluripotent stem cells.,potential,0.3558654,of,0.5645705,generative-model,0.46479023
Generation of mesenchyme free intestinal organoids from human induced pluripotent stem cells.,robust,0.50920165,hierarchical,0.6267712,hierarchical-clustering,0.6142049
Generation of mesenchyme free intestinal organoids from human induced pluripotent stem cells.,generation,0.3480911,generative,0.6357137,generative,0.6357137
Generation of mesenchyme free intestinal organoids from human induced pluripotent stem cells.,efficient,0.44278914,feature-engineering,0.5657042,feature-engineering,0.5657042
Generation of mesenchyme free intestinal organoids from human induced pluripotent stem cells.,generation,0.3480911,generative,0.6357137,generative,0.6357137
Generation of mesenchyme free intestinal organoids from human induced pluripotent stem cells.,colonic,0.18444645,of,0.4415968,long-short-term,0.32336777
Generation of mesenchyme free intestinal organoids from human induced pluripotent stem cells.,epithelium,0.17127109,layer,0.5740502,convolutional-layer,0.4233354
Generation of mesenchyme free intestinal organoids from human induced pluripotent stem cells.,colonic-epithelium,0.16996133,layer,0.5467082,convolutional-layer,0.45278585
Generation of mesenchyme free intestinal organoids from human induced pluripotent stem cells.,hios,0.29189453,fully,0.45107353,artificial-intelligence,0.42658636
Generation of mesenchyme free intestinal organoids from human induced pluripotent stem cells.,generation,0.3480911,generative,0.6357137,generative,0.6357137
Generation of mesenchyme free intestinal organoids from human induced pluripotent stem cells.,colonic,0.18444645,of,0.4415968,long-short-term,0.32336777
Generation of mesenchyme free intestinal organoids from human induced pluripotent stem cells.,way,0.4425121,forward,0.5844119,generative,0.55701363
Generation of mesenchyme free intestinal organoids from human induced pluripotent stem cells.,variety,0.35310775,natural,0.5234163,generative,0.4781817
Generation of mesenchyme free intestinal organoids from human induced pluripotent stem cells.,track,0.4388718,tracking,0.7933724,object-tracking,0.5832878
Generation of mesenchyme free intestinal organoids from human induced pluripotent stem cells.,serum,0.20734212,normalization,0.47724307,batch-normalization,0.4486353
Generation of mesenchyme free intestinal organoids from human induced pluripotent stem cells.,report,0.3090002,of,0.56646246,data-engineering,0.3762592
Generation of mesenchyme free intestinal organoids from human induced pluripotent stem cells.,purification,0.35144264,batch,0.5245397,data-engineering,0.46335468
Generation of mesenchyme free intestinal organoids from human induced pluripotent stem cells.,mesenchyme,0.1955433,neural,0.5262888,generative,0.41705346
Generation of mesenchyme free intestinal organoids from human induced pluripotent stem cells.,kinetics,0.24096473,rate,0.50796926,stochastic,0.49935678
Generation of mesenchyme free intestinal organoids from human induced pluripotent stem cells.,follow,0.28552625,tracking,0.48513734,batch-normalization,0.39173082
Generation of mesenchyme free intestinal organoids from human induced pluripotent stem cells.,enabling,0.46592075,feature-engineering,0.6214503,feature-engineering,0.6214503
Generation of mesenchyme free intestinal organoids from human induced pluripotent stem cells.,emergence,0.3708834,selection,0.5590699,generative,0.5377345
Generation of mesenchyme free intestinal organoids from human induced pluripotent stem cells.,diseases,0.31957155,recurrent,0.41244444,classification,0.40266854
Generation of mesenchyme free intestinal organoids from human induced pluripotent stem cells.,development,0.34732813,generative,0.56588423,generative,0.56588423
Generation of mesenchyme free intestinal organoids from human induced pluripotent stem cells.,demonstrating,0.32530028,of,0.67624867,generative,0.46174815
Generation of mesenchyme free intestinal organoids from human induced pluripotent stem cells.,correction,0.379902,normalization,0.6389029,batch-normalization,0.60501325
Generation of mesenchyme free intestinal organoids from human induced pluripotent stem cells.,affect,0.23161066,of,0.50835335,long-short-term,0.3772871
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,center,0.2469751,unit,0.5969413,data-science,0.3881536
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,studies,0.30135098,data,0.6349237,component-analysis,0.41327482
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,using,0.47332245,analysis,0.5968549,component-analysis,0.526608
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,validated,0.5041009,cross-validation,0.58167183,cross-validation,0.58167183
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,targeted,0.37903738,of,0.52138686,feature-engineering,0.502902
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,methods,0.50049126,data,0.5400177,machine-learning,0.50049126
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,center-studies,0.41663605,data,0.5193964,dimensionality-reduction,0.5061245
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,studies-using,0.48369747,data-science,0.564998,data-science,0.564998
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,study,0.3645851,of,0.5728763,statistical,0.44204497
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,included,0.34673893,of,0.58040446,component-analysis,0.47413814
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,chronic,0.22727785,recurrent,0.5279353,long-short-term,0.4292153
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,hfref,0.30238003,dropout,0.33754063,dropout,0.33754063
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,patients,0.30007,recurrent,0.5332828,dropout,0.3918751
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,study-included,0.39136794,data,0.4876554,natural-language,0.47046185
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,hfref-patients,0.30008307,dropout,0.42149666,dropout,0.42149666
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,one,0.335046,one,1.0,one-hot,0.4275648
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,unknown,0.31894603,of,0.52799743,confusion-matrix,0.43751484
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,metabolite,0.27332738,principal,0.44271863,batch-normalization,0.37130743
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,demonstrating,0.32530028,of,0.67624867,generative,0.46174815
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,unknown-metabolite,0.42047998,discriminative,0.51118,principal-component-analysis,0.4465927
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,potentially,0.36810714,of,0.5786935,long-short-term,0.45597216
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,clinically,0.3702051,recurrent,0.5046643,confusion-matrix,0.40397355
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,useful,0.40063038,discriminative,0.489146,feature-engineering,0.43842706
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,diagnostic,0.47116143,classification,0.5651491,classification,0.5651491
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,panel,0.3446437,analysis,0.44153908,component-analysis,0.42843887
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,clinically-useful,0.52353287,discriminative,0.52936786,machine-learning,0.52353287
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,left,0.2544507,tracking,0.42924023,object-tracking,0.3633091
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,ventricular,0.24852064,rate,0.37094042,long-short-term,0.34148398
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,ejection,0.30230433,function,0.43955976,gradient,0.35697576
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,fraction,0.25137818,component,0.50911963,gradient,0.48876822
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,left-ventricular,0.30000108,batch-normalization,0.40942025,batch-normalization,0.40942025
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,ventricular-ejection,0.26988763,rate,0.43059248,gradient,0.41159958
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,ejection-fraction,0.36681443,stochastic-gradient,0.5523829,stochastic-gradient,0.5523829
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,learning,0.709237,learning,1.0,deep-learning,0.8286492
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,methods,0.50049126,data,0.5400177,machine-learning,0.50049126
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,reduced,0.24137571,reduction,0.7564339,boosting,0.47559226
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,ejection,0.30230433,function,0.43955976,gradient,0.35697576
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,fraction,0.25137818,component,0.50911963,gradient,0.48876822
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,reduced-ejection,0.3536169,data-augmentation,0.49796093,data-augmentation,0.49796093
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,ejection-fraction,0.36681443,stochastic-gradient,0.5523829,stochastic-gradient,0.5523829
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,novel,0.4652171,feature-engineering,0.5132146,feature-engineering,0.5132146
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,diagnostic,0.47116143,classification,0.5651491,classification,0.5651491
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,panel,0.3446437,analysis,0.44153908,component-analysis,0.42843887
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,diagnostic,0.47116143,classification,0.5651491,classification,0.5651491
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,value,0.3544725,of,0.52001536,statistical,0.45314136
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,seems,0.25899655,of,0.5433607,long-short-term,0.41636422
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,diagnostic-value,0.5247328,classification-algorithm,0.6824364,classification-algorithm,0.6824364
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,forest,0.4787075,forest,1.0,random-forest,0.7738863
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,models,0.53762007,model,0.8940372,markov-model,0.7015921
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,fitted,0.39998794,linear,0.5574912,regression,0.5374051
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,fasting,0.22235955,normalization,0.46940017,batch-normalization,0.4534999
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,serum,0.20734212,normalization,0.47724307,batch-normalization,0.4486353
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,samples,0.3088399,analysis,0.4981357,batch-normalization,0.44174457
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,fasting-serum,0.29681677,batch-normalization,0.5141444,batch-normalization,0.5141444
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,serum-samples,0.3388298,principal-component-analysis,0.47999853,principal-component-analysis,0.47999853
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,controls,0.2521493,naive,0.47579613,statistical,0.41853178
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,without,0.31691062,of,0.5951073,long-short-term,0.4268921
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,controls-without,0.3578989,naive,0.46928722,artificial-intelligence,0.4563385
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,two,0.35955608,one,0.79919666,clustering,0.43817294
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,innovative,0.5771038,data-engineering,0.7216599,data-engineering,0.7216599
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,tools,0.65752256,data-engineering,0.6720511,data-engineering,0.6720511
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,vs,0.22635552,transfer,0.4263924,statistical,0.3002486
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,selected,0.38157707,selection,0.6797303,feature-selection,0.48698312
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,metabolites,0.28512323,principal,0.43836063,principal-components,0.38017994
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,correlated,0.29206502,of,0.49750805,regression,0.45794123
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,confirm,0.28446677,support,0.5519786,component-analysis,0.36139983
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,clinical,0.44080526,data,0.48532635,data-science,0.45343333
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,utility,0.4781499,discriminative,0.54359984,feature-engineering,0.50812626
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,clinical-utility,0.5272242,classification-algorithm,0.5460291,classification-algorithm,0.5460291
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,feature,0.5878884,feature,0.99999994,feature-selection,0.6322505
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,selection,0.46716303,selection,1.0,feature-selection,0.6859601
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,based,0.49998575,classification-algorithm,0.5639226,classification-algorithm,0.5639226
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,feature-selection,0.61733264,feature-selection,1.0,feature-selection,1.0
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,selection-based,0.6835047,feature-selection,0.7765494,feature-selection,0.7765494
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,feature-selection-based,0.69353485,feature-selection,0.94755024,feature-selection,0.94755024
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,metabolites,0.28512323,principal,0.43836063,principal-components,0.38017994
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,panel,0.3446437,analysis,0.44153908,component-analysis,0.42843887
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,hfref,0.30238003,dropout,0.33754063,dropout,0.33754063
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,lvef,0.2523713,function,0.33373237,dropout,0.3101137
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,lpc,0.2313722,nlp,0.45152405,nlp,0.45152405
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,two,0.35955608,one,0.79919666,clustering,0.43817294
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,isomers,0.22839233,nearest-neighbors,0.4226886,nearest-neighbors,0.4226886
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,predictive,0.55290145,cross-validation,0.6141345,cross-validation,0.6141345
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,value,0.3544725,of,0.52001536,statistical,0.45314136
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,predictive-value,0.58114254,classification-algorithm,0.6611153,classification-algorithm,0.6611153
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,model,0.48485535,model,1.0,markov-model,0.7005576
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,based,0.49998575,classification-algorithm,0.5639226,classification-algorithm,0.5639226
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,model-based,0.71087694,bayesian,0.8056512,bayesian,0.8056512
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,eight,0.35167286,one,0.694713,principal-components,0.3837485
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,metabolites,0.28512323,principal,0.43836063,principal-components,0.38017994
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,uric,0.22812682,batch-normalization,0.35721985,batch-normalization,0.35721985
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,acid,0.19370206,of,0.41044196,clustering,0.30169246
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,uric-acid,0.23625787,normalization,0.34788406,one-hot,0.34462526
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,test,0.4037762,statistical,0.5031551,statistical,0.5031551
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,set,0.5244544,of,0.5846941,classifiers,0.5500933
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,test-set,0.4657093,cross-validation,0.5603128,cross-validation,0.5603128
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,resampled,0.5533529,ground-truth,0.6383382,ground-truth,0.6383382
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,data,0.46434748,data,1.0,data-science,0.5533528
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,proposed,0.55786884,classification-algorithm,0.6311488,classification-algorithm,0.6311488
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,markers,0.32439512,of,0.43581337,clustering,0.41091266
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,metabolic,0.3235007,of,0.46523505,batch-normalization,0.4536144
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,derangement,0.24587096,normalization,0.5680877,batch-normalization,0.44559163
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,mass,0.22818582,fourier-transform,0.42889374,fourier-transform,0.42889374
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,spectrometry,0.38271606,fourier-transform,0.7034797,fourier-transform,0.7034797
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,mass-spectrometry,0.41853824,fourier-transform,0.67876333,fourier-transform,0.67876333
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,machine,0.7094662,machine,1.0,machine-learning,0.7094662
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,learning,0.709237,learning,1.0,deep-learning,0.8286492
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,machine-learning,1.0,machine-learning,1.0,machine-learning,1.0
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,liquid,0.3025719,bag,0.49495625,fourier-transform,0.48004717
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,chromatography,0.32117847,fourier-transform,0.5653838,fourier-transform,0.5653838
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,liquid-chromatography,0.35577852,fourier-transform,0.6001456,fourier-transform,0.6001456
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,linear,0.42916322,linear,0.99999994,regression,0.66034734
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,modelling,0.60003346,model,0.7264041,markov-model,0.6926701
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,large,0.2849899,few,0.5687306,clustering,0.4101745
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,scale,0.32819444,intelligence,0.5046051,dimensionality-reduction,0.48168033
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,large-scale,0.52361417,data-engineering,0.66056526,data-engineering,0.66056526
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,heart,0.28300244,rate,0.49867767,batch-normalization,0.3427502
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,failure,0.32964212,recurrent,0.52057266,confusion-matrix,0.44323406
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,heart-failure,0.36450487,long-short-term,0.44014218,long-short-term,0.44014218
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,functional,0.3902081,function,0.728652,learning-function,0.5807885
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,parameters,0.38939354,normalization,0.54973936,batch-normalization,0.547323
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,enables,0.47243777,feature-engineering,0.56644535,feature-engineering,0.56644535
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,identification,0.4527572,analysis,0.6100153,classification,0.5378393
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,docosahexaenoic,0.16591056,feed,0.319057,natural-language,0.28429115
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,acid,0.19370206,of,0.41044196,clustering,0.30169246
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,docosahexaenoic-acid,0.17097358,feed,0.30193868,long-short-term-memory,0.29176438
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,deoxycholic,0.1392269,gradient,0.30937433,gradient,0.30937433
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,acid,0.19370206,of,0.41044196,clustering,0.30169246
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,current,0.3530666,rectified,0.52906346,generative-model,0.40904555
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,knowledge,0.5362035,science,0.551701,data-science,0.5440523
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,current-knowledge,0.58308554,artificial-intelligence,0.6585175,artificial-intelligence,0.6585175
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,combined,0.39749897,of,0.5690281,one-shot,0.52384484
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,approach,0.5412675,segmentation-algorithm,0.6046611,segmentation-algorithm,0.6046611
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,combined-approach,0.518173,dimensionality-reduction,0.5651655,dimensionality-reduction,0.5651655
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,check,0.3157034,bag,0.48872578,batch-normalization,0.4401188
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,feasibility,0.45202792,data-engineering,0.52147615,data-engineering,0.52147615
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,untargeted,0.49386254,batch-normalization,0.5001885,batch-normalization,0.5001885
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,metabolomics,0.52971125,data-science,0.5546232,data-science,0.5546232
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,untargeted-metabolomics,0.57483965,machine-learning,0.57483965,machine-learning,0.57483965
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,study,0.3645851,of,0.5728763,statistical,0.44204497
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,hfref,0.30238003,dropout,0.33754063,dropout,0.33754063
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,selection,0.46716303,selection,1.0,feature-selection,0.6859601
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,clinical,0.44080526,data,0.48532635,data-science,0.45343333
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,metabolomics,0.52971125,data-science,0.5546232,data-science,0.5546232
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,machine,0.7094662,machine,1.0,machine-learning,0.7094662
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,verified,0.3810478,of,0.5807613,supervised,0.42818904
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,unrestrained,0.3023086,ground,0.46660483,object-tracking,0.4095975
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,simple,0.44104093,one-shot,0.5431666,one-shot,0.5431666
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,resulted,0.23350117,of,0.5964589,boosting,0.43415624
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,random,0.45551494,random,1.0,random-forest,0.65894985
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,multi,0.37771758,multi-class,0.4810482,segmentation,0.43055838
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,gaps,0.32191202,few,0.4649526,nearest-neighbors,0.4472242
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,followed,0.25369444,of,0.5874107,supervised,0.45495358
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,fingerprinted,0.49076578,analysis,0.5964424,principal-component-analysis,0.50564104
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,echocardiographic,0.41065523,object-tracking,0.4180337,object-tracking,0.4180337
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,disease,0.296938,recurrent,0.4731025,classification,0.35271814
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,crucial,0.31994545,feature,0.5223625,feature-engineering,0.4773315
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,create,0.48630154,feature-engineering,0.66006124,feature-engineering,0.66006124
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,comparable,0.29340464,short-term,0.5384172,long-short-term,0.45359015
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,common,0.32574984,feature,0.5597373,clustering,0.43115532
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,combination,0.385488,of,0.5245792,boosting,0.5027329
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,bnp,0.26722732,logistic-regression,0.30094945,logistic-regression,0.30094945
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,aim,0.4029312,feature-engineering,0.41751927,feature-engineering,0.41751927
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,accuracy,0.5511073,cross-validation,0.64088035,cross-validation,0.64088035
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,learning,0.709237,learning,1.0,deep-learning,0.8286492
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,methods,0.50049126,data,0.5400177,machine-learning,0.50049126
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,represents,0.35351515,feature,0.5842386,generative,0.4147461
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,nowadays,0.43350342,few,0.49678335,data-engineering,0.4668975
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,provide,0.40841419,support,0.64934516,feature-engineering,0.47702065
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,functional,0.3902081,function,0.728652,learning-function,0.5807885
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,quantitative,0.4330744,analysis,0.6747154,component-analysis,0.558002
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,maps,0.3992074,segmentation-algorithm,0.46592468,segmentation-algorithm,0.46592468
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,functional-quantitative,0.56007373,learning-function,0.60383534,learning-function,0.60383534
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,multiple,0.39569393,of,0.53341115,regression,0.48948324
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,quantitative,0.4330744,analysis,0.6747154,component-analysis,0.558002
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,maps,0.3992074,segmentation-algorithm,0.46592468,segmentation-algorithm,0.46592468
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,underlying,0.37239885,neural,0.55211174,generative,0.49267903
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,physiological,0.3332913,function,0.550024,learning-function,0.4524702
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,processes,0.34218454,processing,0.59430957,generative,0.5664364
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,specific,0.3244285,of,0.6059094,clustering,0.45887482
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,vascular,0.27131236,neural,0.45896766,convolutional,0.3685425
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,receptors,0.2335811,function,0.40644348,clustering,0.36239648
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,reflecting,0.32153195,of,0.5920901,generative,0.5091561
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,complementary,0.43292302,feature-selection,0.4982301,feature-selection,0.4982301
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,variables,0.4636312,logistic-regression,0.6604836,logistic-regression,0.6604836
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,red,0.19007081,ground,0.49455693,bagging,0.3593925
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,blood,0.16939776,normalization,0.4272251,batch-normalization,0.40715772
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,cells,0.20327199,naive,0.5115537,generative,0.40616876
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,red-blood,0.19407341,batch-normalization,0.43402684,batch-normalization,0.43402684
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,blood-cells,0.17295663,batch-normalization,0.37377203,batch-normalization,0.37377203
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,red-blood-cells,0.19965789,batch-normalization,0.41524243,batch-normalization,0.41524243
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,probabilistic,0.70926243,bayesian,0.80275774,bayesian,0.80275774
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,framework,0.5690361,hierarchical,0.6853048,hierarchical-clustering,0.6804691
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,based,0.49998575,classification-algorithm,0.5639226,classification-algorithm,0.5639226
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,probabilistic-framework,0.69375676,bayesian-network,0.8012667,bayesian-network,0.8012667
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,framework-based,0.65389234,hierarchical,0.710599,hierarchical-clustering,0.69644606
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,extracted,0.39326945,analysis,0.5438888,principal-components,0.4903554
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,complementary,0.43292302,feature-selection,0.4982301,feature-selection,0.4982301
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,information,0.5191034,data,0.708436,data-science,0.5937191
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,complementary-information,0.6204088,natural-language-processing,0.6582403,natural-language-processing,0.6582403
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,different,0.37681934,of,0.61590904,clustering,0.46857932
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,pathological,0.35600212,of,0.48665273,classification,0.46512192
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,conditions,0.21472734,short-term,0.4503411,feature-reduction,0.43574768
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,pathological-conditions,0.51076865,generative-model,0.5692146,generative-model,0.5692146
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,new,0.43019778,of,0.526482,feature-reduction,0.4579819
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,kinetic,0.3498273,batch-normalization,0.5463363,batch-normalization,0.5463363
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,models,0.53762007,model,0.8940372,markov-model,0.7015921
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,kinetic-models,0.5413325,markov-model,0.72035944,markov-model,0.72035944
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,indicator,0.30241644,of,0.49207017,regression,0.40722144
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,dilution,0.28007412,batch-normalization,0.5536016,batch-normalization,0.5536016
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,principles,0.48908663,feature-engineering,0.61818725,feature-engineering,0.61818725
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,indicator-dilution,0.45181882,batch-normalization,0.5992564,batch-normalization,0.5992564
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,immense,0.40552402,data-engineering,0.5726059,data-engineering,0.5726059
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,diagnostic,0.47116143,classification,0.5651491,classification,0.5651491
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,possibilities,0.41161513,feature-engineering,0.536671,feature-engineering,0.536671
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,molecular,0.39914468,of,0.516936,clustering,0.43655443
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,imaging,0.41700524,tracking,0.55048084,segmentation,0.5337068
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,modality,0.45219088,feature,0.49997124,object-tracking,0.48294973
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,molecular-imaging,0.5302876,fourier-transform,0.5611471,fourier-transform,0.5611471
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,ultrasound,0.3534931,tracking,0.46466017,segmentation,0.44147727
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,contrast,0.24962384,of,0.5428885,feature-reduction,0.41914925
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,agents,0.2697791,of,0.44812918,boosting,0.36205623
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,ultrasound-contrast,0.36298335,few-shot,0.5516553,one-shot,0.5293921
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,contrast-agents,0.4076742,few-shot,0.57054424,one-shot,0.5247811
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,uca,0.17775008,natural,0.28895235,keras,0.28649676
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,intravascular,0.26833332,of,0.40842503,confusion-matrix,0.39186925
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,kinetics,0.24096473,rate,0.50796926,stochastic,0.49935678
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,us,0.36534783,decision,0.49831933,segmentation,0.39571765
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,imaging,0.41700524,tracking,0.55048084,segmentation,0.5337068
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,based,0.49998575,classification-algorithm,0.5639226,classification-algorithm,0.5639226
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,us-imaging,0.40286157,few-shot,0.55071914,ground-truth,0.5038403
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,imaging-based,0.5931791,segmentation,0.61653924,segmentation,0.61653924
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,functional,0.3902081,function,0.728652,learning-function,0.5807885
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,imaging,0.41700524,tracking,0.55048084,segmentation,0.5337068
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,functional-imaging,0.5916216,learning-function,0.65333986,learning-function,0.65333986
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,uca,0.17775008,natural,0.28895235,keras,0.28649676
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,kinetics,0.24096473,rate,0.50796926,stochastic,0.49935678
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,intravascular,0.26833332,of,0.40842503,confusion-matrix,0.39186925
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,indicator,0.30241644,of,0.49207017,regression,0.40722144
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,available,0.4144769,data,0.62807965,data-science,0.46192533
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,methods,0.50049126,data,0.5400177,machine-learning,0.50049126
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,ucas,0.2993749,few-shot,0.41593334,natural-language,0.3779945
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,provide,0.40841419,support,0.64934516,feature-engineering,0.47702065
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,quantitative,0.4330744,analysis,0.6747154,component-analysis,0.558002
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,dce,0.38223657,tensorflow,0.41652268,tensorflow,0.41652268
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,several,0.40139607,few,0.7607186,clustering,0.4671372
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,models,0.53762007,model,0.8940372,markov-model,0.7015921
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,dynamic,0.4720998,stochastic,0.62950635,stochastic,0.62950635
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,contrast,0.24962384,of,0.5428885,feature-reduction,0.41914925
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,dynamic-contrast,0.5072008,few-shot,0.6506878,convolutional-layer,0.6122665
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,diagnostic,0.47116143,classification,0.5651491,classification,0.5651491
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,accuracy,0.5511073,cross-validation,0.64088035,cross-validation,0.64088035
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,diagnostic-accuracy,0.60124797,classification-algorithm,0.7229502,classification-algorithm,0.7229502
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,us,0.36534783,decision,0.49831933,segmentation,0.39571765
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,imaging,0.41700524,tracking,0.55048084,segmentation,0.5337068
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,us-imaging,0.40286157,few-shot,0.55071914,ground-truth,0.5038403
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,ultimate,0.32951707,of,0.5112179,dimensionality-reduction,0.46057975
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,approach,0.5412675,segmentation-algorithm,0.6046611,segmentation-algorithm,0.6046611
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,spatiotemporal,0.48208904,stochastic,0.69261265,stochastic,0.69261265
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,analysis,0.46507934,analysis,0.99999994,component-analysis,0.69613737
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,rights,0.3170033,adversarial,0.6281444,data-science,0.57488894
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,reserved,0.28677964,of,0.4776592,supervised,0.3944377
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,rheology,0.27184528,fourier-transform,0.4622374,fourier-transform,0.4622374
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,comparable,0.29340464,short-term,0.5384172,long-short-term,0.45359015
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,recent,0.35249484,of,0.545993,data-engineering,0.4259707
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,introduction,0.37159568,of,0.5877248,feature-engineering,0.47346386
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,optimal,0.39098042,selection,0.5284126,algorithm,0.5276129
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,combination,0.385488,of,0.5245792,boosting,0.5027329
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,microbubbles,0.31536633,few-shot,0.45110768,vector-machine,0.41152263
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,encapsulated,0.23147336,layer,0.46764338,feature-engineering,0.37925676
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,integrative,0.58874464,feature-engineering,0.6174096,feature-engineering,0.6174096
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,approach,0.5412675,segmentation-algorithm,0.6046611,segmentation-algorithm,0.6046611
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,increased,0.26921988,reduction,0.6514183,boosting,0.46515882
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,complexity,0.5197527,dimensionality,0.67757803,dimensionality-reduction,0.6318618
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,future,0.42505926,data-engineering,0.5647982,data-engineering,0.5647982
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,perspective,0.47613347,data-science,0.6021619,data-science,0.6021619
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,enhanced,0.30543873,of,0.59523904,boosting,0.57908714
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,ultrasound,0.3534931,tracking,0.46466017,segmentation,0.44147727
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,enhanced-ultrasound,0.42050695,one-shot,0.5475807,one-shot,0.5475807
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,emerging,0.45052218,feature-engineering,0.5309333,feature-engineering,0.5309333
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,machine,0.7094662,machine,1.0,machine-learning,0.7094662
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,elsevier,0.26603332,science,0.59524655,data-science,0.53140587
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,inc,0.2706048,bag,0.52860194,bagging,0.41463643
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,current,0.3530666,rectified,0.52906346,generative-model,0.40904555
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,value,0.3544725,of,0.52001536,statistical,0.45314136
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,current-value,0.4665884,cross-entropy,0.6602702,cross-entropy,0.6602702
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,critically,0.3436439,of,0.5690512,long-short-term,0.40989497
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,discussed,0.32159716,of,0.5174893,confusion-matrix,0.45636517
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,comprehensive,0.5203603,data,0.6056672,data-engineering,0.58421016
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,review,0.41215214,data,0.5581161,data-science,0.47600204
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,combined,0.39749897,of,0.5690281,one-shot,0.52384484
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,use,0.43753043,of,0.5506158,feature-reduction,0.49910897
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,combined-use,0.46988732,multi-class,0.53384775,decision-tree,0.508625
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,biocompatible,0.31048048,engineering,0.5643099,feature-engineering,0.5473614
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,shell,0.247044,layer,0.5677038,hidden-layer,0.46333283
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,aiding,0.4829287,of,0.593449,feature-engineering,0.529452
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,diagnosis,0.32391536,classification,0.53521544,classification,0.53521544
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,novel,0.4652171,feature-engineering,0.5132146,feature-engineering,0.5132146
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,ucas,0.2993749,few-shot,0.41593334,natural-language,0.3779945
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,advanced,0.4209618,of,0.47114033,machine-learning,0.4209618
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,dce,0.38223657,tensorflow,0.41652268,tensorflow,0.41652268
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,imaging,0.41700524,tracking,0.55048084,segmentation,0.5337068
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,us,0.36534783,decision,0.49831933,segmentation,0.39571765
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,ultrasound,0.3534931,tracking,0.46466017,segmentation,0.44147727
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,ucas,0.2993749,few-shot,0.41593334,natural-language,0.3779945
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,dce,0.38223657,tensorflow,0.41652268,tensorflow,0.41652268
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,vasculature,0.26349625,function,0.4843496,segmentation,0.44949728
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,temporal,0.34829444,semantic,0.54608697,semantic,0.54608697
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,targeted,0.37903738,of,0.52138686,feature-engineering,0.502902
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,spatial,0.49177253,object,0.63807136,object-tracking,0.6315731
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,requires,0.35710368,of,0.62298405,stochastic,0.42198688
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,published,0.42179614,data,0.6147139,data-science,0.54664624
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,proposed,0.55786884,classification-algorithm,0.6311488,classification-algorithm,0.6311488
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,parallel,0.38849422,convolutional-layer,0.55327755,convolutional-layer,0.55327755
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,opened,0.2775012,connected,0.5252083,data-engineering,0.413235
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,micro,0.26967415,of,0.4380535,batch-normalization,0.35495925
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,medicine,0.41121995,science,0.6522808,data-science,0.6045255
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,interpretation,0.4612863,data,0.6427045,component-analysis,0.59010094
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,improving,0.40742207,boosting,0.54548407,boosting,0.54548407
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,extraction,0.414975,batch-normalization,0.5036997,batch-normalization,0.5036997
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,developed,0.44693142,fully,0.53855187,generative-model,0.49309453
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,biology,0.47010514,science,0.6525451,data-engineering,0.59721386
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,article,0.4330988,science,0.5622481,data-science,0.5520143
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,advances,0.45830926,data-engineering,0.5886656,data-engineering,0.5886656
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,chast,0.33566284,truth,0.48918223,dimensionality-reduction,0.46396378
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,expression,0.32038707,encoding,0.59633577,clustering,0.442253
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,level,0.23847455,of,0.54773176,batch-normalization,0.45912555
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,showed,0.20766163,of,0.5296177,regression,0.37027335
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,better,0.4230538,of,0.5337099,feature-reduction,0.47485045
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,cardiac,0.29562658,of,0.42777455,long-short-term,0.35708636
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,contractile,0.24631684,function,0.5049658,long-short-term,0.36120063
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,function,0.3447219,function,1.0,learning-function,0.5767432
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,expression-level,0.52689433,learning-function,0.5769394,learning-function,0.5769394
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,level-showed,0.39652866,batch-normalization,0.5117904,batch-normalization,0.5117904
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,cardiac-contractile,0.28040218,function,0.462255,long-short-term,0.41422477
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,contractile-function,0.34134534,function,0.65128064,learning-function,0.5746569
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,important,0.33620566,principal,0.5803634,feature-engineering,0.43471682
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,factor,0.23388772,component,0.48280093,principal-components,0.43733668
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,affecting,0.27039212,of,0.651947,generative,0.41997433
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,patient,0.2998137,confusion,0.5356896,confusion-matrix,0.41404122
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,prognosis,0.32841474,recurrent,0.50268024,classification,0.44778624
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,factor-affecting,0.35449854,generative,0.48697388,generative,0.48697388
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,patient-prognosis,0.45218295,decision-tree,0.52728176,decision-tree,0.52728176
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,several,0.40139607,few,0.7607186,clustering,0.4671372
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,circulating,0.26450798,of,0.4713916,clustering,0.36910847
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,long,0.20028201,long,1.0,long-short-term,0.6505779
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,noncoding,0.40509766,encoding,0.560657,machine-learning,0.40509766
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,rnas,0.35904947,encoding,0.46177882,machine-learning,0.35904947
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,long-noncoding,0.4072781,encoding,0.6053978,long-short-term-memory,0.5015209
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,noncoding-rnas,0.47222376,encoding,0.5307437,machine-learning,0.47222376
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,multivariate,0.54642415,logistic,0.86571586,logistic-regression,0.84866464
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,regression,0.4967034,regression,1.0,regression,1.0
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,analysis,0.46507934,analysis,0.99999994,component-analysis,0.69613737
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,indicated,0.2502363,of,0.5998554,principal-components,0.4305639
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,multivariate-regression,0.5443023,logistic-regression,0.9139348,logistic-regression,0.9139348
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,regression-analysis,0.5946686,logistic-regression,0.8366122,logistic-regression,0.8366122
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,left,0.2544507,tracking,0.42924023,object-tracking,0.3633091
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,ventricular,0.24852064,rate,0.37094042,long-short-term,0.34148398
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,ejection,0.30230433,function,0.43955976,gradient,0.35697576
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,fraction,0.25137818,component,0.50911963,gradient,0.48876822
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,left-ventricular,0.30000108,batch-normalization,0.40942025,batch-normalization,0.40942025
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,ventricular-ejection,0.26988763,rate,0.43059248,gradient,0.41159958
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,ejection-fraction,0.36681443,stochastic-gradient,0.5523829,stochastic-gradient,0.5523829
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,chast,0.33566284,truth,0.48918223,dimensionality-reduction,0.46396378
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,levels,0.20457911,normalization,0.52984333,batch-normalization,0.45617118
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,obviously,0.22270305,of,0.42061973,batch-normalization,0.36563608
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,decreased,0.23506472,reduction,0.66483074,boosting,0.42738107
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,obviously-decreased,0.33129588,reduction,0.53785145,batch-normalization,0.48357546
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,stage,0.30396575,classification,0.4731305,classification,0.4731305
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,ami,0.25497627,data,0.35898826,batch-normalization,0.3477032
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,remain,0.23401183,fully,0.5900476,long-short-term,0.39730668
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,unclear,0.29818678,fully,0.5238396,long-short-term,0.43300012
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,e,0.13297717,natural,0.39189428,component-analysis,0.28603846
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,h,0.19856977,short-term,0.43919927,long-short-term,0.36116964
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,cardiac,0.29562658,of,0.42777455,long-short-term,0.35708636
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,contractile,0.24631684,function,0.5049658,long-short-term,0.36120063
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,function,0.3447219,function,1.0,learning-function,0.5767432
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,cardiac-contractile,0.28040218,function,0.462255,long-short-term,0.41422477
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,contractile-function,0.34134534,function,0.65128064,learning-function,0.5746569
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,ami,0.25497627,data,0.35898826,batch-normalization,0.3477032
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,cardiac,0.29562658,of,0.42777455,long-short-term,0.35708636
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,remodeling,0.31788215,function,0.5278843,segmentation,0.44361526
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,remains,0.24202663,fully,0.5171005,bagging,0.35608193
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,cardiac-remodeling,0.38380635,function,0.4901194,long-short-term,0.45137346
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,controls,0.2521493,naive,0.47579613,statistical,0.41853178
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,without,0.31691062,of,0.5951073,long-short-term,0.4268921
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,ami,0.25497627,data,0.35898826,batch-normalization,0.3477032
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,controls-without,0.3578989,naive,0.46928722,artificial-intelligence,0.4563385
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,left,0.2544507,tracking,0.42924023,object-tracking,0.3633091
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,ventricular,0.24852064,rate,0.37094042,long-short-term,0.34148398
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,short,0.24294135,short,0.99999994,long-short-term,0.66049826
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,left-ventricular,0.30000108,batch-normalization,0.40942025,batch-normalization,0.40942025
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,expression,0.32038707,encoding,0.59633577,clustering,0.442253
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,level,0.23847455,of,0.54773176,batch-normalization,0.45912555
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,expression-level,0.52689433,learning-function,0.5769394,learning-function,0.5769394
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,different,0.37681934,of,0.61590904,clustering,0.46857932
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,time,0.31186903,long,0.57547164,batch-normalization,0.47628766
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,points,0.3419253,of,0.4826713,segmentation-algorithm,0.44694978
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,different-time,0.41522157,cross-entropy,0.53656876,cross-entropy,0.53656876
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,time-points,0.33956447,short-term,0.44880888,batch-normalization,0.41509414
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,chronic,0.22727785,recurrent,0.5279353,long-short-term,0.4292153
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,pathological,0.35600212,of,0.48665273,classification,0.46512192
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,process,0.3445285,cascade,0.57959485,generative,0.5472986
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,pathological-process,0.5644745,graphics-processing,0.6763705,graphics-processing,0.6763705
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,acute,0.21222305,short-term,0.51624244,long-short-term,0.3867746
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,myocardial,0.25335935,normalization,0.40452614,batch-normalization,0.38271224
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,infarction,0.22924727,recurrent,0.4099214,confusion-matrix,0.3685401
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,acute-myocardial,0.23951635,confusion-matrix,0.40166956,confusion-matrix,0.40166956
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,myocardial-infarction,0.25818947,normalization,0.3545368,long-short-term,0.351139
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,acute-myocardial-infarction,0.25814062,confusion-matrix,0.39158085,confusion-matrix,0.39158085
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,axis,0.1392472,centroid-based,0.423569,centroid-based,0.423569
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,shortening,0.17673878,long,0.59330624,long-short-term,0.51378095
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,rate,0.24866687,rate,1.0,dropout,0.44953537
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,cardiac,0.29562658,of,0.42777455,long-short-term,0.35708636
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,function,0.3447219,function,1.0,learning-function,0.5767432
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,cardiac-function,0.4069733,function,0.6227769,learning-function,0.6182186
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,expression,0.32038707,encoding,0.59633577,clustering,0.442253
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,levels,0.20457911,normalization,0.52984333,batch-normalization,0.45617118
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,expression-levels,0.45874587,learning-function,0.55601394,learning-function,0.55601394
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,cardiac,0.29562658,of,0.42777455,long-short-term,0.35708636
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,remodeling,0.31788215,function,0.5278843,segmentation,0.44361526
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,cardiac-remodeling,0.38380635,function,0.4901194,long-short-term,0.45137346
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,stage,0.30396575,classification,0.4731305,classification,0.4731305
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,ami,0.25497627,data,0.35898826,batch-normalization,0.3477032
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,circulating,0.26450798,of,0.4713916,clustering,0.36910847
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,levels,0.20457911,normalization,0.52984333,batch-normalization,0.45617118
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,h,0.19856977,short-term,0.43919927,long-short-term,0.36116964
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,cardiac,0.29562658,of,0.42777455,long-short-term,0.35708636
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,hypertrophy,0.24932764,normalization,0.46860057,batch-normalization,0.41493565
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,cardiac-hypertrophy,0.31550246,normalization,0.43038815,long-short-term,0.42026454
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,substantially,0.32717326,of,0.5883337,long-short-term,0.45811647
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,decreased,0.23506472,reduction,0.66483074,boosting,0.42738107
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,ami,0.25497627,data,0.35898826,batch-normalization,0.3477032
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,population,0.2958798,selection,0.5071889,clustering,0.47966808
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,days,0.20857571,short-term,0.53915894,long-short-term,0.4190845
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,mortality,0.2609817,short-term,0.505676,logistic-regression,0.49414968
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,rate,0.24866687,rate,1.0,dropout,0.44953537
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,mortality-rate,0.36486575,rate,0.5465963,logistic-regression,0.53036416
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,circulating,0.26450798,of,0.4713916,clustering,0.36910847
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,lncrnas,0.39817604,classifiers,0.4339132,classifiers,0.4339132
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,ami,0.25497627,data,0.35898826,batch-normalization,0.3477032
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,patients,0.30007,recurrent,0.5332828,dropout,0.3918751
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,ami-patients,0.33510944,logistic-regression,0.44628996,logistic-regression,0.44628996
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,chast,0.33566284,truth,0.48918223,dimensionality-reduction,0.46396378
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,standardized,0.4341382,computer-vision,0.5060257,computer-vision,0.5060257
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,significantly,0.27887642,of,0.5214151,long-short-term,0.39056638
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,increased,0.26921988,reduction,0.6514183,boosting,0.46515882
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,significantly-increased,0.30354688,reduction,0.5746703,boosting,0.45880336
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,reportedly,0.23249823,few,0.519469,bagging,0.38245368
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,involved,0.26651675,of,0.5396308,feed-forward,0.42281044
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,quartile,0.23501194,logistic,0.51510084,logistic-regression,0.47468472
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,values,0.28403002,batch-normalization,0.5186162,batch-normalization,0.5186162
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,potential,0.3558654,of,0.5645705,generative-model,0.46479023
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,roles,0.29737037,function,0.5381723,generative,0.4343859
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,positively,0.2408255,of,0.47970766,regression,0.39266258
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,associated,0.30827495,of,0.57598466,long-short-term,0.46578532
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,positively-associated,0.3594351,clustering,0.5658173,clustering,0.5658173
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,may,0.30907542,of,0.58654004,long-short-term,0.43985203
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,serve,0.37730122,of,0.4837274,feature-engineering,0.47067174
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,independent,0.39991486,of,0.5904635,regression,0.57876456
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,predictor,0.43901688,regression,0.5961869,regression,0.5961869
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,independent-predictor,0.6123905,logistic-regression,0.70282865,logistic-regression,0.70282865
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,grouped,0.40923864,classification,0.58771443,classification,0.58771443
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,according,0.3602386,classification,0.6492659,classification,0.6492659
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,elsevier,0.26603332,science,0.59524655,data-science,0.53140587
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,b,0.19558734,of,0.43435428,short-term-memory,0.31717262
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,consecutively,0.32380694,unit,0.48644823,supervised,0.41597083
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,enrolled,0.3208215,supervised,0.42658707,supervised,0.42658707
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,consecutively-enrolled,0.41632706,supervised,0.48233104,supervised,0.48233104
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,clinical,0.44080526,data,0.48532635,data-science,0.45343333
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,parameters,0.38939354,normalization,0.54973936,batch-normalization,0.547323
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,clinical-parameters,0.64596903,statistical,0.66793346,statistical,0.66793346
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,cardiovascular,0.31674606,short-term,0.442761,learning-function,0.4027721
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,diseases,0.31957155,recurrent,0.41244444,classification,0.40266854
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,cardiovascular-diseases,0.3900246,learning-function,0.41476324,learning-function,0.41476324
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,candidate,0.35861892,encoding,0.51264024,feature-selection,0.4453258
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,biomarker,0.43929577,classifiers,0.45752043,classifiers,0.45752043
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,candidate-biomarker,0.553829,machine-learning,0.553829,machine-learning,0.553829
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,blood,0.16939776,normalization,0.4272251,batch-normalization,0.40715772
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,samples,0.3088399,analysis,0.4981357,batch-normalization,0.44174457
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,blood-samples,0.38363302,batch-normalization,0.5377045,batch-normalization,0.5377045
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,associated,0.30827495,of,0.57598466,long-short-term,0.46578532
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,transcript,0.2666745,encoding,0.5988406,batch-normalization,0.35447773
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,three,0.36911732,one,0.78425425,clustering,0.4299444
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,patients,0.30007,recurrent,0.5332828,dropout,0.3918751
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,three-patients,0.42115462,confusion-matrix,0.499186,confusion-matrix,0.499186
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,highest,0.25175208,of,0.5054526,boosting,0.3963222
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,quartiles,0.26269093,logistic,0.5587156,logistic-regression,0.53158706
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,highest-quartiles,0.34351578,logistic,0.49006516,logistic-regression,0.46235102
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,ami,0.25497627,data,0.35898826,batch-normalization,0.3477032
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,controls,0.2521493,naive,0.47579613,statistical,0.41853178
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,remodeling,0.31788215,function,0.5278843,segmentation,0.44361526
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,patients,0.30007,recurrent,0.5332828,dropout,0.3918751
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,quartiles,0.26269093,logistic,0.5587156,logistic-regression,0.53158706
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,lncrnas,0.39817604,classifiers,0.4339132,classifiers,0.4339132
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,v,0.16266164,rate,0.35976145,softmax,0.2951627
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,study,0.3645851,of,0.5728763,statistical,0.44204497
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,results,0.32376552,data,0.6932311,batch-normalization,0.44826904
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,published,0.42179614,data,0.6147139,data-science,0.54664624
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,post,0.27536392,confusion,0.47820356,bagging,0.44161102
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,phase,0.23814097,hidden-layer,0.45645207,hidden-layer,0.45645207
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,p,0.26795468,support,0.40805867,regression,0.40253854
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,methods,0.50049126,data,0.5400177,machine-learning,0.50049126
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,measured,0.25103813,of,0.539739,batch-normalization,0.45439726
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,however,0.31437585,few,0.63182676,statistical,0.44065386
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,fifty,0.30319983,one,0.48874712,one-hot,0.3066399
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,early,0.32400474,short-term,0.57188475,long-short-term,0.50726265
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,conclusion,0.35530132,data,0.5299138,long-short-term,0.45073265
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,compared,0.3359061,of,0.52794564,long-short-term,0.42386633
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,collected,0.33035916,data,0.5686942,ground-truth,0.3838368
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,biomarkers,0.45449477,classifiers,0.49574262,classifiers,0.49574262
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,background,0.3259285,of,0.51277274,long-short-term,0.46426663
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,goes,0.34525603,hidden,0.53050196,data-science,0.4353512
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,beyond,0.34655812,of,0.53781354,dimensionality-reduction,0.42561156
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,standard,0.3833671,batch-normalization,0.52681863,batch-normalization,0.52681863
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,clinical,0.44080526,data,0.48532635,data-science,0.45343333
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,biomarkers,0.45449477,classifiers,0.49574262,classifiers,0.49574262
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,beyond-standard,0.4512607,truth,0.57201105,batch-normalization,0.5700356
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,clinical-biomarkers,0.5669663,machine-learning,0.5669663,machine-learning,0.5669663
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,essential,0.28451368,components,0.5479382,component-analysis,0.4103359
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,step,0.34883037,forward,0.61124456,feature-reduction,0.52921283
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,towards,0.26157683,forward,0.5590818,generative,0.45313805
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,personalized,0.5869211,data-engineering,0.6371769,data-engineering,0.6371769
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,poor,0.31379676,confusion,0.5027573,long-short-term,0.43808374
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,metabolic,0.3235007,of,0.46523505,batch-normalization,0.4536144
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,health,0.36509717,data-science,0.5754831,data-science,0.5754831
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,outcome,0.33788118,short-term,0.5818455,long-short-term,0.48316076
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,metabolic-health,0.39143825,data-science,0.45844424,data-science,0.45844424
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,health-outcome,0.43268,data-science,0.57306904,data-science,0.57306904
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,comprehensive,0.5203603,data,0.6056672,data-engineering,0.58421016
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,multimodal,0.53923947,deep-learning,0.57608044,deep-learning,0.57608044
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,health,0.36509717,data-science,0.5754831,data-science,0.5754831
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,assessments,0.4087205,data,0.5759542,component-analysis,0.47014043
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,unsupervised,0.76376486,unsupervised,0.99999994,unsupervised,0.99999994
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,machine,0.7094662,machine,1.0,machine-learning,0.7094662
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,learning,0.709237,learning,1.0,deep-learning,0.8286492
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,methods,0.50049126,data,0.5400177,machine-learning,0.50049126
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,machine-learning,1.0,machine-learning,1.0,machine-learning,1.0
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,preventative,0.37422732,decision,0.51258266,decision-tree,0.46882105
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,health,0.36509717,data-science,0.5754831,data-science,0.5754831
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,risk,0.35860935,recurrent,0.53675485,logistic-regression,0.52381086
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,assessment,0.4002061,analysis,0.5275976,component-analysis,0.49803802
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,preventative-health,0.44452533,decision-tree,0.53666496,decision-tree,0.53666496
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,health-risk,0.4075771,style,0.53961045,decision-tree,0.5137303
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,risk-assessment,0.5291727,decision-tree,0.6316601,decision-tree,0.6316601
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,health-risk-assessment,0.5157614,decision-tree,0.6157348,decision-tree,0.6157348
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,biomarkers,0.45449477,classifiers,0.49574262,classifiers,0.49574262
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,identified,0.35725033,analysis,0.56593037,clustering,0.45719695
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,distinct,0.36295342,feature,0.580647,clustering,0.5409523
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,subsets,0.43637866,naive,0.6284895,clustering,0.53487885
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,collected,0.33035916,data,0.5686942,ground-truth,0.3838368
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,data,0.46434748,data,1.0,data-science,0.5533528
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,features,0.51742536,feature,0.8268872,feature-selection,0.5487305
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,data-features,0.75084364,machine-learning,0.75084364,machine-learning,0.75084364
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,identify,0.46963936,analysis,0.5445881,clustering,0.4863696
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,multimodal,0.53923947,deep-learning,0.57608044,deep-learning,0.57608044
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,biomarker,0.43929577,classifiers,0.45752043,classifiers,0.45752043
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,signatures,0.5135738,feature,0.63312745,classifiers,0.5664035
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,diabetes,0.29301462,logistic-regression,0.35688502,logistic-regression,0.35688502
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,signature,0.46610928,feature,0.6392228,classifiers,0.52970886
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,included,0.34673893,of,0.58040446,component-analysis,0.47413814
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,identified,0.35725033,analysis,0.56593037,clustering,0.45719695
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,potential,0.3558654,of,0.5645705,generative-model,0.46479023
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,early,0.32400474,short-term,0.57188475,long-short-term,0.50726265
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,signatures,0.5135738,feature,0.63312745,classifiers,0.5664035
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,potential-early,0.3398872,stochastic,0.5556284,stochastic,0.5556284
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,established,0.40618747,of,0.60100454,classification,0.47434023
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,clinical,0.44080526,data,0.48532635,data-science,0.45343333
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,biomarkers,0.45449477,classifiers,0.49574262,classifiers,0.49574262
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,clinical-biomarkers,0.5669663,machine-learning,0.5669663,machine-learning,0.5669663
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,rapidly,0.31091517,fully,0.52853787,generative,0.40081567
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,moving,0.43464398,tracking,0.6973538,object-tracking,0.58278155
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,towards,0.26157683,forward,0.5590818,generative,0.45313805
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,rapidly-moving,0.39653802,tracking,0.5615056,object-tracking,0.5289422
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,multimodal,0.53923947,deep-learning,0.57608044,deep-learning,0.57608044
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,data,0.46434748,data,1.0,data-science,0.5533528
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,integration,0.5065657,feature-engineering,0.66811013,feature-engineering,0.66811013
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,data-integration,0.65431446,data-engineering,0.7278706,data-engineering,0.7278706
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,similar,0.29237732,of,0.56832373,long-short-term,0.4732089
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,health,0.36509717,data-science,0.5754831,data-science,0.5754831
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,statuses,0.30647206,style,0.42594853,logistic-regression,0.40497175
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,health-statuses,0.42461663,style,0.5520959,decision-tree,0.5377338
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,longitudinal,0.3201388,data,0.4832245,regression,0.4622656
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,validation,0.5362086,cross-validation,0.74016297,cross-validation,0.74016297
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,cohort,0.3892265,logistic-regression,0.5412916,logistic-regression,0.5412916
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,validation-cohort,0.5867096,cross-validation,0.68933964,cross-validation,0.68933964
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,lean,0.3062906,feed,0.47777596,batch-normalization,0.41364604
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,mass,0.22818582,fourier-transform,0.42889374,fourier-transform,0.42889374
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,percentage,0.22209123,reduction,0.5092495,dropout,0.39063072
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,lean-mass,0.38473934,fourier-transform,0.5005195,fourier-transform,0.5005195
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,mass-percentage,0.3300187,batch-normalization,0.48050812,batch-normalization,0.48050812
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,body,0.2149021,of,0.4173455,segmentation,0.3712382
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,mass,0.22818582,fourier-transform,0.42889374,fourier-transform,0.42889374
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,index,0.27978244,function,0.407383,classification-algorithm,0.3994653
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,body-mass,0.2804671,logistic,0.4619771,logistic-regression,0.45644483
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,mass-index,0.2927159,batch-normalization,0.44462848,batch-normalization,0.44462848
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,body-mass-index,0.30087414,tfidf,0.43545467,tfidf,0.43545467
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,uncovering,0.48280096,hidden,0.6364043,feature-engineering,0.607255
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,novel,0.4652171,feature-engineering,0.5132146,feature-engineering,0.5132146
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,biomarkers,0.45449477,classifiers,0.49574262,classifiers,0.49574262
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,palmitoyl,0.15603068,encoding,0.28871566,transfer-learning,0.27530354
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,found,0.2840244,of,0.6208722,clustering,0.44675255
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,novel,0.4652171,feature-engineering,0.5132146,feature-engineering,0.5132146
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,associations,0.41113383,regression,0.58898914,regression,0.58898914
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,novel,0.4652171,feature-engineering,0.5132146,feature-engineering,0.5132146
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,biomarker,0.43929577,classifiers,0.45752043,classifiers,0.45752043
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,signatures,0.5135738,feature,0.63312745,classifiers,0.5664035
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,gut,0.23751628,feed,0.4522162,generative,0.32370585
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,microbiome,0.41896057,natural,0.44561404,feature-engineering,0.42372507
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,health,0.36509717,data-science,0.5754831,data-science,0.5754831
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,gut-microbiome,0.35468173,feature-engineering,0.39424896,feature-engineering,0.39424896
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,microbiome-health,0.51420015,data-science,0.57057106,data-science,0.57057106
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,microbiome,0.41896057,natural,0.44561404,feature-engineering,0.42372507
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,genera,0.3353559,tree,0.49005437,random-forest,0.4479549
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,intestinimonas,0.30306628,batch,0.34613648,deep-learning,0.32645217
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,driven,0.33295566,stochastic,0.55241346,stochastic,0.55241346
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,paradigm,0.5094469,reinforcement-learning,0.5952247,reinforcement-learning,0.5952247
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,based,0.49998575,classification-algorithm,0.5639226,classification-algorithm,0.5639226
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,paradigm-based,0.69457364,feature-engineering,0.7317209,feature-engineering,0.7317209
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,novel,0.4652171,feature-engineering,0.5132146,feature-engineering,0.5132146
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,biomarkers,0.45449477,classifiers,0.49574262,classifiers,0.49574262
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,potential,0.3558654,of,0.5645705,generative-model,0.46479023
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,biomarker,0.43929577,classifiers,0.45752043,classifiers,0.45752043
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,cardiometabolic,0.36018297,logistic-regression,0.43154526,logistic-regression,0.43154526
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,biomarkers,0.45449477,classifiers,0.49574262,classifiers,0.49574262
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,disease,0.296938,recurrent,0.4731025,classification,0.35271814
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,risk,0.35860935,recurrent,0.53675485,logistic-regression,0.52381086
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,disease-risk,0.44242084,logistic-regression,0.48454326,logistic-regression,0.48454326
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,disease,0.296938,recurrent,0.4731025,classification,0.35271814
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,signatures,0.5135738,feature,0.63312745,classifiers,0.5664035
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,method,0.482283,algorithm,0.63295126,algorithm,0.63295126
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,identified,0.35725033,analysis,0.56593037,clustering,0.45719695
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,individuals,0.32092994,naive,0.486303,dropout,0.42173886
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,individuals,0.32092994,naive,0.486303,dropout,0.42173886
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,based,0.49998575,classification-algorithm,0.5639226,classification-algorithm,0.5639226
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,individuals-based,0.62281734,artificial-intelligence,0.6393113,artificial-intelligence,0.6393113
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,uremic,0.24009383,of,0.37126812,batch-normalization,0.35515535
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,toxin,0.1594879,of,0.39929807,one-shot,0.3046599
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,uremic-toxin,0.28142375,one-shot,0.36301243,one-shot,0.36301243
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,unclassified,0.36789292,classification,0.60314643,classification,0.60314643
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,genus,0.33567297,tree,0.5002655,random-forest,0.45443052
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,subset,0.42092714,feature,0.57910776,clustering,0.5495737
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,membership,0.50740504,adversarial,0.6039171,classification-algorithm,0.5906961
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,modern,0.4505404,science,0.535432,data-science,0.5250178
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,medicine,0.41121995,science,0.6522808,data-science,0.6045255
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,integrated,0.53518295,data-engineering,0.633208,data-engineering,0.633208
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,analysis,0.46507934,analysis,0.99999994,component-analysis,0.69613737
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,insulin,0.22629064,unit,0.40084893,batch-normalization,0.32209873
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,resistance,0.23395967,selection,0.4553234,long-short-term,0.34529024
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,insulin-resistance,0.26955065,function,0.38102794,long-short-term,0.36459094
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,including,0.3233776,of,0.6619886,clustering,0.40625107
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,metabolome,0.41197848,batch-normalization,0.49083576,batch-normalization,0.49083576
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,erysipelotrichaceae,0.27209622,tree,0.4312681,random-forest,0.38307005
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,family,0.2727693,support,0.5085263,clustering,0.40444815
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,driven,0.33295566,stochastic,0.55241346,stochastic,0.55241346
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,stratification,0.45885193,classification-algorithm,0.6005924,classification-algorithm,0.6005924
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,diverse,0.38913006,of,0.5461366,feature-engineering,0.51537836
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,modalities,0.46641335,computer-vision,0.480308,computer-vision,0.480308
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,disease,0.296938,recurrent,0.4731025,classification,0.35271814
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,subtypes,0.31414166,classification,0.53066176,classification,0.53066176
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,disease-subtypes,0.4546033,clustering,0.5029541,clustering,0.5029541
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,different,0.37681934,of,0.61590904,clustering,0.46857932
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,modalities,0.46641335,computer-vision,0.480308,computer-vision,0.480308
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,cresol,0.22329722,batch,0.41073003,feature-reduction,0.35790205
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,sulfate,0.19182658,layer,0.40709388,gradient,0.38957754
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,better,0.4230538,of,0.5337099,feature-reduction,0.47485045
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,predictor,0.43901688,regression,0.5961869,regression,0.5961869
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,another,0.3071552,one,0.80370224,clustering,0.4124617
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,metabolite,0.27332738,principal,0.44271863,batch-normalization,0.37130743
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,advanced,0.4209618,of,0.47114033,machine-learning,0.4209618
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,imaging,0.41700524,tracking,0.55048084,segmentation,0.5337068
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,advanced-imaging,0.51100856,deep-learning,0.5166912,deep-learning,0.5166912
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,results,0.32376552,data,0.6932311,batch-normalization,0.44826904
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,demonstrate,0.37134898,of,0.5097414,feature-engineering,0.4652517
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,results-demonstrate,0.45842522,data,0.60937816,dimensionality-reduction,0.53237516
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,health,0.36509717,data-science,0.5754831,data-science,0.5754831
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,signatures,0.5135738,feature,0.63312745,classifiers,0.5664035
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,identified,0.35725033,analysis,0.56593037,clustering,0.45719695
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,data,0.46434748,data,1.0,data-science,0.5533528
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,methods,0.50049126,data,0.5400177,machine-learning,0.50049126
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,diabetes,0.29301462,logistic-regression,0.35688502,logistic-regression,0.35688502
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,potential,0.3558654,of,0.5645705,generative-model,0.46479023
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,microbiome,0.41896057,natural,0.44561404,feature-engineering,0.42372507
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,individuals,0.32092994,naive,0.486303,dropout,0.42173886
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,stratification,0.45885193,classification-algorithm,0.6005924,classification-algorithm,0.6005924
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,results,0.32376552,data,0.6932311,batch-normalization,0.44826904
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,utilized,0.48087895,of,0.59412074,feature-engineering,0.5390619
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,stearoyl,0.14041308,fourier-transform,0.28465343,fourier-transform,0.28465343
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,stages,0.324753,generative,0.5243855,generative,0.5243855
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,set,0.5244544,of,0.5846941,classifiers,0.5500933
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,p,0.26795468,support,0.40805867,regression,0.40253854
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,oleoyl,0.14171425,transfer-learning,0.30168304,transfer-learning,0.30168304
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,methodology,0.5520129,data-engineering,0.61297953,data-engineering,0.61297953
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,linolenoyl,0.14677835,fourier,0.3278867,fourier,0.3278867
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,identification,0.4527572,analysis,0.6100153,classification,0.5378393
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,hypertension,0.28340828,dropout,0.4223115,dropout,0.4223115
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,gpc,0.24658187,fourier-transform,0.38916683,fourier-transform,0.38916683
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,glucose,0.22612295,batch-normalization,0.39605165,batch-normalization,0.39605165
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,genetics,0.4164791,science,0.57405317,data-science,0.5206231
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,enyl,0.11221218,centroid-based,0.35623255,centroid-based,0.35623255
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,dihomo,0.120742545,words,0.26714844,semantic,0.26567364
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,conclusions,0.37109232,data,0.55923915,long-short-term,0.4627594
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,combination,0.385488,of,0.5245792,boosting,0.5027329
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,cinnamoylglycine,0.21150604,fourier-transform,0.29528016,fourier-transform,0.29528016
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,background,0.3259285,of,0.51277274,long-short-term,0.46426663
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,additionally,0.37098312,of,0.6596129,feature-reduction,0.453403
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,abundance,0.31865036,forest,0.4966442,clustering,0.48465613
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,learning,0.709237,learning,1.0,deep-learning,0.8286492
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,analyses,0.43295383,analysis,0.9146549,principal-component-analysis,0.66157085
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,may,0.30907542,of,0.58654004,long-short-term,0.43985203
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,demonstrate,0.37134898,of,0.5097414,feature-engineering,0.4652517
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,specific,0.3244285,of,0.6059094,clustering,0.45887482
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,food,0.28933978,feed,0.7019788,reinforcement-learning,0.45328835
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,allergy,0.22422166,feed,0.3838807,component-analysis,0.35398978
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,endotypes,0.4484415,classifiers,0.5054419,classifiers,0.5054419
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,learning-analyses,0.73141456,learning-rate,0.8136856,learning-rate,0.8136856
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,may-demonstrate,0.3861785,of,0.5578029,dimensionality-reduction,0.508286
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,demonstrate-specific,0.4003331,feature-engineering,0.5374218,feature-engineering,0.5374218
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,specific-food,0.36439767,component-analysis,0.5041379,component-analysis,0.5041379
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,food-allergy,0.24571703,feed,0.4553915,reinforcement-learning,0.3806717
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,allergic,0.20212972,naive,0.35798216,component-analysis,0.31613114
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,patients,0.30007,recurrent,0.5332828,dropout,0.3918751
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,experience,0.41404068,short-term,0.55279255,artificial-intelligence,0.491909
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,stereotypical,0.4109174,generative,0.6248472,generative,0.6248472
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,symptoms,0.2751398,confusion,0.5089627,dropout,0.40571758
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,following,0.27415842,of,0.60616374,long-short-term,0.4591148
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,allergen,0.2713676,boosting,0.3783444,boosting,0.3783444
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,exposure,0.22801533,short-term,0.55545235,long-short-term,0.45469296
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,allergic-patients,0.26765358,recurrent,0.4416922,confusion-matrix,0.38354355
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,patients-experience,0.43408185,decision,0.52515787,decision-tree,0.49148422
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,allergen-exposure,0.2629245,naive,0.44858372,boosting,0.40338808
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,symptoms,0.2751398,confusion,0.5089627,dropout,0.40571758
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,experienced,0.33214465,one,0.53318346,supervised,0.47342923
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,following,0.27415842,of,0.60616374,long-short-term,0.4591148
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,allergen,0.2713676,boosting,0.3783444,boosting,0.3783444
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,exposure,0.22801533,short-term,0.55545235,long-short-term,0.45469296
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,allergen-exposure,0.2629245,naive,0.44858372,boosting,0.40338808
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,allergen,0.2713676,boosting,0.3783444,boosting,0.3783444
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,immunotherapy,0.32406864,boosting,0.52817047,boosting,0.52817047
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,may,0.30907542,of,0.58654004,long-short-term,0.43985203
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,modulate,0.28013808,function,0.51941574,feed-forward,0.47073716
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,allergen-immunotherapy,0.3170349,boosting,0.47659248,boosting,0.47659248
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,immunotherapy-may,0.35096395,boosting,0.49354127,boosting,0.49354127
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,study,0.3645851,of,0.5728763,statistical,0.44204497
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,selections,0.50927883,selection,0.862301,feature-selection,0.7102623
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,authors,0.45811802,data,0.5259881,natural-language-processing,0.4706872
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,assessment,0.4002061,analysis,0.5275976,component-analysis,0.49803802
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,may,0.30907542,of,0.58654004,long-short-term,0.43985203
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,impact,0.3818503,of,0.5528908,dimensionality-reduction,0.4648105
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,upon,0.2366915,of,0.6212549,boosting,0.40359378
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,risk,0.35860935,recurrent,0.53675485,logistic-regression,0.52381086
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,impact-upon,0.33178985,data-science,0.515056,data-science,0.515056
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,supervised,0.6546646,supervised,1.0,supervised,1.0
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,oral,0.24590528,of,0.46959797,boosting,0.3483035
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,food,0.28933978,feed,0.7019788,reinforcement-learning,0.45328835
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,challenge,0.32916635,boosting,0.49348646,boosting,0.49348646
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,food-challenge,0.3038055,feed,0.4922949,reinforcement-learning,0.43195444
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,oral-food-challenge,0.30731916,feed,0.49639526,reinforcement-learning,0.44326484
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,specific,0.3244285,of,0.6059094,clustering,0.45887482
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,reaction,0.16487643,transfer,0.4593661,feature-reduction,0.43431032
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,phenotypes,0.3480116,feature-selection,0.513654,feature-selection,0.513654
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,exist,0.33952302,few,0.54263353,clustering,0.42993432
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,food,0.28933978,feed,0.7019788,reinforcement-learning,0.45328835
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,allergy,0.22422166,feed,0.3838807,component-analysis,0.35398978
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,encompasses,0.36157057,feature,0.557433,generative,0.41740352
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,food-allergy,0.24571703,feed,0.4553915,reinforcement-learning,0.3806717
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,food,0.28933978,feed,0.7019788,reinforcement-learning,0.45328835
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,anaphylaxis,0.21861179,recurrent,0.35571,component-analysis,0.35138503
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,may,0.30907542,of,0.58654004,long-short-term,0.43985203
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,food-anaphylaxis,0.21147168,feed,0.44846576,reinforcement-learning,0.42100972
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,unpublished,0.31680372,science,0.5618892,data-science,0.5491295
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,literature,0.42831737,data,0.58552843,data-science,0.5381381
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,relating,0.42100638,of,0.6561698,dimensionality-reduction,0.53452516
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,clinically,0.3702051,recurrent,0.5046643,confusion-matrix,0.40397355
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,useful,0.40063038,discriminative,0.489146,feature-engineering,0.43842706
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,predictors,0.46376368,logistic,0.67381907,logistic-regression,0.66900885
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,clinically-useful,0.52353287,discriminative,0.52936786,machine-learning,0.52353287
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,applying,0.54891497,batch-normalization,0.58278275,batch-normalization,0.58278275
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,unbiased,0.56795436,bayesian,0.60999364,bayesian,0.60999364
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,machine,0.7094662,machine,1.0,machine-learning,0.7094662
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,facilitating,0.39405596,of,0.5844613,feature-engineering,0.54718345
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,risk,0.35860935,recurrent,0.53675485,logistic-regression,0.52381086
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,stratification,0.45885193,classification-algorithm,0.6005924,classification-algorithm,0.6005924
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,risk-stratification,0.56299007,classification-algorithm,0.6976296,classification-algorithm,0.6976296
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,different,0.37681934,of,0.61590904,clustering,0.46857932
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,reaction,0.16487643,transfer,0.4593661,feature-reduction,0.43431032
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,phenotypes,0.3480116,feature-selection,0.513654,feature-selection,0.513654
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,major,0.2356064,principal,0.70253855,principal-components,0.42016473
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,research,0.45694843,science,0.7194936,data-science,0.70924157
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,theme,0.44838244,data-science,0.5933243,data-science,0.5933243
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,different,0.37681934,of,0.61590904,clustering,0.46857932
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,clinical,0.44080526,data,0.48532635,data-science,0.45343333
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,phenotypes,0.3480116,feature-selection,0.513654,feature-selection,0.513654
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,clinical,0.44080526,data,0.48532635,data-science,0.45343333
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,experience,0.41404068,short-term,0.55279255,artificial-intelligence,0.491909
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,clinical-experience,0.5050136,natural-language,0.5508604,natural-language,0.5508604
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,food,0.28933978,feed,0.7019788,reinforcement-learning,0.45328835
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,allergy,0.22422166,feed,0.3838807,component-analysis,0.35398978
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,food-allergy,0.24571703,feed,0.4553915,reinforcement-learning,0.3806717
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,predict,0.51602554,model,0.53463185,classification-algorithm,0.52342355
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,patients,0.30007,recurrent,0.5332828,dropout,0.3918751
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,allergic,0.20212972,naive,0.35798216,component-analysis,0.31613114
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,reactions,0.1660865,cascade,0.4665857,feature-reduction,0.4390803
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,allergic-reactions,0.23228706,component-analysis,0.43687272,component-analysis,0.43687272
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,allergic,0.20212972,naive,0.35798216,component-analysis,0.31613114
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,individuals,0.32092994,naive,0.486303,dropout,0.42173886
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,reaction,0.16487643,transfer,0.4593661,feature-reduction,0.43431032
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,phenotypes,0.3480116,feature-selection,0.513654,feature-selection,0.513654
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,severe,0.24462184,recurrent,0.581337,confusion-matrix,0.37568426
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,food,0.28933978,feed,0.7019788,reinforcement-learning,0.45328835
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,many,0.40940517,few,0.752018,feature-engineering,0.48454586
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,food,0.28933978,feed,0.7019788,reinforcement-learning,0.45328835
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,food,0.28933978,feed,0.7019788,reinforcement-learning,0.45328835
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,hypersensitivities,0.20373355,of,0.43954408,reinforcement-learning,0.34065476
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,different,0.37681934,of,0.61590904,clustering,0.46857932
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,pathophysiology,0.33863446,feature,0.44530085,classification,0.3943317
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,different,0.37681934,of,0.61590904,clustering,0.46857932
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,cohorts,0.38747132,logistic-regression,0.5306275,logistic-regression,0.5306275
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,severe,0.24462184,recurrent,0.581337,confusion-matrix,0.37568426
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,anaphylaxis,0.21861179,recurrent,0.35571,component-analysis,0.35138503
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,clinical,0.44080526,data,0.48532635,data-science,0.45343333
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,practice,0.50552624,decision,0.59237766,data-science,0.5843962
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,clinical-practice,0.5274042,data-science,0.57205796,data-science,0.57205796
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,anaphylaxis,0.21861179,recurrent,0.35571,component-analysis,0.35138503
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,caused,0.14436965,of,0.53973085,long-short-term,0.3204536
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,prescribe,0.32745886,decision,0.52214897,supervised,0.4749533
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,eai,0.23726672,style,0.3486308,classification-algorithm,0.34635186
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,nonfood,0.3797534,feed,0.5717542,reinforcement-learning,0.5286365
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,triggers,0.23982553,cascade,0.5948624,feed-forward,0.46089596
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,integrating,0.6117625,data-engineering,0.6982796,data-engineering,0.6982796
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,datasets,0.6397797,data,0.71337724,classifiers,0.68077624
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,important,0.33620566,principal,0.5803634,feature-engineering,0.43471682
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,area,0.23419946,layer,0.46823567,ground-truth,0.38642365
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,endotype,0.3800202,feature,0.45493954,classification-algorithm,0.4418667
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,discovery,0.46891084,data-engineering,0.5077522,data-engineering,0.5077522
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,endotype-discovery,0.563213,machine-learning,0.563213,machine-learning,0.563213
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,elsevier,0.26603332,science,0.59524655,data-science,0.53140587
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,inc,0.2706048,bag,0.52860194,bagging,0.41463643
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,current,0.3530666,rectified,0.52906346,generative-model,0.40904555
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,inability,0.2910858,fully,0.5528337,generative,0.41253537
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,patient,0.2998137,confusion,0.5356896,confusion-matrix,0.41404122
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,management,0.38786528,decision,0.59816897,decision-tree,0.49756956
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,patient-management,0.49625677,decision,0.5863574,decision-tree,0.55497044
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,one,0.335046,one,1.0,one-hot,0.4275648
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,patient,0.2998137,confusion,0.5356896,confusion-matrix,0.41404122
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,one-patient,0.44901627,confusion-matrix,0.5221636,confusion-matrix,0.5221636
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,data,0.46434748,data,1.0,data-science,0.5533528
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,sources,0.32459462,data,0.5118194,data-science,0.4587717
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,data-sources,0.58246005,data-science,0.72726756,data-science,0.72726756
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,available,0.4144769,data,0.62807965,data-science,0.46192533
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,data,0.46434748,data,1.0,data-science,0.5533528
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,available-data,0.56933975,data,0.68208367,data-augmentation,0.5826951
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,similar,0.29237732,of,0.56832373,long-short-term,0.4732089
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,way,0.4425121,forward,0.5844119,generative,0.55701363
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,emerging,0.45052218,feature-engineering,0.5309333,feature-engineering,0.5309333
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,evidence,0.28723752,data,0.5728123,generative,0.3943918
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,food,0.28933978,feed,0.7019788,reinforcement-learning,0.45328835
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,risk,0.35860935,recurrent,0.53675485,logistic-regression,0.52381086
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,phenotypes,0.3480116,feature-selection,0.513654,feature-selection,0.513654
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,exist,0.33952302,few,0.54263353,clustering,0.42993432
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,research,0.45694843,science,0.7194936,data-science,0.70924157
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,patient,0.2998137,confusion,0.5356896,confusion-matrix,0.41404122
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,data,0.46434748,data,1.0,data-science,0.5533528
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,way,0.4425121,forward,0.5844119,generative,0.55701363
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,emerging,0.45052218,feature-engineering,0.5309333,feature-engineering,0.5309333
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,whether,0.32171756,short-term,0.5290759,long-short-term,0.47851244
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,varies,0.25008774,of,0.58237076,clustering,0.4035787
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,severity,0.30823207,classification,0.46052065,classification,0.46052065
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,robust,0.50920165,hierarchical,0.6267712,hierarchical-clustering,0.6142049
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,results,0.32376552,data,0.6932311,batch-normalization,0.44826904
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,remains,0.24202663,fully,0.5171005,bagging,0.35608193
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,relevance,0.48173976,of,0.5866257,feature-engineering,0.50181127
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,range,0.23189357,linear,0.4532097,gradient,0.36315575
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,published,0.42179614,data,0.6147139,data-science,0.54664624
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,perhaps,0.29040864,of,0.598087,generative,0.48131824
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,objective,0.4122544,of,0.5255821,component-analysis,0.42220753
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,number,0.2996383,few,0.57847273,clustering,0.4387715
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,much,0.30250478,few,0.5868126,long-short-term,0.42466134
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,manner,0.26802608,fully,0.46465638,feed-forward,0.4349473
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,likely,0.28872275,one,0.55131567,generative,0.3953101
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,improvements,0.44787854,reduction,0.58757085,dimensionality-reduction,0.5122088
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,impacting,0.3629099,of,0.59977853,feature-engineering,0.48356816
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,given,0.30785376,of,0.54849017,boosting,0.4329715
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,g,0.17250246,feed,0.40076,n-gram,0.27758121
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,future,0.42505926,data-engineering,0.5647982,data-engineering,0.5647982
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,e,0.13297717,natural,0.39189428,component-analysis,0.28603846
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,discuss,0.4084479,decision,0.5208974,feature-engineering,0.46463755
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,devices,0.37494427,data-engineering,0.5315442,data-engineering,0.5315442
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,determined,0.2643224,of,0.6221287,batch-normalization,0.4203323
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,decision,0.5239193,decision,1.0,decision-tree,0.75800127
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,currently,0.3947763,fully,0.5423527,bagging,0.41457367
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,confirm,0.28446677,support,0.5519786,component-analysis,0.36139983
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,conclusion,0.35530132,data,0.5299138,long-short-term,0.45073265
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,community,0.43578458,forest,0.55286825,data-science,0.5462896
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,clearly,0.32579756,fully,0.612451,clustering,0.4479503
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,asthma,0.23373649,recurrent,0.34173506,dropout,0.3397969
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,another,0.3071552,one,0.80370224,clustering,0.4124617
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,predict,0.51602554,model,0.53463185,classification-algorithm,0.52342355
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,ml,0.29010946,bag,0.4418462,gradient,0.3396448
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,approaches,0.55614823,feature-engineering,0.60571706,feature-engineering,0.60571706
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,may,0.30907542,of,0.58654004,long-short-term,0.43985203
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,facilitate,0.4181755,support,0.56775236,feature-engineering,0.53415316
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,optimal,0.39098042,selection,0.5284126,algorithm,0.5276129
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,candidate,0.35861892,encoding,0.51264024,feature-selection,0.4453258
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,selection,0.46716303,selection,1.0,feature-selection,0.6859601
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,approaches-may,0.57559586,artificial-intelligence,0.61427546,artificial-intelligence,0.61427546
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,candidate-selection,0.48441714,selection,0.70170665,feature-selection,0.693887
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,ml,0.29010946,bag,0.4418462,gradient,0.3396448
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,based,0.49998575,classification-algorithm,0.5639226,classification-algorithm,0.5639226
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,risk,0.35860935,recurrent,0.53675485,logistic-regression,0.52381086
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,stratification,0.45885193,classification-algorithm,0.6005924,classification-algorithm,0.6005924
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,system,0.3589455,generative-model,0.49815983,generative-model,0.49815983
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,based-risk,0.4441741,classification-algorithm,0.5520804,classification-algorithm,0.5520804
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,risk-stratification,0.56299007,classification-algorithm,0.6976296,classification-algorithm,0.6976296
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,stratification-system,0.6078895,classification-algorithm,0.7379116,classification-algorithm,0.7379116
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,patients,0.30007,recurrent,0.5332828,dropout,0.3918751
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,undergoing,0.27656338,short-term,0.4795418,long-short-term,0.4059016
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,crt,0.32862252,xgboost,0.42611885,xgboost,0.42611885
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,implantation,0.22275168,augmentation,0.43728024,data-augmentation,0.39965343
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,along,0.27615035,of,0.6050292,gradient,0.5078886
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,patients-undergoing,0.33248952,recurrent,0.5009053,segmentation-algorithm,0.42138797
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,crt-implantation,0.31165522,artificial-intelligence,0.41811883,artificial-intelligence,0.41811883
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,patients,0.30007,recurrent,0.5332828,dropout,0.3918751
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,undergoing,0.27656338,short-term,0.4795418,long-short-term,0.4059016
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,cardiac,0.29562658,of,0.42777455,long-short-term,0.35708636
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,resynchronization,0.39953724,regularization,0.47187176,data-augmentation,0.44759983
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,therapy,0.2707135,short-term,0.45926765,boosting,0.40244865
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,patients-undergoing,0.33248952,recurrent,0.5009053,segmentation-algorithm,0.42138797
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,cardiac-resynchronization,0.42309296,regularization,0.5030165,long-short-term,0.50235635
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,patients,0.30007,recurrent,0.5332828,dropout,0.3918751
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,undergoing,0.27656338,short-term,0.4795418,long-short-term,0.4059016
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,crt,0.32862252,xgboost,0.42611885,xgboost,0.42611885
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,implantation,0.22275168,augmentation,0.43728024,data-augmentation,0.39965343
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,patients-undergoing,0.33248952,recurrent,0.5009053,segmentation-algorithm,0.42138797
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,crt-implantation,0.31165522,artificial-intelligence,0.41811883,artificial-intelligence,0.41811883
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,patients,0.30007,recurrent,0.5332828,dropout,0.3918751
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,undergoing,0.27656338,short-term,0.4795418,long-short-term,0.4059016
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,crt,0.32862252,xgboost,0.42611885,xgboost,0.42611885
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,implantation,0.22275168,augmentation,0.43728024,data-augmentation,0.39965343
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,patients-undergoing,0.33248952,recurrent,0.5009053,segmentation-algorithm,0.42138797
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,crt-implantation,0.31165522,artificial-intelligence,0.41811883,artificial-intelligence,0.41811883
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,receiver,0.45132244,logistic,0.6124048,logistic-regression,0.57750404
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,operating,0.38906178,machine,0.49189845,graphics-processing,0.47077706
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,characteristic,0.34942827,feature,0.7124056,clustering,0.48287967
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,curves,0.3120853,linear,0.58335835,regression,0.52966225
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,receiver-operating,0.4694291,logistic,0.6941327,logistic-regression,0.6736918
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,operating-characteristic,0.503636,discriminative,0.62105864,principal-component-analysis,0.5886377
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,characteristic-curves,0.4370462,linear,0.5743904,principal-components,0.5698416
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,receiver-operating-characteristic,0.503338,logistic-regression,0.6653639,logistic-regression,0.6653639
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,exhibited,0.18898472,of,0.49406686,feature-reduction,0.35593373
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,good,0.29142508,few,0.4427599,bagging,0.41576368
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,discriminative,0.6014031,discriminative,1.0,classifiers,0.61642647
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,capabilities,0.5088383,feature-engineering,0.598551,feature-engineering,0.598551
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,seattle,0.33045092,federated,0.49662054,data-science,0.42863312
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,heart,0.28300244,rate,0.49867767,batch-normalization,0.3427502
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,failure,0.32964212,recurrent,0.52057266,confusion-matrix,0.44323406
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,model,0.48485535,model,1.0,markov-model,0.7005576
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,heart-failure,0.36450487,long-short-term,0.44014218,long-short-term,0.44014218
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,already,0.38231075,few,0.6682862,generative,0.4315048
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,existing,0.59232044,machine-learning,0.59232044,machine-learning,0.59232044
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,risk,0.35860935,recurrent,0.53675485,logistic-regression,0.52381086
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,scores,0.40591323,intelligence,0.56987673,principal-components,0.4971624
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,already-existing,0.511203,hidden,0.6549581,dimensionality-reduction,0.60767925
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,risk-scores,0.5303495,classification-algorithm,0.6701063,classification-algorithm,0.6701063
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,deaths,0.23965356,logistic-regression,0.3835408,logistic-regression,0.3835408
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,respectively,0.23184536,of,0.43360457,cross-validation,0.35765702
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,predict,0.51602554,model,0.53463185,classification-algorithm,0.52342355
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,multiple,0.39569393,of,0.53341115,regression,0.48948324
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,ml,0.29010946,bag,0.4418462,gradient,0.3396448
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,models,0.53762007,model,0.8940372,markov-model,0.7015921
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,patients,0.30007,recurrent,0.5332828,dropout,0.3918751
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,random,0.45551494,random,1.0,random-forest,0.65894985
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,forest,0.4787075,forest,1.0,random-forest,0.7738863
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,demonstrated,0.2929331,of,0.6025795,feature-reduction,0.39724052
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,random-forest,0.6331641,random-forest,1.0,random-forest,1.0
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,oxford,0.30943334,science,0.4440493,data-science,0.4327346
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,university,0.39088657,science,0.60339034,data-science,0.5440467
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,press,0.34600213,science,0.5130155,reinforcement-learning,0.49471456
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,implant,0.26786992,augmentation,0.46334848,computer-vision,0.44764102
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,clinical,0.44080526,data,0.48532635,data-science,0.45343333
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,features,0.51742536,feature,0.8268872,feature-selection,0.5487305
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,clinical-features,0.7113935,machine-learning,0.7113935,machine-learning,0.7113935
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,best,0.4535247,decision,0.5130525,classifiers,0.47293013
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,performing,0.5002452,supervised,0.5804485,supervised,0.5804485
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,model,0.48485535,model,1.0,markov-model,0.7005576
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,best-performing,0.60806346,classifiers,0.6350411,classifiers,0.6350411
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,crt,0.32862252,xgboost,0.42611885,xgboost,0.42611885
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,patients,0.30007,recurrent,0.5332828,dropout,0.3918751
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,crt-patients,0.33636093,dropout,0.4246713,dropout,0.4246713
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,estimated,0.3423246,rate,0.5632778,regression,0.49483663
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,risk,0.35860935,recurrent,0.53675485,logistic-regression,0.52381086
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,existing,0.59232044,machine-learning,0.59232044,machine-learning,0.59232044
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,scores,0.40591323,intelligence,0.56987673,principal-components,0.4971624
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,crt,0.32862252,xgboost,0.42611885,xgboost,0.42611885
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,score,0.38515997,classification-algorithm,0.5352135,classification-algorithm,0.5352135
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,crt-score,0.5320836,classification-algorithm,0.62816477,classification-algorithm,0.62816477
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,crt,0.32862252,xgboost,0.42611885,xgboost,0.42611885
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,discriminative,0.6014031,discriminative,1.0,classifiers,0.61642647
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,ability,0.39144984,function,0.5937173,generative,0.47758824
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,evaluated,0.35501102,of,0.6190806,supervised,0.4124783
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,scores,0.40591323,intelligence,0.56987673,principal-components,0.4971624
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,score,0.38515997,classification-algorithm,0.5352135,classification-algorithm,0.5352135
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,implant,0.26786992,augmentation,0.46334848,computer-vision,0.44764102
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,parameters,0.38939354,normalization,0.54973936,batch-normalization,0.547323
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,best,0.4535247,decision,0.5130525,classifiers,0.47293013
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,performance,0.50728506,learning-function,0.63351834,learning-function,0.63351834
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,best-performance,0.6208144,machine-learning,0.6208144,machine-learning,0.6208144
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,training,0.54553735,learning,0.69909495,supervised,0.6973169
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,cohort,0.3892265,logistic-regression,0.5412916,logistic-regression,0.5412916
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,training-cohort,0.56637955,supervised,0.62740886,supervised,0.62740886
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,test,0.4037762,statistical,0.5031551,statistical,0.5031551
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,cohort,0.3892265,logistic-regression,0.5412916,logistic-regression,0.5412916
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,retrospective,0.41400534,data,0.524399,logistic-regression,0.49798495
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,database,0.5014348,data,0.6331146,data-science,0.5991977
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,personalized,0.5869211,data-engineering,0.6371769,data-engineering,0.6371769
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,assessment,0.4002061,analysis,0.5275976,component-analysis,0.49803802
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,machine,0.7094662,machine,1.0,machine-learning,0.7094662
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,learning,0.709237,learning,1.0,deep-learning,0.8286492
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,machine-learning,1.0,machine-learning,1.0,machine-learning,1.0
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,linear,0.42916322,linear,0.99999994,regression,0.66034734
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,association,0.32292235,regression,0.5094141,regression,0.5094141
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,linear-association,0.5390345,linear,0.66817987,cross-entropy,0.6278651
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,independent,0.39991486,of,0.5904635,regression,0.57876456
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,cohort,0.3892265,logistic-regression,0.5412916,logistic-regression,0.5412916
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,european,0.25183123,federated,0.5800549,data-science,0.42842963
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,society,0.29418135,science,0.5518952,data-science,0.5205302
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,cause,0.19388393,of,0.47843847,confusion-matrix,0.34079778
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,death,0.21479979,of,0.42234862,dropout,0.37818787
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,cause-death,0.3774225,logistic-regression,0.49973837,logistic-regression,0.49973837
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,year,0.310051,one,0.48338404,supervised,0.40979916
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,follow,0.28552625,tracking,0.48513734,batch-normalization,0.39173082
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,year-follow,0.45824456,random-forest,0.503012,random-forest,0.503012
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,cause,0.19388393,of,0.47843847,confusion-matrix,0.34079778
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,mortality,0.2609817,short-term,0.505676,logistic-regression,0.49414968
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,cause-mortality,0.3407904,logistic-regression,0.5863885,logistic-regression,0.5863885
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,trained,0.56898797,supervised,0.69370055,supervised,0.69370055
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,classifiers,0.8333409,classifiers,1.0,classifiers,1.0
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,three,0.36911732,one,0.78425425,clustering,0.4299444
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,pre,0.25544113,confusion,0.45880464,supervised,0.38061306
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,year,0.310051,one,0.48338404,supervised,0.40979916
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,mortality,0.2609817,short-term,0.505676,logistic-regression,0.49414968
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,year-mortality,0.32198924,logistic-regression,0.59586096,logistic-regression,0.59586096
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,crt,0.32862252,xgboost,0.42611885,xgboost,0.42611885
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,model,0.48485535,model,1.0,markov-model,0.7005576
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,models,0.53762007,model,0.8940372,markov-model,0.7015921
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,year,0.310051,one,0.48338404,supervised,0.40979916
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,mortality,0.2609817,short-term,0.505676,logistic-regression,0.49414968
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,trained,0.56898797,supervised,0.69370055,supervised,0.69370055
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,pre,0.25544113,confusion,0.45880464,supervised,0.38061306
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,valid,0.43003386,discriminative,0.5328561,dimensionality-reduction,0.4960052
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,utilization,0.3202109,of,0.5174322,data-engineering,0.46732223
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,train,0.54995465,learning,0.60963345,learning-rate,0.5978736
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,thirty,0.328524,one,0.5351969,machine-learning,0.328524
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,tested,0.37172255,of,0.5634051,boosting,0.4195229
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,superior,0.3107968,convolutional-layer,0.48167366,convolutional-layer,0.48167366
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,semmelweis,0.29981518,science,0.52076197,data-science,0.4734311
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,selected,0.38157707,selection,0.6797303,feature-selection,0.48698312
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,screen,0.37577426,feature-selection,0.4468516,feature-selection,0.4468516
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,results,0.32376552,data,0.6932311,batch-normalization,0.44826904
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,published,0.42179614,data,0.6147139,data-science,0.54664624
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,prognostication,0.52734506,classification,0.6003281,classification,0.6003281
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,predictors,0.46376368,logistic,0.67381907,logistic-regression,0.66900885
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,prediction,0.6361519,classification-algorithm,0.67946094,classification-algorithm,0.67946094
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,period,0.19663066,short-term,0.5791412,long-short-term,0.5108645
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,p,0.26795468,support,0.40805867,regression,0.40253854
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,outperformed,0.597012,classifiers,0.62406605,classifiers,0.62406605
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,non,0.2869836,of,0.5523051,generative,0.4181043
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,methods,0.50049126,data,0.5400177,machine-learning,0.50049126
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,eaarn,0.27176046,relu,0.36953267,relu,0.36953267
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,develop,0.4619095,generative,0.52892005,generative,0.52892005
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,conclusion,0.35530132,data,0.5299138,long-short-term,0.45073265
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,com,0.2709802,forward,0.4350169,component-analysis,0.39468163
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,ci,0.2746623,logistic,0.43534693,logistic-regression,0.38379127
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,cardiology,0.36460787,data-science,0.5008054,data-science,0.5008054
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,capturing,0.5054417,tracking,0.64595747,data-engineering,0.54683834
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,behalf,0.26374853,adversarial,0.5247171,data-science,0.51911336
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,available,0.4144769,data,0.62807965,data-science,0.46192533
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,author,0.4029289,adversarial,0.58311844,data-science,0.55950665
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,areas,0.3090546,forest,0.4990691,ground-truth,0.40763968
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,among,0.33676732,of,0.57348,clustering,0.49404603
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,aims,0.42995954,of,0.465683,feature-engineering,0.4555406
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,aim,0.4029312,feature-engineering,0.41751927,feature-engineering,0.41751927
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,separate,0.43314856,one,0.6195628,principal-components,0.56720483
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,alarm,0.36723477,confusion,0.4937298,bagging,0.48478365
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,types,0.34274656,components,0.5868779,classification,0.4932717
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,leads,0.24188918,of,0.52666616,long-short-term,0.42311493
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,significant,0.29367286,statistical,0.582669,statistical,0.582669
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,results,0.32376552,data,0.6932311,batch-normalization,0.44826904
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,proposed,0.55786884,classification-algorithm,0.6311488,classification-algorithm,0.6311488
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,method,0.482283,algorithm,0.63295126,algorithm,0.63295126
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,obtains,0.47235447,cross-entropy,0.5800483,cross-entropy,0.5800483
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,better,0.4230538,of,0.5337099,feature-reduction,0.47485045
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,results,0.32376552,data,0.6932311,batch-normalization,0.44826904
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,compared,0.3359061,of,0.52794564,long-short-term,0.42386633
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,proposed-method,0.58707035,segmentation-algorithm,0.64815617,segmentation-algorithm,0.64815617
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,results-compared,0.4718868,data,0.59823704,batch-normalization,0.52176905
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,considering,0.45019245,of,0.67813045,dimensionality-reduction,0.55091655
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,three,0.36911732,one,0.78425425,clustering,0.4299444
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,different,0.37681934,of,0.61590904,clustering,0.46857932
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,signals,0.3700128,components,0.5488684,feed-forward,0.52579325
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,three-different,0.4282337,convolutional-layer,0.5688442,convolutional-layer,0.5688442
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,apply,0.5701554,machine-learning,0.5701554,machine-learning,0.5701554
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,convolutional,0.77214557,convolutional,1.0,convolutional,1.0
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,neural,0.5080686,neural,1.0,neural-network,0.7153882
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,networks,0.53880787,network,0.91573685,neural-network,0.776492
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,neural-networks,0.6930727,neural-network,0.983446,neural-network,0.983446
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,convolutional-neural-networks,0.719952,neural-network,0.9242079,neural-network,0.9242079
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,classical,0.4391411,component-analysis,0.5297215,component-analysis,0.5297215
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,machine,0.7094662,machine,1.0,machine-learning,0.7094662
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,learning,0.709237,learning,1.0,deep-learning,0.8286492
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,approaches,0.55614823,feature-engineering,0.60571706,feature-engineering,0.60571706
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,machine-learning,1.0,machine-learning,1.0,machine-learning,1.0
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,learning-approaches,0.67542875,learning,0.83603513,reinforcement-learning,0.78956765
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,ventricular,0.24852064,rate,0.37094042,long-short-term,0.34148398
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,tachycardia,0.24803029,confusion,0.47294974,backpropagation,0.36588052
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,arrhythmia,0.31342128,recurrent,0.4357065,long-short-term,0.4199577
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,ventricular-tachycardia,0.29253852,recurrent-neural-network,0.42605597,recurrent-neural-network,0.42605597
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,false,0.35507816,truth,0.5399609,overfitting,0.4766646
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,alarm,0.36723477,confusion,0.4937298,bagging,0.48478365
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,reduction,0.22531602,reduction,1.0,feature-reduction,0.59547573
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,task,0.5084964,object-tracking,0.69268537,object-tracking,0.69268537
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,false-alarm,0.38646132,overfitting,0.53979486,overfitting,0.53979486
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,true,0.33280522,hidden,0.5787613,cross-entropy,0.49111807
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,alarms,0.39792955,bagging,0.49223575,bagging,0.49223575
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,using,0.47332245,analysis,0.5968549,component-analysis,0.526608
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,single,0.31087106,one,0.6951874,one-shot,0.4602274
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,evaluation,0.39017528,analysis,0.5728766,component-analysis,0.5049392
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,results,0.32376552,data,0.6932311,batch-normalization,0.44826904
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,demonstrate,0.37134898,of,0.5097414,feature-engineering,0.4652517
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,results-demonstrate,0.45842522,data,0.60937816,dimensionality-reduction,0.53237516
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,proposed,0.55786884,classification-algorithm,0.6311488,classification-algorithm,0.6311488
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,method,0.482283,algorithm,0.63295126,algorithm,0.63295126
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,achieves,0.44483572,algorithm,0.54118717,algorithm,0.54118717
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,proposed-method,0.58707035,segmentation-algorithm,0.64815617,segmentation-algorithm,0.64815617
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,method,0.482283,algorithm,0.63295126,algorithm,0.63295126
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,efficiently,0.40916896,fully,0.5936789,boosting,0.5113429
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,using,0.47332245,analysis,0.5968549,component-analysis,0.526608
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,deep,0.38070458,deep,0.99999994,deep-learning,0.4875875
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,learning,0.709237,learning,1.0,deep-learning,0.8286492
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,model,0.48485535,model,1.0,markov-model,0.7005576
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,deep-learning,0.80843407,deep-learning,1.0,deep-learning,1.0
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,cardiology,0.36460787,data-science,0.5008054,data-science,0.5008054
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,challenge,0.32916635,boosting,0.49348646,boosting,0.49348646
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,term,0.33795053,term,1.0,long-short-term,0.62770975
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,memory,0.4292574,memory,1.0,short-term-memory,0.84619105
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,units,0.22430237,unit,0.8786867,graphics-processing-unit,0.4210918
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,term-memory,0.5094611,term-memory,1.0,short-term-memory,0.9158474
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,memory-units,0.45511383,memory,0.7794356,short-term-memory,0.72868276
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,temporal,0.34829444,semantic,0.54608697,semantic,0.54608697
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,information,0.5191034,data,0.708436,data-science,0.5937191
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,presented,0.41586217,of,0.5919795,confusion-matrix,0.4850164
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,temporal-information,0.63289034,natural-language-processing,0.7390524,natural-language-processing,0.7390524
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,requiring,0.34214786,bagging,0.5274158,bagging,0.5274158
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,prior,0.3322774,of,0.5738043,bagging,0.45032665
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,knowledge,0.5362035,science,0.551701,data-science,0.5440523
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,prior-knowledge,0.7137895,machine-learning,0.7137895,machine-learning,0.7137895
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,intensive,0.3777817,unit,0.63598263,supervised,0.5086147
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,care,0.3144728,decision,0.58130515,data-science,0.46943653
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,units,0.22430237,unit,0.8786867,graphics-processing-unit,0.4210918
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,intensive-care,0.3613196,unit,0.6286151,supervised,0.43243152
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,care-units,0.28602797,unit,0.62475854,graphics-processing-unit,0.49246418
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,intensive-care-units,0.335075,unit,0.6964505,graphics-processing-unit,0.47762764
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,automatically,0.65330756,segmentation,0.6840899,segmentation,0.6840899
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,extract,0.38952202,components,0.49913663,kernel,0.46366778
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,time,0.31186903,long,0.57547164,batch-normalization,0.47628766
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,segmented,0.47492567,segmentation,0.7682447,segmentation,0.7682447
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,input,0.49092877,feed-forward,0.58275104,feed-forward,0.58275104
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,signal,0.35809803,cascade,0.5273956,segmentation,0.5076722
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,input-signal,0.49023712,feed-forward,0.6825534,feed-forward,0.6825534
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,step,0.34883037,forward,0.61124456,feature-reduction,0.52921283
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,training,0.54553735,learning,0.69909495,supervised,0.6973169
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,algorithm,0.7180419,algorithm,1.0,algorithm,1.0
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,step-training,0.4957015,reinforcement-learning,0.6602988,reinforcement-learning,0.6602988
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,e,0.13297717,natural,0.39189428,component-analysis,0.28603846
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,pre,0.25544113,confusion,0.45880464,supervised,0.38061306
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,false,0.35507816,truth,0.5399609,overfitting,0.4766646
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,alarms,0.39792955,bagging,0.49223575,bagging,0.49223575
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,false-alarms,0.3914136,overfitting,0.5578419,overfitting,0.5578419
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,proposed,0.55786884,classification-algorithm,0.6311488,classification-algorithm,0.6311488
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,network,0.50771487,network,1.0,neural-network,0.7589166
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,alarm,0.36723477,confusion,0.4937298,bagging,0.48478365
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,type,0.21671848,of,0.48202556,classification,0.43098688
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,alarm,0.36723477,confusion,0.4937298,bagging,0.48478365
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,classification,0.5994266,classification,1.0,classification,1.0
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,arrhythmia,0.31342128,recurrent,0.4357065,long-short-term,0.4199577
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,analysis,0.46507934,analysis,0.99999994,component-analysis,0.69613737
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,signal,0.35809803,cascade,0.5273956,segmentation,0.5076722
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,segments,0.20835683,long,0.50645375,segmentation,0.5040661
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,g,0.17250246,feed,0.40076,n-gram,0.27758121
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,without,0.31691062,of,0.5951073,long-short-term,0.4268921
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,ignoring,0.4645506,overfitting,0.66261554,overfitting,0.66261554
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,study,0.3645851,of,0.5728763,statistical,0.44204497
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,proposes,0.58663464,generative,0.62937045,generative,0.62937045
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,physionet,0.5939415,machine-learning,0.5939415,machine-learning,0.5939415
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,computing,0.68506473,computer,0.71702296,graphics-processing,0.71574765
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,modal,0.38678244,generative,0.5693065,generative,0.5693065
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,biosignals,0.5487596,graphics-processing,0.5676129,graphics-processing,0.5676129
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,long,0.20028201,long,1.0,long-short-term,0.6505779
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,short,0.24294135,short,0.99999994,long-short-term,0.66049826
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,long-short,0.2976559,long-short,1.0,long-short-term,0.8378484
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,lead,0.26196307,of,0.48279357,long-short-term,0.38915557
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,ecg,0.36941645,regularization,0.4321748,batch-normalization,0.42148602
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,lead-ecg,0.30319262,ground-truth,0.3875106,ground-truth,0.3875106
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,invariant,0.40743944,feature,0.55612445,stochastic,0.5271915
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,features,0.51742536,feature,0.8268872,feature-selection,0.5487305
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,important,0.33620566,principal,0.5803634,feature-engineering,0.43471682
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,regions,0.3024192,segmentation,0.47672227,segmentation,0.47672227
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,existing,0.59232044,machine-learning,0.59232044,machine-learning,0.59232044
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,algorithms,0.7612198,algorithm,0.9050166,algorithm,0.9050166
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,engineered,0.37719113,engineering,0.7976402,feature-engineering,0.6990664
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,features,0.51742536,feature,0.8268872,feature-selection,0.5487305
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,either,0.26875237,of,0.590966,long-short-term,0.46668065
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,rule,0.4328546,algorithm,0.54952157,algorithm,0.54952157
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,effectively,0.35745823,fully,0.574593,boosting,0.5027187
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,suppresses,0.20229673,function,0.46377707,boosting,0.43847156
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,dataset,0.6046342,data,0.68842554,classifiers,0.6499833
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,provided,0.3982859,of,0.61110586,supervised,0.49344742
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,build,0.6148592,data-engineering,0.644665,data-engineering,0.644665
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,rules,0.55864805,classification-algorithm,0.6441051,classification-algorithm,0.6441051
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,based,0.49998575,classification-algorithm,0.5639226,classification-algorithm,0.5639226
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,methods,0.50049126,data,0.5400177,machine-learning,0.50049126
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,based-methods,0.55121374,principal-component-analysis,0.5691826,principal-component-analysis,0.5691826
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,attention,0.39793617,memory,0.5744239,learning-function,0.5478152
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,mechanism,0.2780391,cascade,0.59194523,feed-forward,0.5341974
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,current,0.3530666,rectified,0.52906346,generative-model,0.40904555
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,work,0.42713583,support,0.5373766,learning-function,0.5011815
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,alarm,0.36723477,confusion,0.4937298,bagging,0.48478365
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,single,0.31087106,one,0.6951874,one-shot,0.4602274
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,training,0.54553735,learning,0.69909495,supervised,0.6973169
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,e,0.13297717,natural,0.39189428,component-analysis,0.28603846
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,work,0.42713583,support,0.5373766,learning-function,0.5011815
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,two,0.35955608,one,0.79919666,clustering,0.43817294
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,tuning,0.40517503,learning-function,0.57897633,learning-function,0.57897633
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,trained,0.56898797,supervised,0.69370055,supervised,0.69370055
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,specificity,0.3365721,discriminative,0.5238579,cross-validation,0.4765169
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,sensitivity,0.28808302,discriminative,0.5372434,cross-validation,0.48943394
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,put,0.404855,forward,0.58324677,bagging,0.5284234
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,multi,0.37771758,multi-class,0.4810482,segmentation,0.43055838
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,literature,0.42831737,data,0.58552843,data-science,0.5381381
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,likely,0.28872275,one,0.55131567,generative,0.3953101
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,icus,0.36236465,unit,0.5851696,supervised,0.41840452
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,hand,0.3085481,of,0.49105775,one-hot,0.40915227
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,fine,0.34155148,deep,0.5234429,generative,0.45868355
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,experiments,0.36827093,data,0.55053914,stochastic-gradient,0.48057425
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,emphasis,0.38577473,of,0.5659702,feature-engineering,0.5268483
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,depending,0.24005598,of,0.5352007,gradient,0.37833202
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,contribute,0.30676693,of,0.5196437,feed-forward,0.40432224
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,consider,0.39825162,decision,0.60730267,stochastic,0.47927415
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,capture,0.4189438,tracking,0.5820073,object-tracking,0.4910211
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,auc,0.32985288,cross-validation,0.5105883,cross-validation,0.5105883
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,addition,0.30500388,of,0.6910241,feature-reduction,0.48914018
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,investigate,0.3396353,of,0.48247698,feature-engineering,0.41061842
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,blood,0.16939776,normalization,0.4272251,batch-normalization,0.40715772
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,glucose,0.22612295,batch-normalization,0.39605165,batch-normalization,0.39605165
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,control,0.27050394,of,0.5093193,artificial-intelligence,0.40948874
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,among,0.33676732,of,0.57348,clustering,0.49404603
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,patients,0.30007,recurrent,0.5332828,dropout,0.3918751
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,blood-glucose,0.2670272,batch-normalization,0.4206398,batch-normalization,0.4206398
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,glucose-control,0.28146687,batch,0.46154743,batch-normalization,0.40631634
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,back,0.29330805,bagging,0.50546145,bagging,0.50546145
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,propagation,0.3947974,backpropagation,0.6999179,backpropagation,0.6999179
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,artificial,0.4622418,artificial,1.0,artificial-intelligence,0.6597898
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,neural,0.5080686,neural,1.0,neural-network,0.7153882
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,network,0.50771487,network,1.0,neural-network,0.7589166
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,back-propagation,0.67986405,backpropagation,0.9545809,backpropagation,0.9545809
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,propagation-artificial,0.610842,backpropagation,0.7285884,backpropagation,0.7285884
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,artificial-neural,0.5541204,recurrent-neural-network,0.7487964,recurrent-neural-network,0.7487964
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,neural-network,0.7034505,neural-network,1.0,neural-network,1.0
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,back-propagation-artificial,0.69574845,backpropagation,0.85061574,backpropagation,0.85061574
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,artificial-neural-network,0.6767229,neural-network,0.9082352,neural-network,0.9082352
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,three,0.36911732,one,0.78425425,clustering,0.4299444
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,common,0.32574984,feature,0.5597373,clustering,0.43115532
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,machine,0.7094662,machine,1.0,machine-learning,0.7094662
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,learning,0.709237,learning,1.0,deep-learning,0.8286492
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,algorithms,0.7612198,algorithm,0.9050166,algorithm,0.9050166
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,machine-learning,1.0,machine-learning,1.0,machine-learning,1.0
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,machine-learning-algorithms,0.93336535,machine-learning,0.93336535,machine-learning,0.93336535
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,rf,0.349212,xgboost,0.44135672,xgboost,0.44135672
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,support,0.3815906,support,1.0,support-vector,0.66958183
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,vector,0.45570993,vector,1.0,vector-machine,0.7596456
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,machine,0.7094662,machine,1.0,machine-learning,0.7094662
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,support-vector,0.6102658,support-vector,1.0,support-vector,1.0
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,vector-machine,0.68567467,vector-machine,1.0,vector-machine,1.0
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,support-vector-machine,0.71415544,support-vector-machine,1.0,support-vector-machine,1.0
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,controlled,0.25206095,of,0.4703986,supervised,0.39651048
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,blood,0.16939776,normalization,0.4272251,batch-normalization,0.40715772
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,glucose,0.22612295,batch-normalization,0.39605165,batch-normalization,0.39605165
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,rate,0.24866687,rate,1.0,dropout,0.44953537
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,controlled-blood,0.33641487,batch,0.52279115,batch-normalization,0.52129084
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,blood-glucose,0.2670272,batch-normalization,0.4206398,batch-normalization,0.4206398
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,glucose-rate,0.2790258,rate,0.39101517,gradient-descent,0.36261845
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,predict,0.51602554,model,0.53463185,classification-algorithm,0.52342355
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,blood,0.16939776,normalization,0.4272251,batch-normalization,0.40715772
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,glucose,0.22612295,batch-normalization,0.39605165,batch-normalization,0.39605165
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,status,0.24755386,confusion,0.47135156,classification,0.37683836
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,blood-glucose,0.2670272,batch-normalization,0.4206398,batch-normalization,0.4206398
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,atherosclerotic,0.24541524,of,0.33148155,generative-model,0.3187185
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,cardiovascular,0.31674606,short-term,0.442761,learning-function,0.4027721
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,disease,0.296938,recurrent,0.4731025,classification,0.35271814
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,history,0.32837912,recurrent,0.5897511,regression,0.3962426
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,atherosclerotic-cardiovascular,0.29341784,logistic-regression,0.36804122,logistic-regression,0.36804122
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,cardiovascular-disease,0.39733815,logistic-regression,0.43556237,logistic-regression,0.43556237
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,disease-history,0.40492538,recurrent,0.51072866,generative-model,0.45912486
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,atherosclerotic-cardiovascular-disease,0.3574118,logistic-regression,0.419603,logistic-regression,0.419603
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,consecutive,0.32570636,one,0.46467566,long-short-term,0.38155502
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,participants,0.4160846,object-tracking,0.5017827,object-tracking,0.5017827
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,recruited,0.32712573,federated,0.46469644,supervised,0.46036208
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,type,0.21671848,of,0.48202556,classification,0.43098688
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,diabetes,0.29301462,logistic-regression,0.35688502,logistic-regression,0.35688502
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,mellitus,0.26868707,logistic,0.37140065,logistic-regression,0.36157686
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,diabetes-mellitus,0.22767697,logistic-regression,0.32544836,logistic-regression,0.32544836
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,blood,0.16939776,normalization,0.4272251,batch-normalization,0.40715772
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,glucose,0.22612295,batch-normalization,0.39605165,batch-normalization,0.39605165
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,control,0.27050394,of,0.5093193,artificial-intelligence,0.40948874
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,blood-glucose,0.2670272,batch-normalization,0.4206398,batch-normalization,0.4206398
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,glucose-control,0.28146687,batch,0.46154743,batch-normalization,0.40631634
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,machine,0.7094662,machine,1.0,machine-learning,0.7094662
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,learning,0.709237,learning,1.0,deep-learning,0.8286492
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,algorithms,0.7612198,algorithm,0.9050166,algorithm,0.9050166
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,machine-learning,1.0,machine-learning,1.0,machine-learning,1.0
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,machine-learning-algorithms,0.93336535,machine-learning,0.93336535,machine-learning,0.93336535
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,predict,0.51602554,model,0.53463185,classification-algorithm,0.52342355
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,glycemic,0.2709547,short-term,0.46233743,long-short-term,0.40283203
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,control,0.27050394,of,0.5093193,artificial-intelligence,0.40948874
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,glycemic-control,0.32543755,reinforcement-learning,0.45738462,reinforcement-learning,0.45738462
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,machine,0.7094662,machine,1.0,machine-learning,0.7094662
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,learning,0.709237,learning,1.0,deep-learning,0.8286492
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,models,0.53762007,model,0.8940372,markov-model,0.7015921
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,machine-learning,1.0,machine-learning,1.0,machine-learning,1.0
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,poor,0.31379676,confusion,0.5027573,long-short-term,0.43808374
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,glycemic,0.2709547,short-term,0.46233743,long-short-term,0.40283203
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,control,0.27050394,of,0.5093193,artificial-intelligence,0.40948874
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,poor-glycemic,0.248357,short-term,0.45986652,long-short-term,0.41630745
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,glycemic-control,0.32543755,reinforcement-learning,0.45738462,reinforcement-learning,0.45738462
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,poor-glycemic-control,0.31512585,short-term,0.47569674,reinforcement-learning,0.47284377
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,multivariable,0.4951204,logistic,0.92394704,logistic-regression,0.87944424
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,analysis,0.46507934,analysis,0.99999994,component-analysis,0.69613737
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,found,0.2840244,of,0.6208722,clustering,0.44675255
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,multivariable-analysis,0.5803782,logistic-regression,0.81528103,logistic-regression,0.81528103
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,multicenter,0.3527286,data,0.45474106,data-science,0.40863585
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,study,0.3645851,of,0.5728763,statistical,0.44204497
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,aimed,0.41358173,of,0.52896386,feature-engineering,0.45929232
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,multicenter-study,0.4196073,decision-tree,0.4834358,decision-tree,0.4834358
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,study-aimed,0.48830283,data-science,0.57568187,data-science,0.57568187
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,collected,0.33035916,data,0.5686942,ground-truth,0.3838368
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,via,0.29305607,connected,0.5425352,feed-forward,0.46278888
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,questionnaire,0.36053145,style,0.5356899,computer-vision,0.49106652
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,building,0.47144645,feature-engineering,0.6313234,feature-engineering,0.6313234
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,predictive,0.55290145,cross-validation,0.6141345,cross-validation,0.6141345
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,models,0.53762007,model,0.8940372,markov-model,0.7015921
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,address,0.44480386,data-engineering,0.55924773,data-engineering,0.55924773
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,variable,0.37856048,of,0.60098064,regression,0.54398334
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,collinearity,0.4452989,cross-entropy,0.6942476,cross-entropy,0.6942476
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,traditional,0.49153316,style,0.54303825,dimensionality-reduction,0.5295658
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,logistic,0.5418149,logistic,1.0,logistic-regression,0.9215903
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,model,0.48485535,model,1.0,markov-model,0.7005576
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,logistic-model,0.64029217,logistic-regression,0.83197933,logistic-regression,0.83197933
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,stepwise,0.44603032,regression,0.64645815,regression,0.64645815
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,logistic,0.5418149,logistic,1.0,logistic-regression,0.9215903
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,regression,0.4967034,regression,1.0,regression,1.0
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,stepwise-logistic,0.63347363,logistic-regression,0.81944203,logistic-regression,0.81944203
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,logistic-regression,0.5787163,logistic-regression,0.99999994,logistic-regression,0.99999994
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,logistic,0.5418149,logistic,1.0,logistic-regression,0.9215903
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,regression,0.4967034,regression,1.0,regression,1.0
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,models,0.53762007,model,0.8940372,markov-model,0.7015921
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,logistic-regression,0.5787163,logistic-regression,0.99999994,logistic-regression,0.99999994
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,regression-models,0.62212193,logistic-regression,0.784806,logistic-regression,0.784806
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,logistic-regression-models,0.65618646,logistic-regression,0.9369557,logistic-regression,0.9369557
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,developing,0.3854496,generative,0.5648606,generative,0.5648606
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,diabetic,0.24483135,of,0.40444782,generative-model,0.34931552
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,complications,0.26551193,recurrent,0.5320816,overfitting,0.39361054
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,blood,0.16939776,normalization,0.4272251,batch-normalization,0.40715772
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,pressure,0.2060274,gradient,0.4962673,gradient,0.4962673
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,blood-pressure,0.2672683,batch-normalization,0.4510358,batch-normalization,0.4510358
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,elastic,0.33551437,matrix,0.5838161,convolutional-layer,0.55458903
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,network,0.50771487,network,1.0,neural-network,0.7589166
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,elastic-network,0.54883814,neural-network,0.7880025,neural-network,0.7880025
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,learning,0.709237,learning,1.0,deep-learning,0.8286492
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,algorithm,0.7180419,algorithm,1.0,algorithm,1.0
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,svm,0.7572857,classifiers,0.82308555,classifiers,0.82308555
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,patients,0.30007,recurrent,0.5332828,dropout,0.3918751
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,family,0.2727693,support,0.5085263,clustering,0.40444815
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,history,0.32837912,recurrent,0.5897511,regression,0.3962426
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,family-history,0.4140233,logistic-regression,0.5042606,logistic-regression,0.5042606
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,centers,0.2627507,unit,0.52476054,fully-connected,0.41052085
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,january,0.2596028,science,0.43337005,data-science,0.36495665
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,december,0.26343572,science,0.4644758,data-science,0.38875848
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,hypertension,0.28340828,dropout,0.4223115,dropout,0.4223115
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,history,0.32837912,recurrent,0.5897511,regression,0.3962426
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,en,0.24416539,of,0.39597213,relu,0.3923469
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,regression,0.4967034,regression,1.0,regression,1.0
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,total,0.21723771,of,0.5102532,principal-components,0.3630478
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,cholesterol,0.15921682,reduction,0.33627644,gradient,0.32767534
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,total-cholesterol,0.20466265,batch-normalization,0.41337907,batch-normalization,0.41337907
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,six,0.34044427,one,0.7164377,supervised,0.39660886
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,cities,0.3682479,forest,0.5913323,random-forest,0.5352074
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,six-cities,0.450876,data-science,0.5188091,data-science,0.5188091
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,risk,0.35860935,recurrent,0.53675485,logistic-regression,0.52381086
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,factors,0.3420733,components,0.5413606,logistic-regression,0.48293567
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,risk-factors,0.40161455,logistic-regression,0.57501113,logistic-regression,0.57501113
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,related,0.30849367,of,0.6150687,clustering,0.41455543
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,data,0.46434748,data,1.0,data-science,0.5533528
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,related-data,0.5691057,decision-tree,0.5942725,decision-tree,0.5942725
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,random,0.45551494,random,1.0,random-forest,0.65894985
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,forest,0.4787075,forest,1.0,random-forest,0.7738863
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,random-forest,0.6331641,random-forest,1.0,random-forest,1.0
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,protective,0.2287128,boosting,0.50660264,boosting,0.50660264
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,factors,0.3420733,components,0.5413606,logistic-regression,0.48293567
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,north,0.2755952,forest,0.57288945,random-forest,0.4948758
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,china,0.33313718,forest,0.5247432,random-forest,0.43039554
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,north-china,0.2537488,forest,0.5435156,random-forest,0.522511
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,higher,0.27819592,reduction,0.545787,boosting,0.41506222
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,risk,0.35860935,recurrent,0.53675485,logistic-regression,0.52381086
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,higher-risk,0.39451247,classification-algorithm,0.4998359,classification-algorithm,0.4998359
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,glycosylated,0.22923844,encoding,0.38698512,graphics-processing-unit,0.31008467
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,hemoglobin,0.17575482,unit,0.36903322,batch-normalization,0.35301796
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,glycosylated-hemoglobin,0.2868504,fourier-transform,0.38377392,fourier-transform,0.38377392
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,figures,0.32811058,embeddings,0.4922109,embeddings,0.4922109
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,increased,0.26921988,reduction,0.6514183,boosting,0.46515882
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,dimensional,0.48426318,dimensionality,0.8024132,dimensionality-reduction,0.765376
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,reduction,0.22531602,reduction,1.0,feature-reduction,0.59547573
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,dimensional-reduction,0.500841,dimensionality-reduction,0.8667338,dimensionality-reduction,0.8667338
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,closely,0.2736098,of,0.49007973,clustering,0.38611364
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,related,0.30849367,of,0.6150687,clustering,0.41455543
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,closely-related,0.367908,encoding,0.5209203,clustering,0.5133598
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,central,0.26715183,connected,0.51433957,segmentation,0.35878396
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,adiposity,0.28871882,regression,0.44370317,regression,0.44370317
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,biochemical,0.38832766,of,0.4984446,batch-normalization,0.4401914
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,indices,0.35250193,normalization,0.5109062,batch-normalization,0.46939105
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,basic,0.41761222,feature-engineering,0.51117486,feature-engineering,0.51117486
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,information,0.5191034,data,0.708436,data-science,0.5937191
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,application,0.46535254,data-engineering,0.5603031,data-engineering,0.5603031
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,value,0.3544725,of,0.52001536,statistical,0.45314136
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,application-value,0.61441076,segmentation-algorithm,0.64666367,segmentation-algorithm,0.64666367
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,alternative,0.40815938,selection,0.5193968,feature-reduction,0.51698333
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,choices,0.44790885,decision,0.7299797,reinforcement-learning,0.5794667
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,duration,0.2387858,long,0.5601611,long-short-term,0.53869605
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,treated,0.19958335,of,0.5218221,long-short-term,0.35705733
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,respectively,0.23184536,of,0.43360457,cross-validation,0.35765702
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,insulin,0.22629064,unit,0.40084893,batch-normalization,0.32209873
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,dose,0.24218819,shot,0.48689568,boosting,0.43495926
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,insulin-dose,0.22419454,batch-normalization,0.36583662,batch-normalization,0.36583662
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,higher,0.27819592,reduction,0.545787,boosting,0.41506222
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,sensitivity,0.28808302,discriminative,0.5372434,cross-validation,0.48943394
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,higher-sensitivity,0.37772757,of,0.5459686,feature-selection,0.5415414
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,elevated,0.19494015,normalization,0.5246306,batch-normalization,0.44167417
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,ann,0.57569355,perceptron,0.68935764,perceptron,0.68935764
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,machine,0.7094662,machine,1.0,machine-learning,0.7094662
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,control,0.27050394,of,0.5093193,artificial-intelligence,0.40948874
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,rf,0.349212,xgboost,0.44135672,xgboost,0.44135672
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,patients,0.30007,recurrent,0.5332828,dropout,0.3918751
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,logistic,0.5418149,logistic,1.0,logistic-regression,0.9215903
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,diabetes,0.29301462,logistic-regression,0.35688502,logistic-regression,0.35688502
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,complications,0.26551193,recurrent,0.5320816,overfitting,0.39361054
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,svm,0.7572857,classifiers,0.82308555,classifiers,0.82308555
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,sensitivity,0.28808302,discriminative,0.5372434,cross-validation,0.48943394
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,respectively,0.23184536,of,0.43360457,cross-validation,0.35765702
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,insulin,0.22629064,unit,0.40084893,batch-normalization,0.32209873
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,hypertension,0.28340828,dropout,0.4223115,dropout,0.4223115
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,en,0.24416539,of,0.39597213,relu,0.3923469
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,ann,0.57569355,perceptron,0.68935764,perceptron,0.68935764
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,well,0.34264985,of,0.59718275,bagging,0.4145819
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,used,0.46049535,of,0.5630944,generative-model,0.4901716
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,simulate,0.47065336,model,0.6309376,generative-model,0.5932154
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,results,0.32376552,data,0.6932311,batch-normalization,0.44826904
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,prognosis,0.32841474,recurrent,0.50268024,classification,0.44778624
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,performed,0.3864032,analysis,0.5711501,supervised,0.4789877
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,moreover,0.34991172,of,0.5596781,boosting,0.44273305
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,methods,0.50049126,data,0.5400177,machine-learning,0.50049126
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,half,0.24439552,one,0.6213776,one-hot,0.46021485
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,explore,0.4359874,feature-engineering,0.5121693,feature-engineering,0.5121693
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,exercise,0.35312283,supervised,0.5316645,supervised,0.5316645
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,curve,0.29765248,linear,0.52257633,regression,0.49561262
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,conclusions,0.37109232,data,0.55923915,long-short-term,0.4627594
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,compare,0.43674475,short-term,0.510365,statistical,0.44797724
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,combining,0.54477555,feature-engineering,0.60671854,feature-engineering,0.60671854
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,bp,0.21030092,long,0.36319643,bagging,0.3426011
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,background,0.3259285,of,0.51277274,long-short-term,0.46426663
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,areas,0.3090546,forest,0.4990691,ground-truth,0.40763968
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,additionally,0.37098312,of,0.6596129,feature-reduction,0.453403
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,addition,0.30500388,of,0.6910241,feature-reduction,0.48914018
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,accuracy,0.5511073,cross-validation,0.64088035,cross-validation,0.64088035
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,health,0.36509717,data-science,0.5754831,data-science,0.5754831
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,care,0.3144728,decision,0.58130515,data-science,0.46943653
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,provider,0.39704412,decision,0.6417395,supervised,0.5116296
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,networks,0.53880787,network,0.91573685,neural-network,0.776492
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,health-care,0.38342735,data-science,0.5536263,data-science,0.5536263
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,care-provider,0.36397547,decision,0.57332385,decision-tree,0.5017805
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,health-care-provider,0.3840783,decision,0.5633486,decision-tree,0.53823745
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,machine,0.7094662,machine,1.0,machine-learning,0.7094662
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,learning,0.709237,learning,1.0,deep-learning,0.8286492
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,methods,0.50049126,data,0.5400177,machine-learning,0.50049126
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,offered,0.39209563,of,0.5531078,supervised,0.53973377
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,machine-learning,1.0,machine-learning,1.0,machine-learning,1.0
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,deploy,0.44857013,data-engineering,0.5443614,data-engineering,0.5443614
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,targeted,0.37903738,of,0.52138686,feature-engineering,0.502902
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,interventions,0.3916263,decision,0.5218073,reinforcement-learning,0.50423867
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,aimed,0.41358173,of,0.52896386,feature-engineering,0.45929232
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,interventions-aimed,0.43765154,decision,0.5587222,data-science,0.5453635
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,compare,0.43674475,short-term,0.510365,statistical,0.44797724
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,machine,0.7094662,machine,1.0,machine-learning,0.7094662
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,learning,0.709237,learning,1.0,deep-learning,0.8286492
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,approaches,0.55614823,feature-engineering,0.60571706,feature-engineering,0.60571706
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,machine-learning,1.0,machine-learning,1.0,machine-learning,1.0
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,learning-approaches,0.67542875,learning,0.83603513,reinforcement-learning,0.78956765
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,emr,0.398122,nlp,0.47697225,nlp,0.47697225
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,derived,0.3584563,of,0.54769456,generative,0.5265686
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,information,0.5191034,data,0.708436,data-science,0.5937191
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,home,0.36099303,supervised,0.52895296,supervised,0.52895296
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,days,0.20857571,short-term,0.53915894,long-short-term,0.4190845
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,loss,0.26544642,reduction,0.62177265,dropout,0.42517614
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,greater,0.2528603,of,0.59163296,long-short-term,0.44578376
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,home-days,0.19382535,supervised,0.4175611,supervised,0.4175611
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,conducted,0.39637828,data,0.556862,statistical,0.4670034
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,including,0.3233776,of,0.6619886,clustering,0.40625107
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,medicare,0.3291487,decision,0.5025023,decision-tree,0.4950005
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,efficient,0.44278914,feature-engineering,0.5657042,feature-engineering,0.5657042
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,modeling,0.6237119,model,0.757579,generative-model,0.6999146
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,approach,0.5412675,segmentation-algorithm,0.6046611,segmentation-algorithm,0.6046611
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,based,0.49998575,classification-algorithm,0.5639226,classification-algorithm,0.5639226
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,modeling-approach,0.5900446,generative-model,0.66789985,generative-model,0.66789985
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,approach-based,0.6241528,dimensionality-reduction,0.6780842,dimensionality-reduction,0.6780842
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,boosted,0.437288,boosting,0.8743134,boosting,0.8743134
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,modeling,0.6237119,model,0.757579,generative-model,0.6999146
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,consistently,0.3349427,few,0.5762741,clustering,0.4464267
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,provided,0.3982859,of,0.61110586,supervised,0.49344742
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,home,0.36099303,supervised,0.52895296,supervised,0.52895296
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,time,0.31186903,long,0.57547164,batch-normalization,0.47628766
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,loss,0.26544642,reduction,0.62177265,dropout,0.42517614
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,outcomes,0.38239923,short-term,0.6164659,long-short-term,0.5239928
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,home-time,0.44820952,supervised,0.57408345,supervised,0.57408345
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,time-loss,0.38833702,dropout,0.5081322,dropout,0.5081322
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,home,0.36099303,supervised,0.52895296,supervised,0.52895296
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,days,0.20857571,short-term,0.53915894,long-short-term,0.4190845
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,loss,0.26544642,reduction,0.62177265,dropout,0.42517614
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,claims,0.38039714,data,0.5667363,data-science,0.52730644
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,home-days,0.19382535,supervised,0.4175611,supervised,0.4175611
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,modeled,0.50262785,model,0.7314758,stochastic,0.6500211
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,using,0.47332245,analysis,0.5968549,component-analysis,0.526608
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,logistic,0.5418149,logistic,1.0,logistic-regression,0.9215903
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,regression,0.4967034,regression,1.0,regression,1.0
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,logistic-regression,0.5787163,logistic-regression,0.99999994,logistic-regression,0.99999994
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,predicting,0.521454,classification-algorithm,0.5589481,classification-algorithm,0.5589481
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,key,0.35973132,principal,0.614877,feature-engineering,0.498355
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,hf,0.293398,long-short-term,0.35116297,long-short-term,0.35116297
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,outcomes,0.38239923,short-term,0.6164659,long-short-term,0.5239928
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,hf-outcomes,0.46735668,reinforcement-learning,0.5581314,reinforcement-learning,0.5581314
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,hf,0.293398,long-short-term,0.35116297,long-short-term,0.35116297
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,hospitalization,0.23343414,confusion,0.51795703,logistic-regression,0.47011706
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,hf-hospitalization,0.3093966,short-term,0.50356686,logistic-regression,0.47130394
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,health,0.36509717,data-science,0.5754831,data-science,0.5754831
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,care,0.3144728,decision,0.58130515,data-science,0.46943653
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,professionals,0.4456144,data-science,0.6296647,data-science,0.6296647
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,health-care,0.38342735,data-science,0.5536263,data-science,0.5536263
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,care-professionals,0.45030648,data-science,0.58510965,data-science,0.58510965
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,health-care-professionals,0.44610283,data-science,0.59542996,data-science,0.59542996
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,home,0.36099303,supervised,0.52895296,supervised,0.52895296
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,days,0.20857571,short-term,0.53915894,long-short-term,0.4190845
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,loss,0.26544642,reduction,0.62177265,dropout,0.42517614
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,home-days,0.19382535,supervised,0.4175611,supervised,0.4175611
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,home,0.36099303,supervised,0.52895296,supervised,0.52895296
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,time,0.31186903,long,0.57547164,batch-normalization,0.47628766
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,loss,0.26544642,reduction,0.62177265,dropout,0.42517614
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,home-time,0.44820952,supervised,0.57408345,supervised,0.57408345
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,time-loss,0.38833702,dropout,0.5081322,dropout,0.5081322
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,predicting,0.521454,classification-algorithm,0.5589481,classification-algorithm,0.5589481
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,key,0.35973132,principal,0.614877,feature-engineering,0.498355
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,outcomes,0.38239923,short-term,0.6164659,long-short-term,0.5239928
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,key-outcomes,0.5402813,reinforcement-learning,0.6226386,reinforcement-learning,0.6226386
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,logistic,0.5418149,logistic,1.0,logistic-regression,0.9215903
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,regression,0.4967034,regression,1.0,regression,1.0
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,based,0.49998575,classification-algorithm,0.5639226,classification-algorithm,0.5639226
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,logistic-regression,0.5787163,logistic-regression,0.99999994,logistic-regression,0.99999994
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,regression-based,0.7112489,logistic-regression,0.80462235,logistic-regression,0.80462235
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,logistic-regression-based,0.69706494,logistic-regression,0.94030905,logistic-regression,0.94030905
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,various,0.35606545,of,0.6378319,generative,0.45850474
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,threshold,0.29357433,normalization,0.45138514,statistical,0.44599557
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,probabilities,0.46948612,markov,0.62650263,markov,0.62650263
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,massachusetts,0.25937253,federated,0.4842942,data-science,0.39887464
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,providers,0.42136738,decision,0.6396354,data-science,0.54606366
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,least,0.35598263,one,0.71392226,supervised,0.5070516
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,absolute,0.27931842,reduction,0.5066942,batch-normalization,0.479002
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,shrinkage,0.28317183,regularization,0.4725503,segmentation-algorithm,0.4553033
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,least-absolute,0.40296656,principal-components,0.547401,principal-components,0.547401
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,least-absolute-shrinkage,0.49224246,cross-entropy,0.7002046,cross-entropy,0.7002046
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,electronic,0.40248027,computer,0.57442594,dimensionality-reduction,0.53097373
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,medical,0.37876463,data-science,0.59196365,data-science,0.59196365
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,record,0.35823005,data,0.5543083,computer-vision,0.5094532
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,electronic-medical,0.4678722,data-engineering,0.6155994,data-engineering,0.6155994
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,medical-record,0.44228226,computer-vision,0.6220123,computer-vision,0.6220123
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,electronic-medical-record,0.4773038,computer-vision,0.614151,computer-vision,0.614151
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,accurate,0.50905025,algorithm,0.5474155,algorithm,0.5474155
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,risk,0.35860935,recurrent,0.53675485,logistic-regression,0.52381086
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,stratification,0.45885193,classification-algorithm,0.6005924,classification-algorithm,0.6005924
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,risk-stratification,0.56299007,classification-algorithm,0.6976296,classification-algorithm,0.6976296
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,traditional,0.49153316,style,0.54303825,dimensionality-reduction,0.5295658
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,logistic,0.5418149,logistic,1.0,logistic-regression,0.9215903
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,regression,0.4967034,regression,1.0,regression,1.0
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,logistic-regression,0.5787163,logistic-regression,0.99999994,logistic-regression,0.99999994
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,selection,0.46716303,selection,1.0,feature-selection,0.6859601
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,operation,0.315604,data-augmentation,0.48509696,data-augmentation,0.48509696
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,regression,0.4967034,regression,1.0,regression,1.0
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,based,0.49998575,classification-algorithm,0.5639226,classification-algorithm,0.5639226
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,predictive,0.55290145,cross-validation,0.6141345,cross-validation,0.6141345
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,models,0.53762007,model,0.8940372,markov-model,0.7015921
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,based,0.49998575,classification-algorithm,0.5639226,classification-algorithm,0.5639226
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,models,0.53762007,model,0.8940372,markov-model,0.7015921
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,appeared,0.23899546,of,0.611557,generative,0.43490046
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,based-models,0.65913326,markov-model,0.75586486,markov-model,0.75586486
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,lowest,0.23623991,rate,0.46416223,statistical,0.3728755
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,brier,0.4430912,cross-validation,0.574417,cross-validation,0.574417
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,scores,0.40591323,intelligence,0.56987673,principal-components,0.4971624
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,trained,0.56898797,supervised,0.69370055,supervised,0.69370055
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,using,0.47332245,analysis,0.5968549,component-analysis,0.526608
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,data,0.46434748,data,1.0,data-science,0.5533528
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,top,0.29891562,forward,0.47741628,bagging,0.40812773
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,cost,0.3742721,dimensionality-reduction,0.51791906,dimensionality-reduction,0.51791906
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,decile,0.31104296,logistic,0.55240625,logistic-regression,0.53723705
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,net,0.3123865,forest,0.48918653,fully-connected,0.43314534
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,benefit,0.39640212,short-term,0.5466547,long-short-term,0.48296973
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,estimates,0.4180187,data,0.6103505,bayesian,0.60268915
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,net-benefit,0.47351333,decision-tree,0.62398076,decision-tree,0.62398076
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,good,0.29142508,few,0.4427599,bagging,0.41576368
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,calibration,0.50641084,batch-normalization,0.6344988,batch-normalization,0.6344988
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,across,0.3330416,gradient,0.4622073,gradient,0.4622073
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,generally,0.31490302,few,0.62595755,long-short-term,0.51732695
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,similar,0.29237732,of,0.56832373,long-short-term,0.4732089
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,performance,0.50728506,learning-function,0.63351834,learning-function,0.63351834
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,emr,0.398122,nlp,0.47697225,nlp,0.47697225
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,vs,0.22635552,transfer,0.4263924,statistical,0.3002486
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,claims,0.38039714,data,0.5667363,data-science,0.52730644
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,vs,0.22635552,transfer,0.4263924,statistical,0.3002486
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,testing,0.4056496,analysis,0.49134174,component-analysis,0.48690635
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,set,0.5244544,of,0.5846941,classifiers,0.5500933
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,testing-set,0.5234463,cross-validation,0.5532317,cross-validation,0.5532317
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,gbms,0.31444976,recurrent-neural-network,0.41777417,recurrent-neural-network,0.41777417
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,predicting,0.521454,classification-algorithm,0.5589481,classification-algorithm,0.5589481
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,mortality,0.2609817,short-term,0.505676,logistic-regression,0.49414968
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,boosted,0.437288,boosting,0.8743134,boosting,0.8743134
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,modeling,0.6237119,model,0.757579,generative-model,0.6999146
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,logistic,0.5418149,logistic,1.0,logistic-regression,0.9215903
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,regression,0.4967034,regression,1.0,regression,1.0
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,logistic-regression,0.5787163,logistic-regression,0.99999994,logistic-regression,0.99999994
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,networks,0.53880787,network,0.91573685,neural-network,0.776492
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,hf,0.293398,long-short-term,0.35116297,long-short-term,0.35116297
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,hospitalization,0.23343414,confusion,0.51795703,logistic-regression,0.47011706
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,hf-hospitalization,0.3093966,short-term,0.50356686,logistic-regression,0.47130394
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,using,0.47332245,analysis,0.5968549,component-analysis,0.526608
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,claims,0.38039714,data,0.5667363,data-science,0.52730644
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,outcomes,0.38239923,short-term,0.6164659,long-short-term,0.5239928
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,vs,0.22635552,transfer,0.4263924,statistical,0.3002486
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,claims,0.38039714,data,0.5667363,data-science,0.52730644
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,net,0.3123865,forest,0.48918653,fully-connected,0.43314534
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,benefit,0.39640212,short-term,0.5466547,long-short-term,0.48296973
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,net-benefit,0.47351333,decision-tree,0.62398076,decision-tree,0.62398076
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,regression,0.4967034,regression,1.0,regression,1.0
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,trees,0.48644733,tree,0.87266016,random-forest,0.65992284
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,regression-trees,0.61828065,logistic-regression,0.8033117,logistic-regression,0.8033117
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,emr,0.398122,nlp,0.47697225,nlp,0.47697225
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,predictors,0.46376368,logistic,0.67381907,logistic-regression,0.66900885
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,main,0.3070703,principal,0.7875631,principal-components,0.51314574
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,outcomes,0.38239923,short-term,0.6164659,long-short-term,0.5239928
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,network,0.50771487,network,1.0,neural-network,0.7589166
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,january,0.2596028,science,0.43337005,data-science,0.36495665
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,december,0.26343572,science,0.4644758,data-science,0.38875848
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,training,0.54553735,learning,0.69909495,supervised,0.6973169
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,set,0.5244544,of,0.5846941,classifiers,0.5500933
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,training-set,0.57264864,learning-rate,0.6640283,learning-rate,0.6640283
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,brier,0.4430912,cross-validation,0.574417,cross-validation,0.574417
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,score,0.38515997,classification-algorithm,0.5352135,classification-algorithm,0.5352135
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,brier-score,0.5376122,classification-algorithm,0.6556068,classification-algorithm,0.6556068
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,patients,0.30007,recurrent,0.5332828,dropout,0.3918751
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,augmenting,0.37820423,augmentation,0.7638645,boosting,0.6477699
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,claims,0.38039714,data,0.5667363,data-science,0.52730644
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,year,0.310051,one,0.48338404,supervised,0.40979916
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,follow,0.28552625,tracking,0.48513734,batch-normalization,0.39173082
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,year-follow,0.45824456,random-forest,0.503012,random-forest,0.503012
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,recall,0.44827557,memory,0.7156959,short-term-memory,0.699399
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,curves,0.3120853,linear,0.58335835,regression,0.52966225
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,random,0.45551494,random,1.0,random-forest,0.65894985
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,forests,0.47881076,forest,0.9348211,random-forest,0.7701128
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,random-forests,0.62062037,random-forest,0.9874096,random-forest,0.9874096
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,limited,0.33893847,of,0.6210327,long-short-term,0.4736513
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,improvement,0.39264548,reduction,0.6142903,feature-reduction,0.5138227
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,includes,0.35423023,of,0.5967927,component-analysis,0.45854867
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,physicians,0.39576703,decision,0.6153769,data-science,0.51622474
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,improve,0.45207965,boosting,0.5098576,boosting,0.5098576
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,prediction,0.6361519,classification-algorithm,0.67946094,classification-algorithm,0.67946094
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,high,0.267004,of,0.57459104,gradient,0.44240427
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,cost,0.3742721,dimensionality-reduction,0.51791906,dimensionality-reduction,0.51791906
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,high-cost,0.44621217,data-engineering,0.5274703,data-engineering,0.5274703
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,heart,0.28300244,rate,0.49867767,batch-normalization,0.3427502
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,failure,0.32964212,recurrent,0.52057266,confusion-matrix,0.44323406
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,heart-failure,0.36450487,long-short-term,0.44014218,long-short-term,0.44014218
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,decision,0.5239193,decision,1.0,decision-tree,0.75800127
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,curves,0.3120853,linear,0.58335835,regression,0.52966225
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,cause,0.19388393,of,0.47843847,confusion-matrix,0.34079778
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,mortality,0.2609817,short-term,0.505676,logistic-regression,0.49414968
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,cause-mortality,0.3407904,logistic-regression,0.5863885,logistic-regression,0.5863885
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,c,0.17513797,of,0.44327667,gradient,0.31114018
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,statistics,0.5117099,statistical,0.7675688,statistical,0.7675688
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,c-statistics,0.5277507,logistic-regression,0.66689,logistic-regression,0.66689
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,added,0.32371867,of,0.5926449,batch-normalization,0.4530739
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,value,0.3544725,of,0.52001536,statistical,0.45314136
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,added-value,0.53720057,graphics-processing,0.61733323,graphics-processing,0.61733323
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,improving,0.40742207,boosting,0.54548407,boosting,0.54548407
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,patients,0.30007,recurrent,0.5332828,dropout,0.3918751
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,gbm,0.27682787,matrix,0.38361079,recurrent-neural-network,0.36784935
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,enrolled,0.3208215,supervised,0.42658707,supervised,0.42658707
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,patients,0.30007,recurrent,0.5332828,dropout,0.3918751
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,additional,0.35377294,of,0.63162684,feature-reduction,0.4511183
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,predictors,0.46376368,logistic,0.67381907,logistic-regression,0.66900885
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,prognostic,0.4482512,classifiers,0.50372314,classifiers,0.50372314
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,study,0.3645851,of,0.5728763,statistical,0.44204497
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,highest,0.25175208,of,0.5054526,boosting,0.3963222
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,discrimination,0.45913857,discriminative,0.7581123,feature-selection,0.5504295
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,higher,0.27819592,reduction,0.545787,boosting,0.41506222
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,auprcs,0.36054546,hierarchical-clustering,0.5602612,hierarchical-clustering,0.5602612
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,hf,0.293398,long-short-term,0.35116297,long-short-term,0.35116297
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,outcomes,0.38239923,short-term,0.6164659,long-short-term,0.5239928
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,models,0.53762007,model,0.8940372,markov-model,0.7015921
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,claims,0.38039714,data,0.5667363,data-science,0.52730644
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,similar,0.29237732,of,0.56832373,long-short-term,0.4732089
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,mortality,0.2609817,short-term,0.505676,logistic-regression,0.49414968
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,gbms,0.31444976,recurrent-neural-network,0.41777417,recurrent-neural-network,0.41777417
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,data,0.46434748,data,1.0,data-science,0.5533528
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,cost,0.3742721,dimensionality-reduction,0.51791906,dimensionality-reduction,0.51791906
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,calibration,0.50641084,batch-normalization,0.6344988,batch-normalization,0.6344988
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,patients,0.30007,recurrent,0.5332828,dropout,0.3918751
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,predictors,0.46376368,logistic,0.67381907,logistic-regression,0.66900885
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,study,0.3645851,of,0.5728763,statistical,0.44204497
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,higher,0.27819592,reduction,0.545787,boosting,0.41506222
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,gbm,0.27682787,matrix,0.38361079,recurrent-neural-network,0.36784935
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,discrimination,0.45913857,discriminative,0.7581123,feature-selection,0.5504295
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,auprcs,0.36054546,hierarchical-clustering,0.5602612,hierarchical-clustering,0.5602612
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,years,0.32825696,intelligence,0.42702603,regression,0.3811771
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,total,0.21723771,of,0.5102532,principal-components,0.3630478
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,tested,0.37172255,of,0.5634051,boosting,0.4195229
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,setting,0.34333664,decision,0.51606584,supervised,0.4146531
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,selecting,0.505623,selection,0.8441505,feature-selection,0.6558554
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,sd,0.2870951,naive,0.38090894,softmax,0.36839682
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,results,0.32376552,data,0.6932311,batch-normalization,0.44826904
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,relevance,0.48173976,of,0.5866257,feature-engineering,0.50181127
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,quality,0.37286326,dimensionality-reduction,0.49494588,dimensionality-reduction,0.49494588
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,precision,0.465316,ground-truth,0.56614435,ground-truth,0.56614435
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,period,0.19663066,short-term,0.5791412,long-short-term,0.5108645
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,performed,0.3864032,analysis,0.5711501,supervised,0.4789877
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,participants,0.4160846,object-tracking,0.5017827,object-tracking,0.5017827
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,obtained,0.32073808,of,0.62274206,batch-normalization,0.46598285
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,objectives,0.41173956,of,0.53322846,feature-engineering,0.42803428
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,measures,0.3789752,principal-components,0.5349536,principal-components,0.5349536
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,mean,0.24598047,reduction,0.46440193,batch-normalization,0.434582
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,life,0.3004927,style,0.49334684,long-short-term,0.46358624
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,institutions,0.42489433,federated,0.6177274,data-science,0.6069261
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,inclusion,0.306788,selection,0.55001795,dimensionality-reduction,0.42888808
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,included,0.34673893,of,0.58040446,component-analysis,0.47413814
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,importance,0.3427571,of,0.5794183,feature-engineering,0.46667784
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,however,0.31437585,few,0.63182676,statistical,0.44065386
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,gradient,0.3245376,gradient,1.0,gradient,1.0
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,focus,0.37578377,of,0.53003526,data-science,0.48246473
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,evaluate,0.37214977,of,0.4977158,decision-tree,0.4090718
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,emrs,0.52594805,data-science,0.5437053,data-science,0.5437053
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,differences,0.3361535,statistical,0.57447433,statistical,0.57447433
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,design,0.47555828,data-engineering,0.6477308,data-engineering,0.6477308
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,critical,0.3026405,of,0.57185876,feature-engineering,0.44590998
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,conclusions,0.37109232,data,0.55923915,long-short-term,0.4627594
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,comprise,0.29845196,feature,0.53566235,fully-connected,0.4318143
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,clinicians,0.48196417,decision,0.63309145,data-science,0.5435997
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,classification,0.5994266,classification,1.0,classification,1.0
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,ci,0.2746623,logistic,0.43534693,logistic-regression,0.38379127
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,calculated,0.36281493,monte,0.54373723,monte,0.54373723
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,boston,0.2823125,federated,0.46505076,artificial-intelligence,0.43758357
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,area,0.23419946,layer,0.46823567,ground-truth,0.38642365
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,analyzed,0.38529366,analysis,0.6994013,component-analysis,0.5263994
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,age,0.30743492,intelligence,0.4774798,regression,0.47452933
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,analyzed,0.38529366,analysis,0.6994013,component-analysis,0.5263994
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,using,0.47332245,analysis,0.5968549,component-analysis,0.526608
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,unsupervised,0.76376486,unsupervised,0.99999994,unsupervised,0.99999994
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,machine,0.7094662,machine,1.0,machine-learning,0.7094662
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,learning,0.709237,learning,1.0,deep-learning,0.8286492
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,analyzed-using,0.55247,analysis,0.5967355,principal-component-analysis,0.57609487
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,machine-learning,1.0,machine-learning,1.0,machine-learning,1.0
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,cognitive,0.5010079,memory,0.72449946,learning-function,0.7178915
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,impairment,0.36711594,function,0.6770178,learning-function,0.55798244
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,may,0.30907542,of,0.58654004,long-short-term,0.43985203
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,help,0.45596504,support,0.55435,machine-learning,0.45596504
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,predict,0.51602554,model,0.53463185,classification-algorithm,0.52342355
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,cognitive-impairment,0.46379438,learning-function,0.65946823,learning-function,0.65946823
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,unsupervised,0.76376486,unsupervised,0.99999994,unsupervised,0.99999994
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,machine,0.7094662,machine,1.0,machine-learning,0.7094662
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,learning,0.709237,learning,1.0,deep-learning,0.8286492
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,framework,0.5690361,hierarchical,0.6853048,hierarchical-clustering,0.6804691
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,machine-learning,1.0,machine-learning,1.0,machine-learning,1.0
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,identified,0.35725033,analysis,0.56593037,clustering,0.45719695
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,using,0.47332245,analysis,0.5968549,component-analysis,0.526608
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,feature,0.5878884,feature,0.99999994,feature-selection,0.6322505
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,selection,0.46716303,selection,1.0,feature-selection,0.6859601
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,feature-selection,0.61733264,feature-selection,1.0,feature-selection,1.0
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,ad,0.3459351,memory,0.48189065,semantic,0.46080723
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,within,0.2920679,of,0.57602364,clustering,0.4610753
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,years,0.32825696,intelligence,0.42702603,regression,0.3811771
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,may,0.30907542,of,0.58654004,long-short-term,0.43985203
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,help,0.45596504,support,0.55435,machine-learning,0.45596504
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,distinguish,0.4136919,discriminative,0.5568397,classification,0.4541072
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,subtle,0.35819805,confusion,0.5472425,feature-selection,0.4957855
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,cognitive,0.5010079,memory,0.72449946,learning-function,0.7178915
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,alterations,0.3407031,normalization,0.5792735,batch-normalization,0.44323376
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,screening,0.38869897,selection,0.4576743,data-engineering,0.4313178
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,early,0.32400474,short-term,0.57188475,long-short-term,0.50726265
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,evidence,0.28723752,data,0.5728123,generative,0.3943918
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,screening-early,0.34961754,decision-tree,0.474201,decision-tree,0.474201
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,framingham,0.42399347,classification-algorithm,0.51203847,classification-algorithm,0.51203847
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,heart,0.28300244,rate,0.49867767,batch-normalization,0.3427502
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,study,0.3645851,of,0.5728763,statistical,0.44204497
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,heart-study,0.4083336,long-short-term,0.4331752,long-short-term,0.4331752
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,model,0.48485535,model,1.0,markov-model,0.7005576
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,yielded,0.30928922,of,0.5085689,cross-validation,0.42442602
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,early,0.32400474,short-term,0.57188475,long-short-term,0.50726265
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,ad,0.3459351,memory,0.48189065,semantic,0.46080723
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,screening,0.38869897,selection,0.4576743,data-engineering,0.4313178
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,early-ad,0.3476733,long-short-term-memory,0.48493895,long-short-term-memory,0.48493895
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,boston,0.2823125,federated,0.46505076,artificial-intelligence,0.43758357
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,naming,0.5187148,semantic,0.8218374,semantic,0.8218374
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,tests,0.37449622,statistical,0.48559177,statistical,0.48559177
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,boston-naming,0.47395325,natural-language-processing,0.6495007,natural-language-processing,0.6495007
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,precede,0.30643106,feature,0.52356064,stochastic,0.44196934
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,clinical,0.44080526,data,0.48532635,data-science,0.45343333
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,evidence,0.28723752,data,0.5728123,generative,0.3943918
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,analyzed,0.38529366,analysis,0.6994013,component-analysis,0.5263994
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,using,0.47332245,analysis,0.5968549,component-analysis,0.526608
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,analyzed-using,0.55247,analysis,0.5967355,principal-component-analysis,0.57609487
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,ad,0.3459351,memory,0.48189065,semantic,0.46080723
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,clinical,0.44080526,data,0.48532635,data-science,0.45343333
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,trials,0.31393725,short-term,0.4483273,data-science,0.40647802
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,clinical-trials,0.4615081,data-science,0.54023623,data-science,0.54023623
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,clinical,0.44080526,data,0.48532635,data-science,0.45343333
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,practice,0.50552624,decision,0.59237766,data-science,0.5843962
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,clinical-practice,0.5274042,data-science,0.57205796,data-science,0.57205796
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,np,0.25966394,transfer,0.36141515,confusion-matrix,0.3595096
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,tests,0.37449622,statistical,0.48559177,statistical,0.48559177
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,np-tests,0.38064826,statistical,0.47230342,statistical,0.47230342
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,visual,0.42333114,vision,0.8021078,computer-vision,0.6560297
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,reproduction,0.30214858,generative,0.5646367,generative,0.5646367
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,visual-reproduction,0.48968628,learning-function,0.6998917,learning-function,0.6998917
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,viable,0.26926097,fully,0.49949867,feature-reduction,0.41061884
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,option,0.35068518,decision,0.5267865,algorithm,0.43552527
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,trails,0.38271976,forest,0.49983144,random-forest,0.49643284
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,b,0.19558734,of,0.43435428,short-term-memory,0.31717262
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,trails-b,0.3798893,bag-of-words,0.51630044,bag-of-words,0.51630044
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,logical,0.5823424,semantic,0.64397424,semantic,0.64397424
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,memory,0.4292574,memory,1.0,short-term-memory,0.84619105
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,logical-memory,0.5704675,short-term-memory,0.79775226,short-term-memory,0.79775226
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,including,0.3233776,of,0.6619886,clustering,0.40625107
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,age,0.30743492,intelligence,0.4774798,regression,0.47452933
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,demographic,0.39590356,logistic,0.5839036,logistic-regression,0.5444477
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,data,0.46434748,data,1.0,data-science,0.5533528
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,demographic-data,0.5274874,logistic-regression,0.63079095,logistic-regression,0.63079095
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,delayed,0.24917814,short-term,0.5145566,long-short-term,0.49292946
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,recall,0.44827557,memory,0.7156959,short-term-memory,0.699399
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,delayed-recall,0.438713,short-term-memory,0.6789827,short-term-memory,0.6789827
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,coordinating,0.2982455,network,0.5673367,fully-connected,0.45646852
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,center,0.2469751,unit,0.5969413,data-science,0.3881536
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,coordinating-center,0.41575038,nearest-neighbors,0.5668042,nearest-neighbors,0.5668042
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,attractive,0.37016675,feature-engineering,0.52500945,feature-engineering,0.52500945
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,modality,0.45219088,feature,0.49997124,object-tracking,0.48294973
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,approach,0.5412675,segmentation-algorithm,0.6046611,segmentation-algorithm,0.6046611
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,could,0.34235194,of,0.59299076,boosting,0.42074972
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,approach-could,0.5263736,dimensionality-reduction,0.64798146,dimensionality-reduction,0.64798146
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,longitudinal,0.3201388,data,0.4832245,regression,0.4622656
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,np,0.25966394,transfer,0.36141515,confusion-matrix,0.3595096
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,subsequent,0.25077623,of,0.65363204,long-short-term,0.46481046
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,development,0.34732813,generative,0.56588423,generative,0.56588423
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,risk,0.35860935,recurrent,0.53675485,logistic-regression,0.52381086
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,individuals,0.32092994,naive,0.486303,dropout,0.42173886
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,risk-individuals,0.4398975,logistic-regression,0.5542923,logistic-regression,0.5542923
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,results,0.32376552,data,0.6932311,batch-normalization,0.44826904
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,suggest,0.26874092,data,0.5391823,long-short-term,0.40288782
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,results-suggest,0.39010245,data,0.5769403,batch-normalization,0.5080625
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,national,0.37516904,federated,0.6891889,data-science,0.5990771
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,alzheimer,0.2948662,memory,0.47752225,semantic,0.47042826
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,predict,0.51602554,model,0.53463185,classification-algorithm,0.52342355
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,nacc,0.31844947,reinforcement-learning,0.5478634,reinforcement-learning,0.5478634
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,respectively,0.23184536,of,0.43360457,cross-validation,0.35765702
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,ad,0.3459351,memory,0.48189065,semantic,0.46080723
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,np,0.25966394,transfer,0.36141515,confusion-matrix,0.3595096
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,risk,0.35860935,recurrent,0.53675485,logistic-regression,0.52381086
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,results,0.32376552,data,0.6932311,batch-normalization,0.44826904
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,respectively,0.23184536,of,0.43360457,cross-validation,0.35765702
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,nacc,0.31844947,reinforcement-learning,0.5478634,reinforcement-learning,0.5478634
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,development,0.34732813,generative,0.56588423,generative,0.56588423
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,alzheimer,0.2948662,memory,0.47752225,semantic,0.47042826
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,testing,0.4056496,analysis,0.49134174,component-analysis,0.48690635
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,subset,0.42092714,feature,0.57910776,clustering,0.5495737
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,specificity,0.3365721,discriminative,0.5238579,cross-validation,0.4765169
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,sensitivity,0.28808302,discriminative,0.5372434,cross-validation,0.48943394
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,progression,0.31600362,recurrent,0.52875245,regression,0.51750124
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,processed,0.38347393,processing,0.73790264,graphics-processing,0.5473553
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,neuropsychological,0.48125446,intelligence,0.66859627,language-processing,0.63995373
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,n,0.24332823,of,0.45693433,long-short-term,0.34114176
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,methods,0.50049126,data,0.5400177,machine-learning,0.50049126
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,low,0.23602332,of,0.5820825,long-short-term,0.45172954
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,introduction,0.37159568,of,0.5877248,feature-engineering,0.47346386
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,immediate,0.24514383,short-term,0.61681336,long-short-term,0.49847144
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,high,0.267004,of,0.57459104,gradient,0.44240427
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,fhs,0.27065933,feature-reduction,0.4008338,feature-reduction,0.4008338
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,features,0.51742536,feature,0.8268872,feature-selection,0.5487305
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,disease,0.296938,recurrent,0.4731025,classification,0.35271814
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,discussion,0.40282863,decision,0.59222,data-science,0.5158012
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,context,0.48856658,feature-engineering,0.6062584,feature-engineering,0.6062584
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,authors,0.45811802,data,0.5259881,natural-language-processing,0.4706872
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,accuracy,0.5511073,cross-validation,0.64088035,cross-validation,0.64088035
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,study,0.3645851,of,0.5728763,statistical,0.44204497
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,sits,0.21982574,nearest,0.45392975,fully-connected,0.38476235
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,among,0.33676732,of,0.57348,clustering,0.49404603
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,many,0.40940517,few,0.752018,feature-engineering,0.48454586
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,studies,0.30135098,data,0.6349237,component-analysis,0.41327482
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,reporting,0.41789776,data,0.54032123,natural-language,0.48204225
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,difficulties,0.4353067,confusion,0.6336199,confusion-matrix,0.5077321
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,obtaining,0.39410537,of,0.6090371,batch-normalization,0.50309825
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,statistically,0.37798828,statistical,0.71961004,statistical,0.71961004
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,significant,0.29367286,statistical,0.582669,statistical,0.582669
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,findings,0.35685748,data,0.65714294,component-analysis,0.38599753
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,studies-reporting,0.41849104,data,0.59903216,component-analysis,0.52817595
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,statistically-significant,0.47618386,statistical,0.73292255,statistical,0.73292255
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,cardiac,0.29562658,of,0.42777455,long-short-term,0.35708636
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,nephrology,0.37874436,data-science,0.49670663,data-science,0.49670663
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,diabetes,0.29301462,logistic-regression,0.35688502,logistic-regression,0.35688502
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,mellitus,0.26868707,logistic,0.37140065,logistic-regression,0.36157686
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,patients,0.30007,recurrent,0.5332828,dropout,0.3918751
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,diabetes-mellitus,0.22767697,logistic-regression,0.32544836,logistic-regression,0.32544836
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,wilcoxon,0.40963846,logistic,0.63199633,statistical,0.6052394
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,signed,0.41015986,decision,0.55671465,statistical,0.53744936
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,ranked,0.47250757,classifiers,0.5532665,classifiers,0.5532665
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,sum,0.37477192,principal-components,0.5799091,principal-components,0.5799091
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,tests,0.37449622,statistical,0.48559177,statistical,0.48559177
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,wilcoxon-signed,0.47211316,logistic-regression,0.6406642,logistic-regression,0.6406642
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,signed-ranked,0.5112475,statistical,0.6551435,statistical,0.6551435
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,ranked-sum,0.64405626,classification-algorithm,0.6923059,classification-algorithm,0.6923059
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,ongoing,0.36421978,support,0.564979,data-science,0.49493372
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,randomized,0.35587335,short-term,0.45843548,supervised,0.43708503
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,trial,0.31537512,short-term,0.4622394,supervised,0.43136692
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,randomized-trial,0.37882477,reinforcement-learning,0.48877108,reinforcement-learning,0.48877108
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,charlson,0.34645292,logistic,0.58463025,logistic-regression,0.55989134
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,comorbidity,0.36230576,logistic-regression,0.5492995,logistic-regression,0.5492995
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,index,0.27978244,function,0.407383,classification-algorithm,0.3994653
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,scores,0.40591323,intelligence,0.56987673,principal-components,0.4971624
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,charlson-comorbidity,0.40820372,logistic-regression,0.6315925,logistic-regression,0.6315925
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,comorbidity-index,0.40820995,dimensionality,0.5921909,classification-algorithm,0.5632595
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,index-scores,0.41410083,classification-algorithm,0.5433916,classification-algorithm,0.5433916
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,charlson-comorbidity-index,0.43323728,logistic-regression,0.6085185,logistic-regression,0.6085185
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,professional,0.4295174,data-science,0.6055003,data-science,0.6055003
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,collaboration,0.45193252,data-science,0.6360742,data-science,0.6360742
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,within,0.2920679,of,0.57602364,clustering,0.4610753
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,patient,0.2998137,confusion,0.5356896,confusion-matrix,0.41404122
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,collaboration-within,0.57027143,data-science,0.63515216,data-science,0.63515216
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,within-patient,0.38444814,logistic-regression,0.58497363,logistic-regression,0.58497363
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,compare,0.43674475,short-term,0.510365,statistical,0.44797724
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,care,0.3144728,decision,0.58130515,data-science,0.46943653
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,utilization,0.3202109,of,0.5174322,data-engineering,0.46732223
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,frequencies,0.28467548,statistical,0.43060437,statistical,0.43060437
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,care-utilization,0.38104892,graphics-processing-unit,0.49487683,graphics-processing-unit,0.49487683
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,statistically,0.37798828,statistical,0.71961004,statistical,0.71961004
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,significant,0.29367286,statistical,0.582669,statistical,0.582669
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,statistically-significant,0.47618386,statistical,0.73292255,statistical,0.73292255
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,often,0.38066354,few,0.61593103,confusion-matrix,0.50351226
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,insufficiently,0.37154958,fully,0.71821,long-short-term,0.44856513
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,coordinated,0.30360126,connected,0.5486424,fully-connected,0.4853616
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,multiple,0.39569393,of,0.53341115,regression,0.48948324
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,chronic,0.22727785,recurrent,0.5279353,long-short-term,0.4292153
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,conditions,0.21472734,short-term,0.4503411,feature-reduction,0.43574768
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,multiple-chronic,0.5377462,generative-model,0.5717372,generative-model,0.5717372
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,chronic-conditions,0.39491835,long-short-term,0.5398425,long-short-term,0.5398425
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,total,0.21723771,of,0.5102532,principal-components,0.3630478
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,care,0.3144728,decision,0.58130515,data-science,0.46943653
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,utilization,0.3202109,of,0.5174322,data-engineering,0.46732223
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,total-care,0.329894,logistic-regression,0.45679557,logistic-regression,0.45679557
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,care-utilization,0.38104892,graphics-processing-unit,0.49487683,graphics-processing-unit,0.49487683
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,care,0.3144728,decision,0.58130515,data-science,0.46943653
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,utilization,0.3202109,of,0.5174322,data-engineering,0.46732223
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,patterns,0.37740147,of,0.55208683,clustering,0.526253
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,care-utilization,0.38104892,graphics-processing-unit,0.49487683,graphics-processing-unit,0.49487683
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,care,0.3144728,decision,0.58130515,data-science,0.46943653
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,utilization,0.3202109,of,0.5174322,data-engineering,0.46732223
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,data,0.46434748,data,1.0,data-science,0.5533528
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,care-utilization,0.38104892,graphics-processing-unit,0.49487683,graphics-processing-unit,0.49487683
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,hnd,0.22168215,feed,0.31967995,nlp,0.26902932
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,patients,0.30007,recurrent,0.5332828,dropout,0.3918751
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,recruited,0.32712573,federated,0.46469644,supervised,0.46036208
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,patients-recruited,0.3668033,naive,0.47276974,dropout,0.42125747
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,innovative,0.5771038,data-engineering,0.7216599,data-engineering,0.7216599
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,methods,0.50049126,data,0.5400177,machine-learning,0.50049126
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,beyond,0.34655812,of,0.53781354,dimensionality-reduction,0.42561156
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,including,0.3233776,of,0.6619886,clustering,0.40625107
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,diagnostic,0.47116143,classification,0.5651491,classification,0.5651491
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,data,0.46434748,data,1.0,data-science,0.5533528
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,hnd,0.22168215,feed,0.31967995,nlp,0.26902932
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,patient,0.2998137,confusion,0.5356896,confusion-matrix,0.41404122
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,care,0.3144728,decision,0.58130515,data-science,0.46943653
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,patient-care,0.42835277,decision,0.5498397,data-science,0.51768845
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,integrated,0.53518295,data-engineering,0.633208,data-engineering,0.633208
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,care,0.3144728,decision,0.58130515,data-science,0.46943653
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,interventions,0.3916263,decision,0.5218073,reinforcement-learning,0.50423867
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,integrated-care,0.52360755,support-vector-machine,0.57864916,support-vector-machine,0.57864916
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,study,0.3645851,of,0.5728763,statistical,0.44204497
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,aims,0.42995954,of,0.465683,feature-engineering,0.4555406
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,study-aims,0.4779567,data-science,0.58556443,data-science,0.58556443
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,care,0.3144728,decision,0.58130515,data-science,0.46943653
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,utilization,0.3202109,of,0.5174322,data-engineering,0.46732223
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,care-utilization,0.38104892,graphics-processing-unit,0.49487683,graphics-processing-unit,0.49487683
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,hnd,0.22168215,feed,0.31967995,nlp,0.26902932
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,patients,0.30007,recurrent,0.5332828,dropout,0.3918751
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,patients,0.30007,recurrent,0.5332828,dropout,0.3918751
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,included,0.34673893,of,0.58040446,component-analysis,0.47413814
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,utilization,0.3202109,of,0.5174322,data-engineering,0.46732223
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,indicators,0.3974086,data,0.52769357,regression,0.47159168
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,study,0.3645851,of,0.5728763,statistical,0.44204497
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,patient,0.2998137,confusion,0.5356896,confusion-matrix,0.41404122
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,characteristics,0.345204,of,0.5401758,feature-engineering,0.49030614
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,patient-characteristics,0.5715629,component-analysis,0.6350744,component-analysis,0.6350744
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,mcc,0.24493814,network,0.3447355,cnn,0.3321532
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,patients,0.30007,recurrent,0.5332828,dropout,0.3918751
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,mcc-patients,0.3100825,short-term-memory,0.42134237,short-term-memory,0.42134237
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,diabetes,0.29301462,logistic-regression,0.35688502,logistic-regression,0.35688502
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,traditional,0.49153316,style,0.54303825,dimensionality-reduction,0.5295658
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,care,0.3144728,decision,0.58130515,data-science,0.46943653
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,traditional-care,0.5152409,style,0.58563066,component-analysis,0.5682602
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,centered,0.26747966,connected,0.5116449,dimensionality-reduction,0.43869326
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,care,0.3144728,decision,0.58130515,data-science,0.46943653
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,centered-care,0.46810907,dimensionality-reduction,0.56104267,dimensionality-reduction,0.56104267
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,care,0.3144728,decision,0.58130515,data-science,0.46943653
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,received,0.24654314,one,0.48884487,supervised,0.36404985
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,care,0.3144728,decision,0.58130515,data-science,0.46943653
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,providers,0.42136738,decision,0.6396354,data-science,0.54606366
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,care-providers,0.3850856,decision,0.574746,natural-language,0.51159275
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,care,0.3144728,decision,0.58130515,data-science,0.46943653
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,outcomes,0.38239923,short-term,0.6164659,long-short-term,0.5239928
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,hnd,0.22168215,feed,0.31967995,nlp,0.26902932
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,center,0.2469751,unit,0.5969413,data-science,0.3881536
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,two,0.35955608,one,0.79919666,clustering,0.43817294
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,groups,0.2727722,statistical,0.4438421,statistical,0.4438421
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,two-groups,0.46960184,principal-components,0.6137319,principal-components,0.6137319
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,two,0.35955608,one,0.79919666,clustering,0.43817294
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,arms,0.19280764,forward,0.4111012,numpy,0.38180867
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,two-arms,0.37653953,hidden-markov-model,0.48923838,hidden-markov-model,0.48923838
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,several,0.40139607,few,0.7607186,clustering,0.4671372
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,diagnoses,0.36627516,classification,0.5711745,classification,0.5711745
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,regional,0.3415305,of,0.48470795,clustering,0.44821864
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,database,0.5014348,data,0.6331146,data-science,0.5991977
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,previous,0.32983518,data,0.5377847,long-short-term,0.40795568
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,research,0.45694843,science,0.7194936,data-science,0.70924157
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,positive,0.26811236,of,0.49572036,component-analysis,0.37181294
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,effect,0.21449387,short-term,0.5886732,long-short-term,0.47619703
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,positive-effect,0.39337867,component-analysis,0.54256165,component-analysis,0.54256165
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,machine,0.7094662,machine,1.0,machine-learning,0.7094662
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,learning,0.709237,learning,1.0,deep-learning,0.8286492
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,machine-learning,1.0,machine-learning,1.0,machine-learning,1.0
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,kidney,0.15772529,function,0.35472965,batch-normalization,0.2715908
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,diseases,0.31957155,recurrent,0.41244444,classification,0.40266854
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,kidney-diseases,0.37285793,generative-model,0.4159481,generative-model,0.4159481
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,key,0.35973132,principal,0.614877,feature-engineering,0.498355
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,components,0.34729862,components,1.0,principal-components,0.7107156
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,key-components,0.45249745,components,0.8270838,principal-components,0.7550851
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,initial,0.31501165,of,0.6574379,batch-normalization,0.5031359
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,effects,0.2624804,short-term,0.63497096,long-short-term,0.5306107
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,high,0.267004,of,0.57459104,gradient,0.44240427
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,utilizers,0.38370574,data-engineering,0.4154038,data-engineering,0.4154038
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,high-utilizers,0.4168629,feature-reduction,0.46690294,feature-reduction,0.46690294
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,high,0.267004,of,0.57459104,gradient,0.44240427
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,level,0.23847455,of,0.54773176,batch-normalization,0.45912555
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,high-level,0.42987236,feature-engineering,0.48657054,feature-engineering,0.48657054
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,hereafter,0.29414096,fully,0.39536,relu,0.39223558
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,referred,0.37044153,of,0.52606237,supervised,0.44715232
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,different,0.37681934,of,0.61590904,clustering,0.46857932
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,specialties,0.40478784,data-science,0.55496883,data-science,0.55496883
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,diagnoses,0.36627516,classification,0.5711745,classification,0.5711745
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,profiles,0.32975978,analysis,0.60014224,component-analysis,0.47511807
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,descriptive,0.5193677,statistical,0.67267853,statistical,0.67267853
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,statistics,0.5117099,statistical,0.7675688,statistical,0.7675688
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,control,0.27050394,of,0.5093193,artificial-intelligence,0.40948874
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,group,0.26103544,of,0.44356787,statistical,0.3923795
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,control-group,0.2875058,statistical,0.4468634,statistical,0.4468634
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,health,0.36509717,data-science,0.5754831,data-science,0.5754831
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,care,0.3144728,decision,0.58130515,data-science,0.46943653
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,health-care,0.38342735,data-science,0.5536263,data-science,0.5536263
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,patients,0.30007,recurrent,0.5332828,dropout,0.3918751
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,care,0.3144728,decision,0.58130515,data-science,0.46943653
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,hnd,0.22168215,feed,0.31967995,nlp,0.26902932
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,methods,0.50049126,data,0.5400177,machine-learning,0.50049126
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,integrated,0.53518295,data-engineering,0.633208,data-engineering,0.633208
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,diagnostic,0.47116143,classification,0.5651491,classification,0.5651491
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,mcc,0.24493814,network,0.3447355,cnn,0.3321532
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,health,0.36509717,data-science,0.5754831,data-science,0.5754831
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,characteristics,0.345204,of,0.5401758,feature-engineering,0.49030614
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,variation,0.31815147,of,0.53702235,batch-normalization,0.50698346
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,sub,0.24888316,deep,0.47158134,dimensionality-reduction,0.38515002
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,similar,0.29237732,of,0.56832373,long-short-term,0.4732089
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,sicker,0.31854892,decision,0.4600651,decision-tree,0.4177562
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,shown,0.30073658,of,0.5506151,long-short-term,0.40438446
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,results,0.32376552,data,0.6932311,batch-normalization,0.44826904
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,rct,0.27889624,short-term,0.40694678,dropout,0.39453214
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,purpose,0.4149922,of,0.5072116,feature-engineering,0.43333688
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,person,0.34439647,truth,0.5306937,semantic,0.47287142
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,performed,0.3864032,analysis,0.5711501,supervised,0.4789877
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,perform,0.48924625,supervised,0.522915,supervised,0.522915
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,multidisciplinary,0.47898895,supervised,0.5768018,supervised,0.5768018
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,intervention,0.350297,supervised,0.5352158,supervised,0.5352158
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,inter,0.27781403,short,0.5159079,statistical,0.42732772
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,intensive,0.3777817,unit,0.63598263,supervised,0.5086147
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,informed,0.41308606,decision,0.7293202,data-science,0.5219193
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,indication,0.29457265,decision,0.53943455,feature-reduction,0.44814366
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,impact,0.3818503,of,0.5528908,dimensionality-reduction,0.4648105
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,however,0.31437585,few,0.63182676,statistical,0.44065386
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,heart,0.28300244,rate,0.49867767,batch-normalization,0.3427502
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,explored,0.42671436,of,0.58866113,feature-engineering,0.5368307
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,explore,0.4359874,feature-engineering,0.5121693,feature-engineering,0.5121693
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,experienced,0.33214465,one,0.53318346,supervised,0.47342923
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,expected,0.3492193,of,0.6009193,generative-model,0.4702528
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,evaluate,0.37214977,of,0.4977158,decision-tree,0.4090718
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,describe,0.47142854,feature-engineering,0.5045319,feature-engineering,0.5045319
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,counterparts,0.2626415,neighbors,0.480222,feature-engineering,0.3658591
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,conducted,0.39637828,data,0.556862,statistical,0.4670034
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,conclusion,0.35530132,data,0.5299138,long-short-term,0.45073265
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,comparison,0.38020527,analysis,0.5798166,statistical,0.52489424
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,collected,0.33035916,data,0.5686942,ground-truth,0.3838368
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,cardiovascular,0.31674606,short-term,0.442761,learning-function,0.4027721
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,beginning,0.3284063,few,0.55860555,generative,0.42997605
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,wave,0.30110258,fourier,0.49904785,fourier,0.49904785
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,morphology,0.2675687,function,0.49906468,hierarchical-clustering,0.4668909
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,might,0.3331341,of,0.5952132,long-short-term,0.42997545
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,improve,0.45207965,boosting,0.5098576,boosting,0.5098576
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,lqts,0.2900984,long-short,0.4302971,long-short-term,0.36276805
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,diagnosis,0.32391536,classification,0.53521544,classification,0.53521544
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,wave-morphology,0.4028812,convolutional-layer,0.5788212,convolutional-layer,0.5788212
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,lqts-diagnosis,0.38003546,classification-algorithm,0.5571039,classification-algorithm,0.5571039
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,extended,0.35070464,long,0.59380597,long-short-term,0.4819066
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,model,0.48485535,model,1.0,markov-model,0.7005576
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,especially,0.32290015,of,0.63661283,long-short-term,0.46837103
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,performed,0.3864032,analysis,0.5711501,supervised,0.4789877
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,better,0.4230538,of,0.5337099,feature-reduction,0.47485045
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,extended-model,0.5371492,markov-model,0.7089032,markov-model,0.7089032
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,model-especially,0.56339836,generative-model,0.6723183,generative-model,0.6723183
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,model,0.48485535,model,1.0,markov-model,0.7005576
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,improves,0.40151155,short-term,0.5473423,boosting,0.54011893
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,lqts,0.2900984,long-short,0.4302971,long-short-term,0.36276805
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,diagnosis,0.32391536,classification,0.53521544,classification,0.53521544
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,lqts-diagnosis,0.38003546,classification-algorithm,0.5571039,classification-algorithm,0.5571039
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,improve,0.45207965,boosting,0.5098576,boosting,0.5098576
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,lqts,0.2900984,long-short,0.4302971,long-short-term,0.36276805
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,diagnosis,0.32391536,classification,0.53521544,classification,0.53521544
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,lqts-diagnosis,0.38003546,classification-algorithm,0.5571039,classification-algorithm,0.5571039
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,wave,0.30110258,fourier,0.49904785,fourier,0.49904785
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,morphology,0.2675687,function,0.49906468,hierarchical-clustering,0.4668909
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,parameters,0.38939354,normalization,0.54973936,batch-normalization,0.547323
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,wave-morphology,0.4028812,convolutional-layer,0.5788212,convolutional-layer,0.5788212
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,wave,0.30110258,fourier,0.49904785,fourier,0.49904785
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,morphology,0.2675687,function,0.49906468,hierarchical-clustering,0.4668909
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,characterizations,0.43711513,analysis,0.62847626,feature-engineering,0.599119
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,wave-morphology,0.4028812,convolutional-layer,0.5788212,convolutional-layer,0.5788212
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,wave,0.30110258,fourier,0.49904785,fourier,0.49904785
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,morphology,0.2675687,function,0.49906468,hierarchical-clustering,0.4668909
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,features,0.51742536,feature,0.8268872,feature-selection,0.5487305
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,wave-morphology,0.4028812,convolutional-layer,0.5788212,convolutional-layer,0.5788212
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,retrospective,0.41400534,data,0.524399,logistic-regression,0.49798495
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,cohort,0.3892265,logistic-regression,0.5412916,logistic-regression,0.5412916
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,consisting,0.31601414,of,0.5531132,fully-connected,0.48309147
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,retrospective-cohort,0.43706983,logistic-regression,0.5578455,logistic-regression,0.5578455
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,remains,0.24202663,fully,0.5171005,bagging,0.35608193
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,challenging,0.4561266,hidden,0.5622939,feature-engineering,0.53377354
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,due,0.21681537,of,0.5734476,confusion-matrix,0.40250766
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,negative,0.21900582,of,0.48486513,feed-forward,0.34958985
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,family,0.2727693,support,0.5085263,clustering,0.40444815
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,members,0.29508376,neighbors,0.5086213,clustering,0.43552995
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,negative-family,0.3614682,neighbors,0.48203123,clustering,0.46384513
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,family-members,0.33334583,neighbors,0.5395162,clustering,0.4703678
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,external,0.24276523,connected,0.4833919,data-augmentation,0.40820563
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,cohort,0.3892265,logistic-regression,0.5412916,logistic-regression,0.5412916
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,consisting,0.31601414,of,0.5531132,fully-connected,0.48309147
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,combining,0.54477555,feature-engineering,0.60671854,feature-engineering,0.60671854
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,new,0.43019778,of,0.526482,feature-reduction,0.4579819
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,polynomial,0.5622206,regularization,0.746692,perceptron,0.6775931
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,combining-new,0.53643364,feature-engineering,0.57286894,feature-engineering,0.57286894
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,followed,0.25369444,of,0.5874107,supervised,0.45495358
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,first,0.36139184,of,0.61145455,generative,0.4096663
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,hermite,0.50678504,cross-entropy,0.6424697,cross-entropy,0.6424697
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,clinical,0.44080526,data,0.48532635,data-science,0.45343333
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,qtc,0.20024626,confusion,0.33291048,softmax,0.32517615
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,cut,0.2894359,shot,0.49446067,embeddings,0.4174049
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,best,0.4535247,decision,0.5130525,classifiers,0.47293013
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,overall,0.37212962,rate,0.62994075,dropout,0.45315623
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,accuracy,0.5511073,cross-validation,0.64088035,cross-validation,0.64088035
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,best-overall,0.43374795,softmax,0.5145483,softmax,0.5145483
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,overall-accuracy,0.5563677,segmentation-algorithm,0.63250494,segmentation-algorithm,0.63250494
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,baseline,0.32763094,normalization,0.56518495,batch-normalization,0.4727359
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,qtc,0.20024626,confusion,0.33291048,softmax,0.32517615
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,cut,0.2894359,shot,0.49446067,embeddings,0.4174049
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,lqts,0.2900984,long-short,0.4302971,long-short-term,0.36276805
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,patients,0.30007,recurrent,0.5332828,dropout,0.3918751
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,lqts-patients,0.28641874,dropout,0.43106252,dropout,0.43106252
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,first,0.36139184,of,0.61145455,generative,0.4096663
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,hg,0.19902162,gradient,0.41446126,gradient,0.41446126
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,qtc,0.20024626,confusion,0.33291048,softmax,0.32517615
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,age,0.30743492,intelligence,0.4774798,regression,0.47452933
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,wave,0.30110258,fourier,0.49904785,fourier,0.49904785
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,morphology,0.2675687,function,0.49906468,hierarchical-clustering,0.4668909
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,wave-morphology,0.4028812,convolutional-layer,0.5788212,convolutional-layer,0.5788212
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,wave,0.30110258,fourier,0.49904785,fourier,0.49904785
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,morphologies,0.32324117,hierarchical,0.6003127,hierarchical-clustering,0.58791447
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,diagnosing,0.40313917,classification,0.5332097,classification,0.5332097
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,lqts,0.2900984,long-short,0.4302971,long-short-term,0.36276805
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,patients,0.30007,recurrent,0.5332828,dropout,0.3918751
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,genotype,0.280303,logistic,0.40705204,logistic-regression,0.40549934
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,different,0.37681934,of,0.61590904,clustering,0.46857932
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,features,0.51742536,feature,0.8268872,feature-selection,0.5487305
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,best,0.4535247,decision,0.5130525,classifiers,0.47293013
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,fit,0.46463946,model,0.59496266,markov-model,0.5721518
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,best-fit,0.447972,bayesian,0.61406475,bayesian,0.61406475
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,controls,0.2521493,naive,0.47579613,statistical,0.41853178
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,weight,0.22983359,feed,0.526222,batch-normalization,0.30978125
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,coefficients,0.3492348,cross-entropy,0.5971279,cross-entropy,0.5971279
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,three,0.36911732,one,0.78425425,clustering,0.4299444
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,support,0.3815906,support,1.0,support-vector,0.66958183
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,precordial,0.3146254,confusion,0.41063756,segmentation-algorithm,0.3909576
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,leads,0.24188918,of,0.52666616,long-short-term,0.42311493
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,low,0.23602332,of,0.5820825,long-short-term,0.45172954
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,sensitivity,0.28808302,discriminative,0.5372434,cross-validation,0.48943394
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,low-sensitivity,0.34108734,discriminative,0.5348624,long-short-term,0.4797652
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,linear,0.42916322,linear,0.99999994,regression,0.66034734
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,combination,0.385488,of,0.5245792,boosting,0.5027329
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,linear-combination,0.45705736,linear,0.62626755,segmentation-algorithm,0.5851694
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,limb,0.22134939,deep,0.4425934,recurrent-neural-network,0.38869008
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,leads,0.24188918,of,0.52666616,long-short-term,0.42311493
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,limb-leads,0.32399854,segmentation-algorithm,0.48136303,segmentation-algorithm,0.48136303
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,elsevier,0.26603332,science,0.59524655,data-science,0.53140587
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,inc,0.2706048,bag,0.52860194,bagging,0.41463643
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,diagnosing,0.40313917,classification,0.5332097,classification,0.5332097
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,long,0.20028201,long,1.0,long-short-term,0.6505779
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,considerable,0.29929298,of,0.58251405,statistical,0.44682032
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,overlap,0.38858992,feature,0.58340186,clustering,0.5132319
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,average,0.3150683,rate,0.48881143,batch-normalization,0.44438002
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,complex,0.27214053,components,0.5436033,component-analysis,0.4161712
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,qt,0.2508495,long-short,0.40151817,softmax,0.36617848
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,syndrome,0.20306323,recurrent,0.42346346,confusion-matrix,0.3198145
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,qt-syndrome,0.23417094,recurrent,0.39798972,confusion-matrix,0.35791302
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,corrected,0.32759202,normalization,0.6201657,batch-normalization,0.5621621
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,qt,0.2508495,long-short,0.40151817,softmax,0.36617848
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,corrected-qt,0.42215443,batch-normalization,0.61149037,batch-normalization,0.61149037
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,models,0.53762007,model,0.8940372,markov-model,0.7015921
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,fed,0.301457,feed,0.7557408,supervised,0.35448015
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,healthy,0.31399268,naive,0.5051062,artificial-intelligence,0.3681498
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,subjects,0.34547177,descent,0.47816435,short-term-memory,0.43421033
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,healthy-subjects,0.47015825,natural-language-processing,0.53944534,natural-language-processing,0.53944534
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,finally,0.426572,of,0.64012104,generative,0.48128563
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,used,0.46049535,of,0.5630944,generative-model,0.4901716
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,model,0.48485535,model,1.0,markov-model,0.7005576
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,lqts,0.2900984,long-short,0.4302971,long-short-term,0.36276805
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,qtc,0.20024626,confusion,0.33291048,softmax,0.32517615
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,hg,0.19902162,gradient,0.41446126,gradient,0.41446126
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,age,0.30743492,intelligence,0.4774798,regression,0.47452933
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,qt,0.2508495,long-short,0.40151817,softmax,0.36617848
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,used,0.46049535,of,0.5630944,generative-model,0.4901716
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,subjects,0.34547177,descent,0.47816435,short-term-memory,0.43421033
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,models,0.53762007,model,0.8940372,markov-model,0.7015921
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,controls,0.2521493,naive,0.47579613,statistical,0.41853178
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,well,0.34264985,of,0.59718275,bagging,0.4145819
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,vector,0.45570993,vector,1.0,vector-machine,0.7596456
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,svm,0.7572857,classifiers,0.82308555,classifiers,0.82308555
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,study,0.3645851,of,0.5728763,statistical,0.44204497
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,stt,0.2594178,one-hot,0.39893216,one-hot,0.39893216
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,specific,0.3244285,of,0.6059094,clustering,0.45887482
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,sex,0.24554862,regression,0.45148212,regression,0.45148212
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,segments,0.20835683,long,0.50645375,segmentation,0.5040661
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,robustness,0.5587801,cross-entropy,0.7043761,cross-entropy,0.7043761
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,results,0.32376552,data,0.6932311,batch-normalization,0.44826904
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,published,0.42179614,data,0.6147139,data-science,0.54664624
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,polynomials,0.5212662,regularization,0.70712537,cross-entropy,0.6504
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,patient,0.2998137,confusion,0.5356896,confusion-matrix,0.41404122
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,offs,0.3043862,forward,0.4852444,batch-normalization,0.39438322
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,objective,0.4122544,of,0.5255821,component-analysis,0.42220753
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,methods,0.50049126,data,0.5400177,machine-learning,0.50049126
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,machine,0.7094662,machine,1.0,machine-learning,0.7094662
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,lqt,0.25338978,long-short,0.38073975,recurrent-neural-network,0.33022195
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,interval,0.25114498,decision,0.39202803,bayesian,0.37118626
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,ii,0.22929578,of,0.43728137,classification,0.3694628
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,gender,0.3412779,logistic,0.5728083,logistic-regression,0.5565392
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,gauss,0.4384244,regularization,0.5909213,kernel,0.562618
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,fitting,0.5384489,overfitting,0.6565988,overfitting,0.6565988
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,fitted,0.39998794,linear,0.5574912,regression,0.5374051
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,error,0.4427557,overfitting,0.6119009,overfitting,0.6119009
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,conclusion,0.35530132,data,0.5299138,long-short-term,0.45073265
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,classified,0.3846122,classification,0.68709266,classification,0.68709266
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,check,0.3157034,bag,0.48872578,batch-normalization,0.4401188
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,characterizing,0.48746985,of,0.6211066,feature-engineering,0.5950916
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,characterized,0.27792567,feature,0.5646106,fourier,0.42356855
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,characterize,0.38834387,analysis,0.5293422,feature-engineering,0.4687357
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,based,0.49998575,classification-algorithm,0.5639226,classification-algorithm,0.5639226
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,background,0.3259285,of,0.51277274,long-short-term,0.46426663
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,adding,0.39491612,of,0.6120679,boosting,0.53433573
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,reduced,0.24137571,reduction,0.7564339,boosting,0.47559226
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,left,0.2544507,tracking,0.42924023,object-tracking,0.3633091
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,ventricular,0.24852064,rate,0.37094042,long-short-term,0.34148398
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,ejection,0.30230433,function,0.43955976,gradient,0.35697576
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,fraction,0.25137818,component,0.50911963,gradient,0.48876822
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,left-ventricular,0.30000108,batch-normalization,0.40942025,batch-normalization,0.40942025
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,ventricular-ejection,0.26988763,rate,0.43059248,gradient,0.41159958
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,ejection-fraction,0.36681443,stochastic-gradient,0.5523829,stochastic-gradient,0.5523829
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,mineralocorticoid,0.2177006,short-term,0.3448191,long-short-term,0.32826918
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,receptor,0.22411162,function,0.41526195,clustering,0.36801085
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,antagonists,0.24215083,discriminative,0.39012936,learning-function,0.31474212
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,mineralocorticoid-receptor,0.24360989,function,0.35304862,batch-normalization,0.34086508
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,receptor-antagonists,0.23002487,discriminative,0.38725716,feed-forward,0.3471454
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,mineralocorticoid-receptor-antagonists,0.2412014,short-term,0.36669463,feed-forward,0.34416416
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,angiotensin,0.21236175,matrix,0.35242182,feed-forward,0.31253523
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,receptor,0.22411162,function,0.41526195,clustering,0.36801085
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,blockers,0.19200467,augmentation,0.36206824,long-short-term,0.31719163
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,angiotensin-receptor,0.24978769,matrix,0.3305658,confusion-matrix,0.30484858
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,receptor-blockers,0.22819279,short-term,0.3749142,regression,0.3211386
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,angiotensin-receptor-blockers,0.217114,short-term,0.34574157,dropout,0.30021757
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,reduced,0.24137571,reduction,0.7564339,boosting,0.47559226
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,ejection,0.30230433,function,0.43955976,gradient,0.35697576
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,fraction,0.25137818,component,0.50911963,gradient,0.48876822
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,reduced-ejection,0.3536169,data-augmentation,0.49796093,data-augmentation,0.49796093
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,ejection-fraction,0.36681443,stochastic-gradient,0.5523829,stochastic-gradient,0.5523829
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,remained,0.16570066,fully,0.51440436,bagging,0.35868454
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,similar,0.29237732,of,0.56832373,long-short-term,0.4732089
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,previously,0.31365848,fully,0.5461891,long-short-term,0.40718085
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,published,0.42179614,data,0.6147139,data-science,0.54664624
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,registries,0.3656261,federated,0.56838566,data-science,0.54973173
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,similar,0.29237732,of,0.56832373,long-short-term,0.4732089
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,previously-published,0.5093185,data,0.6091289,graphics-processing,0.55212224
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,esc,0.25699985,neural,0.4043423,feature-engineering,0.34129012
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,heart,0.28300244,rate,0.49867767,batch-normalization,0.3427502
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,failure,0.32964212,recurrent,0.52057266,confusion-matrix,0.44323406
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,published,0.42179614,data,0.6147139,data-science,0.54664624
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,heart-failure,0.36450487,long-short-term,0.44014218,long-short-term,0.44014218
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,patients,0.30007,recurrent,0.5332828,dropout,0.3918751
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,reached,0.2565554,of,0.53159845,batch-normalization,0.42460278
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,target,0.31799266,of,0.4775706,feature-selection,0.44359237
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,doses,0.1979529,of,0.43779314,boosting,0.42837995
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,esc,0.25699985,neural,0.4043423,feature-engineering,0.34129012
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,hf,0.293398,long-short-term,0.35116297,long-short-term,0.35116297
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,guidelines,0.41964787,decision,0.5691749,classification-algorithm,0.5532488
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,despite,0.27514282,few,0.5803892,long-short-term,0.43284553
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,esc-hf,0.3341534,naive-bayes,0.41578367,naive-bayes,0.41578367
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,mineralocorticoid,0.2177006,short-term,0.3448191,long-short-term,0.32826918
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,receptor,0.22411162,function,0.41526195,clustering,0.36801085
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,antagonists,0.24215083,discriminative,0.39012936,learning-function,0.31474212
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,mineralocorticoid-receptor,0.24360989,function,0.35304862,batch-normalization,0.34086508
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,receptor-antagonists,0.23002487,discriminative,0.38725716,feed-forward,0.3471454
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,mineralocorticoid-receptor-antagonists,0.2412014,short-term,0.36669463,feed-forward,0.34416416
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,esc,0.25699985,neural,0.4043423,feature-engineering,0.34129012
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,hf,0.293398,long-short-term,0.35116297,long-short-term,0.35116297
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,guidelines,0.41964787,decision,0.5691749,classification-algorithm,0.5532488
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,recommendations,0.40738833,decision,0.6199442,classification-algorithm,0.5130223
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,esc-hf,0.3341534,naive-bayes,0.41578367,naive-bayes,0.41578367
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,angiotensin,0.21236175,matrix,0.35242182,feed-forward,0.31253523
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,receptor,0.22411162,function,0.41526195,clustering,0.36801085
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,blockers,0.19200467,augmentation,0.36206824,long-short-term,0.31719163
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,angiotensin-receptor,0.24978769,matrix,0.3305658,confusion-matrix,0.30484858
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,receptor-blockers,0.22819279,short-term,0.3749142,regression,0.3211386
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,angiotensin-receptor-blockers,0.217114,short-term,0.34574157,dropout,0.30021757
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,angiotensin,0.21236175,matrix,0.35242182,feed-forward,0.31253523
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,april,0.23971057,science,0.43506294,data-science,0.36705714
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,respectively,0.23184536,of,0.43360457,cross-validation,0.35765702
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,converting,0.30355832,of,0.48566324,graphics-processing,0.44267887
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,enzyme,0.21657495,encoding,0.44885126,feature-reduction,0.38085908
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,inhibitors,0.25381407,cascade,0.4157439,feed-forward,0.3175553
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,converting-enzyme,0.27783775,graphics-processing,0.39753565,graphics-processing,0.39753565
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,enzyme-inhibitors,0.2689559,feature-reduction,0.36576074,feature-reduction,0.36576074
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,converting-enzyme-inhibitors,0.28889734,feature-reduction,0.39039016,feature-reduction,0.39039016
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,converting,0.30355832,of,0.48566324,graphics-processing,0.44267887
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,enzyme,0.21657495,encoding,0.44885126,feature-reduction,0.38085908
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,inhibitor,0.21582735,cascade,0.38918662,feed-forward,0.33560163
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,converting-enzyme,0.27783775,graphics-processing,0.39753565,graphics-processing,0.39753565
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,enzyme-inhibitor,0.2843934,confusion-matrix,0.40808702,confusion-matrix,0.40808702
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,converting-enzyme-inhibitor,0.28342104,confusion-matrix,0.3920804,confusion-matrix,0.3920804
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,enrolled,0.3208215,supervised,0.42658707,supervised,0.42658707
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,patients,0.30007,recurrent,0.5332828,dropout,0.3918751
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,sacubitril,0.2503674,softmax,0.29302943,softmax,0.29302943
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,catalan,0.34036678,natural-language,0.56032276,natural-language,0.56032276
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,hospitals,0.3611768,federated,0.5191455,data-science,0.48155567
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,results,0.32376552,data,0.6932311,batch-normalization,0.44826904
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,also,0.32850838,of,0.65908813,clustering,0.45826355
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,suggest,0.26874092,data,0.5391823,long-short-term,0.40288782
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,results-also,0.42109147,data,0.53291214,batch-normalization,0.4941916
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,outpatient,0.32741785,supervised,0.5282031,supervised,0.5282031
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,cardiology,0.36460787,data-science,0.5008054,data-science,0.5008054
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,clinics,0.36601138,federated,0.5085162,supervised,0.4989932
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,linx,0.29177636,artificial-intelligence,0.44978774,artificial-intelligence,0.44978774
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,registry,0.31939733,federated,0.5197936,data-science,0.4680016
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,shows,0.2765087,of,0.56087804,feature-reduction,0.39955372
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,target,0.31799266,of,0.4775706,feature-selection,0.44359237
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,doses,0.1979529,of,0.43779314,boosting,0.42837995
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,heart,0.28300244,rate,0.49867767,batch-normalization,0.3427502
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,failure,0.32964212,recurrent,0.52057266,confusion-matrix,0.44323406
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,heart-failure,0.36450487,long-short-term,0.44014218,long-short-term,0.44014218
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,esc,0.25699985,neural,0.4043423,feature-engineering,0.34129012
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,guidelines,0.41964787,decision,0.5691749,classification-algorithm,0.5532488
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,esc-guidelines,0.42309523,classification-algorithm,0.5511715,classification-algorithm,0.5511715
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,february,0.2361417,science,0.4573572,data-science,0.39795965
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,may,0.30907542,of,0.58654004,long-short-term,0.43985203
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,previous,0.32983518,data,0.5377847,long-short-term,0.40795568
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,registries,0.3656261,federated,0.56838566,data-science,0.54973173
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,pharmacological,0.32013503,of,0.48491696,learning-function,0.4119643
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,recommendations,0.40738833,decision,0.6199442,classification-algorithm,0.5130223
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,hf,0.293398,long-short-term,0.35116297,long-short-term,0.35116297
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,drugs,0.30897486,of,0.42460242,classifiers,0.33720028
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,hf-drugs,0.40540618,tfidf,0.41314226,tfidf,0.41314226
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,linx,0.29177636,artificial-intelligence,0.44978774,artificial-intelligence,0.44978774
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,registry,0.31939733,federated,0.5197936,data-science,0.4680016
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,sons,0.24153107,neighbors,0.42599985,artificial-intelligence,0.3507973
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,ltd,0.17568776,long-short-term-memory,0.37555107,long-short-term-memory,0.37555107
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,new,0.43019778,of,0.526482,feature-reduction,0.4579819
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,version,0.42881647,computer,0.4811054,natural-language,0.47869903
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,new-version,0.45198312,dimensionality-reduction,0.59238076,dimensionality-reduction,0.59238076
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,monotherapy,0.2469272,short-term,0.43261433,dropout,0.37552747
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,decreased,0.23506472,reduction,0.66483074,boosting,0.42738107
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,low,0.23602332,of,0.5820825,long-short-term,0.45172954
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,proportion,0.24881616,reduction,0.5001526,clustering,0.44429505
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,low-proportion,0.34052467,long-short-term,0.49688902,long-short-term,0.49688902
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,john,0.22368689,science,0.49282092,data-science,0.42671943
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,wiley,0.26784617,science,0.5360337,data-science,0.46017712
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,hospitals,0.3611768,federated,0.5191455,data-science,0.48155567
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,according,0.3602386,classification,0.6492659,classification,0.6492659
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,european,0.25183123,federated,0.5800549,data-science,0.42842963
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,society,0.29418135,science,0.5518952,data-science,0.5205302
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,appropriate,0.34253043,decision,0.57744575,confusion-matrix,0.45587587
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,adherence,0.24866252,short-term,0.4634843,dropout,0.44456872
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,appropriate-adherence,0.35518524,short-term,0.50914854,reinforcement-learning,0.49509007
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,almost,0.2402496,few,0.5824453,generative,0.36206198
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,one,0.335046,one,1.0,one-hot,0.4275648
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,sectional,0.32761967,dimensionality,0.4547644,ground-truth,0.43991083
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,study,0.3645851,of,0.5728763,statistical,0.44204497
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,sectional-study,0.48882532,principal-component-analysis,0.5959736,principal-component-analysis,0.5959736
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,higher,0.27819592,reduction,0.545787,boosting,0.41506222
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,level,0.23847455,of,0.54773176,batch-normalization,0.45912555
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,higher-level,0.5617593,semantic,0.6494054,semantic,0.6494054
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,esc,0.25699985,neural,0.4043423,feature-engineering,0.34129012
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,blockers,0.19200467,augmentation,0.36206824,long-short-term,0.31719163
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,angiotensin,0.21236175,matrix,0.35242182,feed-forward,0.31253523
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,hf,0.293398,long-short-term,0.35116297,long-short-term,0.35116297
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,guidelines,0.41964787,decision,0.5691749,classification-algorithm,0.5532488
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,patients,0.30007,recurrent,0.5332828,dropout,0.3918751
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,sacubitril,0.2503674,softmax,0.29302943,softmax,0.29302943
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,results,0.32376552,data,0.6932311,batch-normalization,0.44826904
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,registry,0.31939733,federated,0.5197936,data-science,0.4680016
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,hospitals,0.3611768,federated,0.5191455,data-science,0.48155567
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,cardiology,0.36460787,data-science,0.5008054,data-science,0.5008054
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,study,0.3645851,of,0.5728763,statistical,0.44204497
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,level,0.23847455,of,0.54773176,batch-normalization,0.45912555
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,valsartan,0.23053317,softmax,0.32515165,softmax,0.32515165
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,use,0.43753043,of,0.5506158,feature-reduction,0.49910897
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,treatment,0.239264,short-term,0.5206091,long-short-term,0.41699445
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,titration,0.24766257,batch,0.44303173,batch-normalization,0.44135973
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,released,0.20576447,of,0.48016924,generative,0.3306319
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,quarter,0.27887166,one,0.53984976,one-hot,0.39879453
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,publication,0.4165166,data-science,0.64893234,data-science,0.64893234
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,prescription,0.3508556,decision,0.48317343,supervised,0.43501857
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,prescribed,0.29896754,supervised,0.4962438,supervised,0.4962438
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,population,0.2958798,selection,0.5071889,clustering,0.47966808
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,observational,0.46483666,data,0.5993095,data-science,0.5474411
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,multicentre,0.3350155,data,0.41933888,decision-tree,0.40981406
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,months,0.25947675,short-term,0.51117545,regression,0.43146035
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,methods,0.50049126,data,0.5400177,machine-learning,0.50049126
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,management,0.38786528,decision,0.59816897,decision-tree,0.49756956
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,ivabradine,0.28964567,rate,0.362122,batch-normalization,0.3495861
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,greater,0.2528603,of,0.59163296,long-short-term,0.44578376
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,describe,0.47142854,feature-engineering,0.5045319,feature-engineering,0.5045319
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,cross,0.22060364,shot,0.42420566,cross-entropy,0.41595078
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,consequence,0.2850999,of,0.5766497,stochastic,0.5059791
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,conclusions,0.37109232,data,0.55923915,long-short-term,0.4627594
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,complexity,0.5197527,dimensionality,0.67757803,dimensionality-reduction,0.6318618
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,compared,0.3359061,of,0.52794564,long-short-term,0.42386633
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,class,0.353845,multi-class,0.5162764,classification,0.4708274
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,beta,0.16640052,of,0.43937695,long-short-term,0.33801323
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,behalf,0.26374853,adversarial,0.5247171,data-science,0.51911336
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,authors,0.45811802,data,0.5259881,natural-language-processing,0.4706872
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,aims,0.42995954,of,0.465683,feature-engineering,0.4555406
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,aim,0.4029312,feature-engineering,0.41751927,feature-engineering,0.41751927
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,accomplished,0.35906243,of,0.58169246,supervised,0.46376693
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,new,0.43019778,of,0.526482,feature-reduction,0.4579819
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,dihydropyridine,0.19378793,unit,0.35049394,centroid-based,0.32282513
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,calcium,0.1688616,of,0.4092465,batch-normalization,0.32412365
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,channel,0.22694653,rectified,0.5908533,fully-connected,0.3853672
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,blockers,0.19200467,augmentation,0.36206824,long-short-term,0.31719163
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,dihydropyridine-calcium,0.21499002,cascade,0.36890817,feature-reduction,0.3302008
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,calcium-channel,0.21559022,rectified,0.36678898,recurrent-neural-network,0.32807642
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,channel-blockers,0.2624011,rectified,0.4616939,recurrent-neural-network,0.3494621
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,calcium-channel-blockers,0.2228401,rectified,0.37417394,long-short-term,0.33241332
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,mmol,0.15849689,batch,0.3925764,gradient,0.31515598
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,creatinine,0.22273314,batch-normalization,0.44722414,batch-normalization,0.44722414
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,mg,0.22385968,one,0.49652064,confusion-matrix,0.33858854
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,diabetic,0.24483135,of,0.40444782,generative-model,0.34931552
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,hypertensive,0.24280556,confusion,0.39384258,dropout,0.38042948
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,patients,0.30007,recurrent,0.5332828,dropout,0.3918751
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,treated,0.19958335,of,0.5218221,long-short-term,0.35705733
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,diabetic-hypertensive,0.25962204,batch-normalization,0.35621998,batch-normalization,0.35621998
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,patients-treated,0.24310255,naive,0.5169474,dropout,0.3840875
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,calcium,0.1688616,of,0.4092465,batch-normalization,0.32412365
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,channel,0.22694653,rectified,0.5908533,fully-connected,0.3853672
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,blockers,0.19200467,augmentation,0.36206824,long-short-term,0.31719163
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,calcium-channel,0.21559022,rectified,0.36678898,recurrent-neural-network,0.32807642
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,channel-blockers,0.2624011,rectified,0.4616939,recurrent-neural-network,0.3494621
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,calcium-channel-blockers,0.2228401,rectified,0.37417394,long-short-term,0.33241332
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,diabetic,0.24483135,of,0.40444782,generative-model,0.34931552
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,hypertensive,0.24280556,confusion,0.39384258,dropout,0.38042948
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,patients,0.30007,recurrent,0.5332828,dropout,0.3918751
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,diabetic-hypertensive,0.25962204,batch-normalization,0.35621998,batch-normalization,0.35621998
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,validated,0.5041009,cross-validation,0.58167183,cross-validation,0.58167183
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,digital,0.477605,computer,0.65233046,computer-vision,0.64728856
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,device,0.3480761,computer-vision,0.53478765,computer-vision,0.53478765
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,significant,0.29367286,statistical,0.582669,statistical,0.582669
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,difference,0.30501923,statistical,0.58389574,statistical,0.58389574
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,among,0.33676732,of,0.57348,clustering,0.49404603
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,significant-difference,0.5025467,statistical,0.6970428,statistical,0.6970428
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,clinitek,0.3533402,batch,0.44946873,softmax,0.43329296
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,device,0.3480761,computer-vision,0.53478765,computer-vision,0.53478765
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,analyzer,0.36496788,computer-vision,0.52616334,computer-vision,0.52616334
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,angiotensin,0.21236175,matrix,0.35242182,feed-forward,0.31253523
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,aldosterone,0.1929466,batch-normalization,0.3580841,batch-normalization,0.3580841
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,system,0.3589455,generative-model,0.49815983,generative-model,0.49815983
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,angiotensin-aldosterone,0.22349332,batch-normalization,0.3440629,batch-normalization,0.3440629
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,mean,0.24598047,reduction,0.46440193,batch-normalization,0.434582
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,age,0.30743492,intelligence,0.4774798,regression,0.47452933
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,mean-age,0.36020356,logistic-regression,0.4738658,logistic-regression,0.4738658
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,different,0.37681934,of,0.61590904,clustering,0.46857932
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,drug,0.31867066,of,0.44600964,confusion-matrix,0.3956731
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,combinations,0.36110437,selection,0.5790795,feature-selection,0.49289522
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,drug-combinations,0.42170393,feature-selection,0.47556275,feature-selection,0.47556275
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,mg,0.22385968,one,0.49652064,confusion-matrix,0.33858854
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,albumin,0.22195332,batch-normalization,0.3835964,batch-normalization,0.3835964
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,unselected,0.31268442,selection,0.53035414,long-short-term,0.44738114
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,patients,0.30007,recurrent,0.5332828,dropout,0.3918751
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,males,0.23722412,descent,0.48490888,generative,0.409998
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,p,0.26795468,support,0.40805867,regression,0.40253854
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,lercanidipine,0.23442611,softmax,0.34732014,softmax,0.34732014
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,amlodipine,0.21553871,softmax,0.3309914,softmax,0.3309914
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,macroalbuminuria,0.24644944,logistic-regression,0.3813094,logistic-regression,0.3813094
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,mmol,0.15849689,batch,0.3925764,gradient,0.31515598
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,creatinine,0.22273314,batch-normalization,0.44722414,batch-normalization,0.44722414
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,mg,0.22385968,one,0.49652064,confusion-matrix,0.33858854
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,creatinine,0.22273314,batch-normalization,0.44722414,batch-normalization,0.44722414
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,ratio,0.19492707,rate,0.48224086,regression,0.41092375
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,years,0.32825696,intelligence,0.42702603,regression,0.3811771
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,months,0.25947675,short-term,0.51117545,regression,0.43146035
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,urinary,0.1650207,recurrent,0.36951765,batch-normalization,0.3133106
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,albumin,0.22195332,batch-normalization,0.3835964,batch-normalization,0.3835964
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,urinary-albumin,0.21676707,batch-normalization,0.38862073,batch-normalization,0.38862073
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,several,0.40139607,few,0.7607186,clustering,0.4671372
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,combinations,0.36110437,selection,0.5790795,feature-selection,0.49289522
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,subjects,0.34547177,descent,0.47816435,short-term-memory,0.43421033
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,similar,0.29237732,of,0.56832373,long-short-term,0.4732089
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,effect,0.21449387,short-term,0.5886732,long-short-term,0.47619703
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,similar-effect,0.4125065,cross-entropy,0.6356142,cross-entropy,0.6356142
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,renal,0.24304676,of,0.44795883,batch-normalization,0.32135162
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,outcomes,0.38239923,short-term,0.6164659,long-short-term,0.5239928
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,renal-outcomes,0.4363191,reinforcement-learning,0.5238619,reinforcement-learning,0.5238619
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,raas,0.26324448,batch-normalization,0.37994117,batch-normalization,0.37994117
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,inhibitors,0.25381407,cascade,0.4157439,feed-forward,0.3175553
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,raas-inhibitors,0.29858747,short-term,0.35669982,batch-normalization,0.34433544
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,pait,0.26834357,recurrent,0.4431019,supervised,0.38918602
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,survey,0.3824309,data,0.5356909,data-science,0.4980834
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,low,0.23602332,of,0.5820825,long-short-term,0.45172954
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,number,0.2996383,few,0.57847273,clustering,0.4387715
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,low-number,0.374609,stochastic-gradient,0.5590123,stochastic-gradient,0.5590123
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,kidney,0.15772529,function,0.35472965,batch-normalization,0.2715908
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,disease,0.296938,recurrent,0.4731025,classification,0.35271814
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,kidney-disease,0.3797998,logistic-regression,0.42294642,logistic-regression,0.42294642
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,early,0.32400474,short-term,0.57188475,long-short-term,0.50726265
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,marker,0.31352368,of,0.4506512,clustering,0.37936708
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,early-marker,0.39424428,generative,0.45397404,generative,0.45397404
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,decreased,0.23506472,reduction,0.66483074,boosting,0.42738107
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,occurrence,0.30364993,of,0.6225994,clustering,0.4847598
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,blood,0.16939776,normalization,0.4272251,batch-normalization,0.40715772
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,pressure,0.2060274,gradient,0.4962673,gradient,0.4962673
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,blood-pressure,0.2672683,batch-normalization,0.4510358,batch-normalization,0.4510358
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,without,0.31691062,of,0.5951073,long-short-term,0.4268921
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,albuminuria,0.26090467,batch-normalization,0.4054845,batch-normalization,0.4054845
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,control,0.27050394,of,0.5093193,artificial-intelligence,0.40948874
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,albuminuria,0.26090467,batch-normalization,0.4054845,batch-normalization,0.4054845
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,albuminuria,0.26090467,batch-normalization,0.4054845,batch-normalization,0.4054845
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,translates,0.39658672,of,0.5055193,generative,0.4578531
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,significantly,0.27887642,of,0.5214151,long-short-term,0.39056638
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,lowered,0.18627976,reduction,0.65848374,boosting,0.464316
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,significantly,0.27887642,of,0.5214151,long-short-term,0.39056638
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,higher,0.27819592,reduction,0.545787,boosting,0.41506222
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,significantly-higher,0.29000503,rate,0.5078902,boosting,0.4130143
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,treatments,0.26565588,short-term,0.48925674,long-short-term,0.39913934
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,decrease,0.23670179,reduction,0.82910776,boosting,0.45522925
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,previous,0.32983518,data,0.5377847,long-short-term,0.40795568
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,treatment,0.239264,short-term,0.5206091,long-short-term,0.41699445
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,previous-treatment,0.340545,short-term,0.6024548,long-short-term,0.5646151
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,g,0.17250246,feed,0.40076,n-gram,0.27758121
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,enalapril,0.21186753,short-term,0.32675815,softmax,0.31497574
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,compared,0.3359061,of,0.52794564,long-short-term,0.42386633
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,enalapril-compared,0.3596309,batch-normalization,0.42578796,batch-normalization,0.42578796
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,analysed,0.367141,analysis,0.6864278,component-analysis,0.5451744
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,data,0.46434748,data,1.0,data-science,0.5533528
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,amlodipine,0.21553871,softmax,0.3309914,softmax,0.3309914
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,perindopril,0.2525813,supervised,0.34886077,supervised,0.34886077
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,amlodipine-perindopril,0.26366693,segmentation-algorithm,0.36394066,segmentation-algorithm,0.36394066
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,ramipril,0.24136904,dropout,0.3365736,dropout,0.3365736
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,albuminuria,0.26090467,batch-normalization,0.4054845,batch-normalization,0.4054845
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,patients,0.30007,recurrent,0.5332828,dropout,0.3918751
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,p,0.26795468,support,0.40805867,regression,0.40253854
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,macroalbuminuria,0.24644944,logistic-regression,0.3813094,logistic-regression,0.3813094
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,lercanidipine,0.23442611,softmax,0.34732014,softmax,0.34732014
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,amlodipine,0.21553871,softmax,0.3309914,softmax,0.3309914
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,albuminuria,0.26090467,batch-normalization,0.4054845,batch-normalization,0.4054845
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,significantly,0.27887642,of,0.5214151,long-short-term,0.39056638
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,treatments,0.26565588,short-term,0.48925674,long-short-term,0.39913934
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,treatment,0.239264,short-term,0.5206091,long-short-term,0.41699445
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,subjects,0.34547177,descent,0.47816435,short-term-memory,0.43421033
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,ramipril,0.24136904,dropout,0.3365736,dropout,0.3365736
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,perindopril,0.2525813,supervised,0.34886077,supervised,0.34886077
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,g,0.17250246,feed,0.40076,n-gram,0.27758121
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,enalapril,0.21186753,short-term,0.32675815,softmax,0.31497574
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,data,0.46434748,data,1.0,data-science,0.5533528
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,verapamil,0.15715419,augmentation,0.37120128,long-short-term,0.3069136
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,valsartan,0.23053317,softmax,0.32515165,softmax,0.32515165
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,using,0.47332245,analysis,0.5968549,component-analysis,0.526608
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,use,0.43753043,of,0.5506158,feature-reduction,0.49910897
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,trandolapril,0.23162031,softmax,0.33527014,softmax,0.33527014
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,showing,0.2942307,of,0.65089273,generative,0.4462347
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,results,0.32376552,data,0.6932311,batch-normalization,0.44826904
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,renin,0.22382896,normalization,0.36536643,batch-normalization,0.34999466
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,reduction,0.22531602,reduction,1.0,feature-reduction,0.59547573
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,reduced,0.24137571,reduction,0.7564339,boosting,0.47559226
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,prevalence,0.2908883,rate,0.45596814,dropout,0.4310696
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,present,0.39618495,of,0.63723874,generative,0.48216146
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,normoalbuminuria,0.24098578,logistic-regression,0.3805732,logistic-regression,0.3805732
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,nitrendipine,0.19841793,rate,0.3529254,softmax,0.30387923
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,microalbuminuria,0.27848715,batch-normalization,0.40940595,batch-normalization,0.40940595
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,methods,0.50049126,data,0.5400177,machine-learning,0.50049126
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,measured,0.25103813,of,0.539739,batch-normalization,0.45439726
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,maintained,0.2353631,of,0.5370453,long-short-term,0.46462637
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,loss,0.26544642,reduction,0.62177265,dropout,0.42517614
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,introduction,0.37159568,of,0.5877248,feature-engineering,0.47346386
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,frequency,0.2874047,rate,0.5399102,long-short-term,0.4518629
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,felodipine,0.18635236,rate,0.3289777,softmax,0.3279845
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,favoring,0.23114672,of,0.5335792,feature-reduction,0.48474675
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,evaluate,0.37214977,of,0.4977158,decision-tree,0.4090718
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,due,0.21681537,of,0.5734476,confusion-matrix,0.40250766
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,defined,0.3575971,of,0.529315,classification,0.50848204
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,conclusions,0.37109232,data,0.55923915,long-short-term,0.4627594
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,combined,0.39749897,of,0.5690281,one-shot,0.52384484
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,changes,0.28767496,normalization,0.57879114,batch-normalization,0.43861648
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,cardiovascular,0.31674606,short-term,0.442761,learning-function,0.4027721
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,baseline,0.32763094,normalization,0.56518495,batch-normalization,0.4727359
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,assessed,0.33986524,of,0.605934,component-analysis,0.41855076
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,analyzed,0.38529366,analysis,0.6994013,component-analysis,0.5263994
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,aims,0.42995954,of,0.465683,feature-engineering,0.4555406
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,forest,0.4787075,forest,1.0,random-forest,0.7738863
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,prognostic,0.4482512,classifiers,0.50372314,classifiers,0.50372314
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,model,0.48485535,model,1.0,markov-model,0.7005576
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,using,0.47332245,analysis,0.5968549,component-analysis,0.526608
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,features,0.51742536,feature,0.8268872,feature-selection,0.5487305
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,model-using,0.6327779,markov-model,0.7362481,markov-model,0.7362481
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,constructed,0.46166873,vector,0.5928328,feature-engineering,0.5708643
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,showed,0.20766163,of,0.5296177,regression,0.37027335
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,comparable,0.29340464,short-term,0.5384172,long-short-term,0.45359015
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,predicting,0.521454,classification-algorithm,0.5589481,classification-algorithm,0.5589481
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,accuracy,0.5511073,cross-validation,0.64088035,cross-validation,0.64088035
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,constructed,0.46166873,vector,0.5928328,feature-engineering,0.5708643
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,using,0.47332245,analysis,0.5968549,component-analysis,0.526608
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,computational,0.6708919,machine-learning,0.6708919,machine-learning,0.6708919
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,approaches,0.55614823,feature-engineering,0.60571706,feature-engineering,0.60571706
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,receiver,0.45132244,logistic,0.6124048,logistic-regression,0.57750404
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,operating,0.38906178,machine,0.49189845,graphics-processing,0.47077706
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,characteristic,0.34942827,feature,0.7124056,clustering,0.48287967
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,curve,0.29765248,linear,0.52257633,regression,0.49561262
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,receiver-operating,0.4694291,logistic,0.6941327,logistic-regression,0.6736918
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,operating-characteristic,0.503636,discriminative,0.62105864,principal-component-analysis,0.5886377
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,characteristic-curve,0.4523504,logistic-regression,0.590831,logistic-regression,0.590831
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,receiver-operating-characteristic,0.503338,logistic-regression,0.6653639,logistic-regression,0.6653639
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,e,0.13297717,natural,0.39189428,component-analysis,0.28603846
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,stained,0.21173327,embeddings,0.46531138,embeddings,0.46531138
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,whole,0.3066609,of,0.548425,batch-normalization,0.49255443
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,term,0.33795053,term,1.0,long-short-term,0.62770975
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,survival,0.29004025,short-term,0.53135407,long-short-term,0.4573617
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,groups,0.2727722,statistical,0.4438421,statistical,0.4438421
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,according,0.3602386,classification,0.6492659,classification,0.6492659
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,term-survival,0.35680708,term,0.51277125,long-short-term,0.46569207
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,groups-according,0.35497624,classification,0.5353061,classification,0.5353061
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,quantitative,0.4330744,analysis,0.6747154,component-analysis,0.558002
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,image,0.5164337,segmentation,0.7261368,segmentation,0.7261368
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,features,0.51742536,feature,0.8268872,feature-selection,0.5487305
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,image-features,0.67678905,object-tracking,0.74212396,object-tracking,0.74212396
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,west,0.2518829,forest,0.5750145,random-forest,0.47122505
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,china,0.33313718,forest,0.5247432,random-forest,0.43039554
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,hospital,0.2768838,unit,0.588941,data-science,0.39080185
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,west-china,0.25945646,federated,0.51015335,random-forest,0.47378728
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,tnm,0.34285188,classification,0.51704764,classification,0.51704764
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,staging,0.4282661,classification,0.6301632,classification,0.6301632
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,systems,0.40840507,components,0.5468041,feature-engineering,0.5135208
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,tnm-staging,0.3748222,classification,0.5424533,classification,0.5424533
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,staging-systems,0.540706,classification-algorithm,0.6114006,classification-algorithm,0.6114006
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,tnm-staging-systems,0.49167687,classification-algorithm,0.5896743,classification-algorithm,0.5896743
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,fully,0.35142052,fully,1.0,fully-connected,0.479315
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,automated,0.59409094,computer,0.65719736,computer-vision,0.6319458
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,pipeline,0.6340066,machine-learning,0.6340066,machine-learning,0.6340066
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,fully-automated,0.6318835,segmentation,0.66880524,segmentation,0.66880524
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,automated-pipeline,0.69670653,machine-learning,0.69670653,machine-learning,0.69670653
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,external,0.24276523,connected,0.4833919,data-augmentation,0.40820563
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,validation,0.5362086,cross-validation,0.74016297,cross-validation,0.74016297
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,sets,0.56201714,data,0.64498734,classifiers,0.6231737
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,external-validation,0.5778746,cross-validation,0.7483893,cross-validation,0.7483893
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,validation-sets,0.6394471,cross-validation,0.6830417,cross-validation,0.6830417
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,distinguish,0.4136919,discriminative,0.5568397,classification,0.4541072
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,hepatocellular,0.27745682,recurrent,0.3445,dropout,0.31920356
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,carcinoma,0.22882068,recurrent,0.4219923,recurrent-neural-network,0.31928775
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,hepatocellular-carcinoma,0.27856165,recurrent,0.3306688,recurrent-neural-network,0.32398444
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,different,0.37681934,of,0.61590904,clustering,0.46857932
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,time,0.31186903,long,0.57547164,batch-normalization,0.47628766
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,points,0.3419253,of,0.4826713,segmentation-algorithm,0.44694978
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,different-time,0.41522157,cross-entropy,0.53656876,cross-entropy,0.53656876
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,time-points,0.33956447,short-term,0.44880888,batch-normalization,0.41509414
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,develop,0.4619095,generative,0.52892005,generative,0.52892005
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,quantitative,0.4330744,analysis,0.6747154,component-analysis,0.558002
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,feature,0.5878884,feature,0.99999994,feature-selection,0.6322505
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,cancer,0.27383438,recurrent,0.4065063,generative,0.3468409
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,genome,0.4030719,encoding,0.5035916,clustering,0.41891688
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,atlas,0.47819,segmentation,0.58426917,segmentation,0.58426917
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,cancer-genome,0.43351012,hierarchical-clustering,0.47030208,hierarchical-clustering,0.47030208
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,genome-atlas,0.5716713,machine-learning,0.5716713,machine-learning,0.5716713
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,assigned,0.33371645,one,0.48061687,supervised,0.45563483
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,risk,0.35860935,recurrent,0.53675485,logistic-regression,0.52381086
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,scores,0.40591323,intelligence,0.56987673,principal-components,0.4971624
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,assigned-risk,0.43967026,classification-algorithm,0.5435153,classification-algorithm,0.5435153
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,risk-scores,0.5303495,classification-algorithm,0.6701063,classification-algorithm,0.6701063
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,adjacent,0.20600006,nearest,0.584751,nearest-neighbors,0.46469045
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,normal,0.22889833,function,0.57724285,batch-normalization,0.4663512
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,tissues,0.21297011,of,0.47614664,generative,0.371554
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,adjacent-normal,0.32572567,segmentation-algorithm,0.5006708,segmentation-algorithm,0.5006708
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,normal-tissues,0.3600987,batch-normalization,0.5370549,batch-normalization,0.5370549
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,adjacent,0.20600006,nearest,0.584751,nearest-neighbors,0.46469045
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,normal,0.22889833,function,0.57724285,batch-normalization,0.4663512
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,tissue,0.23679586,of,0.5202017,segmentation,0.4076932
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,adjacent-normal,0.32572567,segmentation-algorithm,0.5006708,segmentation-algorithm,0.5006708
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,normal-tissue,0.3625743,batch-normalization,0.55140346,batch-normalization,0.55140346
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,diagnostic,0.47116143,classification,0.5651491,classification,0.5651491
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,classifier,0.7923145,classifiers,0.9369072,classifiers,0.9369072
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,based,0.49998575,classification-algorithm,0.5639226,classification-algorithm,0.5639226
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,classifier-based,0.81608856,classifiers,0.88412046,classifiers,0.88412046
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,classify,0.6052253,classification,0.76345325,classification,0.76345325
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,tissue,0.23679586,of,0.5202017,segmentation,0.4076932
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,slides,0.32076606,embeddings,0.5194787,embeddings,0.5194787
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,tissue-slides,0.37510005,segmentation,0.48465955,segmentation,0.48465955
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,tissue,0.23679586,of,0.5202017,segmentation,0.4076932
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,microarray,0.5102731,analysis,0.58474267,machine-learning,0.5102731
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,images,0.46598992,segmentation,0.6703193,segmentation,0.6703193
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,tissue-microarray,0.46106756,ground-truth,0.5078309,ground-truth,0.5078309
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,significantly,0.27887642,of,0.5214151,long-short-term,0.39056638
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,stratify,0.4761734,classification-algorithm,0.58222234,classification-algorithm,0.58222234
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,patients,0.30007,recurrent,0.5332828,dropout,0.3918751
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,successfully,0.37413275,fully,0.61316407,one-shot,0.4433375
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,distinguish,0.4136919,discriminative,0.5568397,classification,0.4541072
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,hcc,0.283109,dropout,0.3499322,dropout,0.3499322
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,prognostic,0.4482512,classifiers,0.50372314,classifiers,0.50372314
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,model,0.48485535,model,1.0,markov-model,0.7005576
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,learning,0.709237,learning,1.0,deep-learning,0.8286492
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,models,0.53762007,model,0.8940372,markov-model,0.7015921
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,derived,0.3584563,of,0.54769456,generative,0.5265686
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,predicting,0.521454,classification-algorithm,0.5589481,classification-algorithm,0.5589481
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,patients,0.30007,recurrent,0.5332828,dropout,0.3918751
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,quantitative,0.4330744,analysis,0.6747154,component-analysis,0.558002
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,features,0.51742536,feature,0.8268872,feature-selection,0.5487305
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,image,0.5164337,segmentation,0.7261368,segmentation,0.7261368
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,features,0.51742536,feature,0.8268872,feature-selection,0.5487305
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,image-features,0.67678905,object-tracking,0.74212396,object-tracking,0.74212396
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,features,0.51742536,feature,0.8268872,feature-selection,0.5487305
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,based,0.49998575,classification-algorithm,0.5639226,classification-algorithm,0.5639226
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,models,0.53762007,model,0.8940372,markov-model,0.7015921
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,based-models,0.65913326,markov-model,0.75586486,markov-model,0.75586486
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,histopathological,0.320109,classification,0.4345668,classification,0.4345668
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,slides,0.32076606,embeddings,0.5194787,embeddings,0.5194787
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,survival,0.29004025,short-term,0.53135407,long-short-term,0.4573617
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,outcomes,0.38239923,short-term,0.6164659,long-short-term,0.5239928
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,statistical,0.6074636,statistical,1.0,statistical,1.0
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,models,0.53762007,model,0.8940372,markov-model,0.7015921
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,slide,0.3389761,graphics,0.481772,embeddings,0.45277554
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,images,0.46598992,segmentation,0.6703193,segmentation,0.6703193
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,histopathological,0.320109,classification,0.4345668,classification,0.4345668
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,images,0.46598992,segmentation,0.6703193,segmentation,0.6703193
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,auc,0.32985288,cross-validation,0.5105883,cross-validation,0.5105883
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,hcc,0.283109,dropout,0.3499322,dropout,0.3499322
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,patients,0.30007,recurrent,0.5332828,dropout,0.3918751
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,hcc-patients,0.2871855,naive,0.39607275,logistic-regression,0.37747955
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,extracted,0.39326945,analysis,0.5438888,principal-components,0.4903554
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,features,0.51742536,feature,0.8268872,feature-selection,0.5487305
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,surgical,0.33963326,recurrent,0.47206855,supervised,0.43774873
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,resection,0.24736592,recurrent,0.48921275,segmentation,0.4060747
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,surgical-resection,0.31427485,recurrent,0.47594935,segmentation-algorithm,0.4293403
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,learning,0.709237,learning,1.0,deep-learning,0.8286492
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,methods,0.50049126,data,0.5400177,machine-learning,0.50049126
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,histopathological,0.320109,classification,0.4345668,classification,0.4345668
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,slide,0.3389761,graphics,0.481772,embeddings,0.45277554
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,hcc,0.283109,dropout,0.3499322,dropout,0.3499322
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,diagnosis,0.32391536,classification,0.53521544,classification,0.53521544
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,findings,0.35685748,data,0.65714294,component-analysis,0.38599753
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,suggest,0.26874092,data,0.5391823,long-short-term,0.40288782
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,assist,0.42529124,support,0.5996513,support-vector-machine,0.4783134
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,clinicians,0.48196417,decision,0.63309145,data-science,0.5435997
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,predict,0.51602554,model,0.53463185,classification-algorithm,0.52342355
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,patients,0.30007,recurrent,0.5332828,dropout,0.3918751
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,prognosis,0.32841474,recurrent,0.50268024,classification,0.44778624
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,prediction,0.6361519,classification-algorithm,0.67946094,classification-algorithm,0.67946094
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,prognosis-prediction,0.6084378,classification-algorithm,0.7090471,classification-algorithm,0.7090471
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,features,0.51742536,feature,0.8268872,feature-selection,0.5487305
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,survival,0.29004025,short-term,0.53135407,long-short-term,0.4573617
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,hcc,0.283109,dropout,0.3499322,dropout,0.3499322
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,prognosis,0.32841474,recurrent,0.50268024,classification,0.44778624
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,predict,0.51602554,model,0.53463185,classification-algorithm,0.52342355
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,methods,0.50049126,data,0.5400177,machine-learning,0.50049126
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,extracted,0.39326945,analysis,0.5438888,principal-components,0.4903554
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,auc,0.32985288,cross-validation,0.5105883,cross-validation,0.5105883
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,used,0.46049535,of,0.5630944,generative-model,0.4901716
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,train,0.54995465,learning,0.60963345,learning-rate,0.5978736
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,total,0.21723771,of,0.5102532,principal-components,0.3630478
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,test,0.4037762,statistical,0.5031551,statistical,0.5031551
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,surgery,0.29565036,recurrent,0.47230634,computer-vision,0.40172684
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,study,0.3645851,of,0.5728763,statistical,0.44204497
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,shorter,0.23315734,short,0.7006648,long-short-term,0.5485222
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,set,0.5244544,of,0.5846941,classifiers,0.5500933
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,results,0.32376552,data,0.6932311,batch-normalization,0.44826904
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,random,0.45551494,random,1.0,random-forest,0.65894985
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,objective,0.4122544,of,0.5255821,component-analysis,0.42220753
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,moreover,0.34991172,of,0.5596781,boosting,0.44273305
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,machine,0.7094662,machine,1.0,machine-learning,0.7094662
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,longer,0.23865971,long,0.7401756,long-short-term,0.6004038
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,hepatectomy,0.2561172,normalization,0.3538031,batch-normalization,0.3521162
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,hematoxylin,0.26143408,embeddings,0.50571984,embeddings,0.50571984
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,h,0.19856977,short-term,0.43919927,long-short-term,0.36116964
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,eosin,0.21414353,embeddings,0.45989728,embeddings,0.45989728
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,conclusions,0.37109232,data,0.55923915,long-short-term,0.4627594
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,area,0.23419946,layer,0.46823567,ground-truth,0.38642365
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,analyze,0.47400552,analysis,0.62964547,component-analysis,0.5131476
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,aim,0.4029312,feature-engineering,0.41751927,feature-engineering,0.41751927
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,able,0.41518557,fully,0.6125249,bagging,0.45371854
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,among,0.33676732,of,0.57348,clustering,0.49404603
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,people,0.36805943,natural-language,0.4770279,natural-language,0.4770279
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,prescribed,0.29896754,supervised,0.4962438,supervised,0.4962438
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,loop,0.25155255,feed-forward,0.5677347,feed-forward,0.5677347
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,diuretics,0.23099658,confusion,0.36058313,supervised,0.2963397
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,loop-diuretics,0.23589051,softmax,0.33254164,softmax,0.33254164
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,less,0.2680999,of,0.53796744,long-short-term,0.4390034
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,common,0.32574984,feature,0.5597373,clustering,0.43115532
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,among,0.33676732,of,0.57348,clustering,0.49404603
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,individuals,0.32092994,naive,0.486303,dropout,0.42173886
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,less-common,0.32227132,feature,0.4719941,feature-selection,0.4509194
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,among-individuals,0.4295547,random-forest,0.5782765,random-forest,0.5782765
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,dimensional,0.48426318,dimensionality,0.8024132,dimensionality-reduction,0.765376
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,dementia,0.36825818,semantic,0.5159805,semantic,0.5159805
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,assessment,0.4002061,analysis,0.5275976,component-analysis,0.49803802
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,scale,0.32819444,intelligence,0.5046051,dimensionality-reduction,0.48168033
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,assessment-scale,0.48645484,artificial-intelligence,0.5621098,artificial-intelligence,0.5621098
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,drug,0.31867066,of,0.44600964,confusion-matrix,0.3956731
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,classes,0.42913696,multi-class,0.5125835,classification,0.5097946
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,among,0.33676732,of,0.57348,clustering,0.49404603
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,people,0.36805943,natural-language,0.4770279,natural-language,0.4770279
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,drug-classes,0.45029837,multi-class,0.5080737,classifiers,0.48209432
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,collected,0.33035916,data,0.5686942,ground-truth,0.3838368
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,concerning,0.2891674,of,0.5967124,statistical,0.44185388
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,drug,0.31867066,of,0.44600964,confusion-matrix,0.3956731
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,use,0.43753043,of,0.5506158,feature-reduction,0.49910897
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,drug-use,0.40210387,reinforcement-learning,0.50853264,reinforcement-learning,0.50853264
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,performed,0.3864032,analysis,0.5711501,supervised,0.4789877
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,including,0.3233776,of,0.6619886,clustering,0.40625107
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,people,0.36805943,natural-language,0.4770279,natural-language,0.4770279
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,performed-including,0.4457607,of,0.5789391,feature-reduction,0.5303113
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,angiotensin,0.21236175,matrix,0.35242182,feed-forward,0.31253523
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,ii,0.22929578,of,0.43728137,classification,0.3694628
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,receptor,0.22411162,function,0.41526195,clustering,0.36801085
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,blockers,0.19200467,augmentation,0.36206824,long-short-term,0.31719163
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,angiotensin-ii,0.178305,matrix,0.35608318,feed-forward,0.2816677
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,ii-receptor,0.23426425,selection,0.3108907,classification,0.28121862
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,receptor-blockers,0.22819279,short-term,0.3749142,regression,0.3211386
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,angiotensin-ii-receptor,0.21117805,matrix,0.33910444,feed-forward,0.29659617
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,ii-receptor-blockers,0.20472963,augmentation,0.3407123,data-augmentation,0.28809693
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,people,0.36805943,natural-language,0.4770279,natural-language,0.4770279
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,prescribed,0.29896754,supervised,0.4962438,supervised,0.4962438
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,asa,0.2115478,one,0.35373527,classification-algorithm,0.30813506
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,mineralocorticoid,0.2177006,short-term,0.3448191,long-short-term,0.32826918
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,receptor,0.22411162,function,0.41526195,clustering,0.36801085
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,antagonists,0.24215083,discriminative,0.39012936,learning-function,0.31474212
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,mineralocorticoid-receptor,0.24360989,function,0.35304862,batch-normalization,0.34086508
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,receptor-antagonists,0.23002487,discriminative,0.38725716,feed-forward,0.3471454
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,mineralocorticoid-receptor-antagonists,0.2412014,short-term,0.36669463,feed-forward,0.34416416
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,two,0.35955608,one,0.79919666,clustering,0.43817294
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,questionnaire,0.36053145,style,0.5356899,computer-vision,0.49106652
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,surveys,0.381772,data,0.5966315,data-science,0.5135532
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,two-questionnaire,0.42420405,computer-vision,0.52133465,computer-vision,0.52133465
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,questionnaire-surveys,0.4021408,style,0.5460592,natural-language,0.5065266
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,especially,0.32290015,of,0.63661283,long-short-term,0.46837103
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,regarding,0.3395273,decision,0.5699087,statistical,0.42642856
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,adherence,0.24866252,short-term,0.4634843,dropout,0.44456872
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,converting,0.30355832,of,0.48566324,graphics-processing,0.44267887
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,enzyme,0.21657495,encoding,0.44885126,feature-reduction,0.38085908
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,inhibitors,0.25381407,cascade,0.4157439,feed-forward,0.3175553
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,converting-enzyme,0.27783775,graphics-processing,0.39753565,graphics-processing,0.39753565
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,enzyme-inhibitors,0.2689559,feature-reduction,0.36576074,feature-reduction,0.36576074
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,converting-enzyme-inhibitors,0.28889734,feature-reduction,0.39039016,feature-reduction,0.39039016
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,associated,0.30827495,of,0.57598466,long-short-term,0.46578532
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,factors,0.3420733,components,0.5413606,logistic-regression,0.48293567
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,within,0.2920679,of,0.57602364,clustering,0.4610753
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,associated-factors,0.3549658,components,0.5559017,principal-components,0.50584686
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,elderly,0.3021084,short-term,0.47582904,short-term-memory,0.41010565
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,people,0.36805943,natural-language,0.4770279,natural-language,0.4770279
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,living,0.30422944,of,0.47259963,generative,0.4134596
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,elderly-people,0.38119054,natural-language,0.47879356,natural-language,0.47879356
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,people-living,0.38167542,forest,0.50183386,random-forest,0.48820892
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,cardiovascular,0.31674606,short-term,0.442761,learning-function,0.4027721
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,drug,0.31867066,of,0.44600964,confusion-matrix,0.3956731
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,treatment,0.239264,short-term,0.5206091,long-short-term,0.41699445
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,cardiovascular-drug,0.37675548,short-term,0.4220984,learning-function,0.406007
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,drug-treatment,0.31844795,dropout,0.50925237,dropout,0.50925237
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,severe,0.24462184,recurrent,0.581337,confusion-matrix,0.37568426
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,cognitive,0.5010079,memory,0.72449946,learning-function,0.7178915
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,impairment,0.36711594,function,0.6770178,learning-function,0.55798244
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,cognitive-impairment,0.46379438,learning-function,0.65946823,learning-function,0.65946823
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,increasing,0.30868235,of,0.6603997,boosting,0.50417006
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,cognitive,0.5010079,memory,0.72449946,learning-function,0.7178915
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,impairment,0.36711594,function,0.6770178,learning-function,0.55798244
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,cognitive-impairment,0.46379438,learning-function,0.65946823,learning-function,0.65946823
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,cardiovascular,0.31674606,short-term,0.442761,learning-function,0.4027721
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,agents,0.2697791,of,0.44812918,boosting,0.36205623
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,used,0.46049535,of,0.5630944,generative-model,0.4901716
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,four,0.34899807,one,0.769816,clustering,0.40005642
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,different,0.37681934,of,0.61590904,clustering,0.46857932
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,levels,0.20457911,normalization,0.52984333,batch-normalization,0.45617118
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,four-different,0.41243976,gradient-descent,0.47228,gradient-descent,0.47228
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,different-levels,0.41089186,short-term,0.54519963,dimensionality-reduction,0.53838897
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,loop,0.25155255,feed-forward,0.5677347,feed-forward,0.5677347
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,diuretics,0.23099658,confusion,0.36058313,supervised,0.2963397
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,loop-diuretics,0.23589051,softmax,0.33254164,softmax,0.33254164
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,people,0.36805943,natural-language,0.4770279,natural-language,0.4770279
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,cognitive,0.5010079,memory,0.72449946,learning-function,0.7178915
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,impairment,0.36711594,function,0.6770178,learning-function,0.55798244
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,cognitive-impairment,0.46379438,learning-function,0.65946823,learning-function,0.65946823
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,four,0.34899807,one,0.769816,clustering,0.40005642
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,levels,0.20457911,normalization,0.52984333,batch-normalization,0.45617118
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,four-levels,0.4202314,artificial-intelligence,0.5147466,artificial-intelligence,0.5147466
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,cardiovascular,0.31674606,short-term,0.442761,learning-function,0.4027721
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,drugs,0.30897486,of,0.42460242,classifiers,0.33720028
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,living,0.30422944,of,0.47259963,generative,0.4134596
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,treatment,0.239264,short-term,0.5206091,long-short-term,0.41699445
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,patterns,0.37740147,of,0.55208683,clustering,0.526253
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,different,0.37681934,of,0.61590904,clustering,0.46857932
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,drugs,0.30897486,of,0.42460242,classifiers,0.33720028
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,different-drugs,0.36411637,dimensionality-reduction,0.49331728,dimensionality-reduction,0.49331728
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,cognitive,0.5010079,memory,0.72449946,learning-function,0.7178915
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,function,0.3447219,function,1.0,learning-function,0.5767432
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,cognitive-function,0.5181581,learning-function,0.80076265,learning-function,0.80076265
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,daily,0.3039257,short-term,0.50002974,supervised,0.42771563
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,living,0.30422944,of,0.47259963,generative,0.4134596
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,daily-living,0.40681958,learning-function,0.5415403,learning-function,0.5415403
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,significantly,0.27887642,of,0.5214151,long-short-term,0.39056638
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,lower,0.20975146,of,0.5471319,regression,0.3982392
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,significantly-lower,0.2796454,of,0.50498235,long-short-term,0.40800315
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,nursing,0.4038462,data-science,0.5539012,data-science,0.5539012
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,homes,0.35261095,forest,0.5058284,supervised,0.4463648
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,nursing-homes,0.38488325,natural-language,0.5146845,natural-language,0.5146845
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,northern,0.20469333,forest,0.50761646,random-forest,0.46055424
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,sweden,0.22899875,federated,0.44999325,random-forest,0.38226134
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,mddas,0.39942205,intelligence,0.47346106,principal-components,0.4703199
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,heart,0.28300244,rate,0.49867767,batch-normalization,0.3427502
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,failure,0.32964212,recurrent,0.52057266,confusion-matrix,0.44323406
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,heart-failure,0.36450487,long-short-term,0.44014218,long-short-term,0.44014218
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,describe,0.47142854,feature-engineering,0.5045319,feature-engineering,0.5045319
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,changes,0.28767496,normalization,0.57879114,batch-normalization,0.43861648
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,atrial,0.2285939,long-short,0.40266213,long-short-term,0.38994598
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,fibrillation,0.29544818,recurrent,0.4121878,long-short-term,0.3982905
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,atrial-fibrillation,0.26383367,long-short,0.47894955,long-short-term,0.454661
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,compared,0.3359061,of,0.52794564,long-short-term,0.42386633
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,results,0.32376552,data,0.6932311,batch-normalization,0.44826904
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,indicate,0.24175897,data,0.567966,long-short-term,0.36935285
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,results-indicate,0.34559378,data,0.5741026,component-analysis,0.46714354
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,diuretics,0.23099658,confusion,0.36058313,supervised,0.2963397
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,use,0.43753043,of,0.5506158,feature-reduction,0.49910897
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,blockers,0.19200467,augmentation,0.36206824,long-short-term,0.31719163
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,angiotensin,0.21236175,matrix,0.35242182,feed-forward,0.31253523
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,used,0.46049535,of,0.5630944,generative-model,0.4901716
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,results,0.32376552,data,0.6932311,batch-normalization,0.44826904
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,compared,0.3359061,of,0.52794564,long-short-term,0.42386633
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,warfarin,0.24901685,batch-normalization,0.33795637,batch-normalization,0.33795637
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,using,0.47332245,analysis,0.5968549,component-analysis,0.526608
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,study,0.3645851,of,0.5728763,statistical,0.44204497
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,room,0.23075368,unit,0.51926804,bagging,0.43791366
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,relation,0.30160776,of,0.5984683,regression,0.51309836
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,purpose,0.4149922,of,0.5072116,feature-engineering,0.43333688
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,proxy,0.29851508,decision,0.5198714,decision-tree,0.4172846
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,proportion,0.24881616,reduction,0.5001526,clustering,0.44429505
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,prescription,0.3508556,decision,0.48317343,supervised,0.43501857
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,population,0.2958798,selection,0.5071889,clustering,0.47966808
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,pattern,0.33640617,feature,0.582756,clustering,0.5010694
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,multi,0.37771758,multi-class,0.4810482,segmentation,0.43055838
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,mras,0.2565925,data,0.36491024,segmentation-algorithm,0.34318715
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,methods,0.50049126,data,0.5400177,machine-learning,0.50049126
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,increased,0.26921988,reduction,0.6514183,boosting,0.46515882
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,improvement,0.39264548,reduction,0.6142903,feature-reduction,0.5138227
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,improved,0.40049985,normalization,0.5598826,boosting,0.5069493
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,guidelines,0.41964787,decision,0.5691749,classification-algorithm,0.5532488
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,functioning,0.3547554,function,0.7269659,learning-function,0.5524495
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,effect,0.21449387,short-term,0.5886732,long-short-term,0.47619703
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,data,0.46434748,data,1.0,data-science,0.5533528
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,conclusion,0.35530132,data,0.5299138,long-short-term,0.45073265
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,cognition,0.4696165,memory,0.7184951,learning-function,0.70557344
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,arbs,0.25137073,logistic-regression,0.35386714,logistic-regression,0.35386714
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,analyse,0.4442591,analysis,0.62307084,component-analysis,0.54296315
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,aim,0.4029312,feature-engineering,0.41751927,feature-engineering,0.41751927
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,adl,0.3357573,language,0.449008,learning-function,0.44404155
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,activities,0.25071037,of,0.4766258,learning-function,0.38030344
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,acei,0.26178795,feed,0.37105787,dropout,0.3253736
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,cvd,0.25363478,hierarchical,0.35325012,logistic-regression,0.34885177
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,prediction,0.6361519,classification-algorithm,0.67946094,classification-algorithm,0.67946094
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,beyond,0.34655812,of,0.53781354,dimensionality-reduction,0.42561156
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,established,0.40618747,of,0.60100454,classification,0.47434023
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,risk,0.35860935,recurrent,0.53675485,logistic-regression,0.52381086
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,markers,0.32439512,of,0.43581337,clustering,0.41091266
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,risk-markers,0.43061054,classification-algorithm,0.5166445,classification-algorithm,0.5166445
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,highly,0.2917056,fully,0.5556702,generative,0.4456749
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,controlled,0.25206095,of,0.4703986,supervised,0.39651048
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,ubiquitous,0.35192633,feature,0.48518807,stochastic,0.45829654
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,posttranslational,0.36005986,processing,0.5605519,graphics-processing,0.4503562
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,modification,0.33522165,feature-reduction,0.5318271,feature-reduction,0.5318271
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,highly-controlled,0.34245896,fully-connected,0.54589516,fully-connected,0.54589516
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,posttranslational-modification,0.44237396,processing,0.5566296,feature-engineering,0.5306916
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,clinically,0.3702051,recurrent,0.5046643,confusion-matrix,0.40397355
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,applied,0.44175404,of,0.5047146,bagging,0.47554293
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,risk,0.35860935,recurrent,0.53675485,logistic-regression,0.52381086
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,prediction,0.6361519,classification-algorithm,0.67946094,classification-algorithm,0.67946094
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,scores,0.40591323,intelligence,0.56987673,principal-components,0.4971624
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,clinically-applied,0.41355485,short-term,0.5010193,generative-model,0.47839904
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,risk-prediction,0.64593977,classification-algorithm,0.71407217,classification-algorithm,0.71407217
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,based,0.49998575,classification-algorithm,0.5639226,classification-algorithm,0.5639226
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,type,0.21671848,of,0.48202556,classification,0.43098688
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,diabetes,0.29301462,logistic-regression,0.35688502,logistic-regression,0.35688502
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,score,0.38515997,classification-algorithm,0.5352135,classification-algorithm,0.5352135
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,glycans,0.30252072,components,0.42726883,graphics-processing-unit,0.38497198
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,improve,0.45207965,boosting,0.5098576,boosting,0.5098576
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,type,0.21671848,of,0.48202556,classification,0.43098688
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,diabetes,0.29301462,logistic-regression,0.35688502,logistic-regression,0.35688502
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,prospective,0.38588464,data,0.49630898,logistic-regression,0.4399855
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,european,0.25183123,federated,0.5800549,data-science,0.42842963
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,prospective,0.38588464,data,0.49630898,logistic-regression,0.4399855
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,investigation,0.33686116,analysis,0.63110995,component-analysis,0.46827114
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,precisely,0.39328516,fully,0.5896492,generative,0.5141876
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,targeted,0.37903738,of,0.52138686,feature-engineering,0.502902
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,primary,0.24268678,principal,0.5205563,long-short-term,0.38049072
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,prevention,0.29446518,recurrent,0.44918782,feature-reduction,0.4041679
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,precisely-targeted,0.4585904,feature-engineering,0.60658693,feature-engineering,0.60658693
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,primary-prevention,0.36895162,reinforcement-learning,0.5062002,reinforcement-learning,0.5062002
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,e,0.13297717,natural,0.39189428,component-analysis,0.28603846
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,myocardial,0.25335935,normalization,0.40452614,batch-normalization,0.38271224
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,infarction,0.22924727,recurrent,0.4099214,confusion-matrix,0.3685401
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,myocardial-infarction,0.25818947,normalization,0.3545368,long-short-term,0.351139
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,finland,0.2133127,federated,0.47343546,random-forest,0.38252193
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,cardiovascular,0.31674606,short-term,0.442761,learning-function,0.4027721
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,risk,0.35860935,recurrent,0.53675485,logistic-regression,0.52381086
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,study,0.3645851,of,0.5728763,statistical,0.44204497
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,cardiovascular-risk,0.3523693,logistic-regression,0.46172044,logistic-regression,0.46172044
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,epic,0.32504463,data-science,0.4807823,data-science,0.4807823
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,potsdam,0.28862125,federated,0.50802076,data-science,0.42667055
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,cohort,0.3892265,logistic-regression,0.5412916,logistic-regression,0.5412916
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,weighted,0.5247781,bayes,0.59804296,bayes,0.59804296
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,c,0.17513797,of,0.44327667,gradient,0.31114018
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,index,0.27978244,function,0.407383,classification-algorithm,0.3994653
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,c-index,0.44994968,classification-algorithm,0.5805235,classification-algorithm,0.5805235
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,weighted,0.5247781,bayes,0.59804296,bayes,0.59804296
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,c,0.17513797,of,0.44327667,gradient,0.31114018
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,indices,0.35250193,normalization,0.5109062,batch-normalization,0.46939105
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,men,0.23664121,descent,0.5239919,regression,0.38136965
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,c-indices,0.3910091,classification-algorithm,0.52079076,classification-algorithm,0.52079076
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,glycan,0.3606348,graphics-processing-unit,0.44152093,graphics-processing-unit,0.44152093
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,profiling,0.46470833,analysis,0.7003745,component-analysis,0.50180626
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,may,0.30907542,of,0.58654004,long-short-term,0.43985203
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,thus,0.33923393,of,0.6779618,feature-reduction,0.46172875
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,glycan-profiling,0.43568337,data-engineering,0.52914107,data-engineering,0.52914107
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,glycan,0.3606348,graphics-processing-unit,0.44152093,graphics-processing-unit,0.44152093
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,profiling,0.46470833,analysis,0.7003745,component-analysis,0.50180626
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,integrates,0.5621971,data-engineering,0.59582233,data-engineering,0.59582233
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,information,0.5191034,data,0.708436,data-science,0.5937191
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,glycan-profiling,0.43568337,data-engineering,0.52914107,data-engineering,0.52914107
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,weighted,0.5247781,bayes,0.59804296,bayes,0.59804296
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,prediction,0.6361519,classification-algorithm,0.67946094,classification-algorithm,0.67946094
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,scores,0.40591323,intelligence,0.56987673,principal-components,0.4971624
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,type,0.21671848,of,0.48202556,classification,0.43098688
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,diabetes,0.29301462,logistic-regression,0.35688502,logistic-regression,0.35688502
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,american,0.31403136,federated,0.55841243,classification,0.43444416
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,diabetes,0.29301462,logistic-regression,0.35688502,logistic-regression,0.35688502
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,association,0.32292235,regression,0.5094141,regression,0.5094141
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,american-diabetes,0.30231935,descent,0.48514694,logistic-regression,0.4245246
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,verified,0.3810478,of,0.5807613,supervised,0.42818904
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,incident,0.28040045,of,0.4411097,regression,0.40331167
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,cases,0.31566036,recurrent,0.52791375,classification,0.4471408
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,nonlinear,0.54885405,stochastic,0.72081184,stochastic,0.72081184
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,model,0.48485535,model,1.0,markov-model,0.7005576
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,building,0.47144645,feature-engineering,0.6313234,feature-engineering,0.6313234
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,model-building,0.68002605,markov-model,0.70943654,markov-model,0.70943654
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,enzymatic,0.28399962,processing,0.487253,graphics-processing,0.44487932
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,protein,0.31929362,encoding,0.5525089,clustering,0.36023882
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,glycosylation,0.26004755,encoding,0.43154466,clustering,0.37545538
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,protein-glycosylation,0.352023,encoding,0.4903405,feature-engineering,0.4686532
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,internal,0.22486365,of,0.4487089,dimensionality-reduction,0.37939572
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,validation,0.5362086,cross-validation,0.74016297,cross-validation,0.74016297
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,cohort,0.3892265,logistic-regression,0.5412916,logistic-regression,0.5412916
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,internal-validation,0.5682592,cross-validation,0.7429799,cross-validation,0.7429799
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,validation-cohort,0.5867096,cross-validation,0.68933964,cross-validation,0.68933964
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,baseline,0.32763094,normalization,0.56518495,batch-normalization,0.4727359
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,plasma,0.21912897,normalization,0.4569842,batch-normalization,0.43571177
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,samples,0.3088399,analysis,0.4981357,batch-normalization,0.44174457
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,plasma-samples,0.3857342,batch-normalization,0.57754487,batch-normalization,0.57754487
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,validated,0.5041009,cross-validation,0.58167183,cross-validation,0.58167183
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,machine,0.7094662,machine,1.0,machine-learning,0.7094662
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,learning,0.709237,learning,1.0,deep-learning,0.8286492
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,machine-learning,1.0,machine-learning,1.0,machine-learning,1.0
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,plasma,0.21912897,normalization,0.4569842,batch-normalization,0.43571177
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,protein,0.31929362,encoding,0.5525089,clustering,0.36023882
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,n,0.24332823,of,0.45693433,long-short-term,0.34114176
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,plasma-protein,0.30011278,matrix,0.4759191,batch-normalization,0.46748668
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,protein-n,0.31070453,matrix,0.37898764,nearest-neighbors,0.34970856
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,years,0.32825696,intelligence,0.42702603,regression,0.3811771
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,diabetes,0.29301462,logistic-regression,0.35688502,logistic-regression,0.35688502
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,risk,0.35860935,recurrent,0.53675485,logistic-regression,0.52381086
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,diabetes-risk,0.31318665,logistic-regression,0.45215243,logistic-regression,0.45215243
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,selected,0.38157707,selection,0.6797303,feature-selection,0.48698312
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,predictive,0.55290145,cross-validation,0.6141345,cross-validation,0.6141345
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,n,0.24332823,of,0.45693433,long-short-term,0.34114176
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,risk,0.35860935,recurrent,0.53675485,logistic-regression,0.52381086
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,stratification,0.45885193,classification-algorithm,0.6005924,classification-algorithm,0.6005924
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,risk-stratification,0.56299007,classification-algorithm,0.6976296,classification-algorithm,0.6976296
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,applied,0.44175404,of,0.5047146,bagging,0.47554293
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,separately,0.39380828,fully,0.5633712,principal-components,0.5318056
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,chromatographic,0.369452,fourier-transform,0.5574235,fourier-transform,0.5574235
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,profiling,0.46470833,analysis,0.7003745,component-analysis,0.50180626
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,years,0.32825696,intelligence,0.42702603,regression,0.3811771
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,cardiovascular,0.31674606,short-term,0.442761,learning-function,0.4027721
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,diseases,0.31957155,recurrent,0.41244444,classification,0.40266854
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,cardiovascular-diseases,0.3900246,learning-function,0.41476324,learning-function,0.41476324
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,plasma,0.21912897,normalization,0.4569842,batch-normalization,0.43571177
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,n,0.24332823,of,0.45693433,long-short-term,0.34114176
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,plasma-n,0.14097744,batch-normalization,0.39218163,batch-normalization,0.39218163
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,n,0.24332823,of,0.45693433,long-short-term,0.34114176
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,glycan,0.3606348,graphics-processing-unit,0.44152093,graphics-processing-unit,0.44152093
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,groups,0.2727722,statistical,0.4438421,statistical,0.4438421
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,cvd,0.25363478,hierarchical,0.35325012,logistic-regression,0.34885177
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,separately,0.39380828,fully,0.5633712,principal-components,0.5318056
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,cvd,0.25363478,hierarchical,0.35325012,logistic-regression,0.34885177
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,incidence,0.2452303,rate,0.58344483,logistic-regression,0.39874467
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,cvd-incidence,0.33083835,classification-algorithm,0.46867758,classification-algorithm,0.46867758
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,selected,0.38157707,selection,0.6797303,feature-selection,0.48698312
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,n,0.24332823,of,0.45693433,long-short-term,0.34114176
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,glycans,0.30252072,components,0.42726883,graphics-processing-unit,0.38497198
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,improved,0.40049985,normalization,0.5598826,boosting,0.5069493
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,participants,0.4160846,object-tracking,0.5017827,object-tracking,0.5017827
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,time,0.31186903,long,0.57547164,batch-normalization,0.47628766
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,ci,0.2746623,logistic,0.43534693,logistic-regression,0.38379127
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,externally,0.32474232,fully,0.5824851,generative,0.47579893
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,validated,0.5041009,cross-validation,0.58167183,cross-validation,0.58167183
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,externally-validated,0.58167505,cross-validation,0.6227927,cross-validation,0.6227927
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,strongly,0.22741725,of,0.54725957,clustering,0.4178764
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,predictive,0.55290145,cross-validation,0.6141345,cross-validation,0.6141345
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,stroke,0.30895793,language,0.41435713,learning-function,0.39194655
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,moderately,0.2182832,fully,0.51514554,long-short-term,0.4002989
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,predictive,0.55290145,cross-validation,0.6141345,cross-validation,0.6141345
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,moderately-predictive,0.5870111,classifiers,0.66191286,classifiers,0.66191286
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,research,0.45694843,science,0.7194936,data-science,0.70924157
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,design,0.47555828,data-engineering,0.6477308,data-engineering,0.6477308
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,research-design,0.560832,data-engineering,0.74561894,data-engineering,0.74561894
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,relative,0.28452736,of,0.6192827,long-short-term,0.43953407
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,abundance,0.31865036,forest,0.4966442,clustering,0.48465613
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,relative-abundance,0.46854696,stochastic-gradient,0.57620156,stochastic-gradient,0.57620156
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,random,0.45551494,random,1.0,random-forest,0.65894985
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,subsample,0.39854974,cross-validation,0.5581946,cross-validation,0.5581946
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,predict,0.51602554,model,0.53463185,classification-algorithm,0.52342355
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,incidence,0.2452303,rate,0.58344483,logistic-regression,0.39874467
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,median,0.20747668,logistic-regression,0.37743634,logistic-regression,0.37743634
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,follow,0.28552625,tracking,0.48513734,batch-normalization,0.39173082
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,median-follow,0.43611428,logistic-regression,0.5188215,logistic-regression,0.5188215
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,constructed,0.46166873,vector,0.5928328,feature-engineering,0.5708643
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,case,0.3180016,one,0.57942057,confusion-matrix,0.4208076
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,cohorts,0.38747132,logistic-regression,0.5306275,logistic-regression,0.5306275
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,including,0.3233776,of,0.6619886,clustering,0.40625107
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,cardiometabolic,0.36018297,logistic-regression,0.43154526,logistic-regression,0.43154526
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,diseases,0.31957155,recurrent,0.41244444,classification,0.40266854
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,established,0.40618747,of,0.60100454,classification,0.47434023
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,based,0.49998575,classification-algorithm,0.5639226,classification-algorithm,0.5639226
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,glycan,0.3606348,graphics-processing-unit,0.44152093,graphics-processing-unit,0.44152093
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,cvd,0.25363478,hierarchical,0.35325012,logistic-regression,0.34885177
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,glycans,0.30252072,components,0.42726883,graphics-processing-unit,0.38497198
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,cohort,0.3892265,logistic-regression,0.5412916,logistic-regression,0.5412916
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,men,0.23664121,descent,0.5239919,regression,0.38136965
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,information,0.5191034,data,0.708436,data-science,0.5937191
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,n,0.24332823,of,0.45693433,long-short-term,0.34114176
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,workflow,0.6382985,graphics-processing,0.6869749,graphics-processing,0.6869749
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,women,0.25528732,descent,0.50278515,dropout,0.37675467
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,useful,0.40063038,discriminative,0.489146,feature-engineering,0.43842706
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,results,0.32376552,data,0.6932311,batch-normalization,0.44826904
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,physician,0.3408745,decision,0.61277664,supervised,0.47927952
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,objective,0.4122544,of,0.5255821,component-analysis,0.42220753
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,methods,0.50049126,data,0.5400177,machine-learning,0.50049126
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,investigate,0.3396353,of,0.48247698,feature-engineering,0.41061842
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,glycome,0.41131133,component-analysis,0.4454196,component-analysis,0.4454196
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,generated,0.38782007,generative,0.5987155,generative,0.5987155
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,finrisk,0.3541572,logistic-regression,0.4908291,logistic-regression,0.4908291
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,finding,0.42779976,of,0.66083217,generative,0.50100887
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,cvds,0.39705318,logistic-regression,0.4255269,logistic-regression,0.4255269
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,cross,0.22060364,shot,0.42420566,cross-entropy,0.41595078
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,context,0.48856658,feature-engineering,0.6062584,feature-engineering,0.6062584
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,construction,0.4612354,data-engineering,0.66766787,data-engineering,0.66766787
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,conclusions,0.37109232,data,0.55923915,long-short-term,0.4627594
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,cancer,0.27383438,recurrent,0.4065063,generative,0.3468409
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,accuracy,0.5511073,cross-validation,0.64088035,cross-validation,0.64088035
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,ability,0.39144984,function,0.5937173,generative,0.47758824
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,mouse,0.30437678,model,0.5410154,generative-model,0.41324437
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,skeletal,0.21809755,of,0.4196552,segmentation,0.33136374
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,muscle,0.19602863,neural,0.42647707,supervised,0.33558244
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,myoblasts,0.17909151,neural,0.40907112,feed-forward,0.31695417
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,promoted,0.23901781,of,0.51878786,boosting,0.46147045
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,myotube,0.18161911,neural,0.39440024,feed-forward,0.34517053
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,differentiation,0.28601187,neural,0.5331595,generative,0.49685726
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,skeletal-muscle,0.19935827,of,0.34726727,long-short-term,0.31534088
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,mouse,0.30437678,model,0.5410154,generative-model,0.41324437
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,skeletal,0.21809755,of,0.4196552,segmentation,0.33136374
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,muscle,0.19602863,neural,0.42647707,supervised,0.33558244
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,myoblast,0.20792124,neural,0.44953674,recurrent-neural-network,0.33792087
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,cell,0.2212203,of,0.48460138,generative,0.39753264
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,lines,0.2397678,of,0.42859763,generative,0.3835748
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,using,0.47332245,analysis,0.5968549,component-analysis,0.526608
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,skeletal-muscle,0.19935827,of,0.34726727,long-short-term,0.31534088
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,cell-lines,0.3067491,naive,0.41776058,generative,0.41620326
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,lines-using,0.46161762,neighbors,0.5033876,nearest-neighbors,0.4901663
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,gene,0.32125705,encoding,0.7317275,clustering,0.4378482
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,encodes,0.27206546,encoding,0.84670615,feature-selection,0.37526625
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,multiple,0.39569393,of,0.53341115,regression,0.48948324
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,protein,0.31929362,encoding,0.5525089,clustering,0.36023882
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,isoforms,0.2606838,encoding,0.5361434,generative,0.32303253
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,multiple-protein,0.55562544,generative-model,0.5795299,generative-model,0.5795299
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,protein-isoforms,0.32793096,encoding,0.5053517,hierarchical-clustering,0.3983102
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,found,0.2840244,of,0.6208722,clustering,0.44675255
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,increased,0.26921988,reduction,0.6514183,boosting,0.46515882
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,protein,0.31929362,encoding,0.5525089,clustering,0.36023882
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,levels,0.20457911,normalization,0.52984333,batch-normalization,0.45617118
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,protein-levels,0.40918148,batch-normalization,0.5309417,batch-normalization,0.5309417
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,treating,0.29028994,of,0.50922996,generative-model,0.3998669
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,skeletal,0.21809755,of,0.4196552,segmentation,0.33136374
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,muscle,0.19602863,neural,0.42647707,supervised,0.33558244
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,atrophy,0.27299517,dropout,0.4630158,dropout,0.4630158
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,skeletal-muscle,0.19935827,of,0.34726727,long-short-term,0.31534088
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,muscle-atrophy,0.29573235,convolutional-layer,0.4293111,convolutional-layer,0.4293111
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,gene,0.32125705,encoding,0.7317275,clustering,0.4378482
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,activation,0.23066127,cascade,0.649269,feed-forward,0.4652444
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,approach,0.5412675,segmentation-algorithm,0.6046611,segmentation-algorithm,0.6046611
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,gene-activation,0.39011258,encoding,0.566907,feature-selection,0.54786956
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,like,0.32318482,of,0.5448733,relu,0.44626954
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,growth,0.15232143,of,0.446648,regression,0.38592952
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,factor,0.23388772,component,0.48280093,principal-components,0.43733668
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,like-growth,0.23573145,hierarchical-clustering,0.47026685,hierarchical-clustering,0.47026685
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,growth-factor,0.23745704,matrix,0.47862527,feed-forward,0.36959824
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,systemic,0.28055844,of,0.49342385,boosting,0.37910926
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,versus,0.2693575,of,0.48449945,long-short-term,0.40994066
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,localized,0.23634818,of,0.48577005,clustering,0.42260903
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,signaling,0.29640946,cascade,0.70725644,feed-forward,0.5819744
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,mrna,0.25853646,encoding,0.5590567,batch-normalization,0.35810667
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,transcript,0.2666745,encoding,0.5988406,batch-normalization,0.35447773
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,variants,0.36893952,encoding,0.5375725,clustering,0.45973128
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,mrna-transcript,0.28743476,encoding,0.5513371,feed-forward,0.40523252
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,transcript-variants,0.50784075,encoding,0.6385015,feature-selection,0.52478975
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,class,0.353845,multi-class,0.5162764,classification,0.4708274
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,mrna,0.25853646,encoding,0.5590567,batch-normalization,0.35810667
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,variants,0.36893952,encoding,0.5375725,clustering,0.45973128
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,multiple,0.39569393,of,0.53341115,regression,0.48948324
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,isoforms,0.2606838,encoding,0.5361434,generative,0.32303253
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,cell,0.2212203,of,0.48460138,generative,0.39753264
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,culture,0.22639796,batch,0.5173928,batch-normalization,0.4015891
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,media,0.20665605,matrix,0.43112892,feature-reduction,0.39949167
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,cell-culture,0.31896567,batch,0.54244936,feature-engineering,0.4684932
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,culture-media,0.31197265,batch,0.4819577,batch-normalization,0.4483167
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,mrna,0.25853646,encoding,0.5590567,batch-normalization,0.35810667
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,variants,0.36893952,encoding,0.5375725,clustering,0.45973128
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,increasing,0.30868235,of,0.6603997,boosting,0.50417006
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,gene,0.32125705,encoding,0.7317275,clustering,0.4378482
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,expression,0.32038707,encoding,0.59633577,clustering,0.442253
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,gene-expression,0.5495992,classifiers,0.5527793,classifiers,0.5527793
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,enhancing,0.30714625,boosting,0.59843874,boosting,0.59843874
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,signaling,0.29640946,cascade,0.70725644,feed-forward,0.5819744
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,key,0.35973132,principal,0.614877,feature-engineering,0.498355
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,positive,0.26811236,of,0.49572036,component-analysis,0.37181294
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,regulator,0.23058486,encoding,0.51183397,feed-forward,0.49325994
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,positive-regulator,0.3892346,feed-forward,0.6071365,feed-forward,0.6071365
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,sgrna,0.4297451,feature-selection,0.4800939,feature-selection,0.4800939
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,target,0.31799266,of,0.4775706,feature-selection,0.44359237
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,location,0.30333143,nearest,0.62363535,clustering,0.46779895
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,sgrna-target,0.47891352,nearest-neighbors,0.5021471,nearest-neighbors,0.5021471
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,target-location,0.51726294,object-tracking,0.6521895,object-tracking,0.6521895
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,diverse,0.38913006,of,0.5461366,feature-engineering,0.51537836
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,biology,0.47010514,science,0.6525451,data-engineering,0.59721386
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,seen,0.2411227,of,0.61171174,long-short-term,0.3944841
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,increased,0.26921988,reduction,0.6514183,boosting,0.46515882
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,cellular,0.33255053,of,0.55018497,generative,0.4558165
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,phosphorylation,0.24651355,cascade,0.48268026,feed-forward,0.40188718
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,potential,0.3558654,of,0.5645705,generative-model,0.46479023
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,therapeutic,0.3659354,of,0.48352462,boosting,0.41573292
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,applications,0.4878226,data-engineering,0.70112944,data-engineering,0.70112944
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,potential-therapeutic,0.39089105,generative-model,0.49393243,generative-model,0.49393243
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,multiple,0.39569393,of,0.53341115,regression,0.48948324
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,muscle,0.19602863,neural,0.42647707,supervised,0.33558244
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,atrophy,0.27299517,dropout,0.4630158,dropout,0.4630158
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,muscle-atrophy,0.29573235,convolutional-layer,0.4293111,convolutional-layer,0.4293111
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,class,0.353845,multi-class,0.5162764,classification,0.4708274
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,signaling,0.29640946,cascade,0.70725644,feed-forward,0.5819744
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,muscle,0.19602863,neural,0.42647707,supervised,0.33558244
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,wasting,0.25251395,feed,0.45005438,boosting,0.35331774
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,muscle-wasting,0.2844817,confusion,0.39908123,batch-normalization,0.38224196
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,muscle,0.19602863,neural,0.42647707,supervised,0.33558244
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,mass,0.22818582,fourier-transform,0.42889374,fourier-transform,0.42889374
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,muscle-mass,0.32133824,generative-model,0.40470544,generative-model,0.40470544
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,novel,0.4652171,feature-engineering,0.5132146,feature-engineering,0.5132146
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,approach,0.5412675,segmentation-algorithm,0.6046611,segmentation-algorithm,0.6046611
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,novel-approach,0.5125241,reinforcement-learning,0.6562369,reinforcement-learning,0.6562369
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,selectively,0.2788085,of,0.49033487,feature-selection,0.44159085
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,increased,0.26921988,reduction,0.6514183,boosting,0.46515882
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,selectively-increased,0.3808404,of,0.5807165,boosting,0.5335884
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,induced,0.2259351,of,0.5615651,boosting,0.4303583
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,atrophy,0.27299517,dropout,0.4630158,dropout,0.4630158
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,induced-atrophy,0.29928565,short-term,0.44138587,convolutional-layer,0.4309748
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,sgrna,0.4297451,feature-selection,0.4800939,feature-selection,0.4800939
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,experimental,0.40167695,model,0.6248311,generative-model,0.6004326
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,biology,0.47010514,science,0.6525451,data-engineering,0.59721386
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,cellular,0.33255053,of,0.55018497,generative,0.4558165
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,proliferation,0.24054871,neural,0.4592081,regression,0.38529342
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,cellular-proliferation,0.30313745,neural,0.44702926,generative,0.4440372
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,using,0.47332245,analysis,0.5968549,component-analysis,0.526608
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,tissue,0.23679586,of,0.5202017,segmentation,0.4076932
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,expression,0.32038707,encoding,0.59633577,clustering,0.442253
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,tissue-expression,0.39019126,neural,0.5086417,feature-engineering,0.4904617
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,prevented,0.17704698,reduction,0.5312941,boosting,0.39043245
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,dexamethasone,0.17659423,short-term,0.4560084,long-short-term,0.3725043
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,novel,0.4652171,feature-engineering,0.5132146,feature-engineering,0.5132146
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,strategy,0.47490904,feature-engineering,0.59725416,feature-engineering,0.59725416
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,main,0.3070703,principal,0.7875631,principal-components,0.51314574
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,effector,0.28626198,function,0.51726604,feed-forward,0.43374175
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,guide,0.47455525,decision,0.5901101,data-engineering,0.51958454
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,rna,0.357179,encoding,0.44869584,vector-machine,0.39839315
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,guide-rna,0.48595515,vector-machine,0.5258722,vector-machine,0.5258722
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,genome,0.4030719,encoding,0.5035916,clustering,0.41891688
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,engineering,0.45206007,engineering,1.0,data-engineering,0.85518026
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,genome-engineering,0.6048634,data-engineering,0.83009064,data-engineering,0.83009064
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,findings,0.35685748,data,0.65714294,component-analysis,0.38599753
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,suggest,0.26874092,data,0.5391823,long-short-term,0.40288782
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,differentiation,0.28601187,neural,0.5331595,generative,0.49685726
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,complicates,0.37391865,of,0.58318055,confusion-matrix,0.48312658
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,treatment,0.239264,short-term,0.5206091,long-short-term,0.41699445
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,american,0.31403136,federated,0.55841243,classification,0.43444416
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,societies,0.34185767,federated,0.6009963,data-science,0.5610749
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,also,0.32850838,of,0.65908813,clustering,0.45826355
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,showed,0.20766163,of,0.5296177,regression,0.37027335
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,also-showed,0.28968182,of,0.49911186,dimensionality-reduction,0.41159767
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,increased,0.26921988,reduction,0.6514183,boosting,0.46515882
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,potential,0.3558654,of,0.5645705,generative-model,0.46479023
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,expression,0.32038707,encoding,0.59633577,clustering,0.442253
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,showed,0.20766163,of,0.5296177,regression,0.37027335
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,well,0.34264985,of,0.59718275,bagging,0.4145819
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,vitro,0.292481,of,0.48112682,generative,0.40355864
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,single,0.31087106,one,0.6951874,one-shot,0.4602274
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,recapitulate,0.40523744,feature-engineering,0.52577233,feature-engineering,0.52577233
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,quality,0.37286326,dimensionality-reduction,0.49494588,dimensionality-reduction,0.49494588
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,potency,0.19916415,discriminative,0.4425937,boosting,0.3652883
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,particularly,0.32789055,of,0.62868786,long-short-term,0.49770588
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,overexpression,0.29621348,encoding,0.530388,feed-forward,0.39775345
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,occur,0.24370867,of,0.53400475,long-short-term,0.41742977
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,myotubes,0.16658409,neural,0.348309,clustering,0.32378003
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,life,0.3004927,style,0.49334684,long-short-term,0.46358624
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,insulin,0.22629064,unit,0.40084893,batch-normalization,0.32209873
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,injury,0.262506,shot,0.44338763,data-augmentation,0.37271294
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,human,0.30336243,of,0.5175895,feature-engineering,0.40631005
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,function,0.3447219,function,1.0,learning-function,0.5767432
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,disease,0.296938,recurrent,0.4731025,classification,0.35271814
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,differ,0.26580223,of,0.45475316,statistical,0.3820433
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,crispr,0.43237233,data-engineering,0.49372852,data-engineering,0.49372852
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,changing,0.3457114,of,0.60639,feature-reduction,0.4856776
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,age,0.30743492,intelligence,0.4774798,regression,0.47452933
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,affects,0.21790305,of,0.5773267,long-short-term,0.4001173
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,sod,0.22904798,reduction,0.31911826,fourier-transform,0.29286325
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,mda,0.22752835,normalization,0.33347362,batch-normalization,0.32173502
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,iqa,0.466146,ground-truth,0.4958604,ground-truth,0.4958604
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,ai,0.25513044,artificial-intelligence,0.38274616,artificial-intelligence,0.38274616
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,chop,0.23859908,long-short-term,0.35091794,long-short-term,0.35091794
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,chop,0.23859908,long-short-term,0.35091794,long-short-term,0.35091794
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,n,0.24332823,of,0.45693433,long-short-term,0.34114176
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,map,0.3543614,bagging,0.4165985,bagging,0.4165985
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,hr,0.24641928,rate,0.5365405,bagging,0.39750856
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,spo,0.30758917,bagging,0.47931948,bagging,0.47931948
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,n,0.24332823,of,0.45693433,long-short-term,0.34114176
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,peak,0.23109604,gradient,0.48941624,gradient,0.48941624
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,p,0.26795468,support,0.40805867,regression,0.40253854
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,h,0.19856977,short-term,0.43919927,long-short-term,0.36116964
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,p,0.26795468,support,0.40805867,regression,0.40253854
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,pao,0.19672337,feature-reduction,0.34453356,feature-reduction,0.34453356
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,qa,0.328584,monte-carlo,0.39809552,monte-carlo,0.39809552
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,tidal,0.24118362,bagging,0.40870094,bagging,0.40870094
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,carbon,0.26589063,feature-reduction,0.4548865,feature-reduction,0.4548865
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,dioxide,0.22722796,reduction,0.41583416,feature-reduction,0.40167737
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,partial,0.2411548,fully,0.4745357,regression,0.43076634
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,pressure,0.2060274,gradient,0.4962673,gradient,0.4962673
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,carbon-dioxide,0.23870757,feature-reduction,0.43296984,feature-reduction,0.43296984
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,partial-pressure,0.36368287,artificial-intelligence,0.50934815,artificial-intelligence,0.50934815
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,arterial,0.27257246,augmentation,0.4504157,gradient,0.4443115
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,oxygen,0.22381568,reduction,0.44402215,feature-reduction,0.3957175
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,partial,0.2411548,fully,0.4745357,regression,0.43076634
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,pressure,0.2060274,gradient,0.4962673,gradient,0.4962673
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,difference,0.30501923,statistical,0.58389574,statistical,0.58389574
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,arterial-oxygen,0.2823195,gradient,0.4446986,gradient,0.4446986
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,oxygen-partial,0.302199,feature-reduction,0.5813131,feature-reduction,0.5813131
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,partial-pressure,0.36368287,artificial-intelligence,0.50934815,artificial-intelligence,0.50934815
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,pressure-difference,0.36471558,cross-entropy,0.57146573,cross-entropy,0.57146573
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,oxygen-partial-pressure,0.34774765,feature-reduction,0.5764106,feature-reduction,0.5764106
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,iqa,0.466146,ground-truth,0.4958604,ground-truth,0.4958604
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,apoptotic,0.25514302,cascade,0.43370223,feed-forward,0.35026777
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,index,0.27978244,function,0.407383,classification-algorithm,0.3994653
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,apoptotic-index,0.34340036,stochastic,0.42731482,stochastic,0.42731482
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,oxygen,0.22381568,reduction,0.44402215,feature-reduction,0.3957175
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,partial,0.2411548,fully,0.4745357,regression,0.43076634
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,pressure,0.2060274,gradient,0.4962673,gradient,0.4962673
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,oxygen-partial,0.302199,feature-reduction,0.5813131,feature-reduction,0.5813131
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,partial-pressure,0.36368287,artificial-intelligence,0.50934815,artificial-intelligence,0.50934815
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,oxygen-partial-pressure,0.34774765,feature-reduction,0.5764106,feature-reduction,0.5764106
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,il,0.17175047,monte,0.3419046,monte,0.3419046
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,lung,0.26692057,of,0.3928769,bagging,0.36409828
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,cancer,0.27383438,recurrent,0.4065063,generative,0.3468409
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,undergoing,0.27656338,short-term,0.4795418,long-short-term,0.4059016
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,thoracoscopic,0.31950566,segmentation-algorithm,0.39032823,segmentation-algorithm,0.39032823
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,lobectomy,0.2556746,recurrent,0.3900475,semantic,0.36312217
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,lung-cancer,0.29581597,decision-tree,0.3364873,decision-tree,0.3364873
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,hr,0.24641928,rate,0.5365405,bagging,0.39750856
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,oxygen,0.22381568,reduction,0.44402215,feature-reduction,0.3957175
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,saturation,0.2695647,gradient,0.47808188,gradient,0.47808188
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,oxygen-saturation,0.23776144,feature-reduction,0.5207893,feature-reduction,0.5207893
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,map,0.3543614,bagging,0.4165985,bagging,0.4165985
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,heart,0.28300244,rate,0.49867767,batch-normalization,0.3427502
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,rate,0.24866687,rate,1.0,dropout,0.44953537
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,heart-rate,0.4407577,learning-rate,0.54865026,learning-rate,0.54865026
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,underwent,0.251209,recurrent,0.4136293,supervised,0.35678548
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,elective,0.28293884,recurrent,0.4786067,supervised,0.4186884
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,thoracoscopic,0.31950566,segmentation-algorithm,0.39032823,segmentation-algorithm,0.39032823
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,lobectomy,0.2556746,recurrent,0.3900475,semantic,0.36312217
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,il,0.17175047,monte,0.3419046,monte,0.3419046
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,p,0.26795468,support,0.40805867,regression,0.40253854
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,il,0.17175047,monte,0.3419046,monte,0.3419046
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,hour,0.27539003,bag,0.52061355,supervised,0.37945712
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,tnf,0.15280242,naive,0.34630367,tf-idf,0.2688402
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,pulmonary,0.27012008,recurrent,0.39649367,long-short-term,0.32169557
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,protective,0.2287128,boosting,0.50660264,boosting,0.50660264
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,mechanism,0.2780391,cascade,0.59194523,feed-forward,0.5341974
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,could,0.34235194,of,0.59299076,boosting,0.42074972
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,pulmonary-protective,0.3176161,long-short-term,0.489357,long-short-term,0.489357
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,binding,0.27773649,of,0.45710018,nearest-neighbors,0.40653253
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,protein,0.31929362,encoding,0.5525089,clustering,0.36023882
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,homologous,0.2608494,encoding,0.60800725,feature-selection,0.39625388
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,protein,0.31929362,encoding,0.5525089,clustering,0.36023882
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,binding-protein,0.33615637,encoding,0.5213111,feed-forward,0.41663548
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,protein-homologous,0.3737775,encoding,0.57704985,feed-forward,0.43177903
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,homologous-protein,0.31367373,encoding,0.57537585,component-analysis,0.41391587
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,sod,0.22904798,reduction,0.31911826,fourier-transform,0.29286325
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,mda,0.22752835,normalization,0.33347362,batch-normalization,0.32173502
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,ai,0.25513044,artificial-intelligence,0.38274616,artificial-intelligence,0.38274616
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,il,0.17175047,monte,0.3419046,monte,0.3419046
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,reducing,0.26140445,reduction,0.74160737,boosting,0.5133524
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,chop,0.23859908,long-short-term,0.35091794,long-short-term,0.35091794
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,chop,0.23859908,long-short-term,0.35091794,long-short-term,0.35091794
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,mrna,0.25853646,encoding,0.5590567,batch-normalization,0.35810667
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,mean,0.24598047,reduction,0.46440193,batch-normalization,0.434582
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,arterial,0.27257246,augmentation,0.4504157,gradient,0.4443115
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,pressure,0.2060274,gradient,0.4962673,gradient,0.4962673
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,mean-arterial,0.3416868,batch-normalization,0.50238883,batch-normalization,0.50238883
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,arterial-pressure,0.318011,gradient,0.486531,gradient,0.486531
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,mean-arterial-pressure,0.3725517,tensorflow,0.50904167,tensorflow,0.50904167
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,iqa,0.466146,ground-truth,0.4958604,ground-truth,0.4958604
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,immediately,0.23933741,short-term,0.47347653,one-hot,0.40441123
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,p,0.26795468,support,0.40805867,regression,0.40253854
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,airway,0.22946814,bagging,0.39862382,bagging,0.39862382
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,pressure,0.2060274,gradient,0.4962673,gradient,0.4962673
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,peak,0.23109604,gradient,0.48941624,gradient,0.48941624
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,airway-pressure,0.30194947,bagging,0.45084995,bagging,0.45084995
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,pressure-peak,0.24851583,fourier,0.48418617,fourier,0.48418617
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,alveolar,0.20294523,matrix,0.3980087,confusion-matrix,0.32685
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,ai,0.25513044,artificial-intelligence,0.38274616,artificial-intelligence,0.38274616
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,chop,0.23859908,long-short-term,0.35091794,long-short-term,0.35091794
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,il,0.17175047,monte,0.3419046,monte,0.3419046
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,unilateral,0.32771435,recurrent,0.5424,recurrent-neural-network,0.43683177
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,pulmonary,0.27012008,recurrent,0.39649367,long-short-term,0.32169557
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,ventilation,0.27897805,bagging,0.4853503,bagging,0.4853503
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,pulmonary-ventilation,0.315311,bagging,0.4239483,bagging,0.4239483
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,bilateral,0.3142376,recurrent,0.5268234,convolutional,0.44078895
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,pulmonary,0.27012008,recurrent,0.39649367,long-short-term,0.32169557
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,ventilation,0.27897805,bagging,0.4853503,bagging,0.4853503
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,pulmonary-ventilation,0.315311,bagging,0.4239483,bagging,0.4239483
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,tumor,0.23345715,of,0.4070977,regression,0.3830863
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,necrosis,0.13728917,of,0.39391375,regression,0.3165221
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,factor,0.23388772,component,0.48280093,principal-components,0.43733668
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,tumor-necrosis,0.17264141,matrix,0.3434254,boosting,0.29771045
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,necrosis-factor,0.2518684,cascade,0.4094454,principal-component,0.37788132
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,tumor-necrosis-factor,0.2309803,matrix,0.38553926,boosting,0.33476132
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,super,0.37175536,shot,0.5203413,one-hot,0.4360347
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,oxide,0.2015453,layer,0.46443787,learning-function,0.3595099
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,dismutase,0.23660295,encoding,0.34845784,fourier-transform,0.33302718
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,super-oxide,0.2705912,dimensionality-reduction,0.47903556,dimensionality-reduction,0.47903556
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,super-oxide-dismutase,0.26995337,feature-reduction,0.4609405,feature-reduction,0.4609405
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,second,0.3157444,one,0.6801673,generative,0.44190797
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,affiliated,0.3504666,nearest,0.5106459,clustering,0.4152682
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,hospital,0.2768838,unit,0.588941,data-science,0.39080185
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,affiliated-hospital,0.3895444,unit,0.50103164,supervised,0.4596948
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,improving,0.40742207,boosting,0.54548407,boosting,0.54548407
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,oxidative,0.2292116,cascade,0.4921013,feature-reduction,0.39866948
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,stress,0.25135952,short-term,0.46436286,long-short-term,0.43407696
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,oxidative-stress,0.31784338,generative-model,0.44570386,generative-model,0.44570386
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,elderly,0.3021084,short-term,0.47582904,short-term-memory,0.41010565
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,patients,0.30007,recurrent,0.5332828,dropout,0.3918751
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,elderly-patients,0.31014603,dropout,0.4163887,dropout,0.4163887
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,end,0.22421888,long,0.5453975,long-short-term,0.36503828
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,interleukin,0.2092636,naive,0.38037264,short-term-memory,0.34282282
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,dexmedetomidine,0.26012486,data-augmentation,0.36828512,data-augmentation,0.36828512
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,could,0.34235194,of,0.59299076,boosting,0.42074972
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,attenuate,0.2554348,reduction,0.46206194,boosting,0.41479498
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,n,0.24332823,of,0.45693433,long-short-term,0.34114176
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,spontaneous,0.2555595,recurrent,0.54341316,long-short-term,0.44304562
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,breathing,0.35209614,bagging,0.512692,bagging,0.512692
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,recovery,0.28707236,short-term,0.59335697,long-short-term,0.506847
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,spontaneous-breathing,0.3811678,bagging,0.5149439,bagging,0.5149439
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,spo,0.30758917,bagging,0.47931948,bagging,0.47931948
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,lung,0.26692057,of,0.3928769,bagging,0.36409828
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,cancer,0.27383438,recurrent,0.4065063,generative,0.3468409
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,lung-cancer,0.29581597,decision-tree,0.3364873,decision-tree,0.3364873
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,map,0.3543614,bagging,0.4165985,bagging,0.4165985
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,hr,0.24641928,rate,0.5365405,bagging,0.39750856
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,pmid,0.17205057,science,0.31445533,bag-of-words,0.26444918
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,october,0.23776051,science,0.46905673,data-science,0.39997986
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,march,0.25898194,science,0.47958314,data-science,0.40582275
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,spontaneous,0.2555595,recurrent,0.54341316,long-short-term,0.44304562
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,breathing,0.35209614,bagging,0.512692,bagging,0.512692
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,spontaneous-breathing,0.3811678,bagging,0.5149439,bagging,0.5149439
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,elderly,0.3021084,short-term,0.47582904,short-term-memory,0.41010565
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,patients,0.30007,recurrent,0.5332828,dropout,0.3918751
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,elderly-patients,0.31014603,dropout,0.4163887,dropout,0.4163887
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,peak,0.23109604,gradient,0.48941624,gradient,0.48941624
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,lung,0.26692057,of,0.3928769,bagging,0.36409828
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,tissue,0.23679586,of,0.5202017,segmentation,0.4076932
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,lung-tissue,0.25610813,batch-normalization,0.40314072,batch-normalization,0.40314072
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,lung,0.26692057,of,0.3928769,bagging,0.36409828
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,injury,0.262506,shot,0.44338763,data-augmentation,0.37271294
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,lung-injury,0.30569544,learning-function,0.35851276,learning-function,0.35851276
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,alveolar,0.20294523,matrix,0.3980087,confusion-matrix,0.32685
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,damage,0.27088127,function,0.48203948,generative,0.40220195
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,recovery,0.28707236,short-term,0.59335697,long-short-term,0.506847
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,time,0.31186903,long,0.57547164,batch-normalization,0.47628766
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,recovery-time,0.46701622,batch-normalization,0.62980163,batch-normalization,0.62980163
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,zhengzhou,0.24365059,science,0.37731874,pytorch,0.33329725
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,university,0.39088657,science,0.60339034,data-science,0.5440467
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,two,0.35955608,one,0.79919666,clustering,0.43817294
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,groups,0.2727722,statistical,0.4438421,statistical,0.4438421
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,two-groups,0.46960184,principal-components,0.6137319,principal-components,0.6137319
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,tracheal,0.17855802,of,0.37379938,bagging,0.36196265
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,intubation,0.2624027,bagging,0.4638163,bagging,0.4638163
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,tracheal-intubation,0.28115076,bagging,0.48606086,bagging,0.48606086
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,significantly,0.27887642,of,0.5214151,long-short-term,0.39056638
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,shorter,0.23315734,short,0.7006648,long-short-term,0.5485222
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,significantly,0.27887642,of,0.5214151,long-short-term,0.39056638
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,lower,0.20975146,of,0.5471319,regression,0.3982392
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,significantly-lower,0.2796454,of,0.50498235,long-short-term,0.40800315
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,significantly,0.27887642,of,0.5214151,long-short-term,0.39056638
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,higher,0.27819592,reduction,0.545787,boosting,0.41506222
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,significantly-higher,0.29000503,rate,0.5078902,boosting,0.4130143
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,random,0.45551494,random,1.0,random-forest,0.65894985
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,phenotype,0.28173286,feature,0.51151407,feature-selection,0.4975547
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,postoperative,0.25341886,recurrent,0.50502723,computer-vision,0.3969509
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,awake,0.32721922,words,0.48881316,object-tracking,0.439033
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,mediated,0.1966965,cascade,0.5268023,feed-forward,0.4459417
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,apoptosis,0.22776133,cascade,0.46111506,feed-forward,0.37718636
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,mediated-apoptosis,0.23641786,cascade,0.4814019,feed-forward,0.4198906
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,inflammatory,0.19824001,cascade,0.43951106,generative-model,0.38795525
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,factors,0.3420733,components,0.5413606,logistic-regression,0.48293567
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,anesthetic,0.29171485,of,0.39854127,data-augmentation,0.3783091
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,induction,0.22102317,of,0.52603287,long-short-term,0.44878548
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,agitation,0.22799543,confusion,0.6246381,confusion-matrix,0.4674005
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,occurrence,0.30364993,of,0.6225994,clustering,0.4847598
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,group,0.26103544,of,0.44356787,statistical,0.3923795
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,c,0.17513797,of,0.44327667,gradient,0.31114018
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,group-c,0.18789625,one-shot,0.32843167,one-shot,0.32843167
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,dexmedetomidine,0.26012486,data-augmentation,0.36828512,data-augmentation,0.36828512
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,group,0.26103544,of,0.44356787,statistical,0.3923795
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,control,0.27050394,of,0.5093193,artificial-intelligence,0.40948874
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,group,0.26103544,of,0.44356787,statistical,0.3923795
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,control-group,0.2875058,statistical,0.4468634,statistical,0.4468634
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,elapsed,0.30047274,short-term,0.43489587,long-short-term,0.3979167
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,time,0.31186903,long,0.57547164,batch-normalization,0.47628766
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,elapsed-time,0.41446674,one-shot,0.4978272,one-shot,0.4978272
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,p,0.26795468,support,0.40805867,regression,0.40253854
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,protein,0.31929362,encoding,0.5525089,clustering,0.36023882
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,pao,0.19672337,feature-reduction,0.34453356,feature-reduction,0.34453356
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,peak,0.23109604,gradient,0.48941624,gradient,0.48941624
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,il,0.17175047,monte,0.3419046,monte,0.3419046
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,tnf,0.15280242,naive,0.34630367,tf-idf,0.2688402
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,end,0.22421888,long,0.5453975,long-short-term,0.36503828
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,dexmedetomidine,0.26012486,data-augmentation,0.36828512,data-augmentation,0.36828512
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,group,0.26103544,of,0.44356787,statistical,0.3923795
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,time,0.31186903,long,0.57547164,batch-normalization,0.47628766
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,values,0.28403002,batch-normalization,0.5186162,batch-normalization,0.5186162
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,total,0.21723771,of,0.5102532,principal-components,0.3630478
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,surgery,0.29565036,recurrent,0.47230634,computer-vision,0.40172684
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,selected,0.38157707,selection,0.6797303,feature-selection,0.48698312
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,results,0.32376552,data,0.6932311,batch-normalization,0.44826904
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,related,0.30849367,of,0.6150687,clustering,0.41455543
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,recorded,0.299657,rectified,0.55581653,computer-vision,0.443301
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,ratios,0.18493193,rate,0.42238456,regression,0.41522446
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,publisher,0.3885098,data-science,0.6134455,data-science,0.6134455
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,objective,0.4122544,of,0.5255821,component-analysis,0.42220753
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,methods,0.50049126,data,0.5400177,machine-learning,0.50049126
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,medline,0.44432086,data-science,0.5824888,data-science,0.5824888
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,malondialdehyde,0.19929554,reduction,0.3618797,fourier-transform,0.35799217
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,levels,0.20457911,normalization,0.52984333,batch-normalization,0.45617118
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,j,0.12432591,science,0.31094742,cross-entropy,0.2885616
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,issn,0.34779435,data-science,0.47779685,data-science,0.47779685
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,inhibition,0.21671593,reduction,0.58642584,feed-forward,0.44581953
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,indexed,0.3858727,semantic,0.49446192,semantic,0.49446192
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,extent,0.258318,of,0.64978826,dimensionality-reduction,0.43577164
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,expression,0.32038707,encoding,0.59633577,clustering,0.442253
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,evaluate,0.37214977,of,0.4977158,decision-tree,0.4090718
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,et,0.21257874,science,0.40568537,bagging,0.326393
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,enhancer,0.31055215,encoding,0.48501134,feed-forward,0.39416587
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,effect,0.21449387,short-term,0.5886732,long-short-term,0.47619703
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,doi,0.2357645,data-science,0.3312925,data-science,0.3312925
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,divided,0.31782648,one,0.5082367,classification,0.4014557
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,detected,0.25814283,of,0.52368605,clustering,0.37524593
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,conscious,0.35195976,learning-function,0.47870794,learning-function,0.47870794
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,conclusions,0.37109232,data,0.55923915,long-short-term,0.4627594
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,compared,0.3359061,of,0.52794564,long-short-term,0.42386633
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,co,0.23682216,ground,0.42757797,feature-reduction,0.3969199
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,cma,0.26199263,network,0.39313567,component-analysis,0.362921
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,ccaat,0.22436021,encoding,0.4029963,bag-of-words,0.35262758
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,receiving,0.27153072,of,0.5197021,boosting,0.41845503
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,mimetic,0.2918735,natural,0.48951066,feature-engineering,0.4293661
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,peptide,0.3208105,encoding,0.44188768,boosting,0.35291767
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,administered,0.23933353,of,0.47672778,boosting,0.39902678
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,via,0.29305607,connected,0.5425352,feed-forward,0.46278888
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,drinking,0.31476432,feed,0.52662104,reinforcement-learning,0.4468941
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,water,0.30284643,feed,0.5419835,gradient,0.42149428
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,mimetic-peptide,0.39188892,feature-engineering,0.45720488,feature-engineering,0.45720488
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,peptide-administered,0.3456116,boosting,0.4713434,boosting,0.4713434
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,via-drinking,0.340958,reinforcement-learning,0.5032118,reinforcement-learning,0.5032118
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,drinking-water,0.32435203,feed,0.5478481,random-forest,0.407558
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,fat,0.22005057,feed,0.48228577,segmentation,0.36863354
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,diet,0.23870954,feed,0.6865525,supervised,0.36359084
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,fed,0.301457,feed,0.7557408,supervised,0.35448015
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,mice,0.24457785,naive,0.4783403,short-term-memory,0.38200378
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,improved,0.40049985,normalization,0.5598826,boosting,0.5069493
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,insulin,0.22629064,unit,0.40084893,batch-normalization,0.32209873
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,sensitivity,0.28808302,discriminative,0.5372434,cross-validation,0.48943394
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,associated,0.30827495,of,0.57598466,long-short-term,0.46578532
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,fat-diet,0.20103073,feed,0.47533706,kernel,0.34574616
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,diet-fed,0.22306089,feed,0.48020792,feed-forward,0.3110004
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,fed-mice,0.27086926,feed,0.46290284,batch-normalization,0.39187187
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,improved-insulin,0.3339586,batch-normalization,0.43363523,batch-normalization,0.43363523
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,insulin-sensitivity,0.24837527,function,0.4442757,batch-normalization,0.40178967
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,sensitivity-associated,0.3566,of,0.5229589,clustering,0.5096481
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,fat-diet-fed,0.18909307,feed,0.41757149,feed-forward,0.3247398
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,mimetic,0.2918735,natural,0.48951066,feature-engineering,0.4293661
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,peptide,0.3208105,encoding,0.44188768,boosting,0.35291767
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,administered,0.23933353,of,0.47672778,boosting,0.39902678
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,mimetic-peptide,0.39188892,feature-engineering,0.45720488,feature-engineering,0.45720488
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,peptide-administered,0.3456116,boosting,0.4713434,boosting,0.4713434
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,ai,0.25513044,artificial-intelligence,0.38274616,artificial-intelligence,0.38274616
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,mimetic,0.2918735,natural,0.48951066,feature-engineering,0.4293661
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,peptides,0.3394723,encoding,0.4170969,boosting,0.3558063
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,treatment,0.239264,short-term,0.5206091,long-short-term,0.41699445
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,led,0.28597406,of,0.6366651,boosting,0.411306
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,treatment-led,0.3739287,short-term,0.5132314,dropout,0.5084819
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,data,0.46434748,data,1.0,data-science,0.5533528
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,provides,0.41792372,of,0.5261056,feature-engineering,0.4872959
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,compelling,0.41525716,data,0.59411526,feature-engineering,0.5221603
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,proof,0.41112384,truth,0.54702806,feature-engineering,0.5196251
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,data-provides,0.6202822,data-science,0.7247083,data-science,0.7247083
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,improved,0.40049985,normalization,0.5598826,boosting,0.5069493
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,blood,0.16939776,normalization,0.4272251,batch-normalization,0.40715772
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,glucose,0.22612295,batch-normalization,0.39605165,batch-normalization,0.39605165
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,clearance,0.2511453,rate,0.48930377,batch-normalization,0.42699638
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,blood-glucose,0.2670272,batch-normalization,0.4206398,batch-normalization,0.4206398
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,glucose-clearance,0.28751153,batch-normalization,0.4740383,batch-normalization,0.4740383
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,high,0.267004,of,0.57459104,gradient,0.44240427
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,density,0.25813383,layer,0.4929318,gradient,0.48885438
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,lipoprotein,0.22208765,tf-idf,0.3608624,tf-idf,0.3608624
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,particles,0.25576374,stochastic-gradient,0.48749006,stochastic-gradient,0.48749006
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,high-density,0.2854991,layer,0.42330095,gradient,0.40636635
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,density-lipoprotein,0.2429603,tf-idf,0.4027466,tf-idf,0.4027466
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,lipoprotein-particles,0.34635645,stochastic-gradient,0.49495187,stochastic-gradient,0.49495187
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,high-density-lipoprotein,0.28167933,batch-normalization,0.40595478,batch-normalization,0.40595478
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,also,0.32850838,of,0.65908813,clustering,0.45826355
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,showed,0.20766163,of,0.5296177,regression,0.37027335
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,altered,0.28369883,of,0.5963239,generative,0.4193554
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,expression,0.32038707,encoding,0.59633577,clustering,0.442253
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,also-showed,0.28968182,of,0.49911186,dimensionality-reduction,0.41159767
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,altered-expression,0.412562,feature-selection,0.557325,feature-selection,0.557325
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,fold,0.32232243,of,0.4827961,convolutional,0.39711127
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,auc,0.32985288,cross-validation,0.5105883,cross-validation,0.5105883
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,decrease,0.23670179,reduction,0.82910776,boosting,0.45522925
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,compared,0.3359061,of,0.52794564,long-short-term,0.42386633
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,reduced,0.24137571,reduction,0.7564339,boosting,0.47559226
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,hepatic,0.22217517,of,0.408211,batch-normalization,0.34534258
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,macrophage,0.22891665,matrix,0.43859345,clustering,0.35980862
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,infiltration,0.24753922,layer,0.43824458,clustering,0.37248868
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,macrophage-infiltration,0.28759837,naive,0.4730282,short-term-memory,0.38691437
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,improve,0.45207965,boosting,0.5098576,boosting,0.5098576
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,insulin,0.22629064,unit,0.40084893,batch-normalization,0.32209873
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,sensitivity,0.28808302,discriminative,0.5372434,cross-validation,0.48943394
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,insulin-sensitivity,0.24837527,function,0.4442757,batch-normalization,0.40178967
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,ai,0.25513044,artificial-intelligence,0.38274616,artificial-intelligence,0.38274616
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,mimetic,0.2918735,natural,0.48951066,feature-engineering,0.4293661
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,peptide,0.3208105,encoding,0.44188768,boosting,0.35291767
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,mimetic-peptide,0.39188892,feature-engineering,0.45720488,feature-engineering,0.45720488
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,improved,0.40049985,normalization,0.5598826,boosting,0.5069493
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,insulin,0.22629064,unit,0.40084893,batch-normalization,0.32209873
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,tolerance,0.28092206,short-term,0.51278496,long-short-term,0.44540006
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,improved-insulin,0.3339586,batch-normalization,0.43363523,batch-normalization,0.43363523
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,insulin-tolerance,0.28475654,short-term,0.43753603,long-short-term,0.41479504
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,improved,0.40049985,normalization,0.5598826,boosting,0.5069493
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,glucose,0.22612295,batch-normalization,0.39605165,batch-normalization,0.39605165
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,homeostasis,0.24268803,function,0.58911395,feed-forward,0.42720363
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,glucose-homeostasis,0.299007,feed-forward,0.4742095,feed-forward,0.4742095
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,fat,0.22005057,feed,0.48228577,segmentation,0.36863354
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,diet,0.23870954,feed,0.6865525,supervised,0.36359084
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,fat-diet,0.20103073,feed,0.47533706,kernel,0.34574616
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,mimetic,0.2918735,natural,0.48951066,feature-engineering,0.4293661
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,peptides,0.3394723,encoding,0.4170969,boosting,0.3558063
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,could,0.34235194,of,0.59299076,boosting,0.42074972
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,ai,0.25513044,artificial-intelligence,0.38274616,artificial-intelligence,0.38274616
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,mimetic,0.2918735,natural,0.48951066,feature-engineering,0.4293661
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,peptides,0.3394723,encoding,0.4170969,boosting,0.3558063
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,fold,0.32232243,of,0.4827961,convolutional,0.39711127
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,decrease,0.23670179,reduction,0.82910776,boosting,0.45522925
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,compared,0.3359061,of,0.52794564,long-short-term,0.42386633
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,fold-decrease,0.39245546,reduction,0.5429677,batch-normalization,0.4995628
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,fold,0.32232243,of,0.4827961,convolutional,0.39711127
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,auc,0.32985288,cross-validation,0.5105883,cross-validation,0.5105883
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,compared,0.3359061,of,0.52794564,long-short-term,0.42386633
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,insulin,0.22629064,unit,0.40084893,batch-normalization,0.32209873
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,tolerance,0.28092206,short-term,0.51278496,long-short-term,0.44540006
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,tests,0.37449622,statistical,0.48559177,statistical,0.48559177
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,insulin-tolerance,0.28475654,short-term,0.43753603,long-short-term,0.41479504
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,tolerance-tests,0.34494105,short-term-memory,0.48979798,short-term-memory,0.48979798
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,insulin,0.22629064,unit,0.40084893,batch-normalization,0.32209873
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,tolerance,0.28092206,short-term,0.51278496,long-short-term,0.44540006
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,test,0.4037762,statistical,0.5031551,statistical,0.5031551
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,insulin-tolerance,0.28475654,short-term,0.43753603,long-short-term,0.41479504
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,tolerance-test,0.3201354,short-term-memory,0.47404006,short-term-memory,0.47404006
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,insulin-tolerance-test,0.30295074,short-term-memory,0.43992877,short-term-memory,0.43992877
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,induced,0.2259351,of,0.5615651,boosting,0.4303583
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,insulin,0.22629064,unit,0.40084893,batch-normalization,0.32209873
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,resistance,0.23395967,selection,0.4553234,long-short-term,0.34529024
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,induced-insulin,0.23706785,short-term,0.39598745,long-short-term,0.36744803
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,insulin-resistance,0.26955065,function,0.38102794,long-short-term,0.36459094
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,new,0.43019778,of,0.526482,feature-reduction,0.4579819
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,therapeutic,0.3659354,of,0.48352462,boosting,0.41573292
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,option,0.35068518,decision,0.5267865,algorithm,0.43552527
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,new-therapeutic,0.3548655,normalization,0.42601833,one-shot,0.41742682
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,therapeutic-option,0.4075905,feature-engineering,0.5243293,feature-engineering,0.5243293
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,intraperitoneal,0.20122352,one-shot,0.3847499,one-shot,0.3847499
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,injection,0.21726662,shot,0.46511483,one-shot,0.44853872
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,bi,0.2604679,hierarchical-clustering,0.43775064,hierarchical-clustering,0.43775064
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,intraperitoneal-injection,0.25576895,one-shot,0.4909076,one-shot,0.4909076
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,hepatic,0.22217517,of,0.408211,batch-normalization,0.34534258
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,mrna,0.25853646,encoding,0.5590567,batch-normalization,0.35810667
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,expression,0.32038707,encoding,0.59633577,clustering,0.442253
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,hepatic-mrna,0.23533252,batch-normalization,0.42116562,batch-normalization,0.42116562
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,mrna-expression,0.2990228,encoding,0.5055611,feed-forward,0.3768012
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,ai,0.25513044,artificial-intelligence,0.38274616,artificial-intelligence,0.38274616
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,injected,0.19899152,shot,0.43160263,boosting,0.3551404
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,directly,0.29203913,of,0.58113813,clustering,0.40171087
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,key,0.35973132,principal,0.614877,feature-engineering,0.498355
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,markers,0.32439512,of,0.43581337,clustering,0.41091266
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,involved,0.26651675,of,0.5396308,feed-forward,0.42281044
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,key-markers,0.42983308,component-analysis,0.4895905,component-analysis,0.4895905
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,glucose,0.22612295,batch-normalization,0.39605165,batch-normalization,0.39605165
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,tolerance,0.28092206,short-term,0.51278496,long-short-term,0.44540006
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,test,0.4037762,statistical,0.5031551,statistical,0.5031551
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,glucose-tolerance,0.3149302,batch-normalization,0.38830137,batch-normalization,0.38830137
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,tolerance-test,0.3201354,short-term-memory,0.47404006,short-term-memory,0.47404006
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,glucose-tolerance-test,0.32055682,batch-normalization,0.43126833,batch-normalization,0.43126833
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,reduce,0.314935,reduction,0.63468504,boosting,0.4613787
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,hepatic,0.22217517,of,0.408211,batch-normalization,0.34534258
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,inflammation,0.22370426,cascade,0.4429949,generative-model,0.3706867
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,decreased,0.23506472,reduction,0.66483074,boosting,0.42738107
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,hepatic,0.22217517,of,0.408211,batch-normalization,0.34534258
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,inflammation,0.22370426,cascade,0.4429949,generative-model,0.3706867
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,test,0.4037762,statistical,0.5031551,statistical,0.5031551
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,whether,0.32171756,short-term,0.5290759,long-short-term,0.47851244
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,apo,0.24596831,discriminative,0.29206568,tf-idf,0.28953674
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,test-whether,0.4463819,reinforcement-learning,0.559227,reinforcement-learning,0.559227
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,metabolic,0.3235007,of,0.46523505,batch-normalization,0.4536144
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,test,0.4037762,statistical,0.5031551,statistical,0.5031551
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,results,0.32376552,data,0.6932311,batch-normalization,0.44826904
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,test-results,0.34867293,data,0.47694188,statistical,0.45966953
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,major,0.2356064,principal,0.70253855,principal-components,0.42016473
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,apolipoprotein,0.25016165,tf-idf,0.31200302,tf-idf,0.31200302
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,found,0.2840244,of,0.6208722,clustering,0.44675255
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,mimetic,0.2918735,natural,0.48951066,feature-engineering,0.4293661
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,peptides,0.3394723,encoding,0.4170969,boosting,0.3558063
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,mice,0.24457785,naive,0.4783403,short-term-memory,0.38200378
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,insulin,0.22629064,unit,0.40084893,batch-normalization,0.32209873
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,resistance,0.23395967,selection,0.4553234,long-short-term,0.34529024
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,insulin-resistance,0.26955065,function,0.38102794,long-short-term,0.36459094
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,fold,0.32232243,of,0.4827961,convolutional,0.39711127
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,compared,0.3359061,of,0.52794564,long-short-term,0.42386633
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,reduced,0.24137571,reduction,0.7564339,boosting,0.47559226
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,infiltration,0.24753922,layer,0.43824458,clustering,0.37248868
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,reduced,0.24137571,reduction,0.7564339,boosting,0.47559226
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,expression,0.32038707,encoding,0.59633577,clustering,0.442253
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,reduced-expression,0.3747721,encoding,0.5343579,boosting,0.4885286
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,glucose,0.22612295,batch-normalization,0.39605165,batch-normalization,0.39605165
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,tolerance,0.28092206,short-term,0.51278496,long-short-term,0.44540006
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,glucose-tolerance,0.3149302,batch-normalization,0.38830137,batch-normalization,0.38830137
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,hepatic,0.22217517,of,0.408211,batch-normalization,0.34534258
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,inflammation,0.22370426,cascade,0.4429949,generative-model,0.3706867
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,genes,0.32912976,encoding,0.71535945,clustering,0.43737888
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,associated,0.30827495,of,0.57598466,long-short-term,0.46578532
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,genes-associated,0.37071562,encoding,0.58060443,clustering,0.46099043
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,associated,0.30827495,of,0.57598466,long-short-term,0.46578532
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,genes,0.32912976,encoding,0.71535945,clustering,0.43737888
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,associated-genes,0.38436568,encoding,0.5684857,clustering,0.46885455
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,xxxf,0.22052765,tfidf,0.3340549,tfidf,0.3340549
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,showed,0.20766163,of,0.5296177,regression,0.37027335
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,inflammatory,0.19824001,cascade,0.43951106,generative-model,0.38795525
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,markers,0.32439512,of,0.43581337,clustering,0.41091266
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,inflammatory-markers,0.28920448,components,0.44646454,generative-model,0.4311884
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,fed,0.301457,feed,0.7557408,supervised,0.35448015
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,ifn,0.16607872,naive,0.38697833,naive-bayes,0.33626795
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,time,0.31186903,long,0.57547164,batch-normalization,0.47628766
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,pcr,0.34162766,analysis,0.4623741,logistic-regression,0.38891542
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,time-pcr,0.32452363,analysis,0.42748302,logistic-regression,0.41675538
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,respective,0.28371117,of,0.6179571,statistical,0.40656513
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,pathways,0.30476987,cascade,0.6938149,feed-forward,0.5254793
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,previously,0.31365848,fully,0.5461891,long-short-term,0.40718085
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,demonstrated,0.2929331,of,0.6025795,feature-reduction,0.39724052
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,previously-demonstrated,0.37792188,of,0.59028196,dimensionality-reduction,0.5216695
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,male,0.26790547,naive,0.47688544,generative,0.42885694
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,lipid,0.23492281,of,0.44637915,clustering,0.37238947
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,synthesis,0.23195125,cascade,0.44733208,feature-engineering,0.42246765
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,lipid-synthesis,0.26245883,natural,0.43175346,feature-engineering,0.42926267
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,length,0.1402078,long,0.6515323,long-short-term,0.43421984
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,apo,0.24596831,discriminative,0.29206568,tf-idf,0.28953674
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,hdls,0.2415817,nlp,0.34905428,nlp,0.34905428
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,gluconeogenic,0.24663872,feed-forward,0.42031178,feed-forward,0.42031178
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,enzymes,0.25064033,encoding,0.4579606,feature-reduction,0.35283113
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,five,0.3705204,one,0.7489015,principal-components,0.4074809
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,weeks,0.22652107,term,0.52859676,supervised,0.4119058
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,five-weeks,0.30150756,short-term,0.48763472,supervised,0.46849373
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,findings,0.35685748,data,0.65714294,component-analysis,0.38599753
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,suggest,0.26874092,data,0.5391823,long-short-term,0.40288782
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,clinically,0.3702051,recurrent,0.5046643,confusion-matrix,0.40397355
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,feasible,0.4521153,one-shot,0.48722428,one-shot,0.48722428
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,clinically-feasible,0.54337966,feature-reduction,0.5538282,feature-reduction,0.5538282
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,weeks,0.22652107,term,0.52859676,supervised,0.4119058
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,overall,0.37212962,rate,0.62994075,dropout,0.45315623
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,suppression,0.24727267,reduction,0.62000287,boosting,0.50863206
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,xxxf,0.22052765,tfidf,0.3340549,tfidf,0.3340549
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,associated,0.30827495,of,0.57598466,long-short-term,0.46578532
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,treatment,0.239264,short-term,0.5206091,long-short-term,0.41699445
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,ai,0.25513044,artificial-intelligence,0.38274616,artificial-intelligence,0.38274616
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,peptides,0.3394723,encoding,0.4170969,boosting,0.3558063
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,glucose,0.22612295,batch-normalization,0.39605165,batch-normalization,0.39605165
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,high,0.267004,of,0.57459104,gradient,0.44240427
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,inflammation,0.22370426,cascade,0.4429949,generative-model,0.3706867
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,results,0.32376552,data,0.6932311,batch-normalization,0.44826904
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,apolipoprotein,0.25016165,tf-idf,0.31200302,tf-idf,0.31200302
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,apo,0.24596831,discriminative,0.29206568,tf-idf,0.28953674
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,xxxf,0.22052765,tfidf,0.3340549,tfidf,0.3340549
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,suppression,0.24727267,reduction,0.62000287,boosting,0.50863206
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,weekly,0.31133008,short-term,0.49189126,supervised,0.47765696
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,total,0.21723771,of,0.5102532,principal-components,0.3630478
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,suppressed,0.1800454,reduction,0.5064377,boosting,0.45223624
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,suggesting,0.24045295,of,0.6157647,clustering,0.43733796
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,study,0.3645851,of,0.5728763,statistical,0.44204497
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,real,0.4954688,truth,0.5802553,ground-truth,0.56635034
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,pepck,0.16287875,encoding,0.34524238,feed-forward,0.3279683
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,p,0.26795468,support,0.40805867,regression,0.40253854
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,overnutrition,0.30107185,feed,0.50031924,long-short-term,0.39979285
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,ns,0.26156068,bag,0.48808247,bagging,0.4119292
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,mimetics,0.33374968,natural,0.4763019,feature-engineering,0.47427905
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,methods,0.50049126,data,0.5400177,machine-learning,0.50049126
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,macrophages,0.20754936,naive,0.47024828,short-term-memory,0.3296041
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,liver,0.22774608,of,0.3980642,batch-normalization,0.34184414
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,lipogenic,0.22927466,feed-forward,0.39948875,feed-forward,0.39948875
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,l,0.15310754,of,0.37313756,bagging,0.32610148
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,iv,0.2348194,one,0.40236133,classification,0.3413719
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,il,0.17175047,monte,0.3419046,monte,0.3419046
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,iii,0.2227494,classification,0.42103207,classification,0.42103207
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,ii,0.22929578,of,0.43728137,classification,0.3694628
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,hfd,0.26948723,feed,0.34567845,feed-forward,0.3432696
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,gluconeogenesis,0.2250691,feed-forward,0.41510007,feed-forward,0.41510007
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,full,0.3269437,fully,0.61890495,softmax,0.42416686
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,emulate,0.5355338,feature-engineering,0.6525404,feature-engineering,0.6525404
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,effects,0.2624804,short-term,0.63497096,long-short-term,0.5306107
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,effect,0.21449387,short-term,0.5886732,long-short-term,0.47619703
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,development,0.34732813,generative,0.56588423,generative,0.56588423
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,contributes,0.27235785,of,0.5690483,feed-forward,0.4287781
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,conducted,0.39637828,data,0.556862,statistical,0.4670034
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,conclusion,0.35530132,data,0.5299138,long-short-term,0.45073265
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,concept,0.50769854,feature-engineering,0.6208862,feature-engineering,0.6208862
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,chrebp,0.24124688,feed-forward,0.41858518,feed-forward,0.41858518
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,background,0.3259285,of,0.51277274,long-short-term,0.46426663
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,assessed,0.33986524,of,0.605934,component-analysis,0.41855076
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,assess,0.36162603,of,0.49566716,decision-tree,0.39463407
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,apoa,0.15227385,tf-idf,0.3105898,tf-idf,0.3105898
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,aim,0.4029312,feature-engineering,0.41751927,feature-engineering,0.41751927
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,orchestrating,0.35173565,cascade,0.5870936,feed-forward,0.5815563
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,many,0.40940517,few,0.752018,feature-engineering,0.48454586
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,cellular,0.33255053,of,0.55018497,generative,0.4558165
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,processes,0.34218454,processing,0.59430957,generative,0.5664364
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,including,0.3233776,of,0.6619886,clustering,0.40625107
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,cell,0.2212203,of,0.48460138,generative,0.39753264
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,volume,0.268351,segmentation,0.4447226,segmentation,0.4447226
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,regulation,0.2640685,function,0.5839784,feed-forward,0.52085924
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,processes-including,0.41022062,processing,0.5805423,feature-engineering,0.5687783
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,cell-volume,0.31974113,batch-normalization,0.45531183,batch-normalization,0.45531183
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,volume-regulation,0.3452528,function,0.5382032,feed-forward,0.48900428
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,also,0.32850838,of,0.65908813,clustering,0.45826355
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,evaluated,0.35501102,of,0.6190806,supervised,0.4124783
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,several,0.40139607,few,0.7607186,clustering,0.4671372
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,amino,0.2694568,encoding,0.535731,n-gram,0.39453936
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,acid,0.19370206,of,0.41044196,clustering,0.30169246
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,molecular,0.39914468,of,0.516936,clustering,0.43655443
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,features,0.51742536,feature,0.8268872,feature-selection,0.5487305
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,amino-acid,0.3166765,encoding,0.59917235,n-gram,0.43549806
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,acid-molecular,0.32440633,fourier-transform,0.45767015,fourier-transform,0.45767015
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,various,0.35606545,of,0.6378319,generative,0.45850474
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,bioinformatics,0.6332302,data-science,0.6393348,data-science,0.6393348
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,tools,0.65752256,data-engineering,0.6720511,data-engineering,0.6720511
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,focused,0.39696395,of,0.5549927,feature-engineering,0.52445924
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,bioinformatics-tools,0.708507,machine-learning,0.708507,machine-learning,0.708507
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,matthews,0.35158494,cross-validation,0.505366,cross-validation,0.505366
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,correlation,0.355416,regression,0.5743689,regression,0.5743689
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,coefficient,0.3133128,cross-entropy,0.5560355,cross-entropy,0.5560355
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,correlation-coefficient,0.52219236,cross-entropy,0.7120375,cross-entropy,0.7120375
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,potassium,0.12511921,rectified,0.48884782,batch-normalization,0.3201604
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,channel,0.22694653,rectified,0.5908533,fully-connected,0.3853672
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,ligand,0.266578,nearest-neighbors,0.4023533,nearest-neighbors,0.4023533
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,peptides,0.3394723,encoding,0.4170969,boosting,0.3558063
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,potassium-channel,0.221403,rectified,0.47862282,recurrent-neural-network,0.37573358
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,channel-ligand,0.3190366,nearest-neighbors,0.5003544,nearest-neighbors,0.5003544
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,bioinformatics,0.6332302,data-science,0.6393348,data-science,0.6393348
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,software,0.6104226,computer,0.74513555,computer-vision,0.6394764
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,written,0.41921648,language,0.61362135,natural-language,0.6081295
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,bioinformatics-software,0.7104967,machine-learning,0.7104967,machine-learning,0.7104967
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,python,0.49233255,graphics,0.590139,scikit-learn,0.5497436
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,programming,0.5925679,generative,0.6016841,generative,0.6016841
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,language,0.5009864,language,0.99999994,natural-language,0.84818214
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,programming-language,0.6667137,natural-language,0.8309064,natural-language,0.8309064
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,primary,0.24268678,principal,0.5205563,long-short-term,0.38049072
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,structure,0.3356646,hierarchical,0.5517567,hierarchical-clustering,0.5486842
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,information,0.5191034,data,0.708436,data-science,0.5937191
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,primary-structure,0.49286565,hierarchical-clustering,0.65367484,hierarchical-clustering,0.65367484
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,structure-information,0.59802353,feature-engineering,0.6851082,feature-engineering,0.6851082
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,predict,0.51602554,model,0.53463185,classification-algorithm,0.52342355
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,peptide,0.3208105,encoding,0.44188768,boosting,0.35291767
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,ligands,0.29595453,nearest-neighbors,0.43555987,nearest-neighbors,0.43555987
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,peptide-ligands,0.3852876,nearest-neighbors,0.44004714,nearest-neighbors,0.44004714
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,experimentally,0.390577,model,0.56690073,generative-model,0.5571948
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,verified,0.3810478,of,0.5807613,supervised,0.42818904
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,activity,0.21813896,function,0.53536034,boosting,0.38798416
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,experimentally-verified,0.48999488,generative-model,0.5811516,generative-model,0.5811516
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,electrical,0.30196193,rectified,0.55534476,recurrent-neural-network,0.5164039
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,impulse,0.3521143,backpropagation,0.534884,backpropagation,0.534884
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,formation,0.17913832,of,0.50848174,generative,0.45268857
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,electrical-impulse,0.40459785,artificial-intelligence,0.5873885,artificial-intelligence,0.5873885
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,impulse-formation,0.37693006,generative,0.57465667,generative,0.57465667
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,considered,0.36321384,of,0.60548925,feature-reduction,0.4442021
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,promising,0.40802234,feature-engineering,0.526417,feature-engineering,0.526417
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,alternatives,0.40609932,decision,0.54255396,dimensionality-reduction,0.5263909
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,artificial,0.4622418,artificial,1.0,artificial-intelligence,0.6597898
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,neural,0.5080686,neural,1.0,neural-network,0.7153882
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,network,0.50771487,network,1.0,neural-network,0.7589166
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,artificial-neural,0.5541204,recurrent-neural-network,0.7487964,recurrent-neural-network,0.7487964
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,neural-network,0.7034505,neural-network,1.0,neural-network,1.0
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,artificial-neural-network,0.6767229,neural-network,0.9082352,neural-network,0.9082352
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,predict,0.51602554,model,0.53463185,classification-algorithm,0.52342355
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,ligand,0.266578,nearest-neighbors,0.4023533,nearest-neighbors,0.4023533
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,peptides,0.3394723,encoding,0.4170969,boosting,0.3558063
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,support,0.3815906,support,1.0,support-vector,0.66958183
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,vector,0.45570993,vector,1.0,vector-machine,0.7596456
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,machine,0.7094662,machine,1.0,machine-learning,0.7094662
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,support-vector,0.6102658,support-vector,1.0,support-vector,1.0
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,vector-machine,0.68567467,vector-machine,1.0,vector-machine,1.0
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,support-vector-machine,0.71415544,support-vector-machine,1.0,support-vector-machine,1.0
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,potassium,0.12511921,rectified,0.48884782,batch-normalization,0.3201604
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,channels,0.25009197,rectified,0.590422,fully-connected,0.43491313
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,play,0.23933098,feature,0.4321588,feed-forward,0.39953205
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,potassium-channels,0.2130136,rectified,0.48207366,recurrent-neural-network,0.3790651
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,channels-play,0.38881052,rectified,0.5182862,recurrent-neural-network,0.5086828
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,high,0.267004,of,0.57459104,gradient,0.44240427
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,predictive,0.55290145,cross-validation,0.6141345,cross-validation,0.6141345
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,capacity,0.29071927,function,0.5448774,boosting,0.4162461
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,high-predictive,0.6527121,classifiers,0.66488165,classifiers,0.66488165
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,predictive-capacity,0.55849963,discriminative,0.6163842,cross-entropy,0.61313546
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,novel,0.4652171,feature-engineering,0.5132146,feature-engineering,0.5132146
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,ligand,0.266578,nearest-neighbors,0.4023533,nearest-neighbors,0.4023533
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,peptides,0.3394723,encoding,0.4170969,boosting,0.3558063
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,random,0.45551494,random,1.0,random-forest,0.65894985
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,forest,0.4787075,forest,1.0,random-forest,0.7738863
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,algorithm,0.7180419,algorithm,1.0,algorithm,1.0
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,random-forest,0.6331641,random-forest,1.0,random-forest,1.0
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,biological,0.44501913,natural,0.6314477,feature-engineering,0.5497216
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,data,0.46434748,data,1.0,data-science,0.5533528
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,used,0.46049535,of,0.5630944,generative-model,0.4901716
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,tool,0.58027077,machine-learning,0.58027077,machine-learning,0.58027077
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,called,0.4316384,term,0.49134967,generative,0.47478232
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,pplk,0.25344288,keras,0.44765437,keras,0.44765437
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,tool-called,0.56033504,object-tracking,0.63459146,object-tracking,0.63459146
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,many,0.40940517,few,0.752018,feature-engineering,0.48454586
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,diseases,0.31957155,recurrent,0.41244444,classification,0.40266854
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,many-diseases,0.5517936,hidden-markov-model,0.5785643,hidden-markov-model,0.5785643
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,ligand,0.266578,nearest-neighbors,0.4023533,nearest-neighbors,0.4023533
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,peptides,0.3394723,encoding,0.4170969,boosting,0.3558063
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,potassium,0.12511921,rectified,0.48884782,batch-normalization,0.3201604
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,channels,0.25009197,rectified,0.590422,fully-connected,0.43491313
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,potassium-channels,0.2130136,rectified,0.48207366,recurrent-neural-network,0.3790651
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,random,0.45551494,random,1.0,random-forest,0.65894985
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,forest,0.4787075,forest,1.0,random-forest,0.7738863
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,random-forest,0.6331641,random-forest,1.0,random-forest,1.0
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,current,0.3530666,rectified,0.52906346,generative-model,0.40904555
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,tools,0.65752256,data-engineering,0.6720511,data-engineering,0.6720511
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,novel,0.4652171,feature-engineering,0.5132146,feature-engineering,0.5132146
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,tool,0.58027077,machine-learning,0.58027077,machine-learning,0.58027077
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,high,0.267004,of,0.57459104,gradient,0.44240427
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,reliability,0.44636852,cross-validation,0.63492304,cross-validation,0.63492304
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,high-reliability,0.5352712,artificial-intelligence,0.62663436,artificial-intelligence,0.62663436
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,four,0.34899807,one,0.769816,clustering,0.40005642
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,machine,0.7094662,machine,1.0,machine-learning,0.7094662
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,four-machine,0.6901172,machine,0.78480977,vector-machine,0.74045897
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,first,0.36139184,of,0.61145455,generative,0.4096663
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,tool,0.58027077,machine-learning,0.58027077,machine-learning,0.58027077
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,specificity,0.3365721,discriminative,0.5238579,cross-validation,0.4765169
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,sensitivity,0.28808302,discriminative,0.5372434,cross-validation,0.48943394
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,accuracy,0.5511073,cross-validation,0.64088035,cross-validation,0.64088035
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,validating,0.5773407,cross-validation,0.60521513,cross-validation,0.60521513
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,models,0.53762007,model,0.8940372,markov-model,0.7015921
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,plasma,0.21912897,normalization,0.4569842,batch-normalization,0.43571177
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,membrane,0.2560242,layer,0.5360652,gradient-descent,0.40451998
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,plasma-membrane,0.2355837,gradient-descent,0.42587876,gradient-descent,0.42587876
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,nearest,0.44164038,nearest,1.0,nearest-neighbors,0.73016953
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,neighbors,0.4643042,neighbors,1.0,nearest-neighbors,0.8016597
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,nearest-neighbors,0.52685773,nearest-neighbors,1.0,nearest-neighbors,1.0
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,molecules,0.31138086,components,0.5355045,nearest-neighbors,0.43995067
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,used,0.46049535,of,0.5630944,generative-model,0.4901716
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,model,0.48485535,model,1.0,markov-model,0.7005576
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,generated,0.38782007,generative,0.5987155,generative,0.5987155
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,model-generated,0.5891756,generative-model,0.7446239,generative-model,0.7446239
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,learning,0.709237,learning,1.0,deep-learning,0.8286492
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,algorithms,0.7612198,algorithm,0.9050166,algorithm,0.9050166
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,key,0.35973132,principal,0.614877,feature-engineering,0.498355
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,role,0.2562992,function,0.5340955,feed-forward,0.4137928
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,key-role,0.3073906,principal,0.5076912,feed-forward,0.4910158
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,hormone,0.18720049,short-term,0.39104265,long-short-term,0.35081857
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,secretion,0.20700249,of,0.43475774,boosting,0.36509198
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,hormone-secretion,0.18199654,short-term,0.36063176,long-short-term,0.32771656
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,friendly,0.42858094,data-engineering,0.5538969,data-engineering,0.5538969
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,interface,0.35153443,layer,0.5218713,feature-engineering,0.47348917
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,different,0.37681934,of,0.61590904,clustering,0.46857932
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,activities,0.25071037,of,0.4766258,learning-function,0.38030344
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,cardiovascular,0.31674606,short-term,0.442761,learning-function,0.4027721
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,diseases,0.31957155,recurrent,0.41244444,classification,0.40266854
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,cardiovascular-diseases,0.3900246,learning-function,0.41476324,learning-function,0.41476324
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,applied,0.44175404,of,0.5047146,bagging,0.47554293
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,research,0.45694843,science,0.7194936,data-science,0.70924157
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,applied-research,0.56093246,data-science,0.7020048,data-science,0.7020048
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,peptides,0.3394723,encoding,0.4170969,boosting,0.3558063
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,used,0.46049535,of,0.5630944,generative-model,0.4901716
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,pplk,0.25344288,keras,0.44765437,keras,0.44765437
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,work,0.42713583,support,0.5373766,learning-function,0.5011815
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,using,0.47332245,analysis,0.5968549,component-analysis,0.526608
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,treatment,0.239264,short-term,0.5206091,long-short-term,0.41699445
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,training,0.54553735,learning,0.69909495,supervised,0.6973169
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,study,0.3645851,of,0.5728763,statistical,0.44204497
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,showed,0.20766163,of,0.5296177,regression,0.37027335
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,regulating,0.26515597,function,0.55162895,feed-forward,0.5337373
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,prediction,0.6361519,classification-algorithm,0.67946094,classification-algorithm,0.67946094
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,obtained,0.32073808,of,0.62274206,batch-normalization,0.46598285
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,none,0.2957736,one,0.6308826,statistical,0.4030655
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,ions,0.2515515,nearest-neighbors,0.48551613,nearest-neighbors,0.48551613
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,however,0.31437585,few,0.63182676,statistical,0.44065386
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,flow,0.2860778,gradient,0.52486,gradient,0.52486
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,discovery,0.46891084,data-engineering,0.5077522,data-engineering,0.5077522
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,developed,0.44693142,fully,0.53855187,generative-model,0.49309453
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,currently,0.3947763,fully,0.5423527,bagging,0.41457367
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,cancer,0.27383438,recurrent,0.4065063,generative,0.3468409
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,c,0.17513797,of,0.44327667,gradient,0.31114018
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,basic,0.41761222,feature-engineering,0.51117486,feature-engineering,0.51117486
Machine learning: a long way from implementation in cardiovascular disease.,none,0.2957736,one,0.6308826,statistical,0.4030655
Machine learning: a long way from implementation in cardiovascular disease.,declared,0.31163847,truth,0.54465926,supervised,0.44572228
Machine learning: a long way from implementation in cardiovascular disease.,interest,0.4194936,of,0.5624063,feature-engineering,0.5448084
Machine learning: a long way from implementation in cardiovascular disease.,statement,0.41524586,decision,0.57848424,data-science,0.5259262
Machine learning: a long way from implementation in cardiovascular disease.,competing,0.38505203,adversarial,0.5235929,nearest-neighbors,0.50362813
Machine learning: a long way from implementation in cardiovascular disease.,interests,0.39628386,adversarial,0.64900696,data-science,0.6049399
Machine learning: a long way from implementation in cardiovascular disease.,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
Machine learning: a long way from implementation in cardiovascular disease.,pmid,0.17205057,science,0.31445533,bag-of-words,0.26444918
Machine learning: a long way from implementation in cardiovascular disease.,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
Machine learning: a long way from implementation in cardiovascular disease.,conflict,0.34163117,adversarial,0.6768328,reinforcement-learning,0.55245674
Machine learning: a long way from implementation in cardiovascular disease.,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
Machine learning: a long way from implementation in cardiovascular disease.,heartjnl,0.34159458,graphics,0.4285684,computer-vision,0.415358
Machine learning: a long way from implementation in cardiovascular disease.,doi,0.2357645,data-science,0.3312925,data-science,0.3312925
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,based,0.49998575,classification-algorithm,0.5639226,classification-algorithm,0.5639226
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,groups,0.2727722,statistical,0.4438421,statistical,0.4438421
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,phenogroups,0.36202842,nearest-neighbors,0.4739781,nearest-neighbors,0.4739781
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,based,0.49998575,classification-algorithm,0.5639226,classification-algorithm,0.5639226
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,echocardiogram,0.3293193,tracking,0.3590386,batch-normalization,0.35628206
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,data,0.46434748,data,1.0,data-science,0.5533528
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,using,0.47332245,analysis,0.5968549,component-analysis,0.526608
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,machine,0.7094662,machine,1.0,machine-learning,0.7094662
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,learning,0.709237,learning,1.0,deep-learning,0.8286492
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,machine-learning,1.0,machine-learning,1.0,machine-learning,1.0
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,chronic,0.22727785,recurrent,0.5279353,long-short-term,0.4292153
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,obstructive,0.29236183,recurrent,0.45574522,confusion-matrix,0.3350963
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,pulmonary,0.27012008,recurrent,0.39649367,long-short-term,0.32169557
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,disease,0.296938,recurrent,0.4731025,classification,0.35271814
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,chronic-obstructive,0.2802394,recurrent,0.50352967,confusion-matrix,0.39456382
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,obstructive-pulmonary,0.31164497,recurrent,0.4760642,recurrent-neural-network,0.42644972
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,pulmonary-disease,0.39629358,logistic-regression,0.42455766,logistic-regression,0.42455766
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,including,0.3233776,of,0.6619886,clustering,0.40625107
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,biomarkers,0.45449477,classifiers,0.49574262,classifiers,0.49574262
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,identified,0.35725033,analysis,0.56593037,clustering,0.45719695
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,distinct,0.36295342,feature,0.580647,clustering,0.5409523
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,hfpef,0.33180216,dropout,0.33254394,dropout,0.33254394
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,phenogroups,0.36202842,nearest-neighbors,0.4739781,nearest-neighbors,0.4739781
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,plasma,0.21912897,normalization,0.4569842,batch-normalization,0.43571177
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,proteins,0.35976675,components,0.56075835,component-analysis,0.40436536
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,differed,0.27527156,of,0.50769126,clustering,0.4100513
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,plasma-proteins,0.31472564,matrix,0.46084073,batch-normalization,0.43615133
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,days,0.20857571,short-term,0.53915894,long-short-term,0.4190845
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,mid,0.23007318,bagging,0.4472025,bagging,0.4472025
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,using,0.47332245,analysis,0.5968549,component-analysis,0.526608
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,machine,0.7094662,machine,1.0,machine-learning,0.7094662
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,learning,0.709237,learning,1.0,deep-learning,0.8286492
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,machine-learning,1.0,machine-learning,1.0,machine-learning,1.0
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,identified,0.35725033,analysis,0.56593037,clustering,0.45719695
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,six,0.34044427,one,0.7164377,supervised,0.39660886
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,phenogroups,0.36202842,nearest-neighbors,0.4739781,nearest-neighbors,0.4739781
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,identified-six,0.38998863,one,0.4679864,classification-algorithm,0.46266878
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,rennes,0.30740654,monte,0.4826678,monte,0.4826678
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,cohort,0.3892265,logistic-regression,0.5412916,logistic-regression,0.5412916
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,study,0.3645851,of,0.5728763,statistical,0.44204497
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,cohort-study,0.4088606,logistic-regression,0.6062193,logistic-regression,0.6062193
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,preserved,0.28254378,function,0.6360263,short-term-memory,0.44489402
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,ejection,0.30230433,function,0.43955976,gradient,0.35697576
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,fraction,0.25137818,component,0.50911963,gradient,0.48876822
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,preserved-ejection,0.305955,batch-normalization,0.5166229,batch-normalization,0.5166229
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,ejection-fraction,0.36681443,stochastic-gradient,0.5523829,stochastic-gradient,0.5523829
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,laboratory,0.36435357,data,0.49052244,batch-normalization,0.46476662
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,variables,0.4636312,logistic-regression,0.6604836,logistic-regression,0.6604836
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,collected,0.33035916,data,0.5686942,ground-truth,0.3838368
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,false,0.35507816,truth,0.5399609,overfitting,0.4766646
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,discovery,0.46891084,data-engineering,0.5077522,data-engineering,0.5077522
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,rate,0.24866687,rate,1.0,dropout,0.44953537
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,false-discovery,0.51771593,cross-validation,0.54243845,cross-validation,0.54243845
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,false-discovery-rate,0.5663643,cross-entropy,0.6065474,cross-entropy,0.6065474
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,concomitant,0.22088565,of,0.6553842,long-short-term,0.42871487
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,atrial,0.2285939,long-short,0.40266213,long-short-term,0.38994598
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,fibrillation,0.29544818,recurrent,0.4121878,long-short-term,0.3982905
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,atrial-fibrillation,0.26383367,long-short,0.47894955,long-short-term,0.454661
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,composite,0.3212868,hierarchical,0.520792,hierarchical-clustering,0.4888802
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,end,0.22421888,long,0.5453975,long-short-term,0.36503828
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,point,0.30596262,forward,0.54533786,statistical,0.44868034
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,composite-end,0.41464198,dimensionality-reduction,0.5481944,dimensionality-reduction,0.5481944
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,end-point,0.28407684,batch-normalization,0.46041366,batch-normalization,0.46041366
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,versus,0.2693575,of,0.48449945,long-short-term,0.40994066
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,phenogroups,0.36202842,nearest-neighbors,0.4739781,nearest-neighbors,0.4739781
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,derive,0.50512904,stochastic,0.61141795,stochastic,0.61141795
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,hfpef,0.33180216,dropout,0.33254394,dropout,0.33254394
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,phenotype,0.28173286,feature,0.51151407,feature-selection,0.4975547
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,hypertension,0.28340828,dropout,0.4223115,dropout,0.4223115
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,median,0.20747668,logistic-regression,0.37743634,logistic-regression,0.37743634
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,years,0.32825696,intelligence,0.42702603,regression,0.3811771
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,right,0.24704936,confusion,0.43681273,segmentation,0.36243528
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,ventricular,0.24852064,rate,0.37094042,long-short-term,0.34148398
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,function,0.3447219,function,1.0,learning-function,0.5767432
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,right-ventricular,0.30673695,learning-function,0.38528037,learning-function,0.38528037
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,ventricular-function,0.38834563,function,0.57705545,learning-function,0.57408965
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,hfpef,0.33180216,dropout,0.33254394,dropout,0.33254394
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,outpatients,0.31696147,recurrent,0.4245981,supervised,0.4127279
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,af,0.24542028,recurrent,0.4039285,long-short-term,0.39781147
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,anaemia,0.21888798,recurrent,0.38291553,logistic-regression,0.34146923
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,days,0.20857571,short-term,0.53915894,long-short-term,0.4190845
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,compare,0.43674475,short-term,0.510365,statistical,0.44797724
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,clinical,0.44080526,data,0.48532635,data-science,0.45343333
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,characteristics,0.345204,of,0.5401758,feature-engineering,0.49030614
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,clinical-characteristics,0.48064718,feature,0.6024677,component-analysis,0.5396
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,based,0.49998575,classification-algorithm,0.5639226,classification-algorithm,0.5639226
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,clustering,0.59915376,clustering,1.0,clustering,1.0
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,based-clustering,0.7093884,hierarchical-clustering,0.7661519,hierarchical-clustering,0.7661519
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,echocardiogram,0.3293193,tracking,0.3590386,batch-normalization,0.35628206
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,days,0.20857571,short-term,0.53915894,long-short-term,0.4190845
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,kidney,0.15772529,function,0.35472965,batch-normalization,0.2715908
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,disease,0.296938,recurrent,0.4731025,classification,0.35271814
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,kidney-disease,0.3797998,logistic-regression,0.42294642,logistic-regression,0.42294642
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,cardiovascular,0.31674606,short-term,0.442761,learning-function,0.4027721
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,proteins,0.35976675,components,0.56075835,component-analysis,0.40436536
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,months,0.25947675,short-term,0.51117545,regression,0.43146035
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,clinical,0.44080526,data,0.48532635,data-science,0.45343333
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,phenogroup,0.35523534,random-forest,0.46088874,random-forest,0.46088874
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,kidney,0.15772529,function,0.35472965,batch-normalization,0.2715908
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,function,0.3447219,function,1.0,learning-function,0.5767432
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,kidney-function,0.39092225,function,0.59653264,learning-function,0.553277
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,differential,0.33925906,analysis,0.55520564,component-analysis,0.49725807
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,characteristics,0.345204,of,0.5401758,feature-engineering,0.49030614
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,third,0.27270278,one,0.6556418,generative,0.3917287
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,experienced,0.33214465,one,0.53318346,supervised,0.47342923
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,stable,0.23790932,transfer,0.47683778,bagging,0.37850022
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,condition,0.23345311,confusion,0.47072208,confusion-matrix,0.4222471
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,stable-condition,0.364856,short-term,0.55276597,long-short-term,0.5209291
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,significantly,0.27887642,of,0.5214151,long-short-term,0.39056638
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,different,0.37681934,of,0.61590904,clustering,0.46857932
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,significantly-different,0.37907293,of,0.51368916,statistical,0.47980368
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,significant,0.29367286,statistical,0.582669,statistical,0.582669
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,differences,0.3361535,statistical,0.57447433,statistical,0.57447433
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,significant-differences,0.5020617,statistical,0.69704795,statistical,0.69704795
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,see,0.27105612,transfer,0.4389078,transfer-learning,0.36000627
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,rights,0.3170033,adversarial,0.6281444,data-science,0.57488894
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,secondary,0.25856274,recurrent,0.5339868,feature-reduction,0.37561154
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,analyses,0.43295383,analysis,0.9146549,principal-component-analysis,0.66157085
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,risk,0.35860935,recurrent,0.53675485,logistic-regression,0.52381086
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,factors,0.3420733,components,0.5413606,logistic-regression,0.48293567
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,risk-factors,0.40161455,logistic-regression,0.57501113,logistic-regression,0.57501113
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,primary,0.24268678,principal,0.5205563,long-short-term,0.38049072
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,outcome,0.33788118,short-term,0.5818455,long-short-term,0.48316076
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,primary-outcome,0.436515,principal-component-analysis,0.5530643,principal-component-analysis,0.5530643
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,poorer,0.31928182,short-term,0.5013828,long-short-term,0.46519256
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,diastolic,0.27467865,augmentation,0.42852774,gradient,0.4273815
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,higher,0.27819592,reduction,0.545787,boosting,0.41506222
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,burden,0.25295436,reduction,0.41791618,logistic-regression,0.3788216
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,higher-burden,0.38733912,logistic-regression,0.50028306,logistic-regression,0.50028306
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,heterogeneous,0.36404067,feature,0.5641245,hierarchical-clustering,0.5368855
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,syndrome,0.20306323,recurrent,0.42346346,confusion-matrix,0.3198145
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,heart,0.28300244,rate,0.49867767,batch-normalization,0.3427502
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,failure,0.32964212,recurrent,0.52057266,confusion-matrix,0.44323406
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,heart-failure,0.36450487,long-short-term,0.44014218,long-short-term,0.44014218
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,differential,0.33925906,analysis,0.55520564,component-analysis,0.49725807
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,levels,0.20457911,normalization,0.52984333,batch-normalization,0.45617118
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,cause,0.19388393,of,0.47843847,confusion-matrix,0.34079778
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,mortality,0.2609817,short-term,0.505676,logistic-regression,0.49414968
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,cause-mortality,0.3407904,logistic-regression,0.5863885,logistic-regression,0.5863885
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,applied,0.44175404,of,0.5047146,bagging,0.47554293
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,model,0.48485535,model,1.0,markov-model,0.7005576
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,term,0.33795053,term,1.0,long-short-term,0.62770975
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,follow,0.28552625,tracking,0.48513734,batch-normalization,0.39173082
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,term-follow,0.46637923,term,0.62200785,object-tracking,0.54719853
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,rank,0.41467124,statistical,0.5482911,statistical,0.5482911
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,p,0.26795468,support,0.40805867,regression,0.40253854
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,rank-p,0.4353142,k-means,0.5557528,k-means,0.5557528
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,outcomes,0.38239923,short-term,0.6164659,long-short-term,0.5239928
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,across,0.3330416,gradient,0.4622073,gradient,0.4622073
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,baseline,0.32763094,normalization,0.56518495,batch-normalization,0.4727359
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,proteomics,0.5279478,data-engineering,0.56025803,data-engineering,0.56025803
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,phenogroups,0.36202842,nearest-neighbors,0.4739781,nearest-neighbors,0.4739781
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,hfpef,0.33180216,dropout,0.33254394,dropout,0.33254394
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,clinical,0.44080526,data,0.48532635,data-science,0.45343333
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,af,0.24542028,recurrent,0.4039285,long-short-term,0.39781147
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,term,0.33795053,term,1.0,long-short-term,0.62770975
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,proteomics,0.5279478,data-engineering,0.56025803,data-engineering,0.56025803
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,p,0.26795468,support,0.40805867,regression,0.40253854
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,outcomes,0.38239923,short-term,0.6164659,long-short-term,0.5239928
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,well,0.34264985,of,0.59718275,bagging,0.4145819
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,used,0.46049535,of,0.5630944,generative-model,0.4901716
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,use,0.43753043,of,0.5506158,feature-reduction,0.49910897
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,two,0.35955608,one,0.79919666,clustering,0.43817294
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,thirds,0.26812086,one,0.5667644,dropout,0.39347172
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,short,0.24294135,short,0.99999994,long-short-term,0.66049826
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,results,0.32376552,data,0.6932311,batch-normalization,0.44826904
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,published,0.42179614,data,0.6147139,data-science,0.54664624
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,prevalence,0.2908883,rate,0.45596814,dropout,0.4310696
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,permissions,0.33960393,decision,0.563183,data-science,0.5165832
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,older,0.38174838,short-term,0.49749964,short-term-memory,0.4763971
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,observed,0.23725806,of,0.64367145,long-short-term,0.4519785
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,objective,0.4122544,of,0.5255821,component-analysis,0.42220753
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,methods,0.50049126,data,0.5400177,machine-learning,0.50049126
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,longer,0.23865971,long,0.7401756,long-short-term,0.6004038
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,log,0.24333923,regression,0.46448588,regression,0.46448588
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,karolinska,0.2761826,intelligence,0.46421927,artificial-intelligence,0.43169427
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,iqr,0.15119398,logistic,0.2807749,centroid-based,0.2313953
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,inflammatory,0.19824001,cascade,0.43951106,generative-model,0.38795525
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,hr,0.24641928,rate,0.5365405,bagging,0.39750856
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,hospitalisation,0.26346236,logistic-regression,0.45966336,logistic-regression,0.45966336
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,hf,0.293398,long-short-term,0.35116297,long-short-term,0.35116297
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,group,0.26103544,of,0.44356787,statistical,0.3923795
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,fifteen,0.31589776,one,0.5081241,machine-learning,0.31589776
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,female,0.2642398,naive,0.4711159,generative,0.42489284
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,fdr,0.3891313,naive-bayes,0.5173268,naive-bayes,0.5173268
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,employer,0.34532702,adversarial,0.6043779,data-science,0.5358579
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,conclusions,0.37109232,data,0.55923915,long-short-term,0.4627594
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,commercial,0.33454847,batch,0.54504764,data-engineering,0.47706312
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,ci,0.2746623,logistic,0.43534693,logistic-regression,0.38379127
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,bmj,0.30836818,science,0.5976578,data-science,0.5458613
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,aimed,0.41358173,of,0.52896386,feature-engineering,0.45929232
Machine Learning in Fetal Cardiology: What to Expect.,specific,0.3244285,of,0.6059094,clustering,0.45887482
Machine Learning in Fetal Cardiology: What to Expect.,goals,0.4279121,decision,0.5916633,data-science,0.5107982
Machine Learning in Fetal Cardiology: What to Expect.,without,0.31691062,of,0.5951073,long-short-term,0.4268921
Machine Learning in Fetal Cardiology: What to Expect.,explicitly,0.5513934,cross-entropy,0.66198623,cross-entropy,0.66198623
Machine Learning in Fetal Cardiology: What to Expect.,programming,0.5925679,generative,0.6016841,generative,0.6016841
Machine Learning in Fetal Cardiology: What to Expect.,goals-without,0.4439078,adversarial,0.5664021,semantic,0.5447845
Machine Learning in Fetal Cardiology: What to Expect.,compromised,0.24304895,function,0.6047404,generative,0.41966826
Machine Learning in Fetal Cardiology: What to Expect.,cardiovascular,0.31674606,short-term,0.442761,learning-function,0.4027721
Machine Learning in Fetal Cardiology: What to Expect.,system,0.3589455,generative-model,0.49815983,generative-model,0.49815983
Machine Learning in Fetal Cardiology: What to Expect.,potentially,0.36810714,of,0.5786935,long-short-term,0.45597216
Machine Learning in Fetal Cardiology: What to Expect.,associated,0.30827495,of,0.57598466,long-short-term,0.46578532
Machine Learning in Fetal Cardiology: What to Expect.,cardiovascular-system,0.37247,learning-function,0.46217477,learning-function,0.46217477
Machine Learning in Fetal Cardiology: What to Expect.,potentially-associated,0.37823284,of,0.6185838,long-short-term,0.5197214
Machine Learning in Fetal Cardiology: What to Expect.,tissue,0.23679586,of,0.5202017,segmentation,0.4076932
Machine Learning in Fetal Cardiology: What to Expect.,doppler,0.36058235,few-shot,0.4605835,fourier,0.43635902
Machine Learning in Fetal Cardiology: What to Expect.,imaging,0.41700524,tracking,0.55048084,segmentation,0.5337068
Machine Learning in Fetal Cardiology: What to Expect.,among,0.33676732,of,0.57348,clustering,0.49404603
Machine Learning in Fetal Cardiology: What to Expect.,others,0.3625402,one,0.56551903,generative,0.4840395
Machine Learning in Fetal Cardiology: What to Expect.,tissue-doppler,0.409838,tensorflow,0.47538915,tensorflow,0.47538915
Machine Learning in Fetal Cardiology: What to Expect.,doppler-imaging,0.3982539,few-shot,0.5919826,fourier,0.51594585
Machine Learning in Fetal Cardiology: What to Expect.,still,0.32258964,fully,0.6496037,long-short-term,0.43228805
Machine Learning in Fetal Cardiology: What to Expect.,challenging,0.4561266,hidden,0.5622939,feature-engineering,0.53377354
Machine Learning in Fetal Cardiology: What to Expect.,mainly,0.24372631,of,0.6151813,clustering,0.43261412
Machine Learning in Fetal Cardiology: What to Expect.,due,0.21681537,of,0.5734476,confusion-matrix,0.40250766
Machine Learning in Fetal Cardiology: What to Expect.,still-challenging,0.4540205,hidden,0.5576702,feature-engineering,0.52118146
Machine Learning in Fetal Cardiology: What to Expect.,computer,0.6175159,computer,1.0,computer-vision,0.7954619
Machine Learning in Fetal Cardiology: What to Expect.,science,0.449412,science,1.0,data-science,0.8160229
Machine Learning in Fetal Cardiology: What to Expect.,discipline,0.5141143,data-science,0.7299886,data-science,0.7299886
Machine Learning in Fetal Cardiology: What to Expect.,focused,0.39696395,of,0.5549927,feature-engineering,0.52445924
Machine Learning in Fetal Cardiology: What to Expect.,computer-science,0.6156306,data-science,0.82293093,data-science,0.82293093
Machine Learning in Fetal Cardiology: What to Expect.,science-discipline,0.572082,science,0.8219615,data-science,0.81467223
Machine Learning in Fetal Cardiology: What to Expect.,discipline-focused,0.53625053,data-science,0.7158,data-science,0.7158
Machine Learning in Fetal Cardiology: What to Expect.,evaluate,0.37214977,of,0.4977158,decision-tree,0.4090718
Machine Learning in Fetal Cardiology: What to Expect.,fetal,0.24604495,term,0.5358952,generative,0.36244985
Machine Learning in Fetal Cardiology: What to Expect.,cardiac,0.29562658,of,0.42777455,long-short-term,0.35708636
Machine Learning in Fetal Cardiology: What to Expect.,structure,0.3356646,hierarchical,0.5517567,hierarchical-clustering,0.5486842
Machine Learning in Fetal Cardiology: What to Expect.,primary,0.24268678,principal,0.5205563,long-short-term,0.38049072
Machine Learning in Fetal Cardiology: What to Expect.,acquired,0.38099396,of,0.49671435,generative,0.43534002
Machine Learning in Fetal Cardiology: What to Expect.,images,0.46598992,segmentation,0.6703193,segmentation,0.6703193
Machine Learning in Fetal Cardiology: What to Expect.,primary-acquired,0.3061577,recurrent,0.48095456,short-term-memory,0.42023367
Machine Learning in Fetal Cardiology: What to Expect.,optimizing,0.46951592,feature-engineering,0.63126874,feature-engineering,0.63126874
Machine Learning in Fetal Cardiology: What to Expect.,image,0.5164337,segmentation,0.7261368,segmentation,0.7261368
Machine Learning in Fetal Cardiology: What to Expect.,acquisition,0.49771845,learning,0.5805447,transfer-learning,0.5654274
Machine Learning in Fetal Cardiology: What to Expect.,image-acquisition,0.58415407,object-tracking,0.6738556,object-tracking,0.6738556
Machine Learning in Fetal Cardiology: What to Expect.,different,0.37681934,of,0.61590904,clustering,0.46857932
Machine Learning in Fetal Cardiology: What to Expect.,ultrasound,0.3534931,tracking,0.46466017,segmentation,0.44147727
Machine Learning in Fetal Cardiology: What to Expect.,approaches,0.55614823,feature-engineering,0.60571706,feature-engineering,0.60571706
Machine Learning in Fetal Cardiology: What to Expect.,several,0.40139607,few,0.7607186,clustering,0.4671372
Machine Learning in Fetal Cardiology: What to Expect.,fetal,0.24604495,term,0.5358952,generative,0.36244985
Machine Learning in Fetal Cardiology: What to Expect.,conditions,0.21472734,short-term,0.4503411,feature-reduction,0.43574768
Machine Learning in Fetal Cardiology: What to Expect.,fetal,0.24604495,term,0.5358952,generative,0.36244985
Machine Learning in Fetal Cardiology: What to Expect.,cardiac,0.29562658,of,0.42777455,long-short-term,0.35708636
Machine Learning in Fetal Cardiology: What to Expect.,remodeling,0.31788215,function,0.5278843,segmentation,0.44361526
Machine Learning in Fetal Cardiology: What to Expect.,cardiac-remodeling,0.38380635,function,0.4901194,long-short-term,0.45137346
Machine Learning in Fetal Cardiology: What to Expect.,including,0.3233776,of,0.6619886,clustering,0.40625107
Machine Learning in Fetal Cardiology: What to Expect.,conventional,0.4193347,feature-reduction,0.51956415,feature-reduction,0.51956415
Machine Learning in Fetal Cardiology: What to Expect.,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
Machine Learning in Fetal Cardiology: What to Expect.,help,0.45596504,support,0.55435,machine-learning,0.45596504
Machine Learning in Fetal Cardiology: What to Expect.,extract,0.38952202,components,0.49913663,kernel,0.46366778
Machine Learning in Fetal Cardiology: What to Expect.,measurements,0.31488982,data,0.56587404,batch-normalization,0.52457345
Machine Learning in Fetal Cardiology: What to Expect.,fetal,0.24604495,term,0.5358952,generative,0.36244985
Machine Learning in Fetal Cardiology: What to Expect.,cardiac,0.29562658,of,0.42777455,long-short-term,0.35708636
Machine Learning in Fetal Cardiology: What to Expect.,function,0.3447219,function,1.0,learning-function,0.5767432
Machine Learning in Fetal Cardiology: What to Expect.,cardiac-function,0.4069733,function,0.6227769,learning-function,0.6182186
Machine Learning in Fetal Cardiology: What to Expect.,fetal,0.24604495,term,0.5358952,generative,0.36244985
Machine Learning in Fetal Cardiology: What to Expect.,echocardiography,0.3769523,tracking,0.4348407,object-tracking,0.40039602
Machine Learning in Fetal Cardiology: What to Expect.,fetal,0.24604495,term,0.5358952,generative,0.36244985
Machine Learning in Fetal Cardiology: What to Expect.,cardiology,0.36460787,data-science,0.5008054,data-science,0.5008054
Machine Learning in Fetal Cardiology: What to Expect.,cardiac,0.29562658,of,0.42777455,long-short-term,0.35708636
Machine Learning in Fetal Cardiology: What to Expect.,abnormalities,0.3212605,normalization,0.5461266,segmentation,0.4475795
Machine Learning in Fetal Cardiology: What to Expect.,cardiac-abnormalities,0.37233907,normalization,0.5484769,segmentation,0.49279547
Machine Learning in Fetal Cardiology: What to Expect.,fetal,0.24604495,term,0.5358952,generative,0.36244985
Machine Learning in Fetal Cardiology: What to Expect.,heart,0.28300244,rate,0.49867767,batch-normalization,0.3427502
Machine Learning in Fetal Cardiology: What to Expect.,fetal-heart,0.37156522,batch-normalization,0.40617132,batch-normalization,0.40617132
Machine Learning in Fetal Cardiology: What to Expect.,small,0.28058842,few,0.5791491,bagging,0.40911084
Machine Learning in Fetal Cardiology: What to Expect.,size,0.21639656,dimensionality,0.4437346,dimensionality-reduction,0.42483336
Machine Learning in Fetal Cardiology: What to Expect.,small-size,0.33793563,stochastic-gradient,0.46676722,stochastic-gradient,0.46676722
Machine Learning in Fetal Cardiology: What to Expect.,prenatal,0.2500257,term,0.42981777,long-short-term,0.3584568
Machine Learning in Fetal Cardiology: What to Expect.,diagnoses,0.36627516,classification,0.5711745,classification,0.5711745
Machine Learning in Fetal Cardiology: What to Expect.,new,0.43019778,of,0.526482,feature-reduction,0.4579819
Machine Learning in Fetal Cardiology: What to Expect.,technologies,0.5210018,data-engineering,0.7016501,data-engineering,0.7016501
Machine Learning in Fetal Cardiology: What to Expect.,new-technologies,0.5469303,data-engineering,0.7127472,data-engineering,0.7127472
Machine Learning in Fetal Cardiology: What to Expect.,machine,0.7094662,machine,1.0,machine-learning,0.7094662
Machine Learning in Fetal Cardiology: What to Expect.,leaning,0.43592918,forward,0.65813065,bagging,0.563414
Machine Learning in Fetal Cardiology: What to Expect.,machine-leaning,0.84010404,machine-learning,0.84010404,machine-learning,0.84010404
Machine Learning in Fetal Cardiology: What to Expect.,karger,0.34883755,science,0.5591985,data-science,0.5172012
Machine Learning in Fetal Cardiology: What to Expect.,ag,0.15771106,layer,0.34149727,boosting,0.32613033
Machine Learning in Fetal Cardiology: What to Expect.,involuntary,0.26744694,confusion,0.49023283,object-tracking,0.47511387
Machine Learning in Fetal Cardiology: What to Expect.,movements,0.3508495,tracking,0.62560004,object-tracking,0.5994431
Machine Learning in Fetal Cardiology: What to Expect.,great,0.31200224,of,0.56574446,feature-engineering,0.44874108
Machine Learning in Fetal Cardiology: What to Expect.,importance,0.3427571,of,0.5794183,feature-engineering,0.46667784
Machine Learning in Fetal Cardiology: What to Expect.,especially,0.32290015,of,0.63661283,long-short-term,0.46837103
Machine Learning in Fetal Cardiology: What to Expect.,echocardiography,0.3769523,tracking,0.4348407,object-tracking,0.40039602
Machine Learning in Fetal Cardiology: What to Expect.,currently,0.3947763,fully,0.5423527,bagging,0.41457367
Machine Learning in Fetal Cardiology: What to Expect.,used,0.46049535,of,0.5630944,generative-model,0.4901716
Machine Learning in Fetal Cardiology: What to Expect.,currently-used,0.5096789,dimensionality-reduction,0.5162084,dimensionality-reduction,0.5162084
Machine Learning in Fetal Cardiology: What to Expect.,brief,0.2684708,short,0.60593176,long-short-term,0.4455405
Machine Learning in Fetal Cardiology: What to Expect.,overview,0.44348937,data-engineering,0.5364958,data-engineering,0.5364958
Machine Learning in Fetal Cardiology: What to Expect.,perform,0.48924625,supervised,0.522915,supervised,0.522915
Machine Learning in Fetal Cardiology: What to Expect.,tasks,0.539186,object-tracking,0.6899523,object-tracking,0.6899523
Machine Learning in Fetal Cardiology: What to Expect.,optimal,0.39098042,selection,0.5284126,algorithm,0.5276129
Machine Learning in Fetal Cardiology: What to Expect.,assessment,0.4002061,analysis,0.5275976,component-analysis,0.49803802
Machine Learning in Fetal Cardiology: What to Expect.,ml,0.29010946,bag,0.4418462,gradient,0.3396448
Machine Learning in Fetal Cardiology: What to Expect.,techniques,0.5005199,data-augmentation,0.5285406,data-augmentation,0.5285406
Machine Learning in Fetal Cardiology: What to Expect.,imaging,0.41700524,tracking,0.55048084,segmentation,0.5337068
Machine Learning in Fetal Cardiology: What to Expect.,computer,0.6175159,computer,1.0,computer-vision,0.7954619
Machine Learning in Fetal Cardiology: What to Expect.,help,0.45596504,support,0.55435,machine-learning,0.45596504
Machine Learning in Fetal Cardiology: What to Expect.,function,0.3447219,function,1.0,learning-function,0.5767432
Machine Learning in Fetal Cardiology: What to Expect.,perform,0.48924625,supervised,0.522915,supervised,0.522915
Machine Learning in Fetal Cardiology: What to Expect.,ml,0.29010946,bag,0.4418462,gradient,0.3396448
Machine Learning in Fetal Cardiology: What to Expect.,heart,0.28300244,rate,0.49867767,batch-normalization,0.3427502
Machine Learning in Fetal Cardiology: What to Expect.,assessment,0.4002061,analysis,0.5275976,component-analysis,0.49803802
Machine Learning in Fetal Cardiology: What to Expect.,abnormalities,0.3212605,normalization,0.5461266,segmentation,0.4475795
Machine Learning in Fetal Cardiology: What to Expect.,well,0.34264985,of,0.59718275,bagging,0.4145819
Machine Learning in Fetal Cardiology: What to Expect.,use,0.43753043,of,0.5506158,feature-reduction,0.49910897
Machine Learning in Fetal Cardiology: What to Expect.,therefore,0.37519994,of,0.6409915,feature-reduction,0.45783085
Machine Learning in Fetal Cardiology: What to Expect.,teaching,0.54187816,learning,0.6431836,supervised,0.5961263
Machine Learning in Fetal Cardiology: What to Expect.,task,0.5084964,object-tracking,0.69268537,object-tracking,0.69268537
Machine Learning in Fetal Cardiology: What to Expect.,sonographers,0.45355543,ground-truth,0.4873432,ground-truth,0.4873432
Machine Learning in Fetal Cardiology: What to Expect.,segmentation,0.62158525,segmentation,1.0,segmentation,1.0
Machine Learning in Fetal Cardiology: What to Expect.,rules,0.55864805,classification-algorithm,0.6441051,classification-algorithm,0.6441051
Machine Learning in Fetal Cardiology: What to Expect.,review,0.41215214,data,0.5581161,data-science,0.47600204
Machine Learning in Fetal Cardiology: What to Expect.,quantification,0.40637213,analysis,0.5695292,segmentation,0.5086152
Machine Learning in Fetal Cardiology: What to Expect.,provide,0.40841419,support,0.64934516,feature-engineering,0.47702065
Machine Learning in Fetal Cardiology: What to Expect.,potential,0.3558654,of,0.5645705,generative-model,0.46479023
Machine Learning in Fetal Cardiology: What to Expect.,monitoring,0.34263974,tracking,0.5622334,batch-normalization,0.44004613
Machine Learning in Fetal Cardiology: What to Expect.,mode,0.32054085,machine,0.5046243,support-vector-machine,0.43851122
Machine Learning in Fetal Cardiology: What to Expect.,lack,0.28208154,of,0.6011338,long-short-term,0.4458025
Machine Learning in Fetal Cardiology: What to Expect.,improving,0.40742207,boosting,0.54548407,boosting,0.54548407
Machine Learning in Fetal Cardiology: What to Expect.,improve,0.45207965,boosting,0.5098576,boosting,0.5098576
Machine Learning in Fetal Cardiology: What to Expect.,however,0.31437585,few,0.63182676,statistical,0.44065386
Machine Learning in Fetal Cardiology: What to Expect.,fetuses,0.20041004,term,0.43114376,artificial-intelligence,0.3009546
Machine Learning in Fetal Cardiology: What to Expect.,fetus,0.16729473,term,0.51211756,pytorch,0.34263587
Machine Learning in Fetal Cardiology: What to Expect.,expertise,0.53661454,data-science,0.6710733,data-science,0.6710733
Machine Learning in Fetal Cardiology: What to Expect.,evaluation,0.39017528,analysis,0.5728766,component-analysis,0.5049392
Machine Learning in Fetal Cardiology: What to Expect.,diagnosis,0.32391536,classification,0.53521544,classification,0.53521544
Machine Learning in Fetal Cardiology: What to Expect.,demonstrated,0.2929331,of,0.6025795,feature-reduction,0.39724052
Machine Learning in Fetal Cardiology: What to Expect.,basel,0.22441323,science,0.46179432,data-science,0.44397208
Machine Learning in Fetal Cardiology: What to Expect.,aid,0.45667556,computer,0.55178434,artificial-intelligence,0.5012631
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,specific,0.3244285,of,0.6059094,clustering,0.45887482
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,refractive,0.2628693,vision,0.5535393,computer-vision,0.46744806
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,index,0.27978244,function,0.407383,classification-algorithm,0.3994653
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,using,0.47332245,analysis,0.5968549,component-analysis,0.526608
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,correlative,0.4564844,analysis,0.6328751,statistical,0.58337426
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,imaging,0.41700524,tracking,0.55048084,segmentation,0.5337068
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,comprising,0.33471733,of,0.5419,fully-connected,0.50776124
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,odt,0.24114032,softmax,0.42880434,softmax,0.42880434
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,integrated,0.53518295,data-engineering,0.633208,data-engineering,0.633208
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,refractive-index,0.35212588,fourier,0.5934503,fourier,0.5934503
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,using,0.47332245,analysis,0.5968549,component-analysis,0.526608
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,optical,0.41040304,fourier-transform,0.63333535,fourier-transform,0.63333535
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,diffraction,0.32708037,fourier-transform,0.73590386,fourier-transform,0.73590386
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,tomography,0.37376836,computer,0.48697567,segmentation,0.4668427
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,optical-diffraction,0.4663113,fourier,0.70681596,fourier,0.70681596
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,diffraction-tomography,0.4636176,fourier,0.7079618,fourier,0.7079618
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,refractive,0.2628693,vision,0.5535393,computer-vision,0.46744806
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,index,0.27978244,function,0.407383,classification-algorithm,0.3994653
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,measurement,0.35434127,batch-normalization,0.5963583,batch-normalization,0.5963583
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,refractive-index,0.35212588,fourier,0.5934503,fourier,0.5934503
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,high,0.267004,of,0.57459104,gradient,0.44240427
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,mannose,0.2228373,components,0.35842487,graphics-processing-unit,0.32613122
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,receptor,0.22411162,function,0.41526195,clustering,0.36801085
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,specificity,0.3365721,discriminative,0.5238579,cross-validation,0.4765169
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,high-mannose,0.28566366,graphics-processing-unit,0.4019128,graphics-processing-unit,0.4019128
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,mannose-receptor,0.22428706,clustering,0.35012478,clustering,0.35012478
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,receptor-specificity,0.3542526,discriminative,0.52256024,feature-selection,0.4736813
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,free,0.22085115,of,0.48528847,batch-normalization,0.3670413
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,living,0.30422944,of,0.47259963,generative,0.4134596
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,foam,0.19966921,layer,0.44452503,feature-reduction,0.3896505
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,cells,0.20327199,naive,0.5115537,generative,0.40616876
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,free-living,0.31779015,random-forest,0.44176224,random-forest,0.44176224
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,foam-cells,0.21357282,layer,0.4875209,feed-forward,0.40706336
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,cellular,0.33255053,of,0.55018497,generative,0.4558165
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,imaging,0.41700524,tracking,0.55048084,segmentation,0.5337068
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,techniques,0.5005199,data-augmentation,0.5285406,data-augmentation,0.5285406
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,cellular-imaging,0.4823807,generative-model,0.53515863,generative-model,0.53515863
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,imaging-techniques,0.487849,few-shot,0.5558883,segmentation-algorithm,0.53698623
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,dimensional,0.48426318,dimensionality,0.8024132,dimensionality-reduction,0.765376
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,fluorescence,0.30636215,fourier-transform,0.5557604,fourier-transform,0.5557604
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,imaging,0.41700524,tracking,0.55048084,segmentation,0.5337068
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,dimensional-fluorescence,0.52150726,dimensionality,0.67710096,dimensionality-reduction,0.647655
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,fluorescence-imaging,0.41904113,fourier-transform,0.53215253,fourier-transform,0.53215253
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,living,0.30422944,of,0.47259963,generative,0.4134596
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,foam,0.19966921,layer,0.44452503,feature-reduction,0.3896505
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,cells,0.20327199,naive,0.5115537,generative,0.40616876
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,foam-cells,0.21357282,layer,0.4875209,feed-forward,0.40706336
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,related,0.30849367,of,0.6150687,clustering,0.41455543
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,metabolic,0.3235007,of,0.46523505,batch-normalization,0.4536144
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,diseases,0.31957155,recurrent,0.41244444,classification,0.40266854
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,related-metabolic,0.41694856,logistic-regression,0.5483695,logistic-regression,0.5483695
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,foam,0.19966921,layer,0.44452503,feature-reduction,0.3896505
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,cells,0.20327199,naive,0.5115537,generative,0.40616876
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,based,0.49998575,classification-algorithm,0.5639226,classification-algorithm,0.5639226
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,foam-cells,0.21357282,layer,0.4875209,feed-forward,0.40706336
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,cells-based,0.44720644,feature-engineering,0.5948476,feature-engineering,0.5948476
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,explore,0.4359874,feature-engineering,0.5121693,feature-engineering,0.5121693
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,new,0.43019778,of,0.526482,feature-reduction,0.4579819
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,drugs,0.30897486,of,0.42460242,classifiers,0.33720028
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,new-drugs,0.37925828,data-engineering,0.43473715,data-engineering,0.43473715
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,performed,0.3864032,analysis,0.5711501,supervised,0.4789877
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,quantitative,0.4330744,analysis,0.6747154,component-analysis,0.558002
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,morphological,0.38724077,feature,0.5468423,generative,0.5159291
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,quantitative-morphological,0.4761213,analysis,0.5999917,generative-model,0.5673505
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,based,0.49998575,classification-algorithm,0.5639226,classification-algorithm,0.5639226
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,image,0.5164337,segmentation,0.7261368,segmentation,0.7261368
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,analysis,0.46507934,analysis,0.99999994,component-analysis,0.69613737
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,based-image,0.595109,segmentation-algorithm,0.67763567,segmentation-algorithm,0.67763567
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,image-analysis,0.61273,computer-vision,0.7179096,computer-vision,0.7179096
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,demonstrated,0.2929331,of,0.6025795,feature-reduction,0.39724052
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,therapeutic,0.3659354,of,0.48352462,boosting,0.41573292
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,evaluation,0.39017528,analysis,0.5728766,component-analysis,0.5049392
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,therapeutic-evaluation,0.42759246,dimensionality-reduction,0.5321629,dimensionality-reduction,0.5321629
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,odt,0.24114032,softmax,0.42880434,softmax,0.42880434
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,foam,0.19966921,layer,0.44452503,feature-reduction,0.3896505
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,cells,0.20327199,naive,0.5115537,generative,0.40616876
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,foam-cells,0.21357282,layer,0.4875209,feed-forward,0.40706336
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,free,0.22085115,of,0.48528847,batch-normalization,0.3670413
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,manner,0.26802608,fully,0.46465638,feed-forward,0.4349473
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,quantitative,0.4330744,analysis,0.6747154,component-analysis,0.558002
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,methods,0.50049126,data,0.5400177,machine-learning,0.50049126
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,dimensional,0.48426318,dimensionality,0.8024132,dimensionality-reduction,0.765376
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,dynamics,0.40255624,stochastic,0.70136905,stochastic,0.70136905
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,biophysical,0.4648708,feature-engineering,0.5824237,feature-engineering,0.5824237
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,analysis,0.46507934,analysis,0.99999994,component-analysis,0.69613737
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,therapeutic,0.3659354,of,0.48352462,boosting,0.41573292
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,intervention,0.350297,supervised,0.5352158,supervised,0.5352158
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,therapeutic-intervention,0.38933092,supervised,0.47322395,supervised,0.47322395
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,therapeutic,0.3659354,of,0.48352462,boosting,0.41573292
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,effects,0.2624804,short-term,0.63497096,long-short-term,0.5306107
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,therapeutic-effects,0.36623636,generative-model,0.53172517,generative-model,0.53172517
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,targeted,0.37903738,of,0.52138686,feature-engineering,0.502902
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,delivery,0.32787693,transfer,0.49930203,boosting,0.47409874
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,targeted-delivery,0.4015992,feature-engineering,0.5294453,feature-engineering,0.5294453
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,quantitatively,0.42666766,of,0.57824427,batch-normalization,0.50927997
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,evaluated,0.35501102,of,0.6190806,supervised,0.4124783
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,quantitatively-evaluated,0.46046534,of,0.5891716,component-analysis,0.53793186
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,promising,0.40802234,feature-engineering,0.526417,feature-engineering,0.526417
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,tool,0.58027077,machine-learning,0.58027077,machine-learning,0.58027077
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,polyethylene,0.24614145,artificial,0.4340384,feature-reduction,0.40250218
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,glycol,0.21735345,unit,0.3536617,monte,0.34441411
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,polyethylene-glycol,0.23809604,artificial,0.4033474,feature-reduction,0.36502957
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,lipid,0.23492281,of,0.44637915,clustering,0.37238947
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,droplet,0.2718729,stochastic-gradient,0.4709143,stochastic-gradient,0.4709143
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,lipid-droplet,0.2874176,stochastic,0.45121425,stochastic,0.45121425
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,limited,0.33893847,of,0.6210327,long-short-term,0.4736513
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,application,0.46535254,data-engineering,0.5603031,data-engineering,0.5603031
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,limited-application,0.4904601,data-augmentation,0.5453089,data-augmentation,0.5453089
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,lapse,0.30942672,short-term,0.54069066,dropout,0.50691026
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,monitoring,0.34263974,tracking,0.5622334,batch-normalization,0.44004613
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,lapse-monitoring,0.4884346,object-tracking,0.58368206,object-tracking,0.58368206
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,key,0.35973132,principal,0.614877,feature-engineering,0.498355
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,feature,0.5878884,feature,0.99999994,feature-selection,0.6322505
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,key-feature,0.6996952,feature,0.72753495,feature-selection,0.70056176
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,identified,0.35725033,analysis,0.56593037,clustering,0.45719695
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,lds,0.3091482,long-short-term,0.46027583,long-short-term,0.46027583
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,glycol,0.21735345,unit,0.3536617,monte,0.34441411
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,chitosan,0.23365778,matrix,0.41928083,fourier-transform,0.3706862
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,glycol-chitosan,0.2015084,matrix,0.37765414,recurrent-neural-network,0.34084666
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,fluorescein,0.19289115,vision,0.3713245,computer-vision,0.36198956
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,isothiocyanate,0.17673774,fourier-transform,0.31500602,fourier-transform,0.31500602
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,fluorescein-isothiocyanate,0.20210037,fourier-transform,0.34467188,fourier-transform,0.34467188
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,findings,0.35685748,data,0.65714294,component-analysis,0.38599753
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,suggest,0.26874092,data,0.5391823,long-short-term,0.40288782
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,exploiting,0.5385846,feature-engineering,0.7243467,feature-engineering,0.7243467
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,machine,0.7094662,machine,1.0,machine-learning,0.7094662
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,despite,0.27514282,few,0.5803892,long-short-term,0.43284553
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,advances,0.45830926,data-engineering,0.5886656,data-engineering,0.5886656
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,current,0.3530666,rectified,0.52906346,generative-model,0.40904555
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,noninvasive,0.43855414,tracking,0.48694682,machine-learning,0.43855414
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,cell,0.2212203,of,0.48460138,generative,0.39753264
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,level,0.23847455,of,0.54773176,batch-normalization,0.45912555
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,cell-level,0.46827382,stochastic,0.6047394,stochastic,0.6047394
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,attractive,0.37016675,feature-engineering,0.52500945,feature-engineering,0.52500945
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,target,0.31799266,of,0.4775706,feature-selection,0.44359237
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,mannose,0.2228373,components,0.35842487,graphics-processing-unit,0.32613122
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,verifying,0.4551665,of,0.6268448,dimensionality-reduction,0.5116635
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,time,0.31186903,long,0.57547164,batch-normalization,0.47628766
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,three,0.36911732,one,0.78425425,clustering,0.4299444
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,single,0.31087106,one,0.6951874,one-shot,0.4602274
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,precisely,0.39328516,fully,0.5896492,generative,0.5141876
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,nanodrug,0.33608297,feature-engineering,0.46827036,feature-engineering,0.46827036
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,mmr,0.28029406,boosting,0.3709597,boosting,0.3709597
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,lobeglitazone,0.19423881,softmax,0.3544891,softmax,0.3544891
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,lobe,0.22086331,language-processing,0.40059024,language-processing,0.40059024
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,learning,0.709237,learning,1.0,deep-learning,0.8286492
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,ld,0.21766132,long-short-term-memory,0.36369294,long-short-term-memory,0.36369294
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,label,0.31700084,embeddings,0.50531435,embeddings,0.50531435
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,however,0.31437585,few,0.63182676,statistical,0.44065386
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,furthermore,0.33438665,of,0.5529862,clustering,0.42723072
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,designed,0.47411257,feature-engineering,0.5746863,feature-engineering,0.5746863
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,constitutes,0.3460948,of,0.63473797,generative,0.45540607
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,atherosclerosis,0.2715264,of,0.35554427,generative-model,0.35331845
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,affect,0.23161066,of,0.50835335,long-short-term,0.3772871
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,accumulation,0.22826076,of,0.50695926,generative,0.4137243
Supervised machine learning models applied to disease diagnosis and prognosis.,heart,0.28300244,rate,0.49867767,batch-normalization,0.3427502
Supervised machine learning models applied to disease diagnosis and prognosis.,disease,0.296938,recurrent,0.4731025,classification,0.35271814
Supervised machine learning models applied to disease diagnosis and prognosis.,data,0.46434748,data,1.0,data-science,0.5533528
Supervised machine learning models applied to disease diagnosis and prognosis.,using,0.47332245,analysis,0.5968549,component-analysis,0.526608
Supervised machine learning models applied to disease diagnosis and prognosis.,five,0.3705204,one,0.7489015,principal-components,0.4074809
Supervised machine learning models applied to disease diagnosis and prognosis.,machine,0.7094662,machine,1.0,machine-learning,0.7094662
Supervised machine learning models applied to disease diagnosis and prognosis.,learning,0.709237,learning,1.0,deep-learning,0.8286492
Supervised machine learning models applied to disease diagnosis and prognosis.,heart-disease,0.35198575,long-short-term,0.43214932,long-short-term,0.43214932
Supervised machine learning models applied to disease diagnosis and prognosis.,disease-data,0.543054,data-science,0.55269575,data-science,0.55269575
Supervised machine learning models applied to disease diagnosis and prognosis.,machine-learning,1.0,machine-learning,1.0,machine-learning,1.0
Supervised machine learning models applied to disease diagnosis and prognosis.,heart,0.28300244,rate,0.49867767,batch-normalization,0.3427502
Supervised machine learning models applied to disease diagnosis and prognosis.,disease,0.296938,recurrent,0.4731025,classification,0.35271814
Supervised machine learning models applied to disease diagnosis and prognosis.,data,0.46434748,data,1.0,data-science,0.5533528
Supervised machine learning models applied to disease diagnosis and prognosis.,respectively,0.23184536,of,0.43360457,cross-validation,0.35765702
Supervised machine learning models applied to disease diagnosis and prognosis.,heart-disease,0.35198575,long-short-term,0.43214932,long-short-term,0.43214932
Supervised machine learning models applied to disease diagnosis and prognosis.,disease-data,0.543054,data-science,0.55269575,data-science,0.55269575
Supervised machine learning models applied to disease diagnosis and prognosis.,licensee,0.34538037,federated,0.5643549,data-science,0.53677833
Supervised machine learning models applied to disease diagnosis and prognosis.,aims,0.42995954,of,0.465683,feature-engineering,0.4555406
Supervised machine learning models applied to disease diagnosis and prognosis.,press,0.34600213,science,0.5130155,reinforcement-learning,0.49471456
Supervised machine learning models applied to disease diagnosis and prognosis.,prediction,0.6361519,classification-algorithm,0.67946094,classification-algorithm,0.67946094
Supervised machine learning models applied to disease diagnosis and prognosis.,accuracy,0.5511073,cross-validation,0.64088035,cross-validation,0.64088035
Supervised machine learning models applied to disease diagnosis and prognosis.,using,0.47332245,analysis,0.5968549,component-analysis,0.526608
Supervised machine learning models applied to disease diagnosis and prognosis.,prediction-accuracy,0.6702601,classification-algorithm,0.74878794,classification-algorithm,0.74878794
Supervised machine learning models applied to disease diagnosis and prognosis.,test,0.4037762,statistical,0.5031551,statistical,0.5031551
Supervised machine learning models applied to disease diagnosis and prognosis.,data,0.46434748,data,1.0,data-science,0.5533528
Supervised machine learning models applied to disease diagnosis and prognosis.,based,0.49998575,classification-algorithm,0.5639226,classification-algorithm,0.5639226
Supervised machine learning models applied to disease diagnosis and prognosis.,test-data,0.5597484,decision-tree,0.5861767,decision-tree,0.5861767
Supervised machine learning models applied to disease diagnosis and prognosis.,data-based,0.714008,data-science,0.71638703,data-science,0.71638703
Supervised machine learning models applied to disease diagnosis and prognosis.,receiver,0.45132244,logistic,0.6124048,logistic-regression,0.57750404
Supervised machine learning models applied to disease diagnosis and prognosis.,operating,0.38906178,machine,0.49189845,graphics-processing,0.47077706
Supervised machine learning models applied to disease diagnosis and prognosis.,characteristic,0.34942827,feature,0.7124056,clustering,0.48287967
Supervised machine learning models applied to disease diagnosis and prognosis.,receiver-operating,0.4694291,logistic,0.6941327,logistic-regression,0.6736918
Supervised machine learning models applied to disease diagnosis and prognosis.,operating-characteristic,0.503636,discriminative,0.62105864,principal-component-analysis,0.5886377
Supervised machine learning models applied to disease diagnosis and prognosis.,receiver-operating-characteristic,0.503338,logistic-regression,0.6653639,logistic-regression,0.6653639
Supervised machine learning models applied to disease diagnosis and prognosis.,principal,0.3794123,principal,1.0,principal-components,0.72193956
Supervised machine learning models applied to disease diagnosis and prognosis.,component,0.29999307,component,1.0,principal-component,0.687786
Supervised machine learning models applied to disease diagnosis and prognosis.,regression,0.4967034,regression,1.0,regression,1.0
Supervised machine learning models applied to disease diagnosis and prognosis.,principal-component,0.53183436,principal-component,1.0,principal-component,1.0
Supervised machine learning models applied to disease diagnosis and prognosis.,component-regression,0.56340456,component-analysis,0.80367064,component-analysis,0.80367064
Supervised machine learning models applied to disease diagnosis and prognosis.,heart,0.28300244,rate,0.49867767,batch-normalization,0.3427502
Supervised machine learning models applied to disease diagnosis and prognosis.,disease,0.296938,recurrent,0.4731025,classification,0.35271814
Supervised machine learning models applied to disease diagnosis and prognosis.,heart-disease,0.35198575,long-short-term,0.43214932,long-short-term,0.43214932
Supervised machine learning models applied to disease diagnosis and prognosis.,work,0.42713583,support,0.5373766,learning-function,0.5011815
Supervised machine learning models applied to disease diagnosis and prognosis.,analyses,0.43295383,analysis,0.9146549,principal-component-analysis,0.66157085
Supervised machine learning models applied to disease diagnosis and prognosis.,work-analyses,0.5200291,principal-component-analysis,0.6554405,principal-component-analysis,0.6554405
Supervised machine learning models applied to disease diagnosis and prognosis.,random,0.45551494,random,1.0,random-forest,0.65894985
Supervised machine learning models applied to disease diagnosis and prognosis.,forest,0.4787075,forest,1.0,random-forest,0.7738863
Supervised machine learning models applied to disease diagnosis and prognosis.,random-forest,0.6331641,random-forest,1.0,random-forest,1.0
Supervised machine learning models applied to disease diagnosis and prognosis.,predictive,0.55290145,cross-validation,0.6141345,cross-validation,0.6141345
Supervised machine learning models applied to disease diagnosis and prognosis.,ability,0.39144984,function,0.5937173,generative,0.47758824
Supervised machine learning models applied to disease diagnosis and prognosis.,predictive-ability,0.53957814,dimensionality-reduction,0.65306276,dimensionality-reduction,0.65306276
Supervised machine learning models applied to disease diagnosis and prognosis.,important,0.33620566,principal,0.5803634,feature-engineering,0.43471682
Supervised machine learning models applied to disease diagnosis and prognosis.,variables,0.4636312,logistic-regression,0.6604836,logistic-regression,0.6604836
Supervised machine learning models applied to disease diagnosis and prognosis.,best,0.4535247,decision,0.5130525,classifiers,0.47293013
Supervised machine learning models applied to disease diagnosis and prognosis.,performance,0.50728506,learning-function,0.63351834,learning-function,0.63351834
Supervised machine learning models applied to disease diagnosis and prognosis.,best-performance,0.6208144,machine-learning,0.6208144,machine-learning,0.6208144
Supervised machine learning models applied to disease diagnosis and prognosis.,also,0.32850838,of,0.65908813,clustering,0.45826355
Supervised machine learning models applied to disease diagnosis and prognosis.,studied,0.26534057,of,0.63097596,generative-model,0.40392917
Supervised machine learning models applied to disease diagnosis and prognosis.,causes,0.19757006,of,0.55089116,long-short-term,0.3616379
Supervised machine learning models applied to disease diagnosis and prognosis.,cancer,0.27383438,recurrent,0.4065063,generative,0.3468409
Supervised machine learning models applied to disease diagnosis and prognosis.,breast,0.28445923,of,0.40638393,clustering,0.34891048
Supervised machine learning models applied to disease diagnosis and prognosis.,cancer,0.27383438,recurrent,0.4065063,generative,0.3468409
Supervised machine learning models applied to disease diagnosis and prognosis.,breast-cancer,0.24357814,recurrent,0.31327358,component-analysis,0.311931
Supervised machine learning models applied to disease diagnosis and prognosis.,ml,0.29010946,bag,0.4418462,gradient,0.3396448
Supervised machine learning models applied to disease diagnosis and prognosis.,algorithms,0.7612198,algorithm,0.9050166,algorithm,0.9050166
Supervised machine learning models applied to disease diagnosis and prognosis.,ml-algorithms,0.70626605,algorithm,0.85697013,algorithm,0.85697013
Supervised machine learning models applied to disease diagnosis and prognosis.,cancer,0.27383438,recurrent,0.4065063,generative,0.3468409
Supervised machine learning models applied to disease diagnosis and prognosis.,ml,0.29010946,bag,0.4418462,gradient,0.3396448
Supervised machine learning models applied to disease diagnosis and prognosis.,algorithms,0.7612198,algorithm,0.9050166,algorithm,0.9050166
Supervised machine learning models applied to disease diagnosis and prognosis.,roc,0.43121514,logistic,0.6262138,logistic-regression,0.6039296
Supervised machine learning models applied to disease diagnosis and prognosis.,rf,0.349212,xgboost,0.44135672,xgboost,0.44135672
Supervised machine learning models applied to disease diagnosis and prognosis.,provides,0.41792372,of,0.5261056,feature-engineering,0.4872959
Supervised machine learning models applied to disease diagnosis and prognosis.,prognosis,0.32841474,recurrent,0.50268024,classification,0.44778624
Supervised machine learning models applied to disease diagnosis and prognosis.,predict,0.51602554,model,0.53463185,classification-algorithm,0.52342355
Supervised machine learning models applied to disease diagnosis and prognosis.,pcr,0.34162766,analysis,0.4623741,logistic-regression,0.38891542
Supervised machine learning models applied to disease diagnosis and prognosis.,diagnosis,0.32391536,classification,0.53521544,classification,0.53521544
Supervised machine learning models applied to disease diagnosis and prognosis.,curve,0.29765248,linear,0.52257633,regression,0.49561262
Supervised machine learning models applied to disease diagnosis and prognosis.,compute,0.59251976,hidden-markov-model,0.68740803,hidden-markov-model,0.68740803
Supervised machine learning models applied to disease diagnosis and prognosis.,compare,0.43674475,short-term,0.510365,statistical,0.44797724
Supervised machine learning models applied to disease diagnosis and prognosis.,author,0.4029289,adversarial,0.58311844,data-science,0.55950665
Supervised machine learning models applied to disease diagnosis and prognosis.,analyzing,0.53968024,analysis,0.7414384,component-analysis,0.61997235
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;αs&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,increased,0.26921988,reduction,0.6514183,boosting,0.46515882
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;αs&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,camp,0.18017536,cascade,0.41505903,gradient,0.3339354
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;αs&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,levels,0.20457911,normalization,0.52984333,batch-normalization,0.45617118
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;αs&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,within,0.2920679,of,0.57602364,clustering,0.4610753
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;αs&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;αs&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,minutes,0.2827969,short,0.4575076,one-hot,0.4119182
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;αs&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,without,0.31691062,of,0.5951073,long-short-term,0.4268921
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;αs&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,phosphodiesterase,0.21491401,encoding,0.34789324,gradient,0.28218752
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;αs&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,inhibitors,0.25381407,cascade,0.4157439,feed-forward,0.3175553
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;αs&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,camp-levels,0.25445315,batch-normalization,0.44184467,batch-normalization,0.44184467
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;αs&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,levels-within,0.34656146,batch-normalization,0.565933,batch-normalization,0.565933
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;αs&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,phosphodiesterase-inhibitors,0.27055007,of,0.377271,long-short-term,0.3170789
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;αs&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;αs&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;αs&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,'-,0.13585025,words,0.31722736,bag-of-words,0.30911934
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;αs&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,cyclic,0.22142175,cascade,0.44544992,feed-forward,0.35269684
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;αs&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,adenosine,0.20329912,of,0.3698272,gradient,0.2729475
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;αs&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,monophosphate,0.19171125,cascade,0.35430616,gradient-descent,0.3115289
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;αs&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,cyclic-adenosine,0.2201114,cascade,0.37836963,gradient-descent,0.32865685
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;αs&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,adenosine-monophosphate,0.21681285,gradient-descent,0.33753353,gradient-descent,0.33753353
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;αs&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,cyclic-adenosine-monophosphate,0.22282878,cascade,0.3774833,gradient-descent,0.35783267
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;αs&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,impermeable,0.16456082,layer,0.52900696,gradient-descent,0.43152106
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;αs&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,glucocorticoid,0.2026341,short-term,0.44387174,long-short-term,0.41423047
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;αs&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,showed,0.20766163,of,0.5296177,regression,0.37027335
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;αs&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,similarly,0.28201446,of,0.5816662,long-short-term,0.47558495
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;αs&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,rapid,0.30782193,of,0.52859515,long-short-term,0.45410746
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;αs&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,stimulation,0.22520258,augmentation,0.51376045,data-augmentation,0.45147988
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;αs&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,similarly-rapid,0.37677178,long-short-term,0.5343462,long-short-term,0.5343462
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;αs&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,primary,0.24268678,principal,0.5205563,long-short-term,0.38049072
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;αs&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,human,0.30336243,of,0.5175895,feature-engineering,0.40631005
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;αs&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,airway,0.22946814,bagging,0.39862382,bagging,0.39862382
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;αs&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,smooth,0.19535431,matrix,0.46861044,convolutional-layer,0.41037375
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;αs&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,muscle,0.19602863,neural,0.42647707,supervised,0.33558244
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;αs&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,human-airway,0.3934812,ground-truth,0.47406092,ground-truth,0.47406092
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;αs&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,smooth-muscle,0.15457644,matrix,0.4372552,confusion-matrix,0.34572434
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;αs&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,airway-smooth-muscle,0.21569681,matrix,0.4048031,recurrent-neural-network,0.37258488
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;αs&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,g,0.17250246,feed,0.40076,n-gram,0.27758121
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;αs&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,protein,0.31929362,encoding,0.5525089,clustering,0.36023882
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;αs&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,estrogen,0.20631479,short-term,0.39636484,long-short-term,0.3391025
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;αs&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,receptor,0.22411162,function,0.41526195,clustering,0.36801085
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;αs&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,antagonists,0.24215083,discriminative,0.39012936,learning-function,0.31474212
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;αs&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,g-protein,0.26876673,encoding,0.47615886,feed-forward,0.38512486
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;αs&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,protein-estrogen,0.27393937,of,0.3856934,stochastic,0.34122047
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;αs&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,estrogen-receptor,0.22972146,centroid-based,0.35176963,centroid-based,0.35176963
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;αs&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,receptor-antagonists,0.23002487,discriminative,0.38725716,feed-forward,0.3471454
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;αs&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,genomic,0.45244905,encoding,0.50617117,clustering,0.48942614
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;αs&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,camp,0.18017536,cascade,0.41505903,gradient,0.3339354
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;αs&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,signaling,0.29640946,cascade,0.70725644,feed-forward,0.5819744
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;αs&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,modality,0.45219088,feature,0.49997124,object-tracking,0.48294973
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;αs&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,contributes,0.27235785,of,0.5690483,feed-forward,0.4287781
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;αs&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,camp-signaling,0.28047222,cascade,0.62268597,feed-forward,0.5372553
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;αs&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,time,0.31186903,long,0.57547164,batch-normalization,0.47628766
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;αs&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,camp,0.18017536,cascade,0.41505903,gradient,0.3339354
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;αs&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,dynamics,0.40255624,stochastic,0.70136905,stochastic,0.70136905
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;αs&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,using,0.47332245,analysis,0.5968549,component-analysis,0.526608
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;αs&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,time-camp,0.34785473,stochastic,0.49458194,stochastic,0.49458194
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;αs&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,dynamics-using,0.6255417,stochastic,0.6696521,stochastic,0.6696521
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;αs&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,gene,0.32125705,encoding,0.7317275,clustering,0.4378482
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;αs&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,expression,0.32038707,encoding,0.59633577,clustering,0.442253
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;αs&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,changes,0.28767496,normalization,0.57879114,batch-normalization,0.43861648
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;αs&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,induced,0.2259351,of,0.5615651,boosting,0.4303583
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;αs&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,gene-expression,0.5495992,classifiers,0.5527793,classifiers,0.5527793
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;αs&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,expression-changes,0.41221738,learning-function,0.5394248,learning-function,0.5394248
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;αs&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,changes-induced,0.28143656,reduction,0.544433,data-augmentation,0.41348577
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;αs&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;αs&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,hours,0.2621256,short-term,0.4799012,supervised,0.38109756
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;αs&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,treated,0.19958335,of,0.5218221,long-short-term,0.35705733
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;αs&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,hasm,0.28108802,matrix,0.4430313,feed-forward,0.37151384
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;αs&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,virtually,0.26679754,fully,0.61199474,generative,0.41252592
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;αs&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,eliminated,0.2514809,of,0.5635375,boosting,0.4246394
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;αs&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,glucocorticoid,0.2026341,short-term,0.44387174,long-short-term,0.41423047
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;αs&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,diverse,0.38913006,of,0.5461366,feature-engineering,0.51537836
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;αs&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,cell,0.2212203,of,0.48460138,generative,0.39753264
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;αs&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,signaling,0.29640946,cascade,0.70725644,feed-forward,0.5819744
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;αs&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,effects,0.2624804,short-term,0.63497096,long-short-term,0.5306107
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;αs&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,cell-signaling,0.3557333,cascade,0.6883489,feed-forward,0.58976066
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;αs&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;αs&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,genes,0.32912976,encoding,0.71535945,clustering,0.43737888
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;αs&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,represent,0.37514454,feature,0.5787041,generative,0.46606725
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;αs&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,genes-represent,0.4989301,encoding,0.6044152,classifiers,0.5256301
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;αs&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,camp,0.18017536,cascade,0.41505903,gradient,0.3339354
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;αs&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,difference,0.30501923,statistical,0.58389574,statistical,0.58389574
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;αs&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,detector,0.4242129,convolutional-layer,0.5489498,convolutional-layer,0.5489498
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;αs&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,difference-detector,0.5454303,segmentation-algorithm,0.6227635,segmentation-algorithm,0.6227635
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;αs&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,requires,0.35710368,of,0.62298405,stochastic,0.42198688
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;αs&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,signaling,0.29640946,cascade,0.70725644,feed-forward,0.5819744
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;αs&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,camp,0.18017536,cascade,0.41505903,gradient,0.3339354
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;αs&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,levels,0.20457911,normalization,0.52984333,batch-normalization,0.45617118
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;αs&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,camp-levels,0.25445315,batch-normalization,0.44184467,batch-normalization,0.44184467
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;αs&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,immortalized,0.28946108,transform,0.4524148,generative,0.37657735
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;αs&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,cell,0.2212203,of,0.48460138,generative,0.39753264
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;αs&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,lines,0.2397678,of,0.42859763,generative,0.3835748
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;αs&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,immortalized-cell,0.377405,stochastic-gradient,0.4530947,stochastic-gradient,0.4530947
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;αs&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,cell-lines,0.3067491,naive,0.41776058,generative,0.41620326
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;αs&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,faseb,0.17490312,science,0.47813684,data-science,0.39063287
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;αs&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,journal,0.37362164,science,0.7173637,data-science,0.6594459
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;αs&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,published,0.42179614,data,0.6147139,data-science,0.54664624
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;αs&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,journal-published,0.48357612,data-science,0.7493354,data-science,0.7493354
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;αs&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,stimulated,0.20216994,of,0.49148273,boosting,0.43653107
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;αs&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,camp,0.18017536,cascade,0.41505903,gradient,0.3339354
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;αs&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,responses,0.23078328,naive,0.5126229,boosting,0.49454907
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;αs&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,camp-responses,0.2510882,encoding,0.43340006,feed-forward,0.43336436
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;αs&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,camp,0.18017536,cascade,0.41505903,gradient,0.3339354
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;αs&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,production,0.266738,of,0.51767635,boosting,0.46983936
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;αs&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,via,0.29305607,connected,0.5425352,feed-forward,0.46278888
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;αs&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,camp-production,0.2388099,cascade,0.5244295,feed-forward,0.42910647
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;αs&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,gene,0.32125705,encoding,0.7317275,clustering,0.4378482
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;αs&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,budesonide,0.1618973,short-term,0.3396296,long-short-term,0.31157213
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;αs&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,signature,0.46610928,feature,0.6392228,classifiers,0.52970886
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;αs&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,without,0.31691062,of,0.5951073,long-short-term,0.4268921
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;αs&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,knockdown,0.27756518,encoding,0.41261983,feed-forward,0.38140994
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;αs&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,g,0.17250246,feed,0.40076,n-gram,0.27758121
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;αs&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,protein,0.31929362,encoding,0.5525089,clustering,0.36023882
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;αs&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,g-protein,0.26876673,encoding,0.47615886,feed-forward,0.38512486
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;αs&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,glucocorticoid,0.2026341,short-term,0.44387174,long-short-term,0.41423047
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;αs&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,treatment,0.239264,short-term,0.5206091,long-short-term,0.41699445
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;αs&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,glucocorticoid-treatment,0.22190277,short-term,0.5194271,long-short-term,0.45842436
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;αs&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,coupled,0.37019002,connected,0.5951823,stochastic-gradient,0.5436393
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;αs&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,receptor,0.22411162,function,0.41526195,clustering,0.36801085
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;αs&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,coupled-receptor,0.4146335,stochastic,0.5324006,stochastic,0.5324006
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;αs&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,genomic,0.45244905,encoding,0.50617117,clustering,0.48942614
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;αs&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,signature,0.46610928,feature,0.6392228,classifiers,0.52970886
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;αs&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,genomic-signature,0.5761401,feature-selection,0.58889204,feature-selection,0.58889204
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;αs&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,cell,0.2212203,of,0.48460138,generative,0.39753264
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;αs&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,surface,0.25082165,layer,0.63621426,clustering,0.4342317
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;αs&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,cell-surface,0.2938358,encoding,0.4642039,clustering,0.45265853
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;αs&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;αs&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,genomic,0.45244905,encoding,0.50617117,clustering,0.48942614
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;αs&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,actions,0.28966114,of,0.48381984,feed-forward,0.47016585
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;αs&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,small,0.28058842,few,0.5791491,bagging,0.40911084
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;αs&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,effects,0.2624804,short-term,0.63497096,long-short-term,0.5306107
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;αs&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,small-effects,0.39228335,stochastic,0.56079066,stochastic,0.56079066
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;αs&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,wiley,0.26784617,science,0.5360337,data-science,0.46017712
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;αs&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,periodicals,0.3509249,science,0.62838554,data-science,0.6050081
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;αs&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,wiley-periodicals,0.3803232,science,0.6006683,data-science,0.58190393
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;αs&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,widely,0.36366525,of,0.42793494,generative-model,0.39908314
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;αs&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,used,0.46049535,of,0.5630944,generative-model,0.4901716
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;αs&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,widely-used,0.5124134,multi-class,0.52119327,machine-learning,0.5124134
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;αs&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,swiftly,0.36860052,fully,0.5489132,generative,0.43261304
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;αs&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,increase,0.28092995,reduction,0.7624404,boosting,0.49543357
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;αs&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,situ,0.21648605,fourier-transform,0.4373082,fourier-transform,0.4373082
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;αs&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,assay,0.28104568,analysis,0.46296048,component-analysis,0.37250015
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;αs&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,sirna,0.30772042,vector,0.4959275,vector-machine,0.41919988
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;αs&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,knockdown,0.27756518,encoding,0.41261983,feed-forward,0.38140994
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;αs&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,sirna-knockdown,0.23632999,vector,0.4188665,vector-machine,0.35153362
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;αs&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,seq,0.41307154,segmentation-algorithm,0.4746839,segmentation-algorithm,0.4746839
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;αs&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,analysis,0.46507934,analysis,0.99999994,component-analysis,0.69613737
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;αs&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,seq-analysis,0.6229216,principal-component-analysis,0.7477407,principal-component-analysis,0.7477407
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;αs&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,measuring,0.28206778,of,0.5194533,dimensionality-reduction,0.46445137
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;αs&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,real,0.4954688,truth,0.5802553,ground-truth,0.56635034
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;αs&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,little,0.27074662,few,0.67553365,long-short-term,0.41808233
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;αs&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,effect,0.21449387,short-term,0.5886732,long-short-term,0.47619703
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;αs&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,leading,0.2514689,of,0.59935343,generative,0.44480726
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;αs&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,us,0.36534783,decision,0.49831933,segmentation,0.39571765
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;αs&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,important,0.33620566,principal,0.5803634,feature-engineering,0.43471682
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;αs&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,class,0.353845,multi-class,0.5162764,classification,0.4708274
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;αs&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,experimental,0.40167695,model,0.6248311,generative-model,0.6004326
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;αs&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,biology,0.47010514,science,0.6525451,data-engineering,0.59721386
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;αs&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,drugs,0.30897486,of,0.42460242,classifiers,0.33720028
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;αs&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,exerts,0.16802764,function,0.45056513,feed-forward,0.39651316
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;αs&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,drugs,0.30897486,of,0.42460242,classifiers,0.33720028
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;αs&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,activate,0.24475634,cascade,0.56470346,feed-forward,0.45859116
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;αs&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,american,0.31403136,federated,0.55841243,classification,0.43444416
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;αs&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,societies,0.34185767,federated,0.6009963,data-science,0.5610749
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;αs&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,camp,0.18017536,cascade,0.41505903,gradient,0.3339354
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;αs&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,glucocorticoids,0.18681435,short-term,0.47338426,long-short-term,0.4219041
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;αs&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,tested,0.37172255,of,0.5634051,boosting,0.4195229
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;αs&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,glucocorticoids,0.18681435,short-term,0.47338426,long-short-term,0.4219041
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;αs&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,alone,0.30137342,short-term,0.55139315,boosting,0.46337873
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;αs&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,rapid,0.30782193,of,0.52859515,long-short-term,0.45410746
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;αs&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,hasm,0.28108802,matrix,0.4430313,feed-forward,0.37151384
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;αs&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,genomic,0.45244905,encoding,0.50617117,clustering,0.48942614
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;αs&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,effects,0.2624804,short-term,0.63497096,long-short-term,0.5306107
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;αs&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,responses,0.23078328,naive,0.5126229,boosting,0.49454907
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;αs&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,production,0.266738,of,0.51767635,boosting,0.46983936
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;αs&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,budesonide,0.1618973,short-term,0.3396296,long-short-term,0.31157213
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;αs&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,glucocorticoids,0.18681435,short-term,0.47338426,long-short-term,0.4219041
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;αs&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,view,0.33550352,data,0.49932158,dimensionality-reduction,0.44604445
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;αs&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,variety,0.35310775,natural,0.5234163,generative,0.4781817
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;αs&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,unappreciated,0.34429172,function,0.53453517,generative,0.43860734
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;αs&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,third,0.27270278,one,0.6556418,generative,0.3917287
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;αs&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,suppression,0.24727267,reduction,0.62000287,boosting,0.50863206
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;αs&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,suggesting,0.24045295,of,0.6157647,clustering,0.43733796
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;αs&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,shifts,0.28182906,of,0.48006222,dimensionality-reduction,0.45091707
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;αs&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,rna,0.357179,encoding,0.44869584,vector-machine,0.39839315
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;αs&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,reported,0.27641866,of,0.6039252,long-short-term,0.38086164
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;αs&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,progesterone,0.2027933,term,0.3787871,long-short-term,0.3148398
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;αs&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,prednisone,0.21904026,short-term,0.38166517,long-short-term,0.33385408
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;αs&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,one,0.335046,one,1.0,one-hot,0.4275648
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;αs&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,non,0.2869836,of,0.5523051,generative,0.4181043
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;αs&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,membrane,0.2560242,layer,0.5360652,gradient-descent,0.40451998
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;αs&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,initiated,0.25754306,of,0.59720325,supervised,0.4324059
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;αs&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,inflammation,0.22370426,cascade,0.4429949,generative-model,0.3706867
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;αs&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,inc,0.2706048,bag,0.52860194,bagging,0.41463643
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;αs&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,implying,0.24500917,of,0.5400089,feed-forward,0.43192574
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;αs&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,identified,0.35725033,analysis,0.56593037,clustering,0.45719695
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;αs&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,hypothesize,0.32929128,of,0.46076187,feed-forward,0.4480695
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;αs&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,growing,0.27809376,of,0.5223601,generative,0.4670505
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;αs&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,found,0.2840244,of,0.6208722,clustering,0.44675255
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;αs&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,fluticasone,0.19584002,short-term,0.32284945,centroid-based,0.2826516
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;αs&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,federation,0.35649908,federated,0.8264686,data-science,0.5365442
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;αs&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,evidence,0.28723752,data,0.5728123,generative,0.3943918
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;αs&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,estradiol,0.16259682,short-term,0.40764993,long-short-term,0.32337362
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;αs&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,collectively,0.4091859,data,0.5741817,generative,0.45478565
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;αs&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,cells,0.20327199,naive,0.5115537,generative,0.40616876
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;αs&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,behalf,0.26374853,adversarial,0.5247171,data-science,0.51911336
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;αs&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,authors,0.45811802,data,0.5259881,natural-language-processing,0.4706872
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;αs&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,analyzed,0.38529366,analysis,0.6994013,component-analysis,0.5263994
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",treated,0.19958335,of,0.5218221,long-short-term,0.35705733
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",septic,0.26922458,recurrent,0.43038785,confusion-matrix,0.3494904
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",rats,0.28034997,naive,0.44411337,long-short-term,0.3748201
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",demonstrated,0.2929331,of,0.6025795,feature-reduction,0.39724052
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",increased,0.26921988,reduction,0.6514183,boosting,0.46515882
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",bacterial,0.29734546,of,0.48457187,feature-reduction,0.40325
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",phagocytosis,0.17920208,cascade,0.39079553,short-term-memory,0.3461818
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",bacterial-phagocytosis,0.2610064,batch,0.406182,feature-reduction,0.40459502
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",investigated,0.30147675,of,0.6179704,generative-model,0.42952073
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",whether,0.32171756,short-term,0.5290759,long-short-term,0.47851244
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",inhibition,0.21671593,reduction,0.58642584,feed-forward,0.44581953
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",prevented,0.17704698,reduction,0.5312941,boosting,0.39043245
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",organ,0.21443385,generative,0.39718252,generative,0.39718252
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",dysfunction,0.3095205,function,0.7029606,learning-function,0.4439212
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",organ-dysfunction,0.3286605,function,0.5775615,learning-function,0.4463088
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",sprague,0.25153637,naive,0.3886536,convolutional-layer,0.2950822
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",dawley,0.23959915,naive,0.3487754,hidden-markov-model,0.26151103
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",rats,0.28034997,naive,0.44411337,long-short-term,0.3748201
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",underwent,0.251209,recurrent,0.4136293,supervised,0.35678548
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",sham,0.23157457,naive,0.39132416,one-hot,0.37237287
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",surgery,0.29565036,recurrent,0.47230634,computer-vision,0.40172684
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",sprague-dawley,0.23685193,naive,0.3557819,long-short-term,0.288027
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",sham-surgery,0.23472127,naive,0.35197037,short-term-memory,0.3333187
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",sprague-dawley-rats,0.2362135,naive,0.3790148,hidden-markov-model,0.31590933
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",inhibition,0.21671593,reduction,0.58642584,feed-forward,0.44581953
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",significantly,0.27887642,of,0.5214151,long-short-term,0.39056638
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",decreased,0.23506472,reduction,0.66483074,boosting,0.42738107
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",bacterial,0.29734546,of,0.48457187,feature-reduction,0.40325
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",levels,0.20457911,normalization,0.52984333,batch-normalization,0.45617118
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",significantly-decreased,0.3262527,reduction,0.5724208,boosting,0.45526758
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",improved,0.40049985,normalization,0.5598826,boosting,0.5069493
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",survival,0.29004025,short-term,0.53135407,long-short-term,0.4573617
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",without,0.31691062,of,0.5951073,long-short-term,0.4268921
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",compromising,0.31690526,boosting,0.53125465,boosting,0.53125465
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",pathogen,0.3132059,adversarial,0.3762204,random-forest,0.3666752
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",clearance,0.2511453,rate,0.48930377,batch-normalization,0.42699638
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",pathogen-clearance,0.37856477,naive,0.45510083,batch-normalization,0.44194594
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",creatinine,0.22273314,batch-normalization,0.44722414,batch-normalization,0.44722414
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",ratios,0.18493193,rate,0.42238456,regression,0.41522446
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",indicating,0.21094829,of,0.63023484,clustering,0.43286642
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",organ,0.21443385,generative,0.39718252,generative,0.39718252
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",protection,0.17893824,boosting,0.48223335,boosting,0.48223335
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",creatinine-ratios,0.28629926,batch-normalization,0.5243508,batch-normalization,0.5243508
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",organ-protection,0.29304785,short-term,0.43796876,feature-reduction,0.43305698
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",inhibition,0.21671593,reduction,0.58642584,feed-forward,0.44581953
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",decreased,0.23506472,reduction,0.66483074,boosting,0.42738107
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",leukocyte,0.22115351,short-term-memory,0.3313641,short-term-memory,0.3313641
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",influx,0.1443982,rectified,0.41958812,gradient-descent,0.39949864
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",inhibition,0.21671593,reduction,0.58642584,feed-forward,0.44581953
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",increased,0.26921988,reduction,0.6514183,boosting,0.46515882
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",survival,0.29004025,short-term,0.53135407,long-short-term,0.4573617
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",inhibition-increased,0.323591,reduction,0.61111224,feed-forward,0.52319574
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",inhibition,0.21671593,reduction,0.58642584,feed-forward,0.44581953
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",improved,0.40049985,normalization,0.5598826,boosting,0.5069493
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",survival,0.29004025,short-term,0.53135407,long-short-term,0.4573617
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",identified,0.35725033,analysis,0.56593037,clustering,0.45719695
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",protein,0.31929362,encoding,0.5525089,clustering,0.36023882
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",kinase,0.22244422,cascade,0.49403343,feed-forward,0.34344023
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",c,0.17513797,of,0.44327667,gradient,0.31114018
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",identified-protein,0.4894181,component-analysis,0.5510871,component-analysis,0.5510871
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",protein-kinase,0.2713312,cascade,0.5171006,feed-forward,0.4069047
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",kinase-c,0.18159854,cascade,0.48900288,feed-forward,0.3500339
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",protein-kinase-c,0.23630346,cascade,0.51803714,feed-forward,0.38995177
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",exhibit,0.2387421,feature,0.5315919,feature-selection,0.41055703
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",direct,0.22395119,of,0.5187454,one-shot,0.4431845
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",bactericidal,0.21165287,boosting,0.35754398,boosting,0.35754398
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",properties,0.31064022,function,0.5521828,feature-engineering,0.53029627
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",reduced,0.24137571,reduction,0.7564339,boosting,0.47559226
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",blood,0.16939776,normalization,0.4272251,batch-normalization,0.40715772
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",urea,0.2245125,batch-normalization,0.3623508,batch-normalization,0.3623508
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",nitrogen,0.25959074,forest,0.46643505,feature-reduction,0.3711414
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",reduced-blood,0.2947647,batch-normalization,0.51658714,batch-normalization,0.51658714
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",blood-urea,0.2559372,batch-normalization,0.44665098,batch-normalization,0.44665098
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",urea-nitrogen,0.2386516,batch,0.45680302,batch-normalization,0.39665717
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",blood-urea-nitrogen,0.2849993,batch-normalization,0.49116284,batch-normalization,0.49116284
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",decreased,0.23506472,reduction,0.66483074,boosting,0.42738107
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",organ,0.21443385,generative,0.39718252,generative,0.39718252
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",injury,0.262506,shot,0.44338763,data-augmentation,0.37271294
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",enhanced,0.30543873,of,0.59523904,boosting,0.57908714
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",pathogen,0.3132059,adversarial,0.3762204,random-forest,0.3666752
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",clearance,0.2511453,rate,0.48930377,batch-normalization,0.42699638
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",pathogen-clearance,0.37856477,naive,0.45510083,batch-normalization,0.44194594
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",increased,0.26921988,reduction,0.6514183,boosting,0.46515882
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",phagocytic,0.21195877,function,0.38862756,short-term-memory,0.36899737
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",activity,0.21813896,function,0.53536034,boosting,0.38798416
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",phagocytic-activity,0.27404386,of,0.43905997,short-term-memory,0.4319155
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",decreased,0.23506472,reduction,0.66483074,boosting,0.42738107
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",endothelial,0.2463533,neural,0.46855402,confusion-matrix,0.34260106
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",permeability,0.20990811,matrix,0.4571835,gradient-descent,0.43536943
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",peritoneal,0.24916586,bag,0.39251524,short-term-memory,0.29212427
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",chemokine,0.3295874,naive,0.42602146,centroid-based,0.3669982
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",levels,0.20457911,normalization,0.52984333,batch-normalization,0.45617118
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",improved,0.40049985,normalization,0.5598826,boosting,0.5069493
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",gas,0.25405633,bag,0.47285086,bagging,0.43151924
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",exchange,0.28460225,gradient-descent,0.52362746,gradient-descent,0.52362746
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",gas-exchange,0.31081975,gradient-descent,0.45056677,gradient-descent,0.45056677
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",intensive,0.3777817,unit,0.63598263,supervised,0.5086147
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",care,0.3144728,decision,0.58130515,data-science,0.46943653
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",units,0.22430237,unit,0.8786867,graphics-processing-unit,0.4210918
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",intensive-care,0.3613196,unit,0.6286151,supervised,0.43243152
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",care-units,0.28602797,unit,0.62475854,graphics-processing-unit,0.49246418
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",intensive-care-units,0.335075,unit,0.6964505,graphics-processing-unit,0.47762764
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",effectively,0.35745823,fully,0.574593,boosting,0.5027187
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",clear,0.30853382,few,0.5001253,bagging,0.4400993
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",pathogens,0.322322,natural,0.41354448,vector-machine,0.3437519
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",peritoneal,0.24916586,bag,0.39251524,short-term-memory,0.29212427
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",macrophages,0.20754936,naive,0.47024828,short-term-memory,0.3296041
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",isolated,0.24300994,of,0.4970751,gradient,0.40058494
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",peritoneal-macrophages,0.28076968,naive,0.42985582,short-term-memory,0.36775
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",inhibition,0.21671593,reduction,0.58642584,feed-forward,0.44581953
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",hours,0.2621256,short-term,0.4799012,supervised,0.38109756
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",post,0.27536392,confusion,0.47820356,bagging,0.44161102
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",hours-post,0.20851612,bag,0.47823077,bagging,0.33611226
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",improved,0.40049985,normalization,0.5598826,boosting,0.5069493
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",survival,0.29004025,short-term,0.53135407,long-short-term,0.4573617
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",kidney,0.15772529,function,0.35472965,batch-normalization,0.2715908
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",dysfunction,0.3095205,function,0.7029606,learning-function,0.4439212
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",inhibitor,0.21582735,cascade,0.38918662,feed-forward,0.33560163
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",peritoneal,0.24916586,bag,0.39251524,short-term-memory,0.29212427
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",cavity,0.20254618,connected,0.45241565,fully-connected,0.3449077
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",peritoneal-cavity,0.2929662,recurrent-neural-network,0.4608704,recurrent-neural-network,0.4608704
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",neutrophil,0.2407179,function,0.3882391,confusion-matrix,0.32218683
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",numbers,0.23955646,few,0.55194294,clustering,0.41978127
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",macrophage,0.22891665,matrix,0.43859345,clustering,0.35980862
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",phenotypes,0.3480116,feature-selection,0.513654,feature-selection,0.513654
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",leading,0.2514689,of,0.59935343,generative,0.44480726
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",cause,0.19388393,of,0.47843847,confusion-matrix,0.34079778
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",leading-cause,0.3739639,stochastic,0.5363524,stochastic,0.5363524
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",inflammatory,0.19824001,cascade,0.43951106,generative-model,0.38795525
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",therapeutics,0.38968325,engineering,0.58271843,data-engineering,0.5621258
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",inflammatory,0.19824001,cascade,0.43951106,generative-model,0.38795525
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",response,0.2143969,of,0.52661085,boosting,0.48192608
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",inflammatory-response,0.26846367,feed-forward,0.48129588,feed-forward,0.48129588
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",important,0.33620566,principal,0.5803634,feature-engineering,0.43471682
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",regulator,0.23058486,encoding,0.51183397,feed-forward,0.49325994
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",important,0.33620566,principal,0.5803634,feature-engineering,0.43471682
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",issue,0.34996036,science,0.61746436,data-science,0.562366
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",experimental,0.40167695,model,0.6248311,generative-model,0.6004326
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",biology,0.47010514,science,0.6525451,data-engineering,0.59721386
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",cecal,0.1731069,feed,0.4121825,batch-normalization,0.27947402
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",ligation,0.24698628,reduction,0.39172673,data-augmentation,0.35466552
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",cecal-ligation,0.25884807,one-shot,0.40489122,one-shot,0.40489122
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",american,0.31403136,federated,0.55841243,classification,0.43444416
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",societies,0.34185767,federated,0.6009963,data-science,0.5610749
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",administered,0.23933353,of,0.47672778,boosting,0.39902678
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",intra,0.23755433,confusion,0.43422022,one-shot,0.40337598
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",surgery,0.29565036,recurrent,0.47230634,computer-vision,0.40172684
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",induce,0.22574255,boosting,0.40946308,boosting,0.40946308
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",sepsis,0.28130865,confusion,0.45988008,transfer-learning,0.34212393
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",blood,0.16939776,normalization,0.4272251,batch-normalization,0.40715772
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",post,0.27536392,confusion,0.47820356,bagging,0.44161102
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",sepsis,0.28130865,confusion,0.45988008,transfer-learning,0.34212393
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",tracheally,0.20579135,bagging,0.42187107,bagging,0.42187107
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",thus,0.33923393,of,0.6779618,feature-reduction,0.46172875
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",study,0.3645851,of,0.5728763,statistical,0.44204497
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",spleen,0.15438233,naive,0.41053015,short-term-memory,0.29665512
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",risk,0.35860935,recurrent,0.53675485,logistic-regression,0.52381086
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",puncture,0.26032788,shot,0.45705152,one-shot,0.35058588
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",previously,0.31365848,fully,0.5461891,long-short-term,0.40718085
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",pbs,0.19465274,batch,0.38583666,embeddings,0.3825985
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",organs,0.19986373,generative,0.42325887,generative,0.42325887
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",mortality,0.2609817,short-term,0.505676,logistic-regression,0.49414968
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",morbidity,0.27463242,recurrent,0.47132403,logistic-regression,0.42021167
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",lung,0.26692057,of,0.3928769,bagging,0.36409828
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",kg,0.22938892,feed,0.46034813,supervised,0.30701393
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",inability,0.2910858,fully,0.5528337,generative,0.41253537
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",importantly,0.38281065,of,0.5300726,boosting,0.5242192
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",immunosuppression,0.25566524,naive,0.47609055,boosting,0.41701895
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",evidence,0.28723752,data,0.5728123,generative,0.3943918
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",development,0.34732813,generative,0.56588423,generative,0.56588423
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",delta,0.17982754,of,0.41157973,gradient,0.38602042
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",clp,0.25082213,nlp,0.35997438,nlp,0.35997438
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",associated,0.30827495,of,0.57598466,long-short-term,0.46578532
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",anti,0.114482366,of,0.3963322,boosting,0.31662655
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",altered,0.28369883,of,0.5963239,generative,0.4193554
Innovations in pharmacological treatment of heart failure.,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
Innovations in pharmacological treatment of heart failure.,new,0.43019778,of,0.526482,feature-reduction,0.4579819
Innovations in pharmacological treatment of heart failure.,promising,0.40802234,feature-engineering,0.526417,feature-engineering,0.526417
Innovations in pharmacological treatment of heart failure.,groups,0.2727722,statistical,0.4438421,statistical,0.4438421
Innovations in pharmacological treatment of heart failure.,maximal,0.22847678,reduction,0.52277833,gradient,0.43409497
Innovations in pharmacological treatment of heart failure.,tolerated,0.25347155,feed,0.5176098,bagging,0.39464796
Innovations in pharmacological treatment of heart failure.,doses,0.1979529,of,0.43779314,boosting,0.42837995
Innovations in pharmacological treatment of heart failure.,maximal-tolerated,0.35406125,short-term,0.5052537,long-short-term,0.46495754
Innovations in pharmacological treatment of heart failure.,hughe,0.20838983,pytorch,0.43754953,pytorch,0.43754953
Innovations in pharmacological treatment of heart failure.,clinical,0.44080526,data,0.48532635,data-science,0.45343333
Innovations in pharmacological treatment of heart failure.,research,0.45694843,science,0.7194936,data-science,0.70924157
Innovations in pharmacological treatment of heart failure.,clinical-research,0.54976255,data-science,0.66737247,data-science,0.66737247
Innovations in pharmacological treatment of heart failure.,renin,0.22382896,normalization,0.36536643,batch-normalization,0.34999466
Innovations in pharmacological treatment of heart failure.,angiotensin,0.21236175,matrix,0.35242182,feed-forward,0.31253523
Innovations in pharmacological treatment of heart failure.,blockade,0.21235548,augmentation,0.46567166,data-augmentation,0.39568862
Innovations in pharmacological treatment of heart failure.,renin-angiotensin,0.27292138,cascade,0.42898363,feed-forward,0.3950637
Innovations in pharmacological treatment of heart failure.,angiotensin,0.21236175,matrix,0.35242182,feed-forward,0.31253523
Innovations in pharmacological treatment of heart failure.,receptor,0.22411162,function,0.41526195,clustering,0.36801085
Innovations in pharmacological treatment of heart failure.,blockers,0.19200467,augmentation,0.36206824,long-short-term,0.31719163
Innovations in pharmacological treatment of heart failure.,angiotensin-receptor,0.24978769,matrix,0.3305658,confusion-matrix,0.30484858
Innovations in pharmacological treatment of heart failure.,receptor-blockers,0.22819279,short-term,0.3749142,regression,0.3211386
Innovations in pharmacological treatment of heart failure.,angiotensin-receptor-blockers,0.217114,short-term,0.34574157,dropout,0.30021757
Innovations in pharmacological treatment of heart failure.,others,0.3625402,one,0.56551903,generative,0.4840395
Innovations in pharmacological treatment of heart failure.,perspective,0.47613347,data-science,0.6021619,data-science,0.6021619
Innovations in pharmacological treatment of heart failure.,drugs,0.30897486,of,0.42460242,classifiers,0.33720028
Innovations in pharmacological treatment of heart failure.,others-perspective,0.5306156,adversarial,0.6706365,artificial-intelligence,0.6475667
Innovations in pharmacological treatment of heart failure.,ace,0.248684,of,0.40128243,confusion-matrix,0.3224533
Innovations in pharmacological treatment of heart failure.,inhibitors,0.25381407,cascade,0.4157439,feed-forward,0.3175553
Innovations in pharmacological treatment of heart failure.,intolerance,0.25522983,confusion,0.4841318,long-short-term,0.41444677
Innovations in pharmacological treatment of heart failure.,ace-inhibitors,0.2874528,function,0.3418663,classification-algorithm,0.31999552
Innovations in pharmacological treatment of heart failure.,heart,0.28300244,rate,0.49867767,batch-normalization,0.3427502
Innovations in pharmacological treatment of heart failure.,failure,0.32964212,recurrent,0.52057266,confusion-matrix,0.44323406
Innovations in pharmacological treatment of heart failure.,treatment,0.239264,short-term,0.5206091,long-short-term,0.41699445
Innovations in pharmacological treatment of heart failure.,heart-failure,0.36450487,long-short-term,0.44014218,long-short-term,0.44014218
Innovations in pharmacological treatment of heart failure.,angiotensin,0.21236175,matrix,0.35242182,feed-forward,0.31253523
Innovations in pharmacological treatment of heart failure.,receptor,0.22411162,function,0.41526195,clustering,0.36801085
Innovations in pharmacological treatment of heart failure.,angiotensin-receptor,0.24978769,matrix,0.3305658,confusion-matrix,0.30484858
Innovations in pharmacological treatment of heart failure.,heart,0.28300244,rate,0.49867767,batch-normalization,0.3427502
Innovations in pharmacological treatment of heart failure.,failure,0.32964212,recurrent,0.52057266,confusion-matrix,0.44323406
Innovations in pharmacological treatment of heart failure.,heart-failure,0.36450487,long-short-term,0.44014218,long-short-term,0.44014218
Innovations in pharmacological treatment of heart failure.,ace,0.248684,of,0.40128243,confusion-matrix,0.3224533
Innovations in pharmacological treatment of heart failure.,inhibitors,0.25381407,cascade,0.4157439,feed-forward,0.3175553
Innovations in pharmacological treatment of heart failure.,ace-inhibitors,0.2874528,function,0.3418663,classification-algorithm,0.31999552
Innovations in pharmacological treatment of heart failure.,l,0.15310754,of,0.37313756,bagging,0.32610148
Innovations in pharmacological treatment of heart failure.,j,0.12432591,science,0.31094742,cross-entropy,0.2885616
Innovations in pharmacological treatment of heart failure.,j,0.12432591,science,0.31094742,cross-entropy,0.2885616
Innovations in pharmacological treatment of heart failure.,symptoms,0.2751398,confusion,0.5089627,dropout,0.40571758
Innovations in pharmacological treatment of heart failure.,relieve,0.21853283,augmentation,0.41163537,relu,0.3713798
Innovations in pharmacological treatment of heart failure.,pharmacological,0.32013503,of,0.48491696,learning-function,0.4119643
Innovations in pharmacological treatment of heart failure.,treatment,0.239264,short-term,0.5206091,long-short-term,0.41699445
Innovations in pharmacological treatment of heart failure.,pharmacological-treatment,0.412372,short-term,0.5782494,dimensionality-reduction,0.5361156
Innovations in pharmacological treatment of heart failure.,omecamtiv,0.3091279,scikit-learn,0.35311747,scikit-learn,0.35311747
Innovations in pharmacological treatment of heart failure.,mecarbil,0.26618668,multi-class,0.31291828,softmax,0.30077147
Innovations in pharmacological treatment of heart failure.,omecamtiv-mecarbil,0.3081746,scikit-learn,0.32972378,scikit-learn,0.32972378
Innovations in pharmacological treatment of heart failure.,neprilysin,0.32175615,matrix,0.42883646,graphics-processing,0.36731273
Innovations in pharmacological treatment of heart failure.,inhibitor,0.21582735,cascade,0.38918662,feed-forward,0.33560163
Innovations in pharmacological treatment of heart failure.,neprilysin-inhibitor,0.3160151,matrix,0.43492448,graphics-processing,0.35951847
Innovations in pharmacological treatment of heart failure.,main,0.3070703,principal,0.7875631,principal-components,0.51314574
Innovations in pharmacological treatment of heart failure.,goal,0.39629012,feed,0.4949946,reinforcement-learning,0.43070507
Innovations in pharmacological treatment of heart failure.,hf,0.293398,long-short-term,0.35116297,long-short-term,0.35116297
Innovations in pharmacological treatment of heart failure.,trial,0.31537512,short-term,0.4622394,supervised,0.43136692
Innovations in pharmacological treatment of heart failure.,hf-trial,0.3693351,reinforcement-learning,0.57908463,reinforcement-learning,0.57908463
Innovations in pharmacological treatment of heart failure.,glucose,0.22612295,batch-normalization,0.39605165,batch-normalization,0.39605165
Innovations in pharmacological treatment of heart failure.,co,0.23682216,ground,0.42757797,feature-reduction,0.3969199
Innovations in pharmacological treatment of heart failure.,especially,0.32290015,of,0.63661283,long-short-term,0.46837103
Innovations in pharmacological treatment of heart failure.,improvement,0.39264548,reduction,0.6142903,feature-reduction,0.5138227
Innovations in pharmacological treatment of heart failure.,diabetes,0.29301462,logistic-regression,0.35688502,logistic-regression,0.35688502
Innovations in pharmacological treatment of heart failure.,mellitus,0.26868707,logistic,0.37140065,logistic-regression,0.36157686
Innovations in pharmacological treatment of heart failure.,diabetes-mellitus,0.22767697,logistic-regression,0.32544836,logistic-regression,0.32544836
Innovations in pharmacological treatment of heart failure.,selected,0.38157707,selection,0.6797303,feature-selection,0.48698312
Innovations in pharmacological treatment of heart failure.,patients,0.30007,recurrent,0.5332828,dropout,0.3918751
Innovations in pharmacological treatment of heart failure.,acei,0.26178795,feed,0.37105787,dropout,0.3253736
Innovations in pharmacological treatment of heart failure.,according,0.3602386,classification,0.6492659,classification,0.6492659
Innovations in pharmacological treatment of heart failure.,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
Innovations in pharmacological treatment of heart failure.,treatment,0.239264,short-term,0.5206091,long-short-term,0.41699445
Innovations in pharmacological treatment of heart failure.,inhibitors,0.25381407,cascade,0.4157439,feed-forward,0.3175553
Innovations in pharmacological treatment of heart failure.,drugs,0.30897486,of,0.42460242,classifiers,0.33720028
Innovations in pharmacological treatment of heart failure.,patients,0.30007,recurrent,0.5332828,dropout,0.3918751
Innovations in pharmacological treatment of heart failure.,acei,0.26178795,feed,0.37105787,dropout,0.3253736
Innovations in pharmacological treatment of heart failure.,valsartan,0.23053317,softmax,0.32515165,softmax,0.32515165
Innovations in pharmacological treatment of heart failure.,transporter,0.24504307,encoding,0.4868907,gradient-descent,0.3382712
Innovations in pharmacological treatment of heart failure.,sodium,0.16956227,rectified,0.40903348,gradient,0.39663744
Innovations in pharmacological treatment of heart failure.,sacubitril,0.2503674,softmax,0.29302943,softmax,0.29302943
Innovations in pharmacological treatment of heart failure.,results,0.32376552,data,0.6932311,batch-normalization,0.44826904
Innovations in pharmacological treatment of heart failure.,replace,0.33409733,fully,0.48599258,feature-engineering,0.40217453
Innovations in pharmacological treatment of heart failure.,quality,0.37286326,dimensionality-reduction,0.49494588,dimensionality-reduction,0.49494588
Innovations in pharmacological treatment of heart failure.,pmid,0.17205057,science,0.31445533,bag-of-words,0.26444918
Innovations in pharmacological treatment of heart failure.,paradigm,0.5094469,reinforcement-learning,0.5952247,reinforcement-learning,0.5952247
Innovations in pharmacological treatment of heart failure.,oedema,0.22938383,recurrent,0.41375312,confusion-matrix,0.34329262
Innovations in pharmacological treatment of heart failure.,mra,0.302826,segmentation,0.4469296,segmentation,0.4469296
Innovations in pharmacological treatment of heart failure.,mortality,0.2609817,short-term,0.505676,logistic-regression,0.49414968
Innovations in pharmacological treatment of heart failure.,morbidity,0.27463242,recurrent,0.47132403,logistic-regression,0.42021167
Innovations in pharmacological treatment of heart failure.,medline,0.44432086,data-science,0.5824888,data-science,0.5824888
Innovations in pharmacological treatment of heart failure.,life,0.3004927,style,0.49334684,long-short-term,0.46358624
Innovations in pharmacological treatment of heart failure.,innovations,0.544312,data-engineering,0.6821101,data-engineering,0.6821101
Innovations in pharmacological treatment of heart failure.,indicated,0.2502363,of,0.5998554,principal-components,0.4305639
Innovations in pharmacological treatment of heart failure.,indexed,0.3858727,semantic,0.49446192,semantic,0.49446192
Innovations in pharmacological treatment of heart failure.,hospitalisations,0.2756348,logistic-regression,0.45729327,logistic-regression,0.45729327
Innovations in pharmacological treatment of heart failure.,given,0.30785376,of,0.54849017,boosting,0.4329715
Innovations in pharmacological treatment of heart failure.,dyspnoe,0.2621243,confusion,0.40760893,confusion-matrix,0.33745217
Innovations in pharmacological treatment of heart failure.,done,0.3374033,bagging,0.49952012,bagging,0.49952012
Innovations in pharmacological treatment of heart failure.,diuretics,0.23099658,confusion,0.36058313,supervised,0.2963397
Innovations in pharmacological treatment of heart failure.,digoxin,0.1970542,rate,0.36538523,batch-normalization,0.32783657
Innovations in pharmacological treatment of heart failure.,decrease,0.23670179,reduction,0.82910776,boosting,0.45522925
Innovations in pharmacological treatment of heart failure.,cornerstone,0.36453068,decision,0.45682034,feature-engineering,0.44295374
Innovations in pharmacological treatment of heart failure.,case,0.3180016,one,0.57942057,confusion-matrix,0.4208076
Innovations in pharmacological treatment of heart failure.,betablockers,0.25067368,confusion,0.4098875,bagging,0.36605984
Innovations in pharmacological treatment of heart failure.,arni,0.2746997,pytorch,0.37769938,pytorch,0.37769938
Innovations in pharmacological treatment of heart failure.,arb,0.25449693,feature-reduction,0.33085245,feature-reduction,0.33085245
Innovations in pharmacological treatment of heart failure.,added,0.32371867,of,0.5926449,batch-normalization,0.4530739
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,proposed,0.55786884,classification-algorithm,0.6311488,classification-algorithm,0.6311488
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,model,0.48485535,model,1.0,markov-model,0.7005576
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,showed,0.20766163,of,0.5296177,regression,0.37027335
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,significant,0.29367286,statistical,0.582669,statistical,0.582669
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,improvement,0.39264548,reduction,0.6142903,feature-reduction,0.5138227
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,proposed-model,0.66141236,markov-model,0.79401195,markov-model,0.79401195
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,significant-improvement,0.46828318,reduction,0.58946306,dimensionality-reduction,0.57268226
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,mmrc,0.31260127,classification-algorithm,0.3874163,classification-algorithm,0.3874163
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,copd,0.2808791,confusion,0.3702452,dropout,0.33500236
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,assessment,0.4002061,analysis,0.5275976,component-analysis,0.49803802
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,test,0.4037762,statistical,0.5031551,statistical,0.5031551
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,copd-assessment,0.46417016,computer-vision,0.51851296,computer-vision,0.51851296
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,assessment-test,0.48515126,intelligence,0.56903607,principal-component-analysis,0.55088335
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,copd-assessment-test,0.49312282,computer-vision,0.54190874,computer-vision,0.54190874
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,modified,0.3452912,feature-reduction,0.4818402,feature-reduction,0.4818402
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,medical,0.37876463,data-science,0.59196365,data-science,0.59196365
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,research,0.45694843,science,0.7194936,data-science,0.70924157
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,council,0.33317888,federated,0.62856495,data-science,0.565513
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,medical-research,0.4856661,data-science,0.7508278,data-science,0.7508278
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,research-council,0.5056758,data-science,0.75955725,data-science,0.75955725
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,chronic,0.22727785,recurrent,0.5279353,long-short-term,0.4292153
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,obstructive,0.29236183,recurrent,0.45574522,confusion-matrix,0.3350963
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,pulmonary,0.27012008,recurrent,0.39649367,long-short-term,0.32169557
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,disease,0.296938,recurrent,0.4731025,classification,0.35271814
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,chronic-obstructive,0.2802394,recurrent,0.50352967,confusion-matrix,0.39456382
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,obstructive-pulmonary,0.31164497,recurrent,0.4760642,recurrent-neural-network,0.42644972
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,pulmonary-disease,0.39629358,logistic-regression,0.42455766,logistic-regression,0.42455766
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,chronic,0.22727785,recurrent,0.5279353,long-short-term,0.4292153
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,obstructive,0.29236183,recurrent,0.45574522,confusion-matrix,0.3350963
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,lung,0.26692057,of,0.3928769,bagging,0.36409828
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,disease,0.296938,recurrent,0.4731025,classification,0.35271814
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,chronic-obstructive,0.2802394,recurrent,0.50352967,confusion-matrix,0.39456382
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,obstructive-lung,0.2990104,confusion-matrix,0.39863968,confusion-matrix,0.39863968
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,lung-disease,0.43316668,support-vector-machine,0.43967578,support-vector-machine,0.43967578
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,incorporates,0.53834164,feature-engineering,0.5993332,feature-engineering,0.5993332
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,previously,0.31365848,fully,0.5461891,long-short-term,0.40718085
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,proposed,0.55786884,classification-algorithm,0.6311488,classification-algorithm,0.6311488
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,parameters,0.38939354,normalization,0.54973936,batch-normalization,0.547323
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,previously-proposed,0.5715951,feature-selection,0.60630167,feature-selection,0.60630167
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,previously,0.31365848,fully,0.5461891,long-short-term,0.40718085
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,reported,0.27641866,of,0.6039252,long-short-term,0.38086164
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,pa,0.19497819,of,0.4099517,long-short-term,0.36123294
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,models,0.53762007,model,0.8940372,markov-model,0.7015921
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,previously-reported,0.35520288,of,0.54962975,feature-reduction,0.4772153
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,top,0.29891562,forward,0.47741628,bagging,0.40812773
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,global,0.4199783,function,0.49309143,dimensionality-reduction,0.48296046
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,causes,0.19757006,of,0.55089116,long-short-term,0.3616379
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,copd,0.2808791,confusion,0.3702452,dropout,0.33500236
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,patients,0.30007,recurrent,0.5332828,dropout,0.3918751
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,within,0.2920679,of,0.57602364,clustering,0.4610753
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,copd-patients,0.32878315,dropout,0.43479308,dropout,0.43479308
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,patients-within,0.38430876,segmentation-algorithm,0.52774274,segmentation-algorithm,0.52774274
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,cat,0.22928731,transfer,0.44282755,support-vector,0.35187167
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,worn,0.30664033,machine,0.5168671,computer-vision,0.4978962
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,wearable,0.53930736,data-engineering,0.6004859,data-engineering,0.6004859
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,devices,0.37494427,data-engineering,0.5315442,data-engineering,0.5315442
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,wearable-devices,0.5386116,artificial-intelligence,0.6357069,artificial-intelligence,0.6357069
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,positive,0.26811236,of,0.49572036,component-analysis,0.37181294
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,prediction,0.6361519,classification-algorithm,0.67946094,classification-algorithm,0.67946094
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,rate,0.24866687,rate,1.0,dropout,0.44953537
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,positive-prediction,0.6166302,classifiers,0.6490401,classifiers,0.6490401
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,prediction-rate,0.5649217,cross-entropy,0.63297474,cross-entropy,0.63297474
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,minute,0.31789744,few,0.49104738,bagging,0.41237196
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,walking,0.40636957,forward,0.509251,object-tracking,0.50271875
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,distance,0.37031242,nearest,0.7198547,nearest-neighbors,0.6041212
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,minute-walking,0.48777494,learning-function,0.5487015,learning-function,0.5487015
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,walking-distance,0.4496845,object-tracking,0.57611835,object-tracking,0.57611835
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,million,0.28250343,federated,0.40785158,data-science,0.3504573
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,lives,0.33908755,vision,0.5003887,supervised,0.43244678
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,copd,0.2808791,confusion,0.3702452,dropout,0.33500236
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,patients,0.30007,recurrent,0.5332828,dropout,0.3918751
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,copd-patients,0.32878315,dropout,0.43479308,dropout,0.43479308
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,readmission,0.31176502,logistic-regression,0.5206301,logistic-regression,0.5206301
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,prediction,0.6361519,classification-algorithm,0.67946094,classification-algorithm,0.67946094
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,criteria,0.4101001,classification-algorithm,0.6435778,classification-algorithm,0.6435778
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,ranked,0.47250757,classifiers,0.5532665,classifiers,0.5532665
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,among,0.33676732,of,0.57348,clustering,0.49404603
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,physicians,0.39576703,decision,0.6153769,data-science,0.51622474
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,predict,0.51602554,model,0.53463185,classification-algorithm,0.52342355
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,day,0.252174,one,0.5237603,supervised,0.401589
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,readmission,0.31176502,logistic-regression,0.5206301,logistic-regression,0.5206301
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,risk,0.35860935,recurrent,0.53675485,logistic-regression,0.52381086
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,day-readmission,0.3925718,logistic-regression,0.53213143,logistic-regression,0.53213143
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,readmission-risk,0.4457845,logistic-regression,0.615977,logistic-regression,0.615977
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,continuous,0.41333556,short-term,0.5995445,long-short-term,0.56591904
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,pa,0.19497819,of,0.4099517,long-short-term,0.36123294
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,monitoring,0.34263974,tracking,0.5622334,batch-normalization,0.44004613
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,pa-monitoring,0.44381326,data-augmentation,0.5164534,data-augmentation,0.5164534
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,existing,0.59232044,machine-learning,0.59232044,machine-learning,0.59232044
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,diagnosis,0.32391536,classification,0.53521544,classification,0.53521544
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,methods,0.50049126,data,0.5400177,machine-learning,0.50049126
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,proposed,0.55786884,classification-algorithm,0.6311488,classification-algorithm,0.6311488
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,model,0.48485535,model,1.0,markov-model,0.7005576
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,proposed-model,0.66141236,markov-model,0.79401195,markov-model,0.79401195
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,copd,0.2808791,confusion,0.3702452,dropout,0.33500236
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,patients,0.30007,recurrent,0.5332828,dropout,0.3918751
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,copd-patients,0.32878315,dropout,0.43479308,dropout,0.43479308
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,test,0.4037762,statistical,0.5031551,statistical,0.5031551
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,subjects,0.34547177,descent,0.47816435,short-term-memory,0.43421033
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,test-subjects,0.4839332,object-tracking,0.54511255,object-tracking,0.54511255
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,clinical,0.44080526,data,0.48532635,data-science,0.45343333
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,assessment,0.4002061,analysis,0.5275976,component-analysis,0.49803802
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,clinical-assessment,0.5153333,classification-algorithm,0.56181896,classification-algorithm,0.56181896
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,qoa,0.2764352,principal-component,0.40373877,principal-component,0.40373877
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,chronic,0.22727785,recurrent,0.5279353,long-short-term,0.4292153
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,diseases,0.31957155,recurrent,0.41244444,classification,0.40266854
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,chronic-diseases,0.37913954,generative-model,0.4821568,generative-model,0.4821568
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,statistical,0.6074636,statistical,1.0,statistical,1.0
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,model,0.48485535,model,1.0,markov-model,0.7005576
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,statistical-model,0.672629,statistical,0.8192668,statistical,0.8192668
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,readmission,0.31176502,logistic-regression,0.5206301,logistic-regression,0.5206301
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,risk,0.35860935,recurrent,0.53675485,logistic-regression,0.52381086
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,readmission-risk,0.4457845,logistic-regression,0.615977,logistic-regression,0.615977
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,global,0.4199783,function,0.49309143,dimensionality-reduction,0.48296046
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,initiative,0.48635054,data-science,0.6267989,data-science,0.6267989
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,especially,0.32290015,of,0.63661283,long-short-term,0.46837103
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,within,0.2920679,of,0.57602364,clustering,0.4610753
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,claimed,0.35122308,of,0.5287969,dimensionality-reduction,0.43041062
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,prevention,0.29446518,recurrent,0.44918782,feature-reduction,0.4041679
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,methods,0.50049126,data,0.5400177,machine-learning,0.50049126
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,potential,0.3558654,of,0.5645705,generative-model,0.46479023
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,readmission,0.31176502,logistic-regression,0.5206301,logistic-regression,0.5206301
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,highest,0.25175208,of,0.5054526,boosting,0.3963222
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,among,0.33676732,of,0.57348,clustering,0.49404603
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,days,0.20857571,short-term,0.53915894,long-short-term,0.4190845
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,new,0.43019778,of,0.526482,feature-reduction,0.4579819
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,parameter,0.45709252,regularization,0.6041261,batch-normalization,0.585888
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,daily,0.3039257,short-term,0.50002974,supervised,0.42771563
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,living,0.30422944,of,0.47259963,generative,0.4134596
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,daily-living,0.40681958,learning-function,0.5415403,learning-function,0.5415403
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,airflow,0.281702,tensorflow,0.42534745,tensorflow,0.42534745
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,obstruction,0.21806201,recurrent,0.5002352,convolutional-layer,0.31055558
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,airflow-obstruction,0.30677462,segmentation-algorithm,0.4072382,segmentation-algorithm,0.4072382
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,adopted,0.5152594,feature-engineering,0.5414686,feature-engineering,0.5414686
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,currently,0.3947763,fully,0.5423527,bagging,0.41457367
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,regularity,0.46697628,regularization,0.7011539,dimensionality-reduction,0.57144207
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,index,0.27978244,function,0.407383,classification-algorithm,0.3994653
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,regularity-index,0.53398705,regularization,0.7520832,cross-entropy,0.7097703
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,mass,0.22818582,fourier-transform,0.42889374,fourier-transform,0.42889374
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,index,0.27978244,function,0.407383,classification-algorithm,0.3994653
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,mass-index,0.2927159,batch-normalization,0.44462848,batch-normalization,0.44462848
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,physical,0.35362238,supervised,0.4900735,supervised,0.4900735
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,activity,0.21813896,function,0.53536034,boosting,0.38798416
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,physical-activity,0.3449481,dimensionality-reduction,0.5422632,dimensionality-reduction,0.5422632
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,based,0.49998575,classification-algorithm,0.5639226,classification-algorithm,0.5639226
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,wrist,0.29544786,object-tracking,0.44297796,object-tracking,0.44297796
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,based,0.49998575,classification-algorithm,0.5639226,classification-algorithm,0.5639226
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,indices,0.35250193,normalization,0.5109062,batch-normalization,0.46939105
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,activity,0.21813896,function,0.53536034,boosting,0.38798416
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,index,0.27978244,function,0.407383,classification-algorithm,0.3994653
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,activity-index,0.43034682,learning-function,0.570632,learning-function,0.570632
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,proposed,0.55786884,classification-algorithm,0.6311488,classification-algorithm,0.6311488
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,hospital,0.2768838,unit,0.588941,data-science,0.39080185
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,discharge,0.22544123,unit,0.49100536,regression,0.34756663
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,hospital-discharge,0.32588977,unit,0.5335343,graphics-processing-unit,0.44286376
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,copd,0.2808791,confusion,0.3702452,dropout,0.33500236
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,pa,0.19497819,of,0.4099517,long-short-term,0.36123294
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,predict,0.51602554,model,0.53463185,classification-algorithm,0.52342355
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,monitoring,0.34263974,tracking,0.5622334,batch-normalization,0.44004613
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,diagnosis,0.32391536,classification,0.53521544,classification,0.53521544
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,index,0.27978244,function,0.407383,classification-algorithm,0.3994653
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,based,0.49998575,classification-algorithm,0.5639226,classification-algorithm,0.5639226
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,activity,0.21813896,function,0.53536034,boosting,0.38798416
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,hospital,0.2768838,unit,0.588941,data-science,0.39080185
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,discharge,0.22544123,unit,0.49100536,regression,0.34756663
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,days,0.20857571,short-term,0.53915894,long-short-term,0.4190845
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,sensitivity,0.28808302,discriminative,0.5372434,cross-validation,0.48943394
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,ri,0.17384462,unit,0.37720853,tf-idf,0.31144303
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,quality,0.37286326,dimensionality-reduction,0.49494588,dimensionality-reduction,0.49494588
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,predicting,0.521454,classification-algorithm,0.5589481,classification-algorithm,0.5589481
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,paper,0.5017176,graphics-processing,0.53198814,graphics-processing,0.53198814
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,moreover,0.34991172,of,0.5596781,boosting,0.44273305
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,introduced,0.43058684,selection,0.545887,feature-engineering,0.50600016
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,gold,0.2888363,feature-reduction,0.43484348,feature-reduction,0.43484348
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,found,0.2840244,of,0.6208722,clustering,0.44675255
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,exercise,0.35312283,supervised,0.5316645,supervised,0.5316645
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,dyspnea,0.30184653,confusion,0.53941786,confusion-matrix,0.38180247
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,discharged,0.23186152,unit,0.5050843,supervised,0.4057806
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,diagnosed,0.29304254,recurrent,0.56110895,classification,0.43035528
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,death,0.21479979,of,0.42234862,dropout,0.37818787
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,data,0.46434748,data,1.0,data-science,0.5533528
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,compared,0.3359061,of,0.52794564,long-short-term,0.42386633
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,collected,0.33035916,data,0.5686942,ground-truth,0.3838368
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,body,0.2149021,of,0.4173455,segmentation,0.3712382
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,bode,0.34274536,classification-algorithm,0.44478664,classification-algorithm,0.44478664
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,ai,0.25513044,artificial-intelligence,0.38274616,artificial-intelligence,0.38274616
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,accelerometer,0.44026852,ground-truth,0.5255096,ground-truth,0.5255096
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,bone,0.24049082,augmentation,0.44196048,data-augmentation,0.38111493
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,marrow,0.2263469,naive,0.3763482,short-term-memory,0.33506393
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,hematopoietic,0.2552904,neural,0.4308925,generative,0.38678306
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,stem,0.2836631,neural,0.48491934,generative,0.47532985
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,cell,0.2212203,of,0.48460138,generative,0.39753264
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,bone-marrow,0.22830209,naive,0.3708741,short-term-memory,0.36834836
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,marrow-hematopoietic,0.25416437,naive,0.42422697,feature-engineering,0.3898954
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,hematopoietic-stem,0.26591018,feature-engineering,0.43072966,feature-engineering,0.43072966
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,stem-cell,0.30539137,neural,0.44801706,generative,0.44345847
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,hematopoietic-stem-cell,0.2893582,neural,0.4609026,feature-engineering,0.45494056
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,+/,0.15578422,naive,0.35220098,naive-bayes,0.26817176
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,associated,0.30827495,of,0.57598466,long-short-term,0.46578532
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,exhibited,0.18898472,of,0.49406686,feature-reduction,0.35593373
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,decreased,0.23506472,reduction,0.66483074,boosting,0.42738107
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,splenic,0.18742537,naive,0.4180041,short-term-memory,0.33421248
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,expansion,0.25787348,selection,0.48671806,generative,0.44413468
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,hsc,0.24524164,naive,0.38988614,long-short-term-memory,0.3747522
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,derived,0.3584563,of,0.54769456,generative,0.5265686
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,mo,0.2106132,term,0.4270478,supervised,0.36016458
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,mice,0.24457785,naive,0.4783403,short-term-memory,0.38200378
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,exhibited,0.18898472,of,0.49406686,feature-reduction,0.35593373
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,increased,0.26921988,reduction,0.6514183,boosting,0.46515882
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,mrna,0.25853646,encoding,0.5590567,batch-normalization,0.35810667
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,mice-exhibited,0.23899068,of,0.45937416,long-short-term-memory,0.45623982
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,inflammatory,0.19824001,cascade,0.43951106,generative-model,0.38795525
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,cytokine,0.2723416,naive,0.4601665,boosting,0.3907313
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,gene,0.32125705,encoding,0.7317275,clustering,0.4378482
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,expression,0.32038707,encoding,0.59633577,clustering,0.442253
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,inflammatory-cytokine,0.3016314,cascade,0.46641478,generative-model,0.44616213
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,cytokine-gene,0.39983827,feed-forward,0.46490604,feed-forward,0.46490604
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,gene-expression,0.5495992,classifiers,0.5527793,classifiers,0.5527793
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,yolk,0.08751954,layer,0.3720411,kernel,0.29938096
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,sac,0.104616426,of,0.4134333,segmentation,0.36827052
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,origin,0.2085904,of,0.56003475,generative,0.46984538
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,drive,0.36829585,feed-forward,0.5426709,feed-forward,0.5426709
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,yolk-sac,0.072647214,layer,0.32510364,pytorch,0.3048718
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,sac-origin,0.2041862,of,0.46968502,feature-selection,0.43933973
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,flow,0.2860778,gradient,0.52486,gradient,0.52486
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,cytometry,0.35215917,analysis,0.47600478,fourier-transform,0.40641344
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,studies,0.30135098,data,0.6349237,component-analysis,0.41327482
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,showed,0.20766163,of,0.5296177,regression,0.37027335
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,flow-cytometry,0.34293124,analysis,0.48240748,stochastic-gradient,0.40600675
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,+/,0.15578422,naive,0.35220098,naive-bayes,0.26817176
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,dependent,0.2523393,of,0.585135,generative,0.43066898
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,transcription,0.30657786,encoding,0.5651444,feed-forward,0.5005915
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,factors,0.3420733,components,0.5413606,logistic-regression,0.48293567
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,involved,0.26651675,of,0.5396308,feed-forward,0.42281044
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,dependent-transcription,0.42320412,encoding,0.56527376,feed-forward,0.56267047
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,transcription-factors,0.4309857,feed-forward,0.5481831,feed-forward,0.5481831
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,factors-involved,0.29520696,cascade,0.49305946,dimensionality-reduction,0.4435308
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,transcriptional,0.33864313,encoding,0.5598241,feed-forward,0.5453118
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,activity,0.21813896,function,0.53536034,boosting,0.38798416
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,focal,0.29132447,recurrent,0.4761212,confusion-matrix,0.44756415
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,adhesion,0.20361927,matrix,0.48585403,clustering,0.4169678
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,kinase,0.22244422,cascade,0.49403343,feed-forward,0.34344023
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,focal-adhesion,0.3020957,recurrent-neural-network,0.5439156,recurrent-neural-network,0.5439156
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,adhesion-kinase,0.25660276,cascade,0.46106654,recurrent-neural-network,0.41191554
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,focal-adhesion-kinase,0.3211078,recurrent-neural-network,0.5259124,recurrent-neural-network,0.5259124
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,downstream,0.2769811,cascade,0.61652684,feed-forward,0.4971591
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,transcription,0.30657786,encoding,0.5651444,feed-forward,0.5005915
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,factors,0.3420733,components,0.5413606,logistic-regression,0.48293567
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,transcription-factors,0.4309857,feed-forward,0.5481831,feed-forward,0.5481831
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,tissue,0.23679586,of,0.5202017,segmentation,0.4076932
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,inflammatory,0.19824001,cascade,0.43951106,generative-model,0.38795525
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,response,0.2143969,of,0.52661085,boosting,0.48192608
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,tissue-inflammatory,0.22874758,matrix,0.43746197,generative-model,0.41980624
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,inflammatory-response,0.26846367,feed-forward,0.48129588,feed-forward,0.48129588
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,arg,0.22821459,encoding,0.35638654,n-gram,0.32234237
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,days,0.20857571,short-term,0.53915894,long-short-term,0.4190845
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,post,0.27536392,confusion,0.47820356,bagging,0.44161102
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,days-post,0.21841627,short-term,0.41982922,long-short-term,0.35639867
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,fak,0.24206558,cascade,0.42333496,feed-forward,0.36818916
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,inhibitor,0.21582735,cascade,0.38918662,feed-forward,0.33560163
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,abrogated,0.16502383,reduction,0.41756195,boosting,0.38774067
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,fak-inhibitor,0.2707175,cascade,0.41896042,feed-forward,0.4135766
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,inhibitor-abrogated,0.24383569,cascade,0.4350734,feed-forward,0.36960527
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,cultured,0.20622738,of,0.47075057,gradient-descent,0.34973246
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,confirmed,0.25544786,of,0.58156097,component-analysis,0.390182
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,proinflammatory,0.23746534,cascade,0.45714468,feed-forward,0.37248206
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,cytokines,0.25923875,naive,0.44550404,boosting,0.37505668
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,response,0.2143969,of,0.52661085,boosting,0.48192608
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,proinflammatory-cytokines,0.31040218,cascade,0.46992368,generative-model,0.42759305
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,causes,0.19757006,of,0.55089116,long-short-term,0.3616379
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,chagas,0.31366038,pytorch,0.3762825,pytorch,0.3762825
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,disease,0.296938,recurrent,0.4731025,classification,0.35271814
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,infected,0.19365644,naive,0.53080636,boosting,0.33861458
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,mice,0.24457785,naive,0.4783403,short-term-memory,0.38200378
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,treated,0.19958335,of,0.5218221,long-short-term,0.35705733
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,infected-mice,0.23909745,naive,0.5644298,logistic-regression,0.3626362
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,mice-treated,0.1928398,naive,0.5162598,short-term-memory,0.34893352
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,chronically,0.17246503,naive,0.54145,long-short-term,0.42928272
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,infected,0.19365644,naive,0.53080636,boosting,0.33861458
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,mice,0.24457785,naive,0.4783403,short-term-memory,0.38200378
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,chronically-infected,0.25076678,naive,0.644981,long-short-term,0.38464624
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,infected-mice,0.23909745,naive,0.5644298,logistic-regression,0.3626362
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,transcription,0.30657786,encoding,0.5651444,feed-forward,0.5005915
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,factors,0.3420733,components,0.5413606,logistic-regression,0.48293567
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,transcription-factors,0.4309857,feed-forward,0.5481831,feed-forward,0.5481831
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,derived,0.3584563,of,0.54769456,generative,0.5265686
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,infected,0.19365644,naive,0.53080636,boosting,0.33861458
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,mice,0.24457785,naive,0.4783403,short-term-memory,0.38200378
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,infected-mice,0.23909745,naive,0.5644298,logistic-regression,0.3626362
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,inflammatory,0.19824001,cascade,0.43951106,generative-model,0.38795525
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,phenotype,0.28173286,feature,0.51151407,feature-selection,0.4975547
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,inflammatory,0.19824001,cascade,0.43951106,generative-model,0.38795525
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,pathology,0.34800982,of,0.4805,generative-model,0.43246388
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,dependent,0.2523393,of,0.585135,generative,0.43066898
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,increase,0.28092995,reduction,0.7624404,boosting,0.49543357
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,mice,0.24457785,naive,0.4783403,short-term-memory,0.38200378
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,response,0.2143969,of,0.52661085,boosting,0.48192608
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,chagas,0.31366038,pytorch,0.3762825,pytorch,0.3762825
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,mice,0.24457785,naive,0.4783403,short-term-memory,0.38200378
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,chagas,0.31366038,pytorch,0.3762825,pytorch,0.3762825
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,disease,0.296938,recurrent,0.4731025,classification,0.35271814
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,splenic,0.18742537,naive,0.4180041,short-term-memory,0.33421248
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,mo,0.2106132,term,0.4270478,supervised,0.36016458
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,surface,0.25082165,layer,0.63621426,clustering,0.4342317
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,expression,0.32038707,encoding,0.59633577,clustering,0.442253
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,surface-expression,0.41333723,encoding,0.5835414,clustering,0.5452006
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,involved,0.26651675,of,0.5396308,feed-forward,0.42281044
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,proinflammatory,0.23746534,cascade,0.45714468,feed-forward,0.37248206
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,mo,0.2106132,term,0.4270478,supervised,0.36016458
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,splenic,0.18742537,naive,0.4180041,short-term-memory,0.33421248
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,compartment,0.2676084,components,0.484317,gradient-descent,0.4457453
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,splenic,0.18742537,naive,0.4180041,short-term-memory,0.33421248
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,infected,0.19365644,naive,0.53080636,boosting,0.33861458
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,trypanosoma,0.27160162,random-forest,0.36912715,random-forest,0.36912715
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,cruzi,0.25767118,pytorch,0.34306636,pytorch,0.34306636
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,trypanosoma-cruzi,0.32827088,random-forest,0.38619387,random-forest,0.38619387
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,sinusoidal,0.2745579,gradient-descent,0.4716065,gradient-descent,0.4716065
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,compartment,0.2676084,components,0.484317,gradient-descent,0.4457453
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,regulatory,0.31905767,feed-forward,0.5235218,feed-forward,0.5235218
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,role,0.2562992,function,0.5340955,feed-forward,0.4137928
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,proinflammatory,0.23746534,cascade,0.45714468,feed-forward,0.37248206
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,phenotype,0.28173286,feature,0.51151407,feature-selection,0.4975547
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,proinflammatory,0.23746534,cascade,0.45714468,feed-forward,0.37248206
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,activation,0.23066127,cascade,0.649269,feed-forward,0.4652444
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,progenitor,0.30548066,neural,0.53428423,generative,0.4894472
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,lineage,0.30294886,generative,0.48872057,generative,0.48872057
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,pathogen,0.3132059,adversarial,0.3762204,random-forest,0.3666752
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,stimulus,0.34569976,object,0.5666635,object-tracking,0.54008806
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,proliferation,0.24054871,neural,0.4592081,regression,0.38529342
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,contributing,0.33847752,of,0.63864183,clustering,0.4658355
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,myocardial,0.25335935,normalization,0.40452614,batch-normalization,0.38271224
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,infiltration,0.24753922,layer,0.43824458,clustering,0.37248868
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,latin,0.36570612,federated,0.52475035,natural-language,0.49884292
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,america,0.3043542,federated,0.5448096,random-forest,0.46004367
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,latin-america,0.3611325,federated,0.5091755,natural-language,0.49868238
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,inherent,0.44092533,dimensionality,0.62533414,feature-engineering,0.60894036
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,capability,0.44582635,feature-engineering,0.52373827,feature-engineering,0.52373827
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,infection,0.22309746,recurrent,0.4494667,boosting,0.3635876
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,heart,0.28300244,rate,0.49867767,batch-normalization,0.3427502
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,failure,0.32964212,recurrent,0.52057266,confusion-matrix,0.44323406
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,heart-failure,0.36450487,long-short-term,0.44014218,long-short-term,0.44014218
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,functional,0.3902081,function,0.728652,learning-function,0.5807885
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,activation,0.23066127,cascade,0.649269,feed-forward,0.4652444
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,frequent,0.27499682,recurrent,0.57372284,long-short-term,0.44767243
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,cause,0.19388393,of,0.47843847,confusion-matrix,0.34079778
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,chronic,0.22727785,recurrent,0.5279353,long-short-term,0.4292153
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,phase,0.23814097,hidden-layer,0.45645207,hidden-layer,0.45645207
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,chronic-phase,0.28850454,naive,0.4678502,short-term-memory,0.4239459
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,also,0.32850838,of,0.65908813,clustering,0.45826355
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,detected,0.25814283,of,0.52368605,clustering,0.37524593
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,agonistic,0.26168025,natural,0.46630585,generative,0.36264765
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,effects,0.2624804,short-term,0.63497096,long-short-term,0.5306107
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,acute,0.21222305,short-term,0.51624244,long-short-term,0.3867746
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,parasitemia,0.20866083,naive,0.37580773,batch-normalization,0.33162525
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,reprogrammed,0.38177913,naive,0.4949561,generative,0.47338226
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,dampened,0.23105602,augmentation,0.49584126,bagging,0.43530977
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,induced,0.2259351,of,0.5615651,boosting,0.4303583
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,fak,0.24206558,cascade,0.42333496,feed-forward,0.36818916
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,agonist,0.20935684,discriminative,0.4141118,feed-forward,0.2964747
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,chronic,0.22727785,recurrent,0.5279353,long-short-term,0.4292153
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,cd,0.20783342,of,0.37830055,long-short-term,0.3296659
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,induced,0.2259351,of,0.5615651,boosting,0.4303583
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,increase,0.28092995,reduction,0.7624404,boosting,0.49543357
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,induced-increase,0.27624512,short-term,0.507344,boosting,0.4616912
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,associated,0.30827495,of,0.57598466,long-short-term,0.46578532
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,yolk,0.08751954,layer,0.3720411,kernel,0.29938096
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,studies,0.30135098,data,0.6349237,component-analysis,0.41327482
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,showed,0.20766163,of,0.5296177,regression,0.37027335
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,sac,0.104616426,of,0.4134333,segmentation,0.36827052
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,increased,0.26921988,reduction,0.6514183,boosting,0.46515882
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,involved,0.26651675,of,0.5396308,feed-forward,0.42281044
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,expression,0.32038707,encoding,0.59633577,clustering,0.442253
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,mo,0.2106132,term,0.4270478,supervised,0.36016458
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,splenic,0.18742537,naive,0.4180041,short-term-memory,0.33421248
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,infected,0.19365644,naive,0.53080636,boosting,0.33861458
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,treated,0.19958335,of,0.5218221,long-short-term,0.35705733
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,proinflammatory,0.23746534,cascade,0.45714468,feed-forward,0.37248206
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,fak,0.24206558,cascade,0.42333496,feed-forward,0.36818916
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,chronically,0.17246503,naive,0.54145,long-short-term,0.42928272
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,chagas,0.31366038,pytorch,0.3762825,pytorch,0.3762825
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,induced,0.2259351,of,0.5615651,boosting,0.4303583
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,increase,0.28092995,reduction,0.7624404,boosting,0.49543357
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,cd,0.20783342,of,0.37830055,long-short-term,0.3296659
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,vs,0.22635552,transfer,0.4263924,statistical,0.3002486
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,untreated,0.20684364,naive,0.5293901,long-short-term,0.38735002
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,tnf,0.15280242,naive,0.34630367,tf-idf,0.2688402
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,tc,0.17672266,transfer,0.3396825,softmax,0.31612098
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,study,0.3645851,of,0.5728763,statistical,0.44204497
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,results,0.32376552,data,0.6932311,batch-normalization,0.44826904
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,respond,0.23937425,naive,0.5081947,boosting,0.40346563
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,pu,0.24493393,relu,0.4207313,relu,0.4207313
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,protein,0.31929362,encoding,0.5525089,clustering,0.36023882
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,phosphorylation,0.24651355,cascade,0.48268026,feed-forward,0.40188718
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,nf,0.24335094,nlp,0.37041497,nlp,0.37041497
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,myocardium,0.2283036,function,0.3991398,segmentation,0.3548869
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,myb,0.25624457,encoding,0.4047655,kernel,0.3414948
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,monocytes,0.24615929,naive,0.53236336,short-term-memory,0.36424077
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,monitored,0.23013821,of,0.51608944,batch-normalization,0.38326645
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,modulating,0.2916656,function,0.5793518,feed-forward,0.55575883
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,migration,0.17838386,neural,0.4264465,gradient,0.42258286
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,methods,0.50049126,data,0.5400177,machine-learning,0.50049126
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,maturation,0.28416622,processing,0.59128743,generative,0.5049704
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,markers,0.32439512,of,0.43581337,clustering,0.41091266
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,macrophages,0.20754936,naive,0.47024828,short-term-memory,0.3296041
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,instead,0.3573236,of,0.5891031,feature-reduction,0.5188961
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,inflammation,0.22370426,cascade,0.4429949,generative-model,0.3706867
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,il,0.17175047,monte,0.3419046,monte,0.3419046
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,however,0.31437585,few,0.63182676,statistical,0.44065386
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,examined,0.295101,of,0.66699874,generative,0.4320032
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,determined,0.2643224,of,0.6221287,batch-normalization,0.4203323
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,controlling,0.30292106,of,0.547873,clustering,0.51796347
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,control,0.27050394,of,0.5093193,artificial-intelligence,0.40948874
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,conclusions,0.37109232,data,0.55923915,long-short-term,0.4627594
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,cells,0.20327199,naive,0.5115537,generative,0.40616876
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,c,0.17513797,of,0.44327667,gradient,0.31114018
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,background,0.3259285,of,0.51277274,long-short-term,0.46426663
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,anti,0.114482366,of,0.3963322,boosting,0.31662655
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,alter,0.25806507,function,0.5040295,stochastic,0.37585503
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,acutely,0.19765878,short-term,0.5356692,long-short-term,0.4370057
Mood disorders and increased risk of non-communicable disease in adults with HIV.,multivariable,0.4951204,logistic,0.92394704,logistic-regression,0.87944424
Mood disorders and increased risk of non-communicable disease in adults with HIV.,cox,0.35329148,logistic,0.6813666,logistic-regression,0.65681994
Mood disorders and increased risk of non-communicable disease in adults with HIV.,models,0.53762007,model,0.8940372,markov-model,0.7015921
Mood disorders and increased risk of non-communicable disease in adults with HIV.,estimated,0.3423246,rate,0.5632778,regression,0.49483663
Mood disorders and increased risk of non-communicable disease in adults with HIV.,mortality,0.2609817,short-term,0.505676,logistic-regression,0.49414968
Mood disorders and increased risk of non-communicable disease in adults with HIV.,risk,0.35860935,recurrent,0.53675485,logistic-regression,0.52381086
Mood disorders and increased risk of non-communicable disease in adults with HIV.,following,0.27415842,of,0.60616374,long-short-term,0.4591148
Mood disorders and increased risk of non-communicable disease in adults with HIV.,multimorbidity,0.45541257,logistic-regression,0.54282117,logistic-regression,0.54282117
Mood disorders and increased risk of non-communicable disease in adults with HIV.,cox-models,0.500478,markov-model,0.7276149,markov-model,0.7276149
Mood disorders and increased risk of non-communicable disease in adults with HIV.,models-estimated,0.56353855,markov-model,0.7306049,markov-model,0.7306049
Mood disorders and increased risk of non-communicable disease in adults with HIV.,mortality-risk,0.4420892,logistic-regression,0.61041725,logistic-regression,0.61041725
Mood disorders and increased risk of non-communicable disease in adults with HIV.,examined,0.295101,of,0.66699874,generative,0.4320032
Mood disorders and increased risk of non-communicable disease in adults with HIV.,whether,0.32171756,short-term,0.5290759,long-short-term,0.47851244
Mood disorders and increased risk of non-communicable disease in adults with HIV.,prevalent,0.30596346,feature,0.48278272,clustering,0.42947072
Mood disorders and increased risk of non-communicable disease in adults with HIV.,mood,0.3215565,style,0.5677599,learning-function,0.5223973
Mood disorders and increased risk of non-communicable disease in adults with HIV.,disorders,0.3129085,function,0.42467374,generative,0.4119473
Mood disorders and increased risk of non-communicable disease in adults with HIV.,mood-disorders,0.3108611,intelligence,0.5032519,dimensionality-reduction,0.48204035
Mood disorders and increased risk of non-communicable disease in adults with HIV.,mortality,0.2609817,short-term,0.505676,logistic-regression,0.49414968
Mood disorders and increased risk of non-communicable disease in adults with HIV.,risk,0.35860935,recurrent,0.53675485,logistic-regression,0.52381086
Mood disorders and increased risk of non-communicable disease in adults with HIV.,following,0.27415842,of,0.60616374,long-short-term,0.4591148
Mood disorders and increased risk of non-communicable disease in adults with HIV.,multimorbidity,0.45541257,logistic-regression,0.54282117,logistic-regression,0.54282117
Mood disorders and increased risk of non-communicable disease in adults with HIV.,mortality-risk,0.4420892,logistic-regression,0.61041725,logistic-regression,0.61041725
Mood disorders and increased risk of non-communicable disease in adults with HIV.,obesity,0.3146031,descent,0.41921628,logistic-regression,0.39891833
Mood disorders and increased risk of non-communicable disease in adults with HIV.,chronic,0.22727785,recurrent,0.5279353,long-short-term,0.4292153
Mood disorders and increased risk of non-communicable disease in adults with HIV.,kidney,0.15772529,function,0.35472965,batch-normalization,0.2715908
Mood disorders and increased risk of non-communicable disease in adults with HIV.,chronic-kidney,0.23062408,short-term,0.40376043,short-term-memory,0.36933333
Mood disorders and increased risk of non-communicable disease in adults with HIV.,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
Mood disorders and increased risk of non-communicable disease in adults with HIV.,incident,0.28040045,of,0.4411097,regression,0.40331167
Mood disorders and increased risk of non-communicable disease in adults with HIV.,multimorbidity,0.45541257,logistic-regression,0.54282117,logistic-regression,0.54282117
Mood disorders and increased risk of non-communicable disease in adults with HIV.,adult,0.25461018,naive,0.5504789,long-short-term,0.46878707
Mood disorders and increased risk of non-communicable disease in adults with HIV.,hiv,0.30580992,natural-language,0.39600608,natural-language,0.39600608
Mood disorders and increased risk of non-communicable disease in adults with HIV.,clinic,0.38176304,unit,0.517299,supervised,0.50589675
Mood disorders and increased risk of non-communicable disease in adults with HIV.,cohort,0.3892265,logistic-regression,0.5412916,logistic-regression,0.5412916
Mood disorders and increased risk of non-communicable disease in adults with HIV.,hiv-clinic,0.36051238,natural-language,0.481004,natural-language,0.481004
Mood disorders and increased risk of non-communicable disease in adults with HIV.,mood,0.3215565,style,0.5677599,learning-function,0.5223973
Mood disorders and increased risk of non-communicable disease in adults with HIV.,disorders,0.3129085,function,0.42467374,generative,0.4119473
Mood disorders and increased risk of non-communicable disease in adults with HIV.,documented,0.28602612,of,0.6228255,long-short-term,0.4125767
Mood disorders and increased risk of non-communicable disease in adults with HIV.,mood-disorders,0.3108611,intelligence,0.5032519,dimensionality-reduction,0.48204035
Mood disorders and increased risk of non-communicable disease in adults with HIV.,mood,0.3215565,style,0.5677599,learning-function,0.5223973
Mood disorders and increased risk of non-communicable disease in adults with HIV.,disorder,0.28393638,dropout,0.44668275,dropout,0.44668275
Mood disorders and increased risk of non-communicable disease in adults with HIV.,diagnosed,0.29304254,recurrent,0.56110895,classification,0.43035528
Mood disorders and increased risk of non-communicable disease in adults with HIV.,mood-disorder,0.303397,intelligence,0.4921553,dimensionality-reduction,0.4841298
Mood disorders and increased risk of non-communicable disease in adults with HIV.,disorder-diagnosed,0.33427525,recurrent,0.46950567,confusion-matrix,0.46554592
Mood disorders and increased risk of non-communicable disease in adults with HIV.,bipolar,0.20807916,long-short,0.39400244,long-short-term,0.38531554
Mood disorders and increased risk of non-communicable disease in adults with HIV.,affective,0.4109118,semantic,0.63524497,semantic,0.63524497
Mood disorders and increased risk of non-communicable disease in adults with HIV.,disorder,0.28393638,dropout,0.44668275,dropout,0.44668275
Mood disorders and increased risk of non-communicable disease in adults with HIV.,bipolar-affective,0.3525555,dimensionality-reduction,0.54170644,dimensionality-reduction,0.54170644
Mood disorders and increased risk of non-communicable disease in adults with HIV.,affective-disorder,0.36971533,dimensionality-reduction,0.58459115,dimensionality-reduction,0.58459115
Mood disorders and increased risk of non-communicable disease in adults with HIV.,adjusted,0.33626905,logistic,0.654571,logistic-regression,0.64486897
Mood disorders and increased risk of non-communicable disease in adults with HIV.,subhazard,0.31348634,logistic,0.61331195,logistic-regression,0.613029
Mood disorders and increased risk of non-communicable disease in adults with HIV.,ratios,0.18493193,rate,0.42238456,regression,0.41522446
Mood disorders and increased risk of non-communicable disease in adults with HIV.,adjusted,0.33626905,logistic,0.654571,logistic-regression,0.64486897
Mood disorders and increased risk of non-communicable disease in adults with HIV.,subhazard,0.31348634,logistic,0.61331195,logistic-regression,0.613029
Mood disorders and increased risk of non-communicable disease in adults with HIV.,ratio,0.19492707,rate,0.48224086,regression,0.41092375
Mood disorders and increased risk of non-communicable disease in adults with HIV.,ncds,0.34624696,data-science,0.45629936,data-science,0.45629936
Mood disorders and increased risk of non-communicable disease in adults with HIV.,may,0.30907542,of,0.58654004,long-short-term,0.43985203
Mood disorders and increased risk of non-communicable disease in adults with HIV.,reduce,0.314935,reduction,0.63468504,boosting,0.4613787
Mood disorders and increased risk of non-communicable disease in adults with HIV.,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
Mood disorders and increased risk of non-communicable disease in adults with HIV.,year,0.310051,one,0.48338404,supervised,0.40979916
Mood disorders and increased risk of non-communicable disease in adults with HIV.,particularly,0.32789055,of,0.62868786,long-short-term,0.49770588
Mood disorders and increased risk of non-communicable disease in adults with HIV.,metabolic,0.3235007,of,0.46523505,batch-normalization,0.4536144
Mood disorders and increased risk of non-communicable disease in adults with HIV.,syndrome,0.20306323,recurrent,0.42346346,confusion-matrix,0.3198145
Mood disorders and increased risk of non-communicable disease in adults with HIV.,metabolic-syndrome,0.3170333,normalization,0.4461956,batch-normalization,0.44316322
Mood disorders and increased risk of non-communicable disease in adults with HIV.,experience,0.41404068,short-term,0.55279255,artificial-intelligence,0.491909
Mood disorders and increased risk of non-communicable disease in adults with HIV.,high,0.267004,of,0.57459104,gradient,0.44240427
Mood disorders and increased risk of non-communicable disease in adults with HIV.,rates,0.24094881,rate,0.8800579,dropout,0.48159522
Mood disorders and increased risk of non-communicable disease in adults with HIV.,high-rates,0.35277367,rate,0.5327759,long-short-term,0.5143385
Mood disorders and increased risk of non-communicable disease in adults with HIV.,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
Mood disorders and increased risk of non-communicable disease in adults with HIV.,ncds,0.34624696,data-science,0.45629936,data-science,0.45629936
Mood disorders and increased risk of non-communicable disease in adults with HIV.,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
Mood disorders and increased risk of non-communicable disease in adults with HIV.,incident,0.28040045,of,0.4411097,regression,0.40331167
Mood disorders and increased risk of non-communicable disease in adults with HIV.,ncds,0.34624696,data-science,0.45629936,data-science,0.45629936
Mood disorders and increased risk of non-communicable disease in adults with HIV.,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
Mood disorders and increased risk of non-communicable disease in adults with HIV.,ncd,0.25243485,nlp,0.3938239,nlp,0.3938239
Mood disorders and increased risk of non-communicable disease in adults with HIV.,mood,0.3215565,style,0.5677599,learning-function,0.5223973
Mood disorders and increased risk of non-communicable disease in adults with HIV.,disorders,0.3129085,function,0.42467374,generative,0.4119473
Mood disorders and increased risk of non-communicable disease in adults with HIV.,mood-disorders,0.3108611,intelligence,0.5032519,dimensionality-reduction,0.48204035
Mood disorders and increased risk of non-communicable disease in adults with HIV.,incident,0.28040045,of,0.4411097,regression,0.40331167
Mood disorders and increased risk of non-communicable disease in adults with HIV.,ncds,0.34624696,data-science,0.45629936,data-science,0.45629936
Mood disorders and increased risk of non-communicable disease in adults with HIV.,risk,0.35860935,recurrent,0.53675485,logistic-regression,0.52381086
Mood disorders and increased risk of non-communicable disease in adults with HIV.,group,0.26103544,of,0.44356787,statistical,0.3923795
Mood disorders and increased risk of non-communicable disease in adults with HIV.,risk-group,0.38251835,classification-algorithm,0.59153104,classification-algorithm,0.59153104
Mood disorders and increased risk of non-communicable disease in adults with HIV.,increased,0.26921988,reduction,0.6514183,boosting,0.46515882
Mood disorders and increased risk of non-communicable disease in adults with HIV.,risk,0.35860935,recurrent,0.53675485,logistic-regression,0.52381086
Mood disorders and increased risk of non-communicable disease in adults with HIV.,increased-risk,0.39064288,logistic-regression,0.491068,logistic-regression,0.491068
Mood disorders and increased risk of non-communicable disease in adults with HIV.,competing,0.38505203,adversarial,0.5235929,nearest-neighbors,0.50362813
Mood disorders and increased risk of non-communicable disease in adults with HIV.,risk,0.35860935,recurrent,0.53675485,logistic-regression,0.52381086
Mood disorders and increased risk of non-communicable disease in adults with HIV.,competing-risk,0.51290536,logistic-regression,0.75165075,logistic-regression,0.75165075
Mood disorders and increased risk of non-communicable disease in adults with HIV.,metabolic,0.3235007,of,0.46523505,batch-normalization,0.4536144
Mood disorders and increased risk of non-communicable disease in adults with HIV.,syndrome,0.20306323,recurrent,0.42346346,confusion-matrix,0.3198145
Mood disorders and increased risk of non-communicable disease in adults with HIV.,metabolic-syndrome,0.3170333,normalization,0.4461956,batch-normalization,0.44316322
Mood disorders and increased risk of non-communicable disease in adults with HIV.,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
Mood disorders and increased risk of non-communicable disease in adults with HIV.,adults,0.2950639,short-term,0.48601514,long-short-term,0.43684626
Mood disorders and increased risk of non-communicable disease in adults with HIV.,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
Mood disorders and increased risk of non-communicable disease in adults with HIV.,first,0.36139184,of,0.61145455,generative,0.4096663
Mood disorders and increased risk of non-communicable disease in adults with HIV.,year,0.310051,one,0.48338404,supervised,0.40979916
Mood disorders and increased risk of non-communicable disease in adults with HIV.,first-year,0.42628863,style,0.5100552,reinforcement-learning,0.47482315
Mood disorders and increased risk of non-communicable disease in adults with HIV.,multimorbidity,0.45541257,logistic-regression,0.54282117,logistic-regression,0.54282117
Mood disorders and increased risk of non-communicable disease in adults with HIV.,ci,0.2746623,logistic,0.43534693,logistic-regression,0.38379127
Mood disorders and increased risk of non-communicable disease in adults with HIV.,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
Mood disorders and increased risk of non-communicable disease in adults with HIV.,study,0.3645851,of,0.5728763,statistical,0.44204497
Mood disorders and increased risk of non-communicable disease in adults with HIV.,period,0.19663066,short-term,0.5791412,long-short-term,0.5108645
Mood disorders and increased risk of non-communicable disease in adults with HIV.,study-period,0.35463333,logistic-regression,0.5018395,logistic-regression,0.5018395
Mood disorders and increased risk of non-communicable disease in adults with HIV.,people,0.36805943,natural-language,0.4770279,natural-language,0.4770279
Mood disorders and increased risk of non-communicable disease in adults with HIV.,living,0.30422944,of,0.47259963,generative,0.4134596
Mood disorders and increased risk of non-communicable disease in adults with HIV.,people-living,0.38167542,forest,0.50183386,random-forest,0.48820892
Mood disorders and increased risk of non-communicable disease in adults with HIV.,major,0.2356064,principal,0.70253855,principal-components,0.42016473
Mood disorders and increased risk of non-communicable disease in adults with HIV.,depression,0.28218034,confusion,0.49540818,dimensionality-reduction,0.47036743
Mood disorders and increased risk of non-communicable disease in adults with HIV.,major-depression,0.26127872,long-short-term-memory,0.49631277,long-short-term-memory,0.49631277
Mood disorders and increased risk of non-communicable disease in adults with HIV.,liver,0.22774608,of,0.3980642,batch-normalization,0.34184414
Mood disorders and increased risk of non-communicable disease in adults with HIV.,disease,0.296938,recurrent,0.4731025,classification,0.35271814
Mood disorders and increased risk of non-communicable disease in adults with HIV.,liver-disease,0.41721886,logistic-regression,0.47586897,logistic-regression,0.47586897
Mood disorders and increased risk of non-communicable disease in adults with HIV.,general,0.3977576,of,0.5577996,learning-function,0.47885123
Mood disorders and increased risk of non-communicable disease in adults with HIV.,population,0.2958798,selection,0.5071889,clustering,0.47966808
Mood disorders and increased risk of non-communicable disease in adults with HIV.,general-population,0.5059907,random-forest,0.65608555,random-forest,0.65608555
Mood disorders and increased risk of non-communicable disease in adults with HIV.,focused,0.39696395,of,0.5549927,feature-engineering,0.52445924
Mood disorders and increased risk of non-communicable disease in adults with HIV.,prevention,0.29446518,recurrent,0.44918782,feature-reduction,0.4041679
Mood disorders and increased risk of non-communicable disease in adults with HIV.,first,0.36139184,of,0.61145455,generative,0.4096663
Mood disorders and increased risk of non-communicable disease in adults with HIV.,ncd,0.25243485,nlp,0.3938239,nlp,0.3938239
Mood disorders and increased risk of non-communicable disease in adults with HIV.,defining,0.46248704,feature,0.62534213,feature-engineering,0.5542367
Mood disorders and increased risk of non-communicable disease in adults with HIV.,cancers,0.2730524,recurrent,0.4093323,classifiers,0.3447146
Mood disorders and increased risk of non-communicable disease in adults with HIV.,cumulative,0.35646293,short-term,0.5375205,logistic-regression,0.47759464
Mood disorders and increased risk of non-communicable disease in adults with HIV.,incidence,0.2452303,rate,0.58344483,logistic-regression,0.39874467
Mood disorders and increased risk of non-communicable disease in adults with HIV.,cumulative-incidence,0.38360164,generative-model,0.5715318,generative-model,0.5715318
Mood disorders and increased risk of non-communicable disease in adults with HIV.,confidence,0.354792,bayes,0.47560617,bayes,0.47560617
Mood disorders and increased risk of non-communicable disease in adults with HIV.,interval,0.25114498,decision,0.39202803,bayesian,0.37118626
Mood disorders and increased risk of non-communicable disease in adults with HIV.,confidence-interval,0.46936446,decision-tree,0.56020504,decision-tree,0.56020504
Mood disorders and increased risk of non-communicable disease in adults with HIV.,communicable,0.3629546,federated,0.56281555,data-science,0.5524583
Mood disorders and increased risk of non-communicable disease in adults with HIV.,disease,0.296938,recurrent,0.4731025,classification,0.35271814
Mood disorders and increased risk of non-communicable disease in adults with HIV.,communicable-disease,0.503264,data-science,0.6032334,data-science,0.6032334
Mood disorders and increased risk of non-communicable disease in adults with HIV.,cardiovascular,0.31674606,short-term,0.442761,learning-function,0.4027721
Mood disorders and increased risk of non-communicable disease in adults with HIV.,disease,0.296938,recurrent,0.4731025,classification,0.35271814
Mood disorders and increased risk of non-communicable disease in adults with HIV.,cardiovascular-disease,0.39733815,logistic-regression,0.43556237,logistic-regression,0.43556237
Mood disorders and increased risk of non-communicable disease in adults with HIV.,conclusively,0.34739083,fully,0.62904775,long-short-term,0.43375432
Mood disorders and increased risk of non-communicable disease in adults with HIV.,associated,0.30827495,of,0.57598466,long-short-term,0.46578532
Mood disorders and increased risk of non-communicable disease in adults with HIV.,conclusively-associated,0.41258383,of,0.5788169,clustering,0.56138873
Mood disorders and increased risk of non-communicable disease in adults with HIV.,ashr,0.23903264,logistic-regression,0.34913146,logistic-regression,0.34913146
Mood disorders and increased risk of non-communicable disease in adults with HIV.,ranging,0.25077263,of,0.45827153,gradient,0.3299821
Mood disorders and increased risk of non-communicable disease in adults with HIV.,risk,0.35860935,recurrent,0.53675485,logistic-regression,0.52381086
Mood disorders and increased risk of non-communicable disease in adults with HIV.,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
Mood disorders and increased risk of non-communicable disease in adults with HIV.,hiv,0.30580992,natural-language,0.39600608,natural-language,0.39600608
Mood disorders and increased risk of non-communicable disease in adults with HIV.,clinic,0.38176304,unit,0.517299,supervised,0.50589675
Mood disorders and increased risk of non-communicable disease in adults with HIV.,ncds,0.34624696,data-science,0.45629936,data-science,0.45629936
Mood disorders and increased risk of non-communicable disease in adults with HIV.,ncd,0.25243485,nlp,0.3938239,nlp,0.3938239
Mood disorders and increased risk of non-communicable disease in adults with HIV.,high,0.267004,of,0.57459104,gradient,0.44240427
Mood disorders and increased risk of non-communicable disease in adults with HIV.,ci,0.2746623,logistic,0.43534693,logistic-regression,0.38379127
Mood disorders and increased risk of non-communicable disease in adults with HIV.,associated,0.30827495,of,0.57598466,long-short-term,0.46578532
Mood disorders and increased risk of non-communicable disease in adults with HIV.,ashr,0.23903264,logistic-regression,0.34913146,logistic-regression,0.34913146
Mood disorders and increased risk of non-communicable disease in adults with HIV.,treatment,0.239264,short-term,0.5206091,long-short-term,0.41699445
Mood disorders and increased risk of non-communicable disease in adults with HIV.,three,0.36911732,one,0.78425425,clustering,0.4299444
Mood disorders and increased risk of non-communicable disease in adults with HIV.,tennessee,0.28158435,federated,0.4818838,random-forest,0.41536725
Mood disorders and increased risk of non-communicable disease in adults with HIV.,setting,0.34333664,decision,0.51606584,supervised,0.4146531
Mood disorders and increased risk of non-communicable disease in adults with HIV.,results,0.32376552,data,0.6932311,batch-normalization,0.44826904
Mood disorders and increased risk of non-communicable disease in adults with HIV.,plwh,0.33266568,decision-tree,0.4121411,decision-tree,0.4121411
Mood disorders and increased risk of non-communicable disease in adults with HIV.,non,0.2869836,of,0.5523051,generative,0.4181043
Mood disorders and increased risk of non-communicable disease in adults with HIV.,nashville,0.30286124,federated,0.5164441,data-science,0.44972378
Mood disorders and increased risk of non-communicable disease in adults with HIV.,methods,0.50049126,data,0.5400177,machine-learning,0.50049126
Mood disorders and increased risk of non-communicable disease in adults with HIV.,included,0.34673893,of,0.58040446,component-analysis,0.47413814
Mood disorders and increased risk of non-communicable disease in adults with HIV.,hypertension,0.28340828,dropout,0.4223115,dropout,0.4223115
Mood disorders and increased risk of non-communicable disease in adults with HIV.,hyperlipidemia,0.26448822,recurrent,0.39010435,logistic-regression,0.368414
Mood disorders and increased risk of non-communicable disease in adults with HIV.,follow,0.28552625,tracking,0.48513734,batch-normalization,0.39173082
Mood disorders and increased risk of non-communicable disease in adults with HIV.,diabetes,0.29301462,logistic-regression,0.35688502,logistic-regression,0.35688502
Mood disorders and increased risk of non-communicable disease in adults with HIV.,dementia,0.36825818,semantic,0.5159805,semantic,0.5159805
Mood disorders and increased risk of non-communicable disease in adults with HIV.,death,0.21479979,of,0.42234862,dropout,0.37818787
Mood disorders and increased risk of non-communicable disease in adults with HIV.,conclusions,0.37109232,data,0.55923915,long-short-term,0.4627594
Mood disorders and increased risk of non-communicable disease in adults with HIV.,care,0.3144728,decision,0.58130515,data-science,0.46943653
Mood disorders and increased risk of non-communicable disease in adults with HIV.,calculated,0.36281493,monte,0.54373723,monte,0.54373723
Mood disorders and increased risk of non-communicable disease in adults with HIV.,burden,0.25295436,reduction,0.41791618,logistic-regression,0.3788216
Mood disorders and increased risk of non-communicable disease in adults with HIV.,baseline,0.32763094,normalization,0.56518495,batch-normalization,0.4727359
Mood disorders and increased risk of non-communicable disease in adults with HIV.,background,0.3259285,of,0.51277274,long-short-term,0.46426663
Mood disorders and increased risk of non-communicable disease in adults with HIV.,assessed,0.33986524,of,0.605934,component-analysis,0.41855076
Mood disorders and increased risk of non-communicable disease in adults with HIV.,aids,0.3577932,natural-language,0.47674245,natural-language,0.47674245
Mood disorders and increased risk of non-communicable disease in adults with HIV.,accumulation,0.22826076,of,0.50695926,generative,0.4137243
"The risk of fractures, acute myocardial infarction, atrial fibrillation and ventricular arrhythmia in geriatric patients exposed to promethazine.",ventricular,0.24852064,rate,0.37094042,long-short-term,0.34148398
"The risk of fractures, acute myocardial infarction, atrial fibrillation and ventricular arrhythmia in geriatric patients exposed to promethazine.",arrhythmia,0.31342128,recurrent,0.4357065,long-short-term,0.4199577
"The risk of fractures, acute myocardial infarction, atrial fibrillation and ventricular arrhythmia in geriatric patients exposed to promethazine.",among,0.33676732,of,0.57348,clustering,0.49404603
"The risk of fractures, acute myocardial infarction, atrial fibrillation and ventricular arrhythmia in geriatric patients exposed to promethazine.",danish,0.26474613,federated,0.5481145,natural-language,0.40359175
"The risk of fractures, acute myocardial infarction, atrial fibrillation and ventricular arrhythmia in geriatric patients exposed to promethazine.",citizens,0.35941344,data-science,0.5687222,data-science,0.5687222
"The risk of fractures, acute myocardial infarction, atrial fibrillation and ventricular arrhythmia in geriatric patients exposed to promethazine.",aged,0.26166397,naive,0.41497838,short-term-memory,0.36555237
"The risk of fractures, acute myocardial infarction, atrial fibrillation and ventricular arrhythmia in geriatric patients exposed to promethazine.",xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
"The risk of fractures, acute myocardial infarction, atrial fibrillation and ventricular arrhythmia in geriatric patients exposed to promethazine.",atrial,0.2285939,long-short,0.40266213,long-short-term,0.38994598
"The risk of fractures, acute myocardial infarction, atrial fibrillation and ventricular arrhythmia in geriatric patients exposed to promethazine.",fibrillation,0.29544818,recurrent,0.4121878,long-short-term,0.3982905
"The risk of fractures, acute myocardial infarction, atrial fibrillation and ventricular arrhythmia in geriatric patients exposed to promethazine.",hospitalization,0.23343414,confusion,0.51795703,logistic-regression,0.47011706
"The risk of fractures, acute myocardial infarction, atrial fibrillation and ventricular arrhythmia in geriatric patients exposed to promethazine.",among,0.33676732,of,0.57348,clustering,0.49404603
"The risk of fractures, acute myocardial infarction, atrial fibrillation and ventricular arrhythmia in geriatric patients exposed to promethazine.",promethazine,0.24053344,confusion,0.41455728,confusion-matrix,0.3746753
"The risk of fractures, acute myocardial infarction, atrial fibrillation and ventricular arrhythmia in geriatric patients exposed to promethazine.",users,0.44838846,computer,0.47765467,computer-vision,0.47360408
"The risk of fractures, acute myocardial infarction, atrial fibrillation and ventricular arrhythmia in geriatric patients exposed to promethazine.",atrial-fibrillation,0.26383367,long-short,0.47894955,long-short-term,0.454661
"The risk of fractures, acute myocardial infarction, atrial fibrillation and ventricular arrhythmia in geriatric patients exposed to promethazine.",ventricular,0.24852064,rate,0.37094042,long-short-term,0.34148398
"The risk of fractures, acute myocardial infarction, atrial fibrillation and ventricular arrhythmia in geriatric patients exposed to promethazine.",arrhythmia,0.31342128,recurrent,0.4357065,long-short-term,0.4199577
"The risk of fractures, acute myocardial infarction, atrial fibrillation and ventricular arrhythmia in geriatric patients exposed to promethazine.",hospitalizations,0.2612055,logistic-regression,0.4695824,logistic-regression,0.4695824
"The risk of fractures, acute myocardial infarction, atrial fibrillation and ventricular arrhythmia in geriatric patients exposed to promethazine.",higher,0.27819592,reduction,0.545787,boosting,0.41506222
"The risk of fractures, acute myocardial infarction, atrial fibrillation and ventricular arrhythmia in geriatric patients exposed to promethazine.",among,0.33676732,of,0.57348,clustering,0.49404603
"The risk of fractures, acute myocardial infarction, atrial fibrillation and ventricular arrhythmia in geriatric patients exposed to promethazine.",patients,0.30007,recurrent,0.5332828,dropout,0.3918751
"The risk of fractures, acute myocardial infarction, atrial fibrillation and ventricular arrhythmia in geriatric patients exposed to promethazine.",higher-among,0.35500407,hierarchical-clustering,0.47490856,hierarchical-clustering,0.47490856
"The risk of fractures, acute myocardial infarction, atrial fibrillation and ventricular arrhythmia in geriatric patients exposed to promethazine.",found,0.2840244,of,0.6208722,clustering,0.44675255
"The risk of fractures, acute myocardial infarction, atrial fibrillation and ventricular arrhythmia in geriatric patients exposed to promethazine.",among,0.33676732,of,0.57348,clustering,0.49404603
"The risk of fractures, acute myocardial infarction, atrial fibrillation and ventricular arrhythmia in geriatric patients exposed to promethazine.",drugs,0.30897486,of,0.42460242,classifiers,0.33720028
"The risk of fractures, acute myocardial infarction, atrial fibrillation and ventricular arrhythmia in geriatric patients exposed to promethazine.",atrial,0.2285939,long-short,0.40266213,long-short-term,0.38994598
"The risk of fractures, acute myocardial infarction, atrial fibrillation and ventricular arrhythmia in geriatric patients exposed to promethazine.",fibrillation,0.29544818,recurrent,0.4121878,long-short-term,0.3982905
"The risk of fractures, acute myocardial infarction, atrial fibrillation and ventricular arrhythmia in geriatric patients exposed to promethazine.",hospitalizations,0.2612055,logistic-regression,0.4695824,logistic-regression,0.4695824
"The risk of fractures, acute myocardial infarction, atrial fibrillation and ventricular arrhythmia in geriatric patients exposed to promethazine.",atrial-fibrillation,0.26383367,long-short,0.47894955,long-short-term,0.454661
"The risk of fractures, acute myocardial infarction, atrial fibrillation and ventricular arrhythmia in geriatric patients exposed to promethazine.",prior,0.3322774,of,0.5738043,bagging,0.45032665
"The risk of fractures, acute myocardial infarction, atrial fibrillation and ventricular arrhythmia in geriatric patients exposed to promethazine.",cardiac,0.29562658,of,0.42777455,long-short-term,0.35708636
"The risk of fractures, acute myocardial infarction, atrial fibrillation and ventricular arrhythmia in geriatric patients exposed to promethazine.",arrhythmia,0.31342128,recurrent,0.4357065,long-short-term,0.4199577
"The risk of fractures, acute myocardial infarction, atrial fibrillation and ventricular arrhythmia in geriatric patients exposed to promethazine.",cardiac-arrhythmia,0.3289079,long-short-term,0.42242622,long-short-term,0.42242622
"The risk of fractures, acute myocardial infarction, atrial fibrillation and ventricular arrhythmia in geriatric patients exposed to promethazine.",statistically,0.37798828,statistical,0.71961004,statistical,0.71961004
"The risk of fractures, acute myocardial infarction, atrial fibrillation and ventricular arrhythmia in geriatric patients exposed to promethazine.",significant,0.29367286,statistical,0.582669,statistical,0.582669
"The risk of fractures, acute myocardial infarction, atrial fibrillation and ventricular arrhythmia in geriatric patients exposed to promethazine.",differences,0.3361535,statistical,0.57447433,statistical,0.57447433
"The risk of fractures, acute myocardial infarction, atrial fibrillation and ventricular arrhythmia in geriatric patients exposed to promethazine.",statistically-significant,0.47618386,statistical,0.73292255,statistical,0.73292255
"The risk of fractures, acute myocardial infarction, atrial fibrillation and ventricular arrhythmia in geriatric patients exposed to promethazine.",significant-differences,0.5020617,statistical,0.69704795,statistical,0.69704795
"The risk of fractures, acute myocardial infarction, atrial fibrillation and ventricular arrhythmia in geriatric patients exposed to promethazine.",logistic,0.5418149,logistic,1.0,logistic-regression,0.9215903
"The risk of fractures, acute myocardial infarction, atrial fibrillation and ventricular arrhythmia in geriatric patients exposed to promethazine.",regression,0.4967034,regression,1.0,regression,1.0
"The risk of fractures, acute myocardial infarction, atrial fibrillation and ventricular arrhythmia in geriatric patients exposed to promethazine.",model,0.48485535,model,1.0,markov-model,0.7005576
"The risk of fractures, acute myocardial infarction, atrial fibrillation and ventricular arrhythmia in geriatric patients exposed to promethazine.",logistic-regression,0.5787163,logistic-regression,0.99999994,logistic-regression,0.99999994
"The risk of fractures, acute myocardial infarction, atrial fibrillation and ventricular arrhythmia in geriatric patients exposed to promethazine.",regression-model,0.60779727,logistic-regression,0.7879311,logistic-regression,0.7879311
"The risk of fractures, acute myocardial infarction, atrial fibrillation and ventricular arrhythmia in geriatric patients exposed to promethazine.",logistic-regression-model,0.6461563,logistic-regression,0.9399874,logistic-regression,0.9399874
"The risk of fractures, acute myocardial infarction, atrial fibrillation and ventricular arrhythmia in geriatric patients exposed to promethazine.",conditional,0.46229088,stochastic,0.6116671,stochastic,0.6116671
"The risk of fractures, acute myocardial infarction, atrial fibrillation and ventricular arrhythmia in geriatric patients exposed to promethazine.",inference,0.6877559,bayesian,0.838166,bayesian,0.838166
"The risk of fractures, acute myocardial infarction, atrial fibrillation and ventricular arrhythmia in geriatric patients exposed to promethazine.",tree,0.44976014,tree,1.0000001,random-forest,0.5821787
"The risk of fractures, acute myocardial infarction, atrial fibrillation and ventricular arrhythmia in geriatric patients exposed to promethazine.",conditional-inference,0.62430096,bayesian-network,0.70069814,bayesian-network,0.70069814
"The risk of fractures, acute myocardial infarction, atrial fibrillation and ventricular arrhythmia in geriatric patients exposed to promethazine.",adjusted,0.33626905,logistic,0.654571,logistic-regression,0.64486897
"The risk of fractures, acute myocardial infarction, atrial fibrillation and ventricular arrhythmia in geriatric patients exposed to promethazine.",odds,0.32792267,logistic,0.6708193,logistic-regression,0.62355316
"The risk of fractures, acute myocardial infarction, atrial fibrillation and ventricular arrhythmia in geriatric patients exposed to promethazine.",ratios,0.18493193,rate,0.42238456,regression,0.41522446
"The risk of fractures, acute myocardial infarction, atrial fibrillation and ventricular arrhythmia in geriatric patients exposed to promethazine.",adjusted-odds,0.37281275,logistic-regression,0.6730614,logistic-regression,0.6730614
"The risk of fractures, acute myocardial infarction, atrial fibrillation and ventricular arrhythmia in geriatric patients exposed to promethazine.",odds-ratios,0.3445117,logistic-regression,0.66145736,logistic-regression,0.66145736
"The risk of fractures, acute myocardial infarction, atrial fibrillation and ventricular arrhythmia in geriatric patients exposed to promethazine.",acute,0.21222305,short-term,0.51624244,long-short-term,0.3867746
"The risk of fractures, acute myocardial infarction, atrial fibrillation and ventricular arrhythmia in geriatric patients exposed to promethazine.",myocardial,0.25335935,normalization,0.40452614,batch-normalization,0.38271224
"The risk of fractures, acute myocardial infarction, atrial fibrillation and ventricular arrhythmia in geriatric patients exposed to promethazine.",infarction,0.22924727,recurrent,0.4099214,confusion-matrix,0.3685401
"The risk of fractures, acute myocardial infarction, atrial fibrillation and ventricular arrhythmia in geriatric patients exposed to promethazine.",acute-myocardial,0.23951635,confusion-matrix,0.40166956,confusion-matrix,0.40166956
"The risk of fractures, acute myocardial infarction, atrial fibrillation and ventricular arrhythmia in geriatric patients exposed to promethazine.",myocardial-infarction,0.25818947,normalization,0.3545368,long-short-term,0.351139
"The risk of fractures, acute myocardial infarction, atrial fibrillation and ventricular arrhythmia in geriatric patients exposed to promethazine.",acute-myocardial-infarction,0.25814062,confusion-matrix,0.39158085,confusion-matrix,0.39158085
"The risk of fractures, acute myocardial infarction, atrial fibrillation and ventricular arrhythmia in geriatric patients exposed to promethazine.",atrial,0.2285939,long-short,0.40266213,long-short-term,0.38994598
"The risk of fractures, acute myocardial infarction, atrial fibrillation and ventricular arrhythmia in geriatric patients exposed to promethazine.",fibrillation,0.29544818,recurrent,0.4121878,long-short-term,0.3982905
"The risk of fractures, acute myocardial infarction, atrial fibrillation and ventricular arrhythmia in geriatric patients exposed to promethazine.",atrial-fibrillation,0.26383367,long-short,0.47894955,long-short-term,0.454661
"The risk of fractures, acute myocardial infarction, atrial fibrillation and ventricular arrhythmia in geriatric patients exposed to promethazine.",danish,0.26474613,federated,0.5481145,natural-language,0.40359175
"The risk of fractures, acute myocardial infarction, atrial fibrillation and ventricular arrhythmia in geriatric patients exposed to promethazine.",registers,0.38369918,federated,0.56615746,data-science,0.532148
"The risk of fractures, acute myocardial infarction, atrial fibrillation and ventricular arrhythmia in geriatric patients exposed to promethazine.",cardiac,0.29562658,of,0.42777455,long-short-term,0.35708636
"The risk of fractures, acute myocardial infarction, atrial fibrillation and ventricular arrhythmia in geriatric patients exposed to promethazine.",arrhythmia,0.31342128,recurrent,0.4357065,long-short-term,0.4199577
"The risk of fractures, acute myocardial infarction, atrial fibrillation and ventricular arrhythmia in geriatric patients exposed to promethazine.",cardiac-arrhythmia,0.3289079,long-short-term,0.42242622,long-short-term,0.42242622
"The risk of fractures, acute myocardial infarction, atrial fibrillation and ventricular arrhythmia in geriatric patients exposed to promethazine.",new,0.43019778,of,0.526482,feature-reduction,0.4579819
"The risk of fractures, acute myocardial infarction, atrial fibrillation and ventricular arrhythmia in geriatric patients exposed to promethazine.",users,0.44838846,computer,0.47765467,computer-vision,0.47360408
"The risk of fractures, acute myocardial infarction, atrial fibrillation and ventricular arrhythmia in geriatric patients exposed to promethazine.",new-users,0.43337005,logistic-regression,0.46214408,logistic-regression,0.46214408
"The risk of fractures, acute myocardial infarction, atrial fibrillation and ventricular arrhythmia in geriatric patients exposed to promethazine.",xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
"The risk of fractures, acute myocardial infarction, atrial fibrillation and ventricular arrhythmia in geriatric patients exposed to promethazine.",days,0.20857571,short-term,0.53915894,long-short-term,0.4190845
"The risk of fractures, acute myocardial infarction, atrial fibrillation and ventricular arrhythmia in geriatric patients exposed to promethazine.",ci,0.2746623,logistic,0.43534693,logistic-regression,0.38379127
"The risk of fractures, acute myocardial infarction, atrial fibrillation and ventricular arrhythmia in geriatric patients exposed to promethazine.",xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
"The risk of fractures, acute myocardial infarction, atrial fibrillation and ventricular arrhythmia in geriatric patients exposed to promethazine.",study,0.3645851,of,0.5728763,statistical,0.44204497
"The risk of fractures, acute myocardial infarction, atrial fibrillation and ventricular arrhythmia in geriatric patients exposed to promethazine.",found,0.2840244,of,0.6208722,clustering,0.44675255
"The risk of fractures, acute myocardial infarction, atrial fibrillation and ventricular arrhythmia in geriatric patients exposed to promethazine.",higher,0.27819592,reduction,0.545787,boosting,0.41506222
"The risk of fractures, acute myocardial infarction, atrial fibrillation and ventricular arrhythmia in geriatric patients exposed to promethazine.",risk,0.35860935,recurrent,0.53675485,logistic-regression,0.52381086
"The risk of fractures, acute myocardial infarction, atrial fibrillation and ventricular arrhythmia in geriatric patients exposed to promethazine.",higher-risk,0.39451247,classification-algorithm,0.4998359,classification-algorithm,0.4998359
"The risk of fractures, acute myocardial infarction, atrial fibrillation and ventricular arrhythmia in geriatric patients exposed to promethazine.",study,0.3645851,of,0.5728763,statistical,0.44204497
"The risk of fractures, acute myocardial infarction, atrial fibrillation and ventricular arrhythmia in geriatric patients exposed to promethazine.",period,0.19663066,short-term,0.5791412,long-short-term,0.5108645
"The risk of fractures, acute myocardial infarction, atrial fibrillation and ventricular arrhythmia in geriatric patients exposed to promethazine.",study-period,0.35463333,logistic-regression,0.5018395,logistic-regression,0.5018395
"The risk of fractures, acute myocardial infarction, atrial fibrillation and ventricular arrhythmia in geriatric patients exposed to promethazine.",study,0.3645851,of,0.5728763,statistical,0.44204497
"The risk of fractures, acute myocardial infarction, atrial fibrillation and ventricular arrhythmia in geriatric patients exposed to promethazine.",outcomes,0.38239923,short-term,0.6164659,long-short-term,0.5239928
"The risk of fractures, acute myocardial infarction, atrial fibrillation and ventricular arrhythmia in geriatric patients exposed to promethazine.",study-outcomes,0.4748817,data-science,0.57153547,data-science,0.57153547
"The risk of fractures, acute myocardial infarction, atrial fibrillation and ventricular arrhythmia in geriatric patients exposed to promethazine.",study,0.3645851,of,0.5728763,statistical,0.44204497
"The risk of fractures, acute myocardial infarction, atrial fibrillation and ventricular arrhythmia in geriatric patients exposed to promethazine.",aimed,0.41358173,of,0.52896386,feature-engineering,0.45929232
"The risk of fractures, acute myocardial infarction, atrial fibrillation and ventricular arrhythmia in geriatric patients exposed to promethazine.",study-aimed,0.48830283,data-science,0.57568187,data-science,0.57568187
"The risk of fractures, acute myocardial infarction, atrial fibrillation and ventricular arrhythmia in geriatric patients exposed to promethazine.",respectively,0.23184536,of,0.43360457,cross-validation,0.35765702
"The risk of fractures, acute myocardial infarction, atrial fibrillation and ventricular arrhythmia in geriatric patients exposed to promethazine.",relevant,0.4346258,of,0.5628227,natural-language,0.5076148
"The risk of fractures, acute myocardial infarction, atrial fibrillation and ventricular arrhythmia in geriatric patients exposed to promethazine.",predictors,0.46376368,logistic,0.67381907,logistic-regression,0.66900885
"The risk of fractures, acute myocardial infarction, atrial fibrillation and ventricular arrhythmia in geriatric patients exposed to promethazine.",relevant,0.4346258,of,0.5628227,natural-language,0.5076148
"The risk of fractures, acute myocardial infarction, atrial fibrillation and ventricular arrhythmia in geriatric patients exposed to promethazine.",predictor,0.43901688,regression,0.5961869,regression,0.5961869
"The risk of fractures, acute myocardial infarction, atrial fibrillation and ventricular arrhythmia in geriatric patients exposed to promethazine.",medical,0.37876463,data-science,0.59196365,data-science,0.59196365
"The risk of fractures, acute myocardial infarction, atrial fibrillation and ventricular arrhythmia in geriatric patients exposed to promethazine.",history,0.32837912,recurrent,0.5897511,regression,0.3962426
"The risk of fractures, acute myocardial infarction, atrial fibrillation and ventricular arrhythmia in geriatric patients exposed to promethazine.",medical-history,0.4635914,data-science,0.6264156,data-science,0.6264156
"The risk of fractures, acute myocardial infarction, atrial fibrillation and ventricular arrhythmia in geriatric patients exposed to promethazine.",data,0.46434748,data,1.0,data-science,0.5533528
"The risk of fractures, acute myocardial infarction, atrial fibrillation and ventricular arrhythmia in geriatric patients exposed to promethazine.",sources,0.32459462,data,0.5118194,data-science,0.4587717
"The risk of fractures, acute myocardial infarction, atrial fibrillation and ventricular arrhythmia in geriatric patients exposed to promethazine.",data-sources,0.58246005,data-science,0.72726756,data-science,0.72726756
"The risk of fractures, acute myocardial infarction, atrial fibrillation and ventricular arrhythmia in geriatric patients exposed to promethazine.",risk,0.35860935,recurrent,0.53675485,logistic-regression,0.52381086
"The risk of fractures, acute myocardial infarction, atrial fibrillation and ventricular arrhythmia in geriatric patients exposed to promethazine.",stratification,0.45885193,classification-algorithm,0.6005924,classification-algorithm,0.6005924
"The risk of fractures, acute myocardial infarction, atrial fibrillation and ventricular arrhythmia in geriatric patients exposed to promethazine.",risk-stratification,0.56299007,classification-algorithm,0.6976296,classification-algorithm,0.6976296
"The risk of fractures, acute myocardial infarction, atrial fibrillation and ventricular arrhythmia in geriatric patients exposed to promethazine.",increased,0.26921988,reduction,0.6514183,boosting,0.46515882
"The risk of fractures, acute myocardial infarction, atrial fibrillation and ventricular arrhythmia in geriatric patients exposed to promethazine.",risk,0.35860935,recurrent,0.53675485,logistic-regression,0.52381086
"The risk of fractures, acute myocardial infarction, atrial fibrillation and ventricular arrhythmia in geriatric patients exposed to promethazine.",increased-risk,0.39064288,logistic-regression,0.491068,logistic-regression,0.491068
"The risk of fractures, acute myocardial infarction, atrial fibrillation and ventricular arrhythmia in geriatric patients exposed to promethazine.",promethazine,0.24053344,confusion,0.41455728,confusion-matrix,0.3746753
"The risk of fractures, acute myocardial infarction, atrial fibrillation and ventricular arrhythmia in geriatric patients exposed to promethazine.",hospitalization,0.23343414,confusion,0.51795703,logistic-regression,0.47011706
"The risk of fractures, acute myocardial infarction, atrial fibrillation and ventricular arrhythmia in geriatric patients exposed to promethazine.",xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
"The risk of fractures, acute myocardial infarction, atrial fibrillation and ventricular arrhythmia in geriatric patients exposed to promethazine.",risk,0.35860935,recurrent,0.53675485,logistic-regression,0.52381086
"The risk of fractures, acute myocardial infarction, atrial fibrillation and ventricular arrhythmia in geriatric patients exposed to promethazine.",used,0.46049535,of,0.5630944,generative-model,0.4901716
"The risk of fractures, acute myocardial infarction, atrial fibrillation and ventricular arrhythmia in geriatric patients exposed to promethazine.",unadjusted,0.36217642,logistic-regression,0.75050235,logistic-regression,0.75050235
"The risk of fractures, acute myocardial infarction, atrial fibrillation and ventricular arrhythmia in geriatric patients exposed to promethazine.",triazolam,0.29982093,discriminative,0.47272325,reinforcement-learning,0.40176928
"The risk of fractures, acute myocardial infarction, atrial fibrillation and ventricular arrhythmia in geriatric patients exposed to promethazine.",secondly,0.45954734,of,0.6712935,generative,0.57302815
"The risk of fractures, acute myocardial infarction, atrial fibrillation and ventricular arrhythmia in geriatric patients exposed to promethazine.",results,0.32376552,data,0.6932311,batch-normalization,0.44826904
"The risk of fractures, acute myocardial infarction, atrial fibrillation and ventricular arrhythmia in geriatric patients exposed to promethazine.",perform,0.48924625,supervised,0.522915,supervised,0.522915
"The risk of fractures, acute myocardial infarction, atrial fibrillation and ventricular arrhythmia in geriatric patients exposed to promethazine.",patient,0.2998137,confusion,0.5356896,confusion-matrix,0.41404122
"The risk of fractures, acute myocardial infarction, atrial fibrillation and ventricular arrhythmia in geriatric patients exposed to promethazine.",p,0.26795468,support,0.40805867,regression,0.40253854
"The risk of fractures, acute myocardial infarction, atrial fibrillation and ventricular arrhythmia in geriatric patients exposed to promethazine.",objectives,0.41173956,of,0.53322846,feature-engineering,0.42803428
"The risk of fractures, acute myocardial infarction, atrial fibrillation and ventricular arrhythmia in geriatric patients exposed to promethazine.",methods,0.50049126,data,0.5400177,machine-learning,0.50049126
"The risk of fractures, acute myocardial infarction, atrial fibrillation and ventricular arrhythmia in geriatric patients exposed to promethazine.",loratadine,0.27364352,one,0.35825744,confusion-matrix,0.33627114
"The risk of fractures, acute myocardial infarction, atrial fibrillation and ventricular arrhythmia in geriatric patients exposed to promethazine.",investigation,0.33686116,analysis,0.63110995,component-analysis,0.46827114
"The risk of fractures, acute myocardial infarction, atrial fibrillation and ventricular arrhythmia in geriatric patients exposed to promethazine.",identify,0.46963936,analysis,0.5445881,clustering,0.4863696
"The risk of fractures, acute myocardial infarction, atrial fibrillation and ventricular arrhythmia in geriatric patients exposed to promethazine.",fractures,0.23601449,augmentation,0.38747475,data-augmentation,0.3867499
"The risk of fractures, acute myocardial infarction, atrial fibrillation and ventricular arrhythmia in geriatric patients exposed to promethazine.",followed,0.25369444,of,0.5874107,supervised,0.45495358
"The risk of fractures, acute myocardial infarction, atrial fibrillation and ventricular arrhythmia in geriatric patients exposed to promethazine.",domperidone,0.2605226,feed,0.3743804,data-augmentation,0.32416713
"The risk of fractures, acute myocardial infarction, atrial fibrillation and ventricular arrhythmia in geriatric patients exposed to promethazine.",conclusion,0.35530132,data,0.5299138,long-short-term,0.45073265
"The risk of fractures, acute myocardial infarction, atrial fibrillation and ventricular arrhythmia in geriatric patients exposed to promethazine.",compute,0.59251976,hidden-markov-model,0.68740803,hidden-markov-model,0.68740803
"The risk of fractures, acute myocardial infarction, atrial fibrillation and ventricular arrhythmia in geriatric patients exposed to promethazine.",compare,0.43674475,short-term,0.510365,statistical,0.44797724
"The risk of fractures, acute myocardial infarction, atrial fibrillation and ventricular arrhythmia in geriatric patients exposed to promethazine.",betahistine,0.2590788,short-term,0.37346584,data-augmentation,0.3364341
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,cleaned,0.3096254,bag,0.53669274,bagging,0.509154
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,segmentation,0.62158525,segmentation,1.0,segmentation,1.0
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,results,0.32376552,data,0.6932311,batch-normalization,0.44826904
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,using,0.47332245,analysis,0.5968549,component-analysis,0.526608
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,conditional,0.46229088,stochastic,0.6116671,stochastic,0.6116671
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,random,0.45551494,random,1.0,random-forest,0.65894985
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,field,0.3582328,forward,0.4830246,generative-model,0.46159878
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,processing,0.46109343,processing,1.0,graphics-processing,0.75397617
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,results-using,0.46982992,data,0.5733055,batch-normalization,0.48212063
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,random-field,0.49083787,random-forest,0.7325227,random-forest,0.7325227
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,five,0.3705204,one,0.7489015,principal-components,0.4074809
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,lesions,0.32295382,recurrent,0.46750677,segmentation,0.40412176
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,gave,0.17497762,of,0.4661737,relu,0.35782668
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,exact,0.40348664,statistical,0.6096237,statistical,0.6096237
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,agreement,0.33578783,ground-truth,0.562427,ground-truth,0.562427
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,exact-agreement,0.44699866,ground-truth,0.6497883,ground-truth,0.6497883
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,altman,0.3402603,principal-component-analysis,0.5025161,principal-component-analysis,0.5025161
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,analysis,0.46507934,analysis,0.99999994,component-analysis,0.69613737
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,suggested,0.30397683,of,0.6234695,clustering,0.4426524
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,strong,0.2620057,of,0.4821326,boosting,0.45579183
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,correlation,0.355416,regression,0.5743689,regression,0.5743689
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,altman-analysis,0.5296148,principal-component-analysis,0.76270497,principal-component-analysis,0.76270497
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,analysis-suggested,0.50981313,analysis,0.76247686,component-analysis,0.70334226
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,strong-correlation,0.5214039,cross-entropy,0.74557215,cross-entropy,0.74557215
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,dataset,0.6046342,data,0.68842554,classifiers,0.6499833
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,included,0.34673893,of,0.58040446,component-analysis,0.47413814
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,vois,0.4301244,ground-truth,0.5902163,ground-truth,0.5902163
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,taken,0.31208742,data,0.5517592,supervised,0.41763523
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,following,0.27415842,of,0.60616374,long-short-term,0.4591148
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,segmentation,0.62158525,segmentation,1.0,segmentation,1.0
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,noise,0.45596915,overfitting,0.5883086,overfitting,0.5883086
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,cleaning,0.38513583,bagging,0.5339494,bagging,0.5339494
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,noise-cleaning,0.50734603,bagging,0.5706917,bagging,0.5706917
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,part,0.25869048,of,0.6214935,component-analysis,0.47792363
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,requires,0.35710368,of,0.62298405,stochastic,0.42198688
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,full,0.3269437,fully,0.61890495,softmax,0.42416686
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,attribution,0.45228666,dimensionality-reduction,0.64022267,dimensionality-reduction,0.64022267
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,part-requires,0.44980425,of,0.52904314,feature-reduction,0.518382
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,intravascular,0.26833332,of,0.40842503,confusion-matrix,0.39186925
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,optical,0.41040304,fourier-transform,0.63333535,fourier-transform,0.63333535
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,coherence,0.39348912,regularization,0.5546586,cross-entropy,0.53685623
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,tomography,0.37376836,computer,0.48697567,segmentation,0.4668427
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,intravascular-optical,0.421439,few-shot,0.5887617,convolutional-layer,0.53424174
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,optical-coherence,0.45506707,few-shot,0.6808274,fourier,0.63143253
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,coherence-tomography,0.51663184,ground-truth,0.6277213,ground-truth,0.6277213
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,optical-coherence-tomography,0.5078306,few-shot,0.69420284,convolutional-layer,0.6391543
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,performing,0.5002452,supervised,0.5804485,supervised,0.5804485
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,percutaneous,0.26580995,short-term,0.41344544,data-augmentation,0.38650423
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,coronary,0.25158757,of,0.3349695,segmentation-algorithm,0.31949025
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,interventions,0.3916263,decision,0.5218073,reinforcement-learning,0.50423867
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,percutaneous-coronary,0.2850216,augmentation,0.4207856,data-augmentation,0.3907336
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,creative,0.5351002,data-science,0.6729189,data-science,0.6729189
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,commons,0.43191135,data-science,0.6148261,data-science,0.6148261
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,attribution,0.45228666,dimensionality-reduction,0.64022267,dimensionality-reduction,0.64022267
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,creative-commons,0.50815237,natural-language-processing,0.65252197,natural-language-processing,0.65252197
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,inhibit,0.20672277,reduction,0.40817326,boosting,0.35371703
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,proper,0.3570277,of,0.5900549,segmentation,0.4722571
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,stent,0.22674266,recurrent,0.4346162,confusion-matrix,0.38714895
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,deployment,0.36206874,data-engineering,0.48678577,data-engineering,0.48678577
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,stent-deployment,0.31455088,decision-tree,0.42200398,decision-tree,0.42200398
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,manually,0.5226127,segmentation,0.59192413,segmentation,0.59192413
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,annotated,0.52481097,encoding,0.556693,classifiers,0.5364969
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,ivoct,0.41648716,ground-truth,0.5920161,ground-truth,0.5920161
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,volumes,0.3091632,segmentation,0.46953943,segmentation,0.46953943
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,manually-annotated,0.6867008,machine-learning,0.6867008,machine-learning,0.6867008
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,automatically,0.65330756,segmentation,0.6840899,segmentation,0.6840899
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,determined,0.2643224,of,0.6221287,batch-normalization,0.4203323
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,calcification,0.24288787,matrix,0.42871797,segmentation,0.42117316
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,depth,0.33388495,deep,0.6041881,ground-truth,0.48930064
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,automatically-determined,0.58568215,segmentation-algorithm,0.66430044,segmentation-algorithm,0.66430044
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,coronary,0.25158757,of,0.3349695,segmentation-algorithm,0.31949025
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,calcification,0.24288787,matrix,0.42871797,segmentation,0.42117316
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,lesions,0.32295382,recurrent,0.46750677,segmentation,0.40412176
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,coronary-calcification,0.33226025,segmentation-algorithm,0.47272786,segmentation-algorithm,0.47272786
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,deployment,0.36206874,data-engineering,0.48678577,data-engineering,0.48678577
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,calcification,0.24288787,matrix,0.42871797,segmentation,0.42117316
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,scores,0.40591323,intelligence,0.56987673,principal-components,0.4971624
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,deployment,0.36206874,data-engineering,0.48678577,data-engineering,0.48678577
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,calcification,0.24288787,matrix,0.42871797,segmentation,0.42117316
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,score,0.38515997,classification-algorithm,0.5352135,classification-algorithm,0.5352135
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,unported,0.2764594,ground,0.47342163,feature-reduction,0.40891936
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,license,0.37433738,data-science,0.4810462,data-science,0.4810462
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,clinical,0.44080526,data,0.48532635,data-science,0.45343333
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,pullbacks,0.42889342,ground-truth,0.5945888,ground-truth,0.5945888
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,two,0.35955608,one,0.79919666,clustering,0.43817294
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,expert,0.5552304,data-science,0.6404677,data-science,0.6404677
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,analysts,0.5297444,data-science,0.6941824,data-science,0.6941824
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,two-expert,0.6078256,machine-learning,0.6078256,machine-learning,0.6078256
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,expert-analysts,0.63157904,data-science,0.7243667,data-science,0.7243667
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,keeping,0.31571785,support,0.5209409,bagging,0.46083993
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,vois,0.4301244,ground-truth,0.5902163,ground-truth,0.5902163
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,intact,0.20905745,fully,0.50804675,generative,0.34300572
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,fujino,0.24180806,graphics,0.42096525,pytorch,0.41976503
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,et,0.21257874,science,0.40568537,bagging,0.326393
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,al,0.23148684,of,0.41219345,confusion-matrix,0.34880346
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,et-al,0.23105708,dimensionality-reduction,0.35698155,dimensionality-reduction,0.35698155
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,convolutional,0.77214557,convolutional,1.0,convolutional,1.0
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,neural,0.5080686,neural,1.0,neural-network,0.7153882
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,network,0.50771487,network,1.0,neural-network,0.7589166
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,neural-network,0.7034505,neural-network,1.0,neural-network,1.0
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,classification,0.5994266,classification,1.0,classification,1.0
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,approach,0.5412675,segmentation-algorithm,0.6046611,segmentation-algorithm,0.6046611
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,could,0.34235194,of,0.59299076,boosting,0.42074972
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,approach-could,0.5263736,dimensionality-reduction,0.64798146,dimensionality-reduction,0.64798146
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,automatically,0.65330756,segmentation,0.6840899,segmentation,0.6840899
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,obtained,0.32073808,of,0.62274206,batch-normalization,0.46598285
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,stent,0.22674266,recurrent,0.4346162,confusion-matrix,0.38714895
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,automatically-obtained,0.6032182,graphics-processing,0.64353186,graphics-processing,0.64353186
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,automatically,0.65330756,segmentation,0.6840899,segmentation,0.6840899
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,obtained,0.32073808,of,0.62274206,batch-normalization,0.46598285
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,lumen,0.18588215,bag,0.48108435,convolutional-layer,0.3811438
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,automatically-obtained,0.6032182,graphics-processing,0.64353186,graphics-processing,0.64353186
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,impact,0.3818503,of,0.5528908,dimensionality-reduction,0.4648105
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,using,0.47332245,analysis,0.5968549,component-analysis,0.526608
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,calcifications,0.29459453,segmentation,0.44597572,segmentation,0.44597572
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,using,0.47332245,analysis,0.5968549,component-analysis,0.526608
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,without,0.31691062,of,0.5951073,long-short-term,0.4268921
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,lesions,0.32295382,recurrent,0.46750677,segmentation,0.40412176
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,mixed,0.2972577,of,0.4628052,generative-model,0.45958292
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,lesions,0.32295382,recurrent,0.46750677,segmentation,0.40412176
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,mixed-lesions,0.46435374,deep-learning,0.51478064,deep-learning,0.51478064
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,performed,0.3864032,analysis,0.5711501,supervised,0.4789877
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,calcification,0.24288787,matrix,0.42871797,segmentation,0.42117316
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,attributes,0.47786054,dimensionality-reduction,0.6120416,dimensionality-reduction,0.6120416
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,obtained,0.32073808,of,0.62274206,batch-normalization,0.46598285
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,sensitivities,0.26293686,discriminative,0.4775945,cross-validation,0.42380488
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,results,0.32376552,data,0.6932311,batch-normalization,0.44826904
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,vascular,0.27131236,neural,0.45896766,convolutional,0.3685425
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,lumen,0.18588215,bag,0.48108435,convolutional-layer,0.3811438
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,vascular-lumen,0.25834358,convolutional-layer,0.45084387,convolutional-layer,0.45084387
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,treatment,0.239264,short-term,0.5206091,long-short-term,0.41699445
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,planning,0.46013993,decision,0.69077367,decision-tree,0.5463208
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,treatment-planning,0.51118636,decision-tree,0.6082097,decision-tree,0.6082097
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,tissue,0.23679586,of,0.5202017,segmentation,0.4076932
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,classes,0.42913696,multi-class,0.5125835,classification,0.5097946
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,tissue-classes,0.52526414,classifiers,0.56226444,classifiers,0.56226444
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,thickness,0.21353433,layer,0.69442725,convolutional-layer,0.47592473
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,attributes,0.47786054,dimensionality-reduction,0.6120416,dimensionality-reduction,0.6120416
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,pretrained,0.57215,learning-function,0.6364049,learning-function,0.6364049
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,segnet,0.57341295,segmentation-algorithm,0.6361444,segmentation-algorithm,0.6361444
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,original,0.41515705,of,0.5401661,feature-reduction,0.51911664
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,publication,0.4165166,data-science,0.64893234,data-science,0.64893234
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,great,0.31200224,of,0.56574446,feature-engineering,0.44874108
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,concern,0.2617717,confusion,0.65010685,data-science,0.43675148
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,fold,0.32232243,of,0.4827961,convolutional,0.39711127
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,cross,0.22060364,shot,0.42420566,cross-entropy,0.41595078
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,fold-cross,0.47423577,xgboost,0.55103475,xgboost,0.55103475
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,comprehensive,0.5203603,data,0.6056672,data-engineering,0.58421016
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,software,0.6104226,computer,0.74513555,computer-vision,0.6394764
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,applied,0.44175404,of,0.5047146,bagging,0.47554293
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,clinically,0.3702051,recurrent,0.5046643,confusion-matrix,0.40397355
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,segment,0.1674358,long,0.5143941,segmentation,0.46774617
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,calcifications,0.29459453,segmentation,0.44597572,segmentation,0.44597572
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,major,0.2356064,principal,0.70253855,principal-components,0.42016473
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,calcifications,0.29459453,segmentation,0.44597572,segmentation,0.44597572
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,vivo,0.31561637,of,0.48691544,generative-model,0.4255858
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,images,0.46598992,segmentation,0.6703193,segmentation,0.6703193
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,segmented,0.47492567,segmentation,0.7682447,segmentation,0.7682447
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,regions,0.3024192,segmentation,0.47672227,segmentation,0.47672227
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,agreement,0.33578783,ground-truth,0.562427,ground-truth,0.562427
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,vois,0.4301244,ground-truth,0.5902163,ground-truth,0.5902163
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,stent,0.22674266,recurrent,0.4346162,confusion-matrix,0.38714895
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,manually,0.5226127,segmentation,0.59192413,segmentation,0.59192413
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,ivoct,0.41648716,ground-truth,0.5920161,ground-truth,0.5920161
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,determined,0.2643224,of,0.6221287,batch-normalization,0.4203323
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,lumen,0.18588215,bag,0.48108435,convolutional-layer,0.3811438
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,calcifications,0.29459453,segmentation,0.44597572,segmentation,0.44597572
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,segmented,0.47492567,segmentation,0.7682447,segmentation,0.7682447
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,images,0.46598992,segmentation,0.6703193,segmentation,0.6703193
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,work,0.42713583,support,0.5373766,learning-function,0.5011815
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,whole,0.3066609,of,0.548425,batch-normalization,0.49255443
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,validation,0.5362086,cross-validation,0.74016297,cross-validation,0.74016297
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,total,0.21723771,of,0.5102532,principal-components,0.3630478
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,task,0.5084964,object-tracking,0.69268537,object-tracking,0.69268537
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,suggest,0.26874092,data,0.5391823,long-short-term,0.40288782
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,spie,0.31960157,data-science,0.4277547,data-science,0.4277547
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,respectively,0.23184536,of,0.43360457,cross-validation,0.35765702
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,reproduction,0.30214858,generative,0.5646367,generative,0.5646367
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,reported,0.27641866,of,0.6039252,long-short-term,0.38086164
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,refined,0.44372547,classification-algorithm,0.47498274,classification-algorithm,0.47498274
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,published,0.42179614,data,0.6147139,data-science,0.54664624
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,method,0.482283,algorithm,0.63295126,algorithm,0.63295126
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,lipidous,0.24707301,of,0.39466053,feature-reduction,0.3394677
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,interest,0.4194936,of,0.5624063,feature-engineering,0.5448084
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,including,0.3233776,of,0.6619886,clustering,0.40625107
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,good,0.29142508,few,0.4427599,bagging,0.41576368
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,giving,0.27247667,of,0.63071287,generative,0.47321296
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,four,0.34899807,one,0.769816,clustering,0.40005642
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,evaluated,0.35501102,of,0.6190806,supervised,0.4124783
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,encouraging,0.41850206,support,0.5758333,supervised,0.49052745
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,doi,0.2357645,data-science,0.3312925,data-science,0.3312925
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,distribution,0.30514538,of,0.5765607,clustering,0.53621584
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,data,0.46434748,data,1.0,data-science,0.5533528
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,created,0.44611198,feature-engineering,0.5674809,feature-engineering,0.5674809
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,consensus,0.41497663,classification-algorithm,0.5168837,classification-algorithm,0.5168837
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,calculate,0.43674397,monte-carlo,0.598953,monte-carlo,0.598953
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,calcified,0.24221024,segmentation,0.4274801,segmentation,0.4274801
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,bland,0.27620202,confusion-matrix,0.4348093,confusion-matrix,0.4348093
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,authors,0.45811802,data,0.5259881,natural-language-processing,0.4706872
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,assessment,0.4002061,analysis,0.5275976,component-analysis,0.49803802
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,annotations,0.65051174,classifiers,0.6550341,classifiers,0.6550341
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,angle,0.22047243,fourier,0.4550084,fourier,0.4550084
Prediction of Left Ventricular Mechanics Using Machine Learning.,altered,0.28369883,of,0.5963239,generative,0.4193554
Prediction of Left Ventricular Mechanics Using Machine Learning.,using,0.47332245,analysis,0.5968549,component-analysis,0.526608
Prediction of Left Ventricular Mechanics Using Machine Learning.,optimal,0.39098042,selection,0.5284126,algorithm,0.5276129
Prediction of Left Ventricular Mechanics Using Machine Learning.,latin,0.36570612,federated,0.52475035,natural-language,0.49884292
Prediction of Left Ventricular Mechanics Using Machine Learning.,hypercube,0.63937163,hidden-markov-model,0.6934447,hidden-markov-model,0.6934447
Prediction of Left Ventricular Mechanics Using Machine Learning.,design,0.47555828,data-engineering,0.6477308,data-engineering,0.6477308
Prediction of Left Ventricular Mechanics Using Machine Learning.,latin-hypercube,0.5575315,bayesian-network,0.62595713,bayesian-network,0.62595713
Prediction of Left Ventricular Mechanics Using Machine Learning.,mechanics,0.4424843,machine,0.527952,stochastic,0.48840755
Prediction of Left Ventricular Mechanics Using Machine Learning.,simulator,0.5710252,computer,0.67927724,computer-vision,0.63387287
Prediction of Left Ventricular Mechanics Using Machine Learning.,using,0.47332245,analysis,0.5968549,component-analysis,0.526608
Prediction of Left Ventricular Mechanics Using Machine Learning.,machine,0.7094662,machine,1.0,machine-learning,0.7094662
Prediction of Left Ventricular Mechanics Using Machine Learning.,learning,0.709237,learning,1.0,deep-learning,0.8286492
Prediction of Left Ventricular Mechanics Using Machine Learning.,machine-learning,1.0,machine-learning,1.0,machine-learning,1.0
Prediction of Left Ventricular Mechanics Using Machine Learning.,predict,0.51602554,model,0.53463185,classification-algorithm,0.52342355
Prediction of Left Ventricular Mechanics Using Machine Learning.,lv,0.2556107,tensorflow,0.3751968,tensorflow,0.3751968
Prediction of Left Ventricular Mechanics Using Machine Learning.,mechanics,0.4424843,machine,0.527952,stochastic,0.48840755
Prediction of Left Ventricular Mechanics Using Machine Learning.,much,0.30250478,few,0.5868126,long-short-term,0.42466134
Prediction of Left Ventricular Mechanics Using Machine Learning.,faster,0.31857643,rate,0.53554505,long-short-term,0.43033096
Prediction of Left Ventricular Mechanics Using Machine Learning.,much-faster,0.36415994,one-shot,0.48680294,one-shot,0.48680294
Prediction of Left Ventricular Mechanics Using Machine Learning.,used,0.46049535,of,0.5630944,generative-model,0.4901716
Prediction of Left Ventricular Mechanics Using Machine Learning.,extreme,0.32125288,of,0.49474275,long-short-term,0.45117995
Prediction of Left Ventricular Mechanics Using Machine Learning.,gradient,0.3245376,gradient,1.0,gradient,1.0
Prediction of Left Ventricular Mechanics Using Machine Learning.,boosting,0.5170957,boosting,1.0,boosting,1.0
Prediction of Left Ventricular Mechanics Using Machine Learning.,gradient-boosting,0.58845866,gradient-descent,0.78475267,gradient-descent,0.78475267
Prediction of Left Ventricular Mechanics Using Machine Learning.,simulation,0.59933746,monte-carlo,0.75438184,monte-carlo,0.75438184
Prediction of Left Ventricular Mechanics Using Machine Learning.,results,0.32376552,data,0.6932311,batch-normalization,0.44826904
Prediction of Left Ventricular Mechanics Using Machine Learning.,show,0.33248252,of,0.51487744,feature-selection,0.44449317
Prediction of Left Ventricular Mechanics Using Machine Learning.,ml,0.29010946,bag,0.4418462,gradient,0.3396448
Prediction of Left Ventricular Mechanics Using Machine Learning.,ml,0.29010946,bag,0.4418462,gradient,0.3396448
Prediction of Left Ventricular Mechanics Using Machine Learning.,results,0.32376552,data,0.6932311,batch-normalization,0.44826904
Prediction of Left Ventricular Mechanics Using Machine Learning.,could,0.34235194,of,0.59299076,boosting,0.42074972
Prediction of Left Ventricular Mechanics Using Machine Learning.,capture,0.4189438,tracking,0.5820073,object-tracking,0.4910211
Prediction of Left Ventricular Mechanics Using Machine Learning.,results-could,0.37463674,data,0.465872,batch-normalization,0.45300645
Prediction of Left Ventricular Mechanics Using Machine Learning.,obtain,0.38573402,of,0.51702356,batch-normalization,0.46553272
Prediction of Left Ventricular Mechanics Using Machine Learning.,training,0.54553735,learning,0.69909495,supervised,0.6973169
Prediction of Left Ventricular Mechanics Using Machine Learning.,fe,0.30323914,feature-reduction,0.41256925,feature-reduction,0.41256925
Prediction of Left Ventricular Mechanics Using Machine Learning.,models,0.53762007,model,0.8940372,markov-model,0.7015921
Prediction of Left Ventricular Mechanics Using Machine Learning.,fe-models,0.58234704,model,0.6824691,generative-model,0.68201643
Prediction of Left Ventricular Mechanics Using Machine Learning.,time,0.31186903,long,0.57547164,batch-normalization,0.47628766
Prediction of Left Ventricular Mechanics Using Machine Learning.,left,0.2544507,tracking,0.42924023,object-tracking,0.3633091
Prediction of Left Ventricular Mechanics Using Machine Learning.,ventricular,0.24852064,rate,0.37094042,long-short-term,0.34148398
Prediction of Left Ventricular Mechanics Using Machine Learning.,time-left,0.40916422,object-tracking,0.63705724,object-tracking,0.63705724
Prediction of Left Ventricular Mechanics Using Machine Learning.,left-ventricular,0.30000108,batch-normalization,0.40942025,batch-normalization,0.40942025
Prediction of Left Ventricular Mechanics Using Machine Learning.,mean,0.24598047,reduction,0.46440193,batch-normalization,0.434582
Prediction of Left Ventricular Mechanics Using Machine Learning.,absolute,0.27931842,reduction,0.5066942,batch-normalization,0.479002
Prediction of Left Ventricular Mechanics Using Machine Learning.,errors,0.4355805,overfitting,0.5895048,overfitting,0.5895048
Prediction of Left Ventricular Mechanics Using Machine Learning.,mean-absolute,0.39863324,cross-entropy,0.5851491,cross-entropy,0.5851491
Prediction of Left Ventricular Mechanics Using Machine Learning.,predict,0.51602554,model,0.53463185,classification-algorithm,0.52342355
Prediction of Left Ventricular Mechanics Using Machine Learning.,lv,0.2556107,tensorflow,0.3751968,tensorflow,0.3751968
Prediction of Left Ventricular Mechanics Using Machine Learning.,behavior,0.3131135,style,0.5405977,reinforcement-learning,0.5272814
Prediction of Left Ventricular Mechanics Using Machine Learning.,different,0.37681934,of,0.61590904,clustering,0.46857932
Prediction of Left Ventricular Mechanics Using Machine Learning.,material,0.29113075,layer,0.5353535,embeddings,0.4504638
Prediction of Left Ventricular Mechanics Using Machine Learning.,properties,0.31064022,function,0.5521828,feature-engineering,0.53029627
Prediction of Left Ventricular Mechanics Using Machine Learning.,different-material,0.44317162,artificial-intelligence,0.6136874,artificial-intelligence,0.6136874
Prediction of Left Ventricular Mechanics Using Machine Learning.,material-properties,0.48148125,feature-engineering,0.636562,feature-engineering,0.636562
Prediction of Left Ventricular Mechanics Using Machine Learning.,reinforced,0.29011825,reinforcement,0.8259795,reinforcement-learning,0.68843716
Prediction of Left Ventricular Mechanics Using Machine Learning.,material,0.29113075,layer,0.5353535,embeddings,0.4504638
Prediction of Left Ventricular Mechanics Using Machine Learning.,model,0.48485535,model,1.0,markov-model,0.7005576
Prediction of Left Ventricular Mechanics Using Machine Learning.,material-model,0.596798,generative-model,0.70287955,generative-model,0.70287955
Prediction of Left Ventricular Mechanics Using Machine Learning.,lv,0.2556107,tensorflow,0.3751968,tensorflow,0.3751968
Prediction of Left Ventricular Mechanics Using Machine Learning.,constitutive,0.30203718,encoding,0.5229391,stochastic,0.47046924
Prediction of Left Ventricular Mechanics Using Machine Learning.,equation,0.44570905,markov-model,0.6179094,markov-model,0.6179094
Prediction of Left Ventricular Mechanics Using Machine Learning.,varied,0.2661568,of,0.56987137,gradient,0.3864601
Prediction of Left Ventricular Mechanics Using Machine Learning.,passive,0.3341275,reinforcement-learning,0.5059211,reinforcement-learning,0.5059211
Prediction of Left Ventricular Mechanics Using Machine Learning.,properties,0.31064022,function,0.5521828,feature-engineering,0.53029627
Prediction of Left Ventricular Mechanics Using Machine Learning.,passive,0.3341275,reinforcement-learning,0.5059211,reinforcement-learning,0.5059211
Prediction of Left Ventricular Mechanics Using Machine Learning.,properties,0.31064022,function,0.5521828,feature-engineering,0.53029627
Prediction of Left Ventricular Mechanics Using Machine Learning.,govern,0.3271321,stochastic,0.5783081,stochastic,0.5783081
Prediction of Left Ventricular Mechanics Using Machine Learning.,volume,0.268351,segmentation,0.4447226,segmentation,0.4447226
Prediction of Left Ventricular Mechanics Using Machine Learning.,results,0.32376552,data,0.6932311,batch-normalization,0.44826904
Prediction of Left Ventricular Mechanics Using Machine Learning.,obtained,0.32073808,of,0.62274206,batch-normalization,0.46598285
Prediction of Left Ventricular Mechanics Using Machine Learning.,volume-results,0.26371795,batch-normalization,0.40746108,batch-normalization,0.40746108
Prediction of Left Ventricular Mechanics Using Machine Learning.,results-obtained,0.37493312,data,0.58166623,batch-normalization,0.49567088
Prediction of Left Ventricular Mechanics Using Machine Learning.,ml,0.29010946,bag,0.4418462,gradient,0.3396448
Prediction of Left Ventricular Mechanics Using Machine Learning.,model,0.48485535,model,1.0,markov-model,0.7005576
Prediction of Left Ventricular Mechanics Using Machine Learning.,based,0.49998575,classification-algorithm,0.5639226,classification-algorithm,0.5639226
Prediction of Left Ventricular Mechanics Using Machine Learning.,model-based,0.71087694,bayesian,0.8056512,bayesian,0.8056512
Prediction of Left Ventricular Mechanics Using Machine Learning.,real,0.4954688,truth,0.5802553,ground-truth,0.56635034
Prediction of Left Ventricular Mechanics Using Machine Learning.,world,0.39139682,federated,0.63472044,data-science,0.5328648
Prediction of Left Ventricular Mechanics Using Machine Learning.,applications,0.4878226,data-engineering,0.70112944,data-engineering,0.70112944
Prediction of Left Ventricular Mechanics Using Machine Learning.,real-world,0.56185627,object-tracking,0.6007177,object-tracking,0.6007177
Prediction of Left Ventricular Mechanics Using Machine Learning.,cross,0.22060364,shot,0.42420566,cross-entropy,0.41595078
Prediction of Left Ventricular Mechanics Using Machine Learning.,myofiber,0.23409155,matrix,0.41113454,confusion-matrix,0.3521245
Prediction of Left Ventricular Mechanics Using Machine Learning.,stress,0.25135952,short-term,0.46436286,long-short-term,0.43407696
Prediction of Left Ventricular Mechanics Using Machine Learning.,varied,0.2661568,of,0.56987137,gradient,0.3864601
Prediction of Left Ventricular Mechanics Using Machine Learning.,active,0.24791542,of,0.5219437,generative,0.39641887
Prediction of Left Ventricular Mechanics Using Machine Learning.,properties,0.31064022,function,0.5521828,feature-engineering,0.53029627
Prediction of Left Ventricular Mechanics Using Machine Learning.,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
Prediction of Left Ventricular Mechanics Using Machine Learning.,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
Prediction of Left Ventricular Mechanics Using Machine Learning.,stress,0.25135952,short-term,0.46436286,long-short-term,0.43407696
Prediction of Left Ventricular Mechanics Using Machine Learning.,predictions,0.5737018,model,0.6239941,markov-model,0.61843884
Prediction of Left Ventricular Mechanics Using Machine Learning.,results,0.32376552,data,0.6932311,batch-normalization,0.44826904
Prediction of Left Ventricular Mechanics Using Machine Learning.,predicted,0.423177,function,0.49677318,classification-algorithm,0.45761842
Prediction of Left Ventricular Mechanics Using Machine Learning.,ml,0.29010946,bag,0.4418462,gradient,0.3396448
Prediction of Left Ventricular Mechanics Using Machine Learning.,model,0.48485535,model,1.0,markov-model,0.7005576
Prediction of Left Ventricular Mechanics Using Machine Learning.,ml,0.29010946,bag,0.4418462,gradient,0.3396448
Prediction of Left Ventricular Mechanics Using Machine Learning.,passive,0.3341275,reinforcement-learning,0.5059211,reinforcement-learning,0.5059211
Prediction of Left Ventricular Mechanics Using Machine Learning.,behavior,0.3131135,style,0.5405977,reinforcement-learning,0.5272814
Prediction of Left Ventricular Mechanics Using Machine Learning.,myofiber,0.23409155,matrix,0.41113454,confusion-matrix,0.3521245
Prediction of Left Ventricular Mechanics Using Machine Learning.,stress,0.25135952,short-term,0.46436286,long-short-term,0.43407696
Prediction of Left Ventricular Mechanics Using Machine Learning.,mechanical,0.29486492,machine,0.4676534,confusion-matrix,0.39948756
Prediction of Left Ventricular Mechanics Using Machine Learning.,properties,0.31064022,function,0.5521828,feature-engineering,0.53029627
Prediction of Left Ventricular Mechanics Using Machine Learning.,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
Prediction of Left Ventricular Mechanics Using Machine Learning.,ml,0.29010946,bag,0.4418462,gradient,0.3396448
Prediction of Left Ventricular Mechanics Using Machine Learning.,lv,0.2556107,tensorflow,0.3751968,tensorflow,0.3751968
Prediction of Left Ventricular Mechanics Using Machine Learning.,stresses,0.2479626,generative,0.4404182,generative,0.4404182
Prediction of Left Ventricular Mechanics Using Machine Learning.,lv,0.2556107,tensorflow,0.3751968,tensorflow,0.3751968
Prediction of Left Ventricular Mechanics Using Machine Learning.,pressures,0.1957578,gradient,0.4714777,gradient,0.4714777
Prediction of Left Ventricular Mechanics Using Machine Learning.,lv,0.2556107,tensorflow,0.3751968,tensorflow,0.3751968
Prediction of Left Ventricular Mechanics Using Machine Learning.,pressure,0.2060274,gradient,0.4962673,gradient,0.4962673
Prediction of Left Ventricular Mechanics Using Machine Learning.,lv-pressure,0.29371738,support-vector-machine,0.47508636,support-vector-machine,0.47508636
Prediction of Left Ventricular Mechanics Using Machine Learning.,shear,0.26918113,stochastic-gradient,0.47270635,stochastic-gradient,0.47270635
Prediction of Left Ventricular Mechanics Using Machine Learning.,stress,0.25135952,short-term,0.46436286,long-short-term,0.43407696
Prediction of Left Ventricular Mechanics Using Machine Learning.,shear-stress,0.2719736,stochastic-gradient,0.49625403,stochastic-gradient,0.49625403
Prediction of Left Ventricular Mechanics Using Machine Learning.,passive,0.3341275,reinforcement-learning,0.5059211,reinforcement-learning,0.5059211
Prediction of Left Ventricular Mechanics Using Machine Learning.,tissue,0.23679586,of,0.5202017,segmentation,0.4076932
Prediction of Left Ventricular Mechanics Using Machine Learning.,passive-tissue,0.30865026,generative-model,0.48601025,generative-model,0.48601025
Prediction of Left Ventricular Mechanics Using Machine Learning.,training,0.54553735,learning,0.69909495,supervised,0.6973169
Prediction of Left Ventricular Mechanics Using Machine Learning.,set,0.5244544,of,0.5846941,classifiers,0.5500933
Prediction of Left Ventricular Mechanics Using Machine Learning.,training-set,0.57264864,learning-rate,0.6640283,learning-rate,0.6640283
Prediction of Left Ventricular Mechanics Using Machine Learning.,myofiber,0.23409155,matrix,0.41113454,confusion-matrix,0.3521245
Prediction of Left Ventricular Mechanics Using Machine Learning.,contractions,0.21301222,rectified,0.45927733,data-augmentation,0.38818306
Prediction of Left Ventricular Mechanics Using Machine Learning.,active,0.24791542,of,0.5219437,generative,0.39641887
Prediction of Left Ventricular Mechanics Using Machine Learning.,behavior,0.3131135,style,0.5405977,reinforcement-learning,0.5272814
Prediction of Left Ventricular Mechanics Using Machine Learning.,active-behavior,0.32063735,style,0.5380595,reinforcement-learning,0.48444155
Prediction of Left Ventricular Mechanics Using Machine Learning.,fe,0.30323914,feature-reduction,0.41256925,feature-reduction,0.41256925
Prediction of Left Ventricular Mechanics Using Machine Learning.,method,0.482283,algorithm,0.63295126,algorithm,0.63295126
Prediction of Left Ventricular Mechanics Using Machine Learning.,fe-method,0.3846666,principal-component-analysis,0.51919484,principal-component-analysis,0.51919484
Prediction of Left Ventricular Mechanics Using Machine Learning.,fe,0.30323914,feature-reduction,0.41256925,feature-reduction,0.41256925
Prediction of Left Ventricular Mechanics Using Machine Learning.,computations,0.59675324,monte-carlo,0.6846578,monte-carlo,0.6846578
Prediction of Left Ventricular Mechanics Using Machine Learning.,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
Prediction of Left Ventricular Mechanics Using Machine Learning.,mmhg,0.17770334,gradient,0.43026078,gradient,0.43026078
Prediction of Left Ventricular Mechanics Using Machine Learning.,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
Prediction of Left Ventricular Mechanics Using Machine Learning.,kpa,0.14628209,softmax,0.29608524,softmax,0.29608524
Prediction of Left Ventricular Mechanics Using Machine Learning.,volume,0.268351,segmentation,0.4447226,segmentation,0.4447226
Prediction of Left Ventricular Mechanics Using Machine Learning.,loops,0.2809666,connected,0.51036936,feed-forward,0.49998966
Prediction of Left Ventricular Mechanics Using Machine Learning.,volume-loops,0.401626,convolutional-layer,0.51530135,convolutional-layer,0.51530135
Prediction of Left Ventricular Mechanics Using Machine Learning.,pressure,0.2060274,gradient,0.4962673,gradient,0.4962673
Prediction of Left Ventricular Mechanics Using Machine Learning.,predictions,0.5737018,model,0.6239941,markov-model,0.61843884
Prediction of Left Ventricular Mechanics Using Machine Learning.,large,0.2849899,few,0.5687306,clustering,0.4101745
Prediction of Left Ventricular Mechanics Using Machine Learning.,group,0.26103544,of,0.44356787,statistical,0.3923795
Prediction of Left Ventricular Mechanics Using Machine Learning.,large-group,0.4778347,deep-learning,0.55820847,deep-learning,0.55820847
Prediction of Left Ventricular Mechanics Using Machine Learning.,hyperelastic,0.44012788,convolutional-layer,0.5824338,convolutional-layer,0.5824338
Prediction of Left Ventricular Mechanics Using Machine Learning.,fiber,0.2578869,feed,0.5233246,convolutional-layer,0.4094853
Prediction of Left Ventricular Mechanics Using Machine Learning.,heart,0.28300244,rate,0.49867767,batch-normalization,0.3427502
Prediction of Left Ventricular Mechanics Using Machine Learning.,resulting,0.2720453,of,0.6416826,generative,0.46999967
Prediction of Left Ventricular Mechanics Using Machine Learning.,finite,0.4797297,stochastic,0.7057915,stochastic,0.7057915
Prediction of Left Ventricular Mechanics Using Machine Learning.,element,0.30212426,component,0.47262436,component-analysis,0.46868354
Prediction of Left Ventricular Mechanics Using Machine Learning.,finite-element,0.54293966,monte-carlo,0.69345236,monte-carlo,0.69345236
Prediction of Left Ventricular Mechanics Using Machine Learning.,xgboost,0.6712872,xgboost,0.99999994,xgboost,0.99999994
Prediction of Left Ventricular Mechanics Using Machine Learning.,volume,0.268351,segmentation,0.4447226,segmentation,0.4447226
Prediction of Left Ventricular Mechanics Using Machine Learning.,xgboost,0.6712872,xgboost,0.99999994,xgboost,0.99999994
Prediction of Left Ventricular Mechanics Using Machine Learning.,pressure,0.2060274,gradient,0.4962673,gradient,0.4962673
Prediction of Left Ventricular Mechanics Using Machine Learning.,cubist,0.4700258,perceptron,0.5632489,perceptron,0.5632489
Prediction of Left Ventricular Mechanics Using Machine Learning.,volume,0.268351,segmentation,0.4447226,segmentation,0.4447226
Prediction of Left Ventricular Mechanics Using Machine Learning.,cubist,0.4700258,perceptron,0.5632489,perceptron,0.5632489
Prediction of Left Ventricular Mechanics Using Machine Learning.,pressure,0.2060274,gradient,0.4962673,gradient,0.4962673
Prediction of Left Ventricular Mechanics Using Machine Learning.,ml,0.29010946,bag,0.4418462,gradient,0.3396448
Prediction of Left Ventricular Mechanics Using Machine Learning.,lv,0.2556107,tensorflow,0.3751968,tensorflow,0.3751968
Prediction of Left Ventricular Mechanics Using Machine Learning.,used,0.46049535,of,0.5630944,generative-model,0.4901716
Prediction of Left Ventricular Mechanics Using Machine Learning.,obtain,0.38573402,of,0.51702356,batch-normalization,0.46553272
Prediction of Left Ventricular Mechanics Using Machine Learning.,training,0.54553735,learning,0.69909495,supervised,0.6973169
Prediction of Left Ventricular Mechanics Using Machine Learning.,fe,0.30323914,feature-reduction,0.41256925,feature-reduction,0.41256925
Prediction of Left Ventricular Mechanics Using Machine Learning.,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
Prediction of Left Ventricular Mechanics Using Machine Learning.,volume,0.268351,segmentation,0.4447226,segmentation,0.4447226
Prediction of Left Ventricular Mechanics Using Machine Learning.,real,0.4954688,truth,0.5802553,ground-truth,0.56635034
Prediction of Left Ventricular Mechanics Using Machine Learning.,predictions,0.5737018,model,0.6239941,markov-model,0.61843884
Prediction of Left Ventricular Mechanics Using Machine Learning.,active,0.24791542,of,0.5219437,generative,0.39641887
Prediction of Left Ventricular Mechanics Using Machine Learning.,xgboost,0.6712872,xgboost,0.99999994,xgboost,0.99999994
Prediction of Left Ventricular Mechanics Using Machine Learning.,cubist,0.4700258,perceptron,0.5632489,perceptron,0.5632489
Prediction of Left Ventricular Mechanics Using Machine Learning.,well,0.34264985,of,0.59718275,bagging,0.4145819
Prediction of Left Ventricular Mechanics Using Machine Learning.,volumes,0.3091632,segmentation,0.46953943,segmentation,0.46953943
Prediction of Left Ventricular Mechanics Using Machine Learning.,tool,0.58027077,machine-learning,0.58027077,machine-learning,0.58027077
Prediction of Left Ventricular Mechanics Using Machine Learning.,systole,0.23489684,regularization,0.44985598,gradient,0.44377923
Prediction of Left Ventricular Mechanics Using Machine Learning.,subjects,0.34547177,descent,0.47816435,short-term-memory,0.43421033
Prediction of Left Ventricular Mechanics Using Machine Learning.,smoother,0.40932763,convolutional-layer,0.57735366,convolutional-layer,0.57735366
Prediction of Left Ventricular Mechanics Using Machine Learning.,simulations,0.5376376,monte,0.77329695,monte,0.77329695
Prediction of Left Ventricular Mechanics Using Machine Learning.,similar,0.29237732,of,0.56832373,long-short-term,0.4732089
Prediction of Left Ventricular Mechanics Using Machine Learning.,shape,0.37408537,dimensionality-reduction,0.59930617,dimensionality-reduction,0.59930617
Prediction of Left Ventricular Mechanics Using Machine Learning.,provide,0.40841419,support,0.64934516,feature-engineering,0.47702065
Prediction of Left Ventricular Mechanics Using Machine Learning.,prediction,0.6361519,classification-algorithm,0.67946094,classification-algorithm,0.67946094
Prediction of Left Ventricular Mechanics Using Machine Learning.,predictability,0.48511764,short-term,0.59298503,cross-entropy,0.58426833
Prediction of Left Ventricular Mechanics Using Machine Learning.,paper,0.5017176,graphics-processing,0.53198814,graphics-processing,0.53198814
Prediction of Left Ventricular Mechanics Using Machine Learning.,myocardium,0.2283036,function,0.3991398,segmentation,0.3548869
Prediction of Left Ventricular Mechanics Using Machine Learning.,improve,0.45207965,boosting,0.5098576,boosting,0.5098576
Prediction of Left Ventricular Mechanics Using Machine Learning.,goal,0.39629012,feed,0.4949946,reinforcement-learning,0.43070507
Prediction of Left Ventricular Mechanics Using Machine Learning.,follows,0.28163645,words,0.47200269,confusion-matrix,0.39147946
Prediction of Left Ventricular Mechanics Using Machine Learning.,experiments,0.36827093,data,0.55053914,stochastic-gradient,0.48057425
Prediction of Left Ventricular Mechanics Using Machine Learning.,diastole,0.24531642,regularization,0.44402522,gradient,0.43375787
Prediction of Left Ventricular Mechanics Using Machine Learning.,describe,0.47142854,feature-engineering,0.5045319,feature-engineering,0.5045319
Prediction of Left Ventricular Mechanics Using Machine Learning.,conducted,0.39637828,data,0.556862,statistical,0.4670034
Prediction of Left Ventricular Mechanics Using Machine Learning.,added,0.32371867,of,0.5926449,batch-normalization,0.4530739
"New flavonoid - &lt;i&gt;N&lt;/i&gt;,&lt;i&gt;N&lt;/i&gt;-dibenzyl(&lt;i&gt;N&lt;/i&gt;-methyl)amine hybrids: Multi-target-directed agents for Alzheimer´s disease endowed with neurogenic properties.",molecular,0.39914468,of,0.516936,clustering,0.43655443
"New flavonoid - &lt;i&gt;N&lt;/i&gt;,&lt;i&gt;N&lt;/i&gt;-dibenzyl(&lt;i&gt;N&lt;/i&gt;-methyl)amine hybrids: Multi-target-directed agents for Alzheimer´s disease endowed with neurogenic properties.",dynamic,0.4720998,stochastic,0.62950635,stochastic,0.62950635
"New flavonoid - &lt;i&gt;N&lt;/i&gt;,&lt;i&gt;N&lt;/i&gt;-dibenzyl(&lt;i&gt;N&lt;/i&gt;-methyl)amine hybrids: Multi-target-directed agents for Alzheimer´s disease endowed with neurogenic properties.",simulations,0.5376376,monte,0.77329695,monte,0.77329695
"New flavonoid - &lt;i&gt;N&lt;/i&gt;,&lt;i&gt;N&lt;/i&gt;-dibenzyl(&lt;i&gt;N&lt;/i&gt;-methyl)amine hybrids: Multi-target-directed agents for Alzheimer´s disease endowed with neurogenic properties.",showed,0.20766163,of,0.5296177,regression,0.37027335
"New flavonoid - &lt;i&gt;N&lt;/i&gt;,&lt;i&gt;N&lt;/i&gt;-dibenzyl(&lt;i&gt;N&lt;/i&gt;-methyl)amine hybrids: Multi-target-directed agents for Alzheimer´s disease endowed with neurogenic properties.",molecular-dynamic,0.5092593,monte-carlo,0.7055199,monte-carlo,0.7055199
"New flavonoid - &lt;i&gt;N&lt;/i&gt;,&lt;i&gt;N&lt;/i&gt;-dibenzyl(&lt;i&gt;N&lt;/i&gt;-methyl)amine hybrids: Multi-target-directed agents for Alzheimer´s disease endowed with neurogenic properties.",linking,0.40631008,connected,0.61701787,clustering,0.5458325
"New flavonoid - &lt;i&gt;N&lt;/i&gt;,&lt;i&gt;N&lt;/i&gt;-dibenzyl(&lt;i&gt;N&lt;/i&gt;-methyl)amine hybrids: Multi-target-directed agents for Alzheimer´s disease endowed with neurogenic properties.",two,0.35955608,one,0.79919666,clustering,0.43817294
"New flavonoid - &lt;i&gt;N&lt;/i&gt;,&lt;i&gt;N&lt;/i&gt;-dibenzyl(&lt;i&gt;N&lt;/i&gt;-methyl)amine hybrids: Multi-target-directed agents for Alzheimer´s disease endowed with neurogenic properties.",privileged,0.34385645,adversarial,0.51034284,feature-engineering,0.5039508
"New flavonoid - &lt;i&gt;N&lt;/i&gt;,&lt;i&gt;N&lt;/i&gt;-dibenzyl(&lt;i&gt;N&lt;/i&gt;-methyl)amine hybrids: Multi-target-directed agents for Alzheimer´s disease endowed with neurogenic properties.",scaffolds,0.33736354,engineering,0.56699574,feature-engineering,0.5517112
"New flavonoid - &lt;i&gt;N&lt;/i&gt;,&lt;i&gt;N&lt;/i&gt;-dibenzyl(&lt;i&gt;N&lt;/i&gt;-methyl)amine hybrids: Multi-target-directed agents for Alzheimer´s disease endowed with neurogenic properties.",xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
"New flavonoid - &lt;i&gt;N&lt;/i&gt;,&lt;i&gt;N&lt;/i&gt;-dibenzyl(&lt;i&gt;N&lt;/i&gt;-methyl)amine hybrids: Multi-target-directed agents for Alzheimer´s disease endowed with neurogenic properties.",monoamine,0.26227042,learning-function,0.416536,learning-function,0.416536
"New flavonoid - &lt;i&gt;N&lt;/i&gt;,&lt;i&gt;N&lt;/i&gt;-dibenzyl(&lt;i&gt;N&lt;/i&gt;-methyl)amine hybrids: Multi-target-directed agents for Alzheimer´s disease endowed with neurogenic properties.",oxidases,0.23813602,feature-reduction,0.404602,feature-reduction,0.404602
"New flavonoid - &lt;i&gt;N&lt;/i&gt;,&lt;i&gt;N&lt;/i&gt;-dibenzyl(&lt;i&gt;N&lt;/i&gt;-methyl)amine hybrids: Multi-target-directed agents for Alzheimer´s disease endowed with neurogenic properties.",hbuche,0.10247962,keras,0.26700372,keras,0.26700372
"New flavonoid - &lt;i&gt;N&lt;/i&gt;,&lt;i&gt;N&lt;/i&gt;-dibenzyl(&lt;i&gt;N&lt;/i&gt;-methyl)amine hybrids: Multi-target-directed agents for Alzheimer´s disease endowed with neurogenic properties.",b,0.19558734,of,0.43435428,short-term-memory,0.31717262
"New flavonoid - &lt;i&gt;N&lt;/i&gt;,&lt;i&gt;N&lt;/i&gt;-dibenzyl(&lt;i&gt;N&lt;/i&gt;-methyl)amine hybrids: Multi-target-directed agents for Alzheimer´s disease endowed with neurogenic properties.",lipoxygenase,0.1801826,cascade,0.3904929,kernel,0.33739853
"New flavonoid - &lt;i&gt;N&lt;/i&gt;,&lt;i&gt;N&lt;/i&gt;-dibenzyl(&lt;i&gt;N&lt;/i&gt;-methyl)amine hybrids: Multi-target-directed agents for Alzheimer´s disease endowed with neurogenic properties.",treat,0.32386008,recurrent,0.48263934,generative-model,0.36353803
"New flavonoid - &lt;i&gt;N&lt;/i&gt;,&lt;i&gt;N&lt;/i&gt;-dibenzyl(&lt;i&gt;N&lt;/i&gt;-methyl)amine hybrids: Multi-target-directed agents for Alzheimer´s disease endowed with neurogenic properties.",neurodegenerative,0.36640078,generative-model,0.4714227,generative-model,0.4714227
"New flavonoid - &lt;i&gt;N&lt;/i&gt;,&lt;i&gt;N&lt;/i&gt;-dibenzyl(&lt;i&gt;N&lt;/i&gt;-methyl)amine hybrids: Multi-target-directed agents for Alzheimer´s disease endowed with neurogenic properties.",diseases,0.31957155,recurrent,0.41244444,classification,0.40266854
"New flavonoid - &lt;i&gt;N&lt;/i&gt;,&lt;i&gt;N&lt;/i&gt;-dibenzyl(&lt;i&gt;N&lt;/i&gt;-methyl)amine hybrids: Multi-target-directed agents for Alzheimer´s disease endowed with neurogenic properties.",target,0.31799266,of,0.4775706,feature-selection,0.44359237
"New flavonoid - &lt;i&gt;N&lt;/i&gt;,&lt;i&gt;N&lt;/i&gt;-dibenzyl(&lt;i&gt;N&lt;/i&gt;-methyl)amine hybrids: Multi-target-directed agents for Alzheimer´s disease endowed with neurogenic properties.",directed,0.29751354,of,0.55436456,boosting,0.4654734
"New flavonoid - &lt;i&gt;N&lt;/i&gt;,&lt;i&gt;N&lt;/i&gt;-dibenzyl(&lt;i&gt;N&lt;/i&gt;-methyl)amine hybrids: Multi-target-directed agents for Alzheimer´s disease endowed with neurogenic properties.",ligands,0.29595453,nearest-neighbors,0.43555987,nearest-neighbors,0.43555987
"New flavonoid - &lt;i&gt;N&lt;/i&gt;,&lt;i&gt;N&lt;/i&gt;-dibenzyl(&lt;i&gt;N&lt;/i&gt;-methyl)amine hybrids: Multi-target-directed agents for Alzheimer´s disease endowed with neurogenic properties.",target-directed,0.45940584,feature-selection,0.6005095,feature-selection,0.6005095
"New flavonoid - &lt;i&gt;N&lt;/i&gt;,&lt;i&gt;N&lt;/i&gt;-dibenzyl(&lt;i&gt;N&lt;/i&gt;-methyl)amine hybrids: Multi-target-directed agents for Alzheimer´s disease endowed with neurogenic properties.",obtaining,0.39410537,of,0.6090371,batch-normalization,0.50309825
"New flavonoid - &lt;i&gt;N&lt;/i&gt;,&lt;i&gt;N&lt;/i&gt;-dibenzyl(&lt;i&gt;N&lt;/i&gt;-methyl)amine hybrids: Multi-target-directed agents for Alzheimer´s disease endowed with neurogenic properties.",effective,0.32842147,of,0.50971246,boosting,0.48854327
"New flavonoid - &lt;i&gt;N&lt;/i&gt;,&lt;i&gt;N&lt;/i&gt;-dibenzyl(&lt;i&gt;N&lt;/i&gt;-methyl)amine hybrids: Multi-target-directed agents for Alzheimer´s disease endowed with neurogenic properties.",drugs,0.30897486,of,0.42460242,classifiers,0.33720028
"New flavonoid - &lt;i&gt;N&lt;/i&gt;,&lt;i&gt;N&lt;/i&gt;-dibenzyl(&lt;i&gt;N&lt;/i&gt;-methyl)amine hybrids: Multi-target-directed agents for Alzheimer´s disease endowed with neurogenic properties.",neurotoxic,0.2471214,of,0.4023993,generative-model,0.37060547
"New flavonoid - &lt;i&gt;N&lt;/i&gt;,&lt;i&gt;N&lt;/i&gt;-dibenzyl(&lt;i&gt;N&lt;/i&gt;-methyl)amine hybrids: Multi-target-directed agents for Alzheimer´s disease endowed with neurogenic properties.",cascades,0.29414117,cascade,0.9014298,feed-forward,0.5830796
"New flavonoid - &lt;i&gt;N&lt;/i&gt;,&lt;i&gt;N&lt;/i&gt;-dibenzyl(&lt;i&gt;N&lt;/i&gt;-methyl)amine hybrids: Multi-target-directed agents for Alzheimer´s disease endowed with neurogenic properties.",could,0.34235194,of,0.59299076,boosting,0.42074972
"New flavonoid - &lt;i&gt;N&lt;/i&gt;,&lt;i&gt;N&lt;/i&gt;-dibenzyl(&lt;i&gt;N&lt;/i&gt;-methyl)amine hybrids: Multi-target-directed agents for Alzheimer´s disease endowed with neurogenic properties.",namely,0.35755846,of,0.578827,dimensionality-reduction,0.46376634
"New flavonoid - &lt;i&gt;N&lt;/i&gt;,&lt;i&gt;N&lt;/i&gt;-dibenzyl(&lt;i&gt;N&lt;/i&gt;-methyl)amine hybrids: Multi-target-directed agents for Alzheimer´s disease endowed with neurogenic properties.",human,0.30336243,of,0.5175895,feature-engineering,0.40631005
"New flavonoid - &lt;i&gt;N&lt;/i&gt;,&lt;i&gt;N&lt;/i&gt;-dibenzyl(&lt;i&gt;N&lt;/i&gt;-methyl)amine hybrids: Multi-target-directed agents for Alzheimer´s disease endowed with neurogenic properties.",cholinesterases,0.2648583,learning-function,0.39252973,learning-function,0.39252973
"New flavonoid - &lt;i&gt;N&lt;/i&gt;,&lt;i&gt;N&lt;/i&gt;-dibenzyl(&lt;i&gt;N&lt;/i&gt;-methyl)amine hybrids: Multi-target-directed agents for Alzheimer´s disease endowed with neurogenic properties.",long,0.20028201,long,1.0,long-short-term,0.6505779
"New flavonoid - &lt;i&gt;N&lt;/i&gt;,&lt;i&gt;N&lt;/i&gt;-dibenzyl(&lt;i&gt;N&lt;/i&gt;-methyl)amine hybrids: Multi-target-directed agents for Alzheimer´s disease endowed with neurogenic properties.",wanted,0.36391008,decision,0.59719455,supervised,0.4787815
"New flavonoid - &lt;i&gt;N&lt;/i&gt;,&lt;i&gt;N&lt;/i&gt;-dibenzyl(&lt;i&gt;N&lt;/i&gt;-methyl)amine hybrids: Multi-target-directed agents for Alzheimer´s disease endowed with neurogenic properties.",remedies,0.35735363,truth,0.49341303,natural-language,0.45924425
"New flavonoid - &lt;i&gt;N&lt;/i&gt;,&lt;i&gt;N&lt;/i&gt;-dibenzyl(&lt;i&gt;N&lt;/i&gt;-methyl)amine hybrids: Multi-target-directed agents for Alzheimer´s disease endowed with neurogenic properties.",long-wanted,0.2564685,term,0.5873649,long-short-term,0.55912006
"New flavonoid - &lt;i&gt;N&lt;/i&gt;,&lt;i&gt;N&lt;/i&gt;-dibenzyl(&lt;i&gt;N&lt;/i&gt;-methyl)amine hybrids: Multi-target-directed agents for Alzheimer´s disease endowed with neurogenic properties.",could,0.34235194,of,0.59299076,boosting,0.42074972
"New flavonoid - &lt;i&gt;N&lt;/i&gt;,&lt;i&gt;N&lt;/i&gt;-dibenzyl(&lt;i&gt;N&lt;/i&gt;-methyl)amine hybrids: Multi-target-directed agents for Alzheimer´s disease endowed with neurogenic properties.",synergistically,0.25447822,boosting,0.4764165,boosting,0.4764165
"New flavonoid - &lt;i&gt;N&lt;/i&gt;,&lt;i&gt;N&lt;/i&gt;-dibenzyl(&lt;i&gt;N&lt;/i&gt;-methyl)amine hybrids: Multi-target-directed agents for Alzheimer´s disease endowed with neurogenic properties.",contribute,0.30676693,of,0.5196437,feed-forward,0.40432224
"New flavonoid - &lt;i&gt;N&lt;/i&gt;,&lt;i&gt;N&lt;/i&gt;-dibenzyl(&lt;i&gt;N&lt;/i&gt;-methyl)amine hybrids: Multi-target-directed agents for Alzheimer´s disease endowed with neurogenic properties.",hybrid,0.3859911,hierarchical-clustering,0.5079969,hierarchical-clustering,0.5079969
"New flavonoid - &lt;i&gt;N&lt;/i&gt;,&lt;i&gt;N&lt;/i&gt;-dibenzyl(&lt;i&gt;N&lt;/i&gt;-methyl)amine hybrids: Multi-target-directed agents for Alzheimer´s disease endowed with neurogenic properties.",xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
"New flavonoid - &lt;i&gt;N&lt;/i&gt;,&lt;i&gt;N&lt;/i&gt;-dibenzyl(&lt;i&gt;N&lt;/i&gt;-methyl)amine hybrids: Multi-target-directed agents for Alzheimer´s disease endowed with neurogenic properties.",valid,0.43003386,discriminative,0.5328561,dimensionality-reduction,0.4960052
"New flavonoid - &lt;i&gt;N&lt;/i&gt;,&lt;i&gt;N&lt;/i&gt;-dibenzyl(&lt;i&gt;N&lt;/i&gt;-methyl)amine hybrids: Multi-target-directed agents for Alzheimer´s disease endowed with neurogenic properties.",approach,0.5412675,segmentation-algorithm,0.6046611,segmentation-algorithm,0.6046611
"New flavonoid - &lt;i&gt;N&lt;/i&gt;,&lt;i&gt;N&lt;/i&gt;-dibenzyl(&lt;i&gt;N&lt;/i&gt;-methyl)amine hybrids: Multi-target-directed agents for Alzheimer´s disease endowed with neurogenic properties.",type,0.21671848,of,0.48202556,classification,0.43098688
"New flavonoid - &lt;i&gt;N&lt;/i&gt;,&lt;i&gt;N&lt;/i&gt;-dibenzyl(&lt;i&gt;N&lt;/i&gt;-methyl)amine hybrids: Multi-target-directed agents for Alzheimer´s disease endowed with neurogenic properties.",screening,0.38869897,selection,0.4576743,data-engineering,0.4313178
"New flavonoid - &lt;i&gt;N&lt;/i&gt;,&lt;i&gt;N&lt;/i&gt;-dibenzyl(&lt;i&gt;N&lt;/i&gt;-methyl)amine hybrids: Multi-target-directed agents for Alzheimer´s disease endowed with neurogenic properties.",type-screening,0.392062,component-analysis,0.5033751,component-analysis,0.5033751
"New flavonoid - &lt;i&gt;N&lt;/i&gt;,&lt;i&gt;N&lt;/i&gt;-dibenzyl(&lt;i&gt;N&lt;/i&gt;-methyl)amine hybrids: Multi-target-directed agents for Alzheimer´s disease endowed with neurogenic properties.",sigma,0.2302704,principal-component,0.4555632,principal-component,0.4555632
"New flavonoid - &lt;i&gt;N&lt;/i&gt;,&lt;i&gt;N&lt;/i&gt;-dibenzyl(&lt;i&gt;N&lt;/i&gt;-methyl)amine hybrids: Multi-target-directed agents for Alzheimer´s disease endowed with neurogenic properties.",receptors,0.2335811,function,0.40644348,clustering,0.36239648
"New flavonoid - &lt;i&gt;N&lt;/i&gt;,&lt;i&gt;N&lt;/i&gt;-dibenzyl(&lt;i&gt;N&lt;/i&gt;-methyl)amine hybrids: Multi-target-directed agents for Alzheimer´s disease endowed with neurogenic properties.",sigma-receptors,0.2588839,discriminative,0.44470894,dimensionality-reduction,0.36247104
"New flavonoid - &lt;i&gt;N&lt;/i&gt;,&lt;i&gt;N&lt;/i&gt;-dibenzyl(&lt;i&gt;N&lt;/i&gt;-methyl)amine hybrids: Multi-target-directed agents for Alzheimer´s disease endowed with neurogenic properties.",repair,0.26407808,augmentation,0.44746083,data-augmentation,0.4345641
"New flavonoid - &lt;i&gt;N&lt;/i&gt;,&lt;i&gt;N&lt;/i&gt;-dibenzyl(&lt;i&gt;N&lt;/i&gt;-methyl)amine hybrids: Multi-target-directed agents for Alzheimer´s disease endowed with neurogenic properties.",properties,0.31064022,function,0.5521828,feature-engineering,0.53029627
"New flavonoid - &lt;i&gt;N&lt;/i&gt;,&lt;i&gt;N&lt;/i&gt;-dibenzyl(&lt;i&gt;N&lt;/i&gt;-methyl)amine hybrids: Multi-target-directed agents for Alzheimer´s disease endowed with neurogenic properties.",relevant,0.4346258,of,0.5628227,natural-language,0.5076148
"New flavonoid - &lt;i&gt;N&lt;/i&gt;,&lt;i&gt;N&lt;/i&gt;-dibenzyl(&lt;i&gt;N&lt;/i&gt;-methyl)amine hybrids: Multi-target-directed agents for Alzheimer´s disease endowed with neurogenic properties.",drug,0.31867066,of,0.44600964,confusion-matrix,0.3956731
"New flavonoid - &lt;i&gt;N&lt;/i&gt;,&lt;i&gt;N&lt;/i&gt;-dibenzyl(&lt;i&gt;N&lt;/i&gt;-methyl)amine hybrids: Multi-target-directed agents for Alzheimer´s disease endowed with neurogenic properties.",protein,0.31929362,encoding,0.5525089,clustering,0.36023882
"New flavonoid - &lt;i&gt;N&lt;/i&gt;,&lt;i&gt;N&lt;/i&gt;-dibenzyl(&lt;i&gt;N&lt;/i&gt;-methyl)amine hybrids: Multi-target-directed agents for Alzheimer´s disease endowed with neurogenic properties.",interactions,0.34362614,nearest-neighbors,0.5320788,nearest-neighbors,0.5320788
"New flavonoid - &lt;i&gt;N&lt;/i&gt;,&lt;i&gt;N&lt;/i&gt;-dibenzyl(&lt;i&gt;N&lt;/i&gt;-methyl)amine hybrids: Multi-target-directed agents for Alzheimer´s disease endowed with neurogenic properties.",protein-interactions,0.48695707,hierarchical-clustering,0.51597965,hierarchical-clustering,0.51597965
"New flavonoid - &lt;i&gt;N&lt;/i&gt;,&lt;i&gt;N&lt;/i&gt;-dibenzyl(&lt;i&gt;N&lt;/i&gt;-methyl)amine hybrids: Multi-target-directed agents for Alzheimer´s disease endowed with neurogenic properties.",new,0.43019778,of,0.526482,feature-reduction,0.4579819
"New flavonoid - &lt;i&gt;N&lt;/i&gt;,&lt;i&gt;N&lt;/i&gt;-dibenzyl(&lt;i&gt;N&lt;/i&gt;-methyl)amine hybrids: Multi-target-directed agents for Alzheimer´s disease endowed with neurogenic properties.",cns,0.26443747,neural,0.522415,recurrent-neural-network,0.38636905
"New flavonoid - &lt;i&gt;N&lt;/i&gt;,&lt;i&gt;N&lt;/i&gt;-dibenzyl(&lt;i&gt;N&lt;/i&gt;-methyl)amine hybrids: Multi-target-directed agents for Alzheimer´s disease endowed with neurogenic properties.",neuronal,0.34720105,neural,0.7294287,learning-rate,0.5253661
"New flavonoid - &lt;i&gt;N&lt;/i&gt;,&lt;i&gt;N&lt;/i&gt;-dibenzyl(&lt;i&gt;N&lt;/i&gt;-methyl)amine hybrids: Multi-target-directed agents for Alzheimer´s disease endowed with neurogenic properties.",regeneration,0.28401783,engineering,0.5518575,generative,0.46367323
"New flavonoid - &lt;i&gt;N&lt;/i&gt;,&lt;i&gt;N&lt;/i&gt;-dibenzyl(&lt;i&gt;N&lt;/i&gt;-methyl)amine hybrids: Multi-target-directed agents for Alzheimer´s disease endowed with neurogenic properties.",neurogenic,0.24777138,neural,0.59490407,recurrent-neural-network,0.41322345
"New flavonoid - &lt;i&gt;N&lt;/i&gt;,&lt;i&gt;N&lt;/i&gt;-dibenzyl(&lt;i&gt;N&lt;/i&gt;-methyl)amine hybrids: Multi-target-directed agents for Alzheimer´s disease endowed with neurogenic properties.",properties,0.31064022,function,0.5521828,feature-engineering,0.53029627
"New flavonoid - &lt;i&gt;N&lt;/i&gt;,&lt;i&gt;N&lt;/i&gt;-dibenzyl(&lt;i&gt;N&lt;/i&gt;-methyl)amine hybrids: Multi-target-directed agents for Alzheimer´s disease endowed with neurogenic properties.",known,0.3344566,of,0.5873189,clustering,0.4164055
"New flavonoid - &lt;i&gt;N&lt;/i&gt;,&lt;i&gt;N&lt;/i&gt;-dibenzyl(&lt;i&gt;N&lt;/i&gt;-methyl)amine hybrids: Multi-target-directed agents for Alzheimer´s disease endowed with neurogenic properties.",activities,0.25071037,of,0.4766258,learning-function,0.38030344
"New flavonoid - &lt;i&gt;N&lt;/i&gt;,&lt;i&gt;N&lt;/i&gt;-dibenzyl(&lt;i&gt;N&lt;/i&gt;-methyl)amine hybrids: Multi-target-directed agents for Alzheimer´s disease endowed with neurogenic properties.",interesting,0.4021179,feature,0.5455024,feature-engineering,0.5443059
"New flavonoid - &lt;i&gt;N&lt;/i&gt;,&lt;i&gt;N&lt;/i&gt;-dibenzyl(&lt;i&gt;N&lt;/i&gt;-methyl)amine hybrids: Multi-target-directed agents for Alzheimer´s disease endowed with neurogenic properties.",mtd,0.2559627,tfidf,0.36260474,tfidf,0.36260474
"New flavonoid - &lt;i&gt;N&lt;/i&gt;,&lt;i&gt;N&lt;/i&gt;-dibenzyl(&lt;i&gt;N&lt;/i&gt;-methyl)amine hybrids: Multi-target-directed agents for Alzheimer´s disease endowed with neurogenic properties.",highlighted,0.429609,of,0.60523915,feature-engineering,0.5701233
"New flavonoid - &lt;i&gt;N&lt;/i&gt;,&lt;i&gt;N&lt;/i&gt;-dibenzyl(&lt;i&gt;N&lt;/i&gt;-methyl)amine hybrids: Multi-target-directed agents for Alzheimer´s disease endowed with neurogenic properties.",due,0.21681537,of,0.5734476,confusion-matrix,0.40250766
"New flavonoid - &lt;i&gt;N&lt;/i&gt;,&lt;i&gt;N&lt;/i&gt;-dibenzyl(&lt;i&gt;N&lt;/i&gt;-methyl)amine hybrids: Multi-target-directed agents for Alzheimer´s disease endowed with neurogenic properties.",first,0.36139184,of,0.61145455,generative,0.4096663
"New flavonoid - &lt;i&gt;N&lt;/i&gt;,&lt;i&gt;N&lt;/i&gt;-dibenzyl(&lt;i&gt;N&lt;/i&gt;-methyl)amine hybrids: Multi-target-directed agents for Alzheimer´s disease endowed with neurogenic properties.",steps,0.35522968,components,0.5477389,feature-reduction,0.4619524
"New flavonoid - &lt;i&gt;N&lt;/i&gt;,&lt;i&gt;N&lt;/i&gt;-dibenzyl(&lt;i&gt;N&lt;/i&gt;-methyl)amine hybrids: Multi-target-directed agents for Alzheimer´s disease endowed with neurogenic properties.",first-steps,0.37432462,feature-reduction,0.55565476,feature-reduction,0.55565476
"New flavonoid - &lt;i&gt;N&lt;/i&gt;,&lt;i&gt;N&lt;/i&gt;-dibenzyl(&lt;i&gt;N&lt;/i&gt;-methyl)amine hybrids: Multi-target-directed agents for Alzheimer´s disease endowed with neurogenic properties.",complex,0.27214053,components,0.5436033,component-analysis,0.4161712
"New flavonoid - &lt;i&gt;N&lt;/i&gt;,&lt;i&gt;N&lt;/i&gt;-dibenzyl(&lt;i&gt;N&lt;/i&gt;-methyl)amine hybrids: Multi-target-directed agents for Alzheimer´s disease endowed with neurogenic properties.",pathologies,0.36750844,feature,0.47752935,generative-model,0.44772106
"New flavonoid - &lt;i&gt;N&lt;/i&gt;,&lt;i&gt;N&lt;/i&gt;-dibenzyl(&lt;i&gt;N&lt;/i&gt;-methyl)amine hybrids: Multi-target-directed agents for Alzheimer´s disease endowed with neurogenic properties.",combine,0.5468378,feature-engineering,0.63213557,feature-engineering,0.63213557
"New flavonoid - &lt;i&gt;N&lt;/i&gt;,&lt;i&gt;N&lt;/i&gt;-dibenzyl(&lt;i&gt;N&lt;/i&gt;-methyl)amine hybrids: Multi-target-directed agents for Alzheimer´s disease endowed with neurogenic properties.",neuro,0.24705967,confusion,0.48527092,confusion-matrix,0.33782724
"New flavonoid - &lt;i&gt;N&lt;/i&gt;,&lt;i&gt;N&lt;/i&gt;-dibenzyl(&lt;i&gt;N&lt;/i&gt;-methyl)amine hybrids: Multi-target-directed agents for Alzheimer´s disease endowed with neurogenic properties.",biological,0.44501913,natural,0.6314477,feature-engineering,0.5497216
"New flavonoid - &lt;i&gt;N&lt;/i&gt;,&lt;i&gt;N&lt;/i&gt;-dibenzyl(&lt;i&gt;N&lt;/i&gt;-methyl)amine hybrids: Multi-target-directed agents for Alzheimer´s disease endowed with neurogenic properties.",evaluation,0.39017528,analysis,0.5728766,component-analysis,0.5049392
"New flavonoid - &lt;i&gt;N&lt;/i&gt;,&lt;i&gt;N&lt;/i&gt;-dibenzyl(&lt;i&gt;N&lt;/i&gt;-methyl)amine hybrids: Multi-target-directed agents for Alzheimer´s disease endowed with neurogenic properties.",targets,0.3564865,components,0.46861184,feature-selection,0.44291896
"New flavonoid - &lt;i&gt;N&lt;/i&gt;,&lt;i&gt;N&lt;/i&gt;-dibenzyl(&lt;i&gt;N&lt;/i&gt;-methyl)amine hybrids: Multi-target-directed agents for Alzheimer´s disease endowed with neurogenic properties.",involved,0.26651675,of,0.5396308,feed-forward,0.42281044
"New flavonoid - &lt;i&gt;N&lt;/i&gt;,&lt;i&gt;N&lt;/i&gt;-dibenzyl(&lt;i&gt;N&lt;/i&gt;-methyl)amine hybrids: Multi-target-directed agents for Alzheimer´s disease endowed with neurogenic properties.",targets-involved,0.37671605,cascade,0.48739988,feature-engineering,0.47541404
"New flavonoid - &lt;i&gt;N&lt;/i&gt;,&lt;i&gt;N&lt;/i&gt;-dibenzyl(&lt;i&gt;N&lt;/i&gt;-methyl)amine hybrids: Multi-target-directed agents for Alzheimer´s disease endowed with neurogenic properties.",permeable,0.22127947,layer,0.49722296,gradient-descent,0.4622275
"New flavonoid - &lt;i&gt;N&lt;/i&gt;,&lt;i&gt;N&lt;/i&gt;-dibenzyl(&lt;i&gt;N&lt;/i&gt;-methyl)amine hybrids: Multi-target-directed agents for Alzheimer´s disease endowed with neurogenic properties.",flavonoid,0.3277109,natural,0.39004242,kernel,0.3797756
"New flavonoid - &lt;i&gt;N&lt;/i&gt;,&lt;i&gt;N&lt;/i&gt;-dibenzyl(&lt;i&gt;N&lt;/i&gt;-methyl)amine hybrids: Multi-target-directed agents for Alzheimer´s disease endowed with neurogenic properties.",nds,0.3597648,hierarchical-clustering,0.4481892,hierarchical-clustering,0.4481892
"New flavonoid - &lt;i&gt;N&lt;/i&gt;,&lt;i&gt;N&lt;/i&gt;-dibenzyl(&lt;i&gt;N&lt;/i&gt;-methyl)amine hybrids: Multi-target-directed agents for Alzheimer´s disease endowed with neurogenic properties.",dbma,0.27671126,bayesian-network,0.43483797,bayesian-network,0.43483797
"New flavonoid - &lt;i&gt;N&lt;/i&gt;,&lt;i&gt;N&lt;/i&gt;-dibenzyl(&lt;i&gt;N&lt;/i&gt;-methyl)amine hybrids: Multi-target-directed agents for Alzheimer´s disease endowed with neurogenic properties.",hybrids,0.23354143,generative,0.42797795,generative,0.42797795
"New flavonoid - &lt;i&gt;N&lt;/i&gt;,&lt;i&gt;N&lt;/i&gt;-dibenzyl(&lt;i&gt;N&lt;/i&gt;-methyl)amine hybrids: Multi-target-directed agents for Alzheimer´s disease endowed with neurogenic properties.",block,0.23053187,augmentation,0.48152325,clustering,0.37764353
"New flavonoid - &lt;i&gt;N&lt;/i&gt;,&lt;i&gt;N&lt;/i&gt;-dibenzyl(&lt;i&gt;N&lt;/i&gt;-methyl)amine hybrids: Multi-target-directed agents for Alzheimer´s disease endowed with neurogenic properties.",neurodegeneration,0.35290885,memory,0.49154523,learning-function,0.46631312
"New flavonoid - &lt;i&gt;N&lt;/i&gt;,&lt;i&gt;N&lt;/i&gt;-dibenzyl(&lt;i&gt;N&lt;/i&gt;-methyl)amine hybrids: Multi-target-directed agents for Alzheimer´s disease endowed with neurogenic properties.",xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
"New flavonoid - &lt;i&gt;N&lt;/i&gt;,&lt;i&gt;N&lt;/i&gt;-dibenzyl(&lt;i&gt;N&lt;/i&gt;-methyl)amine hybrids: Multi-target-directed agents for Alzheimer´s disease endowed with neurogenic properties.",targets,0.3564865,components,0.46861184,feature-selection,0.44291896
"New flavonoid - &lt;i&gt;N&lt;/i&gt;,&lt;i&gt;N&lt;/i&gt;-dibenzyl(&lt;i&gt;N&lt;/i&gt;-methyl)amine hybrids: Multi-target-directed agents for Alzheimer´s disease endowed with neurogenic properties.",nds,0.3597648,hierarchical-clustering,0.4481892,hierarchical-clustering,0.4481892
"New flavonoid - &lt;i&gt;N&lt;/i&gt;,&lt;i&gt;N&lt;/i&gt;-dibenzyl(&lt;i&gt;N&lt;/i&gt;-methyl)amine hybrids: Multi-target-directed agents for Alzheimer´s disease endowed with neurogenic properties.",flavonoid,0.3277109,natural,0.39004242,kernel,0.3797756
"New flavonoid - &lt;i&gt;N&lt;/i&gt;,&lt;i&gt;N&lt;/i&gt;-dibenzyl(&lt;i&gt;N&lt;/i&gt;-methyl)amine hybrids: Multi-target-directed agents for Alzheimer´s disease endowed with neurogenic properties.",dbma,0.27671126,bayesian-network,0.43483797,bayesian-network,0.43483797
"New flavonoid - &lt;i&gt;N&lt;/i&gt;,&lt;i&gt;N&lt;/i&gt;-dibenzyl(&lt;i&gt;N&lt;/i&gt;-methyl)amine hybrids: Multi-target-directed agents for Alzheimer´s disease endowed with neurogenic properties.",block,0.23053187,augmentation,0.48152325,clustering,0.37764353
"New flavonoid - &lt;i&gt;N&lt;/i&gt;,&lt;i&gt;N&lt;/i&gt;-dibenzyl(&lt;i&gt;N&lt;/i&gt;-methyl)amine hybrids: Multi-target-directed agents for Alzheimer´s disease endowed with neurogenic properties.",well,0.34264985,of,0.59718275,bagging,0.4145819
"New flavonoid - &lt;i&gt;N&lt;/i&gt;,&lt;i&gt;N&lt;/i&gt;-dibenzyl(&lt;i&gt;N&lt;/i&gt;-methyl)amine hybrids: Multi-target-directed agents for Alzheimer´s disease endowed with neurogenic properties.",subjected,0.30235678,analysis,0.5038986,one-hot,0.3941942
"New flavonoid - &lt;i&gt;N&lt;/i&gt;,&lt;i&gt;N&lt;/i&gt;-dibenzyl(&lt;i&gt;N&lt;/i&gt;-methyl)amine hybrids: Multi-target-directed agents for Alzheimer´s disease endowed with neurogenic properties.",secretase,0.27026734,processing,0.44761896,graphics-processing,0.44647
"New flavonoid - &lt;i&gt;N&lt;/i&gt;,&lt;i&gt;N&lt;/i&gt;-dibenzyl(&lt;i&gt;N&lt;/i&gt;-methyl)amine hybrids: Multi-target-directed agents for Alzheimer´s disease endowed with neurogenic properties.",profile,0.29077405,analysis,0.5635588,component-analysis,0.44242257
"New flavonoid - &lt;i&gt;N&lt;/i&gt;,&lt;i&gt;N&lt;/i&gt;-dibenzyl(&lt;i&gt;N&lt;/i&gt;-methyl)amine hybrids: Multi-target-directed agents for Alzheimer´s disease endowed with neurogenic properties.",obtained,0.32073808,of,0.62274206,batch-normalization,0.46598285
"New flavonoid - &lt;i&gt;N&lt;/i&gt;,&lt;i&gt;N&lt;/i&gt;-dibenzyl(&lt;i&gt;N&lt;/i&gt;-methyl)amine hybrids: Multi-target-directed agents for Alzheimer´s disease endowed with neurogenic properties.",nd,0.23861468,few-shot,0.3915997,softmax,0.36907095
"New flavonoid - &lt;i&gt;N&lt;/i&gt;,&lt;i&gt;N&lt;/i&gt;-dibenzyl(&lt;i&gt;N&lt;/i&gt;-methyl)amine hybrids: Multi-target-directed agents for Alzheimer´s disease endowed with neurogenic properties.",n,0.24332823,of,0.45693433,long-short-term,0.34114176
"New flavonoid - &lt;i&gt;N&lt;/i&gt;,&lt;i&gt;N&lt;/i&gt;-dibenzyl(&lt;i&gt;N&lt;/i&gt;-methyl)amine hybrids: Multi-target-directed agents for Alzheimer´s disease endowed with neurogenic properties.",multi,0.37771758,multi-class,0.4810482,segmentation,0.43055838
"New flavonoid - &lt;i&gt;N&lt;/i&gt;,&lt;i&gt;N&lt;/i&gt;-dibenzyl(&lt;i&gt;N&lt;/i&gt;-methyl)amine hybrids: Multi-target-directed agents for Alzheimer´s disease endowed with neurogenic properties.",mtdls,0.46171498,feature-engineering,0.49966562,feature-engineering,0.49966562
"New flavonoid - &lt;i&gt;N&lt;/i&gt;,&lt;i&gt;N&lt;/i&gt;-dibenzyl(&lt;i&gt;N&lt;/i&gt;-methyl)amine hybrids: Multi-target-directed agents for Alzheimer´s disease endowed with neurogenic properties.",methyl,0.18410069,transfer,0.37792403,fourier,0.33569422
"New flavonoid - &lt;i&gt;N&lt;/i&gt;,&lt;i&gt;N&lt;/i&gt;-dibenzyl(&lt;i&gt;N&lt;/i&gt;-methyl)amine hybrids: Multi-target-directed agents for Alzheimer´s disease endowed with neurogenic properties.",hmao,0.24643287,dimensionality-reduction,0.3577193,dimensionality-reduction,0.3577193
"New flavonoid - &lt;i&gt;N&lt;/i&gt;,&lt;i&gt;N&lt;/i&gt;-dibenzyl(&lt;i&gt;N&lt;/i&gt;-methyl)amine hybrids: Multi-target-directed agents for Alzheimer´s disease endowed with neurogenic properties.",hlox,0.20819312,naive-bayes,0.31653956,naive-bayes,0.31653956
"New flavonoid - &lt;i&gt;N&lt;/i&gt;,&lt;i&gt;N&lt;/i&gt;-dibenzyl(&lt;i&gt;N&lt;/i&gt;-methyl)amine hybrids: Multi-target-directed agents for Alzheimer´s disease endowed with neurogenic properties.",hache,0.25376832,cross-validation,0.28929424,cross-validation,0.28929424
"New flavonoid - &lt;i&gt;N&lt;/i&gt;,&lt;i&gt;N&lt;/i&gt;-dibenzyl(&lt;i&gt;N&lt;/i&gt;-methyl)amine hybrids: Multi-target-directed agents for Alzheimer´s disease endowed with neurogenic properties.",funnel,0.34377724,nearest-neighbors,0.44237176,nearest-neighbors,0.44237176
"New flavonoid - &lt;i&gt;N&lt;/i&gt;,&lt;i&gt;N&lt;/i&gt;-dibenzyl(&lt;i&gt;N&lt;/i&gt;-methyl)amine hybrids: Multi-target-directed agents for Alzheimer´s disease endowed with neurogenic properties.",fragments,0.2539513,of,0.46703434,principal-components,0.34256917
"New flavonoid - &lt;i&gt;N&lt;/i&gt;,&lt;i&gt;N&lt;/i&gt;-dibenzyl(&lt;i&gt;N&lt;/i&gt;-methyl)amine hybrids: Multi-target-directed agents for Alzheimer´s disease endowed with neurogenic properties.",disease,0.296938,recurrent,0.4731025,classification,0.35271814
"New flavonoid - &lt;i&gt;N&lt;/i&gt;,&lt;i&gt;N&lt;/i&gt;-dibenzyl(&lt;i&gt;N&lt;/i&gt;-methyl)amine hybrids: Multi-target-directed agents for Alzheimer´s disease endowed with neurogenic properties.",dibenzyl,0.20297916,centroid-based,0.4067651,centroid-based,0.4067651
"New flavonoid - &lt;i&gt;N&lt;/i&gt;,&lt;i&gt;N&lt;/i&gt;-dibenzyl(&lt;i&gt;N&lt;/i&gt;-methyl)amine hybrids: Multi-target-directed agents for Alzheimer´s disease endowed with neurogenic properties.",design,0.47555828,data-engineering,0.6477308,data-engineering,0.6477308
"New flavonoid - &lt;i&gt;N&lt;/i&gt;,&lt;i&gt;N&lt;/i&gt;-dibenzyl(&lt;i&gt;N&lt;/i&gt;-methyl)amine hybrids: Multi-target-directed agents for Alzheimer´s disease endowed with neurogenic properties.",battery,0.33177823,intelligence,0.5366107,artificial-intelligence,0.516659
"New flavonoid - &lt;i&gt;N&lt;/i&gt;,&lt;i&gt;N&lt;/i&gt;-dibenzyl(&lt;i&gt;N&lt;/i&gt;-methyl)amine hybrids: Multi-target-directed agents for Alzheimer´s disease endowed with neurogenic properties.",amine,0.25748423,feature-reduction,0.38749048,feature-reduction,0.38749048
"New flavonoid - &lt;i&gt;N&lt;/i&gt;,&lt;i&gt;N&lt;/i&gt;-dibenzyl(&lt;i&gt;N&lt;/i&gt;-methyl)amine hybrids: Multi-target-directed agents for Alzheimer´s disease endowed with neurogenic properties.",alzheimer,0.2948662,memory,0.47752225,semantic,0.47042826
"New flavonoid - &lt;i&gt;N&lt;/i&gt;,&lt;i&gt;N&lt;/i&gt;-dibenzyl(&lt;i&gt;N&lt;/i&gt;-methyl)amine hybrids: Multi-target-directed agents for Alzheimer´s disease endowed with neurogenic properties.",ad,0.3459351,memory,0.48189065,semantic,0.46080723
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-β.,exclusive,0.30971065,of,0.523538,clustering,0.43716317
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-β.,licensee,0.34538037,federated,0.5643549,data-science,0.53677833
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-β.,american,0.31403136,federated,0.55841243,classification,0.43444416
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-β.,association,0.32292235,regression,0.5094141,regression,0.5094141
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-β.,display,0.38842064,feature,0.62053245,feature-selection,0.563305
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-β.,ad,0.3459351,memory,0.48189065,semantic,0.46080723
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-β.,deficiency,0.19004877,function,0.4671089,batch-normalization,0.37441885
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-β.,dependent,0.2523393,of,0.585135,generative,0.43066898
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-β.,mapk,0.2536896,cascade,0.59739983,feed-forward,0.45056283
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-β.,signaling,0.29640946,cascade,0.70725644,feed-forward,0.5819744
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-β.,pathway,0.27141988,cascade,0.7127757,feed-forward,0.5331765
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-β.,mapk-signaling,0.27471697,cascade,0.6819886,feed-forward,0.55644816
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-β.,signaling-pathway,0.3341716,cascade,0.70069504,feed-forward,0.6038469
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-β.,fibroblasts,0.18058866,matrix,0.4928056,confusion-matrix,0.31368023
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-β.,displayed,0.24727404,feature,0.48546267,feature-selection,0.40465993
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-β.,impaired,0.28064826,function,0.6550549,short-term-memory,0.48377025
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-β.,mapk,0.2536896,cascade,0.59739983,feed-forward,0.45056283
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-β.,signaling,0.29640946,cascade,0.70725644,feed-forward,0.5819744
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-β.,pathway,0.27141988,cascade,0.7127757,feed-forward,0.5331765
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-β.,mapk-signaling,0.27471697,cascade,0.6819886,feed-forward,0.55644816
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-β.,signaling-pathway,0.3341716,cascade,0.70069504,feed-forward,0.6038469
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-β.,signaling,0.29640946,cascade,0.70725644,feed-forward,0.5819744
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-β.,pathways,0.30476987,cascade,0.6938149,feed-forward,0.5254793
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-β.,involved,0.26651675,of,0.5396308,feed-forward,0.42281044
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-β.,signaling-pathways,0.33893383,cascade,0.69794536,feed-forward,0.5998782
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-β.,previously,0.31365848,fully,0.5461891,long-short-term,0.40718085
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-β.,undescribed,0.28519922,feature,0.4976996,clustering,0.36468327
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-β.,form,0.27133656,of,0.55080163,generative,0.4777649
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-β.,previously-undescribed,0.40043736,feature,0.5595074,feature-selection,0.51101846
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-β.,key,0.35973132,principal,0.614877,feature-engineering,0.498355
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-β.,extracellular,0.29317284,matrix,0.62536657,confusion-matrix,0.42919844
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-β.,matrix,0.36017767,matrix,0.99999994,confusion-matrix,0.6947298
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-β.,extracellular-matrix,0.37593526,matrix,0.7756901,confusion-matrix,0.5772127
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-β.,chronic,0.22727785,recurrent,0.5279353,long-short-term,0.4292153
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-β.,mucocutaneous,0.23371595,recurrent,0.51977426,keras,0.39111656
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-β.,candidiasis,0.21227497,recurrent,0.39203814,keras,0.32476348
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-β.,causing,0.1470272,of,0.5218761,generative,0.33331656
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-β.,gene,0.32125705,encoding,0.7317275,clustering,0.4378482
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-β.,products,0.19893059,components,0.4911098,component-analysis,0.38407606
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-β.,gene-products,0.4078066,encoding,0.49577343,feature-engineering,0.46159095
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-β.,impaired,0.28064826,function,0.6550549,short-term-memory,0.48377025
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-β.,ex,0.288929,of,0.41632706,generative,0.36303258
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-β.,vivo,0.31561637,of,0.48691544,generative-model,0.4255858
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-β.,ex-vivo,0.335132,generative-model,0.44142258,generative-model,0.44142258
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-β.,dietz,0.18260182,pytorch,0.38045758,pytorch,0.38045758
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-β.,syndrome,0.20306323,recurrent,0.42346346,confusion-matrix,0.3198145
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-β.,caused,0.14436965,of,0.53973085,long-short-term,0.3204536
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-β.,syndrome-caused,0.21827751,recurrent,0.44383645,recurrent-neural-network,0.33035484
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-β.,connective,0.25064147,matrix,0.60000014,confusion-matrix,0.437374
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-β.,tissue,0.23679586,of,0.5202017,segmentation,0.4076932
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-β.,disorders,0.3129085,function,0.42467374,generative,0.4119473
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-β.,connective-tissue,0.30846465,matrix,0.6037579,recurrent-neural-network,0.5281617
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-β.,terminal,0.1515508,long,0.5815784,generative,0.39005107
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-β.,kinase,0.22244422,cascade,0.49403343,feed-forward,0.34344023
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-β.,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-β.,terminal-kinase,0.24964479,cascade,0.48992562,feed-forward,0.43961912
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-β.,dependent,0.2523393,of,0.585135,generative,0.43066898
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-β.,mucocutaneous,0.23371595,recurrent,0.51977426,keras,0.39111656
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-β.,immunity,0.27692312,boosting,0.56300366,boosting,0.56300366
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-β.,unusual,0.23437542,feature,0.56463104,feature-reduction,0.38760623
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-β.,ctd,0.28113365,tfidf,0.33424237,tfidf,0.33424237
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-β.,phenotype,0.28173286,feature,0.51151407,feature-selection,0.4975547
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-β.,gene,0.32125705,encoding,0.7317275,clustering,0.4378482
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-β.,encoding,0.37093452,encoding,0.99999994,feature-selection,0.4971339
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-β.,c,0.17513797,of,0.44327667,gradient,0.31114018
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-β.,gene-encoding,0.38120317,encoding,0.83833957,feature-selection,0.46822703
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-β.,disrupt,0.26663294,function,0.45016778,feature-engineering,0.39671433
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-β.,human,0.30336243,of,0.5175895,feature-engineering,0.40631005
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-β.,il,0.17175047,monte,0.3419046,monte,0.3419046
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-β.,human,0.30336243,of,0.5175895,feature-engineering,0.40631005
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-β.,dependent,0.2523393,of,0.585135,generative,0.43066898
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-β.,immunity,0.27692312,boosting,0.56300366,boosting,0.56300366
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-β.,responsive,0.19582266,fully,0.44069856,generative,0.34531492
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-β.,pathway,0.27141988,cascade,0.7127757,feed-forward,0.5331765
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-β.,dependent,0.2523393,of,0.585135,generative,0.43066898
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-β.,induction,0.22102317,of,0.52603287,long-short-term,0.44878548
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-β.,dependent,0.2523393,of,0.585135,generative,0.43066898
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-β.,homeostasis,0.24268803,function,0.58911395,feed-forward,0.42720363
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-β.,danlos,0.21490288,confusion-matrix,0.403476,confusion-matrix,0.403476
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-β.,syndrome,0.20306323,recurrent,0.42346346,confusion-matrix,0.3198145
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-β.,danlos-syndrome,0.24843499,recurrent,0.4372357,confusion-matrix,0.38600892
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-β.,connective,0.25064147,matrix,0.60000014,confusion-matrix,0.437374
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-β.,tissues,0.21297011,of,0.47614664,generative,0.371554
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-β.,connective-tissues,0.3430095,matrix,0.6044134,recurrent-neural-network,0.55445325
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-β.,transcriptional,0.33864313,encoding,0.5598241,feed-forward,0.5453118
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-β.,pattern,0.33640617,feature,0.582756,clustering,0.5010694
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-β.,rights,0.3170033,adversarial,0.6281444,data-science,0.57488894
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-β.,reserved,0.28677964,of,0.4776592,supervised,0.3944377
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-β.,probably,0.20216683,of,0.6189318,long-short-term,0.43648547
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-β.,due,0.21681537,of,0.5734476,confusion-matrix,0.40250766
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-β.,private,0.410882,decision,0.5400172,data-science,0.5166998
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-β.,splice,0.3258633,encoding,0.5467918,bag-of-words,0.38908023
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-β.,original,0.41515705,of,0.5401661,feature-reduction,0.51911664
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-β.,u,0.1900385,unit,0.40376884,relu,0.36135292
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-β.,often,0.38066354,few,0.61593103,confusion-matrix,0.50351226
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-β.,impair,0.25531146,function,0.560261,short-term-memory,0.40864372
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-β.,nature,0.2731439,of,0.5463233,generative,0.5272707
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-β.,indicates,0.2743193,of,0.6366827,clustering,0.41554892
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-β.,mucosal,0.21299721,of,0.4234106,boosting,0.40373027
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-β.,surfaces,0.29332054,layer,0.5952867,embeddings,0.47604963
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-β.,incompletely,0.21997336,fully,0.73591375,generative,0.3688082
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-β.,understood,0.33540633,fully,0.5863327,stochastic,0.4766314
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-β.,incompletely-understood,0.3823735,fully,0.64859945,stochastic,0.5216556
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-β.,government,0.3715946,federated,0.64645237,data-science,0.6132002
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-β.,works,0.4442468,data,0.5234174,graphics-processing,0.50902706
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-β.,genetic,0.44218406,selection,0.53394234,clustering,0.53279865
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-β.,etiologies,0.32162663,recurrent,0.5298591,confusion-matrix,0.41375434
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-β.,generation,0.3480911,generative,0.6357137,generative,0.6357137
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-β.,family,0.2727693,support,0.5085263,clustering,0.40444815
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-β.,generation-family,0.4786551,generative,0.6602825,generative,0.6602825
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-β.,clinically,0.3702051,recurrent,0.5046643,confusion-matrix,0.40397355
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-β.,overlaps,0.33984774,feature,0.5439323,clustering,0.49236846
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-β.,autosomal,0.25142145,descent,0.42156005,generative,0.36895448
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-β.,dominant,0.24884295,component,0.48866612,generative,0.45397174
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-β.,autosomal-dominant,0.28488988,descent,0.41274726,generative-model,0.38142684
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-β.,different,0.37681934,of,0.61590904,clustering,0.46857932
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-β.,cells,0.20327199,naive,0.5115537,generative,0.40616876
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-β.,site,0.19581059,of,0.46834108,nearest-neighbors,0.3344323
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-β.,variant,0.3217284,encoding,0.47556034,feature-selection,0.41424268
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-β.,jun,0.210586,feed-forward,0.37043476,feed-forward,0.37043476
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-β.,n,0.24332823,of,0.45693433,long-short-term,0.34114176
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-β.,jun-n,0.21143919,cascade,0.4181518,feed-forward,0.3875628
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-β.,eds,0.2789699,fourier-transform,0.4027559,fourier-transform,0.4027559
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-β.,impaired,0.28064826,function,0.6550549,short-term-memory,0.48377025
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-β.,fibroblasts,0.18058866,matrix,0.4928056,confusion-matrix,0.31368023
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-β.,displayed,0.24727404,feature,0.48546267,feature-selection,0.40465993
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-β.,ad,0.3459351,memory,0.48189065,semantic,0.46080723
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-β.,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-β.,il,0.17175047,monte,0.3419046,monte,0.3419046
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-β.,ctd,0.28113365,tfidf,0.33424237,tfidf,0.33424237
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-β.,c,0.17513797,of,0.44327667,gradient,0.31114018
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-β.,variant,0.3217284,encoding,0.47556034,feature-selection,0.41424268
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-β.,jun,0.210586,feed-forward,0.37043476,feed-forward,0.37043476
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-β.,eds,0.2789699,fourier-transform,0.4027559,fourier-transform,0.4027559
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-β.,cells,0.20327199,naive,0.5115537,generative,0.40616876
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-β.,xxxf,0.22052765,tfidf,0.3340549,tfidf,0.3340549
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-β.,xxxa,0.103940696,encoding,0.28463936,nearest-neighbors,0.2823031
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-β.,whereas,0.21473005,of,0.61474305,long-short-term,0.4381357
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-β.,vitro,0.292481,of,0.48112682,generative,0.40355864
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-β.,three,0.36911732,one,0.78425425,clustering,0.4299444
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-β.,tgf,0.14675966,matrix,0.40835786,feed-forward,0.36006683
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-β.,science,0.449412,science,1.0,data-science,0.8160229
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-β.,responses,0.23078328,naive,0.5126229,boosting,0.49454907
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-β.,response,0.2143969,of,0.52661085,boosting,0.48192608
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-β.,report,0.3090002,of,0.56646246,data-engineering,0.3762592
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-β.,regulators,0.29258844,feed-forward,0.51152146,feed-forward,0.51152146
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-β.,patients,0.30007,recurrent,0.5332828,dropout,0.3918751
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-β.,mutations,0.30690983,encoding,0.48844272,feature-selection,0.4252736
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-β.,moreover,0.34991172,of,0.5596781,boosting,0.44273305
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-β.,loss,0.26544642,reduction,0.62177265,dropout,0.42517614
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-β.,loeys,0.18673024,descent,0.34577963,pytorch,0.33722597
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-β.,involvement,0.2576242,of,0.5255257,feed-forward,0.34934357
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-β.,integrity,0.24839588,function,0.56385756,segmentation,0.40543166
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-β.,heterozygous,0.20629463,encoding,0.35905516,feature-selection,0.32592592
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-β.,haploinsufficiency,0.32231086,encoding,0.44735578,feed-forward,0.4297809
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-β.,furthermore,0.33438665,of,0.5529862,clustering,0.42723072
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-β.,function,0.3447219,function,1.0,learning-function,0.5767432
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-β.,f,0.2169397,confusion-matrix,0.37468427,confusion-matrix,0.37468427
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-β.,expression,0.32038707,encoding,0.59633577,clustering,0.442253
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-β.,experiment,0.38590434,batch,0.5287235,batch-normalization,0.5030932
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-β.,essential,0.28451368,components,0.5479382,component-analysis,0.4103359
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-β.,ehlers,0.2592587,intelligence,0.3864156,artificial-intelligence,0.3724231
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-β.,ecm,0.34290513,matrix,0.7409842,confusion-matrix,0.516019
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-β.,development,0.34732813,generative,0.56588423,generative,0.56588423
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-β.,ctds,0.29383504,feature,0.34761077,recurrent-neural-network,0.3222178
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-β.,consistently,0.3349427,few,0.5762741,clustering,0.4464267
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-β.,components,0.34729862,components,1.0,principal-components,0.7107156
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-β.,component,0.29999307,component,1.0,principal-component,0.687786
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-β.,complex,0.27214053,components,0.5436033,component-analysis,0.4161712
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-β.,combination,0.385488,of,0.5245792,boosting,0.5027329
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-β.,cmc,0.19754256,matrix,0.35052574,tfidf,0.3268669
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-β.,claim,0.35702044,truth,0.55100346,bag-of-words,0.47585917
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-β.,candida,0.20578721,one,0.31409255,keras,0.2849025
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-β.,authors,0.45811802,data,0.5259881,natural-language-processing,0.4706872
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-β.,atf,0.252214,tf-idf,0.4323768,tf-idf,0.4323768
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-β.,advancement,0.37068725,engineering,0.5121616,data-engineering,0.48431426
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-β.,accounting,0.37102675,of,0.55534834,clustering,0.52411747
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-β.,abolished,0.13110909,reduction,0.428272,feed-forward,0.34576994
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,coupled,0.37019002,connected,0.5951823,stochastic-gradient,0.5436393
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,inward,0.1888181,rectified,0.6238178,gradient-descent,0.43811753
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,rectifier,0.28300613,rectified,0.65275586,backpropagation,0.45593154
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,potassium,0.12511921,rectified,0.48884782,batch-normalization,0.3201604
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,current,0.3530666,rectified,0.52906346,generative-model,0.40904555
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,inward-rectifier,0.29073623,rectified,0.62413836,backpropagation,0.44888532
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,rectifier-potassium,0.2837497,rectified,0.5803586,gradient-descent,0.4693094
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,potassium-current,0.22526506,rectified,0.5278814,gradient-descent,0.43205756
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,ado,0.21717098,rate,0.2980743,relu,0.29218787
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,induced,0.2259351,of,0.5615651,boosting,0.4303583
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,greater,0.2528603,of,0.59163296,long-short-term,0.44578376
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,rate,0.24866687,rate,1.0,dropout,0.44953537
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,slowing,0.27702895,rate,0.564112,learning-rate,0.45324916
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,ado-induced,0.24775045,of,0.52507687,long-short-term,0.42969143
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,rate-slowing,0.31496048,rate,0.61382836,learning-rate,0.54011655
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,induced,0.2259351,of,0.5615651,boosting,0.4303583
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,inward,0.1888181,rectified,0.6238178,gradient-descent,0.43811753
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,rectifying,0.26498577,rectified,0.729017,backpropagation,0.43862078
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,current,0.3530666,rectified,0.52906346,generative-model,0.40904555
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,inward-rectifying,0.257007,rectified,0.6685119,gradient-descent,0.43490094
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,rectifying-current,0.33370352,rectified,0.73382646,recurrent-neural-network,0.5098481
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,perforated,0.20932572,recurrent,0.4822995,fully-connected,0.39921963
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,patch,0.2752486,reinforcement,0.4673865,hidden-layer,0.3749036
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,clamp,0.23010059,bag,0.4124239,softmax,0.36634463
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,recordings,0.38424575,rectified,0.5232359,computer-vision,0.48527625
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,perforated-patch,0.30644408,recurrent-neural-network,0.48796427,recurrent-neural-network,0.48796427
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,patch-clamp,0.2971104,fourier-transform,0.4500033,fourier-transform,0.4500033
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,perforated-patch-clamp,0.28970894,rectified,0.45379335,recurrent-neural-network,0.4436626
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,subsequent,0.25077623,of,0.65363204,long-short-term,0.46481046
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,negative,0.21900582,of,0.48486513,feed-forward,0.34958985
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,chronotropic,0.22841734,discriminative,0.40212792,long-short-term,0.3744254
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,effects,0.2624804,short-term,0.63497096,long-short-term,0.5306107
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,negative-chronotropic,0.32197064,discriminative,0.493744,learning-function,0.4687047
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,chronotropic-effects,0.32491338,learning-function,0.5438987,learning-function,0.5438987
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,exert,0.18410438,function,0.44539347,feed-forward,0.40230706
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,negative,0.21900582,of,0.48486513,feed-forward,0.34958985
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,chronotropic,0.22841734,discriminative,0.40212792,long-short-term,0.3744254
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,effects,0.2624804,short-term,0.63497096,long-short-term,0.5306107
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,negative-chronotropic,0.32197064,discriminative,0.493744,learning-function,0.4687047
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,chronotropic-effects,0.32491338,learning-function,0.5438987,learning-function,0.5438987
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,physiologically,0.3561905,fully,0.5283963,generative,0.48550883
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,relevant,0.4346258,of,0.5628227,natural-language,0.5076148
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,ado,0.21717098,rate,0.2980743,relu,0.29218787
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,concentrations,0.16781005,of,0.4458394,batch-normalization,0.42195582
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,physiologically-relevant,0.42289183,natural,0.5442251,generative-model,0.53072464
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,selective,0.24381305,selection,0.5152553,feature-selection,0.47347614
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,girk,0.23140046,rectified,0.4814722,learning-function,0.35738915
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,blocker,0.17806688,function,0.35899335,data-augmentation,0.30515236
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,girk,0.23140046,rectified,0.4814722,learning-function,0.35738915
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,expression,0.32038707,encoding,0.59633577,clustering,0.442253
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,enhances,0.28338683,boosting,0.54349446,boosting,0.54349446
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,ikado,0.22712809,keras,0.38624293,keras,0.38624293
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,hf,0.293398,long-short-term,0.35116297,long-short-term,0.35116297
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,san,0.26156235,federated,0.45133483,keras,0.39377424
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,pacemaker,0.27666068,recurrent-neural-network,0.40608007,recurrent-neural-network,0.40608007
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,cells,0.20327199,naive,0.5115537,generative,0.40616876
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,pacemaker-cells,0.31629857,recurrent-neural-network,0.5392158,recurrent-neural-network,0.5392158
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,induced,0.2259351,of,0.5615651,boosting,0.4303583
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,rate,0.24866687,rate,1.0,dropout,0.44953537
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,slowing,0.27702895,rate,0.564112,learning-rate,0.45324916
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,rate-slowing,0.31496048,rate,0.61382836,learning-rate,0.54011655
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,girk,0.23140046,rectified,0.4814722,learning-function,0.35738915
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,mrna,0.25853646,encoding,0.5590567,batch-normalization,0.35810667
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,expression,0.32038707,encoding,0.59633577,clustering,0.442253
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,mrna-expression,0.2990228,encoding,0.5055611,feed-forward,0.3768012
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,induced,0.2259351,of,0.5615651,boosting,0.4303583
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,chronic,0.22727785,recurrent,0.5279353,long-short-term,0.4292153
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,hf,0.293398,long-short-term,0.35116297,long-short-term,0.35116297
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,induced-chronic,0.28936225,short-term,0.5319929,long-short-term,0.48445886
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,slow,0.2498877,rate,0.56280303,long-short-term,0.48838022
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,diastolic,0.27467865,augmentation,0.42852774,gradient,0.4273815
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,depolarization,0.222698,rectified,0.5779494,backpropagation,0.49299282
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,maximum,0.27634987,reduction,0.4912275,batch-normalization,0.4584134
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,diastolic,0.27467865,augmentation,0.42852774,gradient,0.4273815
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,potential,0.3558654,of,0.5645705,generative-model,0.46479023
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,maximum-diastolic-potential,0.42658815,backpropagation,0.56714237,backpropagation,0.56714237
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,girk,0.23140046,rectified,0.4814722,learning-function,0.35738915
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,mrna,0.25853646,encoding,0.5590567,batch-normalization,0.35810667
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,quantification,0.40637213,analysis,0.5695292,segmentation,0.5086152
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,mrna-quantification,0.47750965,batch-normalization,0.6137507,batch-normalization,0.6137507
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,girk,0.23140046,rectified,0.4814722,learning-function,0.35738915
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,blockade,0.21235548,augmentation,0.46567166,data-augmentation,0.39568862
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,may,0.30907542,of,0.58654004,long-short-term,0.43985203
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,canine,0.26931396,of,0.52769995,gradient-descent,0.35120833
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,chronic,0.22727785,recurrent,0.5279353,long-short-term,0.4292153
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,hf,0.293398,long-short-term,0.35116297,long-short-term,0.35116297
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,ado,0.21717098,rate,0.2980743,relu,0.29218787
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,selective,0.24381305,selection,0.5152553,feature-selection,0.47347614
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,antagonist,0.21628487,discriminative,0.38467538,feed-forward,0.30425376
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,bpm,0.20261693,rate,0.44300652,bagging,0.27588257
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,slope,0.26215786,linear,0.49030364,cross-entropy,0.46835062
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,adenosine,0.20329912,of,0.3698272,gradient,0.2729475
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,receptors,0.2335811,function,0.40644348,clustering,0.36239648
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,tpq,0.22967798,dimensionality-reduction,0.4745992,dimensionality-reduction,0.4745992
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,prevented,0.17704698,reduction,0.5312941,boosting,0.39043245
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,ado,0.21717098,rate,0.2980743,relu,0.29218787
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,dpcpx,0.18062729,discriminative,0.266141,backpropagation,0.24898988
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,prevented,0.17704698,reduction,0.5312941,boosting,0.39043245
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,ado,0.21717098,rate,0.2980743,relu,0.29218787
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,hf,0.293398,long-short-term,0.35116297,long-short-term,0.35116297
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,vs,0.22635552,transfer,0.4263924,statistical,0.3002486
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,ctl,0.26552922,naive,0.5056839,short-term-memory,0.44604602
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,ado,0.21717098,rate,0.2980743,relu,0.29218787
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,effects,0.2624804,short-term,0.63497096,long-short-term,0.5306107
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,firing,0.36060143,backpropagation,0.56011117,backpropagation,0.56011117
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,rate,0.24866687,rate,1.0,dropout,0.44953537
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,firing-rate,0.4612188,learning-rate,0.74771154,learning-rate,0.74771154
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,hf,0.293398,long-short-term,0.35116297,long-short-term,0.35116297
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,cells,0.20327199,naive,0.5115537,generative,0.40616876
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,hf,0.293398,long-short-term,0.35116297,long-short-term,0.35116297
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,san,0.26156235,federated,0.45133483,keras,0.39377424
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,cells,0.20327199,naive,0.5115537,generative,0.40616876
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,ado,0.21717098,rate,0.2980743,relu,0.29218787
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,ado,0.21717098,rate,0.2980743,relu,0.29218787
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,sdd,0.25955778,segmentation-algorithm,0.37858844,segmentation-algorithm,0.37858844
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,san,0.26156235,federated,0.45133483,keras,0.39377424
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,tissue,0.23679586,of,0.5202017,segmentation,0.4076932
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,useful,0.40063038,discriminative,0.489146,feature-engineering,0.43842706
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,strategy,0.47490904,feature-engineering,0.59725416,feature-engineering,0.59725416
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,sinus,0.17330457,rate,0.42252666,recurrent-neural-network,0.35145158
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,arrest,0.20072266,recurrent,0.3943223,bagging,0.32782418
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,sinus-arrest,0.18826115,augmentation,0.42882293,long-short-term,0.4083532
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,sinoatrial,0.25311792,recurrent-neural-network,0.45808768,recurrent-neural-network,0.45808768
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,node,0.33007902,recurrent-neural-network,0.46002018,recurrent-neural-network,0.46002018
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,sinoatrial-node,0.35573012,recurrent-neural-network,0.5910697,recurrent-neural-network,0.5910697
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,significantly,0.27887642,of,0.5214151,long-short-term,0.39056638
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,increased,0.26921988,reduction,0.6514183,boosting,0.46515882
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,significantly-increased,0.30354688,reduction,0.5746703,boosting,0.45880336
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,rights,0.3170033,adversarial,0.6281444,data-science,0.57488894
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,reserved,0.28677964,of,0.4776592,supervised,0.3944377
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,observed,0.23725806,of,0.64367145,long-short-term,0.4519785
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,significantly,0.27887642,of,0.5214151,long-short-term,0.39056638
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,normal,0.22889833,function,0.57724285,batch-normalization,0.4663512
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,controls,0.2521493,naive,0.47579613,statistical,0.41853178
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,normal-controls,0.29091465,naive,0.46905735,batch-normalization,0.44612736
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,mitigate,0.37109083,overfitting,0.49619696,overfitting,0.49619696
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,bradycardia,0.23658665,confusion,0.45465383,bagging,0.3656461
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,membrane,0.2560242,layer,0.5360652,gradient-descent,0.40451998
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,hyperpolarization,0.22345033,rectified,0.598604,backpropagation,0.46285695
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,main,0.3070703,principal,0.7875631,principal-components,0.51314574
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,methods,0.50049126,data,0.5400177,machine-learning,0.50049126
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,key,0.35973132,principal,0.614877,feature-engineering,0.498355
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,findings,0.35685748,data,0.65714294,component-analysis,0.38599753
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,key-findings,0.5931077,object-tracking,0.6275683,object-tracking,0.6275683
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,heart,0.28300244,rate,0.49867767,batch-normalization,0.3427502
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,failure,0.32964212,recurrent,0.52057266,confusion-matrix,0.44323406
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,heart-failure,0.36450487,long-short-term,0.44014218,long-short-term,0.44014218
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,g,0.17250246,feed,0.40076,n-gram,0.27758121
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,protein,0.31929362,encoding,0.5525089,clustering,0.36023882
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,g-protein,0.26876673,encoding,0.47615886,feed-forward,0.38512486
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,causing,0.1470272,of,0.5218761,generative,0.33331656
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,hyperpolarization,0.22345033,rectified,0.598604,backpropagation,0.46285695
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,bradycardia,0.23658665,confusion,0.45465383,bagging,0.3656461
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,contributes,0.27235785,of,0.5690483,feed-forward,0.4287781
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,brady,0.2235013,bagging,0.5136188,bagging,0.5136188
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,arrhythmias,0.26929462,long-short-term,0.40093195,long-short-term,0.40093195
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,brady-arrhythmias,0.25053123,long-short-term,0.4226648,long-short-term,0.4226648
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,signaling,0.29640946,cascade,0.70725644,feed-forward,0.5819744
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,assess,0.36162603,of,0.49566716,decision-tree,0.39463407
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,contributions,0.37193105,components,0.5900404,principal-components,0.50173026
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,action,0.25617146,of,0.5591097,generative,0.46361452
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,potentials,0.31223005,rectified,0.5598427,backpropagation,0.49685013
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,action-potentials,0.3412767,rectified,0.59221405,backpropagation,0.55544776
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,girk,0.23140046,rectified,0.4814722,learning-function,0.35738915
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,ado,0.21717098,rate,0.2980743,relu,0.29218787
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,hf,0.293398,long-short-term,0.35116297,long-short-term,0.35116297
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,relevant,0.4346258,of,0.5628227,natural-language,0.5076148
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,ikado,0.22712809,keras,0.38624293,keras,0.38624293
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,san,0.26156235,federated,0.45133483,keras,0.39377424
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,tpq,0.22967798,dimensionality-reduction,0.4745992,dimensionality-reduction,0.4745992
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,dpcpx,0.18062729,discriminative,0.266141,backpropagation,0.24898988
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,ctl,0.26552922,naive,0.5056839,short-term-memory,0.44604602
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,adenosine,0.20329912,of,0.3698272,gradient,0.2729475
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,upregulated,0.23211968,encoding,0.51694846,feed-forward,0.35553855
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,tachypacing,0.27416742,long-short,0.4225192,long-short-term,0.38561463
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,tachy,0.2093395,bagging,0.46313235,bagging,0.46313235
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,studied,0.26534057,of,0.63097596,generative-model,0.40392917
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,significance,0.39249778,statistical,0.67423874,statistical,0.67423874
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,role,0.2562992,function,0.5340955,feed-forward,0.4137928
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,recorded,0.299657,rectified,0.55581653,computer-vision,0.443301
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,p,0.26795468,support,0.40805867,regression,0.40253854
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,measured,0.25103813,of,0.539739,batch-normalization,0.45439726
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,mdp,0.19336107,nlp,0.29339045,nlp,0.29339045
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,known,0.3344566,of,0.5873189,clustering,0.4164055
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,isolated,0.24300994,of,0.4970751,gradient,0.40058494
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,investigated,0.30147675,of,0.6179704,generative-model,0.42952073
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,increase,0.28092995,reduction,0.7624404,boosting,0.49543357
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,frequently,0.3283582,few,0.57415104,clustering,0.41482496
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,dogs,0.2639088,of,0.4063773,artificial-intelligence,0.33557034
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,currents,0.23222095,rectified,0.6628682,backpropagation,0.489811
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,collected,0.33035916,data,0.5686942,ground-truth,0.3838368
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,aps,0.29561242,of,0.43983904,backpropagation,0.4084395
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,aims,0.42995954,of,0.465683,feature-engineering,0.4555406
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,addition,0.30500388,of,0.6910241,feature-reduction,0.48914018
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,respiratory,0.2119393,rate,0.40438467,bagging,0.35663396
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,behavior,0.3131135,style,0.5405977,reinforcement-learning,0.5272814
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,could,0.34235194,of,0.59299076,boosting,0.42074972
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,systematically,0.47082037,feature-engineering,0.5402172,feature-engineering,0.5402172
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,modulate,0.28013808,function,0.51941574,feed-forward,0.47073716
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,cortical,0.3398322,neural,0.6137136,convolutional,0.5222789
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,activity,0.21813896,function,0.53536034,boosting,0.38798416
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,alpha,0.13301267,of,0.41602427,principal-component,0.39112252
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,rhythmic,0.34672552,learning-rate,0.53722566,learning-rate,0.53722566
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,activities,0.25071037,of,0.4766258,learning-function,0.38030344
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,across,0.3330416,gradient,0.4622073,gradient,0.4622073
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,breathing,0.35209614,bagging,0.512692,bagging,0.512692
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,cycles,0.2434696,of,0.40520722,long-short-term,0.39707133
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,alpha-rhythmic,0.30102026,learning-rate,0.55263036,learning-rate,0.55263036
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,alpha,0.13301267,of,0.41602427,principal-component,0.39112252
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,range,0.23189357,linear,0.4532097,gradient,0.36315575
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,across,0.3330416,gradient,0.4622073,gradient,0.4622073
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,widespread,0.35768965,of,0.4953639,generative,0.42742717
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,brain,0.31704307,neural,0.57897407,learning-rate,0.44069666
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,areas,0.3090546,forest,0.4990691,ground-truth,0.40763968
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,alpha-range,0.23946622,linear,0.4878406,cross-entropy,0.45669538
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,brain-areas,0.40732062,neural,0.5799888,learning-function,0.56185097
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,frequency,0.2874047,rate,0.5399102,long-short-term,0.4518629
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,cortical,0.3398322,neural,0.6137136,convolutional,0.5222789
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,phase,0.23814097,hidden-layer,0.45645207,hidden-layer,0.45645207
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,exhibits,0.22407068,feature,0.52375895,generative,0.38686335
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,great,0.31200224,of,0.56574446,feature-engineering,0.44874108
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,flexibility,0.4075504,dimensionality-reduction,0.5794139,dimensionality-reduction,0.5794139
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,cortical-phase,0.3972542,convolutional-layer,0.6025528,convolutional-layer,0.6025528
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,normal,0.22889833,function,0.57724285,batch-normalization,0.4663512
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,breathing,0.35209614,bagging,0.512692,bagging,0.512692
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,modulated,0.29650646,of,0.5227381,feed-forward,0.48507184
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,cortical,0.3398322,neural,0.6137136,convolutional,0.5222789
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,phase,0.23814097,hidden-layer,0.45645207,hidden-layer,0.45645207
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,activity,0.21813896,function,0.53536034,boosting,0.38798416
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,normal-breathing,0.36437842,gradient-descent,0.43234167,gradient-descent,0.43234167
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,breathing-modulated,0.481125,learning-function,0.5607983,learning-function,0.5607983
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,cortical-phase,0.3972542,convolutional-layer,0.6025528,convolutional-layer,0.6025528
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,unrelated,0.23297319,one,0.48459643,feature-selection,0.3719702
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,task,0.5084964,object-tracking,0.69268537,object-tracking,0.69268537
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,effects,0.2624804,short-term,0.63497096,long-short-term,0.5306107
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,could,0.34235194,of,0.59299076,boosting,0.42074972
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,account,0.38509363,of,0.53262895,stochastic,0.5254493
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,effects-could,0.3312898,dimensionality-reduction,0.55299807,dimensionality-reduction,0.55299807
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,diametrically,0.29044515,generative,0.5548062,generative,0.5548062
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,opposed,0.3341823,of,0.5724972,feature-reduction,0.47271034
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,across,0.3330416,gradient,0.4622073,gradient,0.4622073
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,breaths,0.34267682,bagging,0.5810249,bagging,0.5810249
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,diametrically-opposed,0.37227023,dimensionality-reduction,0.6085971,dimensionality-reduction,0.6085971
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,paced,0.34431568,rate,0.4732807,bagging,0.42271987
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,inspiration,0.34913522,deep,0.4679277,bagging,0.45263636
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,could,0.34235194,of,0.59299076,boosting,0.42074972
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,organize,0.43604526,network,0.57996106,hierarchical-clustering,0.5687952
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,participants,0.4160846,object-tracking,0.5017827,object-tracking,0.5017827
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,performed,0.3864032,analysis,0.5711501,supervised,0.4789877
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,paced,0.34431568,rate,0.4732807,bagging,0.42271987
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,breathing,0.35209614,bagging,0.512692,bagging,0.512692
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,paced-breathing,0.39656287,bagging,0.48135412,bagging,0.48135412
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,dynamic,0.4720998,stochastic,0.62950635,stochastic,0.62950635
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,neural,0.5080686,neural,1.0,neural-network,0.7153882
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,network,0.50771487,network,1.0,neural-network,0.7589166
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,integrated,0.53518295,data-engineering,0.633208,data-engineering,0.633208
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,neural-network,0.7034505,neural-network,1.0,neural-network,1.0
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,network-integrated,0.6394992,neural-network,0.748351,neural-network,0.748351
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,rhythmic,0.34672552,learning-rate,0.53722566,learning-rate,0.53722566
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,cortical,0.3398322,neural,0.6137136,convolutional,0.5222789
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,activity,0.21813896,function,0.53536034,boosting,0.38798416
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,widespread,0.35768965,of,0.4953639,generative,0.42742717
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,brain,0.31704307,neural,0.57897407,learning-rate,0.44069666
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,areas,0.3090546,forest,0.4990691,ground-truth,0.40763968
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,brain-areas,0.40732062,neural,0.5799888,learning-function,0.56185097
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,organizing,0.39680806,generative,0.52276504,generative,0.52276504
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,brain,0.31704307,neural,0.57897407,learning-rate,0.44069666
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,processes,0.34218454,processing,0.59430957,generative,0.5664364
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,brain-processes,0.45582807,natural-language-processing,0.64961654,natural-language-processing,0.64961654
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,phase,0.23814097,hidden-layer,0.45645207,hidden-layer,0.45645207
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,angles,0.27146327,centroid-based,0.497497,centroid-based,0.497497
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,underlying,0.37239885,neural,0.55211174,generative,0.49267903
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,phase-angles,0.34308797,fourier,0.6141224,fourier,0.6141224
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,track,0.4388718,tracking,0.7933724,object-tracking,0.5832878
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,respiratory,0.2119393,rate,0.40438467,bagging,0.35663396
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,inputs,0.4202413,feed-forward,0.62812734,feed-forward,0.62812734
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,two,0.35955608,one,0.79919666,clustering,0.43817294
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,rhythmic,0.34672552,learning-rate,0.53722566,learning-rate,0.53722566
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,systems,0.40840507,components,0.5468041,feature-engineering,0.5135208
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,volitionally,0.4074283,reinforcement-learning,0.5711324,reinforcement-learning,0.5711324
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,controlled,0.25206095,of,0.4703986,supervised,0.39651048
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,change,0.30684608,reduction,0.5973228,feature-reduction,0.46143895
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,volitionally-controlled,0.42807853,object-tracking,0.5854641,object-tracking,0.5854641
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,simple,0.44104093,one-shot,0.5431666,one-shot,0.5431666
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,gas,0.25405633,bag,0.47285086,bagging,0.43151924
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,exchange,0.28460225,gradient-descent,0.52362746,gradient-descent,0.52362746
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,gas-exchange,0.31081975,gradient-descent,0.45056677,gradient-descent,0.45056677
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,recurrent,0.32854465,recurrent,1.0,recurrent-neural-network,0.59633
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,temporal,0.34829444,semantic,0.54608697,semantic,0.54608697
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,frame,0.30970967,encoding,0.6068933,bag-of-words,0.41038984
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,neither,0.22002941,fully,0.530203,long-short-term,0.4112466
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,cardiac,0.29562658,of,0.42777455,long-short-term,0.35708636
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,fluctuations,0.33684564,stochastic,0.61881655,stochastic,0.61881655
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,different,0.37681934,of,0.61590904,clustering,0.46857932
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,neurophysiological,0.49097133,learning-function,0.63524336,learning-function,0.63524336
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,systems,0.40840507,components,0.5468041,feature-engineering,0.5135208
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,regularized,0.67971236,regularization,0.91903925,convolutional,0.7763782
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,phase,0.23814097,hidden-layer,0.45645207,hidden-layer,0.45645207
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,pattern,0.33640617,feature,0.582756,clustering,0.5010694
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,phase-pattern,0.40297812,hidden-layer,0.6346823,hidden-layer,0.6346823
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,controlled,0.25206095,of,0.4703986,supervised,0.39651048
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,slow,0.2498877,rate,0.56280303,long-short-term,0.48838022
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,breathing,0.35209614,bagging,0.512692,bagging,0.512692
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,slow-breathing,0.3944078,learning-function,0.5014959,learning-function,0.5014959
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,regulate,0.2604217,function,0.51654714,feed-forward,0.50070786
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,mental,0.36338603,confusion,0.61597085,language-processing,0.48808742
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,processes,0.34218454,processing,0.59430957,generative,0.5664364
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,magnetoencephalography,0.5249738,object-tracking,0.63797367,object-tracking,0.63797367
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,study,0.3645851,of,0.5728763,statistical,0.44204497
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,demonstrates,0.32810378,of,0.5866501,feature-engineering,0.42233235
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,consistent,0.2827828,of,0.55118144,clustering,0.43242198
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,phase,0.23814097,hidden-layer,0.45645207,hidden-layer,0.45645207
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,adjustment,0.3696947,regression,0.6063617,regression,0.6063617
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,phase-adjustment,0.41184813,batch-normalization,0.58613724,batch-normalization,0.58613724
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,cortical,0.3398322,neural,0.6137136,convolutional,0.5222789
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,phase,0.23814097,hidden-layer,0.45645207,hidden-layer,0.45645207
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,cortical-phase,0.3972542,convolutional-layer,0.6025528,convolutional-layer,0.6025528
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,slow,0.2498877,rate,0.56280303,long-short-term,0.48838022
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,inspiratory,0.27689296,bagging,0.41085085,bagging,0.41085085
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,inputs,0.4202413,feed-forward,0.62812734,feed-forward,0.62812734
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,could,0.34235194,of,0.59299076,boosting,0.42074972
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,reorganize,0.31126407,network,0.5360396,hierarchical-clustering,0.47637388
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,respiratory,0.2119393,rate,0.40438467,bagging,0.35663396
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,measurements,0.31488982,data,0.56587404,batch-normalization,0.52457345
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,slow,0.2498877,rate,0.56280303,long-short-term,0.48838022
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,breathing,0.35209614,bagging,0.512692,bagging,0.512692
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,slow-breathing,0.3944078,learning-function,0.5014959,learning-function,0.5014959
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,brain,0.31704307,neural,0.57897407,learning-rate,0.44069666
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,rhythms,0.3235392,learning-rate,0.49108884,learning-rate,0.49108884
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,brain-rhythms,0.37626266,learning-rate,0.59402096,learning-rate,0.59402096
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,noteworthy,0.30126104,feature,0.489644,feature-engineering,0.40072542
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,breathing,0.35209614,bagging,0.512692,bagging,0.512692
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,paced,0.34431568,rate,0.4732807,bagging,0.42271987
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,relative,0.28452736,of,0.6192827,long-short-term,0.43953407
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,modulation,0.31462312,function,0.59933597,feed-forward,0.5696373
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,effects,0.2624804,short-term,0.63497096,long-short-term,0.5306107
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,inspiration,0.34913522,deep,0.4679277,bagging,0.45263636
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,stage,0.30396575,classification,0.4731305,classification,0.4731305
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,effects,0.2624804,short-term,0.63497096,long-short-term,0.5306107
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,became,0.20959085,few,0.5228771,bagging,0.40947422
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,structured,0.49300212,hierarchical,0.5989524,hierarchical-clustering,0.5973344
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,pattern,0.33640617,feature,0.582756,clustering,0.5010694
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,simultaneous,0.3721496,of,0.5856672,one-shot,0.56406254
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,magnetoencephalography,0.5249738,object-tracking,0.63797367,object-tracking,0.63797367
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,mental,0.36338603,confusion,0.61597085,language-processing,0.48808742
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,regulation,0.2640685,function,0.5839784,feed-forward,0.52085924
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,slow,0.2498877,rate,0.56280303,long-short-term,0.48838022
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,train,0.54995465,learning,0.60963345,learning-rate,0.5978736
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,slow,0.2498877,rate,0.56280303,long-short-term,0.48838022
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,relative,0.28452736,of,0.6192827,long-short-term,0.43953407
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,volitional,0.4352277,reinforcement-learning,0.62735635,reinforcement-learning,0.62735635
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,control,0.27050394,of,0.5093193,artificial-intelligence,0.40948874
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,volitional-control,0.47699246,reinforcement-learning,0.64685166,reinforcement-learning,0.64685166
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,subject,0.39455077,of,0.55199313,statistical,0.5067352
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,level,0.23847455,of,0.54773176,batch-normalization,0.45912555
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,subject-level,0.62184185,object-tracking,0.71412957,object-tracking,0.71412957
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,structured,0.49300212,hierarchical,0.5989524,hierarchical-clustering,0.5973344
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,manner,0.26802608,fully,0.46465638,feed-forward,0.4349473
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,specifically,0.35122672,of,0.59676015,generative,0.5001233
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,locked,0.24078561,connected,0.522027,fully-connected,0.4492963
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,results,0.32376552,data,0.6932311,batch-normalization,0.44826904
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,reveal,0.32566452,analysis,0.50432014,clustering,0.41556934
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,numerous,0.32757068,few,0.76187646,generative,0.45826626
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,cognitive,0.5010079,memory,0.72449946,learning-function,0.7178915
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,information,0.5191034,data,0.708436,data-science,0.5937191
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,coding,0.43984842,encoding,0.84977734,feature-selection,0.5026905
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,information-coding,0.6077802,feature-selection,0.6087257,feature-selection,0.6087257
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,indicating,0.21094829,of,0.63023484,clustering,0.43286642
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,unique,0.3996781,feature,0.6177588,feature-engineering,0.5304749
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,external,0.24276523,connected,0.4833919,data-augmentation,0.40820563
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,influences,0.29473758,of,0.5758742,generative,0.47900644
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,emotional,0.38711113,semantic,0.6134369,semantic,0.6134369
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,functions,0.41232014,function,0.8737128,learning-function,0.5841365
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,commonly,0.38716513,of,0.49960154,confusion-matrix,0.4359238
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,associated,0.30827495,of,0.57598466,long-short-term,0.46578532
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,commonly-associated,0.4316697,of,0.5553712,clustering,0.5344238
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,normal,0.22889833,function,0.57724285,batch-normalization,0.4663512
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,frequency,0.2874047,rate,0.5399102,long-short-term,0.4518629
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,phase,0.23814097,hidden-layer,0.45645207,hidden-layer,0.45645207
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,breathing,0.35209614,bagging,0.512692,bagging,0.512692
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,rhythmic,0.34672552,learning-rate,0.53722566,learning-rate,0.53722566
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,integrated,0.53518295,data-engineering,0.633208,data-engineering,0.633208
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,inputs,0.4202413,feed-forward,0.62812734,feed-forward,0.62812734
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,slow,0.2498877,rate,0.56280303,long-short-term,0.48838022
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,adjustment,0.3696947,regression,0.6063617,regression,0.6063617
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,well,0.34264985,of,0.59718275,bagging,0.4145819
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,used,0.46049535,of,0.5630944,generative-model,0.4901716
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,timing,0.32781005,of,0.5694113,long-short-term,0.5227743
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,suggest,0.26874092,data,0.5391823,long-short-term,0.40288782
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,single,0.31087106,one,0.6951874,one-shot,0.4602274
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,revealing,0.33716297,of,0.6226121,clustering,0.47590643
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,response,0.2143969,of,0.52661085,boosting,0.48192608
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,report,0.3090002,of,0.56646246,data-engineering,0.3762592
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,relationship,0.31931284,regression,0.5493294,regression,0.5493294
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,provides,0.41792372,of,0.5261056,feature-engineering,0.4872959
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,often,0.38066354,few,0.61593103,confusion-matrix,0.50351226
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,new,0.43019778,of,0.526482,feature-reduction,0.4579819
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,middle,0.19510958,deep,0.45081678,language-processing,0.36516818
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,low,0.23602332,of,0.5820825,long-short-term,0.45172954
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,likely,0.28872275,one,0.55131567,generative,0.3953101
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,hypothesized,0.35693395,short-term,0.53707504,long-short-term,0.52520865
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,however,0.31437585,few,0.63182676,statistical,0.44065386
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,given,0.30785376,of,0.54849017,boosting,0.4329715
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,found,0.2840244,of,0.6208722,clustering,0.44675255
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,findings,0.35685748,data,0.65714294,component-analysis,0.38599753
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,exhibited,0.18898472,of,0.49406686,feature-reduction,0.35593373
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,essential,0.28451368,components,0.5479382,component-analysis,0.4103359
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,complicated,0.3251716,recurrent,0.6288403,confusion-matrix,0.4934948
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,based,0.49998575,classification-algorithm,0.5639226,classification-algorithm,0.5639226
Implications for REDUCE IT in clinical practice.,inhibitors,0.25381407,cascade,0.4157439,feed-forward,0.3175553
Implications for REDUCE IT in clinical practice.,provides,0.41792372,of,0.5261056,feature-engineering,0.4872959
Implications for REDUCE IT in clinical practice.,additional,0.35377294,of,0.63162684,feature-reduction,0.4511183
Implications for REDUCE IT in clinical practice.,risk,0.35860935,recurrent,0.53675485,logistic-regression,0.52381086
Implications for REDUCE IT in clinical practice.,reduction,0.22531602,reduction,1.0,feature-reduction,0.59547573
Implications for REDUCE IT in clinical practice.,risk-reduction,0.39302793,dimensionality-reduction,0.54107803,dimensionality-reduction,0.54107803
Implications for REDUCE IT in clinical practice.,triglyceride,0.20285241,batch-normalization,0.37365717,batch-normalization,0.37365717
Implications for REDUCE IT in clinical practice.,rich,0.3160888,natural,0.5082195,generative,0.4519166
Implications for REDUCE IT in clinical practice.,lipoproteins,0.21669655,components,0.37059355,tf-idf,0.33776158
Implications for REDUCE IT in clinical practice.,contribute,0.30676693,of,0.5196437,feed-forward,0.40432224
Implications for REDUCE IT in clinical practice.,triglyceride-rich,0.25357983,tf-idf,0.36326712,tf-idf,0.36326712
Implications for REDUCE IT in clinical practice.,rich-lipoproteins,0.25440428,tf-idf,0.40041518,tf-idf,0.40041518
Implications for REDUCE IT in clinical practice.,triglyceride-rich-lipoproteins,0.2509963,tf-idf,0.40055186,tf-idf,0.40055186
Implications for REDUCE IT in clinical practice.,low,0.23602332,of,0.5820825,long-short-term,0.45172954
Implications for REDUCE IT in clinical practice.,density,0.25813383,layer,0.4929318,gradient,0.48885438
Implications for REDUCE IT in clinical practice.,lipoprotein,0.22208765,tf-idf,0.3608624,tf-idf,0.3608624
Implications for REDUCE IT in clinical practice.,cholesterol,0.15921682,reduction,0.33627644,gradient,0.32767534
Implications for REDUCE IT in clinical practice.,low-density,0.22143166,layer,0.37423852,gradient,0.35624427
Implications for REDUCE IT in clinical practice.,density-lipoprotein,0.2429603,tf-idf,0.4027466,tf-idf,0.4027466
Implications for REDUCE IT in clinical practice.,lipoprotein-cholesterol,0.2143431,tf-idf,0.33285147,tf-idf,0.33285147
Implications for REDUCE IT in clinical practice.,low-density-lipoprotein,0.22722314,tf-idf,0.37400493,tf-idf,0.37400493
Implications for REDUCE IT in clinical practice.,density-lipoprotein-cholesterol,0.22921449,batch-normalization,0.37548044,batch-normalization,0.37548044
Implications for REDUCE IT in clinical practice.,type,0.21671848,of,0.48202556,classification,0.43098688
Implications for REDUCE IT in clinical practice.,ii,0.22929578,of,0.43728137,classification,0.3694628
Implications for REDUCE IT in clinical practice.,diabetes,0.29301462,logistic-regression,0.35688502,logistic-regression,0.35688502
Implications for REDUCE IT in clinical practice.,mellitus,0.26868707,logistic,0.37140065,logistic-regression,0.36157686
Implications for REDUCE IT in clinical practice.,type-ii,0.18801436,hidden-layer,0.41575754,hidden-layer,0.41575754
Implications for REDUCE IT in clinical practice.,ii-diabetes,0.24876148,classification,0.28712857,classification,0.28712857
Implications for REDUCE IT in clinical practice.,diabetes-mellitus,0.22767697,logistic-regression,0.32544836,logistic-regression,0.32544836
Implications for REDUCE IT in clinical practice.,type-ii-diabetes,0.24083933,classification-algorithm,0.32946086,classification-algorithm,0.32946086
Implications for REDUCE IT in clinical practice.,especially,0.32290015,of,0.63661283,long-short-term,0.46837103
Implications for REDUCE IT in clinical practice.,among,0.33676732,of,0.57348,clustering,0.49404603
Implications for REDUCE IT in clinical practice.,high,0.267004,of,0.57459104,gradient,0.44240427
Implications for REDUCE IT in clinical practice.,risk,0.35860935,recurrent,0.53675485,logistic-regression,0.52381086
Implications for REDUCE IT in clinical practice.,high-risk,0.3932576,recurrent,0.5357794,classification-algorithm,0.4817328
Implications for REDUCE IT in clinical practice.,substantial,0.29639626,reduction,0.60217476,long-short-term,0.47712374
Implications for REDUCE IT in clinical practice.,residual,0.28154147,of,0.55126905,batch-normalization,0.41545758
Implications for REDUCE IT in clinical practice.,risk,0.35860935,recurrent,0.53675485,logistic-regression,0.52381086
Implications for REDUCE IT in clinical practice.,remains,0.24202663,fully,0.5171005,bagging,0.35608193
Implications for REDUCE IT in clinical practice.,kexin,0.19926156,encoding,0.3289192,graphics-processing,0.30328292
Implications for REDUCE IT in clinical practice.,type,0.21671848,of,0.48202556,classification,0.43098688
Implications for REDUCE IT in clinical practice.,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
Implications for REDUCE IT in clinical practice.,kexin-type,0.2671981,encoding,0.48750857,graphics-processing,0.43884838
Implications for REDUCE IT in clinical practice.,markedly,0.17485408,of,0.50883335,long-short-term,0.36673075
Implications for REDUCE IT in clinical practice.,lower,0.20975146,of,0.5471319,regression,0.3982392
Implications for REDUCE IT in clinical practice.,risk,0.35860935,recurrent,0.53675485,logistic-regression,0.52381086
Implications for REDUCE IT in clinical practice.,markedly-lower,0.19749549,short-term,0.4834903,long-short-term,0.419478
Implications for REDUCE IT in clinical practice.,lower-risk,0.3333922,classification-algorithm,0.48180503,classification-algorithm,0.48180503
Implications for REDUCE IT in clinical practice.,proprotein,0.3252825,encoding,0.5067655,graphics-processing,0.39147222
Implications for REDUCE IT in clinical practice.,convertase,0.25988388,processing,0.46128684,graphics-processing,0.4026299
Implications for REDUCE IT in clinical practice.,subtilisin,0.27480695,graphics-processing,0.42035642,graphics-processing,0.42035642
Implications for REDUCE IT in clinical practice.,proprotein-convertase,0.32895935,encoding,0.51997226,graphics-processing,0.40858257
Implications for REDUCE IT in clinical practice.,guide,0.47455525,decision,0.5901101,data-engineering,0.51958454
Implications for REDUCE IT in clinical practice.,combination,0.385488,of,0.5245792,boosting,0.5027329
Implications for REDUCE IT in clinical practice.,lipid,0.23492281,of,0.44637915,clustering,0.37238947
Implications for REDUCE IT in clinical practice.,established,0.40618747,of,0.60100454,classification,0.47434023
Implications for REDUCE IT in clinical practice.,atherosclerotic,0.24541524,of,0.33148155,generative-model,0.3187185
Implications for REDUCE IT in clinical practice.,cvd,0.25363478,hierarchical,0.35325012,logistic-regression,0.34885177
Implications for REDUCE IT in clinical practice.,atherosclerotic-cvd,0.2331242,generative-model,0.33523968,generative-model,0.33523968
Implications for REDUCE IT in clinical practice.,high,0.267004,of,0.57459104,gradient,0.44240427
Implications for REDUCE IT in clinical practice.,risk,0.35860935,recurrent,0.53675485,logistic-regression,0.52381086
Implications for REDUCE IT in clinical practice.,patients,0.30007,recurrent,0.5332828,dropout,0.3918751
Implications for REDUCE IT in clinical practice.,high-risk,0.3932576,recurrent,0.5357794,classification-algorithm,0.4817328
Implications for REDUCE IT in clinical practice.,risk-patients,0.3696401,logistic-regression,0.5086636,logistic-regression,0.5086636
Implications for REDUCE IT in clinical practice.,high-risk-patients,0.38275498,classification-algorithm,0.50107825,classification-algorithm,0.50107825
Implications for REDUCE IT in clinical practice.,high,0.267004,of,0.57459104,gradient,0.44240427
Implications for REDUCE IT in clinical practice.,ascvd,0.3325327,logistic-regression,0.43486148,logistic-regression,0.43486148
Implications for REDUCE IT in clinical practice.,risk,0.35860935,recurrent,0.53675485,logistic-regression,0.52381086
Implications for REDUCE IT in clinical practice.,ascvd-risk,0.3343684,logistic-regression,0.48624206,logistic-regression,0.48624206
Implications for REDUCE IT in clinical practice.,residual,0.28154147,of,0.55126905,batch-normalization,0.41545758
Implications for REDUCE IT in clinical practice.,risk,0.35860935,recurrent,0.53675485,logistic-regression,0.52381086
Implications for REDUCE IT in clinical practice.,statin,0.26157406,short-term,0.4054023,logistic-regression,0.39016607
Implications for REDUCE IT in clinical practice.,treatment,0.239264,short-term,0.5206091,long-short-term,0.41699445
Implications for REDUCE IT in clinical practice.,statin-treatment,0.24226096,reduction,0.4739871,dropout,0.43347028
Implications for REDUCE IT in clinical practice.,secondary,0.25856274,recurrent,0.5339868,feature-reduction,0.37561154
Implications for REDUCE IT in clinical practice.,prevention,0.29446518,recurrent,0.44918782,feature-reduction,0.4041679
Implications for REDUCE IT in clinical practice.,secondary-prevention,0.4047281,feature-reduction,0.5250945,feature-reduction,0.5250945
Implications for REDUCE IT in clinical practice.,rights,0.3170033,adversarial,0.6281444,data-science,0.57488894
Implications for REDUCE IT in clinical practice.,reserved,0.28677964,of,0.4776592,supervised,0.3944377
Implications for REDUCE IT in clinical practice.,icosapent,0.19018501,short-term,0.37456998,long-short-term,0.3375832
Implications for REDUCE IT in clinical practice.,ethyl,0.2013307,fourier,0.3246025,fourier,0.3246025
Implications for REDUCE IT in clinical practice.,icosapent-ethyl,0.23232423,fourier-transform,0.36886397,fourier-transform,0.36886397
Implications for REDUCE IT in clinical practice.,elevated,0.19494015,normalization,0.5246306,batch-normalization,0.44167417
Implications for REDUCE IT in clinical practice.,triglycerides,0.17761004,batch-normalization,0.3502633,batch-normalization,0.3502633
Implications for REDUCE IT in clinical practice.,decision,0.5239193,decision,1.0,decision-tree,0.75800127
Implications for REDUCE IT in clinical practice.,pathway,0.27141988,cascade,0.7127757,feed-forward,0.5331765
Implications for REDUCE IT in clinical practice.,decision-pathway,0.5547336,decision,0.7437111,decision-tree,0.7064942
Implications for REDUCE IT in clinical practice.,current,0.3530666,rectified,0.52906346,generative-model,0.40904555
Implications for REDUCE IT in clinical practice.,guidelines,0.41964787,decision,0.5691749,classification-algorithm,0.5532488
Implications for REDUCE IT in clinical practice.,ascvd,0.3325327,logistic-regression,0.43486148,logistic-regression,0.43486148
Implications for REDUCE IT in clinical practice.,events,0.28275582,of,0.4981169,stochastic,0.4261601
Implications for REDUCE IT in clinical practice.,statin,0.26157406,short-term,0.4054023,logistic-regression,0.39016607
Implications for REDUCE IT in clinical practice.,therapy,0.2707135,short-term,0.45926765,boosting,0.40244865
Implications for REDUCE IT in clinical practice.,statin-therapy,0.25266686,short-term,0.4041505,dropout,0.39947698
Implications for REDUCE IT in clinical practice.,lowering,0.21700059,reduction,0.69292593,batch-normalization,0.5070027
Implications for REDUCE IT in clinical practice.,therapy,0.2707135,short-term,0.45926765,boosting,0.40244865
Implications for REDUCE IT in clinical practice.,reduction,0.22531602,reduction,1.0,feature-reduction,0.59547573
Implications for REDUCE IT in clinical practice.,patients,0.30007,recurrent,0.5332828,dropout,0.3918751
Implications for REDUCE IT in clinical practice.,ascvd,0.3325327,logistic-regression,0.43486148,logistic-regression,0.43486148
Implications for REDUCE IT in clinical practice.,therapy,0.2707135,short-term,0.45926765,boosting,0.40244865
Implications for REDUCE IT in clinical practice.,synthesized,0.25979662,encoding,0.4240871,generative,0.38417888
Implications for REDUCE IT in clinical practice.,statins,0.24406128,short-term,0.40197155,long-short-term,0.3434062
Implications for REDUCE IT in clinical practice.,shown,0.30073658,of,0.5506151,long-short-term,0.40438446
Implications for REDUCE IT in clinical practice.,recently,0.39159477,few,0.51658726,confusion-matrix,0.4137478
Implications for REDUCE IT in clinical practice.,primary,0.24268678,principal,0.5205563,long-short-term,0.38049072
Implications for REDUCE IT in clinical practice.,ezetimibe,0.20077208,softmax,0.30890355,softmax,0.30890355
Implications for REDUCE IT in clinical practice.,effective,0.32842147,of,0.50971246,boosting,0.48854327
Implications for REDUCE IT in clinical practice.,discussed,0.32159716,of,0.5174893,confusion-matrix,0.45636517
Implications for REDUCE IT in clinical practice.,data,0.46434748,data,1.0,data-science,0.5533528
Implications for REDUCE IT in clinical practice.,context,0.48856658,feature-engineering,0.6062584,feature-engineering,0.6062584
Implications for REDUCE IT in clinical practice.,atherogenesis,0.27284145,cascade,0.45165026,generative-model,0.4039601
Implications for REDUCE IT in clinical practice.,addition,0.30500388,of,0.6910241,feature-reduction,0.48914018
Implications for REDUCE IT in clinical practice.,add,0.36631483,support,0.5752722,dimensionality-reduction,0.4097547
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,preserved,0.28254378,function,0.6360263,short-term-memory,0.44489402
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,left,0.2544507,tracking,0.42924023,object-tracking,0.3633091
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,ventricular,0.24852064,rate,0.37094042,long-short-term,0.34148398
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,systolic,0.25626805,function,0.41296047,gradient,0.40985143
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,function,0.3447219,function,1.0,learning-function,0.5767432
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,left-ventricular,0.30000108,batch-normalization,0.40942025,batch-normalization,0.40942025
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,ventricular-systolic,0.28019562,regularization,0.40448523,gradient,0.40273663
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,systolic-function,0.37460995,function,0.587615,learning-function,0.5712657
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,propensity,0.39547682,clustering,0.5125703,clustering,0.5125703
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,score,0.38515997,classification-algorithm,0.5352135,classification-algorithm,0.5352135
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,matching,0.53057045,feature-selection,0.5917324,feature-selection,0.5917324
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,analysis,0.46507934,analysis,0.99999994,component-analysis,0.69613737
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,propensity-score,0.51315075,logistic-regression,0.7008779,logistic-regression,0.7008779
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,score-matching,0.5441203,logistic-regression,0.65064406,logistic-regression,0.65064406
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,propensity-score-matching,0.52373856,logistic-regression,0.6747075,logistic-regression,0.6747075
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,major,0.2356064,principal,0.70253855,principal-components,0.42016473
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,clinical,0.44080526,data,0.48532635,data-science,0.45343333
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,end,0.22421888,long,0.5453975,long-short-term,0.36503828
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,point,0.30596262,forward,0.54533786,statistical,0.44868034
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,end-point,0.28407684,batch-normalization,0.46041366,batch-normalization,0.46041366
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,clinical-end-point,0.4627107,component-analysis,0.532417,component-analysis,0.532417
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,segment,0.1674358,long,0.5143941,segmentation,0.46774617
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,elevation,0.19980456,normalization,0.61535543,batch-normalization,0.4824157
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,myocardial,0.25335935,normalization,0.40452614,batch-normalization,0.38271224
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,infarction,0.22924727,recurrent,0.4099214,confusion-matrix,0.3685401
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,segment-elevation,0.36838537,segmentation-algorithm,0.58454955,segmentation-algorithm,0.58454955
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,elevation-myocardial,0.3562611,batch-normalization,0.49031034,batch-normalization,0.49031034
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,myocardial-infarction,0.25818947,normalization,0.3545368,long-short-term,0.351139
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,segment-elevation-myocardial,0.39380956,segmentation-algorithm,0.5438169,segmentation-algorithm,0.5438169
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,major,0.2356064,principal,0.70253855,principal-components,0.42016473
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,adverse,0.26837695,short-term,0.54361606,dropout,0.47248027
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,cardiac,0.29562658,of,0.42777455,long-short-term,0.35708636
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,events,0.28275582,of,0.4981169,stochastic,0.4261601
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,major-adverse,0.32477412,logistic-regression,0.49109185,logistic-regression,0.49109185
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,vs,0.22635552,transfer,0.4263924,statistical,0.3002486
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,arbs,0.25137073,logistic-regression,0.35386714,logistic-regression,0.35386714
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,group,0.26103544,of,0.44356787,statistical,0.3923795
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,recurrent,0.32854465,recurrent,1.0,recurrent-neural-network,0.59633
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,myocardial,0.25335935,normalization,0.40452614,batch-normalization,0.38271224
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,infarction,0.22924727,recurrent,0.4099214,confusion-matrix,0.3685401
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,myocardial-infarction,0.25818947,normalization,0.3545368,long-short-term,0.351139
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,term,0.33795053,term,1.0,long-short-term,0.62770975
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,clinical,0.44080526,data,0.48532635,data-science,0.45343333
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,outcomes,0.38239923,short-term,0.6164659,long-short-term,0.5239928
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,clinical-outcomes,0.51200265,data-science,0.5469523,data-science,0.5469523
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,new,0.43019778,of,0.526482,feature-reduction,0.4579819
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,generation,0.3480911,generative,0.6357137,generative,0.6357137
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,drug,0.31867066,of,0.44600964,confusion-matrix,0.3956731
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,new-generation,0.38427538,feature-engineering,0.46666878,feature-engineering,0.46666878
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,converting,0.30355832,of,0.48566324,graphics-processing,0.44267887
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,enzyme,0.21657495,encoding,0.44885126,feature-reduction,0.38085908
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,inhibitors,0.25381407,cascade,0.4157439,feed-forward,0.3175553
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,converting-enzyme,0.27783775,graphics-processing,0.39753565,graphics-processing,0.39753565
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,enzyme-inhibitors,0.2689559,feature-reduction,0.36576074,feature-reduction,0.36576074
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,converting-enzyme-inhibitors,0.28889734,feature-reduction,0.39039016,feature-reduction,0.39039016
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,target,0.31799266,of,0.4775706,feature-selection,0.44359237
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,vessel,0.26050168,segmentation,0.4748637,segmentation,0.4748637
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,revascularization,0.26069185,segmentation-algorithm,0.40030673,segmentation-algorithm,0.40030673
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,target-vessel,0.3071344,segmentation-algorithm,0.3999809,segmentation-algorithm,0.3999809
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,vessel-revascularization,0.30153987,segmentation,0.49196067,segmentation,0.49196067
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,target,0.31799266,of,0.4775706,feature-selection,0.44359237
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,lesion,0.29133987,segmentation,0.43485674,segmentation,0.43485674
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,revascularization,0.26069185,segmentation-algorithm,0.40030673,segmentation-algorithm,0.40030673
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,target-lesion,0.39526072,object-tracking,0.4743684,object-tracking,0.4743684
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,target-lesion-revascularization,0.4096663,segmentation-algorithm,0.52054155,segmentation-algorithm,0.52054155
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,mi,0.3298295,recurrent,0.46290627,confusion-matrix,0.42057228
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,reduction,0.22531602,reduction,1.0,feature-reduction,0.59547573
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,benefits,0.41087294,short-term,0.59437555,long-short-term,0.5303442
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,angiotensin,0.21236175,matrix,0.35242182,feed-forward,0.31253523
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,receptor,0.22411162,function,0.41526195,clustering,0.36801085
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,blockers,0.19200467,augmentation,0.36206824,long-short-term,0.31719163
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,angiotensin-receptor,0.24978769,matrix,0.3305658,confusion-matrix,0.30484858
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,receptor-blockers,0.22819279,short-term,0.3749142,regression,0.3211386
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,angiotensin-receptor-blockers,0.217114,short-term,0.34574157,dropout,0.30021757
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,aceis,0.27091593,logistic-regression,0.3608317,logistic-regression,0.3608317
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,group,0.26103544,of,0.44356787,statistical,0.3923795
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,showed,0.20766163,of,0.5296177,regression,0.37027335
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,group-showed,0.31434453,dimensionality-reduction,0.5093119,dimensionality-reduction,0.5093119
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,maces,0.324784,logistic,0.4775698,logistic-regression,0.47329623
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,defined,0.3575971,of,0.529315,classification,0.50848204
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,cardiac,0.29562658,of,0.42777455,long-short-term,0.35708636
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,death,0.21479979,of,0.42234862,dropout,0.37818787
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,cardiac-death,0.32363433,long-short-term,0.39903343,long-short-term,0.39903343
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,arbs,0.25137073,logistic-regression,0.35386714,logistic-regression,0.35386714
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,group,0.26103544,of,0.44356787,statistical,0.3923795
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,repeat,0.18560003,short,0.46157068,dropout,0.34574726
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,revascularization,0.26069185,segmentation-algorithm,0.40030673,segmentation-algorithm,0.40030673
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,repeat-revascularization,0.35999477,segmentation-algorithm,0.5059043,segmentation-algorithm,0.5059043
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,arb,0.25449693,feature-reduction,0.33085245,feature-reduction,0.33085245
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,group,0.26103544,of,0.44356787,statistical,0.3923795
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,aceis,0.27091593,logistic-regression,0.3608317,logistic-regression,0.3608317
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,group,0.26103544,of,0.44356787,statistical,0.3923795
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,acei,0.26178795,feed,0.37105787,dropout,0.3253736
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,group,0.26103544,of,0.44356787,statistical,0.3923795
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,mi,0.3298295,recurrent,0.46290627,confusion-matrix,0.42057228
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,groups,0.2727722,statistical,0.4438421,statistical,0.4438421
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,year,0.310051,one,0.48338404,supervised,0.40979916
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,follow,0.28552625,tracking,0.48513734,batch-normalization,0.39173082
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,year-follow,0.45824456,random-forest,0.503012,random-forest,0.503012
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,well,0.34264985,of,0.59718275,bagging,0.4145819
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,established,0.40618747,of,0.60100454,classification,0.47434023
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,well-established,0.4767154,model,0.5686673,generative-model,0.56675625
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,significantly,0.27887642,of,0.5214151,long-short-term,0.39056638
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,higher,0.27819592,reduction,0.545787,boosting,0.41506222
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,significantly-higher,0.29000503,rate,0.5078902,boosting,0.4130143
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,relative,0.28452736,of,0.6192827,long-short-term,0.43953407
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,superiority,0.41905624,dimensionality-reduction,0.5629372,dimensionality-reduction,0.5629372
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,prominent,0.25377822,feature,0.58036757,generative,0.45552078
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,ability,0.39144984,function,0.5937173,generative,0.47758824
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,hazard,0.35112607,logistic,0.6028925,logistic-regression,0.5981426
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,ratio,0.19492707,rate,0.48224086,regression,0.41092375
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,hazard-ratio,0.40377024,logistic-regression,0.6386619,logistic-regression,0.6386619
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,eluting,0.2286981,gradient,0.42075065,gradient,0.42075065
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,stents,0.23610935,recurrent,0.39335865,confusion-matrix,0.36982054
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,eluting-stents,0.3272308,confusion-matrix,0.44112298,confusion-matrix,0.44112298
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,cumulative,0.35646293,short-term,0.5375205,logistic-regression,0.47759464
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,incidences,0.24967004,rate,0.5322478,logistic-regression,0.4176092
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,confidence,0.354792,bayes,0.47560617,bayes,0.47560617
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,interval,0.25114498,decision,0.39202803,bayesian,0.37118626
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,confidence-interval,0.46936446,decision-tree,0.56020504,decision-tree,0.56020504
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,cause,0.19388393,of,0.47843847,confusion-matrix,0.34079778
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,death,0.21479979,of,0.42234862,dropout,0.37818787
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,cause-death,0.3774225,logistic-regression,0.49973837,logistic-regression,0.49973837
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,patients,0.30007,recurrent,0.5332828,dropout,0.3918751
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,tvr,0.19812322,dropout,0.33474907,dropout,0.33474907
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,compared,0.3359061,of,0.52794564,long-short-term,0.42386633
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,arbs,0.25137073,logistic-regression,0.35386714,logistic-regression,0.35386714
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,mi,0.3298295,recurrent,0.46290627,confusion-matrix,0.42057228
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,maces,0.324784,logistic,0.4775698,logistic-regression,0.47329623
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,angiotensin,0.21236175,matrix,0.35242182,feed-forward,0.31253523
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,aceis,0.27091593,logistic-regression,0.3608317,logistic-regression,0.3608317
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,tvr,0.19812322,dropout,0.33474907,dropout,0.33474907
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,patients,0.30007,recurrent,0.5332828,dropout,0.3918751
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,total,0.21723771,of,0.5102532,principal-components,0.3630478
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,st,0.22907814,confusion,0.43447053,long-short-term,0.42084157
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,similar,0.29237732,of,0.56832373,long-short-term,0.4732089
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,period,0.19663066,short-term,0.5791412,long-short-term,0.5108645
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,p,0.26795468,support,0.40805867,regression,0.40253854
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,occurrences,0.41557878,recurrent,0.5680895,clustering,0.5230969
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,nstemi,0.255735,confusion,0.39092016,confusion-matrix,0.34600744
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,non,0.2869836,of,0.5523051,generative,0.4181043
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,n,0.24332823,of,0.45693433,long-short-term,0.34114176
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,mortality,0.2609817,short-term,0.505676,logistic-regression,0.49414968
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,long,0.20028201,long,1.0,long-short-term,0.6505779
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,however,0.31437585,few,0.63182676,statistical,0.44065386
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,hence,0.39019012,of,0.69818234,generative,0.5347531
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,era,0.34617627,science,0.459643,data-science,0.44629225
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,enrolled,0.3208215,supervised,0.42658707,supervised,0.42658707
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,decrease,0.23670179,reduction,0.82910776,boosting,0.45522925
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,although,0.29321635,few,0.63117087,long-short-term,0.46243888
Women had favourable reverse left ventricle remodelling after TAVR.,investigate,0.3396353,of,0.48247698,feature-engineering,0.41061842
Women had favourable reverse left ventricle remodelling after TAVR.,whether,0.32171756,short-term,0.5290759,long-short-term,0.47851244
Women had favourable reverse left ventricle remodelling after TAVR.,gender,0.3412779,logistic,0.5728083,logistic-regression,0.5565392
Women had favourable reverse left ventricle remodelling after TAVR.,difference,0.30501923,statistical,0.58389574,statistical,0.58389574
Women had favourable reverse left ventricle remodelling after TAVR.,affects,0.21790305,of,0.5773267,long-short-term,0.4001173
Women had favourable reverse left ventricle remodelling after TAVR.,investigate-whether,0.43650037,feature-engineering,0.5487602,feature-engineering,0.5487602
Women had favourable reverse left ventricle remodelling after TAVR.,gender-difference,0.41584527,dimensionality-reduction,0.60014415,dimensionality-reduction,0.60014415
Women had favourable reverse left ventricle remodelling after TAVR.,multivariable,0.4951204,logistic,0.92394704,logistic-regression,0.87944424
Women had favourable reverse left ventricle remodelling after TAVR.,logistic,0.5418149,logistic,1.0,logistic-regression,0.9215903
Women had favourable reverse left ventricle remodelling after TAVR.,regression,0.4967034,regression,1.0,regression,1.0
Women had favourable reverse left ventricle remodelling after TAVR.,analysis,0.46507934,analysis,0.99999994,component-analysis,0.69613737
Women had favourable reverse left ventricle remodelling after TAVR.,showed,0.20766163,of,0.5296177,regression,0.37027335
Women had favourable reverse left ventricle remodelling after TAVR.,multivariable-logistic,0.61451364,logistic-regression,0.91035736,logistic-regression,0.91035736
Women had favourable reverse left ventricle remodelling after TAVR.,logistic-regression,0.5787163,logistic-regression,0.99999994,logistic-regression,0.99999994
Women had favourable reverse left ventricle remodelling after TAVR.,regression-analysis,0.5946686,logistic-regression,0.8366122,logistic-regression,0.8366122
Women had favourable reverse left ventricle remodelling after TAVR.,analysis-showed,0.4625706,analysis,0.76350164,component-analysis,0.67950296
Women had favourable reverse left ventricle remodelling after TAVR.,multivariable-logistic-regression,0.5977553,logistic-regression,0.9675822,logistic-regression,0.9675822
Women had favourable reverse left ventricle remodelling after TAVR.,logistic-regression-analysis,0.6287248,logistic-regression,0.94918126,logistic-regression,0.94918126
Women had favourable reverse left ventricle remodelling after TAVR.,observed,0.23725806,of,0.64367145,long-short-term,0.4519785
Women had favourable reverse left ventricle remodelling after TAVR.,since,0.2910149,of,0.60419816,bagging,0.3698329
Women had favourable reverse left ventricle remodelling after TAVR.,three,0.36911732,one,0.78425425,clustering,0.4299444
Women had favourable reverse left ventricle remodelling after TAVR.,months,0.25947675,short-term,0.51117545,regression,0.43146035
Women had favourable reverse left ventricle remodelling after TAVR.,later,0.31550664,of,0.5882158,generative,0.48327935
Women had favourable reverse left ventricle remodelling after TAVR.,three-months,0.31882933,short-term,0.6007727,long-short-term,0.5234027
Women had favourable reverse left ventricle remodelling after TAVR.,months-later,0.35143286,term,0.47745293,logistic-regression,0.46066552
Women had favourable reverse left ventricle remodelling after TAVR.,three-months-later,0.38291997,short-term,0.5616329,long-short-term,0.5231447
Women had favourable reverse left ventricle remodelling after TAVR.,earlier,0.30385333,few,0.56727606,long-short-term,0.41828468
Women had favourable reverse left ventricle remodelling after TAVR.,lv,0.2556107,tensorflow,0.3751968,tensorflow,0.3751968
Women had favourable reverse left ventricle remodelling after TAVR.,mass,0.22818582,fourier-transform,0.42889374,fourier-transform,0.42889374
Women had favourable reverse left ventricle remodelling after TAVR.,regression,0.4967034,regression,1.0,regression,1.0
Women had favourable reverse left ventricle remodelling after TAVR.,post,0.27536392,confusion,0.47820356,bagging,0.44161102
Women had favourable reverse left ventricle remodelling after TAVR.,lv-mass,0.32570934,fourier,0.46033573,fourier,0.46033573
Women had favourable reverse left ventricle remodelling after TAVR.,mass-regression,0.5482913,regression,0.8138474,regression,0.8138474
Women had favourable reverse left ventricle remodelling after TAVR.,transcatheter,0.31426883,recurrent,0.38830033,segmentation-algorithm,0.3636296
Women had favourable reverse left ventricle remodelling after TAVR.,aortic,0.23288518,gradient,0.37829,gradient,0.37829
Women had favourable reverse left ventricle remodelling after TAVR.,valve,0.29510486,gradient,0.4132653,gradient,0.4132653
Women had favourable reverse left ventricle remodelling after TAVR.,replacement,0.22170375,artificial,0.48551926,feature-engineering,0.36264867
Women had favourable reverse left ventricle remodelling after TAVR.,aortic-valve,0.24443309,gradient,0.34005976,gradient,0.34005976
Women had favourable reverse left ventricle remodelling after TAVR.,valve-replacement,0.30866817,artificial,0.40727186,artificial-intelligence,0.40078762
Women had favourable reverse left ventricle remodelling after TAVR.,aortic-valve-replacement,0.2911166,gradient-descent,0.38887852,gradient-descent,0.38887852
Women had favourable reverse left ventricle remodelling after TAVR.,clinical,0.44080526,data,0.48532635,data-science,0.45343333
Women had favourable reverse left ventricle remodelling after TAVR.,investigation,0.33686116,analysis,0.63110995,component-analysis,0.46827114
Women had favourable reverse left ventricle remodelling after TAVR.,journal,0.37362164,science,0.7173637,data-science,0.6594459
Women had favourable reverse left ventricle remodelling after TAVR.,foundation,0.4298104,science,0.61830467,data-science,0.59882826
Women had favourable reverse left ventricle remodelling after TAVR.,clinical-investigation,0.48749065,of,0.5408074,data-science,0.53953683
Women had favourable reverse left ventricle remodelling after TAVR.,clinical,0.44080526,data,0.48532635,data-science,0.45343333
Women had favourable reverse left ventricle remodelling after TAVR.,investigation,0.33686116,analysis,0.63110995,component-analysis,0.46827114
Women had favourable reverse left ventricle remodelling after TAVR.,published,0.42179614,data,0.6147139,data-science,0.54664624
Women had favourable reverse left ventricle remodelling after TAVR.,clinical-investigation,0.48749065,of,0.5408074,data-science,0.53953683
Women had favourable reverse left ventricle remodelling after TAVR.,indicating,0.21094829,of,0.63023484,clustering,0.43286642
Women had favourable reverse left ventricle remodelling after TAVR.,female,0.2642398,naive,0.4711159,generative,0.42489284
Women had favourable reverse left ventricle remodelling after TAVR.,gender,0.3412779,logistic,0.5728083,logistic-regression,0.5565392
Women had favourable reverse left ventricle remodelling after TAVR.,female-gender,0.2539025,descent,0.49216962,logistic-regression,0.41627344
Women had favourable reverse left ventricle remodelling after TAVR.,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
Women had favourable reverse left ventricle remodelling after TAVR.,months,0.25947675,short-term,0.51117545,regression,0.43146035
Women had favourable reverse left ventricle remodelling after TAVR.,post,0.27536392,confusion,0.47820356,bagging,0.44161102
Women had favourable reverse left ventricle remodelling after TAVR.,months-post,0.25454217,recurrent,0.42112547,logistic-regression,0.37116194
Women had favourable reverse left ventricle remodelling after TAVR.,repeated,0.34072363,short-term,0.5933522,long-short-term,0.5176369
Women had favourable reverse left ventricle remodelling after TAVR.,upon,0.2366915,of,0.6212549,boosting,0.40359378
Women had favourable reverse left ventricle remodelling after TAVR.,discharge,0.22544123,unit,0.49100536,regression,0.34756663
Women had favourable reverse left ventricle remodelling after TAVR.,lv,0.2556107,tensorflow,0.3751968,tensorflow,0.3751968
Women had favourable reverse left ventricle remodelling after TAVR.,mass,0.22818582,fourier-transform,0.42889374,fourier-transform,0.42889374
Women had favourable reverse left ventricle remodelling after TAVR.,index,0.27978244,function,0.407383,classification-algorithm,0.3994653
Women had favourable reverse left ventricle remodelling after TAVR.,lv-mass,0.32570934,fourier,0.46033573,fourier,0.46033573
Women had favourable reverse left ventricle remodelling after TAVR.,mass-index,0.2927159,batch-normalization,0.44462848,batch-normalization,0.44462848
Women had favourable reverse left ventricle remodelling after TAVR.,lv-mass-index,0.32694644,batch-normalization,0.463955,batch-normalization,0.463955
Women had favourable reverse left ventricle remodelling after TAVR.,higher,0.27819592,reduction,0.545787,boosting,0.41506222
Women had favourable reverse left ventricle remodelling after TAVR.,survival,0.29004025,short-term,0.53135407,long-short-term,0.4573617
Women had favourable reverse left ventricle remodelling after TAVR.,rates,0.24094881,rate,0.8800579,dropout,0.48159522
Women had favourable reverse left ventricle remodelling after TAVR.,survival-rates,0.3448327,rate,0.55089015,long-short-term,0.5071609
Women had favourable reverse left ventricle remodelling after TAVR.,stichting,0.2710153,federated,0.53044665,pytorch,0.48024467
Women had favourable reverse left ventricle remodelling after TAVR.,european,0.25183123,federated,0.5800549,data-science,0.42842963
Women had favourable reverse left ventricle remodelling after TAVR.,society,0.29418135,science,0.5518952,data-science,0.5205302
Women had favourable reverse left ventricle remodelling after TAVR.,lvmi,0.23192333,logistic-regression,0.38602936,logistic-regression,0.38602936
Women had favourable reverse left ventricle remodelling after TAVR.,regression,0.4967034,regression,1.0,regression,1.0
Women had favourable reverse left ventricle remodelling after TAVR.,occurred,0.18829712,of,0.5783524,long-short-term,0.3895034
Women had favourable reverse left ventricle remodelling after TAVR.,favourable,0.23217037,short-term,0.5433668,long-short-term,0.474719
Women had favourable reverse left ventricle remodelling after TAVR.,reverse,0.2939736,forward,0.5330905,feature-reduction,0.40937227
Women had favourable reverse left ventricle remodelling after TAVR.,remodelling,0.3164125,function,0.52429783,segmentation,0.44705176
Women had favourable reverse left ventricle remodelling after TAVR.,reverse-remodelling,0.5127286,feature-reduction,0.55897367,feature-reduction,0.55897367
Women had favourable reverse left ventricle remodelling after TAVR.,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
Women had favourable reverse left ventricle remodelling after TAVR.,days,0.20857571,short-term,0.53915894,long-short-term,0.4190845
Women had favourable reverse left ventricle remodelling after TAVR.,post,0.27536392,confusion,0.47820356,bagging,0.44161102
Women had favourable reverse left ventricle remodelling after TAVR.,days-post,0.21841627,short-term,0.41982922,long-short-term,0.35639867
Women had favourable reverse left ventricle remodelling after TAVR.,favourable,0.23217037,short-term,0.5433668,long-short-term,0.474719
Women had favourable reverse left ventricle remodelling after TAVR.,lv,0.2556107,tensorflow,0.3751968,tensorflow,0.3751968
Women had favourable reverse left ventricle remodelling after TAVR.,remodelling,0.3164125,function,0.52429783,segmentation,0.44705176
Women had favourable reverse left ventricle remodelling after TAVR.,lv-remodelling,0.4040059,function,0.48447517,vector-machine,0.45057893
Women had favourable reverse left ventricle remodelling after TAVR.,greater,0.2528603,of,0.59163296,long-short-term,0.44578376
Women had favourable reverse left ventricle remodelling after TAVR.,lvmi,0.23192333,logistic-regression,0.38602936,logistic-regression,0.38602936
Women had favourable reverse left ventricle remodelling after TAVR.,regression,0.4967034,regression,1.0,regression,1.0
Women had favourable reverse left ventricle remodelling after TAVR.,lvmi,0.23192333,logistic-regression,0.38602936,logistic-regression,0.38602936
Women had favourable reverse left ventricle remodelling after TAVR.,regressed,0.2841616,regression,0.6810293,regression,0.6810293
Women had favourable reverse left ventricle remodelling after TAVR.,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
Women had favourable reverse left ventricle remodelling after TAVR.,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
Women had favourable reverse left ventricle remodelling after TAVR.,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
Women had favourable reverse left ventricle remodelling after TAVR.,greater,0.2528603,of,0.59163296,long-short-term,0.44578376
Women had favourable reverse left ventricle remodelling after TAVR.,baseline,0.32763094,normalization,0.56518495,batch-normalization,0.4727359
Women had favourable reverse left ventricle remodelling after TAVR.,lvmi,0.23192333,logistic-regression,0.38602936,logistic-regression,0.38602936
Women had favourable reverse left ventricle remodelling after TAVR.,lv,0.2556107,tensorflow,0.3751968,tensorflow,0.3751968
Women had favourable reverse left ventricle remodelling after TAVR.,mass,0.22818582,fourier-transform,0.42889374,fourier-transform,0.42889374
Women had favourable reverse left ventricle remodelling after TAVR.,lv-mass,0.32570934,fourier,0.46033573,fourier,0.46033573
Women had favourable reverse left ventricle remodelling after TAVR.,european,0.25183123,federated,0.5800549,data-science,0.42842963
Women had favourable reverse left ventricle remodelling after TAVR.,journal,0.37362164,science,0.7173637,data-science,0.6594459
Women had favourable reverse left ventricle remodelling after TAVR.,lv,0.2556107,tensorflow,0.3751968,tensorflow,0.3751968
Women had favourable reverse left ventricle remodelling after TAVR.,remodelling,0.3164125,function,0.52429783,segmentation,0.44705176
Women had favourable reverse left ventricle remodelling after TAVR.,lv-remodelling,0.4040059,function,0.48447517,vector-machine,0.45057893
Women had favourable reverse left ventricle remodelling after TAVR.,significant,0.29367286,statistical,0.582669,statistical,0.582669
Women had favourable reverse left ventricle remodelling after TAVR.,regression,0.4967034,regression,1.0,regression,1.0
Women had favourable reverse left ventricle remodelling after TAVR.,early,0.32400474,short-term,0.57188475,long-short-term,0.50726265
Women had favourable reverse left ventricle remodelling after TAVR.,regression,0.4967034,regression,1.0,regression,1.0
Women had favourable reverse left ventricle remodelling after TAVR.,early-regression,0.49737614,logistic-regression,0.8017489,logistic-regression,0.8017489
Women had favourable reverse left ventricle remodelling after TAVR.,nine,0.34436068,one,0.6942973,clustering,0.3877343
Women had favourable reverse left ventricle remodelling after TAVR.,months,0.25947675,short-term,0.51117545,regression,0.43146035
Women had favourable reverse left ventricle remodelling after TAVR.,nine-months,0.30172497,short-term,0.52950454,long-short-term,0.4530337
Women had favourable reverse left ventricle remodelling after TAVR.,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
Women had favourable reverse left ventricle remodelling after TAVR.,days,0.20857571,short-term,0.53915894,long-short-term,0.4190845
Women had favourable reverse left ventricle remodelling after TAVR.,lvmi,0.23192333,logistic-regression,0.38602936,logistic-regression,0.38602936
Women had favourable reverse left ventricle remodelling after TAVR.,reduction,0.22531602,reduction,1.0,feature-reduction,0.59547573
Women had favourable reverse left ventricle remodelling after TAVR.,female,0.2642398,naive,0.4711159,generative,0.42489284
Women had favourable reverse left ventricle remodelling after TAVR.,sex,0.24554862,regression,0.45148212,regression,0.45148212
Women had favourable reverse left ventricle remodelling after TAVR.,female-sex,0.14591236,descent,0.3607672,generative,0.33981198
Women had favourable reverse left ventricle remodelling after TAVR.,female,0.2642398,naive,0.4711159,generative,0.42489284
Women had favourable reverse left ventricle remodelling after TAVR.,patients,0.30007,recurrent,0.5332828,dropout,0.3918751
Women had favourable reverse left ventricle remodelling after TAVR.,female-patients,0.23120943,style,0.4125343,dropout,0.39378092
Women had favourable reverse left ventricle remodelling after TAVR.,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
Women had favourable reverse left ventricle remodelling after TAVR.,women,0.25528732,descent,0.50278515,dropout,0.37675467
Women had favourable reverse left ventricle remodelling after TAVR.,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
Women had favourable reverse left ventricle remodelling after TAVR.,patients,0.30007,recurrent,0.5332828,dropout,0.3918751
Women had favourable reverse left ventricle remodelling after TAVR.,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
Women had favourable reverse left ventricle remodelling after TAVR.,men,0.23664121,descent,0.5239919,regression,0.38136965
Women had favourable reverse left ventricle remodelling after TAVR.,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
Women had favourable reverse left ventricle remodelling after TAVR.,g,0.17250246,feed,0.40076,n-gram,0.27758121
Women had favourable reverse left ventricle remodelling after TAVR.,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
Women had favourable reverse left ventricle remodelling after TAVR.,decreased,0.23506472,reduction,0.66483074,boosting,0.42738107
Women had favourable reverse left ventricle remodelling after TAVR.,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
Women had favourable reverse left ventricle remodelling after TAVR.,achieved,0.33526158,of,0.5726348,batch-normalization,0.47712192
Women had favourable reverse left ventricle remodelling after TAVR.,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
Women had favourable reverse left ventricle remodelling after TAVR.,women,0.25528732,descent,0.50278515,dropout,0.37675467
Women had favourable reverse left ventricle remodelling after TAVR.,exhibited,0.18898472,of,0.49406686,feature-reduction,0.35593373
Women had favourable reverse left ventricle remodelling after TAVR.,sons,0.24153107,neighbors,0.42599985,artificial-intelligence,0.3507973
Women had favourable reverse left ventricle remodelling after TAVR.,ltd,0.17568776,long-short-term-memory,0.37555107,long-short-term-memory,0.37555107
Women had favourable reverse left ventricle remodelling after TAVR.,remodelling,0.3164125,function,0.52429783,segmentation,0.44705176
Women had favourable reverse left ventricle remodelling after TAVR.,process,0.3445285,cascade,0.57959485,generative,0.5472986
Women had favourable reverse left ventricle remodelling after TAVR.,periprocedural,0.28023902,recurrent,0.41342586,confusion-matrix,0.3942073
Women had favourable reverse left ventricle remodelling after TAVR.,complications,0.26551193,recurrent,0.5320816,overfitting,0.39361054
Women had favourable reverse left ventricle remodelling after TAVR.,one,0.335046,one,1.0,one-hot,0.4275648
Women had favourable reverse left ventricle remodelling after TAVR.,year,0.310051,one,0.48338404,supervised,0.40979916
Women had favourable reverse left ventricle remodelling after TAVR.,one-year,0.3331107,short-term,0.6098764,dropout,0.50426435
Women had favourable reverse left ventricle remodelling after TAVR.,men,0.23664121,descent,0.5239919,regression,0.38136965
Women had favourable reverse left ventricle remodelling after TAVR.,seemed,0.23116717,of,0.57592016,long-short-term,0.4179144
Women had favourable reverse left ventricle remodelling after TAVR.,male,0.26790547,naive,0.47688544,generative,0.42885694
Women had favourable reverse left ventricle remodelling after TAVR.,patients,0.30007,recurrent,0.5332828,dropout,0.3918751
Women had favourable reverse left ventricle remodelling after TAVR.,male-patients,0.23155841,style,0.39728287,dropout,0.39355528
Women had favourable reverse left ventricle remodelling after TAVR.,left,0.2544507,tracking,0.42924023,object-tracking,0.3633091
Women had favourable reverse left ventricle remodelling after TAVR.,ventricle,0.20552546,segmentation,0.33557552,segmentation,0.33557552
Women had favourable reverse left ventricle remodelling after TAVR.,left-ventricle,0.2691546,batch-normalization,0.40726915,batch-normalization,0.40726915
Women had favourable reverse left ventricle remodelling after TAVR.,john,0.22368689,science,0.49282092,data-science,0.42671943
Women had favourable reverse left ventricle remodelling after TAVR.,wiley,0.26784617,science,0.5360337,data-science,0.46017712
Women had favourable reverse left ventricle remodelling after TAVR.,independent,0.39991486,of,0.5904635,regression,0.57876456
Women had favourable reverse left ventricle remodelling after TAVR.,predictor,0.43901688,regression,0.5961869,regression,0.5961869
Women had favourable reverse left ventricle remodelling after TAVR.,independent-predictor,0.6123905,logistic-regression,0.70282865,logistic-regression,0.70282865
Women had favourable reverse left ventricle remodelling after TAVR.,important,0.33620566,principal,0.5803634,feature-engineering,0.43471682
Women had favourable reverse left ventricle remodelling after TAVR.,role,0.2562992,function,0.5340955,feed-forward,0.4137928
Women had favourable reverse left ventricle remodelling after TAVR.,important-role,0.43382356,dimensionality-reduction,0.5506821,dimensionality-reduction,0.5506821
Women had favourable reverse left ventricle remodelling after TAVR.,better,0.4230538,of,0.5337099,feature-reduction,0.47485045
Women had favourable reverse left ventricle remodelling after TAVR.,lvef,0.2523713,function,0.33373237,dropout,0.3101137
Women had favourable reverse left ventricle remodelling after TAVR.,baseline,0.32763094,normalization,0.56518495,batch-normalization,0.4727359
Women had favourable reverse left ventricle remodelling after TAVR.,began,0.29889137,few,0.57537556,bagging,0.42627174
Women had favourable reverse left ventricle remodelling after TAVR.,almost,0.2402496,few,0.5824453,generative,0.36206198
Women had favourable reverse left ventricle remodelling after TAVR.,one,0.335046,one,1.0,one-hot,0.4275648
Women had favourable reverse left ventricle remodelling after TAVR.,tavr,0.35307115,segmentation-algorithm,0.38979626,segmentation-algorithm,0.38979626
Women had favourable reverse left ventricle remodelling after TAVR.,compared,0.3359061,of,0.52794564,long-short-term,0.42386633
Women had favourable reverse left ventricle remodelling after TAVR.,follows,0.28163645,words,0.47200269,confusion-matrix,0.39147946
Women had favourable reverse left ventricle remodelling after TAVR.,tavr,0.35307115,segmentation-algorithm,0.38979626,segmentation-algorithm,0.38979626
Women had favourable reverse left ventricle remodelling after TAVR.,independently,0.37081808,of,0.48773345,regression,0.4775735
Women had favourable reverse left ventricle remodelling after TAVR.,associated,0.30827495,of,0.57598466,long-short-term,0.46578532
Women had favourable reverse left ventricle remodelling after TAVR.,independently-associated,0.42491236,of,0.5774771,clustering,0.5552769
Women had favourable reverse left ventricle remodelling after TAVR.,tavr,0.35307115,segmentation-algorithm,0.38979626,segmentation-algorithm,0.38979626
Women had favourable reverse left ventricle remodelling after TAVR.,procedure,0.37380904,data-augmentation,0.50385594,data-augmentation,0.50385594
Women had favourable reverse left ventricle remodelling after TAVR.,three,0.36911732,one,0.78425425,clustering,0.4299444
Women had favourable reverse left ventricle remodelling after TAVR.,regression,0.4967034,regression,1.0,regression,1.0
Women had favourable reverse left ventricle remodelling after TAVR.,lv,0.2556107,tensorflow,0.3751968,tensorflow,0.3751968
Women had favourable reverse left ventricle remodelling after TAVR.,lvmi,0.23192333,logistic-regression,0.38602936,logistic-regression,0.38602936
Women had favourable reverse left ventricle remodelling after TAVR.,greater,0.2528603,of,0.59163296,long-short-term,0.44578376
Women had favourable reverse left ventricle remodelling after TAVR.,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
Women had favourable reverse left ventricle remodelling after TAVR.,baseline,0.32763094,normalization,0.56518495,batch-normalization,0.4727359
Women had favourable reverse left ventricle remodelling after TAVR.,tavr,0.35307115,segmentation-algorithm,0.38979626,segmentation-algorithm,0.38979626
Women had favourable reverse left ventricle remodelling after TAVR.,process,0.3445285,cascade,0.57959485,generative,0.5472986
Women had favourable reverse left ventricle remodelling after TAVR.,procedure,0.37380904,data-augmentation,0.50385594,data-augmentation,0.50385594
Women had favourable reverse left ventricle remodelling after TAVR.,nine,0.34436068,one,0.6942973,clustering,0.3877343
Women had favourable reverse left ventricle remodelling after TAVR.,associated,0.30827495,of,0.57598466,long-short-term,0.46578532
Women had favourable reverse left ventricle remodelling after TAVR.,woman,0.25768483,recurrent,0.5042058,confusion-matrix,0.36950934
Women had favourable reverse left ventricle remodelling after TAVR.,total,0.21723771,of,0.5102532,principal-components,0.3630478
Women had favourable reverse left ventricle remodelling after TAVR.,results,0.32376552,data,0.6932311,batch-normalization,0.44826904
Women had favourable reverse left ventricle remodelling after TAVR.,play,0.23933098,feature,0.4321588,feed-forward,0.39953205
Women had favourable reverse left ventricle remodelling after TAVR.,performed,0.3864032,analysis,0.5711501,supervised,0.4789877
Women had favourable reverse left ventricle remodelling after TAVR.,p,0.26795468,support,0.40805867,regression,0.40253854
Women had favourable reverse left ventricle remodelling after TAVR.,mxxx,0.24082746,nearest-neighbors,0.43916452,nearest-neighbors,0.43916452
Women had favourable reverse left ventricle remodelling after TAVR.,methods,0.50049126,data,0.5400177,machine-learning,0.50049126
Women had favourable reverse left ventricle remodelling after TAVR.,median,0.20747668,logistic-regression,0.37743634,logistic-regression,0.37743634
Women had favourable reverse left ventricle remodelling after TAVR.,materials,0.37203065,data-engineering,0.54111993,data-engineering,0.54111993
Women had favourable reverse left ventricle remodelling after TAVR.,increase,0.28092995,reduction,0.7624404,boosting,0.49543357
Women had favourable reverse left ventricle remodelling after TAVR.,half,0.24439552,one,0.6213776,one-hot,0.46021485
Women had favourable reverse left ventricle remodelling after TAVR.,gradual,0.28503633,reduction,0.59723336,batch-normalization,0.50148916
Women had favourable reverse left ventricle remodelling after TAVR.,enrolled,0.3208215,supervised,0.42658707,supervised,0.42658707
Women had favourable reverse left ventricle remodelling after TAVR.,echocardiography,0.3769523,tracking,0.4348407,object-tracking,0.40039602
Women had favourable reverse left ventricle remodelling after TAVR.,despite,0.27514282,few,0.5803892,long-short-term,0.43284553
Women had favourable reverse left ventricle remodelling after TAVR.,contrast,0.24962384,of,0.5428885,feature-reduction,0.41914925
Women had favourable reverse left ventricle remodelling after TAVR.,considered,0.36321384,of,0.60548925,feature-reduction,0.4442021
Women had favourable reverse left ventricle remodelling after TAVR.,conclusion,0.35530132,data,0.5299138,long-short-term,0.45073265
Women had favourable reverse left ventricle remodelling after TAVR.,behalf,0.26374853,adversarial,0.5247171,data-science,0.51911336
Women had favourable reverse left ventricle remodelling after TAVR.,background,0.3259285,of,0.51277274,long-short-term,0.46426663
Women had favourable reverse left ventricle remodelling after TAVR.,authors,0.45811802,data,0.5259881,natural-language-processing,0.4706872
Women had favourable reverse left ventricle remodelling after TAVR.,aim,0.4029312,feature-engineering,0.41751927,feature-engineering,0.41751927
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,proprotein,0.3252825,encoding,0.5067655,graphics-processing,0.39147222
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,convertase,0.25988388,processing,0.46128684,graphics-processing,0.4026299
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,subtilisin,0.27480695,graphics-processing,0.42035642,graphics-processing,0.42035642
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,kexin,0.19926156,encoding,0.3289192,graphics-processing,0.30328292
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,type,0.21671848,of,0.48202556,classification,0.43098688
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,proprotein-convertase,0.32895935,encoding,0.51997226,graphics-processing,0.40858257
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,subtilisin-kexin,0.2830005,graphics-processing,0.40532675,graphics-processing,0.40532675
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,kexin-type,0.2671981,encoding,0.48750857,graphics-processing,0.43884838
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,high,0.267004,of,0.57459104,gradient,0.44240427
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,dose,0.24218819,shot,0.48689568,boosting,0.43495926
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,high,0.267004,of,0.57459104,gradient,0.44240427
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,potency,0.19916415,discriminative,0.4425937,boosting,0.3652883
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,statins,0.24406128,short-term,0.40197155,long-short-term,0.3434062
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,high-dose,0.23992902,short-term,0.516369,long-short-term,0.4399596
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,dose-high,0.2344334,batch-normalization,0.38150328,batch-normalization,0.38150328
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,high-potency,0.28176153,short-term,0.43720004,feature-reduction,0.41678202
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,elevated,0.19494015,normalization,0.5246306,batch-normalization,0.44167417
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,atherosclerotic,0.24541524,of,0.33148155,generative-model,0.3187185
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,cardiovascular,0.31674606,short-term,0.442761,learning-function,0.4027721
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,disease,0.296938,recurrent,0.4731025,classification,0.35271814
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,risk,0.35860935,recurrent,0.53675485,logistic-regression,0.52381086
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,atherosclerotic-cardiovascular,0.29341784,logistic-regression,0.36804122,logistic-regression,0.36804122
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,cardiovascular-disease,0.39733815,logistic-regression,0.43556237,logistic-regression,0.43556237
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,disease-risk,0.44242084,logistic-regression,0.48454326,logistic-regression,0.48454326
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,atherosclerotic-cardiovascular-disease,0.3574118,logistic-regression,0.419603,logistic-regression,0.419603
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,ldlr,0.20127794,tf-idf,0.378558,tf-idf,0.378558
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,apolipoprotein,0.25016165,tf-idf,0.31200302,tf-idf,0.31200302
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,b,0.19558734,of,0.43435428,short-term-memory,0.31717262
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,apolipoprotein-b,0.2448067,tf-idf,0.32602477,tf-idf,0.32602477
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,frequent,0.27499682,recurrent,0.57372284,long-short-term,0.44767243
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,genetic,0.44218406,selection,0.53394234,clustering,0.53279865
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,disorder,0.28393638,dropout,0.44668275,dropout,0.44668275
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,characterized,0.27792567,feature,0.5646106,fourier,0.42356855
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,risk,0.35860935,recurrent,0.53675485,logistic-regression,0.52381086
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,equations,0.47960785,markov-model,0.63062143,markov-model,0.63062143
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,like,0.32318482,of,0.5448733,relu,0.44626954
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,one,0.335046,one,1.0,one-hot,0.4275648
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,risk-equations,0.4774286,logistic-regression,0.66784275,logistic-regression,0.66784275
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,like-one,0.41486907,one,0.54105127,one-hot,0.4815575
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,mainly,0.24372631,of,0.6151813,clustering,0.43261412
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,coronary,0.25158757,of,0.3349695,segmentation-algorithm,0.31949025
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,heart,0.28300244,rate,0.49867767,batch-normalization,0.3427502
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,disease,0.296938,recurrent,0.4731025,classification,0.35271814
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,coronary-heart,0.24738656,long-short-term,0.33648896,long-short-term,0.33648896
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,heart-disease,0.35198575,long-short-term,0.43214932,long-short-term,0.43214932
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,coronary-heart-disease,0.3109823,long-short-term,0.40599877,long-short-term,0.40599877
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,called,0.4316384,term,0.49134967,generative,0.47478232
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,fh,0.17970306,tf-idf,0.34279388,tf-idf,0.34279388
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,phenocopy,0.2671322,feature-selection,0.4496548,feature-selection,0.4496548
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,individuals,0.32092994,naive,0.486303,dropout,0.42173886
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,c,0.17513797,of,0.44327667,gradient,0.31114018
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,levels,0.20457911,normalization,0.52984333,batch-normalization,0.45617118
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,since,0.2910149,of,0.60419816,bagging,0.3698329
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,birth,0.24496669,term,0.50053644,regression,0.39090443
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,c-levels,0.3094396,batch-normalization,0.48311746,batch-normalization,0.48311746
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,since-birth,0.32144362,term,0.48603517,logistic-regression,0.47823015
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,atherosclerotic,0.24541524,of,0.33148155,generative-model,0.3187185
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,cardiovascular,0.31674606,short-term,0.442761,learning-function,0.4027721
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,disease,0.296938,recurrent,0.4731025,classification,0.35271814
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,atherosclerotic-cardiovascular,0.29341784,logistic-regression,0.36804122,logistic-regression,0.36804122
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,cardiovascular-disease,0.39733815,logistic-regression,0.43556237,logistic-regression,0.43556237
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,atherosclerotic-cardiovascular-disease,0.3574118,logistic-regression,0.419603,logistic-regression,0.419603
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,previous,0.32983518,data,0.5377847,long-short-term,0.40795568
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,cardiovascular,0.31674606,short-term,0.442761,learning-function,0.4027721
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,disease,0.296938,recurrent,0.4731025,classification,0.35271814
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,cardiovascular-disease,0.39733815,logistic-regression,0.43556237,logistic-regression,0.43556237
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,subclinical,0.32292283,recurrent,0.5262691,logistic-regression,0.3894464
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,coronary,0.25158757,of,0.3349695,segmentation-algorithm,0.31949025
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,atherosclerosis,0.2715264,of,0.35554427,generative-model,0.35331845
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,coronary-atherosclerosis,0.25254506,short-term,0.34426904,generative-model,0.3401209
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,recent,0.35249484,of,0.545993,data-engineering,0.4259707
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,studies,0.30135098,data,0.6349237,component-analysis,0.41327482
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,show,0.33248252,of,0.51487744,feature-selection,0.44449317
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,regulate,0.2604217,function,0.51654714,feed-forward,0.50070786
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,ldl,0.16037413,tf-idf,0.38286388,tf-idf,0.38286388
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,catabolism,0.20821251,encoding,0.4275161,batch-normalization,0.3744239
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,ldl-catabolism,0.23081703,cascade,0.4447596,feed-forward,0.40389872
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,better,0.4230538,of,0.5337099,feature-reduction,0.47485045
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,treat,0.32386008,recurrent,0.48263934,generative-model,0.36353803
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,ldl,0.16037413,tf-idf,0.38286388,tf-idf,0.38286388
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,latter,0.32148242,of,0.65402865,generative,0.53160214
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,monogenic,0.3862658,generative,0.4953061,generative,0.4953061
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,defects,0.22725588,function,0.5071919,data-augmentation,0.38780612
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,ldl,0.16037413,tf-idf,0.38286388,tf-idf,0.38286388
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,cholesterol,0.15921682,reduction,0.33627644,gradient,0.32767534
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,high,0.267004,of,0.57459104,gradient,0.44240427
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,cardiovascular,0.31674606,short-term,0.442761,learning-function,0.4027721
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,high-cardiovascular,0.33360592,short-term,0.49153328,long-short-term,0.4760727
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,approximately,0.19739147,of,0.56242454,gradient,0.36698094
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,high,0.267004,of,0.57459104,gradient,0.44240427
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,ldl,0.16037413,tf-idf,0.38286388,tf-idf,0.38286388
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,high-ldl,0.22120056,tf-idf,0.3548934,tf-idf,0.3548934
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,monogenic,0.3862658,generative,0.4953061,generative,0.4953061
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,disease,0.296938,recurrent,0.4731025,classification,0.35271814
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,elevated,0.19494015,normalization,0.5246306,batch-normalization,0.44167417
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,ldl,0.16037413,tf-idf,0.38286388,tf-idf,0.38286388
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,elevated,0.19494015,normalization,0.5246306,batch-normalization,0.44167417
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,low,0.23602332,of,0.5820825,long-short-term,0.45172954
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,elevated-low,0.1876381,batch-normalization,0.4101344,batch-normalization,0.4101344
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,elevated,0.19494015,normalization,0.5246306,batch-normalization,0.44167417
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,lipoprotein,0.22208765,tf-idf,0.3608624,tf-idf,0.3608624
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,molecular,0.39914468,of,0.516936,clustering,0.43655443
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,defects,0.22725588,function,0.5071919,data-augmentation,0.38780612
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,c,0.17513797,of,0.44327667,gradient,0.31114018
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,levels,0.20457911,normalization,0.52984333,batch-normalization,0.45617118
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,c-levels,0.3094396,batch-normalization,0.48311746,batch-normalization,0.48311746
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,monogenic,0.3862658,generative,0.4953061,generative,0.4953061
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,cause,0.19388393,of,0.47843847,confusion-matrix,0.34079778
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,fh,0.17970306,tf-idf,0.34279388,tf-idf,0.34279388
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,patients,0.30007,recurrent,0.5332828,dropout,0.3918751
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,fh-patients,0.23655325,dropout,0.3817302,dropout,0.3817302
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,ldl,0.16037413,tf-idf,0.38286388,tf-idf,0.38286388
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,receptor,0.22411162,function,0.41526195,clustering,0.36801085
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,ldl-receptor,0.21912806,tf-idf,0.38305622,tf-idf,0.38305622
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,normolipidemic,0.2093719,batch-normalization,0.33648974,batch-normalization,0.33648974
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,individuals,0.32092994,naive,0.486303,dropout,0.42173886
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,many,0.40940517,few,0.752018,feature-engineering,0.48454586
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,individuals,0.32092994,naive,0.486303,dropout,0.42173886
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,c,0.17513797,of,0.44327667,gradient,0.31114018
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,lowering,0.21700059,reduction,0.69292593,batch-normalization,0.5070027
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,c-lowering,0.27526447,short-term,0.4290733,feature-reduction,0.390024
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,adequate,0.29751444,support,0.50622886,batch-normalization,0.4286505
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,levels,0.20457911,normalization,0.52984333,batch-normalization,0.45617118
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,safeheart,0.4166944,data-science,0.47225568,data-science,0.47225568
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,cohort,0.3892265,logistic-regression,0.5412916,logistic-regression,0.5412916
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,rights,0.3170033,adversarial,0.6281444,data-science,0.57488894
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,reserved,0.28677964,of,0.4776592,supervised,0.3944377
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,reduce,0.314935,reduction,0.63468504,boosting,0.4613787
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,cholesterol,0.15921682,reduction,0.33627644,gradient,0.32767534
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,powered,0.3894925,machine,0.49481973,data-engineering,0.47075737
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,enough,0.35333127,few,0.5868309,long-short-term,0.42954397
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,polygenes,0.4033026,selection,0.49872562,random-forest,0.48959193
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,predominate,0.17538133,of,0.50074863,generative,0.4394589
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,phenotype,0.28173286,feature,0.51151407,feature-selection,0.4975547
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,may,0.30907542,of,0.58654004,long-short-term,0.43985203
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,inhibitors,0.25381407,cascade,0.4157439,feed-forward,0.3175553
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,male,0.26790547,naive,0.47688544,generative,0.42885694
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,sex,0.24554862,regression,0.45148212,regression,0.45148212
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,male-sex,0.13433254,descent,0.35201824,generative,0.33672026
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,main,0.3070703,principal,0.7875631,principal-components,0.51314574
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,stain,0.23425508,embeddings,0.42189342,embeddings,0.42189342
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,low,0.23602332,of,0.5820825,long-short-term,0.45172954
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,hdl,0.19749369,tf-idf,0.41316777,tf-idf,0.41316777
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,low-hdl,0.27795324,tf-idf,0.40926084,tf-idf,0.40926084
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,familial,0.2816954,recurrent,0.49144602,clustering,0.42353097
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,hypercholesterolemia,0.22823447,recurrent,0.36682838,batch-normalization,0.33904594
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,early,0.32400474,short-term,0.57188475,long-short-term,0.50726265
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,onset,0.24765743,of,0.49159142,long-short-term,0.4227278
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,early-onset,0.32172102,recurrent,0.50152946,dropout,0.39138946
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,density,0.25813383,layer,0.4929318,gradient,0.48885438
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,lipoprotein,0.22208765,tf-idf,0.3608624,tf-idf,0.3608624
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,density-lipoprotein,0.2429603,tf-idf,0.4027466,tf-idf,0.4027466
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,risk,0.35860935,recurrent,0.53675485,logistic-regression,0.52381086
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,mainly,0.24372631,of,0.6151813,clustering,0.43261412
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,fh,0.17970306,tf-idf,0.34279388,tf-idf,0.34279388
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,ldl,0.16037413,tf-idf,0.38286388,tf-idf,0.38286388
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,levels,0.20457911,normalization,0.52984333,batch-normalization,0.45617118
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,individuals,0.32092994,naive,0.486303,dropout,0.42173886
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,c,0.17513797,of,0.44327667,gradient,0.31114018
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,cholesterol,0.15921682,reduction,0.33627644,gradient,0.32767534
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,used,0.46049535,of,0.5630944,generative-model,0.4901716
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,subjects,0.34547177,descent,0.47816435,short-term-memory,0.43421033
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,smoking,0.33237135,dropout,0.4579469,dropout,0.4579469
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,situations,0.40340066,adversarial,0.5549935,artificial-intelligence,0.5075135
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,presence,0.2137551,of,0.6171463,gradient,0.4189303
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,order,0.38454574,of,0.59467053,dimensionality-reduction,0.481972
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,obesity,0.3146031,descent,0.41921628,logistic-regression,0.39891833
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,mutations,0.30690983,encoding,0.48844272,feature-selection,0.4252736
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,medications,0.28070474,confusion,0.4577524,supervised,0.37504265
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,lower,0.20975146,of,0.5471319,regression,0.3982392
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,hypertension,0.28340828,dropout,0.4223115,dropout,0.4223115
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,however,0.31437585,few,0.63182676,statistical,0.44065386
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,heterogenous,0.2949931,feature,0.5208106,generative,0.46290013
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,heterogeneity,0.35684997,clustering,0.58751535,clustering,0.58751535
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,genes,0.32912976,encoding,0.71535945,clustering,0.43737888
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,gain,0.345117,feed,0.5581456,transfer-learning,0.42192745
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,function,0.3447219,function,1.0,learning-function,0.5767432
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,ezetimibe,0.20077208,softmax,0.30890355,softmax,0.30890355
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,exposed,0.17486927,of,0.4483599,long-short-term,0.37024927
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,explains,0.3233313,of,0.56729746,stochastic,0.5104919
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,encountered,0.37356037,of,0.5562181,confusion-matrix,0.45413417
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,effects,0.2624804,short-term,0.63497096,long-short-term,0.5306107
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,diabetes,0.29301462,logistic-regression,0.35688502,logistic-regression,0.35688502
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,detection,0.39447892,analysis,0.48924,classification,0.46944988
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,depends,0.28999913,of,0.60277516,stochastic,0.50174546
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,comparison,0.38020527,analysis,0.5798166,statistical,0.52489424
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,caused,0.14436965,of,0.53973085,long-short-term,0.3204536
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,carrying,0.2680949,encoding,0.5444305,feature-selection,0.4684819
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,captured,0.41895577,tracking,0.5643201,ground-truth,0.5193245
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,burden,0.25295436,reduction,0.41791618,logistic-regression,0.3788216
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,apob,0.22971143,tf-idf,0.40899056,tf-idf,0.40899056
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,also,0.32850838,of,0.65908813,clustering,0.45826355
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",rare,0.23936996,few,0.5268981,long-short-term,0.36089045
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",autosomal,0.25142145,descent,0.42156005,generative,0.36895448
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",dominant,0.24884295,component,0.48866612,generative,0.45397174
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",immunodeficiency,0.2825069,naive,0.38981652,vector-machine,0.35260344
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",disorder,0.28393638,dropout,0.44668275,dropout,0.44668275
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",attributable,0.2182658,of,0.54582804,long-short-term,0.4121409
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",autosomal-dominant,0.28488988,descent,0.41274726,generative-model,0.38142684
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",severe,0.24462184,recurrent,0.581337,confusion-matrix,0.37568426
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",chronic,0.22727785,recurrent,0.5279353,long-short-term,0.4292153
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",neutropenia,0.24294737,recurrent,0.4968434,confusion-matrix,0.33884615
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",international,0.35198426,federated,0.6565988,data-science,0.5665215
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",registry,0.31939733,federated,0.5197936,data-science,0.4680016
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",severe-chronic,0.23703578,recurrent,0.49082252,long-short-term,0.41069347
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",quite,0.30007085,few,0.6052937,generative,0.4009419
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",variable,0.37856048,of,0.60098064,regression,0.54398334
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",across,0.3330416,gradient,0.4622073,gradient,0.4622073
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",patient,0.2998137,confusion,0.5356896,confusion-matrix,0.41404122
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",cohorts,0.38747132,logistic-regression,0.5306275,logistic-regression,0.5306275
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",across-patient,0.50721127,cross-entropy,0.6401123,cross-entropy,0.6401123
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",patient-cohorts,0.4935009,logistic-regression,0.57175344,logistic-regression,0.57175344
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",treat,0.32386008,recurrent,0.48263934,generative-model,0.36353803
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",infections,0.23728761,recurrent,0.48452243,keras,0.30937475
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",based,0.49998575,classification-algorithm,0.5639226,classification-algorithm,0.5639226
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",upon,0.2366915,of,0.6212549,boosting,0.40359378
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",long,0.20028201,long,1.0,long-short-term,0.6505779
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",based-upon,0.4824746,feature-engineering,0.5948112,feature-engineering,0.5948112
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",recurrent,0.32854465,recurrent,1.0,recurrent-neural-network,0.59633
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",otitis,0.19054615,recurrent,0.45285463,natural-language,0.31226128
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",media,0.20665605,matrix,0.43112892,feature-reduction,0.39949167
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",otitis-media,0.281678,component-analysis,0.3921208,component-analysis,0.3921208
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",human,0.30336243,of,0.5175895,feature-engineering,0.40631005
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",papilloma,0.20156842,recurrent,0.38309884,pytorch,0.31147784
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",virus,0.27194685,vector,0.4519252,vector-machine,0.4189635
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",human-papilloma,0.33137405,pytorch,0.40429163,pytorch,0.40429163
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",papilloma-virus,0.26352248,pytorch,0.37875727,pytorch,0.37875727
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",human-papilloma-virus,0.35025012,pytorch,0.4246676,pytorch,0.4246676
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",features,0.51742536,feature,0.8268872,feature-selection,0.5487305
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",occur,0.24370867,of,0.53400475,long-short-term,0.41742977
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",consistently,0.3349427,few,0.5762741,clustering,0.4464267
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",congenital,0.2731396,recurrent,0.50797117,convolutional,0.36573476
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",heart,0.28300244,rate,0.49867767,batch-normalization,0.3427502
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",disease,0.296938,recurrent,0.4731025,classification,0.35271814
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",congenital-heart,0.39053822,computer-vision,0.46173987,computer-vision,0.46173987
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",heart-disease,0.35198575,long-short-term,0.43214932,long-short-term,0.43214932
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",congenital-heart-disease,0.42481175,recurrent-neural-network,0.48303035,recurrent-neural-network,0.48303035
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",ongoing,0.36421978,support,0.564979,data-science,0.49493372
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",clinical,0.44080526,data,0.48532635,data-science,0.45343333
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",trials,0.31393725,short-term,0.4483273,data-science,0.40647802
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",clinical-trials,0.4615081,data-science,0.54023623,data-science,0.54023623
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",reviewed,0.37280488,data,0.5809281,classification,0.44087517
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",clinical,0.44080526,data,0.48532635,data-science,0.45343333
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",manifestations,0.3043628,feature,0.51774037,classification,0.3863002
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",another,0.3071552,one,0.80370224,clustering,0.4124617
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",important,0.33620566,principal,0.5803634,feature-engineering,0.43471682
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",complication,0.26272127,recurrent,0.5492595,dropout,0.3673593
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",respiratory,0.2119393,rate,0.40438467,bagging,0.35663396
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",infections,0.23728761,recurrent,0.48452243,keras,0.30937475
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",respiratory-infections,0.3158656,recurrent,0.41466066,recurrent-neural-network,0.3881544
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",treat,0.32386008,recurrent,0.48263934,generative-model,0.36353803
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",whims,0.42268434,truth,0.5609389,data-science,0.5429581
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",clinical,0.44080526,data,0.48532635,data-science,0.45343333
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",consequences,0.33212107,of,0.54692155,long-short-term,0.51459765
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",clinical-consequences,0.5199479,feature-engineering,0.5704995,feature-engineering,0.5704995
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",diverse,0.38913006,of,0.5461366,feature-engineering,0.51537836
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",manifestations,0.3043628,feature,0.51774037,classification,0.3863002
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",families,0.3079673,neighbors,0.49964905,clustering,0.4544287
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",within,0.2920679,of,0.57602364,clustering,0.4610753
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",families,0.3079673,neighbors,0.49964905,clustering,0.4544287
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",within-families,0.43731886,clustering,0.58774656,clustering,0.58774656
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",term,0.33795053,term,1.0,long-short-term,0.62770975
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",observations,0.32199246,data,0.69908524,generative,0.44571877
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",stimulating,0.22020775,boosting,0.5143733,boosting,0.5143733
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",factor,0.23388772,component,0.48280093,principal-components,0.43733668
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",stimulating-factor,0.27713042,components,0.4431072,principal-component,0.43232262
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",recent,0.35249484,of,0.545993,data-engineering,0.4259707
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",findings,0.35685748,data,0.65714294,component-analysis,0.38599753
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",novel,0.4652171,feature-engineering,0.5132146,feature-engineering,0.5132146
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",agents,0.2697791,of,0.44812918,boosting,0.36205623
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",novel-agents,0.47211248,reinforcement-learning,0.5307679,reinforcement-learning,0.5307679
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",natural,0.34621036,natural,1.0,natural-language,0.49809957
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",history,0.32837912,recurrent,0.5897511,regression,0.3962426
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",natural-history,0.4752348,natural,0.6953187,natural-language,0.6063787
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",less,0.2680999,of,0.53796744,long-short-term,0.4390034
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",commonly,0.38716513,of,0.49960154,confusion-matrix,0.4359238
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",less-commonly,0.36901253,one,0.47907206,feature-selection,0.46476415
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",hearing,0.34749007,vision,0.62433,learning-function,0.48902106
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",loss,0.26544642,reduction,0.62177265,dropout,0.42517614
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",hearing-loss,0.39409262,vision,0.5690473,computer-vision,0.53354
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",granulocyte,0.1994723,unit,0.34592837,short-term-memory,0.29992422
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",colony,0.24243957,random-forest,0.40333652,random-forest,0.40333652
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",granulocyte-colony,0.21935473,naive,0.3282728,long-short-term,0.30932692
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",family,0.2727693,support,0.5085263,clustering,0.40444815
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",concerns,0.33428794,confusion,0.6494896,confusion-matrix,0.47983494
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",associated,0.30827495,of,0.57598466,long-short-term,0.46578532
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",malignancies,0.28657573,recurrent,0.47277814,recurrent-neural-network,0.34451386
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",patients,0.30007,recurrent,0.5332828,dropout,0.3918751
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",patients,0.30007,recurrent,0.5332828,dropout,0.3918751
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",enrolled,0.3208215,supervised,0.42658707,supervised,0.42658707
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",whim,0.3689891,bag-of-words,0.44166103,bag-of-words,0.44166103
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",syndrome,0.20306323,recurrent,0.42346346,confusion-matrix,0.3198145
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",whim-syndrome,0.25860456,recurrent,0.42163923,recurrent-neural-network,0.3677413
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",review,0.41215214,data,0.5581161,data-science,0.47600204
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",indicates,0.2743193,of,0.6366827,clustering,0.41554892
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",mild,0.23190956,confusion,0.4743051,bagging,0.423263
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",hypogammaglobulinemia,0.23260507,recurrent,0.4887368,batch-normalization,0.3294939
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",immunodeficiency,0.2825069,naive,0.38981652,vector-machine,0.35260344
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",expand,0.40337217,data-engineering,0.5478628,data-engineering,0.5478628
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",understanding,0.42499995,feature-engineering,0.552827,feature-engineering,0.552827
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",patient,0.2998137,confusion,0.5356896,confusion-matrix,0.41404122
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",neutropenia,0.24294737,recurrent,0.4968434,confusion-matrix,0.33884615
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",important,0.33620566,principal,0.5803634,feature-engineering,0.43471682
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",complication,0.26272127,recurrent,0.5492595,dropout,0.3673593
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",patients,0.30007,recurrent,0.5332828,dropout,0.3918751
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",whims,0.42268434,truth,0.5609389,data-science,0.5429581
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",understanding,0.42499995,feature-engineering,0.552827,feature-engineering,0.552827
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",syndrome,0.20306323,recurrent,0.42346346,confusion-matrix,0.3198145
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",review,0.41215214,data,0.5581161,data-science,0.47600204
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",hypogammaglobulinemia,0.23260507,recurrent,0.4887368,batch-normalization,0.3294939
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",warts,0.17091861,keras,0.4368605,keras,0.4368605
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",vulvular,0.20843,recurrent,0.5023149,confusion-matrix,0.32030526
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",treatment,0.239264,short-term,0.5206091,long-short-term,0.41699445
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",summary,0.3869185,data,0.59051514,component-analysis,0.44181547
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",source,0.2654278,principal,0.47472525,generative-model,0.4532325
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",purpose,0.4149922,of,0.5072116,feature-engineering,0.43333688
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",prevent,0.23429571,of,0.49340016,long-short-term,0.38102832
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",myelokathexis,0.24848115,pytorch,0.42442614,pytorch,0.42442614
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",mutations,0.30690983,encoding,0.48844272,feature-selection,0.4252736
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",morbidity,0.27463242,recurrent,0.47132403,logistic-regression,0.42021167
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",lymphomas,0.29395568,naive,0.35480863,classification,0.33241734
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",lymphocytopenia,0.26975158,naive,0.41932106,short-term-memory,0.37608317
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",however,0.31437585,few,0.63182676,statistical,0.44065386
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",example,0.44778085,feature,0.6351186,feature-engineering,0.5831825
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",effective,0.32842147,of,0.50971246,boosting,0.48854327
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",diversity,0.4204061,clustering,0.57293266,clustering,0.57293266
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",controversial,0.29568425,of,0.49207133,long-short-term,0.45792398
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",common,0.32574984,feature,0.5597373,clustering,0.43115532
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",cervical,0.21034898,recurrent,0.4297998,recurrent-neural-network,0.31456795
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",cellulitis,0.17868587,recurrent,0.4936192,confusion-matrix,0.33643293
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",cause,0.19388393,of,0.47843847,confusion-matrix,0.34079778
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",almost,0.2402496,few,0.5824453,generative,0.36206198
Prime time for ticagrelor monotherapy.,n,0.24332823,of,0.45693433,long-short-term,0.34114176
Prime time for ticagrelor monotherapy.,engl,0.20983538,science,0.3860138,rnn,0.2874289
Prime time for ticagrelor monotherapy.,j,0.12432591,science,0.31094742,cross-entropy,0.2885616
Prime time for ticagrelor monotherapy.,med,0.21494195,confusion,0.45325774,bagging,0.36537588
Prime time for ticagrelor monotherapy.,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
Prime time for ticagrelor monotherapy.,nov,0.26372796,pytorch,0.3735997,pytorch,0.3735997
Prime time for ticagrelor monotherapy.,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
Prime time for ticagrelor monotherapy.,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
Prime time for ticagrelor monotherapy.,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
Prime time for ticagrelor monotherapy.,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
Prime time for ticagrelor monotherapy.,comment,0.27913174,term,0.48209506,data-science,0.40549088
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,time,0.31186903,long,0.57547164,batch-normalization,0.47628766
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,quantitative,0.4330744,analysis,0.6747154,component-analysis,0.558002
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,polymerase,0.2900375,encoding,0.39668864,monte,0.3958352
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,chain,0.19351235,markov,0.4437825,markov,0.4437825
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,reaction,0.16487643,transfer,0.4593661,feature-reduction,0.43431032
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,time-quantitative,0.4209262,analysis,0.5880825,batch-normalization,0.56569195
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,quantitative-polymerase,0.38077006,analysis,0.53598803,monte,0.4813006
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,polymerase-chain,0.25961733,encoding,0.42047226,markov,0.39611366
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,chain-reaction,0.22283293,analysis,0.41961744,markov,0.4056226
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,polymerase-chain-reaction,0.25968674,analysis,0.4264499,markov,0.40685207
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,xxxa,0.103940696,encoding,0.28463936,nearest-neighbors,0.2823031
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,mimic,0.33739525,natural,0.5266358,feature-engineering,0.46741465
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,could,0.34235194,of,0.59299076,boosting,0.42074972
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,partly,0.24294792,fully,0.6539805,long-short-term,0.4301982
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,reverse,0.2939736,forward,0.5330905,feature-reduction,0.40937227
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,found,0.2840244,of,0.6208722,clustering,0.44675255
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,bil,0.23905668,bagging,0.42779893,bagging,0.42779893
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,negatively,0.19863382,function,0.50118184,regression,0.35049492
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,regulated,0.24979803,encoding,0.5367844,feed-forward,0.4816816
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,mir,0.34795114,fourier-transform,0.40859607,fourier-transform,0.40859607
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,negatively-regulated,0.38389558,encoding,0.64858234,feed-forward,0.51651716
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,linked,0.25606114,connected,0.66019666,fully-connected,0.40349507
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,immunosorbent,0.28837162,logistic,0.38276714,fourier-transform,0.35901013
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,assay,0.28104568,analysis,0.46296048,component-analysis,0.37250015
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,also,0.32850838,of,0.65908813,clustering,0.45826355
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,linked-immunosorbent,0.32491302,component-analysis,0.40813425,component-analysis,0.40813425
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,immunosorbent-assay,0.29248106,component-analysis,0.41339135,component-analysis,0.41339135
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,linked-immunosorbent-assay,0.3285583,component-analysis,0.44052616,component-analysis,0.44052616
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,nuclear,0.29904062,of,0.4222371,clustering,0.36110973
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,factor,0.23388772,component,0.48280093,principal-components,0.43733668
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,kappa,0.24868175,discriminative,0.4588089,bayes,0.3875664
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,b,0.19558734,of,0.43435428,short-term-memory,0.31717262
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,nuclear-factor,0.35151532,principal-component,0.5243285,principal-component,0.5243285
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,factor-kappa,0.23342063,cascade,0.45096648,feed-forward,0.35911852
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,kappa-b,0.22491103,cascade,0.39329255,centroid-based,0.35486934
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,nuclear-factor-kappa,0.3095979,matrix,0.44517764,principal-component,0.40912294
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,factor-kappa-b,0.21222854,cascade,0.44179845,centroid-based,0.3414091
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,matrix,0.36017767,matrix,0.99999994,confusion-matrix,0.6947298
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,metalloproteinases,0.28353637,matrix,0.6852367,confusion-matrix,0.4846176
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,matrix-metalloproteinases,0.31312904,matrix,0.77345085,confusion-matrix,0.54633904
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,detect,0.41183126,analysis,0.51244676,clustering,0.43602985
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,inflammatory,0.19824001,cascade,0.43951106,generative-model,0.38795525
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,factor,0.23388772,component,0.48280093,principal-components,0.43733668
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,levels,0.20457911,normalization,0.52984333,batch-normalization,0.45617118
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,factor-levels,0.36059618,batch-normalization,0.48202336,batch-normalization,0.48202336
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,tumor,0.23345715,of,0.4070977,regression,0.3830863
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,necrosis,0.13728917,of,0.39391375,regression,0.3165221
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,factor,0.23388772,component,0.48280093,principal-components,0.43733668
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,tumor-necrosis,0.17264141,matrix,0.3434254,boosting,0.29771045
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,necrosis-factor,0.2518684,cascade,0.4094454,principal-component,0.37788132
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,tumor-necrosis-factor,0.2309803,matrix,0.38553926,boosting,0.33476132
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,greatly,0.32925183,of,0.60406625,boosting,0.47416002
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,destructive,0.27232668,generative,0.52100086,generative,0.52100086
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,disease,0.296938,recurrent,0.4731025,classification,0.35271814
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,mir,0.34795114,fourier-transform,0.40859607,fourier-transform,0.40859607
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,xxxa,0.103940696,encoding,0.28463936,nearest-neighbors,0.2823031
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,inflammatory,0.19824001,cascade,0.43951106,generative-model,0.38795525
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,injury,0.262506,shot,0.44338763,data-augmentation,0.37271294
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,model,0.48485535,model,1.0,markov-model,0.7005576
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,injury-model,0.4423967,model,0.5849784,generative-model,0.5835452
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,induced,0.2259351,of,0.5615651,boosting,0.4303583
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,inflammatory,0.19824001,cascade,0.43951106,generative-model,0.38795525
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,injury,0.262506,shot,0.44338763,data-augmentation,0.37271294
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,induced-inflammatory,0.26462176,generative-model,0.46574545,generative-model,0.46574545
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,western,0.2369854,analysis,0.4211278,component-analysis,0.34579337
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,blot,0.2525668,analysis,0.513041,fourier-transform,0.39106333
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,tested,0.37172255,of,0.5634051,boosting,0.4195229
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,western-blot,0.28945214,analysis,0.47462213,fourier-transform,0.39007807
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,blot-tested,0.404627,principal-component-analysis,0.5048123,principal-component-analysis,0.5048123
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,induced,0.2259351,of,0.5615651,boosting,0.4303583
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,cell,0.2212203,of,0.48460138,generative,0.39753264
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,viability,0.21255259,function,0.46481842,feature-reduction,0.33868396
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,induced-cell,0.26634485,of,0.46156126,stochastic,0.43135005
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,cell-viability,0.26226342,batch-normalization,0.4028484,batch-normalization,0.4028484
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,il,0.17175047,monte,0.3419046,monte,0.3419046
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,xxxa,0.103940696,encoding,0.28463936,nearest-neighbors,0.2823031
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,via,0.29305607,connected,0.5425352,feed-forward,0.46278888
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,jnk,0.20093879,cascade,0.5330882,feed-forward,0.43211234
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,bil,0.23905668,bagging,0.42779893,bagging,0.42779893
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,inhibited,0.15575022,reduction,0.46446392,boosting,0.33858013
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,il,0.17175047,monte,0.3419046,monte,0.3419046
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,signaling,0.29640946,cascade,0.70725644,feed-forward,0.5819744
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,pathways,0.30476987,cascade,0.6938149,feed-forward,0.5254793
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,signaling-pathways,0.33893383,cascade,0.69794536,feed-forward,0.5998782
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,xxxa,0.103940696,encoding,0.28463936,nearest-neighbors,0.2823031
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,mimic,0.33739525,natural,0.5266358,feature-engineering,0.46741465
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,bil,0.23905668,bagging,0.42779893,bagging,0.42779893
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,inhibited,0.15575022,reduction,0.46446392,boosting,0.33858013
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,inflammatory,0.19824001,cascade,0.43951106,generative-model,0.38795525
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,factors,0.3420733,components,0.5413606,logistic-regression,0.48293567
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,cell,0.2212203,of,0.48460138,generative,0.39753264
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,viability,0.21255259,function,0.46481842,feature-reduction,0.33868396
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,cell-viability,0.26226342,batch-normalization,0.4028484,batch-normalization,0.4028484
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,xxxa,0.103940696,encoding,0.28463936,nearest-neighbors,0.2823031
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,level,0.23847455,of,0.54773176,batch-normalization,0.45912555
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,mmps,0.28088403,matrix,0.66546273,confusion-matrix,0.48739702
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,terminal,0.1515508,long,0.5815784,generative,0.39005107
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,kinase,0.22244422,cascade,0.49403343,feed-forward,0.34344023
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,terminal-kinase,0.24964479,cascade,0.48992562,feed-forward,0.43961912
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,related,0.30849367,of,0.6150687,clustering,0.41455543
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,proteins,0.35976675,components,0.56075835,component-analysis,0.40436536
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,related-proteins,0.43194956,components,0.49777842,component-analysis,0.47824526
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,preliminarily,0.36773974,of,0.54904556,feature-reduction,0.45521832
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,studied,0.26534057,of,0.63097596,generative-model,0.40392917
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,opposite,0.18335173,forward,0.45899883,nearest-neighbors,0.43473938
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,effect,0.21449387,short-term,0.5886732,long-short-term,0.47619703
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,jun,0.210586,feed-forward,0.37043476,feed-forward,0.37043476
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,n,0.24332823,of,0.45693433,long-short-term,0.34114176
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,jun-n,0.21143919,cascade,0.4181518,feed-forward,0.3875628
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,high,0.267004,of,0.57459104,gradient,0.44240427
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,disability,0.35275212,intelligence,0.57050866,learning-function,0.49054688
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,high-disability,0.4394648,intelligence,0.58175445,artificial-intelligence,0.56645405
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,cells,0.20327199,naive,0.5115537,generative,0.40616876
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,ankylosing,0.23111828,descent,0.37860397,data-augmentation,0.3062043
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,spondylitis,0.204685,descent,0.3725263,gradient-descent,0.28626597
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,ankylosing-spondylitis,0.25446716,descent,0.39171314,segmentation-algorithm,0.3575512
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,migration,0.17838386,neural,0.4264465,gradient,0.42258286
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,assays,0.28855288,analysis,0.47350433,component-analysis,0.38540024
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,migration-assays,0.2724169,stochastic-gradient,0.4365898,stochastic-gradient,0.4365898
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,mir,0.34795114,fourier-transform,0.40859607,fourier-transform,0.40859607
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,bil,0.23905668,bagging,0.42779893,bagging,0.42779893
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,xxxa,0.103940696,encoding,0.28463936,nearest-neighbors,0.2823031
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,levels,0.20457911,normalization,0.52984333,batch-normalization,0.45617118
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,detect,0.41183126,analysis,0.51244676,clustering,0.43602985
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,injury,0.262506,shot,0.44338763,data-augmentation,0.37271294
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,il,0.17175047,monte,0.3419046,monte,0.3419046
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,tested,0.37172255,of,0.5634051,boosting,0.4195229
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,pathways,0.30476987,cascade,0.6938149,feed-forward,0.5254793
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,jnk,0.20093879,cascade,0.5330882,feed-forward,0.43211234
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,mmps,0.28088403,matrix,0.66546273,confusion-matrix,0.48739702
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,migration,0.17838386,neural,0.4264465,gradient,0.42258286
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,used,0.46049535,of,0.5630944,generative-model,0.4901716
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,transfection,0.26580268,vector,0.5960965,vector-machine,0.46135688
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,study,0.3645851,of,0.5728763,statistical,0.44204497
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,showed,0.20766163,of,0.5296177,regression,0.37027335
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,real,0.4954688,truth,0.5802553,ground-truth,0.56635034
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,pathway,0.27141988,cascade,0.7127757,feed-forward,0.5331765
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,nf,0.24335094,nlp,0.37041497,nlp,0.37041497
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,moreover,0.34991172,of,0.5596781,boosting,0.44273305
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,microrna,0.4338998,recurrent-neural-network,0.44188303,recurrent-neural-network,0.44188303
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,mechanism,0.2780391,cascade,0.59194523,feed-forward,0.5341974
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,interleukin,0.2092636,naive,0.38037264,short-term-memory,0.34282282
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,inc,0.2706048,bag,0.52860194,bagging,0.41463643
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,furthermore,0.33438665,of,0.5529862,clustering,0.42723072
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,functions,0.41232014,function,0.8737128,learning-function,0.5841365
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,function,0.3447219,function,1.0,learning-function,0.5767432
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,finally,0.426572,of,0.64012104,generative,0.48128563
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,expressions,0.35501465,encoding,0.5121615,embeddings,0.45682842
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,enzyme,0.21657495,encoding,0.44885126,feature-reduction,0.38085908
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,effects,0.2624804,short-term,0.63497096,long-short-term,0.5306107
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,downregulation,0.25968617,reduction,0.52367336,feed-forward,0.4713591
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,construct,0.4047066,vector,0.6145139,support-vector,0.58696413
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,changed,0.2769384,of,0.5023751,bagging,0.42530447
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,cck,0.22167978,reinforcement,0.34990886,reinforcement-learning,0.3339272
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,c,0.17513797,of,0.44327667,gradient,0.31114018
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,bilobalide,0.28584826,tree,0.3804068,learning-function,0.3058319
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,based,0.49998575,classification-algorithm,0.5639226,classification-algorithm,0.5639226
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,additionally,0.37098312,of,0.6596129,feature-reduction,0.453403
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",ex,0.288929,of,0.41632706,generative,0.36303258
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",vivo,0.31561637,of,0.48691544,generative-model,0.4255858
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",studies,0.30135098,data,0.6349237,component-analysis,0.41327482
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",suggested,0.30397683,of,0.6234695,clustering,0.4426524
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",decreased,0.23506472,reduction,0.66483074,boosting,0.42738107
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",ache,0.23182264,neural,0.40081736,learning-function,0.34224117
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",activity,0.21813896,function,0.53536034,boosting,0.38798416
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",ex-vivo,0.335132,generative-model,0.44142258,generative-model,0.44142258
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",vivo-studies,0.38369304,data,0.49670026,feature-engineering,0.4581967
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",studies-suggested,0.41998166,component-analysis,0.5828271,component-analysis,0.5828271
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",ache-activity,0.2994419,of,0.4869771,learning-function,0.4749143
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",vivo,0.31561637,of,0.48691544,generative-model,0.4255858
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",behavioral,0.43270424,learning,0.645051,reinforcement-learning,0.6396035
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",studies,0.30135098,data,0.6349237,component-analysis,0.41327482
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",signified,0.30207253,of,0.6525098,statistical,0.525944
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",learning,0.709237,learning,1.0,deep-learning,0.8286492
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",parallel,0.38849422,convolutional-layer,0.55327755,convolutional-layer,0.55327755
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",artificial,0.4622418,artificial,1.0,artificial-intelligence,0.6597898
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",membrane,0.2560242,layer,0.5360652,gradient-descent,0.40451998
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",permeation,0.28776503,layer,0.44237053,gradient-descent,0.43421227
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",assay,0.28104568,analysis,0.46296048,component-analysis,0.37250015
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",parallel-artificial,0.60347,convolutional-layer,0.69727063,convolutional-layer,0.69727063
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",artificial-membrane,0.47451097,artificial,0.72366524,artificial-intelligence,0.5901011
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",membrane-permeation,0.31224024,gradient-descent,0.44904965,gradient-descent,0.44904965
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",good,0.29142508,few,0.4427599,bagging,0.41576368
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",oral,0.24590528,of,0.46959797,boosting,0.3483035
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",absorption,0.20241106,fourier-transform,0.5182072,fourier-transform,0.5182072
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",characteristics,0.345204,of,0.5401758,feature-engineering,0.49030614
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",ascertained,0.29071113,of,0.5930543,component-analysis,0.42920208
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",oral-absorption,0.24357733,fourier-transform,0.51111245,fourier-transform,0.51111245
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",neuroblastoma,0.25346804,neural,0.4635237,recurrent-neural-network,0.38091174
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",cell,0.2212203,of,0.48460138,generative,0.39753264
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",lines,0.2397678,of,0.42859763,generative,0.3835748
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",neuroblastoma-cell,0.27914017,neural,0.50081825,recurrent-neural-network,0.44959873
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",cell-lines,0.3067491,naive,0.41776058,generative,0.41620326
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",neuroblastoma-cell-lines,0.313729,neural,0.48746195,recurrent-neural-network,0.4554356
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",synthesized,0.25979662,encoding,0.4240871,generative,0.38417888
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",compounds,0.29263198,components,0.5131814,dimensionality-reduction,0.39397755
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",suggested,0.30397683,of,0.6234695,clustering,0.4426524
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",significant,0.29367286,statistical,0.582669,statistical,0.582669
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",showed,0.20766163,of,0.5296177,regression,0.37027335
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",significant,0.29367286,statistical,0.582669,statistical,0.582669
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",displacement,0.26953688,tracking,0.5104734,gradient-descent,0.47566164
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",induced,0.2259351,of,0.5615651,boosting,0.4303583
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",cognitive,0.5010079,memory,0.72449946,learning-function,0.7178915
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",dysfunctions,0.35017228,function,0.65545803,learning-function,0.5075237
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",performed,0.3864032,analysis,0.5711501,supervised,0.4789877
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",induced-cognitive,0.50749385,learning-function,0.6913421,learning-function,0.6913421
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",terminal,0.1515508,long,0.5815784,generative,0.39005107
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",phenyl,0.17338067,centroid-based,0.43854228,centroid-based,0.43854228
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",ring,0.2050545,connected,0.46647024,centroid-based,0.4623626
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",considered,0.36321384,of,0.60548925,feature-reduction,0.4442021
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",phenyl-ring,0.25175387,centroid-based,0.50342387,centroid-based,0.50342387
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",also,0.32850838,of,0.65908813,clustering,0.45826355
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",exhibited,0.18898472,of,0.49406686,feature-reduction,0.35593373
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",anti,0.114482366,of,0.3963322,boosting,0.31662655
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",compound,0.23029123,component,0.44195548,dimensionality-reduction,0.358908
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",containing,0.25114298,of,0.51960796,fully-connected,0.38334632
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",butyrylcholinesterase,0.2438598,neural,0.3618741,learning-function,0.32919574
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",aggregation,0.25924718,clustering,0.47166443,clustering,0.47166443
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",activity,0.21813896,function,0.53536034,boosting,0.38798416
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",synthesized,0.25979662,encoding,0.4240871,generative,0.38417888
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",molecular,0.39914468,of,0.516936,clustering,0.43655443
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",hybrids,0.23354143,generative,0.42797795,generative,0.42797795
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",peripheral,0.27531123,of,0.47952008,short-term-memory,0.3612224
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",anionic,0.280469,layer,0.44637448,nearest-neighbors,0.43867198
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",site,0.19581059,of,0.46834108,nearest-neighbors,0.3344323
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",anionic-site,0.29026264,nearest-neighbors,0.5132488,nearest-neighbors,0.5132488
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",enzyme,0.21657495,encoding,0.44885126,feature-reduction,0.38085908
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",kinetics,0.24096473,rate,0.50796926,stochastic,0.49935678
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",study,0.3645851,of,0.5728763,statistical,0.44204497
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",enzyme-kinetics,0.34277123,graphics-processing-unit,0.4747334,graphics-processing-unit,0.4747334
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",kinetics-study,0.5249728,markov-model,0.6197456,markov-model,0.6197456
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",atomic,0.34699506,fourier-transform,0.6088115,fourier-transform,0.6088115
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",force,0.3118553,forward,0.535775,generative-model,0.41757038
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",microscopy,0.33248088,fourier-transform,0.6269648,fourier-transform,0.6269648
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",atomic-force,0.3980965,fourier-transform,0.6148921,fourier-transform,0.6148921
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",force-microscopy,0.37559533,fourier-transform,0.5177797,fourier-transform,0.5177797
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",atomic-force-microscopy,0.39424613,fourier-transform,0.60095835,fourier-transform,0.60095835
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",balanced,0.29853535,of,0.46427843,gradient-descent,0.46074256
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",inhibitory,0.23645243,feed-forward,0.48216188,feed-forward,0.48216188
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",potential,0.3558654,of,0.5645705,generative-model,0.46479023
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",morris,0.35375634,memory,0.5060159,short-term-memory,0.49273154
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",water,0.30284643,feed,0.5419835,gradient,0.42149428
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",maze,0.37116885,learning,0.5548943,reinforcement-learning,0.5362206
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",morris-water,0.41452035,monte-carlo,0.5483748,monte-carlo,0.5483748
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",water-maze,0.4425242,reinforcement-learning,0.6124146,reinforcement-learning,0.6124146
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",morris-water-maze,0.4562862,reinforcement-learning,0.57114047,reinforcement-learning,0.57114047
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",pharmacokinetic,0.40963674,bayesian,0.45921755,bayesian,0.45921755
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",studies,0.30135098,data,0.6349237,component-analysis,0.41327482
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",compound,0.23029123,component,0.44195548,dimensionality-reduction,0.358908
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",hache,0.25376832,cross-validation,0.28929424,cross-validation,0.28929424
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",suggested,0.30397683,of,0.6234695,clustering,0.4426524
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",pampa,0.3576552,forest,0.49113238,random-forest,0.46218443
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",induced,0.2259351,of,0.5615651,boosting,0.4303583
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",thioflavin,0.26738867,fourier-transform,0.46536982,fourier-transform,0.46536982
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",afm,0.30231515,fourier-transform,0.62250924,fourier-transform,0.62250924
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",potential,0.3558654,of,0.5645705,generative-model,0.46479023
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",lead,0.26196307,of,0.48279357,long-short-term,0.38915557
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",antioxidant,0.28505206,natural,0.41360974,learning-function,0.37605202
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",potential,0.3558654,of,0.5645705,generative-model,0.46479023
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",target,0.31799266,of,0.4775706,feature-selection,0.44359237
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",enzymes,0.25064033,encoding,0.4579606,feature-reduction,0.35283113
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",target-enzymes,0.44797385,feature-engineering,0.51815814,feature-engineering,0.51815814
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",rights,0.3170033,adversarial,0.6281444,data-science,0.57488894
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",reserved,0.28677964,of,0.4776592,supervised,0.3944377
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",propidium,0.23675776,monte,0.33983922,monte,0.33983922
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",iodide,0.11335519,layer,0.30783612,centroid-based,0.27504295
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",propidium-iodide,0.24725053,carlo,0.32883793,centroid-based,0.3272993
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",prompted,0.35594875,of,0.65488327,feature-engineering,0.43711334
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",researchers,0.55908495,data-science,0.7127094,data-science,0.7127094
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",neuroprotective,0.305324,learning-function,0.4366417,learning-function,0.4366417
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",ability,0.39144984,function,0.5937173,generative,0.47758824
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",morphological,0.38724077,feature,0.5468423,generative,0.5159291
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",characterization,0.35015094,analysis,0.5907825,feature-engineering,0.50858456
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",mixed,0.2972577,of,0.4628052,generative-model,0.45958292
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",type,0.21671848,of,0.48202556,classification,0.43098688
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",mixed-type,0.2372058,linear,0.39406204,feature-reduction,0.39269882
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",memory,0.4292574,memory,1.0,short-term-memory,0.84619105
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",improvement,0.39264548,reduction,0.6142903,feature-reduction,0.5138227
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",memory-improvement,0.5422376,memory,0.7199047,learning-function,0.7142275
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",functional,0.3902081,function,0.728652,learning-function,0.5807885
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",agents,0.2697791,of,0.44812918,boosting,0.36205623
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",excellent,0.2827652,discriminative,0.44602555,cross-validation,0.40194866
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",blood,0.16939776,normalization,0.4272251,batch-normalization,0.40715772
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",diverse,0.38913006,of,0.5461366,feature-engineering,0.51537836
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",nature,0.2731439,of,0.5463233,generative,0.5272707
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",difluoro,0.17563055,fourier-transform,0.34744707,fourier-transform,0.34744707
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",substitution,0.19450924,selection,0.4146416,feature-selection,0.3898128
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",difluoro-substitution,0.24001542,centroid-based,0.46212715,centroid-based,0.46212715
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",develop,0.4619095,generative,0.52892005,generative,0.52892005
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",multi,0.37771758,multi-class,0.4810482,segmentation,0.43055838
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",brain,0.31704307,neural,0.57897407,learning-rate,0.44069666
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",barrier,0.20779422,layer,0.49755353,convolutional-layer,0.40104946
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",brain-barrier,0.35230377,neural,0.5161718,transfer-learning,0.4740446
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",biological,0.44501913,natural,0.6314477,feature-engineering,0.5497216
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",activities,0.25071037,of,0.4766258,learning-function,0.38030344
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",ache,0.23182264,neural,0.40081736,learning-function,0.34224117
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",assay,0.28104568,analysis,0.46296048,component-analysis,0.37250015
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",ascertained,0.29071113,of,0.5930543,component-analysis,0.42920208
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",phenyl,0.17338067,centroid-based,0.43854228,centroid-based,0.43854228
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",also,0.32850838,of,0.65908813,clustering,0.45826355
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",maze,0.37116885,learning,0.5548943,reinforcement-learning,0.5362206
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",hache,0.25376832,cross-validation,0.28929424,cross-validation,0.28929424
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",sh,0.23336436,of,0.4630851,long-short-term,0.4193005
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",self,0.3628102,style,0.5880609,confusion-matrix,0.4790911
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",secretase,0.27026734,processing,0.44761896,graphics-processing,0.44647
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",scopolamine,0.3542075,learning,0.49095958,reinforcement-learning,0.4729424
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",pyridylpiperazine,0.26832622,centroid-based,0.46514726,centroid-based,0.46514726
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",permeability,0.20990811,matrix,0.4571835,gradient-descent,0.43536943
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",pas,0.19892406,of,0.41884017,long-short-term,0.39021897
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",particular,0.41020766,of,0.6936578,generative,0.5711796
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",oxadiazoles,0.1997869,centroid-based,0.3977083,centroid-based,0.3977083
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",moreover,0.34991172,of,0.5596781,boosting,0.44273305
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",ki,0.1395658,knn,0.27186406,knn,0.27186406
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",inhibition,0.21671593,reduction,0.58642584,feed-forward,0.44581953
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",herein,0.42017996,feature-engineering,0.47987694,feature-engineering,0.47987694
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",hbche,0.22847703,centroid-based,0.32484514,centroid-based,0.32484514
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",disease,0.296938,recurrent,0.4731025,classification,0.35271814
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",designed,0.47411257,feature-engineering,0.5746863,feature-engineering,0.5746863
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",beta,0.16640052,of,0.43937695,long-short-term,0.33801323
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",bbb,0.23222709,tf-idf,0.34800345,tf-idf,0.34800345
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",alzheimer,0.2948662,memory,0.47752225,semantic,0.47042826
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",ad,0.3459351,memory,0.48189065,semantic,0.46080723
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",acetylcholinesterase,0.25143194,neural,0.42211312,learning-function,0.38074988
"Synthesis and in-vitro anti-HIV-1 evaluation of novel pyrazolo[4,3-c]pyridin-4-one derivatives.",molecular,0.39914468,of,0.516936,clustering,0.43655443
"Synthesis and in-vitro anti-HIV-1 evaluation of novel pyrazolo[4,3-c]pyridin-4-one derivatives.",docking,0.5002512,machine-learning,0.5002512,machine-learning,0.5002512
"Synthesis and in-vitro anti-HIV-1 evaluation of novel pyrazolo[4,3-c]pyridin-4-one derivatives.",data,0.46434748,data,1.0,data-science,0.5533528
"Synthesis and in-vitro anti-HIV-1 evaluation of novel pyrazolo[4,3-c]pyridin-4-one derivatives.",showed,0.20766163,of,0.5296177,regression,0.37027335
"Synthesis and in-vitro anti-HIV-1 evaluation of novel pyrazolo[4,3-c]pyridin-4-one derivatives.",molecular-docking,0.539979,monte-carlo,0.5536084,monte-carlo,0.5536084
"Synthesis and in-vitro anti-HIV-1 evaluation of novel pyrazolo[4,3-c]pyridin-4-one derivatives.",data-showed,0.6093962,data-science,0.65091735,data-science,0.65091735
"Synthesis and in-vitro anti-HIV-1 evaluation of novel pyrazolo[4,3-c]pyridin-4-one derivatives.",synthesized,0.25979662,encoding,0.4240871,generative,0.38417888
"Synthesis and in-vitro anti-HIV-1 evaluation of novel pyrazolo[4,3-c]pyridin-4-one derivatives.",sixteen,0.2943609,one,0.48425114,principal-components,0.33035094
"Synthesis and in-vitro anti-HIV-1 evaluation of novel pyrazolo[4,3-c]pyridin-4-one derivatives.",novel,0.4652171,feature-engineering,0.5132146,feature-engineering,0.5132146
"Synthesis and in-vitro anti-HIV-1 evaluation of novel pyrazolo[4,3-c]pyridin-4-one derivatives.",pyrazolo,0.25803497,centroid-based,0.4408679,centroid-based,0.4408679
"Synthesis and in-vitro anti-HIV-1 evaluation of novel pyrazolo[4,3-c]pyridin-4-one derivatives.",active,0.24791542,of,0.5219437,generative,0.39641887
"Synthesis and in-vitro anti-HIV-1 evaluation of novel pyrazolo[4,3-c]pyridin-4-one derivatives.",compound,0.23029123,component,0.44195548,dimensionality-reduction,0.358908
"Synthesis and in-vitro anti-HIV-1 evaluation of novel pyrazolo[4,3-c]pyridin-4-one derivatives.",xxxc,0.2036378,nearest-neighbors,0.39790544,nearest-neighbors,0.39790544
"Synthesis and in-vitro anti-HIV-1 evaluation of novel pyrazolo[4,3-c]pyridin-4-one derivatives.",binds,0.22607647,encoding,0.4392807,nearest-neighbors,0.36304584
"Synthesis and in-vitro anti-HIV-1 evaluation of novel pyrazolo[4,3-c]pyridin-4-one derivatives.",lead,0.26196307,of,0.48279357,long-short-term,0.38915557
"Synthesis and in-vitro anti-HIV-1 evaluation of novel pyrazolo[4,3-c]pyridin-4-one derivatives.",compound,0.23029123,component,0.44195548,dimensionality-reduction,0.358908
"Synthesis and in-vitro anti-HIV-1 evaluation of novel pyrazolo[4,3-c]pyridin-4-one derivatives.",xxxc,0.2036378,nearest-neighbors,0.39790544,nearest-neighbors,0.39790544
"Synthesis and in-vitro anti-HIV-1 evaluation of novel pyrazolo[4,3-c]pyridin-4-one derivatives.",inhibited,0.15575022,reduction,0.46446392,boosting,0.33858013
"Synthesis and in-vitro anti-HIV-1 evaluation of novel pyrazolo[4,3-c]pyridin-4-one derivatives.",lead-compound,0.35317034,natural-language-processing,0.45483425,natural-language-processing,0.45483425
"Synthesis and in-vitro anti-HIV-1 evaluation of novel pyrazolo[4,3-c]pyridin-4-one derivatives.",xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
"Synthesis and in-vitro anti-HIV-1 evaluation of novel pyrazolo[4,3-c]pyridin-4-one derivatives.",reverse,0.2939736,forward,0.5330905,feature-reduction,0.40937227
"Synthesis and in-vitro anti-HIV-1 evaluation of novel pyrazolo[4,3-c]pyridin-4-one derivatives.",transcriptase,0.28947833,encoding,0.38961834,markov,0.34852383
"Synthesis and in-vitro anti-HIV-1 evaluation of novel pyrazolo[4,3-c]pyridin-4-one derivatives.",reverse-transcriptase,0.29292846,analysis,0.40112054,markov,0.38169888
"Synthesis and in-vitro anti-HIV-1 evaluation of novel pyrazolo[4,3-c]pyridin-4-one derivatives.",therapeutic,0.3659354,of,0.48352462,boosting,0.41573292
"Synthesis and in-vitro anti-HIV-1 evaluation of novel pyrazolo[4,3-c]pyridin-4-one derivatives.",indices,0.35250193,normalization,0.5109062,batch-normalization,0.46939105
"Synthesis and in-vitro anti-HIV-1 evaluation of novel pyrazolo[4,3-c]pyridin-4-one derivatives.",xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
"Synthesis and in-vitro anti-HIV-1 evaluation of novel pyrazolo[4,3-c]pyridin-4-one derivatives.",nucleoside,0.25022095,natural,0.32010648,gradient-descent,0.30909598
"Synthesis and in-vitro anti-HIV-1 evaluation of novel pyrazolo[4,3-c]pyridin-4-one derivatives.",binding,0.27773649,of,0.45710018,nearest-neighbors,0.40653253
"Synthesis and in-vitro anti-HIV-1 evaluation of novel pyrazolo[4,3-c]pyridin-4-one derivatives.",pocket,0.2043832,connected,0.38925976,nearest-neighbors,0.32330766
"Synthesis and in-vitro anti-HIV-1 evaluation of novel pyrazolo[4,3-c]pyridin-4-one derivatives.",nucleoside-binding,0.34879553,encoding,0.4586348,nearest-neighbors,0.36456808
"Synthesis and in-vitro anti-HIV-1 evaluation of novel pyrazolo[4,3-c]pyridin-4-one derivatives.",binding-pocket,0.29964286,nearest-neighbors,0.48335186,nearest-neighbors,0.48335186
"Synthesis and in-vitro anti-HIV-1 evaluation of novel pyrazolo[4,3-c]pyridin-4-one derivatives.",value,0.3544725,of,0.52001536,statistical,0.45314136
"Synthesis and in-vitro anti-HIV-1 evaluation of novel pyrazolo[4,3-c]pyridin-4-one derivatives.",xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
"Synthesis and in-vitro anti-HIV-1 evaluation of novel pyrazolo[4,3-c]pyridin-4-one derivatives.",drug,0.31867066,of,0.44600964,confusion-matrix,0.3956731
"Synthesis and in-vitro anti-HIV-1 evaluation of novel pyrazolo[4,3-c]pyridin-4-one derivatives.",resistant,0.18050076,of,0.43052143,long-short-term,0.3630649
"Synthesis and in-vitro anti-HIV-1 evaluation of novel pyrazolo[4,3-c]pyridin-4-one derivatives.",isolates,0.27859962,one,0.3955537,random-forest,0.36172628
"Synthesis and in-vitro anti-HIV-1 evaluation of novel pyrazolo[4,3-c]pyridin-4-one derivatives.",drug-resistant,0.2775198,recurrent,0.46301708,recurrent-neural-network,0.3741199
"Synthesis and in-vitro anti-HIV-1 evaluation of novel pyrazolo[4,3-c]pyridin-4-one derivatives.",resistant-isolates,0.25097734,selection,0.41240638,long-short-term,0.38276586
"Synthesis and in-vitro anti-HIV-1 evaluation of novel pyrazolo[4,3-c]pyridin-4-one derivatives.",bl,0.22854456,numpy,0.33013538,numpy,0.33013538
"Synthesis and in-vitro anti-HIV-1 evaluation of novel pyrazolo[4,3-c]pyridin-4-one derivatives.",cell,0.2212203,of,0.48460138,generative,0.39753264
"Synthesis and in-vitro anti-HIV-1 evaluation of novel pyrazolo[4,3-c]pyridin-4-one derivatives.",line,0.22275111,of,0.4227432,generative,0.38747817
"Synthesis and in-vitro anti-HIV-1 evaluation of novel pyrazolo[4,3-c]pyridin-4-one derivatives.",bl-cell,0.2745953,recurrent-neural-network,0.4156161,recurrent-neural-network,0.4156161
"Synthesis and in-vitro anti-HIV-1 evaluation of novel pyrazolo[4,3-c]pyridin-4-one derivatives.",cell-line,0.29110092,naive,0.43613467,generative,0.3893816
"Synthesis and in-vitro anti-HIV-1 evaluation of novel pyrazolo[4,3-c]pyridin-4-one derivatives.",find,0.43762296,hidden,0.5052148,feature-selection,0.5006215
"Synthesis and in-vitro anti-HIV-1 evaluation of novel pyrazolo[4,3-c]pyridin-4-one derivatives.",novel,0.4652171,feature-engineering,0.5132146,feature-engineering,0.5132146
"Synthesis and in-vitro anti-HIV-1 evaluation of novel pyrazolo[4,3-c]pyridin-4-one derivatives.",anti,0.114482366,of,0.3963322,boosting,0.31662655
"Synthesis and in-vitro anti-HIV-1 evaluation of novel pyrazolo[4,3-c]pyridin-4-one derivatives.",hiv,0.30580992,natural-language,0.39600608,natural-language,0.39600608
"Synthesis and in-vitro anti-HIV-1 evaluation of novel pyrazolo[4,3-c]pyridin-4-one derivatives.",drug,0.31867066,of,0.44600964,confusion-matrix,0.3956731
"Synthesis and in-vitro anti-HIV-1 evaluation of novel pyrazolo[4,3-c]pyridin-4-one derivatives.",development,0.34732813,generative,0.56588423,generative,0.56588423
"Synthesis and in-vitro anti-HIV-1 evaluation of novel pyrazolo[4,3-c]pyridin-4-one derivatives.",hiv-drug,0.28996533,vector-machine,0.36760616,vector-machine,0.36760616
"Synthesis and in-vitro anti-HIV-1 evaluation of novel pyrazolo[4,3-c]pyridin-4-one derivatives.",drug-development,0.4888755,data-engineering,0.58384275,data-engineering,0.58384275
"Synthesis and in-vitro anti-HIV-1 evaluation of novel pyrazolo[4,3-c]pyridin-4-one derivatives.",subtype,0.27499512,classification,0.5114993,classification,0.5114993
"Synthesis and in-vitro anti-HIV-1 evaluation of novel pyrazolo[4,3-c]pyridin-4-one derivatives.",c,0.17513797,of,0.44327667,gradient,0.31114018
"Synthesis and in-vitro anti-HIV-1 evaluation of novel pyrazolo[4,3-c]pyridin-4-one derivatives.",subtype-c,0.2786557,classification,0.40377155,classification,0.40377155
"Synthesis and in-vitro anti-HIV-1 evaluation of novel pyrazolo[4,3-c]pyridin-4-one derivatives.",compound,0.23029123,component,0.44195548,dimensionality-reduction,0.358908
"Synthesis and in-vitro anti-HIV-1 evaluation of novel pyrazolo[4,3-c]pyridin-4-one derivatives.",xxxc,0.2036378,nearest-neighbors,0.39790544,nearest-neighbors,0.39790544
"Synthesis and in-vitro anti-HIV-1 evaluation of novel pyrazolo[4,3-c]pyridin-4-one derivatives.",lead,0.26196307,of,0.48279357,long-short-term,0.38915557
"Synthesis and in-vitro anti-HIV-1 evaluation of novel pyrazolo[4,3-c]pyridin-4-one derivatives.",compound,0.23029123,component,0.44195548,dimensionality-reduction,0.358908
"Synthesis and in-vitro anti-HIV-1 evaluation of novel pyrazolo[4,3-c]pyridin-4-one derivatives.",lead-compound,0.35317034,natural-language-processing,0.45483425,natural-language-processing,0.45483425
"Synthesis and in-vitro anti-HIV-1 evaluation of novel pyrazolo[4,3-c]pyridin-4-one derivatives.",xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
"Synthesis and in-vitro anti-HIV-1 evaluation of novel pyrazolo[4,3-c]pyridin-4-one derivatives.",synthesized,0.25979662,encoding,0.4240871,generative,0.38417888
"Synthesis and in-vitro anti-HIV-1 evaluation of novel pyrazolo[4,3-c]pyridin-4-one derivatives.",compounds,0.29263198,components,0.5131814,dimensionality-reduction,0.39397755
"Synthesis and in-vitro anti-HIV-1 evaluation of novel pyrazolo[4,3-c]pyridin-4-one derivatives.",xxxc,0.2036378,nearest-neighbors,0.39790544,nearest-neighbors,0.39790544
"Synthesis and in-vitro anti-HIV-1 evaluation of novel pyrazolo[4,3-c]pyridin-4-one derivatives.",may,0.30907542,of,0.58654004,long-short-term,0.43985203
"Synthesis and in-vitro anti-HIV-1 evaluation of novel pyrazolo[4,3-c]pyridin-4-one derivatives.",toa,0.21028385,pytorch,0.39021343,pytorch,0.39021343
"Synthesis and in-vitro anti-HIV-1 evaluation of novel pyrazolo[4,3-c]pyridin-4-one derivatives.",assay,0.28104568,analysis,0.46296048,component-analysis,0.37250015
"Synthesis and in-vitro anti-HIV-1 evaluation of novel pyrazolo[4,3-c]pyridin-4-one derivatives.",subtype,0.27499512,classification,0.5114993,classification,0.5114993
"Synthesis and in-vitro anti-HIV-1 evaluation of novel pyrazolo[4,3-c]pyridin-4-one derivatives.",c,0.17513797,of,0.44327667,gradient,0.31114018
"Synthesis and in-vitro anti-HIV-1 evaluation of novel pyrazolo[4,3-c]pyridin-4-one derivatives.",subtype-c,0.2786557,classification,0.40377155,classification,0.40377155
"Synthesis and in-vitro anti-HIV-1 evaluation of novel pyrazolo[4,3-c]pyridin-4-one derivatives.",subtype,0.27499512,classification,0.5114993,classification,0.5114993
"Synthesis and in-vitro anti-HIV-1 evaluation of novel pyrazolo[4,3-c]pyridin-4-one derivatives.",b,0.19558734,of,0.43435428,short-term-memory,0.31717262
"Synthesis and in-vitro anti-HIV-1 evaluation of novel pyrazolo[4,3-c]pyridin-4-one derivatives.",subtype-b,0.26033032,discriminative,0.4072543,clustering,0.38836962
"Synthesis and in-vitro anti-HIV-1 evaluation of novel pyrazolo[4,3-c]pyridin-4-one derivatives.",study,0.3645851,of,0.5728763,statistical,0.44204497
"Synthesis and in-vitro anti-HIV-1 evaluation of novel pyrazolo[4,3-c]pyridin-4-one derivatives.",indicated,0.2502363,of,0.5998554,principal-components,0.4305639
"Synthesis and in-vitro anti-HIV-1 evaluation of novel pyrazolo[4,3-c]pyridin-4-one derivatives.",rights,0.3170033,adversarial,0.6281444,data-science,0.57488894
"Synthesis and in-vitro anti-HIV-1 evaluation of novel pyrazolo[4,3-c]pyridin-4-one derivatives.",reserved,0.28677964,of,0.4776592,supervised,0.3944377
"Synthesis and in-vitro anti-HIV-1 evaluation of novel pyrazolo[4,3-c]pyridin-4-one derivatives.",pbmc,0.20951746,naive,0.50896466,naive-bayes,0.35101295
"Synthesis and in-vitro anti-HIV-1 evaluation of novel pyrazolo[4,3-c]pyridin-4-one derivatives.",assays,0.28855288,analysis,0.47350433,component-analysis,0.38540024
"Synthesis and in-vitro anti-HIV-1 evaluation of novel pyrazolo[4,3-c]pyridin-4-one derivatives.",pbmc-assays,0.2942328,batch-normalization,0.4344054,batch-normalization,0.4344054
"Synthesis and in-vitro anti-HIV-1 evaluation of novel pyrazolo[4,3-c]pyridin-4-one derivatives.",one,0.335046,one,1.0,one-hot,0.4275648
"Synthesis and in-vitro anti-HIV-1 evaluation of novel pyrazolo[4,3-c]pyridin-4-one derivatives.",derivatives,0.23657987,natural,0.40787905,fourier-transform,0.38673443
"Synthesis and in-vitro anti-HIV-1 evaluation of novel pyrazolo[4,3-c]pyridin-4-one derivatives.",one-derivatives,0.28516227,feature-reduction,0.43281657,feature-reduction,0.43281657
"Synthesis and in-vitro anti-HIV-1 evaluation of novel pyrazolo[4,3-c]pyridin-4-one derivatives.",hiv,0.30580992,natural-language,0.39600608,natural-language,0.39600608
"Synthesis and in-vitro anti-HIV-1 evaluation of novel pyrazolo[4,3-c]pyridin-4-one derivatives.",compounds,0.29263198,components,0.5131814,dimensionality-reduction,0.39397755
"Synthesis and in-vitro anti-HIV-1 evaluation of novel pyrazolo[4,3-c]pyridin-4-one derivatives.",continuing,0.3627778,support,0.57228124,supervised,0.49263102
"Synthesis and in-vitro anti-HIV-1 evaluation of novel pyrazolo[4,3-c]pyridin-4-one derivatives.",efforts,0.4454929,data-engineering,0.5764543,data-engineering,0.5764543
"Synthesis and in-vitro anti-HIV-1 evaluation of novel pyrazolo[4,3-c]pyridin-4-one derivatives.",compounds,0.29263198,components,0.5131814,dimensionality-reduction,0.39397755
"Synthesis and in-vitro anti-HIV-1 evaluation of novel pyrazolo[4,3-c]pyridin-4-one derivatives.",xxxa,0.103940696,encoding,0.28463936,nearest-neighbors,0.2823031
"Synthesis and in-vitro anti-HIV-1 evaluation of novel pyrazolo[4,3-c]pyridin-4-one derivatives.",also,0.32850838,of,0.65908813,clustering,0.45826355
"Synthesis and in-vitro anti-HIV-1 evaluation of novel pyrazolo[4,3-c]pyridin-4-one derivatives.",tested,0.37172255,of,0.5634051,boosting,0.4195229
"Synthesis and in-vitro anti-HIV-1 evaluation of novel pyrazolo[4,3-c]pyridin-4-one derivatives.",hiv,0.30580992,natural-language,0.39600608,natural-language,0.39600608
"Synthesis and in-vitro anti-HIV-1 evaluation of novel pyrazolo[4,3-c]pyridin-4-one derivatives.",activity,0.21813896,function,0.53536034,boosting,0.38798416
"Synthesis and in-vitro anti-HIV-1 evaluation of novel pyrazolo[4,3-c]pyridin-4-one derivatives.",hiv-activity,0.3271271,of,0.46926853,dimensionality-reduction,0.44207707
"Synthesis and in-vitro anti-HIV-1 evaluation of novel pyrazolo[4,3-c]pyridin-4-one derivatives.",xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
"Synthesis and in-vitro anti-HIV-1 evaluation of novel pyrazolo[4,3-c]pyridin-4-one derivatives.",xxxc,0.2036378,nearest-neighbors,0.39790544,nearest-neighbors,0.39790544
"Synthesis and in-vitro anti-HIV-1 evaluation of novel pyrazolo[4,3-c]pyridin-4-one derivatives.",active,0.24791542,of,0.5219437,generative,0.39641887
"Synthesis and in-vitro anti-HIV-1 evaluation of novel pyrazolo[4,3-c]pyridin-4-one derivatives.",lead,0.26196307,of,0.48279357,long-short-term,0.38915557
"Synthesis and in-vitro anti-HIV-1 evaluation of novel pyrazolo[4,3-c]pyridin-4-one derivatives.",subtype,0.27499512,classification,0.5114993,classification,0.5114993
"Synthesis and in-vitro anti-HIV-1 evaluation of novel pyrazolo[4,3-c]pyridin-4-one derivatives.",hiv,0.30580992,natural-language,0.39600608,natural-language,0.39600608
"Synthesis and in-vitro anti-HIV-1 evaluation of novel pyrazolo[4,3-c]pyridin-4-one derivatives.",c,0.17513797,of,0.44327667,gradient,0.31114018
"Synthesis and in-vitro anti-HIV-1 evaluation of novel pyrazolo[4,3-c]pyridin-4-one derivatives.",anti,0.114482366,of,0.3963322,boosting,0.31662655
"Synthesis and in-vitro anti-HIV-1 evaluation of novel pyrazolo[4,3-c]pyridin-4-one derivatives.",activity,0.21813896,function,0.53536034,boosting,0.38798416
"Synthesis and in-vitro anti-HIV-1 evaluation of novel pyrazolo[4,3-c]pyridin-4-one derivatives.",xxxx,0.09755032,confusion-matrix,0.3055646,confusion-matrix,0.3055646
"Synthesis and in-vitro anti-HIV-1 evaluation of novel pyrazolo[4,3-c]pyridin-4-one derivatives.",xxxe,0.22290246,nearest-neighbors,0.38452545,nearest-neighbors,0.38452545
"Synthesis and in-vitro anti-HIV-1 evaluation of novel pyrazolo[4,3-c]pyridin-4-one derivatives.",tzm,0.22172168,xgboost,0.3729261,xgboost,0.3729261
"Synthesis and in-vitro anti-HIV-1 evaluation of novel pyrazolo[4,3-c]pyridin-4-one derivatives.",thus,0.33923393,of,0.6779618,feature-reduction,0.46172875
"Synthesis and in-vitro anti-HIV-1 evaluation of novel pyrazolo[4,3-c]pyridin-4-one derivatives.",screened,0.29842114,of,0.48161656,feature-selection,0.35251057
"Synthesis and in-vitro anti-HIV-1 evaluation of novel pyrazolo[4,3-c]pyridin-4-one derivatives.",rxxx,0.21442181,nearest-neighbors,0.32775986,nearest-neighbors,0.32775986
"Synthesis and in-vitro anti-HIV-1 evaluation of novel pyrazolo[4,3-c]pyridin-4-one derivatives.",respectively,0.23184536,of,0.43360457,cross-validation,0.35765702
"Synthesis and in-vitro anti-HIV-1 evaluation of novel pyrazolo[4,3-c]pyridin-4-one derivatives.",pyridin,0.22527397,centroid-based,0.40994835,centroid-based,0.40994835
"Synthesis and in-vitro anti-HIV-1 evaluation of novel pyrazolo[4,3-c]pyridin-4-one derivatives.",non,0.2869836,of,0.5523051,generative,0.4181043
"Synthesis and in-vitro anti-HIV-1 evaluation of novel pyrazolo[4,3-c]pyridin-4-one derivatives.",nnrti,0.27206218,naive-bayes,0.3663888,naive-bayes,0.3663888
"Synthesis and in-vitro anti-HIV-1 evaluation of novel pyrazolo[4,3-c]pyridin-4-one derivatives.",nih,0.2189587,data-science,0.4197886,data-science,0.4197886
"Synthesis and in-vitro anti-HIV-1 evaluation of novel pyrazolo[4,3-c]pyridin-4-one derivatives.",nari,0.25860217,nearest,0.40132722,feature-selection,0.3700527
"Synthesis and in-vitro anti-HIV-1 evaluation of novel pyrazolo[4,3-c]pyridin-4-one derivatives.",found,0.2840244,of,0.6208722,clustering,0.44675255
"Synthesis and in-vitro anti-HIV-1 evaluation of novel pyrazolo[4,3-c]pyridin-4-one derivatives.",explored,0.42671436,of,0.58866113,feature-engineering,0.5368307
"Synthesis and in-vitro anti-HIV-1 evaluation of novel pyrazolo[4,3-c]pyridin-4-one derivatives.",effectively,0.35745823,fully,0.574593,boosting,0.5027187
"Synthesis and in-vitro anti-HIV-1 evaluation of novel pyrazolo[4,3-c]pyridin-4-one derivatives.",dr,0.20867819,bag,0.39944318,dropout,0.39934647
"Synthesis and in-vitro anti-HIV-1 evaluation of novel pyrazolo[4,3-c]pyridin-4-one derivatives.",considered,0.36321384,of,0.60548925,feature-reduction,0.4442021
"Synthesis and in-vitro anti-HIV-1 evaluation of novel pyrazolo[4,3-c]pyridin-4-one derivatives.",confirmed,0.25544786,of,0.58156097,component-analysis,0.390182
"Synthesis and in-vitro anti-HIV-1 evaluation of novel pyrazolo[4,3-c]pyridin-4-one derivatives.",br,0.17463417,ground,0.35063016,long-short-term,0.3162698
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",trypanocidal,0.2558999,natural,0.35268313,centroid-based,0.3323509
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",drugs,0.30897486,of,0.42460242,classifiers,0.33720028
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",four,0.34899807,one,0.769816,clustering,0.40005642
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",decades,0.37954253,few,0.53506094,data-engineering,0.45851755
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",ago,0.29406425,few,0.51532215,confusion-matrix,0.34322655
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",four-decades,0.4480701,artificial-intelligence,0.55304885,artificial-intelligence,0.55304885
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",dependent,0.2523393,of,0.585135,generative,0.43066898
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",cell,0.2212203,of,0.48460138,generative,0.39753264
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",defense,0.23818627,natural,0.44203517,generative,0.44030827
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",mechanism,0.2780391,cascade,0.59194523,feed-forward,0.5341974
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",dependent-cell,0.3871494,generative,0.50081503,generative,0.50081503
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",cell-defense,0.25322747,natural,0.44489506,feature-engineering,0.43872744
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",defense-mechanism,0.39010847,generative,0.511776,generative,0.511776
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",group,0.26103544,of,0.44356787,statistical,0.3923795
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",previously,0.31365848,fully,0.5461891,long-short-term,0.40718085
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",reported,0.27641866,of,0.6039252,long-short-term,0.38086164
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",memantine,0.3145209,memory,0.44772062,learning-function,0.41914505
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",previously-reported,0.35520288,of,0.54962975,feature-reduction,0.4772153
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",increased,0.26921988,reduction,0.6514183,boosting,0.46515882
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",survival,0.29004025,short-term,0.53135407,long-short-term,0.4573617
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",rate,0.24866687,rate,1.0,dropout,0.44953537
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",survival-rate,0.35821748,rate,0.5591353,learning-rate,0.5378479
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",glutamate,0.2451506,learning-rate,0.37607485,learning-rate,0.37607485
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",receptor,0.22411162,function,0.41526195,clustering,0.36801085
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",antagonist,0.21628487,discriminative,0.38467538,feed-forward,0.30425376
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",glutamate-receptor,0.27081782,feed-forward,0.41181934,feed-forward,0.41181934
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",receptor-antagonist,0.22789916,discriminative,0.38973045,feed-forward,0.35338134
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",glutamate-receptor-antagonist,0.24956453,feed-forward,0.41414428,feed-forward,0.41414428
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",central,0.26715183,connected,0.51433957,segmentation,0.35878396
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",nervous,0.27056697,neural,0.6121676,recurrent-neural-network,0.40811306
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",system,0.3589455,generative-model,0.49815983,generative-model,0.49815983
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",central-nervous,0.36151135,neural,0.57494175,recurrent-neural-network,0.5184515
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",nervous-system,0.27770603,neural,0.51351804,generative-model,0.43068177
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",central-nervous-system,0.3520585,neural,0.5314915,recurrent-neural-network,0.5033282
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",cardiac,0.29562658,of,0.42777455,long-short-term,0.35708636
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",parasitic,0.25722092,pytorch,0.4094401,pytorch,0.4094401
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",load,0.29914707,machine,0.46254036,short-term-memory,0.43765795
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",c,0.17513797,of,0.44327667,gradient,0.31114018
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",mice,0.24457785,naive,0.4783403,short-term-memory,0.38200378
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",c-mice,0.21124294,naive,0.46040308,short-term-memory,0.36919817
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",serious,0.27903804,recurrent,0.53278255,overfitting,0.43550265
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",side,0.16146374,connected,0.47764254,feature-reduction,0.35291326
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",effects,0.2624804,short-term,0.63497096,long-short-term,0.5306107
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",side-effects,0.22787218,short-term,0.49080825,dropout,0.45228943
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",serious-side-effects,0.31090188,short-term,0.53443843,dropout,0.51875913
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",neglected,0.360484,hidden,0.5655441,dimensionality-reduction,0.4641359
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",tropical,0.34496617,forest,0.64757335,random-forest,0.5536428
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",disease,0.296938,recurrent,0.4731025,classification,0.35271814
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",tropical-disease,0.5077183,random-forest,0.61241376,random-forest,0.61241376
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",million,0.28250343,federated,0.40785158,data-science,0.3504573
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",people,0.36805943,natural-language,0.4770279,natural-language,0.4770279
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",million-people,0.39395738,random-forest,0.5415114,random-forest,0.5415114
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",results,0.32376552,data,0.6932311,batch-normalization,0.44826904
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",indicate,0.24175897,data,0.567966,long-short-term,0.36935285
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",memantine,0.3145209,memory,0.44772062,learning-function,0.41914505
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",results-indicate,0.34559378,data,0.5741026,component-analysis,0.46714354
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",trypanocidal,0.2558999,natural,0.35268313,centroid-based,0.3323509
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",drug,0.31867066,of,0.44600964,confusion-matrix,0.3956731
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",infected,0.19365644,naive,0.53080636,boosting,0.33861458
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",people,0.36805943,natural-language,0.4770279,natural-language,0.4770279
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",infected-people,0.41464895,naive,0.53832906,support-vector-machine,0.48804325
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",infected,0.19365644,naive,0.53080636,boosting,0.33861458
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",mice,0.24457785,naive,0.4783403,short-term-memory,0.38200378
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",infected-mice,0.23909745,naive,0.5644298,logistic-regression,0.3626362
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",raw,0.35584602,processing,0.48935872,graphics-processing,0.4796581
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",affects,0.21790305,of,0.5773267,long-short-term,0.4001173
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",two,0.35955608,one,0.79919666,clustering,0.43817294
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",compounds,0.29263198,components,0.5131814,dimensionality-reduction,0.39397755
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",present,0.39618495,of,0.63723874,generative,0.48216146
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",work,0.42713583,support,0.5373766,learning-function,0.5011815
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",present-work,0.47764665,style,0.5799788,artificial-intelligence,0.5701526
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",limited,0.33893847,of,0.6210327,long-short-term,0.4736513
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",due,0.21681537,of,0.5734476,confusion-matrix,0.40250766
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",like,0.32318482,of,0.5448733,relu,0.44626954
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",death,0.21479979,of,0.42234862,dropout,0.37818787
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",led,0.28597406,of,0.6366651,boosting,0.411306
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",us,0.36534783,decision,0.49831933,segmentation,0.39571765
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",inflammatory,0.19824001,cascade,0.43951106,generative-model,0.38795525
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",infiltrates,0.24492311,recurrent,0.42701834,confusion-matrix,0.3531012
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",induce,0.22574255,boosting,0.40946308,boosting,0.40946308
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",apoptosis,0.22776133,cascade,0.46111506,feed-forward,0.37718636
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",induce-apoptosis,0.30253816,cascade,0.46402347,feed-forward,0.43669513
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",endemic,0.2917105,forest,0.5462816,random-forest,0.50315607
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",areas,0.3090546,forest,0.4990691,ground-truth,0.40763968
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",endemic-areas,0.35071605,forest,0.57237697,random-forest,0.52715194
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",eliminate,0.32978988,hidden,0.5348174,feature-reduction,0.47195923
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",parasitemia,0.20866083,naive,0.37580773,batch-normalization,0.33162525
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",diminished,0.2149298,reduction,0.48049104,bagging,0.41987002
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",parasitemia,0.20866083,naive,0.37580773,batch-normalization,0.33162525
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",chronic,0.22727785,recurrent,0.5279353,long-short-term,0.4292153
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",phase,0.23814097,hidden-layer,0.45645207,hidden-layer,0.45645207
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",chronic-phase,0.28850454,naive,0.4678502,short-term-memory,0.4239459
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",chemotherapy,0.29346144,recurrent,0.43819082,boosting,0.36939314
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",relies,0.45707843,of,0.5722904,stochastic,0.5493108
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",chagas,0.31366038,pytorch,0.3762825,pytorch,0.3762825
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",disease,0.296938,recurrent,0.4731025,classification,0.35271814
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",avoid,0.30152878,hidden,0.53045076,overfitting,0.52457714
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",seroconversion,0.27852398,boosting,0.4672656,boosting,0.4672656
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",acute,0.21222305,short-term,0.51624244,long-short-term,0.3867746
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",phase,0.23814097,hidden-layer,0.45645207,hidden-layer,0.45645207
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",acute-phase,0.21243435,normalization,0.39054164,component-analysis,0.35816562
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",treated,0.19958335,of,0.5218221,long-short-term,0.35705733
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",mice,0.24457785,naive,0.4783403,short-term-memory,0.38200378
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",treated-mice,0.17886013,naive,0.46874863,logistic-regression,0.3702259
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",macrophages,0.20754936,naive,0.47024828,short-term-memory,0.3296041
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",candidate,0.35861892,encoding,0.51264024,feature-selection,0.4453258
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",drug,0.31867066,of,0.44600964,confusion-matrix,0.3956731
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",candidate-drug,0.43431538,bayesian-network,0.45063326,bayesian-network,0.45063326
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",trypanosoma,0.27160162,random-forest,0.36912715,random-forest,0.36912715
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",cruzi,0.25767118,pytorch,0.34306636,pytorch,0.34306636
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",trypanosoma-cruzi,0.32827088,random-forest,0.38619387,random-forest,0.38619387
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",taken,0.31208742,data,0.5517592,supervised,0.41763523
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",together,0.37164533,data,0.5860126,principal-components,0.4491613
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",taken-together,0.4277146,of,0.53769875,generative,0.5296056
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",oxidant,0.19247721,cascade,0.4706978,feature-reduction,0.4088564
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",non,0.2869836,of,0.5523051,generative,0.4181043
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",also,0.32850838,of,0.65908813,clustering,0.45826355
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",able,0.41518557,fully,0.6125249,bagging,0.45371854
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",activated,0.22293405,cascade,0.52779776,boosting,0.39110917
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",cells,0.20327199,naive,0.5115537,generative,0.40616876
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",activated-cells,0.23198052,naive,0.46437567,stochastic-gradient,0.4301158
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",drugs,0.30897486,of,0.42460242,classifiers,0.33720028
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",memantine,0.3145209,memory,0.44772062,learning-function,0.41914505
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",results,0.32376552,data,0.6932311,batch-normalization,0.44826904
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",effects,0.2624804,short-term,0.63497096,long-short-term,0.5306107
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",disease,0.296938,recurrent,0.4731025,classification,0.35271814
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",drug,0.31867066,of,0.44600964,confusion-matrix,0.3956731
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",treated,0.19958335,of,0.5218221,long-short-term,0.35705733
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",together,0.37164533,data,0.5860126,principal-components,0.4491613
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",non,0.2869836,of,0.5523051,generative,0.4181043
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",macrophages,0.20754936,naive,0.47024828,short-term-memory,0.3296041
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",cruzi,0.25767118,pytorch,0.34306636,pytorch,0.34306636
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",activated,0.22293405,cascade,0.52779776,boosting,0.39110917
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",able,0.41518557,fully,0.6125249,bagging,0.45371854
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",vivo,0.31561637,of,0.48691544,generative-model,0.4255858
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",used,0.46049535,of,0.5630944,generative-model,0.4901716
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",use,0.43753043,of,0.5506158,feature-reduction,0.49910897
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",treatment,0.239264,short-term,0.5206091,long-short-term,0.41699445
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",time,0.31186903,long,0.57547164,batch-normalization,0.47628766
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",showed,0.20766163,of,0.5296177,regression,0.37027335
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",reduce,0.314935,reduction,0.63468504,boosting,0.4613787
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",proposed,0.55786884,classification-algorithm,0.6311488,classification-algorithm,0.6311488
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",propose,0.5486929,convolutional,0.57577854,convolutional,0.57577854
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",pro,0.2456424,data,0.39269125,computer-vision,0.33552143
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",presently,0.37623656,fully,0.55780846,bagging,0.46902514
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",nifurtimox,0.20299008,pytorch,0.31478232,pytorch,0.31478232
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",mammals,0.2980944,of,0.46694326,generative,0.43947917
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",majority,0.29875737,few,0.59443223,clustering,0.40575084
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",lps,0.222569,naive,0.38258457,nlp,0.31730148
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",investigated,0.30147675,of,0.6179704,generative-model,0.42952073
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",infection,0.22309746,recurrent,0.4494667,boosting,0.3635876
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",however,0.31437585,few,0.63182676,statistical,0.44065386
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",finally,0.426572,of,0.64012104,generative,0.48128563
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",fact,0.34625313,of,0.6460043,generative,0.49380827
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",entry,0.22865202,tracking,0.4080185,clustering,0.37071088
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",diminish,0.23644793,reduction,0.492767,boosting,0.44610262
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",diagnosed,0.29304254,recurrent,0.56110895,classification,0.43035528
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",caused,0.14436965,of,0.53973085,long-short-term,0.3204536
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",cases,0.31566036,recurrent,0.52791375,classification,0.4471408
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",benznidazole,0.22181757,naive,0.34804404,pytorch,0.30252564
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",balb,0.17646977,naive,0.4226891,feature-selection,0.31157422
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",americas,0.3200832,federated,0.55974674,random-forest,0.4703853
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",alzheimer,0.2948662,memory,0.47752225,semantic,0.47042826
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",addition,0.30500388,of,0.6910241,feature-reduction,0.48914018
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",activate,0.24475634,cascade,0.56470346,feed-forward,0.45859116
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,oa,0.1941249,principal-components,0.3359616,principal-components,0.3359616
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,groups,0.2727722,statistical,0.4438421,statistical,0.4438421
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,received,0.24654314,one,0.48884487,supervised,0.36404985
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,three,0.36911732,one,0.78425425,clustering,0.4299444
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,different,0.37681934,of,0.61590904,clustering,0.46857932
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,doses,0.1979529,of,0.43779314,boosting,0.42837995
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,oa-groups,0.228656,principal-components,0.45098612,principal-components,0.45098612
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,three-different,0.4282337,convolutional-layer,0.5688442,convolutional-layer,0.5688442
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,different-doses,0.28510445,short-term,0.48818493,dimensionality-reduction,0.47458357
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,traditional,0.49153316,style,0.54303825,dimensionality-reduction,0.5295658
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,chinese,0.30536085,descent,0.43883425,natural-language,0.37194043
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,drug,0.31867066,of,0.44600964,confusion-matrix,0.3956731
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,usually,0.3236929,few,0.6587015,confusion-matrix,0.46715134
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,used,0.46049535,of,0.5630944,generative-model,0.4901716
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,chinese-drug,0.43227133,natural-language,0.5062152,natural-language,0.5062152
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,drug-usually,0.34206095,reinforcement-learning,0.5212501,reinforcement-learning,0.5212501
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,usually-used,0.47684133,dimensionality-reduction,0.5624513,dimensionality-reduction,0.5624513
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,examined,0.295101,of,0.66699874,generative,0.4320032
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,using,0.47332245,analysis,0.5968549,component-analysis,0.526608
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,recombinant,0.27811894,encoding,0.5492526,boosting,0.43946618
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,human,0.30336243,of,0.5175895,feature-engineering,0.40631005
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,il,0.17175047,monte,0.3419046,monte,0.3419046
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,examined-using,0.44385695,supervised,0.5225858,supervised,0.5225858
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,recombinant-human,0.31756264,vector,0.50917757,vector-machine,0.44663042
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,assessed,0.33986524,of,0.605934,component-analysis,0.41855076
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,using,0.47332245,analysis,0.5968549,component-analysis,0.526608
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,histopathological,0.320109,classification,0.4345668,classification,0.4345668
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,examinations,0.30714858,computer,0.4691918,computer-vision,0.46816713
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,histopathological-examinations,0.40444317,classification,0.50907785,classification,0.50907785
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,arthritic,0.22624357,naive,0.39563054,generative-model,0.34881705
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,potential,0.3558654,of,0.5645705,generative-model,0.46479023
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,remains,0.24202663,fully,0.5171005,bagging,0.35608193
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,unexplored,0.34693655,hidden,0.5300567,feature-engineering,0.47666925
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,signaling,0.29640946,cascade,0.70725644,feed-forward,0.5819744
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,pathways,0.30476987,cascade,0.6938149,feed-forward,0.5254793
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,signaling-pathways,0.33893383,cascade,0.69794536,feed-forward,0.5998782
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,treat,0.32386008,recurrent,0.48263934,generative-model,0.36353803
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,cardiovascular,0.31674606,short-term,0.442761,learning-function,0.4027721
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,diseases,0.31957155,recurrent,0.41244444,classification,0.40266854
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,cardiovascular-diseases,0.3900246,learning-function,0.41476324,learning-function,0.41476324
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,novel,0.4652171,feature-engineering,0.5132146,feature-engineering,0.5132146
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,therapeutic,0.3659354,of,0.48352462,boosting,0.41573292
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,strategy,0.47490904,feature-engineering,0.59725416,feature-engineering,0.59725416
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,novel-therapeutic,0.43810356,feature-engineering,0.4684654,feature-engineering,0.4684654
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,normal,0.22889833,function,0.57724285,batch-normalization,0.4663512
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,control,0.27050394,of,0.5093193,artificial-intelligence,0.40948874
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,group,0.26103544,of,0.44356787,statistical,0.3923795
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,normal-control,0.3262686,batch-normalization,0.49163336,batch-normalization,0.49163336
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,control-group,0.2875058,statistical,0.4468634,statistical,0.4468634
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,normal-control-group,0.31090784,batch-normalization,0.43850052,batch-normalization,0.43850052
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,chondrocyte,0.24607936,matrix,0.55121666,data-augmentation,0.40095326
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,apoptosis,0.22776133,cascade,0.46111506,feed-forward,0.37718636
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,observed,0.23725806,of,0.64367145,long-short-term,0.4519785
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,vivo,0.31561637,of,0.48691544,generative-model,0.4255858
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,results,0.32376552,data,0.6932311,batch-normalization,0.44826904
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,indicate,0.24175897,data,0.567966,long-short-term,0.36935285
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,vivo-results,0.32778013,data,0.45388204,short-term-memory,0.38289994
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,results-indicate,0.34559378,data,0.5741026,component-analysis,0.46714354
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,vivo,0.31561637,of,0.48691544,generative-model,0.4255858
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,chondroprotective,0.26208615,natural,0.4285906,feature-engineering,0.38899392
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,effects,0.2624804,short-term,0.63497096,long-short-term,0.5306107
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,inflammatory,0.19824001,cascade,0.43951106,generative-model,0.38795525
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,factor,0.23388772,component,0.48280093,principal-components,0.43733668
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,secretion,0.20700249,of,0.43475774,boosting,0.36509198
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,factor-secretion,0.23369408,cascade,0.44592065,feed-forward,0.42668998
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,primary,0.24268678,principal,0.5205563,long-short-term,0.38049072
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,rabbit,0.16680475,model,0.41564065,generative-model,0.30841333
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,chondrocytes,0.21896526,matrix,0.53694165,feature-engineering,0.3476789
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,oa,0.1941249,principal-components,0.3359616,principal-components,0.3359616
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,may,0.30907542,of,0.58654004,long-short-term,0.43985203
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,arthritic,0.22624357,naive,0.39563054,generative-model,0.34881705
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,effect,0.21449387,short-term,0.5886732,long-short-term,0.47619703
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,rabbit,0.16680475,model,0.41564065,generative-model,0.30841333
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,chondrocytes,0.21896526,matrix,0.53694165,feature-engineering,0.3476789
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,protective,0.2287128,boosting,0.50660264,boosting,0.50660264
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,effects,0.2624804,short-term,0.63497096,long-short-term,0.5306107
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,protective-effects,0.32767677,dimensionality-reduction,0.5807179,dimensionality-reduction,0.5807179
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,vivo,0.31561637,of,0.48691544,generative-model,0.4255858
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,studies,0.30135098,data,0.6349237,component-analysis,0.41327482
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,vivo-studies,0.38369304,data,0.49670026,feature-engineering,0.4581967
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,weeks,0.22652107,term,0.52859676,supervised,0.4119058
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,h,0.19856977,short-term,0.43919927,long-short-term,0.36116964
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,western,0.2369854,analysis,0.4211278,component-analysis,0.34579337
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,blotting,0.27866253,analysis,0.5003886,fourier-transform,0.39758992
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,western-blotting,0.30329487,analysis,0.48630443,fourier-transform,0.40190244
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,rights,0.3170033,adversarial,0.6281444,data-science,0.57488894
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,reserved,0.28677964,of,0.4776592,supervised,0.3944377
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,randomly,0.3220343,random,0.6551696,supervised,0.44383815
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,divided,0.31782648,one,0.5082367,classification,0.4014557
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,partially,0.20260045,fully,0.7885939,feature-reduction,0.4023255
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,regulated,0.24979803,encoding,0.5367844,feed-forward,0.4816816
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,main,0.3070703,principal,0.7875631,principal-components,0.51314574
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,methods,0.50049126,data,0.5400177,machine-learning,0.50049126
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,key,0.35973132,principal,0.614877,feature-engineering,0.498355
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,findings,0.35685748,data,0.65714294,component-analysis,0.38599753
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,key-findings,0.5931077,object-tracking,0.6275683,object-tracking,0.6275683
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,immunohistochemical,0.33600363,analysis,0.475901,embeddings,0.40712407
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,analysis,0.46507934,analysis,0.99999994,component-analysis,0.69613737
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,immunohistochemical-analysis,0.42580518,analysis,0.60065156,component-analysis,0.5584529
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,elsevier,0.26603332,science,0.59524655,data-science,0.53140587
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,inc,0.2706048,bag,0.52860194,bagging,0.41463643
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,broad,0.27333328,of,0.4837885,generative,0.4327035
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,range,0.23189357,linear,0.4532097,gradient,0.36315575
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,broad-range,0.3185445,of,0.43773806,gradient,0.40987515
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,apoptotic,0.25514302,cascade,0.43370223,feed-forward,0.35026777
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,caspase,0.2243264,cascade,0.44918996,feed-forward,0.3468899
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,apoptotic,0.25514302,cascade,0.43370223,feed-forward,0.35026777
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,bcl,0.22315072,long-short,0.3319453,nlp,0.32178164
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,protective,0.2287128,boosting,0.50660264,boosting,0.50660264
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,effect,0.21449387,short-term,0.5886732,long-short-term,0.47619703
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,protective-effect,0.31665024,dimensionality-reduction,0.5765328,dimensionality-reduction,0.5765328
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,inhibitory,0.23645243,feed-forward,0.48216188,feed-forward,0.48216188
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,effect,0.21449387,short-term,0.5886732,long-short-term,0.47619703
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,inhibitory-effect,0.38574862,feed-forward,0.5643095,feed-forward,0.5643095
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,dap,0.22795233,backpropagation,0.35100242,backpropagation,0.35100242
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,inhibits,0.17305002,of,0.43557078,feed-forward,0.37403423
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,dap,0.22795233,backpropagation,0.35100242,backpropagation,0.35100242
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,exerts,0.16802764,function,0.45056513,feed-forward,0.39651316
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,groups,0.2727722,statistical,0.4438421,statistical,0.4438421
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,oa,0.1941249,principal-components,0.3359616,principal-components,0.3359616
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,il,0.17175047,monte,0.3419046,monte,0.3419046
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,inflammatory,0.19824001,cascade,0.43951106,generative-model,0.38795525
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,chondrocytes,0.21896526,matrix,0.53694165,feature-engineering,0.3476789
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,effect,0.21449387,short-term,0.5886732,long-short-term,0.47619703
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,dap,0.22795233,backpropagation,0.35100242,backpropagation,0.35100242
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,studies,0.30135098,data,0.6349237,component-analysis,0.41327482
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,vitro,0.292481,of,0.48112682,generative,0.40355864
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,tumor,0.23345715,of,0.4070977,regression,0.3830863
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,treatment,0.239264,short-term,0.5206091,long-short-term,0.41699445
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,suppression,0.24727267,reduction,0.62000287,boosting,0.50863206
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,study,0.3645851,of,0.5728763,statistical,0.44204497
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,stimulates,0.19210768,of,0.45062223,boosting,0.4109764
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,significance,0.39249778,statistical,0.67423874,statistical,0.67423874
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,rabbits,0.19050285,artificial,0.3786502,one-shot,0.3284272
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,qrt,0.33531904,analysis,0.44826728,principal-component-analysis,0.42198378
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,published,0.42179614,data,0.6147139,data-science,0.54664624
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,provides,0.41792372,of,0.5261056,feature-engineering,0.4872959
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,prospects,0.40447006,engineering,0.60600424,data-engineering,0.57898223
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,production,0.266738,of,0.51767635,boosting,0.46983936
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,pro,0.2456424,data,0.39269125,computer-vision,0.33552143
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,pcr,0.34162766,analysis,0.4623741,logistic-regression,0.38891542
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,osteoarthritis,0.2692076,principal-components,0.34760445,principal-components,0.34760445
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,nf,0.24335094,nlp,0.37041497,nlp,0.37041497
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,neuro,0.24705967,confusion,0.48527092,confusion-matrix,0.33782724
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,mmps,0.28088403,matrix,0.66546273,confusion-matrix,0.48739702
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,mmp,0.2710026,matrix,0.6562914,confusion-matrix,0.4965623
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,mapk,0.2536896,cascade,0.59739983,feed-forward,0.45056283
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,investigate,0.3396353,of,0.48247698,feature-engineering,0.41061842
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,insecticidal,0.28423208,vector,0.41806963,data-engineering,0.382899
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,inhibition,0.21671593,reduction,0.58642584,feed-forward,0.44581953
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,induced,0.2259351,of,0.5615651,boosting,0.4303583
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,however,0.31437585,few,0.63182676,statistical,0.44065386
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,expression,0.32038707,encoding,0.59633577,clustering,0.442253
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,decrease,0.23670179,reduction,0.82910776,boosting,0.45522925
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,daphnetin,0.2342267,natural,0.29531986,decision-tree,0.25972268
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,confirmed,0.25544786,of,0.58156097,component-analysis,0.390182
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,bax,0.1970664,matrix,0.3551219,confusion-matrix,0.34598172
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,bacterial,0.29734546,of,0.48457187,feature-reduction,0.40325
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,authors,0.45811802,data,0.5259881,natural-language-processing,0.4706872
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,attributed,0.19565767,of,0.5502684,feature-reduction,0.408891
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,antioxidant,0.28505206,natural,0.41360974,learning-function,0.37605202
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,anti,0.114482366,of,0.3963322,boosting,0.31662655
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,akt,0.21248668,cascade,0.47864795,feed-forward,0.41708446
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,aims,0.42995954,of,0.465683,feature-engineering,0.4555406
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,aim,0.4029312,feature-engineering,0.41751927,feature-engineering,0.41751927
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,activation,0.23066127,cascade,0.649269,feed-forward,0.4652444
Perioperative use of renin-angiotensin system inhibitors and outcomes in patients undergoing cardiac surgery.,term,0.33795053,term,1.0,long-short-term,0.62770975
Perioperative use of renin-angiotensin system inhibitors and outcomes in patients undergoing cardiac surgery.,survival,0.29004025,short-term,0.53135407,long-short-term,0.4573617
Perioperative use of renin-angiotensin system inhibitors and outcomes in patients undergoing cardiac surgery.,among,0.33676732,of,0.57348,clustering,0.49404603
Perioperative use of renin-angiotensin system inhibitors and outcomes in patients undergoing cardiac surgery.,patients,0.30007,recurrent,0.5332828,dropout,0.3918751
Perioperative use of renin-angiotensin system inhibitors and outcomes in patients undergoing cardiac surgery.,undergoing,0.27656338,short-term,0.4795418,long-short-term,0.4059016
Perioperative use of renin-angiotensin system inhibitors and outcomes in patients undergoing cardiac surgery.,cardiac,0.29562658,of,0.42777455,long-short-term,0.35708636
Perioperative use of renin-angiotensin system inhibitors and outcomes in patients undergoing cardiac surgery.,surgery,0.29565036,recurrent,0.47230634,computer-vision,0.40172684
Perioperative use of renin-angiotensin system inhibitors and outcomes in patients undergoing cardiac surgery.,term-survival,0.35680708,term,0.51277125,long-short-term,0.46569207
Perioperative use of renin-angiotensin system inhibitors and outcomes in patients undergoing cardiac surgery.,patients-undergoing,0.33248952,recurrent,0.5009053,segmentation-algorithm,0.42138797
Perioperative use of renin-angiotensin system inhibitors and outcomes in patients undergoing cardiac surgery.,cardiac-surgery,0.31080824,short-term,0.4062077,supervised,0.40335953
Perioperative use of renin-angiotensin system inhibitors and outcomes in patients undergoing cardiac surgery.,patients,0.30007,recurrent,0.5332828,dropout,0.3918751
Perioperative use of renin-angiotensin system inhibitors and outcomes in patients undergoing cardiac surgery.,undergoing,0.27656338,short-term,0.4795418,long-short-term,0.4059016
Perioperative use of renin-angiotensin system inhibitors and outcomes in patients undergoing cardiac surgery.,coronary,0.25158757,of,0.3349695,segmentation-algorithm,0.31949025
Perioperative use of renin-angiotensin system inhibitors and outcomes in patients undergoing cardiac surgery.,artery,0.24677014,augmentation,0.4092986,regression,0.358252
Perioperative use of renin-angiotensin system inhibitors and outcomes in patients undergoing cardiac surgery.,bypass,0.25634742,augmentation,0.3651942,data-augmentation,0.34456706
Perioperative use of renin-angiotensin system inhibitors and outcomes in patients undergoing cardiac surgery.,graft,0.20611003,augmentation,0.47663623,data-augmentation,0.3842535
Perioperative use of renin-angiotensin system inhibitors and outcomes in patients undergoing cardiac surgery.,patients-undergoing,0.33248952,recurrent,0.5009053,segmentation-algorithm,0.42138797
Perioperative use of renin-angiotensin system inhibitors and outcomes in patients undergoing cardiac surgery.,coronary-artery,0.26203495,short-term,0.35952243,segmentation-algorithm,0.3447641
Perioperative use of renin-angiotensin system inhibitors and outcomes in patients undergoing cardiac surgery.,artery-bypass,0.26528722,data-augmentation,0.3949672,data-augmentation,0.3949672
Perioperative use of renin-angiotensin system inhibitors and outcomes in patients undergoing cardiac surgery.,bypass-graft,0.24493018,augmentation,0.44620183,data-augmentation,0.40486866
Perioperative use of renin-angiotensin system inhibitors and outcomes in patients undergoing cardiac surgery.,coronary-artery-bypass,0.2793821,segmentation-algorithm,0.37145966,segmentation-algorithm,0.37145966
Perioperative use of renin-angiotensin system inhibitors and outcomes in patients undergoing cardiac surgery.,artery-bypass-graft,0.26983583,augmentation,0.43530148,data-augmentation,0.42571285
Perioperative use of renin-angiotensin system inhibitors and outcomes in patients undergoing cardiac surgery.,multicenter,0.3527286,data,0.45474106,data-science,0.40863585
Perioperative use of renin-angiotensin system inhibitors and outcomes in patients undergoing cardiac surgery.,retrospective,0.41400534,data,0.524399,logistic-regression,0.49798495
Perioperative use of renin-angiotensin system inhibitors and outcomes in patients undergoing cardiac surgery.,cohort,0.3892265,logistic-regression,0.5412916,logistic-regression,0.5412916
Perioperative use of renin-angiotensin system inhibitors and outcomes in patients undergoing cardiac surgery.,study,0.3645851,of,0.5728763,statistical,0.44204497
Perioperative use of renin-angiotensin system inhibitors and outcomes in patients undergoing cardiac surgery.,examines,0.3704751,of,0.5396682,generative,0.4880385
Perioperative use of renin-angiotensin system inhibitors and outcomes in patients undergoing cardiac surgery.,association,0.32292235,regression,0.5094141,regression,0.5094141
Perioperative use of renin-angiotensin system inhibitors and outcomes in patients undergoing cardiac surgery.,multicenter-retrospective,0.4413221,data,0.51395905,decision-tree,0.47693127
Perioperative use of renin-angiotensin system inhibitors and outcomes in patients undergoing cardiac surgery.,retrospective-cohort,0.43706983,logistic-regression,0.5578455,logistic-regression,0.5578455
Perioperative use of renin-angiotensin system inhibitors and outcomes in patients undergoing cardiac surgery.,cohort-study,0.4088606,logistic-regression,0.6062193,logistic-regression,0.6062193
Perioperative use of renin-angiotensin system inhibitors and outcomes in patients undergoing cardiac surgery.,study-examines,0.45829496,natural-language,0.5188885,natural-language,0.5188885
Perioperative use of renin-angiotensin system inhibitors and outcomes in patients undergoing cardiac surgery.,term,0.33795053,term,1.0,long-short-term,0.62770975
Perioperative use of renin-angiotensin system inhibitors and outcomes in patients undergoing cardiac surgery.,mortality,0.2609817,short-term,0.505676,logistic-regression,0.49414968
Perioperative use of renin-angiotensin system inhibitors and outcomes in patients undergoing cardiac surgery.,rate,0.24866687,rate,1.0,dropout,0.44953537
Perioperative use of renin-angiotensin system inhibitors and outcomes in patients undergoing cardiac surgery.,compared,0.3359061,of,0.52794564,long-short-term,0.42386633
Perioperative use of renin-angiotensin system inhibitors and outcomes in patients undergoing cardiac surgery.,term-mortality,0.38662237,term,0.5672416,logistic-regression,0.56528795
Perioperative use of renin-angiotensin system inhibitors and outcomes in patients undergoing cardiac surgery.,mortality-rate,0.36486575,rate,0.5465963,logistic-regression,0.53036416
Perioperative use of renin-angiotensin system inhibitors and outcomes in patients undergoing cardiac surgery.,reduce,0.314935,reduction,0.63468504,boosting,0.4613787
Perioperative use of renin-angiotensin system inhibitors and outcomes in patients undergoing cardiac surgery.,treatment,0.239264,short-term,0.5206091,long-short-term,0.41699445
Perioperative use of renin-angiotensin system inhibitors and outcomes in patients undergoing cardiac surgery.,selection,0.46716303,selection,1.0,feature-selection,0.6859601
Perioperative use of renin-angiotensin system inhibitors and outcomes in patients undergoing cardiac surgery.,bias,0.3643996,overfitting,0.54791117,overfitting,0.54791117
Perioperative use of renin-angiotensin system inhibitors and outcomes in patients undergoing cardiac surgery.,treatment-selection,0.46213952,selection,0.67278546,feature-selection,0.6100928
Perioperative use of renin-angiotensin system inhibitors and outcomes in patients undergoing cardiac surgery.,selection-bias,0.53430176,feature-selection,0.7379396,feature-selection,0.7379396
Perioperative use of renin-angiotensin system inhibitors and outcomes in patients undergoing cardiac surgery.,day,0.252174,one,0.5237603,supervised,0.401589
Perioperative use of renin-angiotensin system inhibitors and outcomes in patients undergoing cardiac surgery.,mortality,0.2609817,short-term,0.505676,logistic-regression,0.49414968
Perioperative use of renin-angiotensin system inhibitors and outcomes in patients undergoing cardiac surgery.,compared,0.3359061,of,0.52794564,long-short-term,0.42386633
Perioperative use of renin-angiotensin system inhibitors and outcomes in patients undergoing cardiac surgery.,day-mortality,0.27252924,logistic-regression,0.5142015,logistic-regression,0.5142015
Perioperative use of renin-angiotensin system inhibitors and outcomes in patients undergoing cardiac surgery.,propensity,0.39547682,clustering,0.5125703,clustering,0.5125703
Perioperative use of renin-angiotensin system inhibitors and outcomes in patients undergoing cardiac surgery.,scores,0.40591323,intelligence,0.56987673,principal-components,0.4971624
Perioperative use of renin-angiotensin system inhibitors and outcomes in patients undergoing cardiac surgery.,matching,0.53057045,feature-selection,0.5917324,feature-selection,0.5917324
Perioperative use of renin-angiotensin system inhibitors and outcomes in patients undergoing cardiac surgery.,propensity-scores,0.5173614,logistic-regression,0.70565194,logistic-regression,0.70565194
Perioperative use of renin-angiotensin system inhibitors and outcomes in patients undergoing cardiac surgery.,angiotensin,0.21236175,matrix,0.35242182,feed-forward,0.31253523
Perioperative use of renin-angiotensin system inhibitors and outcomes in patients undergoing cardiac surgery.,system,0.3589455,generative-model,0.49815983,generative-model,0.49815983
Perioperative use of renin-angiotensin system inhibitors and outcomes in patients undergoing cardiac surgery.,inhibitors,0.25381407,cascade,0.4157439,feed-forward,0.3175553
Perioperative use of renin-angiotensin system inhibitors and outcomes in patients undergoing cardiac surgery.,angiotensin-system,0.27046937,short-term,0.37515104,batch-normalization,0.33918542
Perioperative use of renin-angiotensin system inhibitors and outcomes in patients undergoing cardiac surgery.,system-inhibitors,0.39258248,generative-model,0.4493553,generative-model,0.4493553
Perioperative use of renin-angiotensin system inhibitors and outcomes in patients undergoing cardiac surgery.,without,0.31691062,of,0.5951073,long-short-term,0.4268921
Perioperative use of renin-angiotensin system inhibitors and outcomes in patients undergoing cardiac surgery.,preoperative,0.3131417,normalization,0.4852215,computer-vision,0.44933364
Perioperative use of renin-angiotensin system inhibitors and outcomes in patients undergoing cardiac surgery.,rasi,0.19111931,keras,0.40834558,keras,0.40834558
Perioperative use of renin-angiotensin system inhibitors and outcomes in patients undergoing cardiac surgery.,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
Perioperative use of renin-angiotensin system inhibitors and outcomes in patients undergoing cardiac surgery.,without,0.31691062,of,0.5951073,long-short-term,0.4268921
Perioperative use of renin-angiotensin system inhibitors and outcomes in patients undergoing cardiac surgery.,postoperative,0.25341886,recurrent,0.50502723,computer-vision,0.3969509
Perioperative use of renin-angiotensin system inhibitors and outcomes in patients undergoing cardiac surgery.,rasi,0.19111931,keras,0.40834558,keras,0.40834558
Perioperative use of renin-angiotensin system inhibitors and outcomes in patients undergoing cardiac surgery.,valve,0.29510486,gradient,0.4132653,gradient,0.4132653
Perioperative use of renin-angiotensin system inhibitors and outcomes in patients undergoing cardiac surgery.,surgery,0.29565036,recurrent,0.47230634,computer-vision,0.40172684
Perioperative use of renin-angiotensin system inhibitors and outcomes in patients undergoing cardiac surgery.,valve-surgery,0.31645393,segmentation-algorithm,0.4066321,segmentation-algorithm,0.4066321
Perioperative use of renin-angiotensin system inhibitors and outcomes in patients undergoing cardiac surgery.,study,0.3645851,of,0.5728763,statistical,0.44204497
Perioperative use of renin-angiotensin system inhibitors and outcomes in patients undergoing cardiac surgery.,shows,0.2765087,of,0.56087804,feature-reduction,0.39955372
Perioperative use of renin-angiotensin system inhibitors and outcomes in patients undergoing cardiac surgery.,patients,0.30007,recurrent,0.5332828,dropout,0.3918751
Perioperative use of renin-angiotensin system inhibitors and outcomes in patients undergoing cardiac surgery.,without,0.31691062,of,0.5951073,long-short-term,0.4268921
Perioperative use of renin-angiotensin system inhibitors and outcomes in patients undergoing cardiac surgery.,one,0.335046,one,1.0,one-hot,0.4275648
Perioperative use of renin-angiotensin system inhibitors and outcomes in patients undergoing cardiac surgery.,perioperative,0.32009345,short-term,0.5171869,long-short-term,0.39392537
Perioperative use of renin-angiotensin system inhibitors and outcomes in patients undergoing cardiac surgery.,rasi,0.19111931,keras,0.40834558,keras,0.40834558
Perioperative use of renin-angiotensin system inhibitors and outcomes in patients undergoing cardiac surgery.,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
Perioperative use of renin-angiotensin system inhibitors and outcomes in patients undergoing cardiac surgery.,groups,0.2727722,statistical,0.4438421,statistical,0.4438421
Perioperative use of renin-angiotensin system inhibitors and outcomes in patients undergoing cardiac surgery.,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
Perioperative use of renin-angiotensin system inhibitors and outcomes in patients undergoing cardiac surgery.,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
Perioperative use of renin-angiotensin system inhibitors and outcomes in patients undergoing cardiac surgery.,significant,0.29367286,statistical,0.582669,statistical,0.582669
Perioperative use of renin-angiotensin system inhibitors and outcomes in patients undergoing cardiac surgery.,reduction,0.22531602,reduction,1.0,feature-reduction,0.59547573
Perioperative use of renin-angiotensin system inhibitors and outcomes in patients undergoing cardiac surgery.,significant,0.29367286,statistical,0.582669,statistical,0.582669
Perioperative use of renin-angiotensin system inhibitors and outcomes in patients undergoing cardiac surgery.,benefit,0.39640212,short-term,0.5466547,long-short-term,0.48296973
Perioperative use of renin-angiotensin system inhibitors and outcomes in patients undergoing cardiac surgery.,results,0.32376552,data,0.6932311,batch-normalization,0.44826904
Perioperative use of renin-angiotensin system inhibitors and outcomes in patients undergoing cardiac surgery.,suggest,0.26874092,data,0.5391823,long-short-term,0.40288782
Perioperative use of renin-angiotensin system inhibitors and outcomes in patients undergoing cardiac surgery.,results-suggest,0.39010245,data,0.5769403,batch-normalization,0.5080625
Perioperative use of renin-angiotensin system inhibitors and outcomes in patients undergoing cardiac surgery.,remains,0.24202663,fully,0.5171005,bagging,0.35608193
Perioperative use of renin-angiotensin system inhibitors and outcomes in patients undergoing cardiac surgery.,disputable,0.39557967,confusion,0.5680908,data-science,0.5159979
Perioperative use of renin-angiotensin system inhibitors and outcomes in patients undergoing cardiac surgery.,postoperative,0.25341886,recurrent,0.50502723,computer-vision,0.3969509
Perioperative use of renin-angiotensin system inhibitors and outcomes in patients undergoing cardiac surgery.,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
Perioperative use of renin-angiotensin system inhibitors and outcomes in patients undergoing cardiac surgery.,outcome,0.33788118,short-term,0.5818455,long-short-term,0.48316076
Perioperative use of renin-angiotensin system inhibitors and outcomes in patients undergoing cardiac surgery.,effects,0.2624804,short-term,0.63497096,long-short-term,0.5306107
Perioperative use of renin-angiotensin system inhibitors and outcomes in patients undergoing cardiac surgery.,outcome-effects,0.44383186,short-term,0.6246585,logistic-regression,0.57282495
Perioperative use of renin-angiotensin system inhibitors and outcomes in patients undergoing cardiac surgery.,year,0.310051,one,0.48338404,supervised,0.40979916
Perioperative use of renin-angiotensin system inhibitors and outcomes in patients undergoing cardiac surgery.,reduced,0.24137571,reduction,0.7564339,boosting,0.47559226
Perioperative use of renin-angiotensin system inhibitors and outcomes in patients undergoing cardiac surgery.,long,0.20028201,long,1.0,long-short-term,0.6505779
Perioperative use of renin-angiotensin system inhibitors and outcomes in patients undergoing cardiac surgery.,perioperative,0.32009345,short-term,0.5171869,long-short-term,0.39392537
Perioperative use of renin-angiotensin system inhibitors and outcomes in patients undergoing cardiac surgery.,use,0.43753043,of,0.5506158,feature-reduction,0.49910897
Perioperative use of renin-angiotensin system inhibitors and outcomes in patients undergoing cardiac surgery.,rasi,0.19111931,keras,0.40834558,keras,0.40834558
Perioperative use of renin-angiotensin system inhibitors and outcomes in patients undergoing cardiac surgery.,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
Perioperative use of renin-angiotensin system inhibitors and outcomes in patients undergoing cardiac surgery.,postoperative,0.25341886,recurrent,0.50502723,computer-vision,0.3969509
Perioperative use of renin-angiotensin system inhibitors and outcomes in patients undergoing cardiac surgery.,year,0.310051,one,0.48338404,supervised,0.40979916
Perioperative use of renin-angiotensin system inhibitors and outcomes in patients undergoing cardiac surgery.,use,0.43753043,of,0.5506158,feature-reduction,0.49910897
Perioperative use of renin-angiotensin system inhibitors and outcomes in patients undergoing cardiac surgery.,long,0.20028201,long,1.0,long-short-term,0.6505779
Perioperative use of renin-angiotensin system inhibitors and outcomes in patients undergoing cardiac surgery.,vs,0.22635552,transfer,0.4263924,statistical,0.3002486
Perioperative use of renin-angiotensin system inhibitors and outcomes in patients undergoing cardiac surgery.,using,0.47332245,analysis,0.5968549,component-analysis,0.526608
Perioperative use of renin-angiotensin system inhibitors and outcomes in patients undergoing cardiac surgery.,renin,0.22382896,normalization,0.36536643,batch-normalization,0.34999466
Perioperative use of renin-angiotensin system inhibitors and outcomes in patients undergoing cardiac surgery.,outcomes,0.38239923,short-term,0.6164659,long-short-term,0.5239928
Perioperative use of renin-angiotensin system inhibitors and outcomes in patients undergoing cardiac surgery.,n,0.24332823,of,0.45693433,long-short-term,0.34114176
Perioperative use of renin-angiotensin system inhibitors and outcomes in patients undergoing cardiac surgery.,exclusion,0.28090543,selection,0.5888314,gradient,0.43580884
Perioperative use of renin-angiotensin system inhibitors and outcomes in patients undergoing cardiac surgery.,divided,0.31782648,one,0.5082367,classification,0.4014557
Perioperative use of renin-angiotensin system inhibitors and outcomes in patients undergoing cardiac surgery.,associated,0.30827495,of,0.57598466,long-short-term,0.46578532
Treatment of Hypercholesterolemia With PCSK9 Inhibitors in Heart Transplant Recipients. First Experience in Spain.,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
Treatment of Hypercholesterolemia With PCSK9 Inhibitors in Heart Transplant Recipients. First Experience in Spain.,pmid,0.17205057,science,0.31445533,bag-of-words,0.26444918
Treatment of Hypercholesterolemia With PCSK9 Inhibitors in Heart Transplant Recipients. First Experience in Spain.,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
Treatment of Hypercholesterolemia With PCSK9 Inhibitors in Heart Transplant Recipients. First Experience in Spain.,rec,0.21092199,unit,0.44169182,bagging,0.37416506
Treatment of Hypercholesterolemia With PCSK9 Inhibitors in Heart Transplant Recipients. First Experience in Spain.,medline,0.44432086,data-science,0.5824888,data-science,0.5824888
Treatment of Hypercholesterolemia With PCSK9 Inhibitors in Heart Transplant Recipients. First Experience in Spain.,j,0.12432591,science,0.31094742,cross-entropy,0.2885616
Treatment of Hypercholesterolemia With PCSK9 Inhibitors in Heart Transplant Recipients. First Experience in Spain.,indexed,0.3858727,semantic,0.49446192,semantic,0.49446192
Treatment of Hypercholesterolemia With PCSK9 Inhibitors in Heart Transplant Recipients. First Experience in Spain.,doi,0.2357645,data-science,0.3312925,data-science,0.3312925
"Metabolite profiling, arginase inhibition and vasorelaxant activity of Cornus mas, Sorbus aucuparia and Viburnum opulus fruit extracts.",rat,0.27098635,model,0.45597747,generative-model,0.34199628
"Metabolite profiling, arginase inhibition and vasorelaxant activity of Cornus mas, Sorbus aucuparia and Viburnum opulus fruit extracts.",aortic,0.23288518,gradient,0.37829,gradient,0.37829
"Metabolite profiling, arginase inhibition and vasorelaxant activity of Cornus mas, Sorbus aucuparia and Viburnum opulus fruit extracts.",rings,0.21465498,centroid-based,0.4578146,centroid-based,0.4578146
"Metabolite profiling, arginase inhibition and vasorelaxant activity of Cornus mas, Sorbus aucuparia and Viburnum opulus fruit extracts.",relaxation,0.23963365,regularization,0.44061458,data-augmentation,0.4305567
"Metabolite profiling, arginase inhibition and vasorelaxant activity of Cornus mas, Sorbus aucuparia and Viburnum opulus fruit extracts.",assay,0.28104568,analysis,0.46296048,component-analysis,0.37250015
"Metabolite profiling, arginase inhibition and vasorelaxant activity of Cornus mas, Sorbus aucuparia and Viburnum opulus fruit extracts.",rat-aortic,0.29954824,gradient-descent,0.4046952,gradient-descent,0.4046952
"Metabolite profiling, arginase inhibition and vasorelaxant activity of Cornus mas, Sorbus aucuparia and Viburnum opulus fruit extracts.",aortic-rings,0.2924928,data-augmentation,0.40573573,data-augmentation,0.40573573
"Metabolite profiling, arginase inhibition and vasorelaxant activity of Cornus mas, Sorbus aucuparia and Viburnum opulus fruit extracts.",relaxation-assay,0.29828912,batch-normalization,0.47653157,batch-normalization,0.47653157
"Metabolite profiling, arginase inhibition and vasorelaxant activity of Cornus mas, Sorbus aucuparia and Viburnum opulus fruit extracts.",phenylephrine,0.20170295,augmentation,0.4108954,gradient,0.3539108
"Metabolite profiling, arginase inhibition and vasorelaxant activity of Cornus mas, Sorbus aucuparia and Viburnum opulus fruit extracts.",precontracted,0.19208586,rectified,0.42098805,gradient,0.33188298
"Metabolite profiling, arginase inhibition and vasorelaxant activity of Cornus mas, Sorbus aucuparia and Viburnum opulus fruit extracts.",rat,0.27098635,model,0.45597747,generative-model,0.34199628
"Metabolite profiling, arginase inhibition and vasorelaxant activity of Cornus mas, Sorbus aucuparia and Viburnum opulus fruit extracts.",aortic,0.23288518,gradient,0.37829,gradient,0.37829
"Metabolite profiling, arginase inhibition and vasorelaxant activity of Cornus mas, Sorbus aucuparia and Viburnum opulus fruit extracts.",rings,0.21465498,centroid-based,0.4578146,centroid-based,0.4578146
"Metabolite profiling, arginase inhibition and vasorelaxant activity of Cornus mas, Sorbus aucuparia and Viburnum opulus fruit extracts.",phenylephrine-precontracted,0.18810113,augmentation,0.38442847,gradient,0.35350448
"Metabolite profiling, arginase inhibition and vasorelaxant activity of Cornus mas, Sorbus aucuparia and Viburnum opulus fruit extracts.",rat-aortic,0.29954824,gradient-descent,0.4046952,gradient-descent,0.4046952
"Metabolite profiling, arginase inhibition and vasorelaxant activity of Cornus mas, Sorbus aucuparia and Viburnum opulus fruit extracts.",aortic-rings,0.2924928,data-augmentation,0.40573573,data-augmentation,0.40573573
"Metabolite profiling, arginase inhibition and vasorelaxant activity of Cornus mas, Sorbus aucuparia and Viburnum opulus fruit extracts.",brine,0.24953565,batch,0.4929133,stochastic-gradient,0.39069515
"Metabolite profiling, arginase inhibition and vasorelaxant activity of Cornus mas, Sorbus aucuparia and Viburnum opulus fruit extracts.",shrimp,0.1678294,batch,0.37279233,one-hot,0.3142056
"Metabolite profiling, arginase inhibition and vasorelaxant activity of Cornus mas, Sorbus aucuparia and Viburnum opulus fruit extracts.",acute,0.21222305,short-term,0.51624244,long-short-term,0.3867746
"Metabolite profiling, arginase inhibition and vasorelaxant activity of Cornus mas, Sorbus aucuparia and Viburnum opulus fruit extracts.",toxicity,0.2518801,short-term,0.4928156,long-short-term,0.40697476
"Metabolite profiling, arginase inhibition and vasorelaxant activity of Cornus mas, Sorbus aucuparia and Viburnum opulus fruit extracts.",test,0.4037762,statistical,0.5031551,statistical,0.5031551
"Metabolite profiling, arginase inhibition and vasorelaxant activity of Cornus mas, Sorbus aucuparia and Viburnum opulus fruit extracts.",brine-shrimp,0.3003802,batch,0.47973752,one-hot,0.4371491
"Metabolite profiling, arginase inhibition and vasorelaxant activity of Cornus mas, Sorbus aucuparia and Viburnum opulus fruit extracts.",acute-toxicity,0.30457196,short-term,0.48880276,batch-normalization,0.4280659
"Metabolite profiling, arginase inhibition and vasorelaxant activity of Cornus mas, Sorbus aucuparia and Viburnum opulus fruit extracts.",toxicity-test,0.37648788,batch-normalization,0.4735259,batch-normalization,0.4735259
"Metabolite profiling, arginase inhibition and vasorelaxant activity of Cornus mas, Sorbus aucuparia and Viburnum opulus fruit extracts.",study,0.3645851,of,0.5728763,statistical,0.44204497
"Metabolite profiling, arginase inhibition and vasorelaxant activity of Cornus mas, Sorbus aucuparia and Viburnum opulus fruit extracts.",highlights,0.39811388,of,0.5411649,feature-engineering,0.53502977
"Metabolite profiling, arginase inhibition and vasorelaxant activity of Cornus mas, Sorbus aucuparia and Viburnum opulus fruit extracts.",potential,0.3558654,of,0.5645705,generative-model,0.46479023
"Metabolite profiling, arginase inhibition and vasorelaxant activity of Cornus mas, Sorbus aucuparia and Viburnum opulus fruit extracts.",benefits,0.41087294,short-term,0.59437555,long-short-term,0.5303442
"Metabolite profiling, arginase inhibition and vasorelaxant activity of Cornus mas, Sorbus aucuparia and Viburnum opulus fruit extracts.",study-highlights,0.44035497,data-science,0.5544095,data-science,0.5544095
"Metabolite profiling, arginase inhibition and vasorelaxant activity of Cornus mas, Sorbus aucuparia and Viburnum opulus fruit extracts.",opulus,0.27611783,tree,0.51102996,random-forest,0.38960737
"Metabolite profiling, arginase inhibition and vasorelaxant activity of Cornus mas, Sorbus aucuparia and Viburnum opulus fruit extracts.",fruit,0.29721212,kernel,0.5478446,kernel,0.5478446
"Metabolite profiling, arginase inhibition and vasorelaxant activity of Cornus mas, Sorbus aucuparia and Viburnum opulus fruit extracts.",extract,0.38952202,components,0.49913663,kernel,0.46366778
"Metabolite profiling, arginase inhibition and vasorelaxant activity of Cornus mas, Sorbus aucuparia and Viburnum opulus fruit extracts.",exerted,0.1707829,of,0.5055257,feed-forward,0.40725064
"Metabolite profiling, arginase inhibition and vasorelaxant activity of Cornus mas, Sorbus aucuparia and Viburnum opulus fruit extracts.",fruit-extract,0.33136505,kernel,0.53455174,kernel,0.53455174
"Metabolite profiling, arginase inhibition and vasorelaxant activity of Cornus mas, Sorbus aucuparia and Viburnum opulus fruit extracts.",viburnum,0.23540431,tree,0.51962286,kernel,0.37626082
"Metabolite profiling, arginase inhibition and vasorelaxant activity of Cornus mas, Sorbus aucuparia and Viburnum opulus fruit extracts.",opulus,0.27611783,tree,0.51102996,random-forest,0.38960737
"Metabolite profiling, arginase inhibition and vasorelaxant activity of Cornus mas, Sorbus aucuparia and Viburnum opulus fruit extracts.",fruit,0.29721212,kernel,0.5478446,kernel,0.5478446
"Metabolite profiling, arginase inhibition and vasorelaxant activity of Cornus mas, Sorbus aucuparia and Viburnum opulus fruit extracts.",extracts,0.28823897,components,0.55403435,principal-components,0.39844638
"Metabolite profiling, arginase inhibition and vasorelaxant activity of Cornus mas, Sorbus aucuparia and Viburnum opulus fruit extracts.",fruit-extracts,0.33545858,kernel,0.5193236,kernel,0.5193236
"Metabolite profiling, arginase inhibition and vasorelaxant activity of Cornus mas, Sorbus aucuparia and Viburnum opulus fruit extracts.",mas,0.259766,transform,0.37278062,fourier,0.3715388
"Metabolite profiling, arginase inhibition and vasorelaxant activity of Cornus mas, Sorbus aucuparia and Viburnum opulus fruit extracts.",fruit,0.29721212,kernel,0.5478446,kernel,0.5478446
"Metabolite profiling, arginase inhibition and vasorelaxant activity of Cornus mas, Sorbus aucuparia and Viburnum opulus fruit extracts.",extracts,0.28823897,components,0.55403435,principal-components,0.39844638
"Metabolite profiling, arginase inhibition and vasorelaxant activity of Cornus mas, Sorbus aucuparia and Viburnum opulus fruit extracts.",showed,0.20766163,of,0.5296177,regression,0.37027335
"Metabolite profiling, arginase inhibition and vasorelaxant activity of Cornus mas, Sorbus aucuparia and Viburnum opulus fruit extracts.",fruit-extracts,0.33545858,kernel,0.5193236,kernel,0.5193236
"Metabolite profiling, arginase inhibition and vasorelaxant activity of Cornus mas, Sorbus aucuparia and Viburnum opulus fruit extracts.",opulus,0.27611783,tree,0.51102996,random-forest,0.38960737
"Metabolite profiling, arginase inhibition and vasorelaxant activity of Cornus mas, Sorbus aucuparia and Viburnum opulus fruit extracts.",fruit,0.29721212,kernel,0.5478446,kernel,0.5478446
"Metabolite profiling, arginase inhibition and vasorelaxant activity of Cornus mas, Sorbus aucuparia and Viburnum opulus fruit extracts.",extract,0.38952202,components,0.49913663,kernel,0.46366778
"Metabolite profiling, arginase inhibition and vasorelaxant activity of Cornus mas, Sorbus aucuparia and Viburnum opulus fruit extracts.",fruit-extract,0.33136505,kernel,0.53455174,kernel,0.53455174
"Metabolite profiling, arginase inhibition and vasorelaxant activity of Cornus mas, Sorbus aucuparia and Viburnum opulus fruit extracts.",present,0.39618495,of,0.63723874,generative,0.48216146
"Metabolite profiling, arginase inhibition and vasorelaxant activity of Cornus mas, Sorbus aucuparia and Viburnum opulus fruit extracts.",study,0.3645851,of,0.5728763,statistical,0.44204497
"Metabolite profiling, arginase inhibition and vasorelaxant activity of Cornus mas, Sorbus aucuparia and Viburnum opulus fruit extracts.",investigated,0.30147675,of,0.6179704,generative-model,0.42952073
"Metabolite profiling, arginase inhibition and vasorelaxant activity of Cornus mas, Sorbus aucuparia and Viburnum opulus fruit extracts.",present-study,0.49922752,natural-language,0.53023326,natural-language,0.53023326
"Metabolite profiling, arginase inhibition and vasorelaxant activity of Cornus mas, Sorbus aucuparia and Viburnum opulus fruit extracts.",study-investigated,0.4355383,of,0.57214093,component-analysis,0.5110738
"Metabolite profiling, arginase inhibition and vasorelaxant activity of Cornus mas, Sorbus aucuparia and Viburnum opulus fruit extracts.",complex,0.27214053,components,0.5436033,component-analysis,0.4161712
"Metabolite profiling, arginase inhibition and vasorelaxant activity of Cornus mas, Sorbus aucuparia and Viburnum opulus fruit extracts.",metabolite,0.27332738,principal,0.44271863,batch-normalization,0.37130743
"Metabolite profiling, arginase inhibition and vasorelaxant activity of Cornus mas, Sorbus aucuparia and Viburnum opulus fruit extracts.",profiling,0.46470833,analysis,0.7003745,component-analysis,0.50180626
"Metabolite profiling, arginase inhibition and vasorelaxant activity of Cornus mas, Sorbus aucuparia and Viburnum opulus fruit extracts.",metabolite-profiling,0.50809026,analysis,0.57441366,component-analysis,0.5312284
"Metabolite profiling, arginase inhibition and vasorelaxant activity of Cornus mas, Sorbus aucuparia and Viburnum opulus fruit extracts.",chlorogenic,0.31855124,principal-components,0.42391497,principal-components,0.42391497
"Metabolite profiling, arginase inhibition and vasorelaxant activity of Cornus mas, Sorbus aucuparia and Viburnum opulus fruit extracts.",acid,0.19370206,of,0.41044196,clustering,0.30169246
"Metabolite profiling, arginase inhibition and vasorelaxant activity of Cornus mas, Sorbus aucuparia and Viburnum opulus fruit extracts.",accounting,0.37102675,of,0.55534834,clustering,0.52411747
"Metabolite profiling, arginase inhibition and vasorelaxant activity of Cornus mas, Sorbus aucuparia and Viburnum opulus fruit extracts.",significantly,0.27887642,of,0.5214151,long-short-term,0.39056638
"Metabolite profiling, arginase inhibition and vasorelaxant activity of Cornus mas, Sorbus aucuparia and Viburnum opulus fruit extracts.",weaker,0.19608709,neighbors,0.4416936,long-short-term,0.39512345
"Metabolite profiling, arginase inhibition and vasorelaxant activity of Cornus mas, Sorbus aucuparia and Viburnum opulus fruit extracts.",activity,0.21813896,function,0.53536034,boosting,0.38798416
"Metabolite profiling, arginase inhibition and vasorelaxant activity of Cornus mas, Sorbus aucuparia and Viburnum opulus fruit extracts.",highest,0.25175208,of,0.5054526,boosting,0.3963222
"Metabolite profiling, arginase inhibition and vasorelaxant activity of Cornus mas, Sorbus aucuparia and Viburnum opulus fruit extracts.",vasorelaxant,0.18745658,discriminative,0.31154275,learning-function,0.2834013
"Metabolite profiling, arginase inhibition and vasorelaxant activity of Cornus mas, Sorbus aucuparia and Viburnum opulus fruit extracts.",activity,0.21813896,function,0.53536034,boosting,0.38798416
"Metabolite profiling, arginase inhibition and vasorelaxant activity of Cornus mas, Sorbus aucuparia and Viburnum opulus fruit extracts.",aucuparia,0.25139236,forest,0.4870552,random-forest,0.4202793
"Metabolite profiling, arginase inhibition and vasorelaxant activity of Cornus mas, Sorbus aucuparia and Viburnum opulus fruit extracts.",fruit,0.29721212,kernel,0.5478446,kernel,0.5478446
"Metabolite profiling, arginase inhibition and vasorelaxant activity of Cornus mas, Sorbus aucuparia and Viburnum opulus fruit extracts.",extracts,0.28823897,components,0.55403435,principal-components,0.39844638
"Metabolite profiling, arginase inhibition and vasorelaxant activity of Cornus mas, Sorbus aucuparia and Viburnum opulus fruit extracts.",fruit-extracts,0.33545858,kernel,0.5193236,kernel,0.5193236
"Metabolite profiling, arginase inhibition and vasorelaxant activity of Cornus mas, Sorbus aucuparia and Viburnum opulus fruit extracts.",xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
"Metabolite profiling, arginase inhibition and vasorelaxant activity of Cornus mas, Sorbus aucuparia and Viburnum opulus fruit extracts.",xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
"Metabolite profiling, arginase inhibition and vasorelaxant activity of Cornus mas, Sorbus aucuparia and Viburnum opulus fruit extracts.",ms,0.28033274,short,0.4487456,confusion-matrix,0.43990153
"Metabolite profiling, arginase inhibition and vasorelaxant activity of Cornus mas, Sorbus aucuparia and Viburnum opulus fruit extracts.",studies,0.30135098,data,0.6349237,component-analysis,0.41327482
"Metabolite profiling, arginase inhibition and vasorelaxant activity of Cornus mas, Sorbus aucuparia and Viburnum opulus fruit extracts.",revealed,0.23368785,analysis,0.608845,principal-component,0.3856352
"Metabolite profiling, arginase inhibition and vasorelaxant activity of Cornus mas, Sorbus aucuparia and Viburnum opulus fruit extracts.",ms-studies,0.40833855,data,0.5633997,component-analysis,0.52839243
"Metabolite profiling, arginase inhibition and vasorelaxant activity of Cornus mas, Sorbus aucuparia and Viburnum opulus fruit extracts.",studies-revealed,0.33324087,component-analysis,0.5321265,component-analysis,0.5321265
"Metabolite profiling, arginase inhibition and vasorelaxant activity of Cornus mas, Sorbus aucuparia and Viburnum opulus fruit extracts.",three,0.36911732,one,0.78425425,clustering,0.4299444
"Metabolite profiling, arginase inhibition and vasorelaxant activity of Cornus mas, Sorbus aucuparia and Viburnum opulus fruit extracts.",extracts,0.28823897,components,0.55403435,principal-components,0.39844638
"Metabolite profiling, arginase inhibition and vasorelaxant activity of Cornus mas, Sorbus aucuparia and Viburnum opulus fruit extracts.",xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
"Metabolite profiling, arginase inhibition and vasorelaxant activity of Cornus mas, Sorbus aucuparia and Viburnum opulus fruit extracts.",xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
"Metabolite profiling, arginase inhibition and vasorelaxant activity of Cornus mas, Sorbus aucuparia and Viburnum opulus fruit extracts.",mg,0.22385968,one,0.49652064,confusion-matrix,0.33858854
"Metabolite profiling, arginase inhibition and vasorelaxant activity of Cornus mas, Sorbus aucuparia and Viburnum opulus fruit extracts.",cornus,0.27766526,tree,0.4933317,kernel,0.3919991
"Metabolite profiling, arginase inhibition and vasorelaxant activity of Cornus mas, Sorbus aucuparia and Viburnum opulus fruit extracts.",mas,0.259766,transform,0.37278062,fourier,0.3715388
"Metabolite profiling, arginase inhibition and vasorelaxant activity of Cornus mas, Sorbus aucuparia and Viburnum opulus fruit extracts.",arginase,0.23364754,function,0.3735287,batch-normalization,0.29509634
"Metabolite profiling, arginase inhibition and vasorelaxant activity of Cornus mas, Sorbus aucuparia and Viburnum opulus fruit extracts.",activity,0.21813896,function,0.53536034,boosting,0.38798416
"Metabolite profiling, arginase inhibition and vasorelaxant activity of Cornus mas, Sorbus aucuparia and Viburnum opulus fruit extracts.",arginase-activity,0.2766381,function,0.42662165,learning-function,0.36996067
"Metabolite profiling, arginase inhibition and vasorelaxant activity of Cornus mas, Sorbus aucuparia and Viburnum opulus fruit extracts.",sorbus,0.27303737,tree,0.49491435,random-forest,0.4041084
"Metabolite profiling, arginase inhibition and vasorelaxant activity of Cornus mas, Sorbus aucuparia and Viburnum opulus fruit extracts.",aucuparia,0.25139236,forest,0.4870552,random-forest,0.4202793
"Metabolite profiling, arginase inhibition and vasorelaxant activity of Cornus mas, Sorbus aucuparia and Viburnum opulus fruit extracts.",significant,0.29367286,statistical,0.582669,statistical,0.582669
"Metabolite profiling, arginase inhibition and vasorelaxant activity of Cornus mas, Sorbus aucuparia and Viburnum opulus fruit extracts.",inhibition,0.21671593,reduction,0.58642584,feed-forward,0.44581953
"Metabolite profiling, arginase inhibition and vasorelaxant activity of Cornus mas, Sorbus aucuparia and Viburnum opulus fruit extracts.",rights,0.3170033,adversarial,0.6281444,data-science,0.57488894
"Metabolite profiling, arginase inhibition and vasorelaxant activity of Cornus mas, Sorbus aucuparia and Viburnum opulus fruit extracts.",reserved,0.28677964,of,0.4776592,supervised,0.3944377
"Metabolite profiling, arginase inhibition and vasorelaxant activity of Cornus mas, Sorbus aucuparia and Viburnum opulus fruit extracts.",main,0.3070703,principal,0.7875631,principal-components,0.51314574
"Metabolite profiling, arginase inhibition and vasorelaxant activity of Cornus mas, Sorbus aucuparia and Viburnum opulus fruit extracts.",mechanism,0.2780391,cascade,0.59194523,feed-forward,0.5341974
"Metabolite profiling, arginase inhibition and vasorelaxant activity of Cornus mas, Sorbus aucuparia and Viburnum opulus fruit extracts.",important,0.33620566,principal,0.5803634,feature-engineering,0.43471682
"Metabolite profiling, arginase inhibition and vasorelaxant activity of Cornus mas, Sorbus aucuparia and Viburnum opulus fruit extracts.",anti,0.114482366,of,0.3963322,boosting,0.31662655
"Metabolite profiling, arginase inhibition and vasorelaxant activity of Cornus mas, Sorbus aucuparia and Viburnum opulus fruit extracts.",endothelial,0.2463533,neural,0.46855402,confusion-matrix,0.34260106
"Metabolite profiling, arginase inhibition and vasorelaxant activity of Cornus mas, Sorbus aucuparia and Viburnum opulus fruit extracts.",dysfunction,0.3095205,function,0.7029606,learning-function,0.4439212
"Metabolite profiling, arginase inhibition and vasorelaxant activity of Cornus mas, Sorbus aucuparia and Viburnum opulus fruit extracts.",endothelial-dysfunction,0.28977168,function,0.51895845,confusion-matrix,0.39295483
"Metabolite profiling, arginase inhibition and vasorelaxant activity of Cornus mas, Sorbus aucuparia and Viburnum opulus fruit extracts.",diseases,0.31957155,recurrent,0.41244444,classification,0.40266854
"Metabolite profiling, arginase inhibition and vasorelaxant activity of Cornus mas, Sorbus aucuparia and Viburnum opulus fruit extracts.",associated,0.30827495,of,0.57598466,long-short-term,0.46578532
"Metabolite profiling, arginase inhibition and vasorelaxant activity of Cornus mas, Sorbus aucuparia and Viburnum opulus fruit extracts.",diseases-associated,0.3895921,recurrent,0.50674224,classification,0.45247704
"Metabolite profiling, arginase inhibition and vasorelaxant activity of Cornus mas, Sorbus aucuparia and Viburnum opulus fruit extracts.",declared,0.31163847,truth,0.54465926,supervised,0.44572228
"Metabolite profiling, arginase inhibition and vasorelaxant activity of Cornus mas, Sorbus aucuparia and Viburnum opulus fruit extracts.",non,0.2869836,of,0.5523051,generative,0.4181043
"Metabolite profiling, arginase inhibition and vasorelaxant activity of Cornus mas, Sorbus aucuparia and Viburnum opulus fruit extracts.",impaired,0.28064826,function,0.6550549,short-term-memory,0.48377025
"Metabolite profiling, arginase inhibition and vasorelaxant activity of Cornus mas, Sorbus aucuparia and Viburnum opulus fruit extracts.",vasodilation,0.19744855,augmentation,0.44281834,data-augmentation,0.37087578
"Metabolite profiling, arginase inhibition and vasorelaxant activity of Cornus mas, Sorbus aucuparia and Viburnum opulus fruit extracts.",arterial,0.27257246,augmentation,0.4504157,gradient,0.4443115
"Metabolite profiling, arginase inhibition and vasorelaxant activity of Cornus mas, Sorbus aucuparia and Viburnum opulus fruit extracts.",vasodilation,0.19744855,augmentation,0.44281834,data-augmentation,0.37087578
"Metabolite profiling, arginase inhibition and vasorelaxant activity of Cornus mas, Sorbus aucuparia and Viburnum opulus fruit extracts.",respectively,0.23184536,of,0.43360457,cross-validation,0.35765702
"Metabolite profiling, arginase inhibition and vasorelaxant activity of Cornus mas, Sorbus aucuparia and Viburnum opulus fruit extracts.",ml,0.29010946,bag,0.4418462,gradient,0.3396448
"Metabolite profiling, arginase inhibition and vasorelaxant activity of Cornus mas, Sorbus aucuparia and Viburnum opulus fruit extracts.",opulus,0.27611783,tree,0.51102996,random-forest,0.38960737
"Metabolite profiling, arginase inhibition and vasorelaxant activity of Cornus mas, Sorbus aucuparia and Viburnum opulus fruit extracts.",extracts,0.28823897,components,0.55403435,principal-components,0.39844638
"Metabolite profiling, arginase inhibition and vasorelaxant activity of Cornus mas, Sorbus aucuparia and Viburnum opulus fruit extracts.",xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
"Metabolite profiling, arginase inhibition and vasorelaxant activity of Cornus mas, Sorbus aucuparia and Viburnum opulus fruit extracts.",mas,0.259766,transform,0.37278062,fourier,0.3715388
"Metabolite profiling, arginase inhibition and vasorelaxant activity of Cornus mas, Sorbus aucuparia and Viburnum opulus fruit extracts.",ms,0.28033274,short,0.4487456,confusion-matrix,0.43990153
"Metabolite profiling, arginase inhibition and vasorelaxant activity of Cornus mas, Sorbus aucuparia and Viburnum opulus fruit extracts.",aucuparia,0.25139236,forest,0.4870552,random-forest,0.4202793
"Metabolite profiling, arginase inhibition and vasorelaxant activity of Cornus mas, Sorbus aucuparia and Viburnum opulus fruit extracts.",vasodilation,0.19744855,augmentation,0.44281834,data-augmentation,0.37087578
"Metabolite profiling, arginase inhibition and vasorelaxant activity of Cornus mas, Sorbus aucuparia and Viburnum opulus fruit extracts.",respectively,0.23184536,of,0.43360457,cross-validation,0.35765702
"Metabolite profiling, arginase inhibition and vasorelaxant activity of Cornus mas, Sorbus aucuparia and Viburnum opulus fruit extracts.",ml,0.29010946,bag,0.4418462,gradient,0.3396448
"Metabolite profiling, arginase inhibition and vasorelaxant activity of Cornus mas, Sorbus aucuparia and Viburnum opulus fruit extracts.",arginase,0.23364754,function,0.3735287,batch-normalization,0.29509634
"Metabolite profiling, arginase inhibition and vasorelaxant activity of Cornus mas, Sorbus aucuparia and Viburnum opulus fruit extracts.",v,0.16266164,rate,0.35976145,softmax,0.2951627
"Metabolite profiling, arginase inhibition and vasorelaxant activity of Cornus mas, Sorbus aucuparia and Viburnum opulus fruit extracts.",toxic,0.21225749,of,0.45198524,long-short-term,0.3737322
"Metabolite profiling, arginase inhibition and vasorelaxant activity of Cornus mas, Sorbus aucuparia and Viburnum opulus fruit extracts.",tof,0.29606172,few-shot,0.45629573,fourier,0.41240782
"Metabolite profiling, arginase inhibition and vasorelaxant activity of Cornus mas, Sorbus aucuparia and Viburnum opulus fruit extracts.",q,0.22241156,feed,0.3829267,softmax,0.3435977
"Metabolite profiling, arginase inhibition and vasorelaxant activity of Cornus mas, Sorbus aucuparia and Viburnum opulus fruit extracts.",proven,0.375184,of,0.5508748,generative-model,0.42086476
"Metabolite profiling, arginase inhibition and vasorelaxant activity of Cornus mas, Sorbus aucuparia and Viburnum opulus fruit extracts.",hplc,0.30817884,fourier-transform,0.53946066,fourier-transform,0.53946066
"Metabolite profiling, arginase inhibition and vasorelaxant activity of Cornus mas, Sorbus aucuparia and Viburnum opulus fruit extracts.",g,0.17250246,feed,0.40076,n-gram,0.27758121
"Metabolite profiling, arginase inhibition and vasorelaxant activity of Cornus mas, Sorbus aucuparia and Viburnum opulus fruit extracts.",esi,0.25272056,fourier-transform,0.5044373,fourier-transform,0.5044373
"Metabolite profiling, arginase inhibition and vasorelaxant activity of Cornus mas, Sorbus aucuparia and Viburnum opulus fruit extracts.",endothelium,0.20806618,layer,0.46010172,generative,0.35238373
"Metabolite profiling, arginase inhibition and vasorelaxant activity of Cornus mas, Sorbus aucuparia and Viburnum opulus fruit extracts.",effects,0.2624804,short-term,0.63497096,long-short-term,0.5306107
"Metabolite profiling, arginase inhibition and vasorelaxant activity of Cornus mas, Sorbus aucuparia and Viburnum opulus fruit extracts.",dependent,0.2523393,of,0.585135,generative,0.43066898
"Metabolite profiling, arginase inhibition and vasorelaxant activity of Cornus mas, Sorbus aucuparia and Viburnum opulus fruit extracts.",contrast,0.24962384,of,0.5428885,feature-reduction,0.41914925
"Metabolite profiling, arginase inhibition and vasorelaxant activity of Cornus mas, Sorbus aucuparia and Viburnum opulus fruit extracts.",c,0.17513797,of,0.44327667,gradient,0.31114018
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",studied,0.26534057,of,0.63097596,generative-model,0.40392917
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",infectious,0.26894212,recurrent,0.41022912,data-science,0.35497752
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",molecular,0.39914468,of,0.516936,clustering,0.43655443
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",clones,0.29136616,encoding,0.5343508,clustering,0.39923143
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",acquisition,0.49771845,learning,0.5805447,transfer-learning,0.5654274
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",among,0.33676732,of,0.57348,clustering,0.49404603
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",women,0.25528732,descent,0.50278515,dropout,0.37675467
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",using,0.47332245,analysis,0.5968549,component-analysis,0.526608
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",among-women,0.36398342,random-forest,0.5424355,random-forest,0.5424355
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",women-using,0.3445019,descent,0.4950263,natural-language,0.45785576
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",female,0.2642398,naive,0.4711159,generative,0.42489284
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",reproductive,0.2763688,generative,0.5129404,generative,0.5129404
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",tract,0.17745402,recurrent,0.5062193,generative,0.32561263
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",cells,0.20327199,naive,0.5115537,generative,0.40616876
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",compared,0.3359061,of,0.52794564,long-short-term,0.42386633
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",female-reproductive,0.28520834,generative,0.5482463,generative,0.5482463
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",reproductive-tract,0.42124173,generative,0.6128086,generative,0.6128086
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",cells-compared,0.41847062,naive,0.5083889,naive-bayes,0.47852314
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",morbidity,0.27463242,recurrent,0.47132403,logistic-regression,0.42021167
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",worldwide,0.30951637,federated,0.50279367,data-science,0.43083924
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",among,0.33676732,of,0.57348,clustering,0.49404603
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",reproductive,0.2763688,generative,0.5129404,generative,0.5129404
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",lower,0.20975146,of,0.5471319,regression,0.3982392
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",reproductive,0.2763688,generative,0.5129404,generative,0.5129404
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",tract,0.17745402,recurrent,0.5062193,generative,0.32561263
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",due,0.21681537,of,0.5734476,confusion-matrix,0.40250766
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",reproductive-tract,0.42124173,generative,0.6128086,generative,0.6128086
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",tract-due,0.2780017,convolutional,0.4276021,convolutional,0.4276021
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",upper,0.22255614,deep,0.5399081,bagging,0.37077722
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",female,0.2642398,naive,0.4711159,generative,0.42489284
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",reproductive,0.2763688,generative,0.5129404,generative,0.5129404
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",tract,0.17745402,recurrent,0.5062193,generative,0.32561263
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",female-reproductive,0.28520834,generative,0.5482463,generative,0.5482463
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",reproductive-tract,0.42124173,generative,0.6128086,generative,0.6128086
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",acting,0.25467432,of,0.55923325,generative,0.48015943
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",injectable,0.24388754,augmentation,0.46566558,one-shot,0.40602654
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",progestin,0.20123452,short-term,0.38084355,long-short-term,0.33676478
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",contraceptive,0.26979262,decision,0.38513955,natural-language,0.38474274
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",mucosal,0.21299721,of,0.4234106,boosting,0.40373027
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",immune,0.2619304,naive,0.47885698,boosting,0.47579303
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",cell,0.2212203,of,0.48460138,generative,0.39753264
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",distribution,0.30514538,of,0.5765607,clustering,0.53621584
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",mucosal-immune,0.25840542,naive,0.5038828,boosting,0.4409712
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",immune-cell,0.29683498,naive,0.4695148,generative-model,0.40028018
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",cell-distribution,0.42098835,stochastic-gradient,0.6029666,stochastic-gradient,0.6029666
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",healthy,0.31399268,naive,0.5051062,artificial-intelligence,0.3681498
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",female,0.2642398,naive,0.4711159,generative,0.42489284
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",volunteers,0.30726182,naive,0.44522986,one-shot,0.38644004
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",aged,0.26166397,naive,0.41497838,short-term-memory,0.36555237
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",cisgender,0.31205055,adversarial,0.5177537,natural-language,0.5002812
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",women,0.25528732,descent,0.50278515,dropout,0.37675467
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",entry,0.22865202,tracking,0.4080185,clustering,0.37071088
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",using,0.47332245,analysis,0.5968549,component-analysis,0.526608
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",mucosal,0.21299721,of,0.4234106,boosting,0.40373027
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",immune,0.2619304,naive,0.47885698,boosting,0.47579303
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",cells,0.20327199,naive,0.5115537,generative,0.40616876
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",mucosal-immune,0.25840542,naive,0.5038828,boosting,0.4409712
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",immune-cells,0.25092477,naive,0.50141454,generative,0.37804058
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",observational,0.46483666,data,0.5993095,data-science,0.5474411
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",studies,0.30135098,data,0.6349237,component-analysis,0.41327482
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",suggest,0.26874092,data,0.5391823,long-short-term,0.40288782
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",studies-suggest,0.41422692,data,0.5602716,component-analysis,0.55631864
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",copper,0.22155303,layer,0.38076472,feature-reduction,0.35380554
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",intrauterine,0.19251248,term,0.47781944,pytorch,0.39228642
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",device,0.3480761,computer-vision,0.53478765,computer-vision,0.53478765
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",copper-intrauterine,0.20410645,pytorch,0.42019024,pytorch,0.42019024
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",intrauterine-device,0.28574347,term,0.4348393,artificial-intelligence,0.42950496
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",containing,0.25114298,of,0.51960796,fully-connected,0.38334632
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",oral,0.24590528,of,0.46959797,boosting,0.3483035
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",contraceptive,0.26979262,decision,0.38513955,natural-language,0.38474274
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",oral-contraceptive,0.29811966,natural-language,0.45826152,natural-language,0.45826152
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",fusion,0.28159994,data-augmentation,0.43175727,data-augmentation,0.43175727
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",assay,0.28104568,analysis,0.46296048,component-analysis,0.37250015
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",participants,0.4160846,object-tracking,0.5017827,object-tracking,0.5017827
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",comparing,0.42273027,of,0.5523274,statistical,0.50475013
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",fusion,0.28159994,data-augmentation,0.43175727,data-augmentation,0.43175727
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",susceptibility,0.22526515,of,0.40366468,clustering,0.38487655
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",fusion,0.28159994,data-augmentation,0.43175727,data-augmentation,0.43175727
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",susceptibility,0.22526515,of,0.40366468,clustering,0.38487655
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",iud,0.14566326,pytorch,0.35542846,pytorch,0.35542846
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",levonorgestrel,0.165494,batch,0.2908879,tfidf,0.28236002
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",upper,0.22255614,deep,0.5399081,bagging,0.37077722
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",compared,0.3359061,of,0.52794564,long-short-term,0.42386633
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",immune,0.2619304,naive,0.47885698,boosting,0.47579303
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",cells,0.20327199,naive,0.5115537,generative,0.40616876
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",immune-cells,0.25092477,naive,0.50141454,generative,0.37804058
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",entry,0.22865202,tracking,0.4080185,clustering,0.37071088
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",susceptibility,0.22526515,of,0.40366468,clustering,0.38487655
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",containing,0.25114298,of,0.51960796,fully-connected,0.38334632
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",iud,0.14566326,pytorch,0.35542846,pytorch,0.35542846
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",transmission,0.27285886,clustering,0.44531485,clustering,0.44531485
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",risk,0.35860935,recurrent,0.53675485,logistic-regression,0.52381086
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",infection,0.22309746,recurrent,0.4494667,boosting,0.3635876
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",three,0.36911732,one,0.78425425,clustering,0.4299444
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",participants,0.4160846,object-tracking,0.5017827,object-tracking,0.5017827
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",variable,0.37856048,of,0.60098064,regression,0.54398334
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",effects,0.2624804,short-term,0.63497096,long-short-term,0.5306107
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",unexposed,0.1886647,naive,0.46819532,ground-truth,0.3124457
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",controls,0.2521493,naive,0.47579613,statistical,0.41853178
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",understanding,0.42499995,feature-engineering,0.552827,feature-engineering,0.552827
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",effects,0.2624804,short-term,0.63497096,long-short-term,0.5306107
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",transmitted,0.28198218,connected,0.46470797,generative,0.42827857
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",founder,0.2769521,descent,0.48095092,generative,0.45116276
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",transmitted-founder,0.40785396,stochastic,0.55585396,stochastic,0.55585396
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",tissue,0.23679586,of,0.5202017,segmentation,0.4076932
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",composition,0.28646052,components,0.5826185,clustering,0.4698063
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",tissue-composition,0.42612347,convolutional-layer,0.56304073,convolutional-layer,0.56304073
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",sex,0.24554862,regression,0.45148212,regression,0.45148212
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",steroids,0.16143042,term,0.40998086,long-short-term,0.3532647
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",sex-steroids,0.16926737,natural,0.3862512,long-short-term,0.3570993
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",potential,0.3558654,of,0.5645705,generative-model,0.46479023
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",mechanism,0.2780391,cascade,0.59194523,feed-forward,0.5341974
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",peripheral,0.27531123,of,0.47952008,short-term-memory,0.3612224
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",blood,0.16939776,normalization,0.4272251,batch-normalization,0.40715772
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",peripheral-blood,0.30652508,naive,0.49009967,short-term-memory,0.41375494
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",medroxyprogesterone,0.15999864,short-term,0.36808246,long-short-term,0.3094269
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",acetate,0.1438339,gradient,0.39459032,gradient,0.39459032
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",medroxyprogesterone-acetate,0.1689043,short-term,0.32206044,centroid-based,0.32097125
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",luteal,0.1591033,augmentation,0.32696068,long-short-term-memory,0.31412905
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",phase,0.23814097,hidden-layer,0.45645207,hidden-layer,0.45645207
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",luteal-phase,0.23432857,batch,0.4021728,batch-normalization,0.39147764
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",little,0.27074662,few,0.67553365,long-short-term,0.41808233
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",influence,0.28847128,of,0.5577396,dimensionality-reduction,0.44893894
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",leading,0.2514689,of,0.59935343,generative,0.44480726
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",cause,0.19388393,of,0.47843847,confusion-matrix,0.34079778
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",leading-cause,0.3739639,stochastic,0.5363524,stochastic,0.5363524
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",increased,0.26921988,reduction,0.6514183,boosting,0.46515882
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",risk,0.35860935,recurrent,0.53675485,logistic-regression,0.52381086
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",increased-risk,0.39064288,logistic-regression,0.491068,logistic-regression,0.491068
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",higher,0.27819592,reduction,0.545787,boosting,0.41506222
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",rates,0.24094881,rate,0.8800579,dropout,0.48159522
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",higher-rates,0.3992651,rate,0.5115562,long-short-term,0.4924561
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",four,0.34899807,one,0.769816,clustering,0.40005642
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",groups,0.2727722,statistical,0.4438421,statistical,0.4438421
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",four-groups,0.4700577,principal-components,0.5967665,principal-components,0.5967665
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",endometrial,0.20179304,recurrent,0.35371277,dropout,0.29705778
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",biopsies,0.29040152,segmentation,0.3737896,segmentation,0.3737896
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",chronic,0.22727785,recurrent,0.5279353,long-short-term,0.4292153
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",control,0.27050394,of,0.5093193,artificial-intelligence,0.40948874
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",chronic-control,0.36947343,reinforcement-learning,0.5078137,reinforcement-learning,0.5078137
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",control,0.27050394,of,0.5093193,artificial-intelligence,0.40948874
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",samples,0.3088399,analysis,0.4981357,batch-normalization,0.44174457
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",control-samples,0.4556097,statistical,0.55393094,statistical,0.55393094
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",based,0.49998575,classification-algorithm,0.5639226,classification-algorithm,0.5639226
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",hiv,0.30580992,natural-language,0.39600608,natural-language,0.39600608
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",studied,0.26534057,of,0.63097596,generative-model,0.40392917
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",cells,0.20327199,naive,0.5115537,generative,0.40616876
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",susceptibility,0.22526515,of,0.40366468,clustering,0.38487655
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",levonorgestrel,0.165494,batch,0.2908879,tfidf,0.28236002
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",samples,0.3088399,analysis,0.4981357,batch-normalization,0.44174457
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",hiv,0.30580992,natural-language,0.39600608,natural-language,0.39600608
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",virus,0.27194685,vector,0.4519252,vector-machine,0.4189635
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",virion,0.28842628,processing,0.43628433,graphics-processing-unit,0.39573738
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",users,0.44838846,computer,0.47765467,computer-vision,0.47360408
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",unclear,0.29818678,fully,0.5238396,long-short-term,0.43300012
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",subtype,0.27499512,classification,0.5114993,classification,0.5114993
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",study,0.3645851,of,0.5728763,statistical,0.44204497
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",role,0.2562992,function,0.5340955,feed-forward,0.4137928
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",origin,0.2085904,of,0.56003475,generative,0.46984538
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",none,0.2957736,one,0.6308826,statistical,0.4030655
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",n,0.24332823,of,0.45693433,long-short-term,0.34114176
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",mid,0.23007318,bagging,0.4472025,bagging,0.4472025
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",mechanisms,0.33716813,cascade,0.55730975,feed-forward,0.5072272
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",measured,0.25103813,of,0.539739,batch-normalization,0.45439726
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",may,0.30907542,of,0.58654004,long-short-term,0.43985203
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",long,0.20028201,long,1.0,long-short-term,0.6505779
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",likely,0.28872275,one,0.55131567,generative,0.3953101
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",importance,0.3427571,of,0.5794183,feature-engineering,0.46667784
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",highlighting,0.4483893,of,0.6206035,feature-engineering,0.5915537
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",globally,0.41541326,federated,0.5624913,random-forest,0.49394214
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",fuse,0.3846233,segmentation,0.51061046,segmentation,0.51061046
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",found,0.2840244,of,0.6208722,clustering,0.44675255
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",endometrium,0.15920351,layer,0.39992088,generative,0.32761788
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",effect,0.21449387,short-term,0.5886732,long-short-term,0.47619703
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",differences,0.3361535,statistical,0.57447433,statistical,0.57447433
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",differ,0.26580223,of,0.45475316,statistical,0.3820433
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",depo,0.09666467,shot,0.36531046,relu,0.35537565
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",data,0.46434748,data,1.0,data-science,0.5533528
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",contraceptives,0.2528426,confusion,0.3684134,natural-language,0.35454175
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",cervix,0.14919269,term,0.36706322,pytorch,0.3025964
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",c,0.17513797,of,0.44327667,gradient,0.31114018
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",b,0.19558734,of,0.43435428,short-term-memory,0.31717262
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",associated,0.30827495,of,0.57598466,long-short-term,0.46578532
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",aids,0.3577932,natural-language,0.47674245,natural-language,0.47674245
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",activity,0.21813896,function,0.53536034,boosting,0.38798416
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",ability,0.39144984,function,0.5937173,generative,0.47758824
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",aliskiren,0.26036164,softmax,0.33459097,softmax,0.33459097
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",treatment,0.239264,short-term,0.5206091,long-short-term,0.41699445
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",normalized,0.3501855,normalization,0.79768026,batch-normalization,0.69691867
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",pathologically,0.30179298,recurrent,0.45317626,recurrent-neural-network,0.3734901
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",elevated,0.19494015,normalization,0.5246306,batch-normalization,0.44167417
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",plasma,0.21912897,normalization,0.4569842,batch-normalization,0.43571177
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",renin,0.22382896,normalization,0.36536643,batch-normalization,0.34999466
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",activity,0.21813896,function,0.53536034,boosting,0.38798416
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",pathologically-elevated,0.38490027,of,0.54374456,generative-model,0.45865932
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",plasma-renin,0.20040265,batch-normalization,0.4692778,batch-normalization,0.4692778
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",renin-activity,0.23628928,function,0.46620768,batch-normalization,0.42558914
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",plasma-renin-activity,0.23894405,batch-normalization,0.49867404,batch-normalization,0.49867404
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",targeting,0.35599935,boosting,0.504551,boosting,0.504551
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",pathologically,0.30179298,recurrent,0.45317626,recurrent-neural-network,0.3734901
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",elevated,0.19494015,normalization,0.5246306,batch-normalization,0.44167417
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",plasma,0.21912897,normalization,0.4569842,batch-normalization,0.43571177
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",renin,0.22382896,normalization,0.36536643,batch-normalization,0.34999466
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",activity,0.21813896,function,0.53536034,boosting,0.38798416
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",may,0.30907542,of,0.58654004,long-short-term,0.43985203
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",pathologically-elevated,0.38490027,of,0.54374456,generative-model,0.45865932
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",plasma-renin,0.20040265,batch-normalization,0.4692778,batch-normalization,0.4692778
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",renin-activity,0.23628928,function,0.46620768,batch-normalization,0.42558914
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",activity-may,0.38332164,learning-function,0.5159675,learning-function,0.5159675
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",plasma-renin-activity,0.23894405,batch-normalization,0.49867404,batch-normalization,0.49867404
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",elevated,0.19494015,normalization,0.5246306,batch-normalization,0.44167417
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",plasma,0.21912897,normalization,0.4569842,batch-normalization,0.43571177
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",renin,0.22382896,normalization,0.36536643,batch-normalization,0.34999466
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",activity,0.21813896,function,0.53536034,boosting,0.38798416
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",concentrations,0.16781005,of,0.4458394,batch-normalization,0.42195582
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",plasma-renin,0.20040265,batch-normalization,0.4692778,batch-normalization,0.4692778
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",renin-activity,0.23628928,function,0.46620768,batch-normalization,0.42558914
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",plasma-renin-activity,0.23894405,batch-normalization,0.49867404,batch-normalization,0.49867404
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",elevated,0.19494015,normalization,0.5246306,batch-normalization,0.44167417
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",plasma,0.21912897,normalization,0.4569842,batch-normalization,0.43571177
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",renin,0.22382896,normalization,0.36536643,batch-normalization,0.34999466
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",activity,0.21813896,function,0.53536034,boosting,0.38798416
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",reduced,0.24137571,reduction,0.7564339,boosting,0.47559226
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",plasma-renin,0.20040265,batch-normalization,0.4692778,batch-normalization,0.4692778
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",renin-activity,0.23628928,function,0.46620768,batch-normalization,0.42558914
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",activity-reduced,0.40753078,dimensionality-reduction,0.63915527,dimensionality-reduction,0.63915527
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",plasma-renin-activity,0.23894405,batch-normalization,0.49867404,batch-normalization,0.49867404
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",aliskiren,0.26036164,softmax,0.33459097,softmax,0.33459097
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",improved,0.40049985,normalization,0.5598826,boosting,0.5069493
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",cardiac,0.29562658,of,0.42777455,long-short-term,0.35708636
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",systolic,0.25626805,function,0.41296047,gradient,0.40985143
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",function,0.3447219,function,1.0,learning-function,0.5767432
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",systolic-function,0.37460995,function,0.587615,learning-function,0.5712657
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",elevated,0.19494015,normalization,0.5246306,batch-normalization,0.44167417
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",plasma,0.21912897,normalization,0.4569842,batch-normalization,0.43571177
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",renin,0.22382896,normalization,0.36536643,batch-normalization,0.34999466
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",activity,0.21813896,function,0.53536034,boosting,0.38798416
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",plasma-renin,0.20040265,batch-normalization,0.4692778,batch-normalization,0.4692778
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",renin-activity,0.23628928,function,0.46620768,batch-normalization,0.42558914
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",plasma-renin-activity,0.23894405,batch-normalization,0.49867404,batch-normalization,0.49867404
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",plasma,0.21912897,normalization,0.4569842,batch-normalization,0.43571177
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",renin,0.22382896,normalization,0.36536643,batch-normalization,0.34999466
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",activity,0.21813896,function,0.53536034,boosting,0.38798416
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",retards,0.14614382,of,0.46905687,long-short-term,0.37579545
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",plasma-renin,0.20040265,batch-normalization,0.4692778,batch-normalization,0.4692778
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",renin-activity,0.23628928,function,0.46620768,batch-normalization,0.42558914
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",plasma-renin-activity,0.23894405,batch-normalization,0.49867404,batch-normalization,0.49867404
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",improving,0.40742207,boosting,0.54548407,boosting,0.54548407
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",cardiac,0.29562658,of,0.42777455,long-short-term,0.35708636
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",systolic,0.25626805,function,0.41296047,gradient,0.40985143
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",function,0.3447219,function,1.0,learning-function,0.5767432
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",systolic-function,0.37460995,function,0.587615,learning-function,0.5712657
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",significantly,0.27887642,of,0.5214151,long-short-term,0.39056638
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",alter,0.25806507,function,0.5040295,stochastic,0.37585503
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",pathological,0.35600212,of,0.48665273,classification,0.46512192
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",changes,0.28767496,normalization,0.57879114,batch-normalization,0.43861648
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",pathological-changes,0.40971887,normalization,0.49582613,classification,0.4793505
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",appropriately,0.32867995,fully,0.5640376,bagging,0.40499753
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",selected,0.38157707,selection,0.6797303,feature-selection,0.48698312
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",hf,0.293398,long-short-term,0.35116297,long-short-term,0.35116297
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",patients,0.30007,recurrent,0.5332828,dropout,0.3918751
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",appropriately-selected,0.4337747,random,0.56948113,feature-selection,0.49785852
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",hf-patients,0.27912942,dropout,0.4020663,dropout,0.4020663
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",direct,0.22395119,of,0.5187454,one-shot,0.4431845
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",renin,0.22382896,normalization,0.36536643,batch-normalization,0.34999466
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",inhibitor,0.21582735,cascade,0.38918662,feed-forward,0.33560163
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",renin-inhibitor,0.2646875,function,0.37811035,feed-forward,0.35130626
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",blinded,0.37473285,supervised,0.49303147,supervised,0.49303147
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",fashion,0.27774477,fully,0.4587194,feature-reduction,0.44652522
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",beginning,0.3284063,few,0.55860555,generative,0.42997605
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",blinded-fashion,0.39319402,supervised,0.4984747,supervised,0.4984747
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",atrial,0.2285939,long-short,0.40266213,long-short-term,0.38994598
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",natriuretic,0.26007023,function,0.33372766,learning-function,0.3213495
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",peptide,0.3208105,encoding,0.44188768,boosting,0.35291767
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",atrial-natriuretic,0.25092524,long-short-term,0.37958118,long-short-term,0.37958118
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",natriuretic-peptide,0.31423682,batch-normalization,0.36770314,batch-normalization,0.36770314
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",atrial-natriuretic-peptide,0.31243157,batch-normalization,0.39798868,batch-normalization,0.39798868
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",stage,0.30396575,classification,0.4731305,classification,0.4731305
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",c,0.17513797,of,0.44327667,gradient,0.31114018
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",hf,0.293398,long-short-term,0.35116297,long-short-term,0.35116297
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",stage-c,0.22567838,generative,0.43342566,generative,0.43342566
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",c-hf,0.25370315,nearest-neighbors,0.3502115,nearest-neighbors,0.3502115
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",stage,0.30396575,classification,0.4731305,classification,0.4731305
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",b,0.19558734,of,0.43435428,short-term-memory,0.31717262
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",hf,0.293398,long-short-term,0.35116297,long-short-term,0.35116297
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",stage-b,0.26486883,classification-algorithm,0.4149413,classification-algorithm,0.4149413
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",b-hf,0.21976407,nearest-neighbors,0.34248066,nearest-neighbors,0.34248066
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",retarding,0.24549876,of,0.5068949,feature-reduction,0.42980307
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",plasma,0.21912897,normalization,0.4569842,batch-normalization,0.43571177
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",aldosterone,0.1929466,batch-normalization,0.3580841,batch-normalization,0.3580841
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",plasma-aldosterone,0.18710881,batch-normalization,0.44144815,batch-normalization,0.44144815
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",significantly,0.27887642,of,0.5214151,long-short-term,0.39056638
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",reduced,0.24137571,reduction,0.7564339,boosting,0.47559226
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",significantly-reduced,0.3703707,reduction,0.61161596,feature-reduction,0.53799415
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",sarcopenia,0.3667763,tfidf,0.43032652,tfidf,0.43032652
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",p,0.26795468,support,0.40805867,regression,0.40253854
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",cardiac,0.29562658,of,0.42777455,long-short-term,0.35708636
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",output,0.3627781,bag,0.5289762,softmax,0.47921252
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",cardiac-output,0.4087693,learning-function,0.4846991,learning-function,0.4846991
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",stage,0.30396575,classification,0.4731305,classification,0.4731305
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",b,0.19558734,of,0.43435428,short-term-memory,0.31717262
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",stage-b,0.26486883,classification-algorithm,0.4149413,classification-algorithm,0.4149413
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",patients,0.30007,recurrent,0.5332828,dropout,0.3918751
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",frequently,0.3283582,few,0.57415104,clustering,0.41482496
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",aliskiren,0.26036164,softmax,0.33459097,softmax,0.33459097
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",human,0.30336243,of,0.5175895,feature-engineering,0.40631005
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",hf,0.293398,long-short-term,0.35116297,long-short-term,0.35116297
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",experimental,0.40167695,model,0.6248311,generative-model,0.6004326
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",hf,0.293398,long-short-term,0.35116297,long-short-term,0.35116297
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",relevant,0.4346258,of,0.5628227,natural-language,0.5076148
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",model,0.48485535,model,1.0,markov-model,0.7005576
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",prolonged,0.19092911,short-term,0.6621231,long-short-term,0.6502685
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",survival,0.29004025,short-term,0.53135407,long-short-term,0.4573617
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",progressive,0.3352378,recurrent,0.5441647,confusion-matrix,0.47422853
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",stages,0.324753,generative,0.5243855,generative,0.5243855
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",neprilysin,0.32175615,matrix,0.42883646,graphics-processing,0.36731273
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",levels,0.20457911,normalization,0.52984333,batch-normalization,0.45617118
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",lean,0.3062906,feed,0.47777596,batch-normalization,0.41364604
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",mass,0.22818582,fourier-transform,0.42889374,fourier-transform,0.42889374
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",lean-mass,0.38473934,fourier-transform,0.5005195,fourier-transform,0.5005195
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",heart,0.28300244,rate,0.49867767,batch-normalization,0.3427502
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",failure,0.32964212,recurrent,0.52057266,confusion-matrix,0.44323406
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",heart-failure,0.36450487,long-short-term,0.44014218,long-short-term,0.44014218
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",female,0.2642398,naive,0.4711159,generative,0.42489284
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",mice,0.24457785,naive,0.4783403,short-term-memory,0.38200378
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",female-mice,0.20252119,descent,0.3720487,generative,0.36969233
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",extracellular,0.29317284,matrix,0.62536657,confusion-matrix,0.42919844
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",water,0.30284643,feed,0.5419835,gradient,0.42149428
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",ejection,0.30230433,function,0.43955976,gradient,0.35697576
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",fraction,0.25137818,component,0.50911963,gradient,0.48876822
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",ejection-fraction,0.36681443,stochastic-gradient,0.5523829,stochastic-gradient,0.5523829
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",dilated,0.22810468,function,0.40786004,confusion-matrix,0.32808268
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",cardiomyopathy,0.29507846,confusion-matrix,0.3794037,confusion-matrix,0.3794037
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",dilated-cardiomyopathy,0.3131293,confusion-matrix,0.4146229,confusion-matrix,0.4146229
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",dcm,0.3179137,tensorflow,0.32136202,tensorflow,0.32136202
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",data,0.46434748,data,1.0,data-science,0.5533528
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",suggest,0.26874092,data,0.5391823,long-short-term,0.40288782
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",data-suggest,0.5929872,data,0.6553265,data-science,0.65163726
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",corin,0.26377353,function,0.38375765,long-short-term,0.32174432
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",levels,0.20457911,normalization,0.52984333,batch-normalization,0.45617118
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",body,0.2149021,of,0.4173455,segmentation,0.3712382
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",fat,0.22005057,feed,0.48228577,segmentation,0.36863354
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",body-fat,0.22953969,style,0.42705548,tfidf,0.3811146
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",angiotensin,0.21236175,matrix,0.35242182,feed-forward,0.31253523
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",ii,0.22929578,of,0.43728137,classification,0.3694628
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",angiotensin-ii,0.178305,matrix,0.35608318,feed-forward,0.2816677
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",systemic,0.28055844,of,0.49342385,boosting,0.37910926
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",edema,0.23187585,confusion,0.45859054,bagging,0.35474205
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",longitudinal,0.3201388,data,0.4832245,regression,0.4622656
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",development,0.34732813,generative,0.56588423,generative,0.56588423
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",hf,0.293398,long-short-term,0.35116297,long-short-term,0.35116297
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",sarcopenia,0.3667763,tfidf,0.43032652,tfidf,0.43032652
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",p,0.26795468,support,0.40805867,regression,0.40253854
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",edema,0.23187585,confusion,0.45859054,bagging,0.35474205
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",development,0.34732813,generative,0.56588423,generative,0.56588423
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",dcm,0.3179137,tensorflow,0.32136202,tensorflow,0.32136202
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",treated,0.19958335,of,0.5218221,long-short-term,0.35705733
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",translationally,0.36525565,encoding,0.58189636,generative,0.48580003
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",transition,0.2521789,ground,0.5124147,transfer-learning,0.4300129
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",summary,0.3869185,data,0.59051514,component-analysis,0.44181547
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",significance,0.39249778,statistical,0.67423874,statistical,0.67423874
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",replicates,0.39930105,feature-selection,0.45735568,feature-selection,0.45735568
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",reducing,0.26140445,reduction,0.74160737,boosting,0.5133524
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",randomized,0.35587335,short-term,0.45843548,supervised,0.43708503
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",progression,0.31600362,recurrent,0.52875245,regression,0.51750124
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",normalization,0.43240863,normalization,1.0,batch-normalization,0.83571
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",mortality,0.2609817,short-term,0.505676,logistic-regression,0.49414968
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",loss,0.26544642,reduction,0.62177265,dropout,0.42517614
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",examined,0.295101,of,0.66699874,generative,0.4320032
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",controls,0.2521493,naive,0.47579613,statistical,0.41853178
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",comparison,0.38020527,analysis,0.5798166,statistical,0.52489424
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",cachexia,0.2777853,confusion,0.38733333,logistic-regression,0.33359426
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",beneficial,0.32497615,short-term,0.59825146,long-short-term,0.5331938
Sensor Networks for Aerospace Human-Machine Systems.,support,0.3815906,support,1.0,support-vector,0.66958183
Sensor Networks for Aerospace Human-Machine Systems.,diverse,0.38913006,of,0.5461366,feature-engineering,0.51537836
Sensor Networks for Aerospace Human-Machine Systems.,tasks,0.539186,object-tracking,0.6899523,object-tracking,0.6899523
Sensor Networks for Aerospace Human-Machine Systems.,including,0.3233776,of,0.6619886,clustering,0.40625107
Sensor Networks for Aerospace Human-Machine Systems.,data,0.46434748,data,1.0,data-science,0.5533528
Sensor Networks for Aerospace Human-Machine Systems.,processing,0.46109343,processing,1.0,graphics-processing,0.75397617
Sensor Networks for Aerospace Human-Machine Systems.,tasks-including,0.51466346,object-tracking,0.6416332,object-tracking,0.6416332
Sensor Networks for Aerospace Human-Machine Systems.,data-processing,0.66045094,graphics-processing,0.8807796,graphics-processing,0.8807796
Sensor Networks for Aerospace Human-Machine Systems.,atm,0.20317698,numpy,0.34126982,numpy,0.34126982
Sensor Networks for Aerospace Human-Machine Systems.,commercial,0.33454847,batch,0.54504764,data-engineering,0.47706312
Sensor Networks for Aerospace Human-Machine Systems.,airliner,0.37493646,machine,0.5205079,vector-machine,0.48526406
Sensor Networks for Aerospace Human-Machine Systems.,single,0.31087106,one,0.6951874,one-shot,0.4602274
Sensor Networks for Aerospace Human-Machine Systems.,suitable,0.41982245,selection,0.5456965,feature-engineering,0.4980862
Sensor Networks for Aerospace Human-Machine Systems.,data,0.46434748,data,1.0,data-science,0.5533528
Sensor Networks for Aerospace Human-Machine Systems.,analysis,0.46507934,analysis,0.99999994,component-analysis,0.69613737
Sensor Networks for Aerospace Human-Machine Systems.,techniques,0.5005199,data-augmentation,0.5285406,data-augmentation,0.5285406
Sensor Networks for Aerospace Human-Machine Systems.,based,0.49998575,classification-algorithm,0.5639226,classification-algorithm,0.5639226
Sensor Networks for Aerospace Human-Machine Systems.,data-analysis,0.67556036,statistical,0.7199346,statistical,0.7199346
Sensor Networks for Aerospace Human-Machine Systems.,techniques-based,0.6015886,feature-engineering,0.6250907,feature-engineering,0.6250907
Sensor Networks for Aerospace Human-Machine Systems.,obtain,0.38573402,of,0.51702356,batch-normalization,0.46553272
Sensor Networks for Aerospace Human-Machine Systems.,accurate,0.50905025,algorithm,0.5474155,algorithm,0.5474155
Sensor Networks for Aerospace Human-Machine Systems.,cognitive,0.5010079,memory,0.72449946,learning-function,0.7178915
Sensor Networks for Aerospace Human-Machine Systems.,state,0.24944685,ground,0.5794469,stochastic,0.40597248
Sensor Networks for Aerospace Human-Machine Systems.,estimations,0.44116342,batch-normalization,0.60426503,batch-normalization,0.60426503
Sensor Networks for Aerospace Human-Machine Systems.,cognitive-state,0.5574657,learning-function,0.67367953,learning-function,0.67367953
Sensor Networks for Aerospace Human-Machine Systems.,including,0.3233776,of,0.6619886,clustering,0.40625107
Sensor Networks for Aerospace Human-Machine Systems.,air,0.20988894,bag,0.5110363,bagging,0.5097396
Sensor Networks for Aerospace Human-Machine Systems.,traffic,0.35098532,clustering,0.4834436,clustering,0.4834436
Sensor Networks for Aerospace Human-Machine Systems.,management,0.38786528,decision,0.59816897,decision-tree,0.49756956
Sensor Networks for Aerospace Human-Machine Systems.,air-traffic,0.35681722,ground-truth,0.47505683,ground-truth,0.47505683
Sensor Networks for Aerospace Human-Machine Systems.,traffic-management,0.49218047,decision-tree,0.53447175,decision-tree,0.53447175
Sensor Networks for Aerospace Human-Machine Systems.,paper,0.5017176,graphics-processing,0.53198814,graphics-processing,0.53198814
Sensor Networks for Aerospace Human-Machine Systems.,discusses,0.40833443,feature-engineering,0.4978721,feature-engineering,0.4978721
Sensor Networks for Aerospace Human-Machine Systems.,recent,0.35249484,of,0.545993,data-engineering,0.4259707
Sensor Networks for Aerospace Human-Machine Systems.,advances,0.45830926,data-engineering,0.5886656,data-engineering,0.5886656
Sensor Networks for Aerospace Human-Machine Systems.,many,0.40940517,few,0.752018,feature-engineering,0.48454586
Sensor Networks for Aerospace Human-Machine Systems.,unmanned,0.48282644,ground-truth,0.627619,ground-truth,0.627619
Sensor Networks for Aerospace Human-Machine Systems.,aircraft,0.33252585,ground-truth,0.4992718,ground-truth,0.4992718
Sensor Networks for Aerospace Human-Machine Systems.,systems,0.40840507,components,0.5468041,feature-engineering,0.5135208
Sensor Networks for Aerospace Human-Machine Systems.,key,0.35973132,principal,0.614877,feature-engineering,0.498355
Sensor Networks for Aerospace Human-Machine Systems.,neurophysiological,0.49097133,learning-function,0.63524336,learning-function,0.63524336
Sensor Networks for Aerospace Human-Machine Systems.,measurements,0.31488982,data,0.56587404,batch-normalization,0.52457345
Sensor Networks for Aerospace Human-Machine Systems.,used,0.46049535,of,0.5630944,generative-model,0.4901716
Sensor Networks for Aerospace Human-Machine Systems.,various,0.35606545,of,0.6378319,generative,0.45850474
Sensor Networks for Aerospace Human-Machine Systems.,challenging,0.4561266,hidden,0.5622939,feature-engineering,0.53377354
Sensor Networks for Aerospace Human-Machine Systems.,aerospace,0.44318384,data-engineering,0.644886,data-engineering,0.644886
Sensor Networks for Aerospace Human-Machine Systems.,applications,0.4878226,data-engineering,0.70112944,data-engineering,0.70112944
Sensor Networks for Aerospace Human-Machine Systems.,techniques,0.5005199,data-augmentation,0.5285406,data-augmentation,0.5285406
Sensor Networks for Aerospace Human-Machine Systems.,allow,0.4373722,of,0.5533963,feature-engineering,0.5170868
Sensor Networks for Aerospace Human-Machine Systems.,processing,0.46109343,processing,1.0,graphics-processing,0.75397617
Sensor Networks for Aerospace Human-Machine Systems.,based,0.49998575,classification-algorithm,0.5639226,classification-algorithm,0.5639226
Sensor Networks for Aerospace Human-Machine Systems.,inference,0.6877559,bayesian,0.838166,bayesian,0.838166
Sensor Networks for Aerospace Human-Machine Systems.,engine,0.5785463,machine,0.60924566,graphics-processing,0.5922989
Sensor Networks for Aerospace Human-Machine Systems.,sipo,0.29284233,ground-truth,0.38214463,ground-truth,0.38214463
Sensor Networks for Aerospace Human-Machine Systems.,one,0.335046,one,1.0,one-hot,0.4275648
Sensor Networks for Aerospace Human-Machine Systems.,space,0.37602258,hidden,0.5045786,segmentation,0.4642222
Sensor Networks for Aerospace Human-Machine Systems.,operations,0.4005868,data-augmentation,0.49775013,data-augmentation,0.49775013
Sensor Networks for Aerospace Human-Machine Systems.,management,0.38786528,decision,0.59816897,decision-tree,0.49756956
Sensor Networks for Aerospace Human-Machine Systems.,neurophysiological,0.49097133,learning-function,0.63524336,learning-function,0.63524336
Sensor Networks for Aerospace Human-Machine Systems.,observations,0.32199246,data,0.69908524,generative,0.44571877
Sensor Networks for Aerospace Human-Machine Systems.,becoming,0.40052497,few,0.58543956,generative,0.4861775
Sensor Networks for Aerospace Human-Machine Systems.,proper,0.3570277,of,0.5900549,segmentation,0.4722571
Sensor Networks for Aerospace Human-Machine Systems.,sensor,0.39054433,tracking,0.4828847,neural-network,0.47259283
Sensor Networks for Aerospace Human-Machine Systems.,selection,0.46716303,selection,1.0,feature-selection,0.6859601
Sensor Networks for Aerospace Human-Machine Systems.,sensor-selection,0.56339085,feature-selection,0.718543,feature-selection,0.718543
Sensor Networks for Aerospace Human-Machine Systems.,various,0.35606545,of,0.6378319,generative,0.45850474
Sensor Networks for Aerospace Human-Machine Systems.,state,0.24944685,ground,0.5794469,stochastic,0.40597248
Sensor Networks for Aerospace Human-Machine Systems.,operational,0.501031,data-engineering,0.6183307,data-engineering,0.6183307
Sensor Networks for Aerospace Human-Machine Systems.,data,0.46434748,data,1.0,data-science,0.5533528
Sensor Networks for Aerospace Human-Machine Systems.,exchange,0.28460225,gradient-descent,0.52362746,gradient-descent,0.52362746
Sensor Networks for Aerospace Human-Machine Systems.,data,0.46434748,data,1.0,data-science,0.5533528
Sensor Networks for Aerospace Human-Machine Systems.,uas,0.23226662,segmentation-algorithm,0.31417957,segmentation-algorithm,0.31417957
Sensor Networks for Aerospace Human-Machine Systems.,paper,0.5017176,graphics-processing,0.53198814,graphics-processing,0.53198814
Sensor Networks for Aerospace Human-Machine Systems.,addresses,0.49031922,data-science,0.58262885,data-science,0.58262885
Sensor Networks for Aerospace Human-Machine Systems.,cognitive,0.5010079,memory,0.72449946,learning-function,0.7178915
Sensor Networks for Aerospace Human-Machine Systems.,states,0.26295346,ground,0.5876442,confusion-matrix,0.40829715
Sensor Networks for Aerospace Human-Machine Systems.,cognitive-states,0.5461716,learning-function,0.67349267,learning-function,0.67349267
Sensor Networks for Aerospace Human-Machine Systems.,cognitive,0.5010079,memory,0.72449946,learning-function,0.7178915
Sensor Networks for Aerospace Human-Machine Systems.,aerospace,0.44318384,data-engineering,0.644886,data-engineering,0.644886
Sensor Networks for Aerospace Human-Machine Systems.,cyber,0.44149327,adversarial,0.5900159,data-science,0.52468157
Sensor Networks for Aerospace Human-Machine Systems.,physical,0.35362238,supervised,0.4900735,supervised,0.4900735
Sensor Networks for Aerospace Human-Machine Systems.,systems,0.40840507,components,0.5468041,feature-engineering,0.5135208
Sensor Networks for Aerospace Human-Machine Systems.,machine,0.7094662,machine,1.0,machine-learning,0.7094662
Sensor Networks for Aerospace Human-Machine Systems.,systems,0.40840507,components,0.5468041,feature-engineering,0.5135208
Sensor Networks for Aerospace Human-Machine Systems.,statistical,0.6074636,statistical,1.0,statistical,1.0
Sensor Networks for Aerospace Human-Machine Systems.,inference,0.6877559,bayesian,0.838166,bayesian,0.838166
Sensor Networks for Aerospace Human-Machine Systems.,statistical-inference,0.665873,statistical,0.83722985,statistical,0.83722985
Sensor Networks for Aerospace Human-Machine Systems.,sensor,0.39054433,tracking,0.4828847,neural-network,0.47259283
Sensor Networks for Aerospace Human-Machine Systems.,networks,0.53880787,network,0.91573685,neural-network,0.776492
Sensor Networks for Aerospace Human-Machine Systems.,pilot,0.42509323,short-term,0.5009069,decision-tree,0.45956868
Sensor Networks for Aerospace Human-Machine Systems.,operations,0.4005868,data-augmentation,0.49775013,data-augmentation,0.49775013
Sensor Networks for Aerospace Human-Machine Systems.,applications,0.4878226,data-engineering,0.70112944,data-engineering,0.70112944
Sensor Networks for Aerospace Human-Machine Systems.,trusted,0.5142456,adversarial,0.67072165,data-science,0.6207584
Sensor Networks for Aerospace Human-Machine Systems.,autonomy,0.35569185,style,0.6067787,artificial-intelligence,0.546006
Sensor Networks for Aerospace Human-Machine Systems.,technological,0.50801206,data-engineering,0.7099455,data-engineering,0.7099455
Sensor Networks for Aerospace Human-Machine Systems.,developments,0.44840753,data-engineering,0.62717235,data-engineering,0.62717235
Sensor Networks for Aerospace Human-Machine Systems.,states,0.26295346,ground,0.5876442,confusion-matrix,0.40829715
Sensor Networks for Aerospace Human-Machine Systems.,using,0.47332245,analysis,0.5968549,component-analysis,0.526608
Sensor Networks for Aerospace Human-Machine Systems.,states-using,0.45380098,federated,0.5619314,random-forest,0.5558614
Sensor Networks for Aerospace Human-Machine Systems.,sensors,0.39629486,data-engineering,0.52682287,data-engineering,0.52682287
Sensor Networks for Aerospace Human-Machine Systems.,collect,0.4155144,data,0.5811206,data-engineering,0.48633796
Sensor Networks for Aerospace Human-Machine Systems.,results,0.32376552,data,0.6932311,batch-normalization,0.44826904
Sensor Networks for Aerospace Human-Machine Systems.,show,0.33248252,of,0.51487744,feature-selection,0.44449317
Sensor Networks for Aerospace Human-Machine Systems.,remote,0.3797141,ground-truth,0.48204517,ground-truth,0.48204517
Sensor Networks for Aerospace Human-Machine Systems.,sensors,0.39629486,data-engineering,0.52682287,data-engineering,0.52682287
Sensor Networks for Aerospace Human-Machine Systems.,reliable,0.44908422,discriminative,0.5652059,component-analysis,0.4630433
Sensor Networks for Aerospace Human-Machine Systems.,methodology,0.5520129,data-engineering,0.61297953,data-engineering,0.61297953
Sensor Networks for Aerospace Human-Machine Systems.,performance,0.50728506,learning-function,0.63351834,learning-function,0.63351834
Sensor Networks for Aerospace Human-Machine Systems.,characterisation,0.35989636,analysis,0.61083734,feature-engineering,0.49906132
Sensor Networks for Aerospace Human-Machine Systems.,operational,0.501031,data-engineering,0.6183307,data-engineering,0.6183307
Sensor Networks for Aerospace Human-Machine Systems.,performance,0.50728506,learning-function,0.63351834,learning-function,0.63351834
Sensor Networks for Aerospace Human-Machine Systems.,notable,0.28282547,of,0.5796111,statistical,0.40416068
Sensor Networks for Aerospace Human-Machine Systems.,advantages,0.44230303,feature-engineering,0.53069293,feature-engineering,0.53069293
Sensor Networks for Aerospace Human-Machine Systems.,mission,0.38928384,data-science,0.63922644,data-science,0.63922644
Sensor Networks for Aerospace Human-Machine Systems.,execution,0.48271146,graphics-processing,0.6434237,graphics-processing,0.6434237
Sensor Networks for Aerospace Human-Machine Systems.,mission-execution,0.5133881,object-tracking,0.6421348,object-tracking,0.6421348
Sensor Networks for Aerospace Human-Machine Systems.,measurement,0.35434127,batch-normalization,0.5963583,batch-normalization,0.5963583
Sensor Networks for Aerospace Human-Machine Systems.,uncertainties,0.4368887,overfitting,0.64200485,overfitting,0.64200485
Sensor Networks for Aerospace Human-Machine Systems.,machine,0.7094662,machine,1.0,machine-learning,0.7094662
Sensor Networks for Aerospace Human-Machine Systems.,monitors,0.36318505,tracking,0.55393124,computer-vision,0.48361358
Sensor Networks for Aerospace Human-Machine Systems.,machine,0.7094662,machine,1.0,machine-learning,0.7094662
Sensor Networks for Aerospace Human-Machine Systems.,learning,0.709237,learning,1.0,deep-learning,0.8286492
Sensor Networks for Aerospace Human-Machine Systems.,machine-learning,1.0,machine-learning,1.0,machine-learning,1.0
Sensor Networks for Aerospace Human-Machine Systems.,machine,0.7094662,machine,1.0,machine-learning,0.7094662
Sensor Networks for Aerospace Human-Machine Systems.,interfaces,0.409931,feature-engineering,0.54878145,feature-engineering,0.54878145
Sensor Networks for Aerospace Human-Machine Systems.,information,0.5191034,data,0.708436,data-science,0.5937191
Sensor Networks for Aerospace Human-Machine Systems.,sharing,0.49149647,clustering,0.5725338,clustering,0.5725338
Sensor Networks for Aerospace Human-Machine Systems.,information-sharing,0.60257226,dimensionality-reduction,0.66805446,dimensionality-reduction,0.66805446
Sensor Networks for Aerospace Human-Machine Systems.,increasing,0.30868235,of,0.6603997,boosting,0.50417006
Sensor Networks for Aerospace Human-Machine Systems.,level,0.23847455,of,0.54773176,batch-normalization,0.45912555
Sensor Networks for Aerospace Human-Machine Systems.,increasing-level,0.49535093,batch-normalization,0.5748062,batch-normalization,0.5748062
Sensor Networks for Aerospace Human-Machine Systems.,controlled,0.25206095,of,0.4703986,supervised,0.39651048
Sensor Networks for Aerospace Human-Machine Systems.,remotely,0.46859646,tracking,0.57006454,ground-truth,0.5311375
Sensor Networks for Aerospace Human-Machine Systems.,art,0.38493407,natural-language,0.47805047,natural-language,0.47805047
Sensor Networks for Aerospace Human-Machine Systems.,sensors,0.39629486,data-engineering,0.52682287,data-engineering,0.52682287
Sensor Networks for Aerospace Human-Machine Systems.,also,0.32850838,of,0.65908813,clustering,0.45826355
Sensor Networks for Aerospace Human-Machine Systems.,presented,0.41586217,of,0.5919795,confusion-matrix,0.4850164
Sensor Networks for Aerospace Human-Machine Systems.,loop,0.25155255,feed-forward,0.5677347,feed-forward,0.5677347
Sensor Networks for Aerospace Human-Machine Systems.,human,0.30336243,of,0.5175895,feature-engineering,0.40631005
Sensor Networks for Aerospace Human-Machine Systems.,effective,0.32842147,of,0.50971246,boosting,0.48854327
Sensor Networks for Aerospace Human-Machine Systems.,human,0.30336243,of,0.5175895,feature-engineering,0.40631005
Sensor Networks for Aerospace Human-Machine Systems.,tasks,0.539186,object-tracking,0.6899523,object-tracking,0.6899523
Sensor Networks for Aerospace Human-Machine Systems.,support,0.3815906,support,1.0,support-vector,0.66958183
Sensor Networks for Aerospace Human-Machine Systems.,intelligent,0.6262322,artificial-intelligence,0.7647517,artificial-intelligence,0.7647517
Sensor Networks for Aerospace Human-Machine Systems.,automation,0.5910893,graphics-processing,0.70071036,graphics-processing,0.70071036
Sensor Networks for Aerospace Human-Machine Systems.,human,0.30336243,of,0.5175895,feature-engineering,0.40631005
Sensor Networks for Aerospace Human-Machine Systems.,operator,0.4600284,regularization,0.51359886,cross-entropy,0.5117044
Sensor Networks for Aerospace Human-Machine Systems.,human-operator,0.49743387,ground-truth,0.58735955,ground-truth,0.58735955
Sensor Networks for Aerospace Human-Machine Systems.,neurophysiological,0.49097133,learning-function,0.63524336,learning-function,0.63524336
Sensor Networks for Aerospace Human-Machine Systems.,human,0.30336243,of,0.5175895,feature-engineering,0.40631005
Sensor Networks for Aerospace Human-Machine Systems.,operator,0.4600284,regularization,0.51359886,cross-entropy,0.5117044
Sensor Networks for Aerospace Human-Machine Systems.,automation,0.5910893,graphics-processing,0.70071036,graphics-processing,0.70071036
Sensor Networks for Aerospace Human-Machine Systems.,wearable,0.53930736,data-engineering,0.6004859,data-engineering,0.6004859
Sensor Networks for Aerospace Human-Machine Systems.,variety,0.35310775,natural,0.5234163,generative,0.4781817
Sensor Networks for Aerospace Human-Machine Systems.,time,0.31186903,long,0.57547164,batch-normalization,0.47628766
Sensor Networks for Aerospace Human-Machine Systems.,synchronised,0.31269965,connected,0.45791066,long-short-term,0.44432825
Sensor Networks for Aerospace Human-Machine Systems.,seen,0.2411227,of,0.61171174,long-short-term,0.3944841
Sensor Networks for Aerospace Human-Machine Systems.,relationship,0.31931284,regression,0.5493294,regression,0.5493294
Sensor Networks for Aerospace Human-Machine Systems.,real,0.4954688,truth,0.5802553,ground-truth,0.56635034
Sensor Networks for Aerospace Human-Machine Systems.,propagation,0.3947974,backpropagation,0.6999179,backpropagation,0.6999179
Sensor Networks for Aerospace Human-Machine Systems.,order,0.38454574,of,0.59467053,dimensionality-reduction,0.481972
Sensor Networks for Aerospace Human-Machine Systems.,operation,0.315604,data-augmentation,0.48509696,data-augmentation,0.48509696
Sensor Networks for Aerospace Human-Machine Systems.,maximise,0.4045574,selection,0.5396984,feature-engineering,0.50495714
Sensor Networks for Aerospace Human-Machine Systems.,making,0.46086103,decision,0.71635526,generative,0.51182055
Sensor Networks for Aerospace Human-Machine Systems.,led,0.28597406,of,0.6366651,boosting,0.411306
Sensor Networks for Aerospace Human-Machine Systems.,lastly,0.40969157,of,0.6291888,boosting,0.5149216
Sensor Networks for Aerospace Human-Machine Systems.,introduced,0.43058684,selection,0.545887,feature-engineering,0.50600016
Sensor Networks for Aerospace Human-Machine Systems.,interactions,0.34362614,nearest-neighbors,0.5320788,nearest-neighbors,0.5320788
Sensor Networks for Aerospace Human-Machine Systems.,integration,0.5065657,feature-engineering,0.66811013,feature-engineering,0.66811013
Sensor Networks for Aerospace Human-Machine Systems.,implementations,0.71400803,machine-learning,0.71400803,machine-learning,0.71400803
Sensor Networks for Aerospace Human-Machine Systems.,implementation,0.5873812,data-engineering,0.64639926,data-engineering,0.64639926
Sensor Networks for Aerospace Human-Machine Systems.,humans,0.34170303,natural,0.5139721,generative-model,0.41706812
Sensor Networks for Aerospace Human-Machine Systems.,focusing,0.39624733,generative-model,0.558784,generative-model,0.558784
Sensor Networks for Aerospace Human-Machine Systems.,evolution,0.41623777,of,0.57603025,generative,0.5578432
Sensor Networks for Aerospace Human-Machine Systems.,evaluate,0.37214977,of,0.4977158,decision-tree,0.4090718
Sensor Networks for Aerospace Human-Machine Systems.,enhanced,0.30543873,of,0.59523904,boosting,0.57908714
Sensor Networks for Aerospace Human-Machine Systems.,effectiveness,0.38338125,short-term,0.6059195,dimensionality-reduction,0.5238044
Sensor Networks for Aerospace Human-Machine Systems.,due,0.21681537,of,0.5734476,confusion-matrix,0.40250766
Sensor Networks for Aerospace Human-Machine Systems.,discussed,0.32159716,of,0.5174893,confusion-matrix,0.45636517
Sensor Networks for Aerospace Human-Machine Systems.,development,0.34732813,generative,0.56588423,generative,0.56588423
Sensor Networks for Aerospace Human-Machine Systems.,decision,0.5239193,decision,1.0,decision-tree,0.75800127
Sensor Networks for Aerospace Human-Machine Systems.,context,0.48856658,feature-engineering,0.6062584,feature-engineering,0.6062584
Sensor Networks for Aerospace Human-Machine Systems.,collaboration,0.45193252,data-science,0.6360742,data-science,0.6360742
Sensor Networks for Aerospace Human-Machine Systems.,closed,0.26428735,connected,0.5317214,fully-connected,0.4886479
Sensor Networks for Aerospace Human-Machine Systems.,approach,0.5412675,segmentation-algorithm,0.6046611,segmentation-algorithm,0.6046611
Sensor Networks for Aerospace Human-Machine Systems.,adoption,0.5112679,decision,0.6252265,dimensionality-reduction,0.57303023
Sensor Networks for Aerospace Human-Machine Systems.,adapts,0.4296453,stochastic,0.5030963,stochastic,0.5030963
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,gaming,0.55841964,reinforcement-learning,0.59406227,reinforcement-learning,0.59406227
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,using,0.47332245,analysis,0.5968549,component-analysis,0.526608
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,multimodal,0.53923947,deep-learning,0.57608044,deep-learning,0.57608044
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,physiological,0.3332913,function,0.550024,learning-function,0.4524702
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,signals,0.3700128,components,0.5488684,feed-forward,0.52579325
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,including,0.3233776,of,0.6619886,clustering,0.40625107
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,photoplethysmogram,0.39325905,fourier,0.48772976,fourier,0.48772976
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,signals-including,0.4645484,tracking,0.54796684,feature-engineering,0.53923225
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,individually,0.3663717,fully,0.567432,feature-selection,0.46161002
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,customized,0.5419228,data-engineering,0.63732374,data-engineering,0.63732374
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,game,0.5325011,artificial-intelligence,0.58311117,artificial-intelligence,0.58311117
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,craving,0.37764183,reinforcement-learning,0.5774627,reinforcement-learning,0.5774627
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,detection,0.39447892,analysis,0.48924,classification,0.46944988
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,system,0.3589455,generative-model,0.49815983,generative-model,0.49815983
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,detection-system,0.57656574,component-analysis,0.642162,component-analysis,0.642162
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,third,0.27270278,one,0.6556418,generative,0.3917287
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,experiment,0.38590434,batch,0.5287235,batch-normalization,0.5030932
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,using,0.47332245,analysis,0.5968549,component-analysis,0.526608
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,various,0.35606545,of,0.6378319,generative,0.45850474
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,classifiers,0.8333409,classifiers,1.0,classifiers,1.0
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,experiment-using,0.4987199,ground-truth,0.54723275,ground-truth,0.54723275
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,presented,0.41586217,of,0.5919795,confusion-matrix,0.4850164
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,short,0.24294135,short,0.99999994,long-short-term,0.66049826
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,video,0.462111,computer-vision,0.6564621,computer-vision,0.6564621
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,clips,0.25131974,object,0.4173689,object-tracking,0.38960057
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,video-clips,0.4467243,computer-vision,0.6415502,computer-vision,0.6415502
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,knn,0.6303138,knn,1.0,knn,1.0
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,centroid,0.4451253,centroid-based,0.7961559,centroid-based,0.7961559
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,displacement,0.26953688,tracking,0.5104734,gradient-descent,0.47566164
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,machine,0.7094662,machine,1.0,machine-learning,0.7094662
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,learning,0.709237,learning,1.0,deep-learning,0.8286492
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,model,0.48485535,model,1.0,markov-model,0.7005576
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,constructed,0.46166873,vector,0.5928328,feature-engineering,0.5708643
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,machine-learning,1.0,machine-learning,1.0,machine-learning,1.0
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,model-constructed,0.6278399,markov-model,0.7086385,markov-model,0.7086385
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,machine-learning-model,0.9445531,machine-learning,0.9445531,machine-learning,0.9445531
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,various,0.35606545,of,0.6378319,generative,0.45850474
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,physiological,0.3332913,function,0.550024,learning-function,0.4524702
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,signals,0.3700128,components,0.5488684,feed-forward,0.52579325
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,physiological,0.3332913,function,0.550024,learning-function,0.4524702
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,signals,0.3700128,components,0.5488684,feed-forward,0.52579325
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,recorded,0.299657,rectified,0.55581653,computer-vision,0.443301
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,craving,0.37764183,reinforcement-learning,0.5774627,reinforcement-learning,0.5774627
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,detection,0.39447892,analysis,0.48924,classification,0.46944988
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,system,0.3589455,generative-model,0.49815983,generative-model,0.49815983
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,detection-system,0.57656574,component-analysis,0.642162,component-analysis,0.642162
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,different,0.37681934,of,0.61590904,clustering,0.46857932
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,video,0.462111,computer-vision,0.6564621,computer-vision,0.6564621
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,clips,0.25131974,object,0.4173689,object-tracking,0.38960057
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,video-clips,0.4467243,computer-vision,0.6415502,computer-vision,0.6415502
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,internet,0.5267593,data-science,0.6552436,data-science,0.6552436
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,gaming,0.55841964,reinforcement-learning,0.59406227,reinforcement-learning,0.59406227
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,disorder,0.28393638,dropout,0.44668275,dropout,0.44668275
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,internet-gaming,0.5472091,natural-language,0.6376439,natural-language,0.6376439
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,features,0.51742536,feature,0.8268872,feature-selection,0.5487305
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,used,0.46049535,of,0.5630944,generative-model,0.4901716
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,three,0.36911732,one,0.78425425,clustering,0.4299444
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,addictive,0.4151236,reinforcement-learning,0.5742367,reinforcement-learning,0.5742367
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,games,0.5184988,adversarial,0.5790582,data-science,0.5638159
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,linear,0.42916322,linear,0.99999994,regression,0.66034734
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,discriminant,0.6251048,discriminative,0.7571954,principal-components,0.73802483
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,analysis,0.46507934,analysis,0.99999994,component-analysis,0.69613737
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,linear-discriminant,0.63254243,principal-component,0.7563741,principal-component,0.7563741
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,discriminant-analysis,0.6591863,principal-component-analysis,0.81748813,principal-component-analysis,0.81748813
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,intraclass,0.38842225,cross-validation,0.5753608,cross-validation,0.5753608
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,correlation,0.355416,regression,0.5743689,regression,0.5743689
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,coefficient,0.3133128,cross-entropy,0.5560355,cross-entropy,0.5560355
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,intraclass-correlation,0.5193204,cross-entropy,0.695302,cross-entropy,0.695302
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,correlation-coefficient,0.52219236,cross-entropy,0.7120375,cross-entropy,0.7120375
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,intraclass-correlation-coefficient,0.5374546,cross-entropy,0.72722626,cross-entropy,0.72722626
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,increasing,0.30868235,of,0.6603997,boosting,0.50417006
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,public,0.4676953,data-science,0.67764014,data-science,0.67764014
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,concern,0.2617717,confusion,0.65010685,data-science,0.43675148
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,galvanic,0.21124747,artificial-intelligence,0.44379917,artificial-intelligence,0.44379917
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,skin,0.20770611,deep,0.41352117,keras,0.34995416
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,response,0.2143969,of,0.52661085,boosting,0.48192608
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,galvanic-skin,0.24262255,artificial-intelligence,0.48822907,artificial-intelligence,0.48822907
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,skin-response,0.2590545,rectified,0.46267006,logistic-regression,0.4386782
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,cue,0.40408272,object-tracking,0.6292406,object-tracking,0.6292406
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,exposure,0.22801533,short-term,0.55545235,long-short-term,0.45469296
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,therapy,0.2707135,short-term,0.45926765,boosting,0.40244865
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,cue-exposure,0.412118,reinforcement-learning,0.6816329,reinforcement-learning,0.6816329
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,exposure-therapy,0.32819855,short-term,0.49807328,logistic-regression,0.46478862
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,different,0.37681934,of,0.61590904,clustering,0.46857932
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,experimental,0.40167695,model,0.6248311,generative-model,0.6004326
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,conditions,0.21472734,short-term,0.4503411,feature-reduction,0.43574768
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,experimental-conditions,0.47598928,generative-model,0.6308403,generative-model,0.6308403
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,craving,0.37764183,reinforcement-learning,0.5774627,reinforcement-learning,0.5774627
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,detection,0.39447892,analysis,0.48924,classification,0.46944988
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,method,0.482283,algorithm,0.63295126,algorithm,0.63295126
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,detection-method,0.50224614,component-analysis,0.5788982,component-analysis,0.5788982
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,support,0.3815906,support,1.0,support-vector,0.66958183
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,vector,0.45570993,vector,1.0,vector-machine,0.7596456
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,machine,0.7094662,machine,1.0,machine-learning,0.7094662
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,support-vector,0.6102658,support-vector,1.0,support-vector,1.0
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,vector-machine,0.68567467,vector-machine,1.0,vector-machine,1.0
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,support-vector-machine,0.71415544,support-vector-machine,1.0,support-vector-machine,1.0
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,high,0.267004,of,0.57459104,gradient,0.44240427
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,prevalence,0.2908883,rate,0.45596814,dropout,0.4310696
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,rate,0.24866687,rate,1.0,dropout,0.44953537
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,high-prevalence,0.38044217,hidden,0.4506436,random-forest,0.44636112
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,prevalence-rate,0.39341527,logistic-regression,0.5434035,logistic-regression,0.5434035
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,three,0.36911732,one,0.78425425,clustering,0.4299444
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,different,0.37681934,of,0.61590904,clustering,0.46857932
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,days,0.20857571,short-term,0.53915894,long-short-term,0.4190845
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,three-different,0.4282337,convolutional-layer,0.5688442,convolutional-layer,0.5688442
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,previous,0.32983518,data,0.5377847,long-short-term,0.40795568
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,study,0.3645851,of,0.5728763,statistical,0.44204497
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,demonstrated,0.2929331,of,0.6025795,feature-reduction,0.39724052
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,fairly,0.30031136,few,0.6521412,bagging,0.41798443
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,high,0.267004,of,0.57459104,gradient,0.44240427
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,accuracy,0.5511073,cross-validation,0.64088035,cross-validation,0.64088035
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,fairly-high,0.28500527,federated,0.3896182,dropout,0.38857734
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,high-accuracy,0.6229743,ground-truth,0.6391766,ground-truth,0.6391766
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,accumulating,0.3309417,few,0.5436117,generative,0.49855822
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,datasets,0.6397797,data,0.71337724,classifiers,0.68077624
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,recorded,0.299657,rectified,0.55581653,computer-vision,0.443301
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,third,0.27270278,one,0.6556418,generative,0.3917287
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,experiment,0.38590434,batch,0.5287235,batch-normalization,0.5030932
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,achieved,0.33526158,of,0.5726348,batch-normalization,0.47712192
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,using,0.47332245,analysis,0.5968549,component-analysis,0.526608
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,system,0.3589455,generative-model,0.49815983,generative-model,0.49815983
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,needs,0.38735956,support,0.555194,natural-language,0.45190576
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,based,0.49998575,classification-algorithm,0.5639226,classification-algorithm,0.5639226
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,detection,0.39447892,analysis,0.48924,classification,0.46944988
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,based-detection,0.5841876,multi-class,0.59442997,classification-algorithm,0.59231794
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,physiological,0.3332913,function,0.550024,learning-function,0.4524702
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,data,0.46434748,data,1.0,data-science,0.5533528
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,gaming,0.55841964,reinforcement-learning,0.59406227,reinforcement-learning,0.59406227
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,could,0.34235194,of,0.59299076,boosting,0.42074972
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,different,0.37681934,of,0.61590904,clustering,0.46857932
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,days,0.20857571,short-term,0.53915894,long-short-term,0.4190845
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,based,0.49998575,classification-algorithm,0.5639226,classification-algorithm,0.5639226
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,knn,0.6303138,knn,1.0,knn,1.0
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,previous,0.32983518,data,0.5377847,long-short-term,0.40795568
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,study,0.3645851,of,0.5728763,statistical,0.44204497
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,maintaining,0.27131265,of,0.53085643,boosting,0.47813183
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,craving,0.37764183,reinforcement-learning,0.5774627,reinforcement-learning,0.5774627
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,detect,0.41183126,analysis,0.51244676,clustering,0.43602985
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,craving,0.37764183,reinforcement-learning,0.5774627,reinforcement-learning,0.5774627
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,craving,0.37764183,reinforcement-learning,0.5774627,reinforcement-learning,0.5774627
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,states,0.26295346,ground,0.5876442,confusion-matrix,0.40829715
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,second,0.3157444,one,0.6801673,generative,0.44190797
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,experiment,0.38590434,batch,0.5287235,batch-normalization,0.5030932
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,high,0.267004,of,0.57459104,gradient,0.44240427
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,accuracy,0.5511073,cross-validation,0.64088035,cross-validation,0.64088035
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,high-accuracy,0.6229743,ground-truth,0.6391766,ground-truth,0.6391766
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,based,0.49998575,classification-algorithm,0.5639226,classification-algorithm,0.5639226
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,method,0.482283,algorithm,0.63295126,algorithm,0.63295126
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,based-method,0.5263716,principal-component-analysis,0.6056013,principal-component-analysis,0.6056013
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,previous,0.32983518,data,0.5377847,long-short-term,0.40795568
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,experiments,0.36827093,data,0.55053914,stochastic-gradient,0.48057425
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,young,0.26528853,short-term,0.52275395,long-short-term,0.4964258
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,adults,0.2950639,short-term,0.48601514,long-short-term,0.43684626
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,young-adults,0.26927844,short-term-memory,0.46674716,short-term-memory,0.46674716
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,still,0.32258964,fully,0.6496037,long-short-term,0.43228805
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,questionable,0.3146245,confusion,0.6661532,confusion-matrix,0.49656266
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,selected,0.38157707,selection,0.6797303,feature-selection,0.48698312
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,based,0.49998575,classification-algorithm,0.5639226,classification-algorithm,0.5639226
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,selected-based,0.6517608,support-vector-machine,0.65644264,support-vector-machine,0.65644264
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,second,0.3157444,one,0.6801673,generative,0.44190797
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,experiments,0.36827093,data,0.55053914,stochastic-gradient,0.48057425
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,retest,0.36315864,cross-validation,0.5874904,cross-validation,0.5874904
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,reliability,0.44636852,cross-validation,0.63492304,cross-validation,0.63492304
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,retest-reliability,0.4387321,cross-validation,0.6553557,cross-validation,0.6553557
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,repeatedly,0.33862895,few,0.5699206,long-short-term,0.45730793
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,applied,0.44175404,of,0.5047146,bagging,0.47554293
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,random,0.45551494,random,1.0,random-forest,0.65894985
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,forest,0.4787075,forest,1.0,random-forest,0.7738863
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,random-forest,0.6331641,random-forest,1.0,random-forest,1.0
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,practical,0.5342755,data-engineering,0.63994795,data-engineering,0.63994795
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,use,0.43753043,of,0.5506158,feature-reduction,0.49910897
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,practical-use,0.5234554,data-engineering,0.6236222,data-engineering,0.6236222
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,potential,0.3558654,of,0.5645705,generative-model,0.46479023
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,risk,0.35860935,recurrent,0.53675485,logistic-regression,0.52381086
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,potential-risk,0.38858032,recurrent-neural-network,0.5205706,recurrent-neural-network,0.5205706
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,participant,0.42758512,supervised,0.54424495,supervised,0.54424495
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,experienced,0.33214465,one,0.53318346,supervised,0.47342923
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,nine,0.34436068,one,0.6942973,clustering,0.3877343
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,participants,0.4160846,object-tracking,0.5017827,object-tracking,0.5017827
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,nearest,0.44164038,nearest,1.0,nearest-neighbors,0.73016953
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,neighbors,0.4643042,neighbors,1.0,nearest-neighbors,0.8016597
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,nearest-neighbors,0.52685773,nearest-neighbors,1.0,nearest-neighbors,1.0
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,high,0.267004,of,0.57459104,gradient,0.44240427
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,test,0.4037762,statistical,0.5031551,statistical,0.5031551
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,high-test,0.38419574,artificial-intelligence,0.46897912,artificial-intelligence,0.46897912
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,feature,0.5878884,feature,0.99999994,feature-selection,0.6322505
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,vectors,0.42283016,vector,0.9334005,vector-machine,0.711414
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,feature-vectors,0.6130123,feature-selection,0.7407644,feature-selection,0.7407644
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,extensively,0.37251905,fully,0.5856741,generative,0.45637786
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,employed,0.47010878,generative-model,0.5414345,generative-model,0.5414345
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,core,0.30745435,components,0.51753825,dimensionality-reduction,0.4418015
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,factor,0.23388772,component,0.48280093,principal-components,0.43733668
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,classification,0.5994266,classification,1.0,classification,1.0
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,performance,0.50728506,learning-function,0.63351834,learning-function,0.63351834
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,calibration,0.50641084,batch-normalization,0.6344988,batch-normalization,0.6344988
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,sessions,0.40836218,supervised,0.59262615,supervised,0.59262615
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,brain,0.31704307,neural,0.57897407,learning-rate,0.44069666
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,functions,0.41232014,function,0.8737128,learning-function,0.5841365
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,brain-functions,0.44366843,learning-function,0.66489977,learning-function,0.66489977
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,using,0.47332245,analysis,0.5968549,component-analysis,0.526608
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,treatment,0.239264,short-term,0.5206091,long-short-term,0.41699445
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,processes,0.34218454,processing,0.59430957,generative,0.5664364
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,classified,0.3846122,classification,0.68709266,classification,0.68709266
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,whether,0.32171756,short-term,0.5290759,long-short-term,0.47851244
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,gaming,0.55841964,reinforcement-learning,0.59406227,reinforcement-learning,0.59406227
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,addiction,0.42059523,reinforcement-learning,0.53479755,reinforcement-learning,0.53479755
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,treatment,0.239264,short-term,0.5206091,long-short-term,0.41699445
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,addiction-treatment,0.46030945,reinforcement-learning,0.5750681,reinforcement-learning,0.5750681
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,classifiers,0.8333409,classifiers,1.0,classifiers,1.0
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,craving,0.37764183,reinforcement-learning,0.5774627,reinforcement-learning,0.5774627
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,machine,0.7094662,machine,1.0,machine-learning,0.7094662
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,learning,0.709237,learning,1.0,deep-learning,0.8286492
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,experiment,0.38590434,batch,0.5287235,batch-normalization,0.5030932
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,recorded,0.299657,rectified,0.55581653,computer-vision,0.443301
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,datasets,0.6397797,data,0.71337724,classifiers,0.68077624
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,accuracy,0.5511073,cross-validation,0.64088035,cross-validation,0.64088035
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,treatment,0.239264,short-term,0.5206091,long-short-term,0.41699445
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,test,0.4037762,statistical,0.5031551,statistical,0.5031551
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,data,0.46434748,data,1.0,data-science,0.5533528
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,classified,0.3846122,classification,0.68709266,classification,0.68709266
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,addiction,0.42059523,reinforcement-learning,0.53479755,reinforcement-learning,0.53479755
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,without,0.31691062,of,0.5951073,long-short-term,0.4268921
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,user,0.5892831,graphics,0.6527882,computer-vision,0.62567556
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,trained,0.56898797,supervised,0.69370055,supervised,0.69370055
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,train,0.54995465,learning,0.60963345,learning-rate,0.5978736
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,tool,0.58027077,machine-learning,0.58027077,machine-learning,0.58027077
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,thus,0.33923393,of,0.6779618,feature-reduction,0.46172875
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,suggesting,0.24045295,of,0.6157647,clustering,0.43733796
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,reuse,0.4799319,batch,0.5620866,data-engineering,0.5452488
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,repeated,0.34072363,short-term,0.5933522,long-short-term,0.5176369
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,relapse,0.28719485,recurrent,0.5824927,dropout,0.49864832
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,reducing,0.26140445,reduction,0.74160737,boosting,0.5133524
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,proposed,0.55786884,classification-algorithm,0.6311488,classification-algorithm,0.6311488
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,practicality,0.5125015,dimensionality-reduction,0.6218933,dimensionality-reduction,0.6218933
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,organizations,0.44529963,federated,0.635594,data-science,0.61255723
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,non,0.2869836,of,0.5523051,generative,0.4181043
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,monitor,0.3018983,support,0.49704546,support-vector-machine,0.3517431
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,k,0.16369987,rectified,0.45026273,nearest-neighbors,0.34698594
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,investigated,0.30147675,of,0.6179704,generative-model,0.42952073
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,initially,0.3141464,fully,0.60568786,bagging,0.47978413
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,importance,0.3427571,of,0.5794183,feature-engineering,0.46667784
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,implemented,0.60392654,supervised,0.62838364,supervised,0.62838364
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,however,0.31437585,few,0.63182676,statistical,0.44065386
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,first,0.36139184,of,0.61145455,generative,0.4096663
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,enhanced,0.30543873,of,0.59523904,boosting,0.57908714
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,electrooculogram,0.3562957,computer-vision,0.5837594,computer-vision,0.5837594
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,efficacy,0.30193827,short-term,0.5894643,long-short-term,0.48695186
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,effectiveness,0.38338125,short-term,0.6059195,dimensionality-reduction,0.5238044
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,detected,0.25814283,of,0.52368605,clustering,0.37524593
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,designed,0.47411257,feature-engineering,0.5746863,feature-engineering,0.5746863
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,demonstrating,0.32530028,of,0.67624867,generative,0.46174815
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,day,0.252174,one,0.5237603,supervised,0.401589
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,consequently,0.34715277,of,0.67593205,boosting,0.49107498
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,computing,0.68506473,computer,0.71702296,graphics-processing,0.71574765
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,comparable,0.29340464,short-term,0.5384172,long-short-term,0.45359015
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,characteristic,0.34942827,feature,0.7124056,clustering,0.48287967
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,become,0.34259117,few,0.5628189,generative,0.47609246
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,alteration,0.29010773,of,0.61640024,batch-normalization,0.45421952
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,adolescents,0.30669934,intelligence,0.49286765,dropout,0.4643091
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,addition,0.30500388,of,0.6910241,feature-reduction,0.48914018
Blockade of TRPV2 is a Novel Therapy for Cardiomyopathy in Muscular Dystrophy.,transient,0.25056615,of,0.5285465,long-short-term,0.4541571
Blockade of TRPV2 is a Novel Therapy for Cardiomyopathy in Muscular Dystrophy.,receptor,0.22411162,function,0.41526195,clustering,0.36801085
Blockade of TRPV2 is a Novel Therapy for Cardiomyopathy in Muscular Dystrophy.,potential,0.3558654,of,0.5645705,generative-model,0.46479023
Blockade of TRPV2 is a Novel Therapy for Cardiomyopathy in Muscular Dystrophy.,cation,0.21358806,nearest-neighbors,0.43574437,nearest-neighbors,0.43574437
Blockade of TRPV2 is a Novel Therapy for Cardiomyopathy in Muscular Dystrophy.,channel,0.22694653,rectified,0.5908533,fully-connected,0.3853672
Blockade of TRPV2 is a Novel Therapy for Cardiomyopathy in Muscular Dystrophy.,subfamily,0.2620929,encoding,0.47156852,clustering,0.34815705
Blockade of TRPV2 is a Novel Therapy for Cardiomyopathy in Muscular Dystrophy.,v,0.16266164,rate,0.35976145,softmax,0.2951627
Blockade of TRPV2 is a Novel Therapy for Cardiomyopathy in Muscular Dystrophy.,transient-receptor,0.4014735,stochastic,0.5651614,stochastic,0.5651614
Blockade of TRPV2 is a Novel Therapy for Cardiomyopathy in Muscular Dystrophy.,receptor-potential,0.2734695,backpropagation,0.43151256,backpropagation,0.43151256
Blockade of TRPV2 is a Novel Therapy for Cardiomyopathy in Muscular Dystrophy.,potential-cation,0.33443993,feature-reduction,0.54653525,feature-reduction,0.54653525
Blockade of TRPV2 is a Novel Therapy for Cardiomyopathy in Muscular Dystrophy.,cation-channel,0.3183921,rectified,0.49537408,gradient-descent,0.48214588
Blockade of TRPV2 is a Novel Therapy for Cardiomyopathy in Muscular Dystrophy.,transient-receptor-potential,0.35700828,stochastic,0.55868566,stochastic,0.55868566
Blockade of TRPV2 is a Novel Therapy for Cardiomyopathy in Muscular Dystrophy.,sensitive,0.25042155,discriminative,0.47259748,feature-selection,0.4003108
Blockade of TRPV2 is a Novel Therapy for Cardiomyopathy in Muscular Dystrophy.,+-,0.2532669,centroid-based,0.38565287,centroid-based,0.38565287
Blockade of TRPV2 is a Novel Therapy for Cardiomyopathy in Muscular Dystrophy.,permeable,0.22127947,layer,0.49722296,gradient-descent,0.4622275
Blockade of TRPV2 is a Novel Therapy for Cardiomyopathy in Muscular Dystrophy.,channel,0.22694653,rectified,0.5908533,fully-connected,0.3853672
Blockade of TRPV2 is a Novel Therapy for Cardiomyopathy in Muscular Dystrophy.,causes,0.19757006,of,0.55089116,long-short-term,0.3616379
Blockade of TRPV2 is a Novel Therapy for Cardiomyopathy in Muscular Dystrophy.,sustained,0.25385287,short-term,0.5605015,long-short-term,0.5171305
Blockade of TRPV2 is a Novel Therapy for Cardiomyopathy in Muscular Dystrophy.,intracellular,0.24604294,of,0.45033878,stochastic,0.42079455
Blockade of TRPV2 is a Novel Therapy for Cardiomyopathy in Muscular Dystrophy.,ameliorates,0.2427916,function,0.43416852,boosting,0.37466916
Blockade of TRPV2 is a Novel Therapy for Cardiomyopathy in Muscular Dystrophy.,muscle,0.19602863,neural,0.42647707,supervised,0.33558244
Blockade of TRPV2 is a Novel Therapy for Cardiomyopathy in Muscular Dystrophy.,dysgenesis,0.20923461,generative,0.44774094,generative,0.44774094
Blockade of TRPV2 is a Novel Therapy for Cardiomyopathy in Muscular Dystrophy.,potential,0.3558654,of,0.5645705,generative-model,0.46479023
Blockade of TRPV2 is a Novel Therapy for Cardiomyopathy in Muscular Dystrophy.,therapeutic,0.3659354,of,0.48352462,boosting,0.41573292
Blockade of TRPV2 is a Novel Therapy for Cardiomyopathy in Muscular Dystrophy.,target,0.31799266,of,0.4775706,feature-selection,0.44359237
Blockade of TRPV2 is a Novel Therapy for Cardiomyopathy in Muscular Dystrophy.,potential-therapeutic,0.39089105,generative-model,0.49393243,generative-model,0.49393243
Blockade of TRPV2 is a Novel Therapy for Cardiomyopathy in Muscular Dystrophy.,therapeutic-target,0.40078533,feature-engineering,0.4993252,feature-engineering,0.4993252
Blockade of TRPV2 is a Novel Therapy for Cardiomyopathy in Muscular Dystrophy.,improve,0.45207965,boosting,0.5098576,boosting,0.5098576
Blockade of TRPV2 is a Novel Therapy for Cardiomyopathy in Muscular Dystrophy.,cardiac,0.29562658,of,0.42777455,long-short-term,0.35708636
Blockade of TRPV2 is a Novel Therapy for Cardiomyopathy in Muscular Dystrophy.,function,0.3447219,function,1.0,learning-function,0.5767432
Blockade of TRPV2 is a Novel Therapy for Cardiomyopathy in Muscular Dystrophy.,cardiac-function,0.4069733,function,0.6227769,learning-function,0.6182186
Blockade of TRPV2 is a Novel Therapy for Cardiomyopathy in Muscular Dystrophy.,degenerative,0.2655192,generative,0.45321867,generative,0.45321867
Blockade of TRPV2 is a Novel Therapy for Cardiomyopathy in Muscular Dystrophy.,muscular,0.24155878,descent,0.44373417,convolutional-layer,0.36108795
Blockade of TRPV2 is a Novel Therapy for Cardiomyopathy in Muscular Dystrophy.,disease,0.296938,recurrent,0.4731025,classification,0.35271814
Blockade of TRPV2 is a Novel Therapy for Cardiomyopathy in Muscular Dystrophy.,inhibitors,0.25381407,cascade,0.4157439,feed-forward,0.3175553
Blockade of TRPV2 is a Novel Therapy for Cardiomyopathy in Muscular Dystrophy.,available,0.4144769,data,0.62807965,data-science,0.46192533
Blockade of TRPV2 is a Novel Therapy for Cardiomyopathy in Muscular Dystrophy.,inhibitors,0.25381407,cascade,0.4157439,feed-forward,0.3175553
Blockade of TRPV2 is a Novel Therapy for Cardiomyopathy in Muscular Dystrophy.,therapeutic,0.3659354,of,0.48352462,boosting,0.41573292
Blockade of TRPV2 is a Novel Therapy for Cardiomyopathy in Muscular Dystrophy.,applications,0.4878226,data-engineering,0.70112944,data-engineering,0.70112944
Blockade of TRPV2 is a Novel Therapy for Cardiomyopathy in Muscular Dystrophy.,muscular,0.24155878,descent,0.44373417,convolutional-layer,0.36108795
Blockade of TRPV2 is a Novel Therapy for Cardiomyopathy in Muscular Dystrophy.,dystrophy,0.21292573,dropout,0.37161267,dropout,0.37161267
Blockade of TRPV2 is a Novel Therapy for Cardiomyopathy in Muscular Dystrophy.,muscular,0.24155878,descent,0.44373417,convolutional-layer,0.36108795
Blockade of TRPV2 is a Novel Therapy for Cardiomyopathy in Muscular Dystrophy.,cells,0.20327199,naive,0.5115537,generative,0.40616876
Blockade of TRPV2 is a Novel Therapy for Cardiomyopathy in Muscular Dystrophy.,although,0.29321635,few,0.63117087,long-short-term,0.46243888
Blockade of TRPV2 is a Novel Therapy for Cardiomyopathy in Muscular Dystrophy.,treatment,0.239264,short-term,0.5206091,long-short-term,0.41699445
Blockade of TRPV2 is a Novel Therapy for Cardiomyopathy in Muscular Dystrophy.,options,0.39849356,decision,0.59008765,decision-tree,0.4805334
Blockade of TRPV2 is a Novel Therapy for Cardiomyopathy in Muscular Dystrophy.,treatment-options,0.39184833,dropout,0.55722994,dropout,0.55722994
Blockade of TRPV2 is a Novel Therapy for Cardiomyopathy in Muscular Dystrophy.,survival,0.29004025,short-term,0.53135407,long-short-term,0.4573617
Blockade of TRPV2 is a Novel Therapy for Cardiomyopathy in Muscular Dystrophy.,prognosis,0.32841474,recurrent,0.50268024,classification,0.44778624
Blockade of TRPV2 is a Novel Therapy for Cardiomyopathy in Muscular Dystrophy.,survival-prognosis,0.40199178,logistic-regression,0.49026442,logistic-regression,0.49026442
Blockade of TRPV2 is a Novel Therapy for Cardiomyopathy in Muscular Dystrophy.,reports,0.33286974,data,0.6349387,natural-language,0.40497693
Blockade of TRPV2 is a Novel Therapy for Cardiomyopathy in Muscular Dystrophy.,showed,0.20766163,of,0.5296177,regression,0.37027335
Blockade of TRPV2 is a Novel Therapy for Cardiomyopathy in Muscular Dystrophy.,recent,0.35249484,of,0.545993,data-engineering,0.4259707
Blockade of TRPV2 is a Novel Therapy for Cardiomyopathy in Muscular Dystrophy.,reports,0.33286974,data,0.6349387,natural-language,0.40497693
Blockade of TRPV2 is a Novel Therapy for Cardiomyopathy in Muscular Dystrophy.,recent,0.35249484,of,0.545993,data-engineering,0.4259707
Blockade of TRPV2 is a Novel Therapy for Cardiomyopathy in Muscular Dystrophy.,findings,0.35685748,data,0.65714294,component-analysis,0.38599753
Blockade of TRPV2 is a Novel Therapy for Cardiomyopathy in Muscular Dystrophy.,pathophysiological,0.3716724,feature,0.48018768,feed-forward,0.43921173
Blockade of TRPV2 is a Novel Therapy for Cardiomyopathy in Muscular Dystrophy.,feature,0.5878884,feature,0.99999994,feature-selection,0.6322505
Blockade of TRPV2 is a Novel Therapy for Cardiomyopathy in Muscular Dystrophy.,member,0.2264852,encoding,0.4815184,relu,0.36024958
Blockade of TRPV2 is a Novel Therapy for Cardiomyopathy in Muscular Dystrophy.,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
Blockade of TRPV2 is a Novel Therapy for Cardiomyopathy in Muscular Dystrophy.,intractable,0.3506856,recurrent,0.70958704,recurrent-neural-network,0.48154786
Blockade of TRPV2 is a Novel Therapy for Cardiomyopathy in Muscular Dystrophy.,diseases,0.31957155,recurrent,0.41244444,classification,0.40266854
Blockade of TRPV2 is a Novel Therapy for Cardiomyopathy in Muscular Dystrophy.,intractable-diseases,0.5119311,generative-model,0.5418231,generative-model,0.5418231
Blockade of TRPV2 is a Novel Therapy for Cardiomyopathy in Muscular Dystrophy.,heart,0.28300244,rate,0.49867767,batch-normalization,0.3427502
Blockade of TRPV2 is a Novel Therapy for Cardiomyopathy in Muscular Dystrophy.,failure,0.32964212,recurrent,0.52057266,confusion-matrix,0.44323406
Blockade of TRPV2 is a Novel Therapy for Cardiomyopathy in Muscular Dystrophy.,heart-failure,0.36450487,long-short-term,0.44014218,long-short-term,0.44014218
Blockade of TRPV2 is a Novel Therapy for Cardiomyopathy in Muscular Dystrophy.,current,0.3530666,rectified,0.52906346,generative-model,0.40904555
Blockade of TRPV2 is a Novel Therapy for Cardiomyopathy in Muscular Dystrophy.,progress,0.36981016,confusion,0.49840045,data-engineering,0.47150356
Blockade of TRPV2 is a Novel Therapy for Cardiomyopathy in Muscular Dystrophy.,current-progress,0.45110223,recurrent-neural-network,0.53770286,recurrent-neural-network,0.53770286
Blockade of TRPV2 is a Novel Therapy for Cardiomyopathy in Muscular Dystrophy.,dilated,0.22810468,function,0.40786004,confusion-matrix,0.32808268
Blockade of TRPV2 is a Novel Therapy for Cardiomyopathy in Muscular Dystrophy.,cardiomyopathy,0.29507846,confusion-matrix,0.3794037,confusion-matrix,0.3794037
Blockade of TRPV2 is a Novel Therapy for Cardiomyopathy in Muscular Dystrophy.,dilated-cardiomyopathy,0.3131293,confusion-matrix,0.4146229,confusion-matrix,0.4146229
Blockade of TRPV2 is a Novel Therapy for Cardiomyopathy in Muscular Dystrophy.,cardiomyopathy,0.29507846,confusion-matrix,0.3794037,confusion-matrix,0.3794037
Blockade of TRPV2 is a Novel Therapy for Cardiomyopathy in Muscular Dystrophy.,associated,0.30827495,of,0.57598466,long-short-term,0.46578532
Blockade of TRPV2 is a Novel Therapy for Cardiomyopathy in Muscular Dystrophy.,cardiomyopathy-associated,0.3457657,recurrent,0.422559,long-short-term,0.39615625
Blockade of TRPV2 is a Novel Therapy for Cardiomyopathy in Muscular Dystrophy.,cardiomyopathy,0.29507846,confusion-matrix,0.3794037,confusion-matrix,0.3794037
Blockade of TRPV2 is a Novel Therapy for Cardiomyopathy in Muscular Dystrophy.,stretch,0.18874331,long,0.4742212,long-short-term,0.39053383
Blockade of TRPV2 is a Novel Therapy for Cardiomyopathy in Muscular Dystrophy.,sarcolemma,0.16150075,layer,0.42744517,gradient-descent,0.33428013
Blockade of TRPV2 is a Novel Therapy for Cardiomyopathy in Muscular Dystrophy.,review,0.41215214,data,0.5581161,data-science,0.47600204
Blockade of TRPV2 is a Novel Therapy for Cardiomyopathy in Muscular Dystrophy.,recently,0.39159477,few,0.51658726,confusion-matrix,0.4137478
Blockade of TRPV2 is a Novel Therapy for Cardiomyopathy in Muscular Dystrophy.,myocytes,0.18731987,rectified,0.40493298,long-short-term,0.35546944
Blockade of TRPV2 is a Novel Therapy for Cardiomyopathy in Muscular Dystrophy.,limited,0.33893847,of,0.6210327,long-short-term,0.4736513
Blockade of TRPV2 is a Novel Therapy for Cardiomyopathy in Muscular Dystrophy.,introduce,0.58623695,feature-engineering,0.6378248,feature-engineering,0.6378248
Blockade of TRPV2 is a Novel Therapy for Cardiomyopathy in Muscular Dystrophy.,increase,0.28092995,reduction,0.7624404,boosting,0.49543357
Blockade of TRPV2 is a Novel Therapy for Cardiomyopathy in Muscular Dystrophy.,inactivation,0.15532166,reduction,0.50491583,feature-reduction,0.43843913
Blockade of TRPV2 is a Novel Therapy for Cardiomyopathy in Muscular Dystrophy.,furthermore,0.33438665,of,0.5529862,clustering,0.42723072
Blockade of TRPV2 is a Novel Therapy for Cardiomyopathy in Muscular Dystrophy.,discuss,0.4084479,decision,0.5208974,feature-engineering,0.46463755
Blockade of TRPV2 is a Novel Therapy for Cardiomyopathy in Muscular Dystrophy.,development,0.34732813,generative,0.56588423,generative,0.56588423
Blockade of TRPV2 is a Novel Therapy for Cardiomyopathy in Muscular Dystrophy.,concentrated,0.2645433,of,0.5680985,gradient,0.46950975
Blockade of TRPV2 is a Novel Therapy for Cardiomyopathy in Muscular Dystrophy.,clarified,0.31933865,fully,0.6036372,confusion-matrix,0.43603677
Blockade of TRPV2 is a Novel Therapy for Cardiomyopathy in Muscular Dystrophy.,cardiomyocytes,0.24339175,neural,0.40664205,long-short-term,0.3408034
Blockade of TRPV2 is a Novel Therapy for Cardiomyopathy in Muscular Dystrophy.,activated,0.22293405,cascade,0.52779776,boosting,0.39110917
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,patients,0.30007,recurrent,0.5332828,dropout,0.3918751
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,without,0.31691062,of,0.5951073,long-short-term,0.4268921
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,pgd,0.19424695,descent,0.33476946,generative-model,0.31400862
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,exhibited,0.18898472,of,0.49406686,feature-reduction,0.35593373
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,significantly,0.27887642,of,0.5214151,long-short-term,0.39056638
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,higher,0.27819592,reduction,0.545787,boosting,0.41506222
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,frequencies,0.28467548,statistical,0.43060437,statistical,0.43060437
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,patients-without,0.35845584,recurrent,0.4967589,segmentation-algorithm,0.47195318
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,significantly-higher,0.29000503,rate,0.5078902,boosting,0.4130143
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,j,0.12432591,science,0.31094742,cross-entropy,0.2885616
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,respir,0.21898955,bagging,0.42784554,bagging,0.42784554
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,crit,0.18414646,bag,0.51027536,bagging,0.39183062
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,care,0.3144728,decision,0.58130515,data-science,0.46943653
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,med,0.21494195,confusion,0.45325774,bagging,0.36537588
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,care-med,0.31755638,decision,0.5024661,data-science,0.4781319
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,chronic,0.22727785,recurrent,0.5279353,long-short-term,0.4292153
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,obstructive,0.29236183,recurrent,0.45574522,confusion-matrix,0.3350963
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,pulmonary,0.27012008,recurrent,0.39649367,long-short-term,0.32169557
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,disease,0.296938,recurrent,0.4731025,classification,0.35271814
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,chronic-obstructive,0.2802394,recurrent,0.50352967,confusion-matrix,0.39456382
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,obstructive-pulmonary,0.31164497,recurrent,0.4760642,recurrent-neural-network,0.42644972
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,pulmonary-disease,0.39629358,logistic-regression,0.42455766,logistic-regression,0.42455766
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,trend,0.30273274,statistical,0.5180256,statistical,0.5180256
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,toward,0.2507809,forward,0.55439407,feature-engineering,0.45627213
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,reduced,0.24137571,reduction,0.7564339,boosting,0.47559226
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,ilc,0.3089894,naive,0.3944547,naive-bayes,0.3936242
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,populations,0.27454638,selection,0.5276309,clustering,0.4946172
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,immune,0.2619304,naive,0.47885698,boosting,0.47579303
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,cells,0.20327199,naive,0.5115537,generative,0.40616876
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,regulating,0.26515597,function,0.55162895,feed-forward,0.5337373
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,pathologic,0.34354168,classification,0.4743981,classification,0.4743981
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,inflammation,0.22370426,cascade,0.4429949,generative-model,0.3706867
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,immune-cells,0.25092477,naive,0.50141454,generative,0.37804058
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,immune-cells-regulating,0.34747028,feed-forward,0.5102903,feed-forward,0.5102903
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,grade,0.2647515,classification,0.4900908,classification,0.4900908
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,within,0.2920679,of,0.57602364,clustering,0.4610753
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,h,0.19856977,short-term,0.43919927,long-short-term,0.36116964
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,interstitial,0.20352072,recurrent,0.4319849,confusion-matrix,0.35623482
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,lung,0.26692057,of,0.3928769,bagging,0.36409828
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,disease,0.296938,recurrent,0.4731025,classification,0.35271814
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,transplant,0.250427,recurrent,0.40922555,dropout,0.35562313
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,recipients,0.21547928,naive,0.4695959,dropout,0.38850337
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,lung-disease,0.43316668,support-vector-machine,0.43967578,support-vector-machine,0.43967578
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,disease-transplant,0.3120722,recurrent,0.38179255,logistic-regression,0.3691126
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,transplant-recipients,0.26066595,dropout,0.41309595,dropout,0.41309595
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,chronic,0.22727785,recurrent,0.5279353,long-short-term,0.4292153
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,obstructive,0.29236183,recurrent,0.45574522,confusion-matrix,0.3350963
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,pulmonary,0.27012008,recurrent,0.39649367,long-short-term,0.32169557
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,disease,0.296938,recurrent,0.4731025,classification,0.35271814
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,chronic-obstructive,0.2802394,recurrent,0.50352967,confusion-matrix,0.39456382
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,obstructive-pulmonary,0.31164497,recurrent,0.4760642,recurrent-neural-network,0.42644972
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,pulmonary-disease,0.39629358,logistic-regression,0.42455766,logistic-regression,0.42455766
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,seven,0.34317708,one,0.6849233,principal-components,0.39034536
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,patients,0.30007,recurrent,0.5332828,dropout,0.3918751
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,developed,0.44693142,fully,0.53855187,generative-model,0.49309453
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,pgd,0.19424695,descent,0.33476946,generative-model,0.31400862
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,seven-patients,0.36518273,style,0.46885964,principal-components,0.4594
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,derived,0.3584563,of,0.54769456,generative,0.5265686
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,lung,0.26692057,of,0.3928769,bagging,0.36409828
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,ilc,0.3089894,naive,0.3944547,naive-bayes,0.3936242
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,populations,0.27454638,selection,0.5276309,clustering,0.4946172
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,significantly,0.27887642,of,0.5214151,long-short-term,0.39056638
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,decreased,0.23506472,reduction,0.66483074,boosting,0.42738107
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,frequencies,0.28467548,statistical,0.43060437,statistical,0.43060437
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,significantly-decreased,0.3262527,reduction,0.5724208,boosting,0.45526758
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,ilc,0.3089894,naive,0.3944547,naive-bayes,0.3936242
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,subset,0.42092714,feature,0.57910776,clustering,0.5495737
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,composition,0.28646052,components,0.5826185,clustering,0.4698063
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,within,0.2920679,of,0.57602364,clustering,0.4610753
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,elevated,0.19494015,normalization,0.5246306,batch-normalization,0.44167417
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,frequencies,0.28467548,statistical,0.43060437,statistical,0.43060437
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,interstitial,0.20352072,recurrent,0.4319849,confusion-matrix,0.35623482
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,lung,0.26692057,of,0.3928769,bagging,0.36409828
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,disease,0.296938,recurrent,0.4731025,classification,0.35271814
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,lung-disease,0.43316668,support-vector-machine,0.43967578,support-vector-machine,0.43967578
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,lung,0.26692057,of,0.3928769,bagging,0.36409828
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,transplant,0.250427,recurrent,0.40922555,dropout,0.35562313
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,recipients,0.21547928,naive,0.4695959,dropout,0.38850337
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,lung-transplant,0.30343503,short-term,0.38727587,logistic-regression,0.37452766
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,transplant-recipients,0.26066595,dropout,0.41309595,dropout,0.41309595
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,regulating,0.26515597,function,0.55162895,feed-forward,0.5337373
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,lung,0.26692057,of,0.3928769,bagging,0.36409828
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,injury,0.262506,shot,0.44338763,data-augmentation,0.37271294
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,lung-injury,0.30569544,learning-function,0.35851276,learning-function,0.35851276
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,lung,0.26692057,of,0.3928769,bagging,0.36409828
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,transplantation,0.2739988,engineering,0.43863437,data-engineering,0.38886067
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,patients,0.30007,recurrent,0.5332828,dropout,0.3918751
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,lung-transplantation,0.30755916,short-term,0.42917126,long-short-term,0.39542586
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,donor,0.18089789,transfer,0.5044365,transfer-learning,0.35218316
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,immune,0.2619304,naive,0.47885698,boosting,0.47579303
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,cells,0.20327199,naive,0.5115537,generative,0.40616876
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,donor-immune,0.21812215,naive,0.46243733,boosting,0.395452
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,immune-cells,0.25092477,naive,0.50141454,generative,0.37804058
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,natural,0.34621036,natural,1.0,natural-language,0.49809957
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,killer,0.2606235,natural,0.58078134,short-term-memory,0.40593776
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,cells,0.20327199,naive,0.5115537,generative,0.40616876
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,natural-killer,0.2901618,natural,0.6637163,short-term-memory,0.44923985
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,killer-cells,0.20503213,natural,0.48822075,short-term-memory,0.4241841
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,natural-killer-cells,0.25736928,natural,0.6079428,short-term-memory,0.45913988
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,innate,0.33910936,naive,0.49273443,boosting,0.4610679
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,lymphoid,0.24525584,naive,0.48044688,short-term-memory,0.37994775
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,cells,0.20327199,naive,0.5115537,generative,0.40616876
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,lymphoid-cells,0.21366088,naive,0.44743365,short-term-memory,0.37958857
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,determine,0.3371361,of,0.55401844,regression,0.40314794
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,whether,0.32171756,short-term,0.5290759,long-short-term,0.47851244
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,pgd,0.19424695,descent,0.33476946,generative-model,0.31400862
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,jan,0.22191,science,0.48332274,data-science,0.3561494
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,primary,0.24268678,principal,0.5205563,long-short-term,0.38049072
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,graft,0.20611003,augmentation,0.47663623,data-augmentation,0.3842535
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,dysfunction,0.3095205,function,0.7029606,learning-function,0.4439212
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,center,0.2469751,unit,0.5969413,data-science,0.3881536
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,cohort,0.3892265,logistic-regression,0.5412916,logistic-regression,0.5412916
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,study,0.3645851,of,0.5728763,statistical,0.44204497
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,cohort-study,0.4088606,logistic-regression,0.6062193,logistic-regression,0.6062193
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,beneficial,0.32497615,short-term,0.59825146,long-short-term,0.5331938
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,tissue,0.23679586,of,0.5202017,segmentation,0.4076932
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,repair,0.26407808,augmentation,0.44746083,data-augmentation,0.4345641
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,tissue-repair,0.3417675,engineering,0.4667452,feature-engineering,0.45197898
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,distinct,0.36295342,feature,0.580647,clustering,0.5409523
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,ilc,0.3089894,naive,0.3944547,naive-bayes,0.3936242
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,subsets,0.43637866,naive,0.6284895,clustering,0.53487885
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,donor,0.18089789,transfer,0.5044365,transfer-learning,0.35218316
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,tissue,0.23679586,of,0.5202017,segmentation,0.4076932
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,taken,0.31208742,data,0.5517592,supervised,0.41763523
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,donor-tissue,0.2208805,transfer,0.39874104,batch-normalization,0.38637835
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,tissue-taken,0.33138394,matrix,0.45119792,batch-normalization,0.44431204
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,donor,0.18089789,transfer,0.5044365,transfer-learning,0.35218316
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,ilc,0.3089894,naive,0.3944547,naive-bayes,0.3936242
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,subsets,0.43637866,naive,0.6284895,clustering,0.53487885
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,subset,0.42092714,feature,0.57910776,clustering,0.5495737
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,patients,0.30007,recurrent,0.5332828,dropout,0.3918751
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,allograft,0.25330395,augmentation,0.4540987,data-augmentation,0.3919506
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,reperfusion,0.25349236,normalization,0.42956924,batch-normalization,0.38744473
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,resulted,0.23350117,of,0.5964589,boosting,0.43415624
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,ilc,0.3089894,naive,0.3944547,naive-bayes,0.3936242
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,subsets,0.43637866,naive,0.6284895,clustering,0.53487885
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,lung,0.26692057,of,0.3928769,bagging,0.36409828
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,transplantation,0.2739988,engineering,0.43863437,data-engineering,0.38886067
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,lung-transplantation,0.30755916,short-term,0.42917126,long-short-term,0.39542586
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,pgd,0.19424695,descent,0.33476946,generative-model,0.31400862
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,development,0.34732813,generative,0.56588423,generative,0.56588423
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,whether,0.32171756,short-term,0.5290759,long-short-term,0.47851244
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,changes,0.28767496,normalization,0.57879114,batch-normalization,0.43861648
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,surgical,0.33963326,recurrent,0.47206855,supervised,0.43774873
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,biopsies,0.29040152,segmentation,0.3737896,segmentation,0.3737896
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,selective,0.24381305,selection,0.5152553,feature-selection,0.47347614
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,reduction,0.22531602,reduction,1.0,feature-reduction,0.59547573
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,selective-reduction,0.35302824,feature-reduction,0.7962641,feature-reduction,0.7962641
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,poorly,0.28902727,fully,0.6905947,long-short-term,0.39858708
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,understood,0.33540633,fully,0.5863327,stochastic,0.4766314
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,poorly-understood,0.36790985,feature,0.49439994,confusion-matrix,0.47433245
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,main,0.3070703,principal,0.7875631,principal-components,0.51314574
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,results,0.32376552,data,0.6932311,batch-normalization,0.44826904
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,main-results,0.3133425,data,0.5479348,statistical,0.4682034
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,leading,0.2514689,of,0.59935343,generative,0.44480726
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,cause,0.19388393,of,0.47843847,confusion-matrix,0.34079778
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,leading-cause,0.3739639,stochastic,0.5363524,stochastic,0.5363524
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,immunologic,0.28273636,short-term,0.42915487,component-analysis,0.41605204
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,mechanisms,0.33716813,cascade,0.55730975,feed-forward,0.5072272
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,ilcs,0.30416366,naive,0.50403535,hierarchical-clustering,0.38595593
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,may,0.30907542,of,0.58654004,long-short-term,0.43985203
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,heterogeneous,0.36404067,feature,0.5641245,hierarchical-clustering,0.5368855
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,family,0.2727693,support,0.5085263,clustering,0.40444815
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,flow,0.2860778,gradient,0.52486,gradient,0.52486
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,cytometry,0.35215917,analysis,0.47600478,fourier-transform,0.40641344
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,flow-cytometry,0.34293124,analysis,0.48240748,stochastic-gradient,0.40600675
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,early,0.32400474,short-term,0.57188475,long-short-term,0.50726265
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,morbidity,0.27463242,recurrent,0.47132403,logistic-regression,0.42021167
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,characterized,0.27792567,feature,0.5646106,fourier,0.42356855
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,phenotypically,0.29489,naive,0.49567366,generative,0.47749245
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,cell,0.2212203,of,0.48460138,generative,0.39753264
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,resolution,0.31286857,tracking,0.46759,segmentation,0.44991145
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,cell-resolution,0.4918245,convolutional,0.5667912,convolutional,0.5667912
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,allograft,0.25330395,augmentation,0.4540987,data-augmentation,0.3919506
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,reperfusion,0.25349236,normalization,0.42956924,batch-normalization,0.38744473
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,pgd,0.19424695,descent,0.33476946,generative-model,0.31400862
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,ilc,0.3089894,naive,0.3944547,naive-bayes,0.3936242
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,donor,0.18089789,transfer,0.5044365,transfer-learning,0.35218316
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,composition,0.28646052,components,0.5826185,clustering,0.4698063
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,reperfusion,0.25349236,normalization,0.42956924,batch-normalization,0.38744473
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,allograft,0.25330395,augmentation,0.4540987,data-augmentation,0.3919506
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,changes,0.28767496,normalization,0.57879114,batch-normalization,0.43861648
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,suggesting,0.24045295,of,0.6157647,clustering,0.43733796
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,single,0.31087106,one,0.6951874,one-shot,0.4602274
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,regardless,0.26079983,of,0.5475514,long-short-term,0.440047
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,rationale,0.4301394,of,0.5596026,feature-engineering,0.524489
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,performed,0.3864032,analysis,0.5711501,supervised,0.4789877
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,percentage,0.22209123,reduction,0.5092495,dropout,0.39063072
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,objectives,0.41173956,of,0.53322846,feature-engineering,0.42803428
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,never,0.32350218,fully,0.6110853,supervised,0.4091853
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,mortality,0.2609817,short-term,0.505676,logistic-regression,0.49414968
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,methods,0.50049126,data,0.5400177,machine-learning,0.50049126
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,measurements,0.31488982,data,0.56587404,batch-normalization,0.52457345
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,involved,0.26651675,of,0.5396308,feed-forward,0.42281044
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,immediately,0.23933741,short-term,0.47347653,one-hot,0.40441123
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,however,0.31437585,few,0.63182676,statistical,0.44065386
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,examined,0.295101,of,0.66699874,generative,0.4320032
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,diagnosis,0.32391536,classification,0.53521544,classification,0.53521544
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,conversely,0.24351163,of,0.5762197,long-short-term,0.47469643
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,conclusions,0.37109232,data,0.55923915,long-short-term,0.4627594
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,comment,0.27913174,term,0.48209506,data-science,0.40549088
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,associated,0.30827495,of,0.57598466,long-short-term,0.46578532
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,assessed,0.33986524,of,0.605934,component-analysis,0.41855076
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,altered,0.28369883,of,0.5963239,generative,0.4193554
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,alterations,0.3407031,normalization,0.5792735,batch-normalization,0.44323376
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,accompanied,0.21739155,of,0.57653445,generative,0.37658542
Curcumin: a therapeutic strategy in cancers by inhibiting the canonical WNT/β-catenin pathway.,cancer,0.27383438,recurrent,0.4065063,generative,0.3468409
Curcumin: a therapeutic strategy in cancers by inhibiting the canonical WNT/β-catenin pathway.,treatment,0.239264,short-term,0.5206091,long-short-term,0.41699445
Curcumin: a therapeutic strategy in cancers by inhibiting the canonical WNT/β-catenin pathway.,would,0.3569631,of,0.55908126,boosting,0.43412957
Curcumin: a therapeutic strategy in cancers by inhibiting the canonical WNT/β-catenin pathway.,thus,0.33923393,of,0.6779618,feature-reduction,0.46172875
Curcumin: a therapeutic strategy in cancers by inhibiting the canonical WNT/β-catenin pathway.,appear,0.2668634,few,0.5546265,generative,0.42577565
Curcumin: a therapeutic strategy in cancers by inhibiting the canonical WNT/β-catenin pathway.,cancer-treatment,0.32972133,dropout,0.41709578,dropout,0.41709578
Curcumin: a therapeutic strategy in cancers by inhibiting the canonical WNT/β-catenin pathway.,curcumin,0.2724862,of,0.38134724,nlp,0.33011836
Curcumin: a therapeutic strategy in cancers by inhibiting the canonical WNT/β-catenin pathway.,could,0.34235194,of,0.59299076,boosting,0.42074972
Curcumin: a therapeutic strategy in cancers by inhibiting the canonical WNT/β-catenin pathway.,decreases,0.22760506,reduction,0.76619804,boosting,0.48668283
Curcumin: a therapeutic strategy in cancers by inhibiting the canonical WNT/β-catenin pathway.,tumor,0.23345715,of,0.4070977,regression,0.3830863
Curcumin: a therapeutic strategy in cancers by inhibiting the canonical WNT/β-catenin pathway.,growth,0.15232143,of,0.446648,regression,0.38592952
Curcumin: a therapeutic strategy in cancers by inhibiting the canonical WNT/β-catenin pathway.,tumor-growth,0.21435279,batch-normalization,0.39144307,batch-normalization,0.39144307
Curcumin: a therapeutic strategy in cancers by inhibiting the canonical WNT/β-catenin pathway.,substantial,0.29639626,reduction,0.60217476,long-short-term,0.47712374
Curcumin: a therapeutic strategy in cancers by inhibiting the canonical WNT/β-catenin pathway.,pathological,0.35600212,of,0.48665273,classification,0.46512192
Curcumin: a therapeutic strategy in cancers by inhibiting the canonical WNT/β-catenin pathway.,processes,0.34218454,processing,0.59430957,generative,0.5664364
Curcumin: a therapeutic strategy in cancers by inhibiting the canonical WNT/β-catenin pathway.,accompanying,0.30426186,of,0.62855226,generative,0.46214542
Curcumin: a therapeutic strategy in cancers by inhibiting the canonical WNT/β-catenin pathway.,many,0.40940517,few,0.752018,feature-engineering,0.48454586
Curcumin: a therapeutic strategy in cancers by inhibiting the canonical WNT/β-catenin pathway.,key,0.35973132,principal,0.614877,feature-engineering,0.498355
Curcumin: a therapeutic strategy in cancers by inhibiting the canonical WNT/β-catenin pathway.,circadian,0.3172453,learning-function,0.49197105,learning-function,0.49197105
Curcumin: a therapeutic strategy in cancers by inhibiting the canonical WNT/β-catenin pathway.,genes,0.32912976,encoding,0.71535945,clustering,0.43737888
Curcumin: a therapeutic strategy in cancers by inhibiting the canonical WNT/β-catenin pathway.,major,0.2356064,principal,0.70253855,principal-components,0.42016473
Curcumin: a therapeutic strategy in cancers by inhibiting the canonical WNT/β-catenin pathway.,signaling,0.29640946,cascade,0.70725644,feed-forward,0.5819744
Curcumin: a therapeutic strategy in cancers by inhibiting the canonical WNT/β-catenin pathway.,pathways,0.30476987,cascade,0.6938149,feed-forward,0.5254793
Curcumin: a therapeutic strategy in cancers by inhibiting the canonical WNT/β-catenin pathway.,involved,0.26651675,of,0.5396308,feed-forward,0.42281044
Curcumin: a therapeutic strategy in cancers by inhibiting the canonical WNT/β-catenin pathway.,signaling-pathways,0.33893383,cascade,0.69794536,feed-forward,0.5998782
Curcumin: a therapeutic strategy in cancers by inhibiting the canonical WNT/β-catenin pathway.,circadian,0.3172453,learning-function,0.49197105,learning-function,0.49197105
Curcumin: a therapeutic strategy in cancers by inhibiting the canonical WNT/β-catenin pathway.,clock,0.33540702,feed-forward,0.48471153,feed-forward,0.48471153
Curcumin: a therapeutic strategy in cancers by inhibiting the canonical WNT/β-catenin pathway.,disruption,0.24845698,function,0.5378871,clustering,0.41109726
Curcumin: a therapeutic strategy in cancers by inhibiting the canonical WNT/β-catenin pathway.,related,0.30849367,of,0.6150687,clustering,0.41455543
Curcumin: a therapeutic strategy in cancers by inhibiting the canonical WNT/β-catenin pathway.,circadian-clock,0.34000194,feed-forward,0.50137365,feed-forward,0.50137365
Curcumin: a therapeutic strategy in cancers by inhibiting the canonical WNT/β-catenin pathway.,clock-disruption,0.35796866,learning-function,0.48901528,learning-function,0.48901528
Curcumin: a therapeutic strategy in cancers by inhibiting the canonical WNT/β-catenin pathway.,disruption-related,0.36369458,network,0.5080787,long-short-term,0.48295856
Curcumin: a therapeutic strategy in cancers by inhibiting the canonical WNT/β-catenin pathway.,circadian,0.3172453,learning-function,0.49197105,learning-function,0.49197105
Curcumin: a therapeutic strategy in cancers by inhibiting the canonical WNT/β-catenin pathway.,clock,0.33540702,feed-forward,0.48471153,feed-forward,0.48471153
Curcumin: a therapeutic strategy in cancers by inhibiting the canonical WNT/β-catenin pathway.,disruption,0.24845698,function,0.5378871,clustering,0.41109726
Curcumin: a therapeutic strategy in cancers by inhibiting the canonical WNT/β-catenin pathway.,circadian-clock,0.34000194,feed-forward,0.50137365,feed-forward,0.50137365
Curcumin: a therapeutic strategy in cancers by inhibiting the canonical WNT/β-catenin pathway.,clock-disruption,0.35796866,learning-function,0.48901528,learning-function,0.48901528
Curcumin: a therapeutic strategy in cancers by inhibiting the canonical WNT/β-catenin pathway.,tumor,0.23345715,of,0.4070977,regression,0.3830863
Curcumin: a therapeutic strategy in cancers by inhibiting the canonical WNT/β-catenin pathway.,growth,0.15232143,of,0.446648,regression,0.38592952
Curcumin: a therapeutic strategy in cancers by inhibiting the canonical WNT/β-catenin pathway.,control,0.27050394,of,0.5093193,artificial-intelligence,0.40948874
Curcumin: a therapeutic strategy in cancers by inhibiting the canonical WNT/β-catenin pathway.,tumor-growth,0.21435279,batch-normalization,0.39144307,batch-normalization,0.39144307
Curcumin: a therapeutic strategy in cancers by inhibiting the canonical WNT/β-catenin pathway.,growth-control,0.26842496,feed-forward,0.48857814,feed-forward,0.48857814
Curcumin: a therapeutic strategy in cancers by inhibiting the canonical WNT/β-catenin pathway.,tumor-growth-control,0.28362447,batch-normalization,0.46047822,batch-normalization,0.46047822
Curcumin: a therapeutic strategy in cancers by inhibiting the canonical WNT/β-catenin pathway.,control,0.27050394,of,0.5093193,artificial-intelligence,0.40948874
Curcumin: a therapeutic strategy in cancers by inhibiting the canonical WNT/β-catenin pathway.,circadian,0.3172453,learning-function,0.49197105,learning-function,0.49197105
Curcumin: a therapeutic strategy in cancers by inhibiting the canonical WNT/β-catenin pathway.,clocks,0.39426327,stochastic,0.5158131,stochastic,0.5158131
Curcumin: a therapeutic strategy in cancers by inhibiting the canonical WNT/β-catenin pathway.,interesting,0.4021179,feature,0.5455024,feature-engineering,0.5443059
Curcumin: a therapeutic strategy in cancers by inhibiting the canonical WNT/β-catenin pathway.,therapeutic,0.3659354,of,0.48352462,boosting,0.41573292
Curcumin: a therapeutic strategy in cancers by inhibiting the canonical WNT/β-catenin pathway.,strategy,0.47490904,feature-engineering,0.59725416,feature-engineering,0.59725416
Curcumin: a therapeutic strategy in cancers by inhibiting the canonical WNT/β-catenin pathway.,stimulating,0.22020775,boosting,0.5143733,boosting,0.5143733
Curcumin: a therapeutic strategy in cancers by inhibiting the canonical WNT/β-catenin pathway.,expression,0.32038707,encoding,0.59633577,clustering,0.442253
Curcumin: a therapeutic strategy in cancers by inhibiting the canonical WNT/β-catenin pathway.,activity,0.21813896,function,0.53536034,boosting,0.38798416
Curcumin: a therapeutic strategy in cancers by inhibiting the canonical WNT/β-catenin pathway.,levels,0.20457911,normalization,0.52984333,batch-normalization,0.45617118
Curcumin: a therapeutic strategy in cancers by inhibiting the canonical WNT/β-catenin pathway.,activity-levels,0.37671173,learning-function,0.5247619,learning-function,0.5247619
Curcumin: a therapeutic strategy in cancers by inhibiting the canonical WNT/β-catenin pathway.,repress,0.23945524,encoding,0.4895628,feed-forward,0.4823663
Curcumin: a therapeutic strategy in cancers by inhibiting the canonical WNT/β-catenin pathway.,chronic,0.22727785,recurrent,0.5279353,long-short-term,0.4292153
Curcumin: a therapeutic strategy in cancers by inhibiting the canonical WNT/β-catenin pathway.,inflammation,0.22370426,cascade,0.4429949,generative-model,0.3706867
Curcumin: a therapeutic strategy in cancers by inhibiting the canonical WNT/β-catenin pathway.,chronic-inflammation,0.2850436,generative-model,0.48091027,generative-model,0.48091027
Curcumin: a therapeutic strategy in cancers by inhibiting the canonical WNT/β-catenin pathway.,curcumin,0.2724862,of,0.38134724,nlp,0.33011836
Curcumin: a therapeutic strategy in cancers by inhibiting the canonical WNT/β-catenin pathway.,administration,0.2353313,of,0.50649554,boosting,0.44664776
Curcumin: a therapeutic strategy in cancers by inhibiting the canonical WNT/β-catenin pathway.,participates,0.21516952,cascade,0.4825349,feed-forward,0.46948105
Curcumin: a therapeutic strategy in cancers by inhibiting the canonical WNT/β-catenin pathway.,curcumin-administration,0.31941587,reduction,0.45127705,boosting,0.4067459
Curcumin: a therapeutic strategy in cancers by inhibiting the canonical WNT/β-catenin pathway.,curcumin,0.2724862,of,0.38134724,nlp,0.33011836
Curcumin: a therapeutic strategy in cancers by inhibiting the canonical WNT/β-catenin pathway.,could,0.34235194,of,0.59299076,boosting,0.42074972
Curcumin: a therapeutic strategy in cancers by inhibiting the canonical WNT/β-catenin pathway.,tumor,0.23345715,of,0.4070977,regression,0.3830863
Curcumin: a therapeutic strategy in cancers by inhibiting the canonical WNT/β-catenin pathway.,therapy,0.2707135,short-term,0.45926765,boosting,0.40244865
Curcumin: a therapeutic strategy in cancers by inhibiting the canonical WNT/β-catenin pathway.,tumor-therapy,0.30195475,normalization,0.42213959,recurrent-neural-network,0.39574933
Curcumin: a therapeutic strategy in cancers by inhibiting the canonical WNT/β-catenin pathway.,chronic,0.22727785,recurrent,0.5279353,long-short-term,0.4292153
Curcumin: a therapeutic strategy in cancers by inhibiting the canonical WNT/β-catenin pathway.,inflammation,0.22370426,cascade,0.4429949,generative-model,0.3706867
Curcumin: a therapeutic strategy in cancers by inhibiting the canonical WNT/β-catenin pathway.,chronic-inflammation,0.2850436,generative-model,0.48091027,generative-model,0.48091027
Curcumin: a therapeutic strategy in cancers by inhibiting the canonical WNT/β-catenin pathway.,use,0.43753043,of,0.5506158,feature-reduction,0.49910897
Curcumin: a therapeutic strategy in cancers by inhibiting the canonical WNT/β-catenin pathway.,curcumin,0.2724862,of,0.38134724,nlp,0.33011836
Curcumin: a therapeutic strategy in cancers by inhibiting the canonical WNT/β-catenin pathway.,agonists,0.23842508,discriminative,0.41182542,feed-forward,0.3169114
Curcumin: a therapeutic strategy in cancers by inhibiting the canonical WNT/β-catenin pathway.,act,0.23871477,function,0.50990385,generative,0.4057039
Curcumin: a therapeutic strategy in cancers by inhibiting the canonical WNT/β-catenin pathway.,curcumin,0.2724862,of,0.38134724,nlp,0.33011836
Curcumin: a therapeutic strategy in cancers by inhibiting the canonical WNT/β-catenin pathway.,act,0.23871477,function,0.50990385,generative,0.4057039
Curcumin: a therapeutic strategy in cancers by inhibiting the canonical WNT/β-catenin pathway.,cancer,0.27383438,recurrent,0.4065063,generative,0.3468409
Curcumin: a therapeutic strategy in cancers by inhibiting the canonical WNT/β-catenin pathway.,therapy,0.2707135,short-term,0.45926765,boosting,0.40244865
Curcumin: a therapeutic strategy in cancers by inhibiting the canonical WNT/β-catenin pathway.,cancer-therapy,0.30553013,recurrent,0.40244183,recurrent-neural-network,0.36973226
Curcumin: a therapeutic strategy in cancers by inhibiting the canonical WNT/β-catenin pathway.,cancer,0.27383438,recurrent,0.4065063,generative,0.3468409
Curcumin: a therapeutic strategy in cancers by inhibiting the canonical WNT/β-catenin pathway.,process,0.3445285,cascade,0.57959485,generative,0.5472986
Curcumin: a therapeutic strategy in cancers by inhibiting the canonical WNT/β-catenin pathway.,several,0.40139607,few,0.7607186,clustering,0.4671372
Curcumin: a therapeutic strategy in cancers by inhibiting the canonical WNT/β-catenin pathway.,hypotheses,0.48972714,generative,0.59340477,generative,0.59340477
Curcumin: a therapeutic strategy in cancers by inhibiting the canonical WNT/β-catenin pathway.,review,0.41215214,data,0.5581161,data-science,0.47600204
Curcumin: a therapeutic strategy in cancers by inhibiting the canonical WNT/β-catenin pathway.,focuses,0.42775822,feature-engineering,0.5459945,feature-engineering,0.5459945
Curcumin: a therapeutic strategy in cancers by inhibiting the canonical WNT/β-catenin pathway.,positive,0.26811236,of,0.49572036,component-analysis,0.37181294
Curcumin: a therapeutic strategy in cancers by inhibiting the canonical WNT/β-catenin pathway.,effect,0.21449387,short-term,0.5886732,long-short-term,0.47619703
Curcumin: a therapeutic strategy in cancers by inhibiting the canonical WNT/β-catenin pathway.,positive-effect,0.39337867,component-analysis,0.54256165,component-analysis,0.54256165
Curcumin: a therapeutic strategy in cancers by inhibiting the canonical WNT/β-catenin pathway.,oxidative,0.2292116,cascade,0.4921013,feature-reduction,0.39866948
Curcumin: a therapeutic strategy in cancers by inhibiting the canonical WNT/β-catenin pathway.,stress,0.25135952,short-term,0.46436286,long-short-term,0.43407696
Curcumin: a therapeutic strategy in cancers by inhibiting the canonical WNT/β-catenin pathway.,oxidative-stress,0.31784338,generative-model,0.44570386,generative-model,0.44570386
Curcumin: a therapeutic strategy in cancers by inhibiting the canonical WNT/β-catenin pathway.,opposed,0.3341823,of,0.5724972,feature-reduction,0.47271034
Curcumin: a therapeutic strategy in cancers by inhibiting the canonical WNT/β-catenin pathway.,manner,0.26802608,fully,0.46465638,feed-forward,0.4349473
Curcumin: a therapeutic strategy in cancers by inhibiting the canonical WNT/β-catenin pathway.,numerous,0.32757068,few,0.76187646,generative,0.45826626
Curcumin: a therapeutic strategy in cancers by inhibiting the canonical WNT/β-catenin pathway.,studies,0.30135098,data,0.6349237,component-analysis,0.41327482
Curcumin: a therapeutic strategy in cancers by inhibiting the canonical WNT/β-catenin pathway.,catenin,0.23156148,matrix,0.39488822,recurrent-neural-network,0.38639286
Curcumin: a therapeutic strategy in cancers by inhibiting the canonical WNT/β-catenin pathway.,pathway,0.27141988,cascade,0.7127757,feed-forward,0.5331765
Curcumin: a therapeutic strategy in cancers by inhibiting the canonical WNT/β-catenin pathway.,regulating,0.26515597,function,0.55162895,feed-forward,0.5337373
Curcumin: a therapeutic strategy in cancers by inhibiting the canonical WNT/β-catenin pathway.,wnt,0.29870558,cascade,0.528722,feed-forward,0.4739544
Curcumin: a therapeutic strategy in cancers by inhibiting the canonical WNT/β-catenin pathway.,promoting,0.3081315,of,0.5530137,boosting,0.51869273
Curcumin: a therapeutic strategy in cancers by inhibiting the canonical WNT/β-catenin pathway.,cancers,0.2730524,recurrent,0.4093323,classifiers,0.3447146
Curcumin: a therapeutic strategy in cancers by inhibiting the canonical WNT/β-catenin pathway.,thus,0.33923393,of,0.6779618,feature-reduction,0.46172875
Curcumin: a therapeutic strategy in cancers by inhibiting the canonical WNT/β-catenin pathway.,involved,0.26651675,of,0.5396308,feed-forward,0.42281044
Curcumin: a therapeutic strategy in cancers by inhibiting the canonical WNT/β-catenin pathway.,curcumin,0.2724862,of,0.38134724,nlp,0.33011836
Curcumin: a therapeutic strategy in cancers by inhibiting the canonical WNT/β-catenin pathway.,cancer,0.27383438,recurrent,0.4065063,generative,0.3468409
Curcumin: a therapeutic strategy in cancers by inhibiting the canonical WNT/β-catenin pathway.,administration,0.2353313,of,0.50649554,boosting,0.44664776
Curcumin: a therapeutic strategy in cancers by inhibiting the canonical WNT/β-catenin pathway.,wnt,0.29870558,cascade,0.528722,feed-forward,0.4739544
Curcumin: a therapeutic strategy in cancers by inhibiting the canonical WNT/β-catenin pathway.,cancers,0.2730524,recurrent,0.4093323,classifiers,0.3447146
Curcumin: a therapeutic strategy in cancers by inhibiting the canonical WNT/β-catenin pathway.,upregulation,0.25717008,encoding,0.52069056,feed-forward,0.47176182
Curcumin: a therapeutic strategy in cancers by inhibiting the canonical WNT/β-catenin pathway.,upregulated,0.23211968,encoding,0.51694846,feed-forward,0.35553855
Curcumin: a therapeutic strategy in cancers by inhibiting the canonical WNT/β-catenin pathway.,role,0.2562992,function,0.5340955,feed-forward,0.4137928
Curcumin: a therapeutic strategy in cancers by inhibiting the canonical WNT/β-catenin pathway.,regulation,0.2640685,function,0.5839784,feed-forward,0.52085924
Curcumin: a therapeutic strategy in cancers by inhibiting the canonical WNT/β-catenin pathway.,prevention,0.29446518,recurrent,0.44918782,feature-reduction,0.4041679
Curcumin: a therapeutic strategy in cancers by inhibiting the canonical WNT/β-catenin pathway.,presented,0.41586217,of,0.5919795,confusion-matrix,0.4850164
Curcumin: a therapeutic strategy in cancers by inhibiting the canonical WNT/β-catenin pathway.,one,0.335046,one,1.0,one-hot,0.4275648
Curcumin: a therapeutic strategy in cancers by inhibiting the canonical WNT/β-catenin pathway.,invasion,0.2545275,recurrent,0.38706538,segmentation,0.37389204
Curcumin: a therapeutic strategy in cancers by inhibiting the canonical WNT/β-catenin pathway.,interest,0.4194936,of,0.5624063,feature-engineering,0.5448084
Curcumin: a therapeutic strategy in cancers by inhibiting the canonical WNT/β-catenin pathway.,highlighted,0.429609,of,0.60523915,feature-engineering,0.5701233
Curcumin: a therapeutic strategy in cancers by inhibiting the canonical WNT/β-catenin pathway.,downregulation,0.25968617,reduction,0.52367336,feed-forward,0.4713591
Curcumin: a therapeutic strategy in cancers by inhibiting the canonical WNT/β-catenin pathway.,common,0.32574984,feature,0.5597373,clustering,0.43115532
Curcumin: a therapeutic strategy in cancers by inhibiting the canonical WNT/β-catenin pathway.,co,0.23682216,ground,0.42757797,feature-reduction,0.3969199
Curcumin: a therapeutic strategy in cancers by inhibiting the canonical WNT/β-catenin pathway.,appears,0.24184315,of,0.5744952,long-short-term,0.41640618
Curcumin: a therapeutic strategy in cancers by inhibiting the canonical WNT/β-catenin pathway.,acts,0.21332999,function,0.52279186,feed-forward,0.4554162
Curcumin: a therapeutic strategy in cancers by inhibiting the canonical WNT/β-catenin pathway.,action,0.25617146,of,0.5591097,generative,0.46361452
Curcumin: a therapeutic strategy in cancers by inhibiting the canonical WNT/β-catenin pathway.,acting,0.25467432,of,0.55923325,generative,0.48015943
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,modify,0.30843526,function,0.4297077,feature-engineering,0.41803545
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,ectopic,0.20431598,recurrent,0.44096014,recurrent-neural-network,0.3733027
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,overexpression,0.29621348,encoding,0.530388,feed-forward,0.39775345
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,driven,0.33295566,stochastic,0.55241346,stochastic,0.55241346
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,overexpression-driven,0.42546213,feed-forward,0.51180243,feed-forward,0.51180243
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,k,0.16369987,rectified,0.45026273,nearest-neighbors,0.34698594
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,specific,0.3244285,of,0.6059094,clustering,0.45887482
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,demethylase,0.29973885,encoding,0.376154,transfer-learning,0.33524483
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,xxxa,0.103940696,encoding,0.28463936,nearest-neighbors,0.2823031
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,cofactor,0.25699532,component,0.40742758,feed-forward,0.38108712
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,flavin,0.22998701,feature-reduction,0.41171172,feature-reduction,0.41171172
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,adenosine,0.20329912,of,0.3698272,gradient,0.2729475
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,dinucleotide,0.2597326,nearest-neighbors,0.41726694,nearest-neighbors,0.41726694
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,flavin-adenosine,0.22549063,feature-reduction,0.31766805,feature-reduction,0.31766805
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,adenosine-dinucleotide,0.2699474,nearest-neighbors,0.41284287,nearest-neighbors,0.41284287
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,flavin-adenosine-dinucleotide,0.2678694,nearest-neighbors,0.39384064,nearest-neighbors,0.39384064
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,specific,0.3244285,of,0.6059094,clustering,0.45887482
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,histone,0.34839076,encoding,0.37486342,generative,0.35522234
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,demethylase,0.29973885,encoding,0.376154,transfer-learning,0.33524483
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,xxxa,0.103940696,encoding,0.28463936,nearest-neighbors,0.2823031
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,histone-demethylase,0.3452308,encoding,0.3867046,centroid-based,0.36551607
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,extra,0.28651226,one,0.5772979,long-short-term,0.39923257
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,virgin,0.19623284,natural,0.45222312,artificial-intelligence,0.3373568
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,olive,0.25142497,tree,0.46493435,kernel,0.44250548
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,oil,0.21031478,feed,0.44002843,kernel,0.40903962
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,extra-virgin,0.32249492,natural,0.4518364,principal-components,0.43399093
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,virgin-olive,0.28669626,kernel,0.43846032,kernel,0.43846032
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,olive-oil,0.22462073,feed,0.43088534,kernel,0.41823784
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,virgin-olive-oil,0.27300227,kernel,0.44560087,kernel,0.44560087
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,dynamic,0.4720998,stochastic,0.62950635,stochastic,0.62950635
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,simulation,0.59933746,monte-carlo,0.75438184,monte-carlo,0.75438184
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,approaches,0.55614823,feature-engineering,0.60571706,feature-engineering,0.60571706
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,revealed,0.23368785,analysis,0.608845,principal-component,0.3856352
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,dynamic-simulation,0.5905193,generative-model,0.6832844,generative-model,0.6832844
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,biophenol,0.31877688,batch,0.50674427,feature-reduction,0.41341314
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,secoiridoid,0.27252746,principal-components,0.3584252,principal-components,0.3584252
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,naturally,0.34413776,natural,0.80556995,generative,0.45091197
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,present,0.39618495,of,0.63723874,generative,0.48216146
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,biophenol-secoiridoid,0.36473954,principal-components,0.44266924,principal-components,0.44266924
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,naturally-present,0.4057181,natural,0.7077533,natural-language,0.5393713
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,naturally,0.34413776,natural,0.80556995,generative,0.45091197
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,occurring,0.27984077,of,0.6354642,generative,0.4167068
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,phenolic,0.30042058,natural,0.44392532,principal-components,0.40442604
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,inhibitor,0.21582735,cascade,0.38918662,feed-forward,0.33560163
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,naturally-occurring,0.32137293,natural,0.79534197,feature-engineering,0.43011796
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,corest,0.4281189,forest,0.51823413,clustering,0.45586616
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,likely,0.28872275,one,0.55131567,generative,0.3953101
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,disturbing,0.27432585,of,0.57476777,generative,0.48410642
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,transcription,0.30657786,encoding,0.5651444,feed-forward,0.5005915
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,factor,0.23388772,component,0.48280093,principal-components,0.43733668
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,transcription-factor,0.42750043,feed-forward,0.55830014,feed-forward,0.55830014
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,design,0.47555828,data-engineering,0.6477308,data-engineering,0.6477308
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,new,0.43019778,of,0.526482,feature-reduction,0.4579819
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,secoiridoid,0.27252746,principal-components,0.3584252,principal-components,0.3584252
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,vitro,0.292481,of,0.48112682,generative,0.40355864
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,assays,0.28855288,analysis,0.47350433,component-analysis,0.38540024
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,confirmed,0.25544786,of,0.58156097,component-analysis,0.390182
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,vitro-assays,0.29587215,batch,0.4191708,batch-normalization,0.37220052
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,targeted,0.37903738,of,0.52138686,feature-engineering,0.502902
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,distal,0.18749598,long,0.4588611,segmentation,0.36233157
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,enhancer,0.31055215,encoding,0.48501134,feed-forward,0.39416587
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,sex,0.24554862,regression,0.45148212,regression,0.45148212
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,determining,0.34762657,of,0.6342732,stochastic,0.46742433
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,region,0.1874102,of,0.45814058,clustering,0.36756253
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,sex-determining,0.28129026,selection,0.4557094,generative,0.43759304
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,determining-region,0.34215152,analysis,0.5457654,clustering,0.49561998
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,central,0.26715183,connected,0.51433957,segmentation,0.35878396
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,epigenetic,0.4163731,generative,0.5062528,generative,0.5062528
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,regulator,0.23058486,encoding,0.51183397,feed-forward,0.49325994
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,epigenetic-regulator,0.46132863,feed-forward,0.57866454,feed-forward,0.57866454
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,induced,0.2259351,of,0.5615651,boosting,0.4303583
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,pluripotent,0.36851317,neural,0.5311127,generative,0.5096332
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,stem,0.2836631,neural,0.48491934,generative,0.47532985
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,induced-pluripotent,0.39766502,neural,0.5740938,feature-engineering,0.5438956
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,pluripotent-stem,0.39105156,feature-engineering,0.5326755,feature-engineering,0.5326755
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,induced-pluripotent-stem,0.42487574,feature-engineering,0.5752955,feature-engineering,0.5752955
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,oleacein,0.23923272,kernel,0.3496288,kernel,0.3496288
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,fully,0.35142052,fully,1.0,fully-connected,0.479315
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,suppressed,0.1800454,reduction,0.5064377,boosting,0.45223624
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,based,0.49998575,classification-algorithm,0.5639226,classification-algorithm,0.5639226
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,inhibitors,0.25381407,cascade,0.4157439,feed-forward,0.3175553
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,oleacein,0.23923272,kernel,0.3496288,kernel,0.3496288
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,could,0.34235194,of,0.59299076,boosting,0.42074972
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,target,0.31799266,of,0.4775706,feature-selection,0.44359237
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,histone,0.34839076,encoding,0.37486342,generative,0.35522234
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,hxxx,0.24208328,n-gram,0.3608054,n-gram,0.3608054
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,evoo,0.3215179,kernel,0.38700563,kernel,0.38700563
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,direct,0.22395119,of,0.5187454,one-shot,0.4431845
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,inhibitor,0.21582735,cascade,0.38918662,feed-forward,0.33560163
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,target,0.31799266,of,0.4775706,feature-selection,0.44359237
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,recombinant,0.27811894,encoding,0.5492526,boosting,0.43946618
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,co,0.23682216,ground,0.42757797,feature-reduction,0.3969199
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,oleacein,0.23923272,kernel,0.3496288,kernel,0.3496288
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,failed,0.26734912,fully,0.52885306,long-short-term,0.36265334
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,specifically,0.35122672,of,0.59676015,generative,0.5001233
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,occurs,0.21944973,of,0.60348606,generative,0.40320352
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,neurological,0.32212597,language,0.48069352,learning-function,0.45431274
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,disorders,0.3129085,function,0.42467374,generative,0.4119473
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,molecular,0.39914468,of,0.516936,clustering,0.43655443
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,docking,0.5002512,machine-learning,0.5002512,machine-learning,0.5002512
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,molecular-docking,0.539979,monte-carlo,0.5536084,monte-carlo,0.5536084
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,metabolic,0.3235007,of,0.46523505,batch-normalization,0.4536144
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,reprogramming,0.43855083,generative,0.5496726,generative,0.5496726
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,higher,0.27819592,reduction,0.545787,boosting,0.41506222
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,concentrations,0.16781005,of,0.4458394,batch-normalization,0.42195582
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,high,0.267004,of,0.57459104,gradient,0.44240427
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,affinity,0.26327962,gradient,0.40064883,gradient,0.40064883
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,high-affinity,0.28261304,encoding,0.41771364,feature-engineering,0.35247058
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,first,0.36139184,of,0.61145455,generative,0.4096663
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,evidence,0.28723752,data,0.5728123,generative,0.3943918
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,findings,0.35685748,data,0.65714294,component-analysis,0.38599753
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,provide,0.40841419,support,0.64934516,feature-engineering,0.47702065
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,evoo,0.3215179,kernel,0.38700563,kernel,0.38700563
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,contains,0.2587247,encoding,0.5691426,fully-connected,0.36690116
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,constitutive,0.30203718,encoding,0.5229391,stochastic,0.47046924
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,promoter,0.2784518,encoding,0.59602714,feed-forward,0.39776367
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,cancer,0.27383438,recurrent,0.4065063,generative,0.3468409
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,stem,0.2836631,neural,0.48491934,generative,0.47532985
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,cancer-stem,0.30067807,recurrent-neural-network,0.3648517,recurrent-neural-network,0.3648517
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,binding,0.27773649,of,0.45710018,nearest-neighbors,0.40653253
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,site,0.19581059,of,0.46834108,nearest-neighbors,0.3344323
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,binding-site,0.37578773,nearest-neighbors,0.5260326,nearest-neighbors,0.5260326
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,associated,0.30827495,of,0.57598466,long-short-term,0.46578532
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,diseases,0.31957155,recurrent,0.41244444,classification,0.40266854
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,associated-diseases,0.42832243,recurrent,0.48085523,logistic-regression,0.46056253
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,also,0.32850838,of,0.65908813,clustering,0.45826355
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,known,0.3344566,of,0.5873189,clustering,0.4164055
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,box,0.33575195,bag,0.4752586,one-hot,0.41891497
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,low,0.23602332,of,0.5820825,long-short-term,0.45172954
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,concentrations,0.16781005,of,0.4458394,batch-normalization,0.42195582
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,low-concentrations,0.34702718,short-term,0.537073,stochastic-gradient,0.5095271
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,oleacein,0.23923272,kernel,0.3496288,kernel,0.3496288
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,target,0.31799266,of,0.4775706,feature-selection,0.44359237
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,based,0.49998575,classification-algorithm,0.5639226,classification-algorithm,0.5639226
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,low,0.23602332,of,0.5820825,long-short-term,0.45172954
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,cancer,0.27383438,recurrent,0.4065063,generative,0.3468409
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,use,0.43753043,of,0.5506158,feature-reduction,0.49910897
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,template,0.41439134,feature-selection,0.5080123,feature-selection,0.5080123
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,support,0.3815906,support,1.0,support-vector,0.66958183
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,repressor,0.25734353,encoding,0.49874637,feed-forward,0.4536751
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,predicted,0.423177,function,0.49677318,classification-algorithm,0.45761842
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,overall,0.37212962,rate,0.62994075,dropout,0.45315623
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,obesity,0.3146031,descent,0.41921628,logistic-regression,0.39891833
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,lysine,0.23587576,of,0.369767,n-gram,0.29503667
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,like,0.32318482,of,0.5448733,relu,0.44626954
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,l,0.15310754,of,0.37313756,bagging,0.32610148
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,ips,0.27969277,support,0.44808394,bagging,0.4060319
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,interaction,0.32838812,function,0.4945054,nearest-neighbors,0.47909442
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,expression,0.32038707,encoding,0.59633577,clustering,0.442253
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,evaluated,0.35501102,of,0.6190806,supervised,0.4124783
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,conversely,0.24351163,of,0.5762197,long-short-term,0.47469643
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,control,0.27050394,of,0.5093193,artificial-intelligence,0.40948874
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,chromatin,0.33593595,generative,0.44008464,generative,0.44008464
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,cells,0.20327199,naive,0.5115537,generative,0.40616876
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,anchorage,0.25294486,augmentation,0.45468545,data-augmentation,0.39890048
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,alphascreen,0.43596548,graphics-processing,0.44421145,graphics-processing,0.44421145
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,act,0.23871477,function,0.50990385,generative,0.4057039
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,ability,0.39144984,function,0.5937173,generative,0.47758824
Effect of Vasicinone against Paraquat-Induced MAPK/p53-Mediated Apoptosis via the IGF-1R/PI3K/AKT Pathway in a Parkinson's Disease-Associated SH-SY5Y Cell Model.,jnk,0.20093879,cascade,0.5330882,feed-forward,0.43211234
Effect of Vasicinone against Paraquat-Induced MAPK/p53-Mediated Apoptosis via the IGF-1R/PI3K/AKT Pathway in a Parkinson's Disease-Associated SH-SY5Y Cell Model.,mediated,0.1966965,cascade,0.5268023,feed-forward,0.4459417
Effect of Vasicinone against Paraquat-Induced MAPK/p53-Mediated Apoptosis via the IGF-1R/PI3K/AKT Pathway in a Parkinson's Disease-Associated SH-SY5Y Cell Model.,apoptotic,0.25514302,cascade,0.43370223,feed-forward,0.35026777
Effect of Vasicinone against Paraquat-Induced MAPK/p53-Mediated Apoptosis via the IGF-1R/PI3K/AKT Pathway in a Parkinson's Disease-Associated SH-SY5Y Cell Model.,pathways,0.30476987,cascade,0.6938149,feed-forward,0.5254793
Effect of Vasicinone against Paraquat-Induced MAPK/p53-Mediated Apoptosis via the IGF-1R/PI3K/AKT Pathway in a Parkinson's Disease-Associated SH-SY5Y Cell Model.,compared,0.3359061,of,0.52794564,long-short-term,0.42386633
Effect of Vasicinone against Paraquat-Induced MAPK/p53-Mediated Apoptosis via the IGF-1R/PI3K/AKT Pathway in a Parkinson's Disease-Associated SH-SY5Y Cell Model.,tunel,0.22374164,fourier-transform,0.3277893,fourier-transform,0.3277893
Effect of Vasicinone against Paraquat-Induced MAPK/p53-Mediated Apoptosis via the IGF-1R/PI3K/AKT Pathway in a Parkinson's Disease-Associated SH-SY5Y Cell Model.,positive,0.26811236,of,0.49572036,component-analysis,0.37181294
Effect of Vasicinone against Paraquat-Induced MAPK/p53-Mediated Apoptosis via the IGF-1R/PI3K/AKT Pathway in a Parkinson's Disease-Associated SH-SY5Y Cell Model.,apoptotic,0.25514302,cascade,0.43370223,feed-forward,0.35026777
Effect of Vasicinone against Paraquat-Induced MAPK/p53-Mediated Apoptosis via the IGF-1R/PI3K/AKT Pathway in a Parkinson's Disease-Associated SH-SY5Y Cell Model.,nuclei,0.23743671,layer,0.43705913,generative,0.41922343
Effect of Vasicinone against Paraquat-Induced MAPK/p53-Mediated Apoptosis via the IGF-1R/PI3K/AKT Pathway in a Parkinson's Disease-Associated SH-SY5Y Cell Model.,positive-apoptotic,0.28889123,feed-forward,0.49122548,feed-forward,0.49122548
Effect of Vasicinone against Paraquat-Induced MAPK/p53-Mediated Apoptosis via the IGF-1R/PI3K/AKT Pathway in a Parkinson's Disease-Associated SH-SY5Y Cell Model.,akt,0.21248668,cascade,0.47864795,feed-forward,0.41708446
Effect of Vasicinone against Paraquat-Induced MAPK/p53-Mediated Apoptosis via the IGF-1R/PI3K/AKT Pathway in a Parkinson's Disease-Associated SH-SY5Y Cell Model.,cell,0.2212203,of,0.48460138,generative,0.39753264
Effect of Vasicinone against Paraquat-Induced MAPK/p53-Mediated Apoptosis via the IGF-1R/PI3K/AKT Pathway in a Parkinson's Disease-Associated SH-SY5Y Cell Model.,survival,0.29004025,short-term,0.53135407,long-short-term,0.4573617
Effect of Vasicinone against Paraquat-Induced MAPK/p53-Mediated Apoptosis via the IGF-1R/PI3K/AKT Pathway in a Parkinson's Disease-Associated SH-SY5Y Cell Model.,signaling,0.29640946,cascade,0.70725644,feed-forward,0.5819744
Effect of Vasicinone against Paraquat-Induced MAPK/p53-Mediated Apoptosis via the IGF-1R/PI3K/AKT Pathway in a Parkinson's Disease-Associated SH-SY5Y Cell Model.,molecules,0.31138086,components,0.5355045,nearest-neighbors,0.43995067
Effect of Vasicinone against Paraquat-Induced MAPK/p53-Mediated Apoptosis via the IGF-1R/PI3K/AKT Pathway in a Parkinson's Disease-Associated SH-SY5Y Cell Model.,cell-survival,0.30901384,short-term,0.41624504,stochastic,0.40174583
Effect of Vasicinone against Paraquat-Induced MAPK/p53-Mediated Apoptosis via the IGF-1R/PI3K/AKT Pathway in a Parkinson's Disease-Associated SH-SY5Y Cell Model.,survival-signaling,0.38579082,cascade,0.5964277,feed-forward,0.5524507
Effect of Vasicinone against Paraquat-Induced MAPK/p53-Mediated Apoptosis via the IGF-1R/PI3K/AKT Pathway in a Parkinson's Disease-Associated SH-SY5Y Cell Model.,signaling-molecules,0.3875624,cascade,0.6094741,feed-forward,0.54544973
Effect of Vasicinone against Paraquat-Induced MAPK/p53-Mediated Apoptosis via the IGF-1R/PI3K/AKT Pathway in a Parkinson's Disease-Associated SH-SY5Y Cell Model.,mediated,0.1966965,cascade,0.5268023,feed-forward,0.4459417
Effect of Vasicinone against Paraquat-Induced MAPK/p53-Mediated Apoptosis via the IGF-1R/PI3K/AKT Pathway in a Parkinson's Disease-Associated SH-SY5Y Cell Model.,dutp,0.19231156,fourier-transform,0.29837286,fourier-transform,0.29837286
Effect of Vasicinone against Paraquat-Induced MAPK/p53-Mediated Apoptosis via the IGF-1R/PI3K/AKT Pathway in a Parkinson's Disease-Associated SH-SY5Y Cell Model.,nick,0.22385119,words,0.35595623,transfer-learning,0.35041398
Effect of Vasicinone against Paraquat-Induced MAPK/p53-Mediated Apoptosis via the IGF-1R/PI3K/AKT Pathway in a Parkinson's Disease-Associated SH-SY5Y Cell Model.,end,0.22421888,long,0.5453975,long-short-term,0.36503828
Effect of Vasicinone against Paraquat-Induced MAPK/p53-Mediated Apoptosis via the IGF-1R/PI3K/AKT Pathway in a Parkinson's Disease-Associated SH-SY5Y Cell Model.,mediated-dutp,0.2286178,cascade,0.40890273,stochastic,0.39002723
Effect of Vasicinone against Paraquat-Induced MAPK/p53-Mediated Apoptosis via the IGF-1R/PI3K/AKT Pathway in a Parkinson's Disease-Associated SH-SY5Y Cell Model.,dutp-nick,0.23221335,graphics-processing-unit,0.34349856,graphics-processing-unit,0.34349856
Effect of Vasicinone against Paraquat-Induced MAPK/p53-Mediated Apoptosis via the IGF-1R/PI3K/AKT Pathway in a Parkinson's Disease-Associated SH-SY5Y Cell Model.,nick-end,0.23474976,fourier-transform,0.34766698,fourier-transform,0.34766698
Effect of Vasicinone against Paraquat-Induced MAPK/p53-Mediated Apoptosis via the IGF-1R/PI3K/AKT Pathway in a Parkinson's Disease-Associated SH-SY5Y Cell Model.,dutp-nick-end,0.25843498,graphics-processing-unit,0.35952848,graphics-processing-unit,0.35952848
Effect of Vasicinone against Paraquat-Induced MAPK/p53-Mediated Apoptosis via the IGF-1R/PI3K/AKT Pathway in a Parkinson's Disease-Associated SH-SY5Y Cell Model.,western,0.2369854,analysis,0.4211278,component-analysis,0.34579337
Effect of Vasicinone against Paraquat-Induced MAPK/p53-Mediated Apoptosis via the IGF-1R/PI3K/AKT Pathway in a Parkinson's Disease-Associated SH-SY5Y Cell Model.,blotting,0.27866253,analysis,0.5003886,fourier-transform,0.39758992
Effect of Vasicinone against Paraquat-Induced MAPK/p53-Mediated Apoptosis via the IGF-1R/PI3K/AKT Pathway in a Parkinson's Disease-Associated SH-SY5Y Cell Model.,analysis,0.46507934,analysis,0.99999994,component-analysis,0.69613737
Effect of Vasicinone against Paraquat-Induced MAPK/p53-Mediated Apoptosis via the IGF-1R/PI3K/AKT Pathway in a Parkinson's Disease-Associated SH-SY5Y Cell Model.,revealed,0.23368785,analysis,0.608845,principal-component,0.3856352
Effect of Vasicinone against Paraquat-Induced MAPK/p53-Mediated Apoptosis via the IGF-1R/PI3K/AKT Pathway in a Parkinson's Disease-Associated SH-SY5Y Cell Model.,western-blotting,0.30329487,analysis,0.48630443,fourier-transform,0.40190244
Effect of Vasicinone against Paraquat-Induced MAPK/p53-Mediated Apoptosis via the IGF-1R/PI3K/AKT Pathway in a Parkinson's Disease-Associated SH-SY5Y Cell Model.,analysis-revealed,0.40604806,analysis,0.78213704,component-analysis,0.6229236
Effect of Vasicinone against Paraquat-Induced MAPK/p53-Mediated Apoptosis via the IGF-1R/PI3K/AKT Pathway in a Parkinson's Disease-Associated SH-SY5Y Cell Model.,rescued,0.20457655,function,0.43710715,feature-selection,0.3655641
Effect of Vasicinone against Paraquat-Induced MAPK/p53-Mediated Apoptosis via the IGF-1R/PI3K/AKT Pathway in a Parkinson's Disease-Associated SH-SY5Y Cell Model.,terminal,0.1515508,long,0.5815784,generative,0.39005107
Effect of Vasicinone against Paraquat-Induced MAPK/p53-Mediated Apoptosis via the IGF-1R/PI3K/AKT Pathway in a Parkinson's Disease-Associated SH-SY5Y Cell Model.,deoxynucleotide,0.22148693,nearest-neighbors,0.40242982,nearest-neighbors,0.40242982
Effect of Vasicinone against Paraquat-Induced MAPK/p53-Mediated Apoptosis via the IGF-1R/PI3K/AKT Pathway in a Parkinson's Disease-Associated SH-SY5Y Cell Model.,transferase,0.1866062,encoding,0.45251763,transfer-learning,0.36391437
Effect of Vasicinone against Paraquat-Induced MAPK/p53-Mediated Apoptosis via the IGF-1R/PI3K/AKT Pathway in a Parkinson's Disease-Associated SH-SY5Y Cell Model.,terminal-deoxynucleotide,0.29020014,nearest-neighbors,0.39797938,nearest-neighbors,0.39797938
Effect of Vasicinone against Paraquat-Induced MAPK/p53-Mediated Apoptosis via the IGF-1R/PI3K/AKT Pathway in a Parkinson's Disease-Associated SH-SY5Y Cell Model.,underlying,0.37239885,neural,0.55211174,generative,0.49267903
Effect of Vasicinone against Paraquat-Induced MAPK/p53-Mediated Apoptosis via the IGF-1R/PI3K/AKT Pathway in a Parkinson's Disease-Associated SH-SY5Y Cell Model.,molecular,0.39914468,of,0.516936,clustering,0.43655443
Effect of Vasicinone against Paraquat-Induced MAPK/p53-Mediated Apoptosis via the IGF-1R/PI3K/AKT Pathway in a Parkinson's Disease-Associated SH-SY5Y Cell Model.,mechanism,0.2780391,cascade,0.59194523,feed-forward,0.5341974
Effect of Vasicinone against Paraquat-Induced MAPK/p53-Mediated Apoptosis via the IGF-1R/PI3K/AKT Pathway in a Parkinson's Disease-Associated SH-SY5Y Cell Model.,underlying-molecular,0.49347058,stochastic,0.5821592,stochastic,0.5821592
Effect of Vasicinone against Paraquat-Induced MAPK/p53-Mediated Apoptosis via the IGF-1R/PI3K/AKT Pathway in a Parkinson's Disease-Associated SH-SY5Y Cell Model.,molecular-mechanism,0.47277594,stochastic,0.5860506,stochastic,0.5860506
Effect of Vasicinone against Paraquat-Induced MAPK/p53-Mediated Apoptosis via the IGF-1R/PI3K/AKT Pathway in a Parkinson's Disease-Associated SH-SY5Y Cell Model.,sirna,0.30772042,vector,0.4959275,vector-machine,0.41919988
Effect of Vasicinone against Paraquat-Induced MAPK/p53-Mediated Apoptosis via the IGF-1R/PI3K/AKT Pathway in a Parkinson's Disease-Associated SH-SY5Y Cell Model.,completely,0.21044229,fully,0.78808415,hidden-layer,0.3545486
Effect of Vasicinone against Paraquat-Induced MAPK/p53-Mediated Apoptosis via the IGF-1R/PI3K/AKT Pathway in a Parkinson's Disease-Associated SH-SY5Y Cell Model.,abrogated,0.16502383,reduction,0.41756195,boosting,0.38774067
Effect of Vasicinone against Paraquat-Induced MAPK/p53-Mediated Apoptosis via the IGF-1R/PI3K/AKT Pathway in a Parkinson's Disease-Associated SH-SY5Y Cell Model.,related,0.30849367,of,0.6150687,clustering,0.41455543
Effect of Vasicinone against Paraquat-Induced MAPK/p53-Mediated Apoptosis via the IGF-1R/PI3K/AKT Pathway in a Parkinson's Disease-Associated SH-SY5Y Cell Model.,neurodegenerative,0.36640078,generative-model,0.4714227,generative-model,0.4714227
Effect of Vasicinone against Paraquat-Induced MAPK/p53-Mediated Apoptosis via the IGF-1R/PI3K/AKT Pathway in a Parkinson's Disease-Associated SH-SY5Y Cell Model.,disorders,0.3129085,function,0.42467374,generative,0.4119473
Effect of Vasicinone against Paraquat-Induced MAPK/p53-Mediated Apoptosis via the IGF-1R/PI3K/AKT Pathway in a Parkinson's Disease-Associated SH-SY5Y Cell Model.,reactive,0.2102494,confusion,0.43334603,generative,0.40140074
Effect of Vasicinone against Paraquat-Induced MAPK/p53-Mediated Apoptosis via the IGF-1R/PI3K/AKT Pathway in a Parkinson's Disease-Associated SH-SY5Y Cell Model.,oxygen,0.22381568,reduction,0.44402215,feature-reduction,0.3957175
Effect of Vasicinone against Paraquat-Induced MAPK/p53-Mediated Apoptosis via the IGF-1R/PI3K/AKT Pathway in a Parkinson's Disease-Associated SH-SY5Y Cell Model.,species,0.31081003,forest,0.5343407,random-forest,0.4811191
Effect of Vasicinone against Paraquat-Induced MAPK/p53-Mediated Apoptosis via the IGF-1R/PI3K/AKT Pathway in a Parkinson's Disease-Associated SH-SY5Y Cell Model.,reactive-oxygen,0.2526903,feature-reduction,0.4348432,feature-reduction,0.4348432
Effect of Vasicinone against Paraquat-Induced MAPK/p53-Mediated Apoptosis via the IGF-1R/PI3K/AKT Pathway in a Parkinson's Disease-Associated SH-SY5Y Cell Model.,oxygen-species,0.33371967,feature-reduction,0.49900892,feature-reduction,0.49900892
Effect of Vasicinone against Paraquat-Induced MAPK/p53-Mediated Apoptosis via the IGF-1R/PI3K/AKT Pathway in a Parkinson's Disease-Associated SH-SY5Y Cell Model.,reactive-oxygen-species,0.32991892,feature-reduction,0.5018313,feature-reduction,0.5018313
Effect of Vasicinone against Paraquat-Induced MAPK/p53-Mediated Apoptosis via the IGF-1R/PI3K/AKT Pathway in a Parkinson's Disease-Associated SH-SY5Y Cell Model.,quinazoline,0.23761155,centroid-based,0.39394906,centroid-based,0.39394906
Effect of Vasicinone against Paraquat-Induced MAPK/p53-Mediated Apoptosis via the IGF-1R/PI3K/AKT Pathway in a Parkinson's Disease-Associated SH-SY5Y Cell Model.,alkaloid,0.27000225,natural,0.38190535,centroid-based,0.34028548
Effect of Vasicinone against Paraquat-Induced MAPK/p53-Mediated Apoptosis via the IGF-1R/PI3K/AKT Pathway in a Parkinson's Disease-Associated SH-SY5Y Cell Model.,isolated,0.24300994,of,0.4970751,gradient,0.40058494
Effect of Vasicinone against Paraquat-Induced MAPK/p53-Mediated Apoptosis via the IGF-1R/PI3K/AKT Pathway in a Parkinson's Disease-Associated SH-SY5Y Cell Model.,protection,0.17893824,boosting,0.48223335,boosting,0.48223335
Effect of Vasicinone against Paraquat-Induced MAPK/p53-Mediated Apoptosis via the IGF-1R/PI3K/AKT Pathway in a Parkinson's Disease-Associated SH-SY5Y Cell Model.,depended,0.22564669,of,0.59640336,stochastic,0.4189607
Effect of Vasicinone against Paraquat-Induced MAPK/p53-Mediated Apoptosis via the IGF-1R/PI3K/AKT Pathway in a Parkinson's Disease-Associated SH-SY5Y Cell Model.,critically,0.3436439,of,0.5690512,long-short-term,0.40989497
Effect of Vasicinone against Paraquat-Induced MAPK/p53-Mediated Apoptosis via the IGF-1R/PI3K/AKT Pathway in a Parkinson's Disease-Associated SH-SY5Y Cell Model.,mapk,0.2536896,cascade,0.59739983,feed-forward,0.45056283
Effect of Vasicinone against Paraquat-Induced MAPK/p53-Mediated Apoptosis via the IGF-1R/PI3K/AKT Pathway in a Parkinson's Disease-Associated SH-SY5Y Cell Model.,c,0.17513797,of,0.44327667,gradient,0.31114018
Effect of Vasicinone against Paraquat-Induced MAPK/p53-Mediated Apoptosis via the IGF-1R/PI3K/AKT Pathway in a Parkinson's Disease-Associated SH-SY5Y Cell Model.,adhatoda,0.24785757,tree,0.38649827,pytorch,0.36940196
Effect of Vasicinone against Paraquat-Induced MAPK/p53-Mediated Apoptosis via the IGF-1R/PI3K/AKT Pathway in a Parkinson's Disease-Associated SH-SY5Y Cell Model.,vasica,0.2377056,pytorch,0.39617565,pytorch,0.39617565
Effect of Vasicinone against Paraquat-Induced MAPK/p53-Mediated Apoptosis via the IGF-1R/PI3K/AKT Pathway in a Parkinson's Disease-Associated SH-SY5Y Cell Model.,plant,0.34364456,forest,0.58436096,kernel,0.47982314
Effect of Vasicinone against Paraquat-Induced MAPK/p53-Mediated Apoptosis via the IGF-1R/PI3K/AKT Pathway in a Parkinson's Disease-Associated SH-SY5Y Cell Model.,activated,0.22293405,cascade,0.52779776,boosting,0.39110917
Effect of Vasicinone against Paraquat-Induced MAPK/p53-Mediated Apoptosis via the IGF-1R/PI3K/AKT Pathway in a Parkinson's Disease-Associated SH-SY5Y Cell Model.,protein,0.31929362,encoding,0.5525089,clustering,0.36023882
Effect of Vasicinone against Paraquat-Induced MAPK/p53-Mediated Apoptosis via the IGF-1R/PI3K/AKT Pathway in a Parkinson's Disease-Associated SH-SY5Y Cell Model.,kinase,0.22244422,cascade,0.49403343,feed-forward,0.34344023
Effect of Vasicinone against Paraquat-Induced MAPK/p53-Mediated Apoptosis via the IGF-1R/PI3K/AKT Pathway in a Parkinson's Disease-Associated SH-SY5Y Cell Model.,activated-protein,0.35663834,cascade,0.5189711,feed-forward,0.47266394
Effect of Vasicinone against Paraquat-Induced MAPK/p53-Mediated Apoptosis via the IGF-1R/PI3K/AKT Pathway in a Parkinson's Disease-Associated SH-SY5Y Cell Model.,protein-kinase,0.2713312,cascade,0.5171006,feed-forward,0.4069047
Effect of Vasicinone against Paraquat-Induced MAPK/p53-Mediated Apoptosis via the IGF-1R/PI3K/AKT Pathway in a Parkinson's Disease-Associated SH-SY5Y Cell Model.,induced,0.2259351,of,0.5615651,boosting,0.4303583
Effect of Vasicinone against Paraquat-Induced MAPK/p53-Mediated Apoptosis via the IGF-1R/PI3K/AKT Pathway in a Parkinson's Disease-Associated SH-SY5Y Cell Model.,cellular,0.33255053,of,0.55018497,generative,0.4558165
Effect of Vasicinone against Paraquat-Induced MAPK/p53-Mediated Apoptosis via the IGF-1R/PI3K/AKT Pathway in a Parkinson's Disease-Associated SH-SY5Y Cell Model.,apoptosis,0.22776133,cascade,0.46111506,feed-forward,0.37718636
Effect of Vasicinone against Paraquat-Induced MAPK/p53-Mediated Apoptosis via the IGF-1R/PI3K/AKT Pathway in a Parkinson's Disease-Associated SH-SY5Y Cell Model.,induced-cellular,0.2948916,of,0.5035354,convolutional-layer,0.47353777
Effect of Vasicinone against Paraquat-Induced MAPK/p53-Mediated Apoptosis via the IGF-1R/PI3K/AKT Pathway in a Parkinson's Disease-Associated SH-SY5Y Cell Model.,terminal,0.1515508,long,0.5815784,generative,0.39005107
Effect of Vasicinone against Paraquat-Induced MAPK/p53-Mediated Apoptosis via the IGF-1R/PI3K/AKT Pathway in a Parkinson's Disease-Associated SH-SY5Y Cell Model.,kinase,0.22244422,cascade,0.49403343,feed-forward,0.34344023
Effect of Vasicinone against Paraquat-Induced MAPK/p53-Mediated Apoptosis via the IGF-1R/PI3K/AKT Pathway in a Parkinson's Disease-Associated SH-SY5Y Cell Model.,terminal-kinase,0.24964479,cascade,0.48992562,feed-forward,0.43961912
Effect of Vasicinone against Paraquat-Induced MAPK/p53-Mediated Apoptosis via the IGF-1R/PI3K/AKT Pathway in a Parkinson's Disease-Associated SH-SY5Y Cell Model.,cell,0.2212203,of,0.48460138,generative,0.39753264
Effect of Vasicinone against Paraquat-Induced MAPK/p53-Mediated Apoptosis via the IGF-1R/PI3K/AKT Pathway in a Parkinson's Disease-Associated SH-SY5Y Cell Model.,viability,0.21255259,function,0.46481842,feature-reduction,0.33868396
Effect of Vasicinone against Paraquat-Induced MAPK/p53-Mediated Apoptosis via the IGF-1R/PI3K/AKT Pathway in a Parkinson's Disease-Associated SH-SY5Y Cell Model.,cell-viability,0.26226342,batch-normalization,0.4028484,batch-normalization,0.4028484
Effect of Vasicinone against Paraquat-Induced MAPK/p53-Mediated Apoptosis via the IGF-1R/PI3K/AKT Pathway in a Parkinson's Disease-Associated SH-SY5Y Cell Model.,suppressed,0.1800454,reduction,0.5064377,boosting,0.45223624
Effect of Vasicinone against Paraquat-Induced MAPK/p53-Mediated Apoptosis via the IGF-1R/PI3K/AKT Pathway in a Parkinson's Disease-Associated SH-SY5Y Cell Model.,generation,0.3480911,generative,0.6357137,generative,0.6357137
Effect of Vasicinone against Paraquat-Induced MAPK/p53-Mediated Apoptosis via the IGF-1R/PI3K/AKT Pathway in a Parkinson's Disease-Associated SH-SY5Y Cell Model.,protective,0.2287128,boosting,0.50660264,boosting,0.50660264
Effect of Vasicinone against Paraquat-Induced MAPK/p53-Mediated Apoptosis via the IGF-1R/PI3K/AKT Pathway in a Parkinson's Disease-Associated SH-SY5Y Cell Model.,effect,0.21449387,short-term,0.5886732,long-short-term,0.47619703
Effect of Vasicinone against Paraquat-Induced MAPK/p53-Mediated Apoptosis via the IGF-1R/PI3K/AKT Pathway in a Parkinson's Disease-Associated SH-SY5Y Cell Model.,protective-effect,0.31665024,dimensionality-reduction,0.5765328,dimensionality-reduction,0.5765328
Effect of Vasicinone against Paraquat-Induced MAPK/p53-Mediated Apoptosis via the IGF-1R/PI3K/AKT Pathway in a Parkinson's Disease-Associated SH-SY5Y Cell Model.,potential,0.3558654,of,0.5645705,generative-model,0.46479023
Effect of Vasicinone against Paraquat-Induced MAPK/p53-Mediated Apoptosis via the IGF-1R/PI3K/AKT Pathway in a Parkinson's Disease-Associated SH-SY5Y Cell Model.,candidate,0.35861892,encoding,0.51264024,feature-selection,0.4453258
Effect of Vasicinone against Paraquat-Induced MAPK/p53-Mediated Apoptosis via the IGF-1R/PI3K/AKT Pathway in a Parkinson's Disease-Associated SH-SY5Y Cell Model.,oxidative,0.2292116,cascade,0.4921013,feature-reduction,0.39866948
Effect of Vasicinone against Paraquat-Induced MAPK/p53-Mediated Apoptosis via the IGF-1R/PI3K/AKT Pathway in a Parkinson's Disease-Associated SH-SY5Y Cell Model.,stress,0.25135952,short-term,0.46436286,long-short-term,0.43407696
Effect of Vasicinone against Paraquat-Induced MAPK/p53-Mediated Apoptosis via the IGF-1R/PI3K/AKT Pathway in a Parkinson's Disease-Associated SH-SY5Y Cell Model.,oxidative-stress,0.31784338,generative-model,0.44570386,generative-model,0.44570386
Effect of Vasicinone against Paraquat-Induced MAPK/p53-Mediated Apoptosis via the IGF-1R/PI3K/AKT Pathway in a Parkinson's Disease-Associated SH-SY5Y Cell Model.,neuroprotective,0.305324,learning-function,0.4366417,learning-function,0.4366417
Effect of Vasicinone against Paraquat-Induced MAPK/p53-Mediated Apoptosis via the IGF-1R/PI3K/AKT Pathway in a Parkinson's Disease-Associated SH-SY5Y Cell Model.,effect,0.21449387,short-term,0.5886732,long-short-term,0.47619703
Effect of Vasicinone against Paraquat-Induced MAPK/p53-Mediated Apoptosis via the IGF-1R/PI3K/AKT Pathway in a Parkinson's Disease-Associated SH-SY5Y Cell Model.,neuroprotective-effect,0.36804426,learning-function,0.5544108,learning-function,0.5544108
Effect of Vasicinone against Paraquat-Induced MAPK/p53-Mediated Apoptosis via the IGF-1R/PI3K/AKT Pathway in a Parkinson's Disease-Associated SH-SY5Y Cell Model.,jun,0.210586,feed-forward,0.37043476,feed-forward,0.37043476
Effect of Vasicinone against Paraquat-Induced MAPK/p53-Mediated Apoptosis via the IGF-1R/PI3K/AKT Pathway in a Parkinson's Disease-Associated SH-SY5Y Cell Model.,n,0.24332823,of,0.45693433,long-short-term,0.34114176
Effect of Vasicinone against Paraquat-Induced MAPK/p53-Mediated Apoptosis via the IGF-1R/PI3K/AKT Pathway in a Parkinson's Disease-Associated SH-SY5Y Cell Model.,jun-n,0.21143919,cascade,0.4181518,feed-forward,0.3875628
Effect of Vasicinone against Paraquat-Induced MAPK/p53-Mediated Apoptosis via the IGF-1R/PI3K/AKT Pathway in a Parkinson's Disease-Associated SH-SY5Y Cell Model.,induced,0.2259351,of,0.5615651,boosting,0.4303583
Effect of Vasicinone against Paraquat-Induced MAPK/p53-Mediated Apoptosis via the IGF-1R/PI3K/AKT Pathway in a Parkinson's Disease-Associated SH-SY5Y Cell Model.,loss,0.26544642,reduction,0.62177265,dropout,0.42517614
Effect of Vasicinone against Paraquat-Induced MAPK/p53-Mediated Apoptosis via the IGF-1R/PI3K/AKT Pathway in a Parkinson's Disease-Associated SH-SY5Y Cell Model.,findings,0.35685748,data,0.65714294,component-analysis,0.38599753
Effect of Vasicinone against Paraquat-Induced MAPK/p53-Mediated Apoptosis via the IGF-1R/PI3K/AKT Pathway in a Parkinson's Disease-Associated SH-SY5Y Cell Model.,indicated,0.2502363,of,0.5998554,principal-components,0.4305639
Effect of Vasicinone against Paraquat-Induced MAPK/p53-Mediated Apoptosis via the IGF-1R/PI3K/AKT Pathway in a Parkinson's Disease-Associated SH-SY5Y Cell Model.,dependent,0.2523393,of,0.585135,generative,0.43066898
Effect of Vasicinone against Paraquat-Induced MAPK/p53-Mediated Apoptosis via the IGF-1R/PI3K/AKT Pathway in a Parkinson's Disease-Associated SH-SY5Y Cell Model.,manner,0.26802608,fully,0.46465638,feed-forward,0.4349473
Effect of Vasicinone against Paraquat-Induced MAPK/p53-Mediated Apoptosis via the IGF-1R/PI3K/AKT Pathway in a Parkinson's Disease-Associated SH-SY5Y Cell Model.,dependent-manner,0.35112363,component-analysis,0.48481512,component-analysis,0.48481512
Effect of Vasicinone against Paraquat-Induced MAPK/p53-Mediated Apoptosis via the IGF-1R/PI3K/AKT Pathway in a Parkinson's Disease-Associated SH-SY5Y Cell Model.,vasicinone,0.2502563,natural,0.3491879,centroid-based,0.33085
Effect of Vasicinone against Paraquat-Induced MAPK/p53-Mediated Apoptosis via the IGF-1R/PI3K/AKT Pathway in a Parkinson's Disease-Associated SH-SY5Y Cell Model.,reduced,0.24137571,reduction,0.7564339,boosting,0.47559226
Effect of Vasicinone against Paraquat-Induced MAPK/p53-Mediated Apoptosis via the IGF-1R/PI3K/AKT Pathway in a Parkinson's Disease-Associated SH-SY5Y Cell Model.,vasicinone,0.2502563,natural,0.3491879,centroid-based,0.33085
Effect of Vasicinone against Paraquat-Induced MAPK/p53-Mediated Apoptosis via the IGF-1R/PI3K/AKT Pathway in a Parkinson's Disease-Associated SH-SY5Y Cell Model.,increased,0.26921988,reduction,0.6514183,boosting,0.46515882
Effect of Vasicinone against Paraquat-Induced MAPK/p53-Mediated Apoptosis via the IGF-1R/PI3K/AKT Pathway in a Parkinson's Disease-Associated SH-SY5Y Cell Model.,cells,0.20327199,naive,0.5115537,generative,0.40616876
Effect of Vasicinone against Paraquat-Induced MAPK/p53-Mediated Apoptosis via the IGF-1R/PI3K/AKT Pathway in a Parkinson's Disease-Associated SH-SY5Y Cell Model.,induced,0.2259351,of,0.5615651,boosting,0.4303583
Effect of Vasicinone against Paraquat-Induced MAPK/p53-Mediated Apoptosis via the IGF-1R/PI3K/AKT Pathway in a Parkinson's Disease-Associated SH-SY5Y Cell Model.,vasicinone,0.2502563,natural,0.3491879,centroid-based,0.33085
Effect of Vasicinone against Paraquat-Induced MAPK/p53-Mediated Apoptosis via the IGF-1R/PI3K/AKT Pathway in a Parkinson's Disease-Associated SH-SY5Y Cell Model.,cells,0.20327199,naive,0.5115537,generative,0.40616876
Effect of Vasicinone against Paraquat-Induced MAPK/p53-Mediated Apoptosis via the IGF-1R/PI3K/AKT Pathway in a Parkinson's Disease-Associated SH-SY5Y Cell Model.,treatment,0.239264,short-term,0.5206091,long-short-term,0.41699445
Effect of Vasicinone against Paraquat-Induced MAPK/p53-Mediated Apoptosis via the IGF-1R/PI3K/AKT Pathway in a Parkinson's Disease-Associated SH-SY5Y Cell Model.,treated,0.19958335,of,0.5218221,long-short-term,0.35705733
Effect of Vasicinone against Paraquat-Induced MAPK/p53-Mediated Apoptosis via the IGF-1R/PI3K/AKT Pathway in a Parkinson's Disease-Associated SH-SY5Y Cell Model.,study,0.3645851,of,0.5728763,statistical,0.44204497
Effect of Vasicinone against Paraquat-Induced MAPK/p53-Mediated Apoptosis via the IGF-1R/PI3K/AKT Pathway in a Parkinson's Disease-Associated SH-SY5Y Cell Model.,silencing,0.33167142,encoding,0.51854193,feed-forward,0.45553774
Effect of Vasicinone against Paraquat-Induced MAPK/p53-Mediated Apoptosis via the IGF-1R/PI3K/AKT Pathway in a Parkinson's Disease-Associated SH-SY5Y Cell Model.,sh,0.23336436,of,0.4630851,long-short-term,0.4193005
Effect of Vasicinone against Paraquat-Induced MAPK/p53-Mediated Apoptosis via the IGF-1R/PI3K/AKT Pathway in a Parkinson's Disease-Associated SH-SY5Y Cell Model.,ros,0.20205015,confusion,0.4351639,confusion-matrix,0.37891614
Effect of Vasicinone against Paraquat-Induced MAPK/p53-Mediated Apoptosis via the IGF-1R/PI3K/AKT Pathway in a Parkinson's Disease-Associated SH-SY5Y Cell Model.,possibly,0.23571348,of,0.6252128,long-short-term,0.4445187
Effect of Vasicinone against Paraquat-Induced MAPK/p53-Mediated Apoptosis via the IGF-1R/PI3K/AKT Pathway in a Parkinson's Disease-Associated SH-SY5Y Cell Model.,phosphorylation,0.24651355,cascade,0.48268026,feed-forward,0.40188718
Effect of Vasicinone against Paraquat-Induced MAPK/p53-Mediated Apoptosis via the IGF-1R/PI3K/AKT Pathway in a Parkinson's Disease-Associated SH-SY5Y Cell Model.,parkinson,0.31766385,learning-function,0.38886184,learning-function,0.38886184
Effect of Vasicinone against Paraquat-Induced MAPK/p53-Mediated Apoptosis via the IGF-1R/PI3K/AKT Pathway in a Parkinson's Disease-Associated SH-SY5Y Cell Model.,paraquat,0.25923055,of,0.35499278,bagging,0.30435568
Effect of Vasicinone against Paraquat-Induced MAPK/p53-Mediated Apoptosis via the IGF-1R/PI3K/AKT Pathway in a Parkinson's Disease-Associated SH-SY5Y Cell Model.,observed,0.23725806,of,0.64367145,long-short-term,0.4519785
Effect of Vasicinone against Paraquat-Induced MAPK/p53-Mediated Apoptosis via the IGF-1R/PI3K/AKT Pathway in a Parkinson's Disease-Associated SH-SY5Y Cell Model.,mitogen,0.19797315,cascade,0.41057706,feed-forward,0.3337224
Effect of Vasicinone against Paraquat-Induced MAPK/p53-Mediated Apoptosis via the IGF-1R/PI3K/AKT Pathway in a Parkinson's Disease-Associated SH-SY5Y Cell Model.,labeling,0.30766982,embeddings,0.46864867,embeddings,0.46864867
Effect of Vasicinone against Paraquat-Induced MAPK/p53-Mediated Apoptosis via the IGF-1R/PI3K/AKT Pathway in a Parkinson's Disease-Associated SH-SY5Y Cell Model.,explored,0.42671436,of,0.58866113,feature-engineering,0.5368307
Effect of Vasicinone against Paraquat-Induced MAPK/p53-Mediated Apoptosis via the IGF-1R/PI3K/AKT Pathway in a Parkinson's Disease-Associated SH-SY5Y Cell Model.,downregulated,0.23814872,encoding,0.5115197,feed-forward,0.3594731
Effect of Vasicinone against Paraquat-Induced MAPK/p53-Mediated Apoptosis via the IGF-1R/PI3K/AKT Pathway in a Parkinson's Disease-Associated SH-SY5Y Cell Model.,dose,0.24218819,shot,0.48689568,boosting,0.43495926
Effect of Vasicinone against Paraquat-Induced MAPK/p53-Mediated Apoptosis via the IGF-1R/PI3K/AKT Pathway in a Parkinson's Disease-Associated SH-SY5Y Cell Model.,disease,0.296938,recurrent,0.4731025,classification,0.35271814
Effect of Vasicinone against Paraquat-Induced MAPK/p53-Mediated Apoptosis via the IGF-1R/PI3K/AKT Pathway in a Parkinson's Disease-Associated SH-SY5Y Cell Model.,activation,0.23066127,cascade,0.649269,feed-forward,0.4652444
Practical guide for the use of PCSK9 inhibitors in Portugal.,c,0.17513797,of,0.44327667,gradient,0.31114018
Practical guide for the use of PCSK9 inhibitors in Portugal.,levels,0.20457911,normalization,0.52984333,batch-normalization,0.45617118
Practical guide for the use of PCSK9 inhibitors in Portugal.,persist,0.26016572,few,0.57312584,long-short-term,0.505196
Practical guide for the use of PCSK9 inhibitors in Portugal.,despite,0.27514282,few,0.5803892,long-short-term,0.43284553
Practical guide for the use of PCSK9 inhibitors in Portugal.,optimal,0.39098042,selection,0.5284126,algorithm,0.5276129
Practical guide for the use of PCSK9 inhibitors in Portugal.,lipid,0.23492281,of,0.44637915,clustering,0.37238947
Practical guide for the use of PCSK9 inhibitors in Portugal.,c-levels,0.3094396,batch-normalization,0.48311746,batch-normalization,0.48311746
Practical guide for the use of PCSK9 inhibitors in Portugal.,publicado,0.37705308,data-science,0.5283172,data-science,0.5283172
Practical guide for the use of PCSK9 inhibitors in Portugal.,por,0.2476899,one,0.3481292,feature-reduction,0.32251543
Practical guide for the use of PCSK9 inhibitors in Portugal.,elsevier,0.26603332,science,0.59524655,data-science,0.53140587
Practical guide for the use of PCSK9 inhibitors in Portugal.,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
Practical guide for the use of PCSK9 inhibitors in Portugal.,reduces,0.2596901,reduction,0.6328956,boosting,0.4721025
Practical guide for the use of PCSK9 inhibitors in Portugal.,ldl,0.16037413,tf-idf,0.38286388,tf-idf,0.38286388
Practical guide for the use of PCSK9 inhibitors in Portugal.,new,0.43019778,of,0.526482,feature-reduction,0.4579819
Practical guide for the use of PCSK9 inhibitors in Portugal.,therapeutic,0.3659354,of,0.48352462,boosting,0.41573292
Practical guide for the use of PCSK9 inhibitors in Portugal.,option,0.35068518,decision,0.5267865,algorithm,0.43552527
Practical guide for the use of PCSK9 inhibitors in Portugal.,new-therapeutic,0.3548655,normalization,0.42601833,one-shot,0.41742682
Practical guide for the use of PCSK9 inhibitors in Portugal.,therapeutic-option,0.4075905,feature-engineering,0.5243293,feature-engineering,0.5243293
Practical guide for the use of PCSK9 inhibitors in Portugal.,density,0.25813383,layer,0.4929318,gradient,0.48885438
Practical guide for the use of PCSK9 inhibitors in Portugal.,lipoprotein,0.22208765,tf-idf,0.3608624,tf-idf,0.3608624
Practical guide for the use of PCSK9 inhibitors in Portugal.,cholesterol,0.15921682,reduction,0.33627644,gradient,0.32767534
Practical guide for the use of PCSK9 inhibitors in Portugal.,density-lipoprotein,0.2429603,tf-idf,0.4027466,tf-idf,0.4027466
Practical guide for the use of PCSK9 inhibitors in Portugal.,lipoprotein-cholesterol,0.2143431,tf-idf,0.33285147,tf-idf,0.33285147
Practical guide for the use of PCSK9 inhibitors in Portugal.,density-lipoprotein-cholesterol,0.22921449,batch-normalization,0.37548044,batch-normalization,0.37548044
Practical guide for the use of PCSK9 inhibitors in Portugal.,consensus,0.41497663,classification-algorithm,0.5168837,classification-algorithm,0.5168837
Practical guide for the use of PCSK9 inhibitors in Portugal.,document,0.42359865,data,0.58814454,data-science,0.51201344
Practical guide for the use of PCSK9 inhibitors in Portugal.,aims,0.42995954,of,0.465683,feature-engineering,0.4555406
Practical guide for the use of PCSK9 inhibitors in Portugal.,achieve,0.38882452,normalization,0.5210317,batch-normalization,0.5101594
Practical guide for the use of PCSK9 inhibitors in Portugal.,recommended,0.3070693,decision,0.53480643,supervised,0.5100244
Practical guide for the use of PCSK9 inhibitors in Portugal.,ldl,0.16037413,tf-idf,0.38286388,tf-idf,0.38286388
Practical guide for the use of PCSK9 inhibitors in Portugal.,clinical,0.44080526,data,0.48532635,data-science,0.45343333
Practical guide for the use of PCSK9 inhibitors in Portugal.,trials,0.31393725,short-term,0.4483273,data-science,0.40647802
Practical guide for the use of PCSK9 inhibitors in Portugal.,translates,0.39658672,of,0.5055193,generative,0.4578531
Practical guide for the use of PCSK9 inhibitors in Portugal.,clinical-trials,0.4615081,data-science,0.54023623,data-science,0.54023623
Practical guide for the use of PCSK9 inhibitors in Portugal.,good,0.29142508,few,0.4427599,bagging,0.41576368
Practical guide for the use of PCSK9 inhibitors in Portugal.,safety,0.3095734,short-term,0.530321,long-short-term,0.44178027
Practical guide for the use of PCSK9 inhibitors in Portugal.,profile,0.29077405,analysis,0.5635588,component-analysis,0.44242257
Practical guide for the use of PCSK9 inhibitors in Portugal.,good-safety,0.3973284,decision,0.5499319,artificial-intelligence,0.5190916
Practical guide for the use of PCSK9 inhibitors in Portugal.,safety-profile,0.43291327,dimensionality-reduction,0.5595659,dimensionality-reduction,0.5595659
Practical guide for the use of PCSK9 inhibitors in Portugal.,higher,0.27819592,reduction,0.545787,boosting,0.41506222
Practical guide for the use of PCSK9 inhibitors in Portugal.,cardiovascular,0.31674606,short-term,0.442761,learning-function,0.4027721
Practical guide for the use of PCSK9 inhibitors in Portugal.,risk,0.35860935,recurrent,0.53675485,logistic-regression,0.52381086
Practical guide for the use of PCSK9 inhibitors in Portugal.,cardiovascular-risk,0.3523693,logistic-regression,0.46172044,logistic-regression,0.46172044
Practical guide for the use of PCSK9 inhibitors in Portugal.,c,0.17513797,of,0.44327667,gradient,0.31114018
Practical guide for the use of PCSK9 inhibitors in Portugal.,levels,0.20457911,normalization,0.52984333,batch-normalization,0.45617118
Practical guide for the use of PCSK9 inhibitors in Portugal.,c-levels,0.3094396,batch-normalization,0.48311746,batch-normalization,0.48311746
Practical guide for the use of PCSK9 inhibitors in Portugal.,cardiovascular,0.31674606,short-term,0.442761,learning-function,0.4027721
Practical guide for the use of PCSK9 inhibitors in Portugal.,events,0.28275582,of,0.4981169,stochastic,0.4261601
Practical guide for the use of PCSK9 inhibitors in Portugal.,cardiovascular-events,0.37286758,short-term,0.47820756,logistic-regression,0.4564199
Practical guide for the use of PCSK9 inhibitors in Portugal.,clinical,0.44080526,data,0.48532635,data-science,0.45343333
Practical guide for the use of PCSK9 inhibitors in Portugal.,practice,0.50552624,decision,0.59237766,data-science,0.5843962
Practical guide for the use of PCSK9 inhibitors in Portugal.,clinical-practice,0.5274042,data-science,0.57205796,data-science,0.57205796
Practical guide for the use of PCSK9 inhibitors in Portugal.,high,0.267004,of,0.57459104,gradient,0.44240427
Practical guide for the use of PCSK9 inhibitors in Portugal.,ldl,0.16037413,tf-idf,0.38286388,tf-idf,0.38286388
Practical guide for the use of PCSK9 inhibitors in Portugal.,high-ldl,0.22120056,tf-idf,0.3548934,tf-idf,0.3548934
Practical guide for the use of PCSK9 inhibitors in Portugal.,xxx,0.118691005,confusion-matrix,0.29613543,confusion-matrix,0.29613543
Practical guide for the use of PCSK9 inhibitors in Portugal.,rights,0.3170033,adversarial,0.6281444,data-science,0.57488894
Practical guide for the use of PCSK9 inhibitors in Portugal.,reserved,0.28677964,of,0.4776592,supervised,0.3944377
Practical guide for the use of PCSK9 inhibitors in Portugal.,inhibitors,0.25381407,cascade,0.4157439,feed-forward,0.3175553
Practical guide for the use of PCSK9 inhibitors in Portugal.,may,0.30907542,of,0.58654004,long-short-term,0.43985203
Practical guide for the use of PCSK9 inhibitors in Portugal.,benefit,0.39640212,short-term,0.5466547,long-short-term,0.48296973
Practical guide for the use of PCSK9 inhibitors in Portugal.,make,0.41116035,decision,0.569717,feature-engineering,0.49376172
Practical guide for the use of PCSK9 inhibitors in Portugal.,recommendations,0.40738833,decision,0.6199442,classification-algorithm,0.5130223
Practical guide for the use of PCSK9 inhibitors in Portugal.,main,0.3070703,principal,0.7875631,principal-components,0.51314574
Practical guide for the use of PCSK9 inhibitors in Portugal.,data,0.46434748,data,1.0,data-science,0.5533528
Practical guide for the use of PCSK9 inhibitors in Portugal.,important,0.33620566,principal,0.5803634,feature-engineering,0.43471682
Practical guide for the use of PCSK9 inhibitors in Portugal.,strategies,0.49161434,feature-engineering,0.5992338,feature-engineering,0.5992338
Practical guide for the use of PCSK9 inhibitors in Portugal.,additional,0.35377294,of,0.63162684,feature-reduction,0.4511183
Practical guide for the use of PCSK9 inhibitors in Portugal.,reduction,0.22531602,reduction,1.0,feature-reduction,0.59547573
Practical guide for the use of PCSK9 inhibitors in Portugal.,clinical,0.44080526,data,0.48532635,data-science,0.45343333
Practical guide for the use of PCSK9 inhibitors in Portugal.,use,0.43753043,of,0.5506158,feature-reduction,0.49910897
Practical guide for the use of PCSK9 inhibitors in Portugal.,clinical-use,0.48345056,data-science,0.5298956,data-science,0.5298956
Practical guide for the use of PCSK9 inhibitors in Portugal.,lowering,0.21700059,reduction,0.69292593,batch-normalization,0.5070027
Practical guide for the use of PCSK9 inhibitors in Portugal.,therapy,0.2707135,short-term,0.45926765,boosting,0.40244865
Practical guide for the use of PCSK9 inhibitors in Portugal.,high,0.267004,of,0.57459104,gradient,0.44240427
Practical guide for the use of PCSK9 inhibitors in Portugal.,proportion,0.24881616,reduction,0.5001526,clustering,0.44429505
Practical guide for the use of PCSK9 inhibitors in Portugal.,high-proportion,0.37665004,feed,0.5006027,logistic-regression,0.48836076
Practical guide for the use of PCSK9 inhibitors in Portugal.,reducing,0.26140445,reduction,0.74160737,boosting,0.5133524
Practical guide for the use of PCSK9 inhibitors in Portugal.,low,0.23602332,of,0.5820825,long-short-term,0.45172954
Practical guide for the use of PCSK9 inhibitors in Portugal.,lipid,0.23492281,of,0.44637915,clustering,0.37238947
Practical guide for the use of PCSK9 inhibitors in Portugal.,cost,0.3742721,dimensionality-reduction,0.51791906,dimensionality-reduction,0.51791906
Practical guide for the use of PCSK9 inhibitors in Portugal.,therapy,0.2707135,short-term,0.45926765,boosting,0.40244865
Practical guide for the use of PCSK9 inhibitors in Portugal.,levels,0.20457911,normalization,0.52984333,batch-normalization,0.45617118
Practical guide for the use of PCSK9 inhibitors in Portugal.,c,0.17513797,of,0.44327667,gradient,0.31114018
Practical guide for the use of PCSK9 inhibitors in Portugal.,ldl,0.16037413,tf-idf,0.38286388,tf-idf,0.38286388
Practical guide for the use of PCSK9 inhibitors in Portugal.,risk,0.35860935,recurrent,0.53675485,logistic-regression,0.52381086
Practical guide for the use of PCSK9 inhibitors in Portugal.,profile,0.29077405,analysis,0.5635588,component-analysis,0.44242257
Practical guide for the use of PCSK9 inhibitors in Portugal.,therapy,0.2707135,short-term,0.45926765,boosting,0.40244865
Practical guide for the use of PCSK9 inhibitors in Portugal.,high,0.267004,of,0.57459104,gradient,0.44240427
Practical guide for the use of PCSK9 inhibitors in Portugal.,use,0.43753043,of,0.5506158,feature-reduction,0.49910897
Practical guide for the use of PCSK9 inhibitors in Portugal.,reducing,0.26140445,reduction,0.74160737,boosting,0.5133524
Practical guide for the use of PCSK9 inhibitors in Portugal.,cost,0.3742721,dimensionality-reduction,0.51791906,dimensionality-reduction,0.51791906
Practical guide for the use of PCSK9 inhibitors in Portugal.,u,0.1900385,unit,0.40376884,relu,0.36135292
Practical guide for the use of PCSK9 inhibitors in Portugal.,therefore,0.37519994,of,0.6409915,feature-reduction,0.45783085
Practical guide for the use of PCSK9 inhibitors in Portugal.,take,0.35951027,few,0.5340042,supervised,0.4517222
Practical guide for the use of PCSK9 inhibitors in Portugal.,summarize,0.46051407,data,0.5263473,data-engineering,0.47421953
Practical guide for the use of PCSK9 inhibitors in Portugal.,statins,0.24406128,short-term,0.40197155,long-short-term,0.3434062
Practical guide for the use of PCSK9 inhibitors in Portugal.,significantly,0.27887642,of,0.5214151,long-short-term,0.39056638
Practical guide for the use of PCSK9 inhibitors in Portugal.,priority,0.4239555,decision,0.60754585,data-science,0.5443365
Practical guide for the use of PCSK9 inhibitors in Portugal.,portugal,0.29319736,federated,0.50927943,keras,0.45917314
Practical guide for the use of PCSK9 inhibitors in Portugal.,patients,0.30007,recurrent,0.5332828,dropout,0.3918751
Practical guide for the use of PCSK9 inhibitors in Portugal.,one,0.335046,one,1.0,one-hot,0.4275648
Practical guide for the use of PCSK9 inhibitors in Portugal.,lifestyle,0.33702192,style,0.606002,supervised,0.45074543
Practical guide for the use of PCSK9 inhibitors in Portugal.,l,0.15310754,of,0.37313756,bagging,0.32610148
Practical guide for the use of PCSK9 inhibitors in Portugal.,however,0.31437585,few,0.63182676,statistical,0.44065386
Practical guide for the use of PCSK9 inhibitors in Portugal.,given,0.30785376,of,0.54849017,boosting,0.4329715
Practical guide for the use of PCSK9 inhibitors in Portugal.,ezetimibe,0.20077208,softmax,0.30890355,softmax,0.30890355
Practical guide for the use of PCSK9 inhibitors in Portugal.,effectiveness,0.38338125,short-term,0.6059195,dimensionality-reduction,0.5238044
Practical guide for the use of PCSK9 inhibitors in Portugal.,account,0.38509363,of,0.53262895,stochastic,0.5254493
